[{"id":"nct05607004","name":"(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer","tldr":"A phase 2 trial of (Z)-endoxifen in HR-positive / HER2-negative breast cancer, run by Atossa Therapeutics, Inc., active and no longer recruiting.","route":"/trials/nct05607004/","status":"active","kind":"trial","cancerIcon":"breast-hr-positive","sub":"NCT05607004","facets":{"kind":["Trial"],"cancers":["HR-positive / HER2-negative breast cancer","High-risk early HR-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"High-risk early HR-positive breast cancer","href":"/cancers/hr-positive-early-high-risk/","tip":"Most hormone-driven breast cancers are cured with surgery, radiotherapy and five to ten years of endocrine tablets. Women whose tumours are larger, higher grade or have reached the lymph nodes face a higher risk of relapse: two to three years of a CDK4/6 inhibitor added to endocrine therapy cuts recurrence, and genomic tests such as Oncotype DX and MammaPrint decide who also needs chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04252859","name":"[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma","tldr":"A phase 2 trial of FES PET in Breast cancer, run by University of Utah, recorded as terminated on the registry.","route":"/trials/nct04252859/","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT04252859","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07432633","name":"[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications","tldr":"A phase 1/2 trial of [18F]FPyQCP in colorectal cancer, ovarian cancer, gastric & gastro-oesophageal junction cancer and pancreatic ductal adenocarcinoma, run by Blue Earth Diagnostics, now recruiting.","route":"/trials/nct07432633/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT07432633","facets":{"kind":["Trial"],"cancers":["Colorectal cancer","Ovarian cancer","Gastric & gastro-oesophageal junction cancer","Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07702292","name":"[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications","tldr":"A phase 2 trial of [68Ga]BED003 in colorectal cancer, ovarian cancer, gastric & gastro-oesophageal junction cancer and pancreatic ductal adenocarcinoma, run by Blue Earth Diagnostics, now recruiting.","route":"/trials/nct07702292/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT07702292","facets":{"kind":["Trial"],"cancers":["Colorectal cancer","Ovarian cancer","Gastric & gastro-oesophageal junction cancer","Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05619016","name":"[68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors","tldr":"A phase 2 trial of HER2 PET in Breast cancer and HER2-positive gastric cancer, run by Karolinska University Hospital, with a status the registry has not verified recently.","route":"/trials/nct05619016/","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT05619016","facets":{"kind":["Trial"],"cancers":["Breast cancer","HER2-positive gastric cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."},{"label":"HER2-positive gastric cancer","href":"/cancers/gastric-her2-positive/","tip":"HER2-positive gastric cancer overexpresses the HER2 growth receptor and is treated with trastuzumab added to chemotherapy, now usually with pembrolizumab as well. After progression the antibody-drug conjugate trastuzumab deruxtecan gives responses that plain chemotherapy cannot."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00450619","name":"153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer","tldr":"A phase 2 trial of Samarium-153 lexidronam and Sargramostim in Prostate cancer, run by National Cancer Institute (NCI), completed.","route":"/trials/nct00450619/","status":"completed","kind":"trial","cancerIcon":"prostate","sub":"NCT00450619","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07189871","name":"177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors","tldr":"A phase 1/2 trial of 177Lu-BetaBart in prostate cancer, colorectal cancer, non-small-cell lung cancer, ovarian cancer, cervical cancer and endometrial cancer, run by Radiopharm Theranostics, Ltd, now recruiting.","route":"/trials/nct07189871/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT07189871","facets":{"kind":["Trial"],"cancers":["Prostate cancer","Colorectal cancer","Non-small-cell lung cancer","Ovarian cancer","Cervical cancer","Endometrial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05479136","name":"18F-Fluciclovine PET Imaging for Detecting High Grade Glioma Recurrence After Radiochemotherapy","tldr":"A phase 3 trial of Fluciclovine F-18 in Glioma & glioblastoma, run by Nicole Hill, with a status the registry has not verified recently.","route":"/trials/nct05479136/","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT05479136","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04883814","name":"18F-fluoroestradiol (FES) PET/CT for Breast Cancer","tldr":"A phase 2 trial of FES PET in Breast cancer, run by Hoag Memorial Hospital Presbyterian, with a status the registry has not verified recently.","route":"/trials/nct04883814/","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT04883814","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00943449","name":"4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma","tldr":"A phase 2 trial of Resminostat and Sorafenib in Hepatocellular carcinoma, run by 4SC AG, completed.","route":"/trials/nct00943449/","status":"completed","kind":"trial","cancerIcon":"hcc","sub":"NCT00943449","facets":{"kind":["Trial"],"cancers":["Hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06298916","name":"64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer","tldr":"A phase 1/2 trial of 64Cu-LNTH-1363S in sarcomas, oesophageal cancer, gastric & gastro-oesophageal junction cancer, pancreatic ductal adenocarcinoma and colorectal cancer, run by Lantheus Medical Imaging, now recruiting.","route":"/trials/nct06298916/","status":"recruiting","kind":"trial","cancerIcon":"sarcoma","sub":"NCT06298916","facets":{"kind":["Trial"],"cancers":["Sarcomas","Oesophageal cancer","Gastric & gastro-oesophageal junction cancer","Pancreatic ductal adenocarcinoma","Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Sarcomas","href":"/cancers/sarcoma/","tip":"Sarcomas are dozens of rare cancers of bone and connective tissue. GIST was the first solid tumour cured-in-practice by a targeted pill; synovial sarcoma got the first TCR-T therapy."},{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."},{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04868604","name":"64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)","tldr":"A phase 1/2 trial of 64Cu-SAR-bisPSMA in prostate cancer, run by Clarity Pharmaceuticals Ltd, now recruiting.","route":"/trials/nct04868604/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT04868604","facets":{"kind":["Trial"],"cancers":["Prostate cancer","Metastatic castration-resistant prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Metastatic castration-resistant prostate cancer","href":"/cancers/prostate-mcrpc/","tip":"Metastatic castration-resistant prostate cancer is disease that grows despite castrate testosterone. Sequenced treatments now include androgen receptor inhibitors, docetaxel and cabazitaxel, PARP inhibitors for men with BRCA-type mutations, the radioligand 177Lu-PSMA-617 and radium-223 for bone-predominant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06970847","name":"64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer","tldr":"A phase 3 trial of 64Cu-SAR-bisPSMA in prostate cancer, run by Clarity Pharmaceuticals Ltd, active and no longer recruiting.","route":"/trials/nct06970847/","status":"active","kind":"trial","cancerIcon":"prostate","sub":"NCT06970847","facets":{"kind":["Trial"],"cancers":["Prostate cancer","Biochemical recurrence of prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Biochemical recurrence of prostate cancer","href":"/cancers/prostate-bcr/","tip":"Biochemical recurrence of prostate cancer is a rising PSA after surgery or radiotherapy with nothing yet visible on scans. Salvage radiotherapy can still cure it after surgery, and for a fast-doubling PSA the EMBARK trial showed that enzalutamide with or without hormone therapy delays spread."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04847505","name":"68Ga-DOTA-TATE PET/CT Imaging in NETs","tldr":"A phase 3 trial of Gallium-68 DOTATATE in Neuroendocrine tumours, run by Centre de recherche du Centre hospitalier universitaire de Sherbrooke, with a status the registry has not verified recently.","route":"/trials/nct04847505/","kind":"trial","cancerIcon":"neuroendocrine","sub":"NCT04847505","facets":{"kind":["Trial"],"cancers":["Neuroendocrine tumours"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Neuroendocrine tumours","href":"/cancers/neuroendocrine/","tip":"A family of usually slow-growing tumours that start in hormone-producing cells of the gut, pancreas and lungs. They pioneered the idea of using the same molecule to see a tumour on a scan and then to treat it with radiation."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03849118","name":"89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study","tldr":"A phase 3 trial of CAIX PET in Clear cell renal cell carcinoma, run by Telix Pharmaceuticals (Innovations) Pty Limited, completed.","route":"/trials/nct03849118/","status":"completed","kind":"trial","cancerIcon":"clear-cell-rcc","sub":"NCT03849118","facets":{"kind":["Trial"],"cancers":["Clear cell renal cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Clear cell renal cell carcinoma","href":"/cancers/clear-cell-rcc/","tip":"Clear cell is the common kidney cancer, driven by loss of the VHL gene that leaves the tumour behaving as if starved of oxygen and flooding itself with blood vessels. That biology explains why anti-angiogenic drugs, immunotherapy and the HIF-2 alpha blocker belzutifan all work."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06823427","name":"9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma","tldr":"A phase 2 trial of Toripalimab in bladder & urothelial cancer, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.","route":"/trials/nct06823427/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT06823427","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07314723","name":"9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer","tldr":"A phase 2 trial of Toripalimab in bladder & urothelial cancer, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.","route":"/trials/nct07314723/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT07314723","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06079112","name":"9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer","tldr":"A phase 1/2 trial of Toripalimab in bladder & urothelial cancer, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.","route":"/trials/nct06079112/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT06079112","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06592326","name":"9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer","tldr":"A phase 3 trial of Toripalimab, Gemcitabine, Carboplatin and Cisplatin in bladder & urothelial cancer, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.","route":"/trials/nct06592326/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT06592326","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04632108","name":"A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors","tldr":"A phase 1/2 trial of ASKB589 Injection in advanced solid tumours, run by Jiangsu Aosaikang Pharmaceutical Co., Ltd., active and no longer recruiting.","route":"/trials/nct04632108/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04632108","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00923481","name":"A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H..","tldr":"A phase 2 trial of Fostamatinib in Head and neck squamous cell carcinoma and Pheochromocytoma and paraganglioma, run by National Cancer Institute (NCI), completed.","route":"/trials/nct00923481/","status":"completed","kind":"trial","cancerIcon":"head-and-neck","sub":"NCT00923481","facets":{"kind":["Trial"],"cancers":["Head and neck squamous cell carcinoma","Pheochromocytoma and paraganglioma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Pheochromocytoma and paraganglioma","href":"/cancers/pheochromocytoma-paraganglioma/","tip":"Pheochromocytomas and paragangliomas are tumours of adrenaline-producing tissue that cause dangerous blood pressure surges. Surgery after careful blood-pressure blockade cures most, genetic testing finds an inherited cause in nearly half, and for the minority that spread there are now radioactive drugs that home to the tumour and, since 2025, the first oral targeted pill, belzutifan."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04776330","name":"a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease","tldr":"A phase 1/2 trial of BCMA targeted prime CAR-T cells in multiple myeloma, run by Chongqing Precision Biotech Co., Ltd, now recruiting.","route":"/trials/nct04776330/","status":"recruiting","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT04776330","facets":{"kind":["Trial"],"cancers":["Multiple myeloma","Relapsed or refractory multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."},{"label":"Relapsed or refractory multiple myeloma","href":"/cancers/myeloma-relapsed-refractory/","tip":"Myeloma almost always returns, and each return is harder to treat. Two kinds of immune therapy aimed at the BCMA protein on myeloma cells, CAR-T cells (KarMMa-3, CARTITUDE-4) and off-the-shelf bispecific antibodies (MajesTEC), now give deep remissions after other drugs fail, and a second target, GPRC5D, gives another option."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06341114","name":"A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of BAT8008 injection in advanced solid tumours, run by Bio-Thera Solutions, active and no longer recruiting.","route":"/trials/nct06341114/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06341114","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06492005","name":"A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer","tldr":"A phase 2 trial of 9MW2821 in triple-negative breast cancer, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.","route":"/trials/nct06492005/","status":"recruiting","kind":"trial","cancerIcon":"tnbc","sub":"NCT06492005","facets":{"kind":["Trial"],"cancers":["Triple-negative breast cancer","Metastatic triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Metastatic triple-negative breast cancer","href":"/cancers/tnbc-metastatic/","tip":"Triple-negative breast cancer that has spread is not curable, but its treatment has been transformed since 2020. By PD-L1 score, first treatment is pembrolizumab with chemotherapy or with sacituzumab govitecan, or datopotamab deruxtecan or sacituzumab govitecan alone; BRCA carriers can take a PARP inhibitor tablet; and trastuzumab deruxtecan reaches the third of tumours with low HER2."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06922383","name":"A Clinical Study of Arfolitixorin in Patients With mCRC","tldr":"A phase 1/2 trial of Arfolitixorin in colorectal cancer, run by Isofol Medical AB, now recruiting.","route":"/trials/nct06922383/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT06922383","facets":{"kind":["Trial"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07209111","name":"A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)","tldr":"A phase 2 trial of Calderasib and Cetuximab in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting.","route":"/trials/nct07209111/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07209111","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06296706","name":"A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer","tldr":"A phase 3 trial of Docetaxel in gastric & gastro-oesophageal junction cancer, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., now recruiting.","route":"/trials/nct06296706/","status":"recruiting","kind":"trial","cancerIcon":"gastric","sub":"NCT06296706","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06974929","name":"A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer","tldr":"A phase 1/2 trial of HRS-6209 Capsules in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.","route":"/trials/nct06974929/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06974929","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07446153","name":"A Clinical Study of HRS-8364 in the Treatment of Advanced Solid Tumor Subjects","tldr":"A phase 1/2 trial of HRS-8364 Tablet in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.","route":"/trials/nct07446153/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07446153","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05923008","name":"A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors","tldr":"A phase 1/2 trial of IBI130 in advanced solid tumours, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.","route":"/trials/nct05923008/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05923008","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06863272","name":"A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)","tldr":"A phase 1/2 trial of Docetaxel, Ifinatamab deruxtecan, Opevesostat and Enzalutamide in prostate cancer, run by Merck Sharp & Dohme LLC, now recruiting.","route":"/trials/nct06863272/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT06863272","facets":{"kind":["Trial"],"cancers":["Prostate cancer","Metastatic castration-resistant prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Metastatic castration-resistant prostate cancer","href":"/cancers/prostate-mcrpc/","tip":"Metastatic castration-resistant prostate cancer is disease that grows despite castrate testosterone. Sequenced treatments now include androgen receptor inhibitors, docetaxel and cabazitaxel, PARP inhibitors for men with BRCA-type mutations, the radioligand 177Lu-PSMA-617 and radium-223 for bone-predominant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06833073","name":"A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)","tldr":"A phase 2 trial of Intismeran autogene in bladder & urothelial cancer, run by Merck Sharp & Dohme LLC, now recruiting.","route":"/trials/nct06833073/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT06833073","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Non-muscle-invasive bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Non-muscle-invasive bladder cancer","href":"/cancers/non-muscle-invasive-bladder-cancer/","tip":"Most bladder cancers are found while still confined to the lining. They are scraped out through the urethra and, when higher risk, treated with BCG instilled into the bladder; the challenge is the frequent recurrences and the patients whose tumours stop responding to BCG."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06305767","name":"A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)","tldr":"A phase 1/2 trial of Pembrolizumab, Intismeran autogene and Enfortumab vedotin in bladder & urothelial cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","route":"/trials/nct06305767/","status":"active","kind":"trial","cancerIcon":"urothelial","sub":"NCT06305767","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07446387","name":"A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer","tldr":"A phase 2 trial of Iparomlimab and tuvonralimab in Colorectal cancer, run by Jiangsu Cancer Institute & Hospital, not yet recruiting.","route":"/trials/nct07446387/","status":"planned","kind":"trial","cancerIcon":"colorectal","sub":"NCT07446387","facets":{"kind":["Trial"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06208410","name":"A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors","tldr":"A phase 1/2 trial of JS105, Fulvestrant, Dalpiciclib, Toripalimab, Pyrotinib and Capecitabine in advanced solid tumours, run by Risen (Suzhou) Pharma Tech Co., Ltd., now recruiting.","route":"/trials/nct06208410/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06208410","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06398444","name":"A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms","tldr":"A phase 2/3 trial of Lutetium[177Lu] Oxodotreotide Injection in neuroendocrine tumours, run by Sinotau Pharmaceutical Group, now recruiting.","route":"/trials/nct06398444/","status":"recruiting","kind":"trial","cancerIcon":"neuroendocrine","sub":"NCT06398444","facets":{"kind":["Trial"],"cancers":["Neuroendocrine tumours"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Neuroendocrine tumours","href":"/cancers/neuroendocrine/","tip":"A family of usually slow-growing tumours that start in hormone-producing cells of the gut, pancreas and lungs. They pioneered the idea of using the same molecule to see a tumour on a scan and then to treat it with radiation."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05579132","name":"A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)","tldr":"A phase 1/2 trial of MK-1045 in acute lymphoblastic leukaemia, run by MSD R&D (China) Co., Ltd., now recruiting.","route":"/trials/nct05579132/","status":"recruiting","kind":"trial","cancerIcon":"all-leukemia","sub":"NCT05579132","facets":{"kind":["Trial"],"cancers":["Acute lymphoblastic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07286149","name":"A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)","tldr":"A phase 1/2 trial of Calderasib, Patritumab deruxtecan, Sacituzumab tirumotecan and Cetuximab in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting.","route":"/trials/nct07286149/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07286149","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07222488","name":"A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)","tldr":"A phase 1/2 trial of MK-3120 in bladder & urothelial cancer, run by Merck Sharp & Dohme LLC, now recruiting.","route":"/trials/nct07222488/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT07222488","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Non-muscle-invasive bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Non-muscle-invasive bladder cancer","href":"/cancers/non-muscle-invasive-bladder-cancer/","tip":"Most bladder cancers are found while still confined to the lining. They are scraped out through the urethra and, when higher risk, treated with BCG instilled into the bladder; the challenge is the frequent recurrences and the patients whose tumours stop responding to BCG."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07060807","name":"A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)","tldr":"A phase 3 trial of Patritumab deruxtecan, Capecitabine, Doxorubicin and Trastuzumab deruxtecan in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting.","route":"/trials/nct07060807/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07060807","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06431243","name":"A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of Purinostat in advanced solid tumours, run by Chengdu Zenitar Biomedical Technology Co., Ltd, now recruiting.","route":"/trials/nct06431243/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06431243","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06637423","name":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)","tldr":"A phase 1/2 trial of Sacituzumab tirumotecan in bladder & urothelial cancer, run by Merck Sharp & Dohme LLC, now recruiting.","route":"/trials/nct06637423/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT06637423","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Non-muscle-invasive bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Non-muscle-invasive bladder cancer","href":"/cancers/non-muscle-invasive-bladder-cancer/","tip":"Most bladder cancers are found while still confined to the lining. They are scraped out through the urethra and, when higher risk, treated with BCG instilled into the bladder; the challenge is the frequent recurrences and the patients whose tumours stop responding to BCG."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06966700","name":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","tldr":"A phase 3 trial of Sacituzumab tirumotecan, Pembrolizumab, Carboplatin, Doxorubicin, Epirubicin and Cyclophosphamide in triple-negative breast cancer, run by Merck Sharp & Dohme LLC, now recruiting.","route":"/trials/nct06966700/","status":"recruiting","kind":"trial","cancerIcon":"tnbc","sub":"NCT06966700","facets":{"kind":["Trial"],"cancers":["Triple-negative breast cancer","Early triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Early triple-negative breast cancer","href":"/cancers/tnbc-early/","tip":"Early triple-negative breast cancer is treated to cure. For tumours over 2 cm or with node involvement, chemotherapy plus the immunotherapy pembrolizumab before and after surgery has raised cure rates; BRCA carriers with cancer left at surgery add a year of olaparib, and others with residual cancer are offered capecitabine. Whether the tumour has vanished by surgery guides what comes next."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06643754","name":"A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant Tumors","tldr":"A phase 1/2 trial of SHR-3276 in advanced solid tumours, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.","route":"/trials/nct06643754/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06643754","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06778031","name":"A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer","tldr":"A phase 2 trial of Trastuzumab rezetecan, Adebrelimab and SHR-8068 in biliary tract cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.","route":"/trials/nct06778031/","status":"recruiting","kind":"trial","cancerIcon":"cholangiocarcinoma","sub":"NCT06778031","facets":{"kind":["Trial"],"cancers":["Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06434597","name":"A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.","tldr":"A phase 2 trial of SPH5030 in colorectal cancer, run by Shanghai Pharmaceuticals Holding Co., Ltd, now recruiting.","route":"/trials/nct06434597/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT06434597","facets":{"kind":["Trial"],"cancers":["Colorectal cancer","HER2-amplified colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"HER2-amplified colorectal cancer","href":"/cancers/her2-amplified-colorectal/","tip":"A few bowel cancers make too much of the HER2 protein, the same target as in HER2-positive breast cancer. Two HER2 drugs together, tucatinib and trastuzumab, shrink about four in ten of these tumours after chemotherapy has failed, and the antibody-drug conjugate trastuzumab deruxtecan works even when other HER2 drugs have stopped."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07597629","name":"A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer","tldr":"A phase 2 trial of SYS6023 and KN026 in advanced solid tumours, run by CSPC Megalith Biopharmaceutical Co.,Ltd., now recruiting.","route":"/trials/nct07597629/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07597629","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06214143","name":"A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors","tldr":"A phase 1/2 trial of T3011 high dose in advanced solid tumours, run by Shanghai Pharmaceuticals Holding Co., Ltd, now recruiting.","route":"/trials/nct06214143/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06214143","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06459973","name":"A Clinical Study of YL205 in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of intravenous (IV) infusion in advanced solid tumours, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.","route":"/trials/nct06459973/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06459973","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06890884","name":"A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)","tldr":"A phase 2 trial of Zilovertamab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone and Polatuzumab vedotin in diffuse large B-cell lymphoma, run by Merck Sharp & Dohme LLC, now recruiting.","route":"/trials/nct06890884/","status":"recruiting","kind":"trial","cancerIcon":"dlbcl","sub":"NCT06890884","facets":{"kind":["Trial"],"cancers":["Diffuse large B-cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06962267","name":"A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)","tldr":"A phase 2 trial of TQB2916 Injection in pancreatic ductal adenocarcinoma, run by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct06962267/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT06962267","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07672236","name":"A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.","tldr":"A phase 3 trial of BupiZenge 25 mg in advanced solid tumours, run by OncoZenge AB, now recruiting.","route":"/trials/nct07672236/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07672236","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05787613","name":"A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients","tldr":"A phase 2 trial of HLX26 and Serplulimab in non-small-cell lung cancer, run by Shanghai Henlius Biotech, active and no longer recruiting.","route":"/trials/nct05787613/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT05787613","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06566586","name":"A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma","tldr":"A phase 2 trial of TQB3702 tablets+Chemotherapy regimen in non-Hodgkin lymphoma, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting.","route":"/trials/nct06566586/","status":"recruiting","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT06566586","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07222969","name":"A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of VIB305 for Injection in advanced solid tumours, run by Vibrant Sciences Limited, now recruiting.","route":"/trials/nct07222969/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07222969","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06827236","name":"A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer","tldr":"A phase 1/2 trial of Trastuzumab pamirtecan and PM8002 in advanced solid tumours, run by BioNTech SE, now recruiting.","route":"/trials/nct06827236/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06827236","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06892548","name":"A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer","tldr":"A phase 1/2 trial of BNT324 and PM8002 in advanced solid tumours, run by BioNTech SE, now recruiting.","route":"/trials/nct06892548/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06892548","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05755113","name":"A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma","tldr":"A phase 2 trial of Tigilanol Tiglate in sarcomas, run by QBiotics Group Limited, now recruiting.","route":"/trials/nct05755113/","status":"recruiting","kind":"trial","cancerIcon":"sarcoma","sub":"NCT05755113","facets":{"kind":["Trial"],"cancers":["Sarcomas","Soft tissue sarcoma of the extremity"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Sarcomas","href":"/cancers/sarcoma/","tip":"Sarcomas are dozens of rare cancers of bone and connective tissue. GIST was the first solid tumour cured-in-practice by a targeted pill; synovial sarcoma got the first TCR-T therapy."},{"label":"Soft tissue sarcoma of the extremity","href":"/cancers/extremity-soft-tissue-sarcoma/","tip":"Most soft tissue sarcomas arise in an arm or leg. Limb-saving surgery with radiotherapy cures most localised tumours and is as safe as amputation. For spread disease doxorubicin is the backbone: adding ifosfamide shrinks more tumours without lengthening life, and in leiomyosarcoma adding trabectedin doubles the time the disease stays controlled."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05608876","name":"A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer","tldr":"A phase 2 trial of Tigilanol Tiglate in head and neck squamous cell carcinoma, run by QBiotics Group Limited, active and no longer recruiting.","route":"/trials/nct05608876/","status":"active","kind":"trial","cancerIcon":"head-and-neck","sub":"NCT05608876","facets":{"kind":["Trial"],"cancers":["Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07070232","name":"A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors","tldr":"A phase 1/2 trial of PM8002 in advanced solid tumours, run by BioNTech SE, now recruiting.","route":"/trials/nct07070232/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07070232","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04183166","name":"A Clinical Trial Evaluating TG4050 in Head and Neck Cancer","tldr":"A phase 1/2 trial of TG4050 in head and neck squamous cell carcinoma, run by Transgene, active and no longer recruiting.","route":"/trials/nct04183166/","status":"active","kind":"trial","cancerIcon":"head-and-neck","sub":"NCT04183166","facets":{"kind":["Trial"],"cancers":["Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05890742","name":"A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer","tldr":"A phase 3 trial of Sintilimab in colorectal cancer, run by Innovent Biologics (Suzhou) Co. Ltd., active and no longer recruiting.","route":"/trials/nct05890742/","status":"active","kind":"trial","cancerIcon":"colorectal","sub":"NCT05890742","facets":{"kind":["Trial"],"cancers":["Colorectal cancer","Mismatch-repair deficient (MSI-high) colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Mismatch-repair deficient (MSI-high) colorectal cancer","href":"/cancers/msi-high-colorectal/","tip":"Mismatch-repair deficient bowel cancer has lost its DNA spell-checker, so it carries thousands of mutations that the immune system can recognise. Immunotherapy alone controls most metastatic cases for years and makes most localised tumours disappear before surgery, sometimes so completely that no surgery is needed."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07258407","name":"A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer","tldr":"A phase 1/2 trial of TD001 in prostate cancer, run by T.O.A.D. Oncology SA, now recruiting.","route":"/trials/nct07258407/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT07258407","facets":{"kind":["Trial"],"cancers":["Prostate cancer","Metastatic castration-resistant prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Metastatic castration-resistant prostate cancer","href":"/cancers/prostate-mcrpc/","tip":"Metastatic castration-resistant prostate cancer is disease that grows despite castrate testosterone. Sequenced treatments now include androgen receptor inhibitors, docetaxel and cabazitaxel, PARP inhibitors for men with BRCA-type mutations, the radioligand 177Lu-PSMA-617 and radium-223 for bone-predominant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03274414","name":"A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal Passages","tldr":"A phase 2 trial of Endoscopic resection in Nasal cavity and paranasal sinus cancers, run by Memorial Sloan Kettering Cancer Center, completed.","route":"/trials/nct03274414/","status":"completed","kind":"trial","cancerIcon":"sinonasal","sub":"NCT03274414","facets":{"kind":["Trial"],"cancers":["Nasal cavity and paranasal sinus cancers"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Nasal cavity and paranasal sinus cancers","href":"/cancers/sinonasal/","tip":"Cancers of the nose and sinuses are a mixed group, from squamous carcinoma to the nerve-derived esthesioneuroblastoma and the aggressive undifferentiated carcinoma SNUC. Surgery through the nose with an endoscope followed by precise radiotherapy has replaced disfiguring open operations, and giving chemotherapy first to see who responds now guides how SNUC is treated."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07032077","name":"A Clinical Trial of HRS-7058 Combined Anti-tumor Drugs in Subjects With Solid Tumors","tldr":"A phase 2 trial of HRS-7058 in advanced solid tumours, run by Shandong Suncadia Medicine Co., Ltd., now recruiting.","route":"/trials/nct07032077/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07032077","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07405151","name":"A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)","tldr":"A phase 1/2 trial of I-DXd in oesophageal cancer, run by Merck Sharp & Dohme LLC, now recruiting.","route":"/trials/nct07405151/","status":"recruiting","kind":"trial","cancerIcon":"esophageal","sub":"NCT07405151","facets":{"kind":["Trial"],"cancers":["Oesophageal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06783647","name":"A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]","tldr":"A phase 2 trial of Docetaxel, Bevacizumab, Pemetrexed and Carboplatin in advanced solid tumours, run by Nanjing Leads Biolabs Co.,Ltd, now recruiting.","route":"/trials/nct06783647/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06783647","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07111546","name":"A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]","tldr":"A phase 2 trial of Cisplatin, Gemcitabine and Bevacizumab in advanced solid tumours, run by Nanjing Leads Biolabs Co.,Ltd, now recruiting.","route":"/trials/nct07111546/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07111546","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06049290","name":"A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma","tldr":"A phase 1/2 trial of LBL-034 for Injection in multiple myeloma, run by Nanjing Leads Biolabs Co.,Ltd, now recruiting.","route":"/trials/nct06049290/","status":"recruiting","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT06049290","facets":{"kind":["Trial"],"cancers":["Multiple myeloma","Relapsed or refractory multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."},{"label":"Relapsed or refractory multiple myeloma","href":"/cancers/myeloma-relapsed-refractory/","tip":"Myeloma almost always returns, and each return is harder to treat. Two kinds of immune therapy aimed at the BCMA protein on myeloma cells, CAR-T cells (KarMMa-3, CARTITUDE-4) and off-the-shelf bispecific antibodies (MajesTEC), now give deep remissions after other drugs fail, and a second target, GPRC5D, gives another option."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07419295","name":"A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)","tldr":"A phase 3 trial of Sacituzumab tirumotecan, Vinflunine and Docetaxel in bladder & urothelial cancer, run by Merck Sharp & Dohme LLC, now recruiting.","route":"/trials/nct07419295/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT07419295","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07111832","name":"A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer","tldr":"A phase 3 trial of Trastuzumab rezetecan, Adebrelimab and Toripalimab in triple-negative breast cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.","route":"/trials/nct07111832/","status":"recruiting","kind":"trial","cancerIcon":"tnbc","sub":"NCT07111832","facets":{"kind":["Trial"],"cancers":["Triple-negative breast cancer","Metastatic triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Metastatic triple-negative breast cancer","href":"/cancers/tnbc-metastatic/","tip":"Triple-negative breast cancer that has spread is not curable, but its treatment has been transformed since 2020. By PD-L1 score, first treatment is pembrolizumab with chemotherapy or with sacituzumab govitecan, or datopotamab deruxtecan or sacituzumab govitecan alone; BRCA carriers can take a PARP inhibitor tablet; and trastuzumab deruxtecan reaches the third of tumours with low HER2."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07011186","name":"A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies","tldr":"A phase 1/2 trial of Azacitidine in advanced solid tumours, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting.","route":"/trials/nct07011186/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07011186","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07367529","name":"A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection","tldr":"A phase 1/2 trial of TQB6411 in advanced solid tumours, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting.","route":"/trials/nct07367529/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07367529","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07297212","name":"A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma","tldr":"A phase 2 trial of PM8002, Bevacizumab and Temozolomide in glioma & glioblastoma, run by BioNTech SE, now recruiting.","route":"/trials/nct07297212/","status":"recruiting","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT07297212","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06223841","name":"A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors","tldr":"A phase 1/2 trial of IAP0971 in advanced solid tumours, run by SUNHO（China）BioPharmaceutical CO., Ltd., now recruiting.","route":"/trials/nct06223841/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06223841","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06581419","name":"A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors","tldr":"A phase 1/2 trial of IAP0971 in non-small-cell lung cancer, run by SUNHO（China）BioPharmaceutical CO., Ltd., now recruiting.","route":"/trials/nct06581419/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06581419","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05991583","name":"A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors","tldr":"A phase 1/2 trial of IBB0979 in advanced solid tumours, run by SUNHO（China）BioPharmaceutical CO., Ltd., now recruiting.","route":"/trials/nct05991583/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05991583","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06292208","name":"A Clinical Trial to Evaluate Effect of IBD0333 in Patients With Advanced Malignant Tumors","tldr":"A phase 1/2 trial of IBD0333 in advanced solid tumours, run by SUNHO（China）BioPharmaceutical CO., Ltd., now recruiting.","route":"/trials/nct06292208/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06292208","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07582432","name":"A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma","tldr":"A phase 3 trial of Gamunex-C, 10% Injectable Solution in non-Hodgkin lymphoma, run by Grifols Biologicals, LLC, now recruiting.","route":"/trials/nct07582432/","status":"recruiting","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT07582432","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06888921","name":"A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer","tldr":"A phase 1/2 trial of COM701 in ovarian cancer, run by Compugen Ltd, now recruiting.","route":"/trials/nct06888921/","status":"recruiting","kind":"trial","cancerIcon":"ovarian","sub":"NCT06888921","facets":{"kind":["Trial"],"cancers":["Ovarian cancer","Platinum-sensitive ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Platinum-sensitive ovarian cancer","href":"/cancers/platinum-sensitive-ovarian-cancer/","tip":"Platinum-sensitive ovarian cancer is disease that responded to carboplatin and either has not relapsed or relapses more than six months after the last dose. It is treated with further platinum chemotherapy, sometimes repeat surgery, and above all with maintenance PARP inhibitors, which keep BRCA-mutant tumours away for years and have raised long-term survival."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07186842","name":"A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9","tldr":"A phase 1/2 trial of BNT329 in advanced solid tumours, run by BioNTech SE, now recruiting.","route":"/trials/nct07186842/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07186842","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06835530","name":"A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)","tldr":"A phase 2 trial of Geriatric assessment in Non-Hodgkin lymphoma, run by Fondazione Italiana Linfomi - ETS, now recruiting.","route":"/trials/nct06835530/","status":"recruiting","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT06835530","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04711252","name":"A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease","tldr":"A phase 3 trial of Camizestrant and Palbociclib in HR-positive / HER2-negative breast cancer, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct04711252/","status":"active","kind":"trial","cancerIcon":"breast-hr-positive","sub":"NCT04711252","facets":{"kind":["Trial"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03602859","name":"A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer","tldr":"A phase 3 trial of Niraparib and Dostarlimab in ovarian cancer, run by Tesaro, Inc., active and no longer recruiting.","route":"/trials/nct03602859/","status":"active","kind":"trial","cancerIcon":"ovarian","sub":"NCT03602859","facets":{"kind":["Trial"],"cancers":["Ovarian cancer"],"year":["2025"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"year":{"facet":"year","value":"2025"},"tags":[]},"sortKeys":{"year":2025}},{"id":"nct06184035","name":"A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer","tldr":"A phase 1/2 trial of [177Lu]Lu-SN201 in advanced solid tumours, run by Spago Nanomedical AB, now recruiting.","route":"/trials/nct06184035/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06184035","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07692204","name":"A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer","tldr":"A phase 2 trial of SAR445877 in gastric & gastro-oesophageal junction cancer and oesophageal cancer, run by Sanofi, now recruiting.","route":"/trials/nct07692204/","status":"recruiting","kind":"trial","cancerIcon":"gastric","sub":"NCT07692204","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer","Oesophageal cancer","Oesophageal and junctional adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."},{"label":"Oesophageal and junctional adenocarcinoma","href":"/cancers/oesophageal-adenocarcinoma/","tip":"Adenocarcinoma of the lower oesophagus and junction grows out of Barrett's oesophagus, the change in the lining caused by long-standing acid reflux. Chemotherapy or chemoradiation before surgery is standard, and HER2, PD-L1 and claudin 18.2 now guide drugs for advanced disease as they do in stomach cancer."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07231068","name":"A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation","tldr":"A phase 1/2 trial of Dositinib mesylate tablets in non-small-cell lung cancer, run by Henan Genuine Biotech Co., Ltd., now recruiting.","route":"/trials/nct07231068/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07231068","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05736406","name":"A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma","tldr":"A phase 1/2 trial of Aminolevulinic acid (topical, for photodynamic therapy) in glioma & glioblastoma, run by Hemerion Therapeutics, active and no longer recruiting.","route":"/trials/nct05736406/","status":"active","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT05736406","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02441309","name":"A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS)","tldr":"A phase 2 trial of Mifamurtide and Ifosfamide in Osteosarcoma, run by University of Oxford, recorded as terminated on the registry.","route":"/trials/nct02441309/","kind":"trial","cancerIcon":"osteosarcoma","sub":"NCT02441309","facets":{"kind":["Trial"],"cancers":["Osteosarcoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Osteosarcoma","href":"/cancers/osteosarcoma/","tip":"Osteosarcoma is the most common bone cancer, mostly in teenagers. Chemotherapy plus surgery cures about two-thirds when it has not spread; because no new drug has beaten that chemotherapy in a large trial in 30 years, the next gains are being sought in cellular therapy against GD2, HER2 and B7-H3."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07354711","name":"A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors","tldr":"A phase 1/2 trial of 3H-10000 in gastric & gastro-oesophageal junction cancer, run by 3H Pharmaceuticals Co., Ltd., now recruiting.","route":"/trials/nct07354711/","status":"recruiting","kind":"trial","cancerIcon":"gastric","sub":"NCT07354711","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07439094","name":"A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer","tldr":"A phase 1/2 trial of CKD-703 in non-small-cell lung cancer, run by Chong Kun Dang Pharmaceutical, now recruiting.","route":"/trials/nct07439094/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07439094","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","MET exon 14 and MET-amplified non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"MET exon 14 and MET-amplified non-small-cell lung cancer","href":"/cancers/met-altered-nsclc/","tip":"MET-driven lung cancer comes in three forms: an exon 14 skipping mutation treated with the pills capmatinib or tepotinib, MET amplification that often arises as an escape route from EGFR drugs, and high c-Met protein levels that the antibody-drug conjugate telisotuzumab vedotin targets."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05589896","name":"A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies","tldr":"A phase 1/2 trial of an investigational treatment in acute lymphoblastic leukaemia, acute myeloid leukaemia, chronic lymphocytic leukaemia, chronic myeloid leukaemia, myelodysplastic syndromes / neoplasms and hodgkin lymphoma, run by Ossium Health, Inc., active and no longer recruiting.","route":"/trials/nct05589896/","status":"active","kind":"trial","cancerIcon":"all-leukemia","sub":"NCT05589896","facets":{"kind":["Trial"],"cancers":["Acute lymphoblastic leukaemia","Acute myeloid leukaemia","Chronic lymphocytic leukaemia","Chronic myeloid leukaemia","Myelodysplastic syndromes / neoplasms","Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."},{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Chronic myeloid leukaemia","href":"/cancers/cml/","tip":"Chronic myeloid leukaemia is a blood cancer driven by a single fused gene, BCR-ABL1, and the model for oncogene-targeted treatment: imatinib in 2001 and the tyrosine kinase inhibitors that followed turned it into a condition most people live with long-term. About half of patients with a sustained deep molecular response can now stop treatment altogether."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05636215","name":"A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors","tldr":"A phase 1/2 trial of IBI354 in advanced solid tumours, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.","route":"/trials/nct05636215/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05636215","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06253130","name":"A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors","tldr":"A phase 1/2 trial of IMP1734 in advanced solid tumours, run by Eikon Therapeutics, now recruiting.","route":"/trials/nct06253130/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06253130","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06921837","name":"A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer","tldr":"A phase 1/2 trial of BDC-4182 in gastric & gastro-oesophageal junction cancer and oesophageal cancer, run by Bolt Biotherapeutics, Inc., now recruiting.","route":"/trials/nct06921837/","status":"recruiting","kind":"trial","cancerIcon":"gastric","sub":"NCT06921837","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer","Oesophageal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07629960","name":"A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations","tldr":"A phase 1/2 trial of BLU-924 in non-small-cell lung cancer, colorectal cancer and pancreatic ductal adenocarcinoma, run by Blueprint Medicines Corporation, now recruiting.","route":"/trials/nct07629960/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07629960","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","Colorectal cancer","Pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07220616","name":"A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies","tldr":"A phase 1/2 trial of DS3790a in non-Hodgkin lymphoma, run by Daiichi Sankyo, now recruiting.","route":"/trials/nct07220616/","status":"recruiting","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT07220616","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05908643","name":"A First-In-Human Trial of pTTL in Advanced Colorectal Cancer","tldr":"A phase 1/2 trial of pTTL in colorectal cancer, run by Neogap Therapeutics AB, now recruiting.","route":"/trials/nct05908643/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT05908643","facets":{"kind":["Trial"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05584670","name":"A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors","tldr":"A phase 1/2 trial of Cetuximab, ADG126, Bevacizumab, Nivolumab and Ipilimumab in advanced solid tumours, run by Sanofi, now recruiting.","route":"/trials/nct05584670/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05584670","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07147348","name":"A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors","tldr":"A phase 1/2 trial of PM8002 in advanced solid tumours, run by BioNTech SE, now recruiting.","route":"/trials/nct07147348/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07147348","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04686682","name":"A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors","tldr":"A phase 1/2 trial of JAB-8263 in non-small-cell lung cancer, small-cell lung cancer and ovarian cancer, run by Jacobio Pharmaceuticals Co., Ltd., now recruiting.","route":"/trials/nct04686682/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT04686682","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","Small-cell lung cancer","Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."},{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05731271","name":"A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors","tldr":"A phase 1/2 trial of TST003 in colorectal cancer, run by Transcenta Therapeutics (Hangzhou) Co., Ltd., active and no longer recruiting.","route":"/trials/nct05731271/","status":"active","kind":"trial","cancerIcon":"colorectal","sub":"NCT05731271","facets":{"kind":["Trial"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06277219","name":"A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)","tldr":"A phase 1/2 trial of LAT010 in advanced solid tumours, run by Latticon Antibody Therapeutics, Inc, now recruiting.","route":"/trials/nct06277219/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06277219","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06868277","name":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer","tldr":"A phase 3 trial of Rilvegostomig and Pembrolizumab in non-small-cell lung cancer, run by AstraZeneca, now recruiting.","route":"/trials/nct06868277/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06868277","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","PD-L1-high non-small-cell lung cancer without a driver mutation"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"PD-L1-high non-small-cell lung cancer without a driver mutation","href":"/cancers/pdl1-high-nsclc/","tip":"Lung cancers that carry a lot of PD-L1 and no targetable mutation can be treated with an immunotherapy antibody alone instead of chemotherapy. Pembrolizumab keeps about a third of patients alive at five years, roughly double what chemotherapy achieved, and adding chemotherapy is reserved for those who need a fast response."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03591510","name":"A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML","tldr":"A phase 2 trial of Midostaurin, Fludarabine, Cytarabine, Daunorubicin, Idarubicin and Mitoxantrone in acute myeloid leukaemia, run by Novartis Pharmaceuticals, active and no longer recruiting.","route":"/trials/nct03591510/","status":"active","kind":"trial","cancerIcon":"aml","sub":"NCT03591510","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia","Acute myeloid leukaemia in children"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Acute myeloid leukaemia in children","href":"/cancers/aml-paediatric/","tip":"Acute myeloid leukaemia in children carries gene fusions rather than the mutations of ageing, is treated with four or five intensive courses of chemotherapy, and cures around two thirds of children. Adding gemtuzumab ozogamicin lowered relapse in the AAML0531 trial, and the menin inhibitor revumenib is the first targeted drug approved for the KMT2A-rearranged form common in young children."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07105215","name":"A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors","tldr":"A phase 1/2 trial of RC278 in advanced solid tumours, run by RemeGen Co., Ltd., now recruiting.","route":"/trials/nct07105215/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07105215","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07229638","name":"A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors","tldr":"A phase 1/2 trial of SHR-9839(sc) For Injection in advanced solid tumours, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.","route":"/trials/nct07229638/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07229638","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05934331","name":"A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study","tldr":"A phase 2 trial of LM-302, Toripalimab, Capecitabine, Nivolumab, Rivoceranib (apatinib) and Gemcitabine in advanced solid tumours, run by LaNova Medicines Zhejiang Co., Ltd., now recruiting.","route":"/trials/nct05934331/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05934331","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04641247","name":"A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study","tldr":"A phase 2 trial of Niraparib in ovarian cancer, run by GlaxoSmithKline, now recruiting.","route":"/trials/nct04641247/","status":"recruiting","kind":"trial","cancerIcon":"ovarian","sub":"NCT04641247","facets":{"kind":["Trial"],"cancers":["Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05999994","name":"A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer","tldr":"A phase 2 trial of Ramucirumab, Cyclophosphamide, Vinorelbine, Gemcitabine, Docetaxel and Abemaciclib in advanced solid tumours, run by Eli Lilly and Company, now recruiting.","route":"/trials/nct05999994/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05999994","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06630234","name":"A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)","tldr":"A phase 1/2 trial of DCC-3009 in gastrointestinal stromal tumour, run by Deciphera Pharmaceuticals, LLC, now recruiting.","route":"/trials/nct06630234/","status":"recruiting","kind":"trial","cancerIcon":"gist","sub":"NCT06630234","facets":{"kind":["Trial"],"cancers":["Gastrointestinal stromal tumour"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastrointestinal stromal tumour","href":"/cancers/gist/","tip":"GIST is a sarcoma of the gut wall driven almost always by a KIT or PDGFRA mutation. It was the proof that a pill can control a solid tumour: imatinib turned a median survival of about a year into one of eight years or more, and the mutation now dictates which drug to use."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06600789","name":"A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies","tldr":"A phase 1/2 trial of CT7439 Capsules (0.5 mg, 1mg, 3mg, 10mg, 15mg, 20mg) in advanced solid tumours, run by Carrick Therapeutics Limited, now recruiting.","route":"/trials/nct06600789/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06600789","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03934567","name":"A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma","tldr":"A phase 2 trial of Abexinostat in non-Hodgkin lymphoma, run by Xynomic Pharmaceuticals, Inc., active and no longer recruiting.","route":"/trials/nct03934567/","status":"active","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT03934567","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma","Follicular lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."},{"label":"Follicular lymphoma","href":"/cancers/follicular-lymphoma/","tip":"Follicular lymphoma is the most common slow-growing lymphoma, defined in about 85% of cases by a BCL2 translocation. Most people live with it for decades, treated only when it causes problems; it can be controlled repeatedly with anti-CD20 antibodies, chemotherapy, bispecifics or CAR-T but rarely cured, and a small share transform into an aggressive lymphoma each year."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04256317","name":"A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)","tldr":"A phase 2/3 trial of Azacitidine and Venetoclax in myelodysplastic syndromes / neoplasms, acute myeloid leukaemia and chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, run by Taiho Oncology, Inc., now recruiting.","route":"/trials/nct04256317/","status":"recruiting","kind":"trial","cancerIcon":"mds","sub":"NCT04256317","facets":{"kind":["Trial"],"cancers":["Myelodysplastic syndromes / neoplasms","Acute myeloid leukaemia","Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Myelodysplastic syndromes / neoplasms","href":"/cancers/mds/","tip":"Bone-marrow disorders where blood cells are made badly and too few reach the blood; a third progress to acute leukaemia. Treatment ranges from transfusions and growth factors to hypomethylating drugs and, for the fit, transplant."},{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms","href":"/cancers/cmml/","tip":"Chronic myelomonocytic leukaemia and its relatives are bone-marrow cancers that behave partly like myelodysplasia (poorly made blood cells) and partly like a proliferative disease (an excess of monocytes or platelets). Hypomethylating agents produce responses in a minority and stabilise counts in more, transplant can cure the fit, and RAS-pathway and JAK inhibitors are in trials."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06376136","name":"A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors","tldr":"A phase 1/2 trial of BAT8010 for Injection in advanced solid tumours, run by Bio-Thera Solutions, now recruiting.","route":"/trials/nct06376136/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06376136","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06936644","name":"A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation","tldr":"A phase 2 trial of Fulzerasib and Ivonescimab in KRAS G12C-mutant non-small-cell lung cancer, run by Shanghai Chest Hospital, not yet recruiting.","route":"/trials/nct06936644/","status":"planned","kind":"trial","cancerIcon":"kras-g12c-nsclc","sub":"NCT06936644","facets":{"kind":["Trial"],"cancers":["KRAS G12C-mutant non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"KRAS G12C-mutant non-small-cell lung cancer","href":"/cancers/kras-g12c-nsclc/","tip":"KRAS G12C lung cancer carries a mutation that was thought impossible to drug for forty years. Sotorasib and adagrasib now shrink about four in ten tumours after chemotherapy and immunotherapy, though the benefit is measured in months, and newer inhibitors and first-line combinations with immunotherapy are in trials."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00295763","name":"A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen","tldr":"A phase 3 trial of Thyrotropin alfa in Thyroid cancer, run by Genzyme, a Sanofi Company, completed.","route":"/trials/nct00295763/","status":"completed","kind":"trial","cancerIcon":"thyroid","sub":"NCT00295763","facets":{"kind":["Trial"],"cancers":["Thyroid cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Thyroid cancer","href":"/cancers/thyroid/","tip":"Thyroid cancer is usually curable with surgery and radioactive iodine, the original theranostic. Rare aggressive forms respond to RET and BRAF inhibitors."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07636785","name":"A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors","tldr":"A phase 1/2 trial of VMD-102 in hepatocellular carcinoma, uveal melanoma, renal cell carcinoma, non-small-cell lung cancer and colorectal cancer, run by VM Discovery, Inc., now recruiting.","route":"/trials/nct07636785/","status":"recruiting","kind":"trial","cancerIcon":"hcc","sub":"NCT07636785","facets":{"kind":["Trial"],"cancers":["Hepatocellular carcinoma","Uveal melanoma","Renal cell carcinoma","Non-small-cell lung cancer","Colorectal cancer","Advanced hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."},{"label":"Uveal melanoma","href":"/cancers/uveal-melanoma/","tip":"A melanoma inside the eye that is biologically unrelated to skin melanoma: different mutations, no response to standard immunotherapy, and a tendency to spread to the liver years later. Tebentafusp is the first drug ever to extend survival in the metastatic disease."},{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07157033","name":"A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.","tldr":"A phase 1/2 trial of XER-001 in pancreatic ductal adenocarcinoma, run by Xerient Pharma, now recruiting.","route":"/trials/nct07157033/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT07157033","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Locally advanced unresectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06163430","name":"A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)","tldr":"A phase 1/2 trial of TERN-701 in chronic myeloid leukaemia, run by Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), now recruiting.","route":"/trials/nct06163430/","status":"recruiting","kind":"trial","cancerIcon":"cml","sub":"NCT06163430","facets":{"kind":["Trial"],"cancers":["Chronic myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic myeloid leukaemia","href":"/cancers/cml/","tip":"Chronic myeloid leukaemia is a blood cancer driven by a single fused gene, BCR-ABL1, and the model for oncogene-targeted treatment: imatinib in 2001 and the tyrosine kinase inhibitors that followed turned it into a condition most people live with long-term. About half of patients with a sustained deep molecular response can now stop treatment altogether."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05547061","name":"A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy","tldr":"A phase 1/2 trial of Lu-177-DGUL in prostate cancer, run by Cellbion Co., Ltd., active and no longer recruiting.","route":"/trials/nct05547061/","status":"active","kind":"trial","cancerIcon":"prostate","sub":"NCT05547061","facets":{"kind":["Trial"],"cancers":["Prostate cancer","Metastatic castration-resistant prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Metastatic castration-resistant prostate cancer","href":"/cancers/prostate-mcrpc/","tip":"Metastatic castration-resistant prostate cancer is disease that grows despite castrate testosterone. Sequenced treatments now include androgen receptor inhibitors, docetaxel and cabazitaxel, PARP inhibitors for men with BRCA-type mutations, the radioligand 177Lu-PSMA-617 and radium-223 for bone-predominant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06383052","name":"A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC","tldr":"A phase 1/2 trial of 177Lu-NYM032 injection in prostate cancer, run by Norroy Bioscience Co., LTD, active and no longer recruiting.","route":"/trials/nct06383052/","status":"active","kind":"trial","cancerIcon":"prostate","sub":"NCT06383052","facets":{"kind":["Trial"],"cancers":["Prostate cancer","Metastatic castration-resistant prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Metastatic castration-resistant prostate cancer","href":"/cancers/prostate-mcrpc/","tip":"Metastatic castration-resistant prostate cancer is disease that grows despite castrate testosterone. Sequenced treatments now include androgen receptor inhibitors, docetaxel and cabazitaxel, PARP inhibitors for men with BRCA-type mutations, the radioligand 177Lu-PSMA-617 and radium-223 for bone-predominant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06384807","name":"A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors","tldr":"A phase 1/2 trial of Cemiplimab in advanced solid tumours, run by Biohaven Therapeutics Ltd., now recruiting.","route":"/trials/nct06384807/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06384807","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05886920","name":"A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations","tldr":"A phase 1/2 trial of D3S-002 in advanced solid tumours, run by D3 Bio (Wuxi) Co., Ltd, now recruiting.","route":"/trials/nct05886920/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05886920","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07328217","name":"A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors","tldr":"A phase 1/2 trial of GW5282 in advanced solid tumours, run by Dizal Pharmaceuticals, now recruiting.","route":"/trials/nct07328217/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07328217","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05908409","name":"A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies","tldr":"A phase 1/2 trial of IDP-121 in multiple myeloma, diffuse large B-cell lymphoma, non-Hodgkin lymphoma and chronic lymphocytic leukaemia, run by IDP Discovery Pharma S.L., now recruiting.","route":"/trials/nct05908409/","status":"recruiting","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT05908409","facets":{"kind":["Trial"],"cancers":["Multiple myeloma","Diffuse large B-cell lymphoma","Non-Hodgkin lymphoma","Chronic lymphocytic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."},{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."},{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."},{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07629726","name":"A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms","tldr":"A phase 1/2 trial of KK2430 in advanced solid tumours, run by Kyowa Kirin Co., Ltd., now recruiting.","route":"/trials/nct07629726/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07629726","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06480240","name":"A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors","tldr":"A phase 1/2 trial of OBI-992 in advanced solid tumours, run by OBI Pharma, Inc, active and no longer recruiting.","route":"/trials/nct06480240/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06480240","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05463263","name":"A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas","tldr":"A phase 1/2 trial of STP938 in non-Hodgkin lymphoma, run by Step Pharma, SAS, now recruiting.","route":"/trials/nct05463263/","status":"recruiting","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT05463263","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma","Peripheral T-cell lymphomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."},{"label":"Peripheral T-cell lymphomas","href":"/cancers/peripheral-t-cell-lymphoma/","tip":"Peripheral T-cell lymphomas are lymphomas of T cells rather than B cells. They are rarer, more varied and, apart from a few subtypes, harder to treat than B-cell lymphomas; several new drugs help only defined subtypes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07185880","name":"A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients","tldr":"A phase 1/2 trial of MT-125 in glioma & glioblastoma, run by Myosin Therapeutics Inc., now recruiting.","route":"/trials/nct07185880/","status":"recruiting","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT07185880","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06055439","name":"A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy","tldr":"A phase 1/2 trial of CHM-2101 CAR-T cells in neuroendocrine tumours, colorectal cancer and gastric & gastro-oesophageal junction cancer, run by Chimeric Therapeutics, now recruiting.","route":"/trials/nct06055439/","status":"recruiting","kind":"trial","cancerIcon":"neuroendocrine","sub":"NCT06055439","facets":{"kind":["Trial"],"cancers":["Neuroendocrine tumours","Colorectal cancer","Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Neuroendocrine tumours","href":"/cancers/neuroendocrine/","tip":"A family of usually slow-growing tumours that start in hormone-producing cells of the gut, pancreas and lungs. They pioneered the idea of using the same molecule to see a tumour on a scan and then to treat it with radiation."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05394831","name":"A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC","tldr":"A phase 1/2 trial of JIN-A02 in non-small-cell lung cancer, run by J Ints Bio, now recruiting.","route":"/trials/nct05394831/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT05394831","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06265727","name":"A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors","tldr":"A phase 1/2 trial of CRB-701 in advanced solid tumours, run by Corbus Pharmaceuticals Inc., now recruiting.","route":"/trials/nct06265727/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06265727","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06725758","name":"A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours","tldr":"A phase 1/2 trial of ODM-212 in advanced solid tumours, run by Orion Corporation, Orion Pharma, now recruiting.","route":"/trials/nct06725758/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06725758","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06616766","name":"A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946","tldr":"A phase 1/2 trial of YH42946 in non-small-cell lung cancer, run by Yuhan Corporation, now recruiting.","route":"/trials/nct06616766/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06616766","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","EGFR-mutated non-small-cell lung cancer","HER2-mutant non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."},{"label":"HER2-mutant non-small-cell lung cancer","href":"/cancers/her2-mutant-nsclc/","tip":"HER2-mutant lung cancer carries a mutation in the same receptor that drives HER2-positive breast cancer, but the breast cancer antibodies alone did little here. The antibody-drug conjugate trastuzumab deruxtecan shrinks about half of tumours after chemotherapy, and the pill zongertinib about seven in ten, and both are approved."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05199272","name":"A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies","tldr":"A phase 1/2 trial of 23ME-00610 in renal cell carcinoma, ovarian cancer, neuroendocrine tumours and small-cell lung cancer, run by 23andMe, Inc., active and no longer recruiting.","route":"/trials/nct05199272/","status":"active","kind":"trial","cancerIcon":"rcc","sub":"NCT05199272","facets":{"kind":["Trial"],"cancers":["Renal cell carcinoma","Ovarian cancer","Neuroendocrine tumours","Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."},{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Neuroendocrine tumours","href":"/cancers/neuroendocrine/","tip":"A family of usually slow-growing tumours that start in hormone-producing cells of the gut, pancreas and lungs. They pioneered the idea of using the same molecule to see a tumour on a scan and then to treat it with radiation."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05150691","name":"A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors","tldr":"A phase 1/2 trial of Trastuzumab pamirtecan and Pertuzumab in advanced solid tumours, run by DualityBio Inc., now recruiting.","route":"/trials/nct05150691/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05150691","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05914116","name":"A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors","tldr":"A phase 1/2 trial of BNT324 and Enzalutamide in advanced solid tumours, run by DualityBio Inc., now recruiting.","route":"/trials/nct05914116/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05914116","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07160725","name":"A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors","tldr":"A phase 1/2 trial of PM8002 in advanced solid tumours, run by Bristol-Myers Squibb, now recruiting.","route":"/trials/nct07160725/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07160725","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05664243","name":"A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma","tldr":"A phase 1/2 trial of Autologous genetically modified gamma-delta T cells in glioma & glioblastoma, run by In8bio Inc., active and no longer recruiting.","route":"/trials/nct05664243/","status":"active","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT05664243","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06939283","name":"A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma","tldr":"A phase 1/2 trial of WTX-330 in non-Hodgkin lymphoma, run by Werewolf Therapeutics, Inc., active and no longer recruiting.","route":"/trials/nct06939283/","status":"active","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT06939283","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04538742","name":"A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer","tldr":"A phase 1/2 trial of Trastuzumab deruxtecan, Durvalumab, Pertuzumab and Tucatinib in HER2-positive breast cancer, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct04538742/","status":"active","kind":"trial","cancerIcon":"breast-her2-positive","sub":"NCT04538742","facets":{"kind":["Trial"],"cancers":["HER2-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02586857","name":"A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)","tldr":"A phase 1/2 trial of ACP-196 in glioma & glioblastoma, run by Acerta Pharma BV, active and no longer recruiting.","route":"/trials/nct02586857/","status":"active","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT02586857","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":["2020"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"year":{"facet":"year","value":"2020"},"tags":[]},"sortKeys":{"year":2020}},{"id":"nct07766018","name":"A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer","tldr":"A phase 2 trial of Elacestrant in advanced solid tumours, run by Stemline Therapeutics, Inc., now recruiting.","route":"/trials/nct07766018/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07766018","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06668103","name":"A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib","tldr":"A phase 2 trial of ABSK043 in combination with Firmonertinib in non-small-cell lung cancer, run by Abbisko Therapeutics Co, Ltd, now recruiting.","route":"/trials/nct06668103/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06668103","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04379167","name":"A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma","tldr":"A phase 2 trial of Linperlisib in Follicular lymphoma, run by Shanghai YingLi Pharmaceutical Co. Ltd., with a status the registry has not verified recently.","route":"/trials/nct04379167/","kind":"trial","cancerIcon":"follicular-lymphoma","sub":"NCT04379167","facets":{"kind":["Trial"],"cancers":["Follicular lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Follicular lymphoma","href":"/cancers/follicular-lymphoma/","tip":"Follicular lymphoma is the most common slow-growing lymphoma, defined in about 85% of cases by a BCL2 translocation. Most people live with it for decades, treated only when it causes problems; it can be controlled repeatedly with anti-CD20 antibodies, chemotherapy, bispecifics or CAR-T but rarely cured, and a small share transform into an aggressive lymphoma each year."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07623616","name":"A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia","tldr":"A phase 2 trial of Ziftomenib in acute myeloid leukaemia, run by Kyowa Kirin Co., Ltd., now recruiting.","route":"/trials/nct07623616/","status":"recruiting","kind":"trial","cancerIcon":"aml","sub":"NCT07623616","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia","NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia","href":"/cancers/aml-npm1-kmt2a/","tip":"NPM1-mutated and KMT2A-rearranged leukaemias depend on a protein called menin to keep leukaemia genes switched on. Menin inhibitors, revumenib and ziftomenib, are the first drugs to exploit this, and they produce remissions in patients whose leukaemia had come back after everything else."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06111274","name":"A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer","tldr":"A phase 2 trial of Pimicotinib (ABSK021) in pancreatic ductal adenocarcinoma, run by Abbisko Therapeutics Co, Ltd, now recruiting.","route":"/trials/nct06111274/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT06111274","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05548296","name":"A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma","tldr":"A phase 2 trial of Gemcitabine in endometrial cancer, run by Acrivon Therapeutics, now recruiting.","route":"/trials/nct05548296/","status":"recruiting","kind":"trial","cancerIcon":"endometrial","sub":"NCT05548296","facets":{"kind":["Trial"],"cancers":["Endometrial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06593522","name":"A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)","tldr":"A phase 2 trial of Anvumetostat in non-small-cell lung cancer, run by Amgen, active and no longer recruiting.","route":"/trials/nct06593522/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT06593522","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01975701","name":"A Phase 2 Study of BGJ398 in Patients With Recurrent GBM","tldr":"A phase 2 trial of Infigratinib in Glioma & glioblastoma, run by Novartis Pharmaceuticals, completed.","route":"/trials/nct01975701/","status":"completed","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT01975701","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06246110","name":"A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC","tldr":"A phase 2 trial of EIK1001, Pembrolizumab, Pemetrexed and Carboplatin in non-small-cell lung cancer, run by Eikon Therapeutics, active and no longer recruiting.","route":"/trials/nct06246110/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT06246110","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06703255","name":"A Phase 2 Study of HX301 in Patients with High-grade Giloma","tldr":"A phase 1/2 trial of Temozolomide in glioma & glioblastoma, run by Hangzhou Hanx Biopharmaceuticals, Ltd., now recruiting.","route":"/trials/nct06703255/","status":"recruiting","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT06703255","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07562581","name":"A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC","tldr":"A phase 2 trial of Anlotinib in non-small-cell lung cancer, run by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., now recruiting.","route":"/trials/nct07562581/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07562581","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07743112","name":"A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia","tldr":"A phase 2 trial of Azacitidine and Venetoclax in acute myeloid leukaemia, run by Maxinovel Pty., Ltd., now recruiting.","route":"/trials/nct07743112/","status":"recruiting","kind":"trial","cancerIcon":"aml","sub":"NCT07743112","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia","Acute myeloid leukaemia in older or unfit patients"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Acute myeloid leukaemia in older or unfit patients","href":"/cancers/aml-older-unfit/","tip":"Most people with acute myeloid leukaemia are over 65, and many cannot take intensive chemotherapy. Venetoclax with azacitidine, two gentler drugs, doubled remission rates and lengthened life in this group, replacing the old choice between supportive care and low-dose chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06568692","name":"A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer","tldr":"A phase 2 trial of Capecitabine in triple-negative breast cancer, run by Processa Pharmaceuticals, now recruiting.","route":"/trials/nct06568692/","status":"recruiting","kind":"trial","cancerIcon":"tnbc","sub":"NCT06568692","facets":{"kind":["Trial"],"cancers":["Triple-negative breast cancer","Metastatic triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Metastatic triple-negative breast cancer","href":"/cancers/tnbc-metastatic/","tip":"Triple-negative breast cancer that has spread is not curable, but its treatment has been transformed since 2020. By PD-L1 score, first treatment is pembrolizumab with chemotherapy or with sacituzumab govitecan, or datopotamab deruxtecan or sacituzumab govitecan alone; BRCA carriers can take a PARP inhibitor tablet; and trastuzumab deruxtecan reaches the third of tumours with low HER2."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06514794","name":"A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)","tldr":"A phase 2 trial of WU-CART-007 in acute lymphoblastic leukaemia and non-Hodgkin lymphoma, run by Allotera Therapeutics, now recruiting.","route":"/trials/nct06514794/","status":"recruiting","kind":"trial","cancerIcon":"all-leukemia","sub":"NCT06514794","facets":{"kind":["Trial"],"cancers":["Acute lymphoblastic leukaemia","Non-Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."},{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06439771","name":"A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC","tldr":"A phase 2 trial of YL202 should be intravenously infused in advanced solid tumours, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.","route":"/trials/nct06439771/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06439771","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06985147","name":"A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)","tldr":"A phase 2 trial of DISC-3405 in myeloproliferative neoplasms, run by Disc Medicine, Inc, active and no longer recruiting.","route":"/trials/nct06985147/","status":"active","kind":"trial","cancerIcon":"myeloproliferative-neoplasms","sub":"NCT06985147","facets":{"kind":["Trial"],"cancers":["Myeloproliferative neoplasms","Polycythaemia vera"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Myeloproliferative neoplasms","href":"/cancers/myeloproliferative-neoplasms/","tip":"Myeloproliferative neoplasms are slow-growing blood cancers in which the marrow overproduces red cells (polycythaemia vera), platelets (essential thrombocythaemia) or scar tissue (myelofibrosis). Almost all carry a mutation in JAK2, CALR or MPL; treatment aims to prevent clots and control symptoms, and only transplant cures myelofibrosis."},{"label":"Polycythaemia vera","href":"/cancers/polycythaemia-vera/","tip":"Polycythaemia vera is a slow blood cancer in which a single faulty gene, JAK2, makes the bone marrow produce too many red cells. Thick blood causes clots, so treatment thins it (blood removal, aspirin) and, for higher-risk patients, calms the marrow with hydroxyurea, interferon or ruxolitinib; a hepcidin mimic, rusfertide, now controls red cell counts without regular blood removal."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04485949","name":"A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma","tldr":"A phase 2 trial of Temozolomide in glioma & glioblastoma, run by Imvax, active and no longer recruiting.","route":"/trials/nct04485949/","status":"active","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT04485949","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06007690","name":"A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma","tldr":"A phase 3 trial of Bel-sar in uveal melanoma, run by Aura Biosciences, active and no longer recruiting.","route":"/trials/nct06007690/","status":"active","kind":"trial","cancerIcon":"uveal-melanoma","sub":"NCT06007690","facets":{"kind":["Trial"],"cancers":["Uveal melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Uveal melanoma","href":"/cancers/uveal-melanoma/","tip":"A melanoma inside the eye that is biologically unrelated to skin melanoma: different mutations, no response to standard immunotherapy, and a tendency to spread to the liver years later. Tebentafusp is the first drug ever to extend survival in the metastatic disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05243550","name":"A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer","tldr":"A phase 3 trial of UGN-102 in bladder & urothelial cancer, run by UroGen Pharma Ltd., active and no longer recruiting.","route":"/trials/nct05243550/","status":"active","kind":"trial","cancerIcon":"urothelial","sub":"NCT05243550","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Non-muscle-invasive bladder cancer"],"year":["2024"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Non-muscle-invasive bladder cancer","href":"/cancers/non-muscle-invasive-bladder-cancer/","tip":"Most bladder cancers are found while still confined to the lining. They are scraped out through the urethra and, when higher risk, treated with BCG instilled into the bladder; the challenge is the frequent recurrences and the patients whose tumours stop responding to BCG."}],"year":{"facet":"year","value":"2024"},"tags":[]},"sortKeys":{"year":2024}},{"id":"nct03459534","name":"A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs","tldr":"A phase 3 trial of Radotinib HCl in chronic myeloid leukaemia, run by Il-Yang Pharm. Co., Ltd., now recruiting.","route":"/trials/nct03459534/","status":"recruiting","kind":"trial","cancerIcon":"cml","sub":"NCT03459534","facets":{"kind":["Trial"],"cancers":["Chronic myeloid leukaemia","Chronic myeloid leukaemia, chronic phase"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic myeloid leukaemia","href":"/cancers/cml/","tip":"Chronic myeloid leukaemia is a blood cancer driven by a single fused gene, BCR-ABL1, and the model for oncogene-targeted treatment: imatinib in 2001 and the tyrosine kinase inhibitors that followed turned it into a condition most people live with long-term. About half of patients with a sustained deep molecular response can now stop treatment altogether."},{"label":"Chronic myeloid leukaemia, chronic phase","href":"/cancers/cml-chronic-phase/","tip":"Chronic-phase chronic myeloid leukaemia is the disease that imatinib turned from fatal into manageable: a daily pill blocks the BCR::ABL1 protein that drives it. Blood tests track the leukaemia gene to a millionth, newer pills such as asciminib (ASC4FIRST) reach deeper responses faster, and patients with years of undetectable disease can try stopping."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05566041","name":"A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer","tldr":"A phase 3 trial of Etoposide, Carboplatin and Cisplatin in small-cell lung cancer, run by EpicentRx, Inc., active and no longer recruiting.","route":"/trials/nct05566041/","status":"active","kind":"trial","cancerIcon":"sclc","sub":"NCT05566041","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00938652","name":"A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer","tldr":"A phase 3 trial of Gemcitabine, Carboplatin and Iniparib in Breast cancer, run by Sanofi, completed.","route":"/trials/nct00938652/","status":"completed","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT00938652","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05862272","name":"A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis","tldr":"A phase 3 trial of Relugolix in endometrial cancer, run by Sumitomo Pharma Switzerland GmbH, now recruiting.","route":"/trials/nct05862272/","status":"recruiting","kind":"trial","cancerIcon":"endometrial","sub":"NCT05862272","facets":{"kind":["Trial"],"cancers":["Endometrial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05970016","name":"A Phase I/II Clinical Study in Patients with Advanced Solid Tumor.","tldr":"A phase 1/2 trial of TCC1727 tablet（1） in advanced solid tumours, run by Beijing Tide Pharmaceutical Co., Ltd, now recruiting.","route":"/trials/nct05970016/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05970016","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06971523","name":"A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies","tldr":"A phase 1/2 trial of CTS3497 in non-Hodgkin lymphoma, run by CytosinLab Therapeutics Co., Ltd., now recruiting.","route":"/trials/nct06971523/","status":"recruiting","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT06971523","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07136142","name":"A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors","tldr":"A phase 1/2 trial of FH-006 for Injection in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.","route":"/trials/nct07136142/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07136142","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05170958","name":"A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors","tldr":"A phase 1/2 trial of LBL-024 for Injection in advanced solid tumours, run by Nanjing Leads Biolabs Co.,Ltd, now recruiting.","route":"/trials/nct05170958/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05170958","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06737731","name":"A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of SHR-1681 in advanced solid tumours, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.","route":"/trials/nct06737731/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06737731","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07229612","name":"A Phase I/II Clinical Study of SHR-4298 Injection in Patients With Malignant Solid Tumors","tldr":"A phase 1/2 trial of SHR-4298 Injection in advanced solid tumours, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.","route":"/trials/nct07229612/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07229612","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07253116","name":"A Phase I/II Clinical Study of WJ22096 Tablets in Patients With Advanced Tumors","tldr":"A phase 1/2 trial of WJ22096 in advanced solid tumours, run by Nanjing Jingao biomidical technology Co. Ltd., now recruiting.","route":"/trials/nct07253116/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07253116","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04685226","name":"A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors","tldr":"A phase 1/2 trial of ICP-723 in advanced solid tumours, run by Beijing InnoCare Pharma Tech Co., Ltd., now recruiting.","route":"/trials/nct04685226/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04685226","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07069062","name":"A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors","tldr":"A phase 1/2 trial of Test product HY0001a for injection in advanced solid tumours, run by Sichuan Huiyu Pharmaceutical Co., Ltd, now recruiting.","route":"/trials/nct07069062/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07069062","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06922357","name":"A Phase I/II of HRS-6719 in Patients With Advanced/Metastatic Solid Tumors","tldr":"A phase 1/2 trial of HRS-6719 in advanced solid tumours, run by Shandong Suncadia Medicine Co., Ltd., now recruiting.","route":"/trials/nct06922357/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06922357","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07417189","name":"A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )","tldr":"A phase 1/2 trial of ABSK141-400mg in advanced solid tumours, run by Abbisko Therapeutics Co, Ltd, now recruiting.","route":"/trials/nct07417189/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07417189","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06245330","name":"A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors","tldr":"A phase 1/2 trial of AST-001 in pancreatic ductal adenocarcinoma, run by Ascentawits Pharmaceuticals, Ltd, now recruiting.","route":"/trials/nct06245330/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT06245330","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06239155","name":"A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors","tldr":"A phase 1/2 trial of AST-3424 in hepatocellular carcinoma, run by Ascentawits Pharmaceuticals, Ltd, active and no longer recruiting.","route":"/trials/nct06239155/","status":"active","kind":"trial","cancerIcon":"hcc","sub":"NCT06239155","facets":{"kind":["Trial"],"cancers":["Hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06741644","name":"A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors","tldr":"A phase 1/2 trial of Pemetrexed, Carboplatin, Etoposide, Oxaliplatin, Capecitabine and Docetaxel in advanced solid tumours, run by CStone Pharmaceuticals, now recruiting.","route":"/trials/nct06741644/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06741644","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05415072","name":"A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas","tldr":"A phase 1/2 trial of DYP688 in uveal melanoma, run by Novartis Pharmaceuticals, active and no longer recruiting.","route":"/trials/nct05415072/","status":"active","kind":"trial","cancerIcon":"uveal-melanoma","sub":"NCT05415072","facets":{"kind":["Trial"],"cancers":["Uveal melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Uveal melanoma","href":"/cancers/uveal-melanoma/","tip":"A melanoma inside the eye that is biologically unrelated to skin melanoma: different mutations, no response to standard immunotherapy, and a tendency to spread to the liver years later. Tebentafusp is the first drug ever to extend survival in the metastatic disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06064812","name":"A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.","tldr":"A phase 1/2 trial of FWD1802 in advanced solid tumours, run by Forward Pharmaceuticals Co., Ltd., now recruiting.","route":"/trials/nct06064812/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06064812","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07083323","name":"A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors","tldr":"A phase 1/2 trial of HY05350 for injection in advanced solid tumours, run by Sichuan Huiyu Pharmaceutical Co., Ltd, now recruiting.","route":"/trials/nct07083323/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07083323","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06712680","name":"A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes","tldr":"A phase 1/2 trial of Test Product HYP-6589 in advanced solid tumours, run by Sichuan Huiyu Pharmaceutical Co., Ltd, now recruiting.","route":"/trials/nct06712680/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06712680","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05615974","name":"A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors","tldr":"A phase 1/2 trial of Toripalimab and Rituximab in advanced solid tumours, run by LaNova Medicines Limited, now recruiting.","route":"/trials/nct05615974/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05615974","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06682780","name":"A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours","tldr":"A phase 1/2 trial of Docetaxel, Toripalimab, Carboplatin, Niraparib and Lenvatinib in advanced solid tumours, run by LaNova Medicines Limited, now recruiting.","route":"/trials/nct06682780/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06682780","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02734004","name":"A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.","tldr":"A phase 1/2 trial of Olaparib and Bevacizumab in ovarian cancer, small-cell lung cancer and gastric & gastro-oesophageal junction cancer, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct02734004/","status":"active","kind":"trial","cancerIcon":"ovarian","sub":"NCT02734004","facets":{"kind":["Trial"],"cancers":["Ovarian cancer","Small-cell lung cancer","Gastric & gastro-oesophageal junction cancer"],"year":["2023"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."},{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"year":{"facet":"year","value":"2023"},"tags":[]},"sortKeys":{"year":2023}},{"id":"nct07075328","name":"A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma","tldr":"A phase 1/2 trial of an investigational treatment in non-Hodgkin lymphoma, run by Otsuka Medical Devices Co., Ltd. Japan, now recruiting.","route":"/trials/nct07075328/","status":"recruiting","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT07075328","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05902988","name":"A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer","tldr":"A phase 1/2 trial of VLS-1488 in non-small-cell lung cancer, triple-negative breast cancer, head and neck squamous cell carcinoma, ovarian cancer, sarcomas and endometrial cancer, run by Volastra Therapeutics, Inc., now recruiting.","route":"/trials/nct05902988/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT05902988","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","Triple-negative breast cancer","Head and neck squamous cell carcinoma","Ovarian cancer","Sarcomas","Endometrial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06953323","name":"A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors","tldr":"A phase 1/2 trial of Carboplatin, Nedaplatin, Niraparib, Bevacizumab and Toripalimab in advanced solid tumours, run by Wigen Biomedicine Technology (Shanghai) Co., Ltd., now recruiting.","route":"/trials/nct06953323/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06953323","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04539496","name":"A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors","tldr":"A phase 1/2 trial of XZP-3287 and Fulvestrant in advanced solid tumours, run by Sihuan Pharmaceutical Holdings Group Ltd., active and no longer recruiting.","route":"/trials/nct04539496/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04539496","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06084884","name":"A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma","tldr":"A phase 1/2 trial of AZD5851 in hepatocellular carcinoma, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct06084884/","status":"active","kind":"trial","cancerIcon":"hcc","sub":"NCT06084884","facets":{"kind":["Trial"],"cancers":["Hepatocellular carcinoma","Advanced hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."},{"label":"Advanced hepatocellular carcinoma","href":"/cancers/hcc-advanced/","tip":"Advanced hepatocellular carcinoma has invaded the liver's veins or spread beyond it. Sorafenib was the only drug for a decade; now the combination of the immunotherapy atezolizumab with the anti-angiogenic antibody bevacizumab, or the two-antibody regimen durvalumab with tremelimumab, is standard first line, and several further drugs follow it."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05315167","name":"A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors","tldr":"A phase 1/2 trial of PRJ1-3024 in advanced solid tumours, run by Zhuhai Yufan Biotechnologies Co., Ltd, now recruiting.","route":"/trials/nct05315167/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05315167","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06247995","name":"A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.","tldr":"A phase 1/2 trial of Capecitabine in advanced solid tumours, run by Novartis Pharmaceuticals, active and no longer recruiting.","route":"/trials/nct06247995/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06247995","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05761223","name":"A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849","tldr":"A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by 1ST Biotherapeutics, Inc., now recruiting.","route":"/trials/nct05761223/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05761223","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07362940","name":"A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib","tldr":"A phase 1/2 trial of GEN-725 tablets + Dositinib mesylate tablets in non-small-cell lung cancer, run by Henan Genuine Biotech Co., Ltd., now recruiting.","route":"/trials/nct07362940/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07362940","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07811037","name":"A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, Immunogenicity, and Preliminary Efficacy of SGT003 in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of SGT003 in advanced solid tumours, run by Beijing Sungen Biomedical Technology Co., Ltd, now recruiting.","route":"/trials/nct07811037/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07811037","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06797986","name":"A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC.","tldr":"A phase 1/2 trial of BVAC-E6E7 (low level) in head and neck squamous cell carcinoma, run by Cellid Co., Ltd., now recruiting.","route":"/trials/nct06797986/","status":"recruiting","kind":"trial","cancerIcon":"head-and-neck","sub":"NCT06797986","facets":{"kind":["Trial"],"cancers":["Head and neck squamous cell carcinoma","HPV-positive oropharyngeal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"HPV-positive oropharyngeal cancer","href":"/cancers/hpv-positive-oropharyngeal-cancer/","tip":"Throat cancers caused by HPV are usually cured with chemoradiation or robotic surgery, so trials now ask how much treatment can be taken away: swapping cisplatin for cetuximab failed, cutting the radiation dose has worked only after surgery so far, and blood tests for HPV DNA may pick out the patients who can safely have less."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07392736","name":"A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.","tldr":"A phase 1/2 trial of Toripalimab in advanced solid tumours, run by Advenchen Laboratories, LLC, now recruiting.","route":"/trials/nct07392736/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07392736","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07243340","name":"A Phase I/IIa Study of C5252 in Patients With Intracranial Tumor","tldr":"A phase 1/2 trial of Herpes Virus C5252 Injection in glioma & glioblastoma, run by ImmVira Pharma Co. Ltd, now recruiting.","route":"/trials/nct07243340/","status":"recruiting","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT07243340","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07777211","name":"A Phase I/IIa Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer","tldr":"A phase 1/2 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by Beijing Gene Key Life Technology Co., Ltd, active and no longer recruiting.","route":"/trials/nct07777211/","status":"active","kind":"trial","cancerIcon":"pancreatic","sub":"NCT07777211","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07228247","name":"A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors","tldr":"A phase 1/2 trial of HMPL-A251 in advanced solid tumours, run by Hutchmed, now recruiting.","route":"/trials/nct07228247/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07228247","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06959615","name":"A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration","tldr":"A phase 1/2 trial of JAB-23E73 in advanced solid tumours, run by Jacobio Pharmaceuticals Co., Ltd., now recruiting.","route":"/trials/nct06959615/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06959615","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07744763","name":"A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of Farletuzumab-exatecan in advanced solid tumours, run by CSPC Megalith Biopharmaceutical Co.,Ltd., now recruiting.","route":"/trials/nct07744763/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07744763","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06727630","name":"A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma","tldr":"A phase 1/2 trial of PRJ1-3024 in melanoma, run by Zhuhai Yufan Biotechnologies Co., Ltd, now recruiting.","route":"/trials/nct06727630/","status":"recruiting","kind":"trial","cancerIcon":"melanoma","sub":"NCT06727630","facets":{"kind":["Trial"],"cancers":["Melanoma","Advanced melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"label":"Advanced melanoma","href":"/cancers/advanced-melanoma/","tip":"Advanced melanoma has spread beyond what surgery can remove, and it is the cancer in which immunotherapy first proved it could cure some people: about half of those given nivolumab with ipilimumab are alive ten years later. If immunotherapy fails, options include a cell therapy grown from the patient's own immune cells, a virus injected into the tumour, and targeted pills for BRAF-mutant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05951608","name":"A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of AK127 in combination with AK112 in advanced solid tumours, run by Akeso, active and no longer recruiting.","route":"/trials/nct05951608/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05951608","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05133882","name":"A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML","tldr":"A phase 1/2 trial of Clifutinib in acute myeloid leukaemia, run by Sunshine Lake Pharma Co., Ltd., now recruiting.","route":"/trials/nct05133882/","status":"recruiting","kind":"trial","cancerIcon":"aml","sub":"NCT05133882","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06474455","name":"A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of SHR-A1921, SHR-A2009, Aumolertinib, Pemetrexed, Carboplatin and Adebrelimab in advanced solid tumours, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct06474455/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06474455","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05543330","name":"A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC","tldr":"A phase 1/2 trial of Cisplatin in non-small-cell lung cancer, run by Wuhan YZY Biopharma Co., Ltd., now recruiting.","route":"/trials/nct05543330/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT05543330","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07501559","name":"A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)","tldr":"A phase 1/2 trial of JL15003Injection in glioma & glioblastoma, run by Jecho Biopharmaceuticals Co., Ltd., now recruiting.","route":"/trials/nct07501559/","status":"recruiting","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT07501559","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07466160","name":"A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors","tldr":"A phase 1/2 trial of Cisplatin and Carboplatin in advanced solid tumours, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.","route":"/trials/nct07466160/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07466160","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05229497","name":"A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors","tldr":"A phase 1/2 trial of AK117, Carboplatin, Cisplatin and Gemcitabine in advanced solid tumours, run by Akeso, active and no longer recruiting.","route":"/trials/nct05229497/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05229497","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07002177","name":"A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC","tldr":"A phase 1/2 trial of Palbociclib, Ribociclib, Abemaciclib and Everolimus in advanced solid tumours, run by Forward Pharmaceuticals Co., Ltd., now recruiting.","route":"/trials/nct07002177/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07002177","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07283367","name":"A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.","tldr":"A phase 1/2 trial of Bevacizumab, Oxaliplatin and Capecitabine in colorectal cancer, run by Hansoh BioMedical R&D Company, now recruiting.","route":"/trials/nct07283367/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT07283367","facets":{"kind":["Trial"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07547553","name":"A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC","tldr":"A phase 1/2 trial of Will receive HH-009 injection 20 mg/kg, Q3W in hepatocellular carcinoma, run by Huahui Health, now recruiting.","route":"/trials/nct07547553/","status":"recruiting","kind":"trial","cancerIcon":"hcc","sub":"NCT07547553","facets":{"kind":["Trial"],"cancers":["Hepatocellular carcinoma","Advanced hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."},{"label":"Advanced hepatocellular carcinoma","href":"/cancers/hcc-advanced/","tip":"Advanced hepatocellular carcinoma has invaded the liver's veins or spread beyond it. Sorafenib was the only drug for a decade; now the combination of the immunotherapy atezolizumab with the anti-angiogenic antibody bevacizumab, or the two-antibody regimen durvalumab with tremelimumab, is standard first line, and several further drugs follow it."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07241767","name":"A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer","tldr":"A phase 2 trial of Adebrelimab, Carboplatin, Cisplatin and SHR-8068 in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.","route":"/trials/nct07241767/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07241767","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06915142","name":"A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour","tldr":"A phase 2 trial of Adebrelimab, Cetuximab and SHR-A2102 in advanced solid tumours, run by Shandong Suncadia Medicine Co., Ltd., now recruiting.","route":"/trials/nct06915142/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06915142","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07331155","name":"A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]","tldr":"A phase 2 trial of Cisplatin, Tislelizumab and Capecitabine in advanced solid tumours, run by Nanjing Leads Biolabs Co.,Ltd, now recruiting.","route":"/trials/nct07331155/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07331155","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07308106","name":"A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities","tldr":"A phase 2 trial of SKB571 for injection in advanced solid tumours, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07308106/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07308106","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06742892","name":"A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy","tldr":"A phase 2 trial of HLX43 DOSE 1 in hepatocellular carcinoma, run by Shanghai Henlius Biotech, now recruiting.","route":"/trials/nct06742892/","status":"recruiting","kind":"trial","cancerIcon":"hcc","sub":"NCT06742892","facets":{"kind":["Trial"],"cancers":["Hepatocellular carcinoma","Advanced hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."},{"label":"Advanced hepatocellular carcinoma","href":"/cancers/hcc-advanced/","tip":"Advanced hepatocellular carcinoma has invaded the liver's veins or spread beyond it. Sorafenib was the only drug for a decade; now the combination of the immunotherapy atezolizumab with the anti-angiogenic antibody bevacizumab, or the two-antibody regimen durvalumab with tremelimumab, is standard first line, and several further drugs follow it."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06769113","name":"A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy","tldr":"A phase 2 trial of HLX43 in oesophageal cancer, run by Shanghai Henlius Biotech, now recruiting.","route":"/trials/nct06769113/","status":"recruiting","kind":"trial","cancerIcon":"esophageal","sub":"NCT06769113","facets":{"kind":["Trial"],"cancers":["Oesophageal cancer","Oesophageal squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."},{"label":"Oesophageal squamous cell carcinoma","href":"/cancers/oesophageal-squamous-cell-carcinoma/","tip":"Squamous cell carcinoma of the oesophagus, the world's commonest form, is linked to smoking, alcohol and very hot drinks and sits in the upper and middle gullet. It is treated with chemoradiation, with or without surgery, and immunotherapy has recently joined chemotherapy for advanced disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06907615","name":"A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)","tldr":"A phase 2 trial of HLX43 DOSE 1 (2.0 mg/kg) in non-small-cell lung cancer, run by Shanghai Henlius Biotech, now recruiting.","route":"/trials/nct06907615/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06907615","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04486378","name":"A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer","tldr":"A phase 2 trial of RO7198457 intravenous (IV) in colorectal cancer, run by BioNTech SE, active and no longer recruiting.","route":"/trials/nct04486378/","status":"active","kind":"trial","cancerIcon":"colorectal","sub":"NCT04486378","facets":{"kind":["Trial"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07390383","name":"A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]","tldr":"A phase 2 trial of Capecitabine, Tislelizumab and Oxaliplatin in advanced solid tumours, run by Nanjing Leads Biolabs Co.,Ltd, now recruiting.","route":"/trials/nct07390383/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07390383","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07489716","name":"A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer","tldr":"A phase 2 trial of SHR-1826 in non-small-cell lung cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.","route":"/trials/nct07489716/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07489716","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06015503","name":"A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)","tldr":"A phase 2 trial of PLB1004 in non-small-cell lung cancer, run by Avistone Biotechnology Co., Ltd., active and no longer recruiting.","route":"/trials/nct06015503/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT06015503","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06008288","name":"A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.","tldr":"A phase 2 trial of Glecirasib in pancreatic ductal adenocarcinoma, run by Allist Pharmaceuticals, Inc., now recruiting.","route":"/trials/nct06008288/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT06008288","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","KRAS G12C-mutant pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"KRAS G12C-mutant pancreatic ductal adenocarcinoma","href":"/cancers/kras-g12c-pdac/","tip":"KRAS G12C pancreatic cancer is the small slice of pancreatic cancer whose KRAS mutation happens to be the one that the first KRAS drugs were built for. Sotorasib and adagrasib, approved for lung cancer, shrink a share of these tumours after chemotherapy and are listed as options, and newer inhibitors such as elironrasib, olomorasib and the pan-RAS drug daraxonrasib are being tested in this group."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07405801","name":"A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer","tldr":"A phase 2 trial of Inavolisib, Ribociclib and Fulvestrant in advanced solid tumours, run by Hoffmann-La Roche, now recruiting.","route":"/trials/nct07405801/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07405801","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05849298","name":"A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC","tldr":"A phase 2 trial of AAA617 in prostate cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.","route":"/trials/nct05849298/","status":"active","kind":"trial","cancerIcon":"prostate","sub":"NCT05849298","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07591090","name":"A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer","tldr":"A phase 2 trial of AK146D1 in advanced solid tumours, run by Akeso, now recruiting.","route":"/trials/nct07591090/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07591090","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01503502","name":"A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia","tldr":"A phase 2 trial of Flumatinib and Imatinib in Leukaemia, run by Jiangsu HengRui Medicine Co., Ltd., with a status the registry has not verified recently.","route":"/trials/nct01503502/","kind":"trial","cancerIcon":"leukaemia","sub":"NCT01503502","facets":{"kind":["Trial"],"cancers":["Leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Leukaemia","href":"/cancers/leukaemia/","tip":"Leukaemia means cancer of the blood-forming cells, but the four main types share little beyond the name: acute lymphoblastic and acute myeloid leukaemia are emergencies treated with intensive therapy, while chronic lymphocytic and chronic myeloid leukaemia are slow diseases controlled for years with pills. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06832202","name":"A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients","tldr":"A phase 2 trial of HLX22 and Trastuzumab deruxtecan in HER2-positive breast cancer, run by Shanghai Henlius Biotech, now recruiting.","route":"/trials/nct06832202/","status":"recruiting","kind":"trial","cancerIcon":"breast-her2-positive","sub":"NCT06832202","facets":{"kind":["Trial"],"cancers":["HER2-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07230405","name":"A Phase II Study of SKB571 in Patients With Lung Cancer","tldr":"A phase 2 trial of SKB571 for injection in advanced solid tumours, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07230405/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07230405","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07171606","name":"A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients","tldr":"A phase 2 trial of SSGJ-706, Carboplatin and Pemetrexed in non-small-cell lung cancer, run by Shenyang Sunshine Pharmaceutical Co., LTD., now recruiting.","route":"/trials/nct07171606/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07171606","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02050321","name":"A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma","tldr":"A phase 2 trial of Acitretin and Vemurafenib in Melanoma, run by University of Arizona, recorded as terminated on the registry.","route":"/trials/nct02050321/","kind":"trial","cancerIcon":"melanoma","sub":"NCT02050321","facets":{"kind":["Trial"],"cancers":["Melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06839066","name":"A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy","tldr":"A phase 2 trial of HLX43 DOSE 1 in nasopharyngeal carcinoma, run by Shanghai Henlius Biotech, now recruiting.","route":"/trials/nct06839066/","status":"recruiting","kind":"trial","cancerIcon":"nasopharyngeal","sub":"NCT06839066","facets":{"kind":["Trial"],"cancers":["Nasopharyngeal carcinoma","Recurrent and metastatic nasopharyngeal carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Nasopharyngeal carcinoma","href":"/cancers/nasopharyngeal/","tip":"A cancer at the back of the nose caused largely by the Epstein-Barr virus and common in southern China and Southeast Asia. Radiation cures most early cases; adding chemotherapy and, recently, PD-1 immunotherapy has improved outcomes in advanced disease, and a blood test for viral DNA can detect it early."},{"label":"Recurrent and metastatic nasopharyngeal carcinoma","href":"/cancers/recurrent-metastatic-nasopharyngeal-carcinoma/","tip":"Recurrent or metastatic nasopharyngeal carcinoma is nasopharyngeal cancer that has come back after radiotherapy or spread to the bones, liver or lungs. Gemcitabine with cisplatin is the chemotherapy backbone, adding a PD-1 antibody such as toripalimab in JUPITER-02 and later trials lengthened survival and became standard, and local recurrence is treated with endoscopic surgery or re-irradiation."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00006371","name":"A Phase II Trial of Early Medical Adrenalectomy for \"D0.5\" Prostate Cancer","tldr":"A phase 2 trial of Aminoglutethimide in Prostate cancer, run by H. Lee Moffitt Cancer Center and Research Institute, recorded as terminated on the registry.","route":"/trials/nct00006371/","kind":"trial","cancerIcon":"prostate","sub":"NCT00006371","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07444437","name":"A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer","tldr":"A phase 2 trial of LM103 TILs Injection in non-small-cell lung cancer, run by Suzhou BlueHorse Therapeutics Co., Ltd., now recruiting.","route":"/trials/nct07444437/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07444437","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07761429","name":"A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP)","tldr":"A phase 2/3 trial of F520 combined with chemotherapy in cancer of unknown primary, run by Shandong New Time Pharmaceutical Co., LTD, now recruiting.","route":"/trials/nct07761429/","status":"recruiting","kind":"trial","cancerIcon":"cancer-of-unknown-primary","sub":"NCT07761429","facets":{"kind":["Trial"],"cancers":["Cancer of unknown primary","Cancer of unknown primary, unfavourable"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Cancer of unknown primary","href":"/cancers/cancer-of-unknown-primary/","tip":"Cancer found already spread, where doctors cannot find where it started. Genomic profiling finds a drug target in about a third of cases and tumour-agnostic approvals apply directly; the rest still rely on general-purpose chemotherapy, which is what those tests are changing."},{"label":"Cancer of unknown primary, unfavourable","href":"/cancers/cup-unfavourable/","tip":"Unfavourable cancer of unknown primary is the large majority of cases, where a metastatic adenocarcinoma or poorly differentiated carcinoma fits no recognised pattern and its origin cannot be found. Treatment has long been general-purpose platinum chemotherapy, but CUPISCO showed that matching drugs to the tumour's genetic faults after short chemotherapy holds the disease longer."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06844357","name":"A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.","tldr":"A phase 2/3 trial of tirapazamine in hepatocellular carcinoma, run by Zhejiang Raygene Pharmaceuticals Co., Ltd, now recruiting.","route":"/trials/nct06844357/","status":"recruiting","kind":"trial","cancerIcon":"hcc","sub":"NCT06844357","facets":{"kind":["Trial"],"cancers":["Hepatocellular carcinoma","Intermediate hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."},{"label":"Intermediate hepatocellular carcinoma","href":"/cancers/hcc-intermediate/","tip":"Intermediate hepatocellular carcinoma is several tumours inside a working liver, too many to cut out but with no spread beyond it. The standard treatment for two decades has been chemoembolisation through the hepatic artery, and trials now show that adding immunotherapy and anti-angiogenic drugs to it delays progression."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06361888","name":"A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer","tldr":"A phase 2/3 trial of Gemcitabine and Camrelizumab in pancreatic ductal adenocarcinoma, run by Hutchmed, now recruiting.","route":"/trials/nct06361888/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT06361888","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06485219","name":"A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma","tldr":"A phase 2 trial of Purinostat in peripheral T-cell lymphomas, run by Chengdu Zenitar Biomedical Technology Co., Ltd, active and no longer recruiting.","route":"/trials/nct06485219/","status":"active","kind":"trial","cancerIcon":"peripheral-t-cell-lymphoma","sub":"NCT06485219","facets":{"kind":["Trial"],"cancers":["Peripheral T-cell lymphomas","Cutaneous T-cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Peripheral T-cell lymphomas","href":"/cancers/peripheral-t-cell-lymphoma/","tip":"Peripheral T-cell lymphomas are lymphomas of T cells rather than B cells. They are rarer, more varied and, apart from a few subtypes, harder to treat than B-cell lymphomas; several new drugs help only defined subtypes."},{"label":"Cutaneous T-cell lymphoma","href":"/cancers/cutaneous-t-cell-lymphoma/","tip":"Mycosis fungoides is a lymphoma that lives in the skin, looking like eczema or psoriasis for years before it is diagnosed. It is treated with creams, light and skin-directed radiotherapy for as long as possible, then with antibodies such as mogamulizumab and brentuximab vedotin when it spreads to the blood or lymph nodes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06810804","name":"A Phase IIa Study to Evaluate NBQ72S","tldr":"A phase 2 trial of NBQ72S in advanced solid tumours, run by Nantong Bencao Quadriga Medical Technology Co. Ltd., now recruiting.","route":"/trials/nct06810804/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06810804","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07023315","name":"A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma","tldr":"A phase 3 trial of Cadonilimab in gastric & gastro-oesophageal junction cancer, run by Akeso, now recruiting.","route":"/trials/nct07023315/","status":"recruiting","kind":"trial","cancerIcon":"gastric","sub":"NCT07023315","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04914598","name":"A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions","tldr":"A phase 3 trial of Cisplatin in advanced solid tumours, run by Jiangsu Simcere Pharmaceutical Co., Ltd., active and no longer recruiting.","route":"/trials/nct04914598/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04914598","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05262010","name":"A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years","tldr":"A phase 3 trial of 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha) in advanced solid tumours, run by National Vaccine and Serum Institute, China, now recruiting.","route":"/trials/nct05262010/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05262010","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01827605","name":"A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)","tldr":"A phase 3 trial of Ibritumomab tiuxetan in Follicular lymphoma, run by Fondazione Italiana Linfomi - ETS, completed.","route":"/trials/nct01827605/","status":"completed","kind":"trial","cancerIcon":"follicular-lymphoma","sub":"NCT01827605","facets":{"kind":["Trial"],"cancers":["Follicular lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Follicular lymphoma","href":"/cancers/follicular-lymphoma/","tip":"Follicular lymphoma is the most common slow-growing lymphoma, defined in about 85% of cases by a BCL2 translocation. Most people live with it for decades, treated only when it causes problems; it can be controlled repeatedly with anti-CD20 antibodies, chemotherapy, bispecifics or CAR-T but rarely cured, and a small share transform into an aggressive lymphoma each year."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06112379","name":"A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer","tldr":"A phase 3 trial of Durvalumab, Pembrolizumab, Doxorubicin, Epirubicin, Cyclophosphamide and Carboplatin in HR-positive / HER2-negative breast cancer, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct06112379/","status":"active","kind":"trial","cancerIcon":"breast-hr-positive","sub":"NCT06112379","facets":{"kind":["Trial"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07103668","name":"A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients","tldr":"A phase 3 trial of CAR T cells in gastric & gastro-oesophageal junction cancer, run by Suzhou Immunofoco Biotechnology Co., Ltd, now recruiting.","route":"/trials/nct07103668/","status":"recruiting","kind":"trial","cancerIcon":"gastric","sub":"NCT07103668","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer","Claudin 18.2-positive gastric cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Claudin 18.2-positive gastric cancer","href":"/cancers/gastric-cldn18-2-positive/","tip":"Claudin 18.2 is a tight-junction protein normally hidden inside stomach lining cells that becomes exposed on the surface of many stomach cancers. Zolbetuximab, an antibody against it, added to chemotherapy lengthens survival in tumours that express it strongly, and antibody-drug conjugates and CAR-T cells against the same target are in trials."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06313983","name":"A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer","tldr":"A phase 3 trial of Capecitabine and Lapatinib in advanced solid tumours, run by Tianjin Hemay Pharmaceutical Co., Ltd, now recruiting.","route":"/trials/nct06313983/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06313983","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06953999","name":"A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer","tldr":"A phase 3 trial of Gemcitabine and Ivonescimab in pancreatic ductal adenocarcinoma, run by Akeso, now recruiting.","route":"/trials/nct06953999/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT06953999","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06764875","name":"A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer","tldr":"A phase 3 trial of Rilvegostomig, Trastuzumab deruxtecan, Trastuzumab, Pembrolizumab, Capecitabine and Cisplatin in gastric & gastro-oesophageal junction cancer, run by AstraZeneca, now recruiting.","route":"/trials/nct06764875/","status":"recruiting","kind":"trial","cancerIcon":"gastric","sub":"NCT06764875","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer","HER2-positive gastric cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"HER2-positive gastric cancer","href":"/cancers/gastric-her2-positive/","tip":"HER2-positive gastric cancer overexpresses the HER2 growth receptor and is treated with trastuzumab added to chemotherapy, now usually with pembrolizumab as well. After progression the antibody-drug conjugate trastuzumab deruxtecan gives responses that plain chemotherapy cannot."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06057610","name":"A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer","tldr":"A phase 3 trial of Trastuzumab rezetecan, Pertuzumab, Docetaxel and Trastuzumab in HER2-positive breast cancer, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.","route":"/trials/nct06057610/","status":"active","kind":"trial","cancerIcon":"breast-her2-positive","sub":"NCT06057610","facets":{"kind":["Trial"],"cancers":["HER2-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06908304","name":"A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC","tldr":"A phase 3 trial of Cemiplimab, Docetaxel, Vinorelbine and Gemcitabine in non-small-cell lung cancer, run by Maia Biotechnology, now recruiting.","route":"/trials/nct06908304/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06908304","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06126640","name":"A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy","tldr":"A phase 3 trial of Trastuzumab rezetecan and Trastuzumab emtansine in HER2-positive breast cancer, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.","route":"/trials/nct06126640/","status":"active","kind":"trial","cancerIcon":"breast-her2-positive","sub":"NCT06126640","facets":{"kind":["Trial"],"cancers":["HER2-positive breast cancer","Early HER2-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."},{"label":"Early HER2-positive breast cancer","href":"/cancers/her2-positive-early-breast-cancer/","tip":"HER2-positive breast cancer caught early is usually cured. Chemotherapy with the antibodies trastuzumab and pertuzumab comes before surgery; if the tumour has gone by then, antibodies alone finish the year, and if cancer remains, trastuzumab emtansine or trastuzumab deruxtecan take over. Small tumours get a gentler regimen, and trials now ask how much treatment can be left out."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07647328","name":"A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer","tldr":"A phase 3 trial of Camizestrant and Ribociclib in HR-positive / HER2-negative breast cancer, run by AstraZeneca, now recruiting.","route":"/trials/nct07647328/","status":"recruiting","kind":"trial","cancerIcon":"breast-hr-positive","sub":"NCT07647328","facets":{"kind":["Trial"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06764186","name":"A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain","tldr":"A phase 3 trial of Fulvestrant and Capivasertib in advanced solid tumours, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct06764186/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06764186","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06764940","name":"A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases","tldr":"A phase 2 trial of Capecitabine in brain and spinal cord tumours, run by Biostar Pharma, Inc., now recruiting.","route":"/trials/nct06764940/","status":"recruiting","kind":"trial","cancerIcon":"brain-tumours","sub":"NCT06764940","facets":{"kind":["Trial"],"cancers":["Brain and spinal cord tumours","Brain metastases"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Brain and spinal cord tumours","href":"/cancers/brain-tumours/","tip":"Brain and spinal cord tumours range from slow-growing meningiomas and low-grade gliomas to glioblastoma, the commonest malignant brain tumour in adults, and a distinct set of childhood tumours such as medulloblastoma and diffuse midline glioma. Molecular markers now define them, and treatment is surgery, radiotherapy and, for some, drugs chosen by those markers."},{"label":"Brain metastases","href":"/cancers/secondary-brain-tumours/","tip":"Brain metastases are cancers that have spread to the brain from elsewhere, most often from the lung, breast or skin. Focused radiation aimed at each spot (radiosurgery) has largely replaced radiation to the whole brain, and for some cancers modern targeted drugs and immunotherapy reach the brain well enough to shrink the deposits on their own."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06389292","name":"A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia","tldr":"A phase 3 trial of Azacitidine in acute myeloid leukaemia, run by Ascentage Pharma Group Inc., now recruiting.","route":"/trials/nct06389292/","status":"recruiting","kind":"trial","cancerIcon":"aml","sub":"NCT06389292","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia","Acute myeloid leukaemia in older or unfit patients"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Acute myeloid leukaemia in older or unfit patients","href":"/cancers/aml-older-unfit/","tip":"Most people with acute myeloid leukaemia are over 65, and many cannot take intensive chemotherapy. Venetoclax with azacitidine, two gentler drugs, doubled remission rates and lengthened life in this group, replacing the old choice between supportive care and low-dose chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03899636","name":"A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer","tldr":"A phase 3 trial of Modified FOLFIRINOX Regimen in pancreatic ductal adenocarcinoma, run by Angiodynamics, Inc., active and no longer recruiting.","route":"/trials/nct03899636/","status":"active","kind":"trial","cancerIcon":"pancreatic","sub":"NCT03899636","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Locally advanced unresectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06062420","name":"A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202","tldr":"A phase 2 trial of Dostarlimab in head and neck squamous cell carcinoma, run by GlaxoSmithKline, active and no longer recruiting.","route":"/trials/nct06062420/","status":"active","kind":"trial","cancerIcon":"head-and-neck","sub":"NCT06062420","facets":{"kind":["Trial"],"cancers":["Head and neck squamous cell carcinoma","Recurrent or metastatic head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Recurrent or metastatic head and neck squamous cell carcinoma","href":"/cancers/recurrent-metastatic-hnscc/","tip":"When head and neck cancer comes back where it cannot be removed, or spreads elsewhere, it is treated to extend life rather than cure: pembrolizumab, alone or with chemotherapy, is the first choice, cetuximab-based regimens and cheap oral chemotherapy are alternatives, and antibodies that hit two targets at once are in late-stage trials."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05565378","name":"A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer","tldr":"A phase 2 trial of Pembrolizumab and Dostarlimab in non-small-cell lung cancer, run by GlaxoSmithKline, active and no longer recruiting.","route":"/trials/nct05565378/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT05565378","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06496971","name":"A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients","tldr":"A phase 3 trial of Bevacizumab in glioma & glioblastoma and brain and spinal cord tumours, run by NaviFUS Corporation, now recruiting.","route":"/trials/nct06496971/","status":"recruiting","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT06496971","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma","Brain and spinal cord tumours"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."},{"label":"Brain and spinal cord tumours","href":"/cancers/brain-tumours/","tip":"Brain and spinal cord tumours range from slow-growing meningiomas and low-grade gliomas to glioblastoma, the commonest malignant brain tumour in adults, and a distinct set of childhood tumours such as medulloblastoma and diffuse midline glioma. Molecular markers now define them, and treatment is surgery, radiotherapy and, for some, drugs chosen by those markers."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06717126","name":"A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma","tldr":"A phase 2 trial of Roginolisib in uveal melanoma, run by iOnctura, active and no longer recruiting.","route":"/trials/nct06717126/","status":"active","kind":"trial","cancerIcon":"uveal-melanoma","sub":"NCT06717126","facets":{"kind":["Trial"],"cancers":["Uveal melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Uveal melanoma","href":"/cancers/uveal-melanoma/","tip":"A melanoma inside the eye that is biologically unrelated to skin melanoma: different mutations, no response to standard immunotherapy, and a tendency to spread to the liver years later. Tebentafusp is the first drug ever to extend survival in the metastatic disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06776952","name":"A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma","tldr":"A phase 3 trial of Tucidinostat (chidamide) and XNW5004 in peripheral T-cell lymphomas, run by Evopoint Biosciences Inc., now recruiting.","route":"/trials/nct06776952/","status":"recruiting","kind":"trial","cancerIcon":"peripheral-t-cell-lymphoma","sub":"NCT06776952","facets":{"kind":["Trial"],"cancers":["Peripheral T-cell lymphomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Peripheral T-cell lymphomas","href":"/cancers/peripheral-t-cell-lymphoma/","tip":"Peripheral T-cell lymphomas are lymphomas of T cells rather than B cells. They are rarer, more varied and, apart from a few subtypes, harder to treat than B-cell lymphomas; several new drugs help only defined subtypes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07669454","name":"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic® 300mg Capsule in Reducing Cancer-Tumor in Patients With Metastatic Colorectal Cancer Receiving Standard Chemotherapy.","tldr":"A phase 3 trial of Nuvastatic 300 in colorectal cancer, run by Natureceuticals Sdn Bhd, now recruiting.","route":"/trials/nct07669454/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT07669454","facets":{"kind":["Trial"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07172919","name":"A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation","tldr":"A phase 2 trial of Sotorasib and Panitumumab in advanced solid tumours, run by Amgen, now recruiting.","route":"/trials/nct07172919/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07172919","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07569042","name":"A Rollover Study of NBM-BMX in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma","tldr":"A phase 1/2 trial of Temozolomide in advanced solid tumours, run by Novelwise Pharmaceutical Corporation, now recruiting.","route":"/trials/nct07569042/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07569042","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02320435","name":"A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial","tldr":"A phase 3 trial of Pertuzumab and Trastuzumab in advanced solid tumours, run by Hoffmann-La Roche, active and no longer recruiting.","route":"/trials/nct02320435/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT02320435","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06150885","name":"A Safety And Efficacy Study Of Allogeneic CAR Gamma-Delta T Cells in Subjects With Relapsed/Refractory Solid Tumors","tldr":"A phase 1/2 trial of HLA-G-CAR.BiTE allogeneic γδ T cells in advanced solid tumours, run by Ever Supreme Bio Technology Co., Ltd., now recruiting.","route":"/trials/nct06150885/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06150885","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01890746","name":"A Safety and Efficacy Study of Eltrombopag in Subjects With AML","tldr":"A phase 2 trial of Daunorubicin, Cytarabine and Eltrombopag in Leukaemia, run by Novartis Pharmaceuticals, completed.","route":"/trials/nct01890746/","status":"completed","kind":"trial","cancerIcon":"leukaemia","sub":"NCT01890746","facets":{"kind":["Trial"],"cancers":["Leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Leukaemia","href":"/cancers/leukaemia/","tip":"Leukaemia means cancer of the blood-forming cells, but the four main types share little beyond the name: acute lymphoblastic and acute myeloid leukaemia are emergencies treated with intensive therapy, while chronic lymphocytic and chronic myeloid leukaemia are slow diseases controlled for years with pills. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05329766","name":"A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies","tldr":"A phase 2 trial of Domvanalimab, Quemliclustat, Zimberelimab and Oxaliplatin in advanced solid tumours, run by Arcus Biosciences, Inc., active and no longer recruiting.","route":"/trials/nct05329766/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05329766","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03790111","name":"A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer","tldr":"A phase 2 trial of Telotristat ethyl in Biliary tract cancer and Biliary tract cancer, run by TerSera Therapeutics LLC, recorded as terminated on the registry.","route":"/trials/nct03790111/","kind":"trial","cancerIcon":"biliary-tract-cancer","sub":"NCT03790111","facets":{"kind":["Trial"],"cancers":["Biliary tract cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share a poor outlook and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00781612","name":"A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies","tldr":"A phase 2 trial of Docetaxel, Pertuzumab, Trastuzumab, Trastuzumab emtansine and Atezolizumab in advanced solid tumours, run by Genentech, Inc., active and no longer recruiting.","route":"/trials/nct00781612/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT00781612","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05806099","name":"A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL","tldr":"A phase 1/2 trial of MBS303 in non-Hodgkin lymphoma, run by Beijing Mabworks Biotech Co., Ltd., now recruiting.","route":"/trials/nct05806099/","status":"recruiting","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT05806099","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00106431","name":"A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)","tldr":"A phase 2 trial of Romidepsin in Cutaneous T-cell lymphoma, run by Celgene, completed.","route":"/trials/nct00106431/","status":"completed","kind":"trial","cancerIcon":"cutaneous-t-cell-lymphoma","sub":"NCT00106431","facets":{"kind":["Trial"],"cancers":["Cutaneous T-cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Cutaneous T-cell lymphoma","href":"/cancers/cutaneous-t-cell-lymphoma/","tip":"Mycosis fungoides is a lymphoma that lives in the skin, looking like eczema or psoriasis for years before it is diagnosed. It is treated with creams, light and skin-directed radiotherapy for as long as possible, then with antibodies such as mogamulizumab and brentuximab vedotin when it spreads to the blood or lymph nodes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06906471","name":"A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS","tldr":"A phase 1/2 trial of AS1986NS in prostate cancer, run by Antelope Surgical Solutions, Inc, now recruiting.","route":"/trials/nct06906471/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT06906471","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05482971","name":"A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET","tldr":"A phase 2 trial of Ropeginterferon alfa-2b in myeloproliferative neoplasms, run by PharmaEssentia, active and no longer recruiting.","route":"/trials/nct05482971/","status":"active","kind":"trial","cancerIcon":"myeloproliferative-neoplasms","sub":"NCT05482971","facets":{"kind":["Trial"],"cancers":["Myeloproliferative neoplasms","Essential thrombocythaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Myeloproliferative neoplasms","href":"/cancers/myeloproliferative-neoplasms/","tip":"Myeloproliferative neoplasms are slow-growing blood cancers in which the marrow overproduces red cells (polycythaemia vera), platelets (essential thrombocythaemia) or scar tissue (myelofibrosis). Almost all carry a mutation in JAK2, CALR or MPL; treatment aims to prevent clots and control symptoms, and only transplant cures myelofibrosis."},{"label":"Essential thrombocythaemia","href":"/cancers/essential-thrombocythaemia/","tip":"Essential thrombocythaemia is a slow blood cancer in which the marrow makes too many platelets. Most people need only aspirin and monitoring; those at higher risk of clots take a drug to lower the platelet count, usually hydroxyurea or interferon, with anagrelide in reserve."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06812260","name":"A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC","tldr":"A phase 2 trial of HLX10+chemo in small-cell lung cancer, run by Shanghai Henlius Biotech, active and no longer recruiting.","route":"/trials/nct06812260/","status":"active","kind":"trial","cancerIcon":"sclc","sub":"NCT06812260","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer","Extensive-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."},{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07415031","name":"A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies","tldr":"A phase 2 trial of Adagrasib, Pembrolizumab, Cetuximab, Pemetrexed, Docetaxel and Oxaliplatin in advanced solid tumours, run by Mirati Therapeutics Inc., now recruiting.","route":"/trials/nct07415031/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07415031","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06413706","name":"A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy","tldr":"A phase 2 trial of Abemaciclib and Temozolomide in glioma & glioblastoma, run by Eli Lilly and Company, active and no longer recruiting.","route":"/trials/nct06413706/","status":"active","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT06413706","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma","Paediatric high-grade glioma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."},{"label":"Paediatric high-grade glioma","href":"/cancers/paediatric-high-grade-glioma/","tip":"High-grade gliomas in children look like adult glioblastoma under the microscope but are driven by different genes, so they are now classified separately. Surgery and radiotherapy remain the mainstay and chemotherapy adds little; the real gains are in small subsets with a targetable gene change, such as BRAF V600E tumours and the fusion-driven tumours of infants."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06857175","name":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)","tldr":"A phase 3 trial of Docetaxel in bladder & urothelial cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct06857175/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT06857175","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07648914","name":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)","tldr":"A phase 3 trial of Capecitabine in advanced solid tumours, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07648914/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07648914","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06343948","name":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)","tldr":"A phase 3 trial of Eribulin, Vinorelbine, Gemcitabine and Capecitabine in advanced solid tumours, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.","route":"/trials/nct06343948/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06343948","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07582315","name":"A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)","tldr":"A phase 3 trial of Oxaliplatin and Capecitabine in biliary tract cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07582315/","status":"recruiting","kind":"trial","cancerIcon":"cholangiocarcinoma","sub":"NCT07582315","facets":{"kind":["Trial"],"cancers":["Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07518147","name":"A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment","tldr":"A phase 3 trial of Docetaxel in gastric & gastro-oesophageal junction cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07518147/","status":"recruiting","kind":"trial","cancerIcon":"gastric","sub":"NCT07518147","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07678957","name":"A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer","tldr":"A phase 2 trial of BL-M07D1 in HER2-positive breast cancer and HR-positive / HER2-negative breast cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07678957/","status":"recruiting","kind":"trial","cancerIcon":"breast-her2-positive","sub":"NCT07678957","facets":{"kind":["Trial"],"cancers":["HER2-positive breast cancer","HR-positive / HER2-negative breast cancer","HER2-low and HER2-ultralow metastatic breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."},{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"HER2-low and HER2-ultralow metastatic breast cancer","href":"/cancers/her2-low-metastatic-breast-cancer/","tip":"HER2-low is not a new kind of breast cancer but a new way of reading an old test: tumours once called HER2-negative that carry a little HER2 protein. That trace is enough for the antibody-drug conjugate trastuzumab deruxtecan to deliver its chemotherapy payload, and since 2022 it has been the standard for these patients after endocrine therapy or a first chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04576156","name":"A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment","tldr":"A phase 3 trial of Imetelstat in myeloproliferative neoplasms, run by Geron Corporation, active and no longer recruiting.","route":"/trials/nct04576156/","status":"active","kind":"trial","cancerIcon":"myeloproliferative-neoplasms","sub":"NCT04576156","facets":{"kind":["Trial"],"cancers":["Myeloproliferative neoplasms","Primary myelofibrosis"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Myeloproliferative neoplasms","href":"/cancers/myeloproliferative-neoplasms/","tip":"Myeloproliferative neoplasms are slow-growing blood cancers in which the marrow overproduces red cells (polycythaemia vera), platelets (essential thrombocythaemia) or scar tissue (myelofibrosis). Almost all carry a mutation in JAK2, CALR or MPL; treatment aims to prevent clots and control symptoms, and only transplant cures myelofibrosis."},{"label":"Primary myelofibrosis","href":"/cancers/primary-myelofibrosis/","tip":"Primary myelofibrosis is a blood cancer in which the marrow scars over, the spleen swells and patients become anaemic and exhausted. JAK inhibitors, ruxolitinib first (COMFORT) and then fedratinib, pacritinib and momelotinib (MOMENTUM), shrink the spleen and relieve symptoms; only a donor stem cell transplant can cure it."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05883956","name":"A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia","tldr":"A phase 3 trial of Azacitidine and Decitabine in myelodysplastic syndromes / neoplasms, run by Otsuka Australia Pharmaceutical Pty Ltd, active and no longer recruiting.","route":"/trials/nct05883956/","status":"active","kind":"trial","cancerIcon":"mds","sub":"NCT05883956","facets":{"kind":["Trial"],"cancers":["Myelodysplastic syndromes / neoplasms","Higher-risk myelodysplastic syndromes"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Myelodysplastic syndromes / neoplasms","href":"/cancers/mds/","tip":"Bone-marrow disorders where blood cells are made badly and too few reach the blood; a third progress to acute leukaemia. Treatment ranges from transfusions and growth factors to hypomethylating drugs and, for the fit, transplant."},{"label":"Higher-risk myelodysplastic syndromes","href":"/cancers/mds-higher-risk/","tip":"Higher-risk myelodysplastic syndromes behave like a slow leukaemia and often become one. Azacitidine lengthens life and a donor stem cell transplant is the only cure; every attempt to improve on azacitidine in a large trial, including the venetoclax combination tested in VERONA, has so far failed."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05459844","name":"A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs","tldr":"A phase 3 trial of Lutetium[177Lu] Oxodotreotide Injection in neuroendocrine tumours, run by Sinotau Pharmaceutical Group, active and no longer recruiting.","route":"/trials/nct05459844/","status":"active","kind":"trial","cancerIcon":"neuroendocrine","sub":"NCT05459844","facets":{"kind":["Trial"],"cancers":["Neuroendocrine tumours","Pancreatic neuroendocrine tumours","Small intestinal neuroendocrine tumours"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Neuroendocrine tumours","href":"/cancers/neuroendocrine/","tip":"A family of usually slow-growing tumours that start in hormone-producing cells of the gut, pancreas and lungs. They pioneered the idea of using the same molecule to see a tumour on a scan and then to treat it with radiation."},{"label":"Pancreatic neuroendocrine tumours","href":"/cancers/pancreatic-net/","tip":"Pancreatic neuroendocrine tumours arise from the hormone-producing islet cells of the pancreas and behave very differently from ordinary pancreatic cancer, often growing for years. Surgery cures localised tumours; advanced disease is treated in sequence with somatostatin analogues, lutetium-177 dotatate, targeted tablets and oral chemotherapy, and a minority secrete insulin or gastrin."},{"label":"Small intestinal neuroendocrine tumours","href":"/cancers/small-intestinal-net/","tip":"Small intestinal neuroendocrine tumours are slow-growing hormone-producing tumours of the ileum and jejunum, often found only after they have spread to lymph nodes and the liver. Monthly somatostatin analogue injections control symptoms and growth, lutetium-177 dotatate is the main second treatment, and everolimus, cabozantinib and surgery fill in."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04641754","name":"A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer","tldr":"A phase 2 trial of Iruplinalkib in Non-small-cell lung cancer, run by Qilu Pharmaceutical Co., Ltd., with a status the registry has not verified recently.","route":"/trials/nct04641754/","kind":"trial","cancerIcon":"nsclc","sub":"NCT04641754","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05658003","name":"A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer","tldr":"A phase 2 trial of [177Lu]Lu-PSMA-617 in prostate cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.","route":"/trials/nct05658003/","status":"active","kind":"trial","cancerIcon":"prostate","sub":"NCT05658003","facets":{"kind":["Trial"],"cancers":["Prostate cancer","Metastatic castration-resistant prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Metastatic castration-resistant prostate cancer","href":"/cancers/prostate-mcrpc/","tip":"Metastatic castration-resistant prostate cancer is disease that grows despite castrate testosterone. Sequenced treatments now include androgen receptor inhibitors, docetaxel and cabazitaxel, PARP inhibitors for men with BRCA-type mutations, the radioligand 177Lu-PSMA-617 and radium-223 for bone-predominant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07541079","name":"A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)","tldr":"A phase 3 trial of Giredestrant in advanced solid tumours, run by Genentech, Inc., now recruiting.","route":"/trials/nct07541079/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07541079","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04496349","name":"A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL","tldr":"A phase 2 trial of APG-115 in hodgkin lymphoma, run by Ascentage Pharma Group Inc., now recruiting.","route":"/trials/nct04496349/","status":"recruiting","kind":"trial","cancerIcon":"hodgkin-lymphoma","sub":"NCT04496349","facets":{"kind":["Trial"],"cancers":["Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hodgkin lymphoma","href":"/cancers/hodgkin-lymphoma/","tip":"Hodgkin lymphoma is one of the most curable cancers, where the goal is now to cure with less toxicity, using brentuximab and, from 2026, first-line nivolumab."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05645692","name":"A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer","tldr":"A phase 2 trial of Atezolizumab and Tiragolumab in bladder & urothelial cancer, run by Hoffmann-La Roche, active and no longer recruiting.","route":"/trials/nct05645692/","status":"active","kind":"trial","cancerIcon":"urothelial","sub":"NCT05645692","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06244771","name":"A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors","tldr":"A phase 1/2 trial of FMC-376 in non-small-cell lung cancer, colorectal cancer and pancreatic ductal adenocarcinoma, run by Frontier Medicines Corporation, now recruiting.","route":"/trials/nct06244771/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06244771","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","Colorectal cancer","Pancreatic ductal adenocarcinoma","KRAS G12C-mutant colorectal cancer","KRAS G12C-mutant non-small-cell lung cancer","KRAS G12C-mutant pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"KRAS G12C-mutant colorectal cancer","href":"/cancers/kras-g12c-colorectal/","tip":"KRAS G12C bowel cancer carries a mutation that was undruggable for forty years. The first KRAS drugs work only weakly on their own in the bowel, because the tumour switches EGFR back on, so they are given with an anti-EGFR antibody: sotorasib with panitumumab and adagrasib with cetuximab are both approved after chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06970639","name":"A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases","tldr":"A phase 3 trial of Furmonertinib, Carboplatin, Cisplatin, Pemetrexed and Osimertinib in non-small-cell lung cancer, run by Allist Pharmaceuticals, Inc., now recruiting.","route":"/trials/nct06970639/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06970639","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03416179","name":"A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia","tldr":"A phase 3 trial of Glasdegib, CPX-351, Azacitidine and Cytarabine in Leukaemia, run by Pfizer, completed.","route":"/trials/nct03416179/","status":"completed","kind":"trial","cancerIcon":"leukaemia","sub":"NCT03416179","facets":{"kind":["Trial"],"cancers":["Leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Leukaemia","href":"/cancers/leukaemia/","tip":"Leukaemia means cancer of the blood-forming cells, but the four main types share little beyond the name: acute lymphoblastic and acute myeloid leukaemia are emergencies treated with intensive therapy, while chronic lymphocytic and chronic myeloid leukaemia are slow diseases controlled for years with pills. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07124117","name":"A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors","tldr":"A phase 1/2 trial of OBI-902 in advanced solid tumours, run by OBI Pharma, Inc, now recruiting.","route":"/trials/nct07124117/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07124117","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07321574","name":"A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors","tldr":"A phase 2 trial of ABP1011T in small-cell lung cancer, run by Shanghai AB PharmaTech Ltd., now recruiting.","route":"/trials/nct07321574/","status":"recruiting","kind":"trial","cancerIcon":"sclc","sub":"NCT07321574","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04873362","name":"A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy","tldr":"A phase 3 trial of Atezolizumab, Trastuzumab emtansine and Trastuzumab in HER2-positive breast cancer, run by Hoffmann-La Roche, active and no longer recruiting.","route":"/trials/nct04873362/","status":"active","kind":"trial","cancerIcon":"breast-her2-positive","sub":"NCT04873362","facets":{"kind":["Trial"],"cancers":["HER2-positive breast cancer","Early HER2-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."},{"label":"Early HER2-positive breast cancer","href":"/cancers/her2-positive-early-breast-cancer/","tip":"HER2-positive breast cancer caught early is usually cured. Chemotherapy with the antibodies trastuzumab and pertuzumab comes before surgery; if the tumour has gone by then, antibodies alone finish the year, and if cancer remains, trastuzumab emtansine or trastuzumab deruxtecan take over. Small tumours get a gentler regimen, and trials now ask how much treatment can be left out."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04576455","name":"A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)","tldr":"A phase 2 trial of Giredestrant and Fulvestrant in HR-positive / HER2-negative breast cancer, run by Hoffmann-La Roche, active and no longer recruiting.","route":"/trials/nct04576455/","status":"active","kind":"trial","cancerIcon":"breast-hr-positive","sub":"NCT04576455","facets":{"kind":["Trial"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":["2023"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"year":{"facet":"year","value":"2023"},"tags":[]},"sortKeys":{"year":2023}},{"id":"nct06790693","name":"A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer","tldr":"A phase 3 trial of Inavolisib in HR-positive / HER2-negative breast cancer, run by Hoffmann-La Roche, now recruiting.","route":"/trials/nct06790693/","status":"recruiting","kind":"trial","cancerIcon":"breast-hr-positive","sub":"NCT06790693","facets":{"kind":["Trial"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05646862","name":"A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy","tldr":"A phase 3 trial of Inavolisib, Fulvestrant and Alpelisib in HR-positive / HER2-negative breast cancer, run by Hoffmann-La Roche, now recruiting.","route":"/trials/nct05646862/","status":"recruiting","kind":"trial","cancerIcon":"breast-hr-positive","sub":"NCT05646862","facets":{"kind":["Trial"],"cancers":["HR-positive / HER2-negative breast cancer","HR-positive metastatic breast cancer after CDK4/6 inhibitors"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"HR-positive metastatic breast cancer after CDK4/6 inhibitors","href":"/cancers/hr-positive-metastatic-post-cdk46/","tip":"When hormone-positive breast cancer grows through a CDK4/6 inhibitor, a blood test picks the next drug. Tumours with an acquired ESR1 mutation respond to the oral degraders elacestrant, camizestrant and imlunestrant; tumours with PIK3CA, AKT1 or PTEN changes to capivasertib, inavolisib or alpelisib; and once endocrine options run out, antibody-drug conjugates come before chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04802759","name":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer","tldr":"A phase 1/2 trial of Giredestrant, Abemaciclib, Ipatasertib, Inavolisib, Ribociclib and Everolimus in HR-positive / HER2-negative breast cancer, run by Hoffmann-La Roche, now recruiting.","route":"/trials/nct04802759/","status":"recruiting","kind":"trial","cancerIcon":"breast-hr-positive","sub":"NCT04802759","facets":{"kind":["Trial"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03424005","name":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","tldr":"A phase 1/2 trial of Capecitabine, Atezolizumab, Ipatasertib, Bevacizumab, Carboplatin and Eribulin in advanced solid tumours, run by Hoffmann-La Roche, now recruiting.","route":"/trials/nct03424005/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT03424005","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06588478","name":"A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","tldr":"A phase 2 trial of Pirtobrutinib in chronic lymphocytic leukaemia, run by Loxo Oncology, Inc., now recruiting.","route":"/trials/nct06588478/","status":"recruiting","kind":"trial","cancerIcon":"cll","sub":"NCT06588478","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia","Relapsed or refractory chronic lymphocytic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Relapsed or refractory chronic lymphocytic leukaemia","href":"/cancers/cll-relapsed/","tip":"When chronic lymphocytic leukaemia returns, the usual move is to switch drug class: venetoclax-based therapy after a BTK inhibitor, or a BTK inhibitor after venetoclax. Pirtobrutinib (BRUIN) works after the older BTK inhibitors fail, and CAR-T is approved for patients who have run out of both classes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07602777","name":"A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)","tldr":"A phase 1/2 trial of Ris-Rez in sarcomas, run by GlaxoSmithKline, now recruiting.","route":"/trials/nct07602777/","status":"recruiting","kind":"trial","cancerIcon":"sarcoma","sub":"NCT07602777","facets":{"kind":["Trial"],"cancers":["Sarcomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Sarcomas","href":"/cancers/sarcoma/","tip":"Sarcomas are dozens of rare cancers of bone and connective tissue. GIST was the first solid tumour cured-in-practice by a targeted pill; synovial sarcoma got the first TCR-T therapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05885464","name":"A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)","tldr":"A phase 1/2 trial of BEAM-201 in non-Hodgkin lymphoma, run by Beam Therapeutics Inc., active and no longer recruiting.","route":"/trials/nct05885464/","status":"active","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT05885464","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05417321","name":"A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors","tldr":"A phase 1/2 trial of HB0036 in non-small-cell lung cancer, run by Shanghai Huaota Biopharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct05417321/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT05417321","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05893888","name":"A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers","tldr":"A phase 2/3 trial of Cisplatin in head and neck squamous cell carcinoma, run by Privo Technologies, now recruiting.","route":"/trials/nct05893888/","status":"recruiting","kind":"trial","cancerIcon":"head-and-neck","sub":"NCT05893888","facets":{"kind":["Trial"],"cancers":["Head and neck squamous cell carcinoma","Oral cavity cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Oral cavity cancer","href":"/cancers/oral-cavity-cancer/","tip":"Cancer of the mouth and tongue, a head and neck cancer, is caused mainly by tobacco, alcohol and betel quid and is usually visible or feelable early, yet often diagnosed late. Surgery is the mainstay, with radiotherapy or chemoradiation after operation for higher-risk disease, and reconstruction to restore speech and swallowing."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04774718","name":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors","tldr":"A phase 1/2 trial of Alectinib in brain and spinal cord tumours, run by Hoffmann-La Roche, active and no longer recruiting.","route":"/trials/nct04774718/","status":"active","kind":"trial","cancerIcon":"brain-tumours","sub":"NCT04774718","facets":{"kind":["Trial"],"cancers":["Brain and spinal cord tumours"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Brain and spinal cord tumours","href":"/cancers/brain-tumours/","tip":"Brain and spinal cord tumours range from slow-growing meningiomas and low-grade gliomas to glioblastoma, the commonest malignant brain tumour in adults, and a distinct set of childhood tumours such as medulloblastoma and diffuse midline glioma. Molecular markers now define them, and treatment is surgery, radiotherapy and, for some, drugs chosen by those markers."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07567846","name":"A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer","tldr":"A phase 1/2 trial of GDC-1261 in prostate cancer, run by Genentech, Inc., now recruiting.","route":"/trials/nct07567846/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT07567846","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05773820","name":"A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of WJB001 in advanced solid tumours, run by Wigen Biomedicine Technology (Shanghai) Co., Ltd., now recruiting.","route":"/trials/nct05773820/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05773820","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06314373","name":"A Study for HSK39775 in Participants With Solid Tumors","tldr":"A phase 1/2 trial of HSK39775 Monotherapy in advanced solid tumours, run by Xizang Haisco Pharmaceutical Co., Ltd, now recruiting.","route":"/trials/nct06314373/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06314373","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07541430","name":"A Study in Adults With Desmoid Tumors","tldr":"A phase 2 trial of ES014 in desmoid tumour, run by Elpiscience (Suzhou) Biopharma, Ltd., now recruiting.","route":"/trials/nct07541430/","status":"recruiting","kind":"trial","cancerIcon":"desmoid-tumour","sub":"NCT07541430","facets":{"kind":["Trial"],"cancers":["Desmoid tumour"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Desmoid tumour","href":"/cancers/desmoid-tumour/","tip":"Desmoid tumours are locally aggressive growths of fibroblast-like cells, classed with soft-tissue sarcomas, driven by WNT mutations, that never spread to distant organs but can invade nerves, bowel and muscle. Many stop growing or shrink on their own, so watching first is standard; if they progress, the gamma-secretase inhibitor nirogacestat, approved in 2023, shrinks tumours and relieves pain."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07280377","name":"A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab","tldr":"A phase 1/2 trial of Atezolizumab, Gemcitabine and Trifluridine/tipiracil in anal cancer and pancreatic ductal adenocarcinoma, run by Oncolytics Biotech, active and no longer recruiting.","route":"/trials/nct07280377/","status":"active","kind":"trial","cancerIcon":"anal","sub":"NCT07280377","facets":{"kind":["Trial"],"cancers":["Anal cancer","Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Anal cancer","href":"/cancers/anal/","tip":"An HPV-caused cancer of the anal canal that is usually cured without surgery by combined chemotherapy and radiation. Prevention (HPV vaccination, screening of high-risk groups) and immunotherapy for advanced disease are the new fronts."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03148418","name":"A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)","tldr":"A phase 3 trial of Atezolizumab and Bevacizumab in advanced solid tumours, run by Hoffmann-La Roche, active and no longer recruiting.","route":"/trials/nct03148418/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT03148418","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04939610","name":"A Study of 177Lu-FAP-2286 in Advanced Solid Tumors","tldr":"A phase 1/2 trial of FAP-2286 (177Lu / 68Ga) in advanced solid tumours, run by Novartis Pharmaceuticals, now recruiting.","route":"/trials/nct04939610/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04939610","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06378593","name":"A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations","tldr":"A phase 1/2 trial of 3HP-2827 in advanced solid tumours, run by 3H (Suzhou) Pharmaceuticals Co., Ltd., now recruiting.","route":"/trials/nct06378593/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06378593","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05526755","name":"A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)","tldr":"A phase 2 trial of Osimertinib in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct05526755/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT05526755","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07299825","name":"A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer","tldr":"A phase 2 trial of A166 in HER2-positive breast cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07299825/","status":"recruiting","kind":"trial","cancerIcon":"breast-her2-positive","sub":"NCT07299825","facets":{"kind":["Trial"],"cancers":["HER2-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04395677","name":"A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene","tldr":"A phase 2 trial of AB-106 in non-small-cell lung cancer, run by Nuvation Bio Inc., active and no longer recruiting.","route":"/trials/nct04395677/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT04395677","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","ROS1-positive non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"ROS1-positive non-small-cell lung cancer","href":"/cancers/ros1-positive-nsclc/","tip":"ROS1-positive lung cancer is a rare fusion-driven adenocarcinoma treated with a pill. Crizotinib was the first, and the newer drugs repotrectinib and taletrectinib control the disease for about three years, reach the brain and work against the resistance mutation that defeated the older drugs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02107703","name":"A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer","tldr":"A phase 3 trial of Abemaciclib and Fulvestrant in HR-positive / HER2-negative breast cancer, run by Eli Lilly and Company, active and no longer recruiting.","route":"/trials/nct02107703/","status":"active","kind":"trial","cancerIcon":"breast-hr-positive","sub":"NCT02107703","facets":{"kind":["Trial"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":["2018"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"year":{"facet":"year","value":"2018"},"tags":[]},"sortKeys":{"year":2018}},{"id":"nct02763566","name":"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer","tldr":"A phase 3 trial of Abemaciclib and Fulvestrant in advanced solid tumours, run by Eli Lilly and Company, active and no longer recruiting.","route":"/trials/nct02763566/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT02763566","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":["2020"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"year":{"facet":"year","value":"2020"},"tags":[]},"sortKeys":{"year":2020}},{"id":"nct02747004","name":"A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer","tldr":"A phase 2 trial of Abemaciclib and Tamoxifen in advanced solid tumours, run by Eli Lilly and Company, active and no longer recruiting.","route":"/trials/nct02747004/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT02747004","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":["2019"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"year":{"facet":"year","value":"2019"},"tags":[]},"sortKeys":{"year":2019}},{"id":"nct05288166","name":"A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)","tldr":"A phase 3 trial of Abemaciclib and Prednisone in prostate cancer, run by Eli Lilly and Company, active and no longer recruiting.","route":"/trials/nct05288166/","status":"active","kind":"trial","cancerIcon":"prostate","sub":"NCT05288166","facets":{"kind":["Trial"],"cancers":["Prostate cancer","Metastatic hormone-sensitive prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Metastatic hormone-sensitive prostate cancer","href":"/cancers/prostate-mhspc/","tip":"Metastatic hormone-sensitive prostate cancer is disease that has spread but still responds to lowering testosterone. Hormone therapy alone is no longer enough: adding an androgen receptor inhibitor, and docetaxel for high-volume disease, lengthens life by years."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05057494","name":"A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","tldr":"A phase 3 trial of Acalabrutinib, Venetoclax and Obinutuzumab in chronic lymphocytic leukaemia, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct05057494/","status":"active","kind":"trial","cancerIcon":"cll","sub":"NCT05057494","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia","Chronic lymphocytic leukaemia, first treatment"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Chronic lymphocytic leukaemia, first treatment","href":"/cancers/cll-treatment-naive/","tip":"Chronic lymphocytic leukaemia is treated only when it causes problems, and chemotherapy has gone. The first treatment is now either a BTK inhibitor taken indefinitely or a one-year course of venetoclax with obinutuzumab (CLL14), and the two can be combined for a fixed course."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02970318","name":"A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL","tldr":"A phase 3 trial of Acalabrutinib, Rituximab, Idelalisib and Bendamustine in chronic lymphocytic leukaemia, run by Acerta Pharma BV, active and no longer recruiting.","route":"/trials/nct02970318/","status":"active","kind":"trial","cancerIcon":"cll","sub":"NCT02970318","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia","Relapsed or refractory chronic lymphocytic leukaemia"],"year":["2023"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Relapsed or refractory chronic lymphocytic leukaemia","href":"/cancers/cll-relapsed/","tip":"When chronic lymphocytic leukaemia returns, the usual move is to switch drug class: venetoclax-based therapy after a BTK inhibitor, or a BTK inhibitor after venetoclax. Pirtobrutinib (BRUIN) works after the older BTK inhibitors fail, and CAR-T is approved for patients who have run out of both classes."}],"year":{"facet":"year","value":"2023"},"tags":[]},"sortKeys":{"year":2023}},{"id":"nct02717611","name":"A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy","tldr":"A phase 2 trial of Acalabrutinib in chronic lymphocytic leukaemia, run by Acerta Pharma BV, active and no longer recruiting.","route":"/trials/nct02717611/","status":"active","kind":"trial","cancerIcon":"cll","sub":"NCT02717611","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia","Relapsed or refractory chronic lymphocytic leukaemia"],"year":["2022"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Relapsed or refractory chronic lymphocytic leukaemia","href":"/cancers/cll-relapsed/","tip":"When chronic lymphocytic leukaemia returns, the usual move is to switch drug class: venetoclax-based therapy after a BTK inhibitor, or a BTK inhibitor after venetoclax. Pirtobrutinib (BRUIN) works after the older BTK inhibitors fail, and CAR-T is approved for patients who have run out of both classes."}],"year":{"facet":"year","value":"2022"},"tags":[]},"sortKeys":{"year":2022}},{"id":"nct06875310","name":"A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)","tldr":"A phase 3 trial of Adagrasib, Pembrolizumab, Carboplatin, Pemetrexed and Cisplatin in non-small-cell lung cancer, run by Mirati Therapeutics Inc., now recruiting.","route":"/trials/nct06875310/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06875310","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","KRAS G12C-mutant non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"KRAS G12C-mutant non-small-cell lung cancer","href":"/cancers/kras-g12c-nsclc/","tip":"KRAS G12C lung cancer carries a mutation that was thought impossible to drug for forty years. Sotorasib and adagrasib now shrink about four in ten tumours after chemotherapy and immunotherapy, though the benefit is measured in months, and newer inhibitors and first-line combinations with immunotherapy are in trials."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04673942","name":"A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors","tldr":"A phase 2 trial of AdAPT-001 in sarcomas, run by EpicentRx, Inc., active and no longer recruiting.","route":"/trials/nct04673942/","status":"active","kind":"trial","cancerIcon":"sarcoma","sub":"NCT04673942","facets":{"kind":["Trial"],"cancers":["Sarcomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Sarcomas","href":"/cancers/sarcoma/","tip":"Sarcomas are dozens of rare cancers of bone and connective tissue. GIST was the first solid tumour cured-in-practice by a targeted pill; synovial sarcoma got the first TCR-T therapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04557059","name":"A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer","tldr":"A phase 3 trial of Apalutamide in prostate cancer, run by Janssen Pharmaceutica N.V., Belgium, active and no longer recruiting.","route":"/trials/nct04557059/","status":"active","kind":"trial","cancerIcon":"prostate","sub":"NCT04557059","facets":{"kind":["Trial"],"cancers":["Prostate cancer","Localised prostate cancer, high and very high risk"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Localised prostate cancer, high and very high risk","href":"/cancers/prostate-high-risk/","tip":"High-risk prostate cancer has Grade Group 4 or 5 disease, a PSA above 20 or a tumour growing beyond the gland. It is still curable, but needs radiotherapy with two to three years of hormone therapy, or surgery followed by radiotherapy, and adding abiraterone to hormone therapy now lengthens life in the highest-risk men."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06111235","name":"A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT","tldr":"A phase 3 trial of Cretostimogene grenadenorepvec in bladder & urothelial cancer, run by CG Oncology, Inc., active and no longer recruiting.","route":"/trials/nct06111235/","status":"active","kind":"trial","cancerIcon":"urothelial","sub":"NCT06111235","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Non-muscle-invasive bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Non-muscle-invasive bladder cancer","href":"/cancers/non-muscle-invasive-bladder-cancer/","tip":"Most bladder cancers are found while still confined to the lining. They are scraped out through the urethra and, when higher risk, treated with BCG instilled into the bladder; the challenge is the frequent recurrences and the patients whose tumours stop responding to BCG."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01882868","name":"A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan","tldr":"A phase 2 trial of Ziv-aflibercept, Irinotecan and Fluorouracil in Colorectal cancer, run by Sanofi, completed.","route":"/trials/nct01882868/","status":"completed","kind":"trial","cancerIcon":"colorectal","sub":"NCT01882868","facets":{"kind":["Trial"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05859750","name":"A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer","tldr":"A phase 2 trial of Cadonilimab, Gemcitabine, Leucovorin (folinic acid) and Oxaliplatin in pancreatic ductal adenocarcinoma, run by Akeso, now recruiting.","route":"/trials/nct05859750/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT05859750","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05235516","name":"A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer","tldr":"A phase 3 trial of Cadonilimab and Cisplatin in cervical cancer, run by Akeso, active and no longer recruiting.","route":"/trials/nct05235516/","status":"active","kind":"trial","cancerIcon":"cervical","sub":"NCT05235516","facets":{"kind":["Trial"],"cancers":["Cervical cancer","Locally advanced cervical cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."},{"label":"Locally advanced cervical cancer","href":"/cancers/locally-advanced-cervical-cancer/","tip":"Locally advanced cervical cancer has grown beyond the cervix or into the pelvic lymph nodes but not to distant organs. It is treated with cisplatin chemotherapy given alongside external radiotherapy and brachytherapy, and two recent trials have improved on that: adding pembrolizumab, and giving six weeks of chemotherapy before the radiotherapy starts."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05142423","name":"A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of AK109+AK104 in advanced solid tumours, run by Akeso, now recruiting.","route":"/trials/nct05142423/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05142423","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05227664","name":"A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer","tldr":"A phase 2 trial of AK117 in triple-negative breast cancer, run by Akeso, active and no longer recruiting.","route":"/trials/nct05227664/","status":"active","kind":"trial","cancerIcon":"tnbc","sub":"NCT05227664","facets":{"kind":["Trial"],"cancers":["Triple-negative breast cancer","Metastatic triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Metastatic triple-negative breast cancer","href":"/cancers/tnbc-metastatic/","tip":"Triple-negative breast cancer that has spread is not curable, but its treatment has been transformed since 2020. By PD-L1 score, first treatment is pembrolizumab with chemotherapy or with sacituzumab govitecan, or datopotamab deruxtecan or sacituzumab govitecan alone; BRCA carriers can take a PARP inhibitor tablet; and trastuzumab deruxtecan reaches the third of tumours with low HER2."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06938321","name":"A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer","tldr":"A phase 1/2 trial of AK112 in biliary tract cancer, run by Akeso, now recruiting.","route":"/trials/nct06938321/","status":"recruiting","kind":"trial","cancerIcon":"cholangiocarcinoma","sub":"NCT06938321","facets":{"kind":["Trial"],"cancers":["Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07114315","name":"A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer","tldr":"A phase 2 trial of AK112 in pancreatic ductal adenocarcinoma, run by Akeso, now recruiting.","route":"/trials/nct07114315/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT07114315","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06369285","name":"A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer","tldr":"A phase 2 trial of Alisertib in HR-positive / HER2-negative breast cancer, run by Puma Biotechnology, Inc., now recruiting.","route":"/trials/nct06369285/","status":"recruiting","kind":"trial","cancerIcon":"breast-hr-positive","sub":"NCT06369285","facets":{"kind":["Trial"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06095505","name":"A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer","tldr":"A phase 2 trial of Alisertib in small-cell lung cancer, run by Puma Biotechnology, Inc., now recruiting.","route":"/trials/nct06095505/","status":"recruiting","kind":"trial","cancerIcon":"sclc","sub":"NCT06095505","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer","Extensive-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."},{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06385080","name":"A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer","tldr":"A phase 1/2 trial of Amivantamab, Pembrolizumab and Carboplatin in head and neck squamous cell carcinoma, run by Janssen Research & Development, LLC, now recruiting.","route":"/trials/nct06385080/","status":"recruiting","kind":"trial","cancerIcon":"head-and-neck","sub":"NCT06385080","facets":{"kind":["Trial"],"cancers":["Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05488314","name":"A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer","tldr":"A phase 1/2 trial of Capmatinib and Amivantamab in non-small-cell lung cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.","route":"/trials/nct05488314/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT05488314","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06750094","name":"A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy","tldr":"A phase 3 trial of Amivantamab, Cetuximab, Bevacizumab and Leucovorin (folinic acid) in colorectal cancer, run by Janssen Research & Development, LLC, now recruiting.","route":"/trials/nct06750094/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT06750094","facets":{"kind":["Trial"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04988295","name":"A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure","tldr":"A phase 3 trial of Lazertinib, Amivantamab, Pemetrexed and Carboplatin in non-small-cell lung cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.","route":"/trials/nct04988295/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT04988295","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","EGFR-mutated non-small-cell lung cancer"],"year":["2025"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"year":{"facet":"year","value":"2025"},"tags":[]},"sortKeys":{"year":2025}},{"id":"nct06662786","name":"A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","tldr":"A phase 3 trial of Amivantamab, Cetuximab, Leucovorin (folinic acid) and Oxaliplatin in colorectal cancer, run by Janssen Research & Development, LLC, now recruiting.","route":"/trials/nct06662786/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT06662786","facets":{"kind":["Trial"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07227025","name":"A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer","tldr":"A phase 1/2 trial of Amivantamab and Olomorasib in non-small-cell lung cancer, run by Janssen Research & Development, LLC, now recruiting.","route":"/trials/nct07227025/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07227025","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07276399","name":"A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer","tldr":"A phase 3 trial of Amivantamab, Pembrolizumab, Carboplatin and Cisplatin in head and neck squamous cell carcinoma, run by Janssen Research & Development, LLC, now recruiting.","route":"/trials/nct07276399/","status":"recruiting","kind":"trial","cancerIcon":"head-and-neck","sub":"NCT07276399","facets":{"kind":["Trial"],"cancers":["Head and neck squamous cell carcinoma","Recurrent or metastatic head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Recurrent or metastatic head and neck squamous cell carcinoma","href":"/cancers/recurrent-metastatic-hnscc/","tip":"When head and neck cancer comes back where it cannot be removed, or spreads elsewhere, it is treated to extend life rather than cure: pembrolizumab, alone or with chemotherapy, is the first choice, cetuximab-based regimens and cheap oral chemotherapy are alternatives, and antibodies that hit two targets at once are in late-stage trials."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06667076","name":"A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","tldr":"A phase 2 trial of Amivantamab, Lazertinib, Pemetrexed and Carboplatin in non-small-cell lung cancer, run by Janssen Research & Development, LLC, now recruiting.","route":"/trials/nct06667076/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06667076","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05498428","name":"A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer","tldr":"A phase 2 trial of Amivantamab, Lazertinib, Carboplatin and Pemetrexed in non-small-cell lung cancer, run by Janssen Research & Development, LLC, now recruiting.","route":"/trials/nct05498428/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT05498428","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06777316","name":"A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors","tldr":"A phase 1/2 trial of CGT4859 in biliary tract cancer, run by Cogent Biosciences, Inc., active and no longer recruiting.","route":"/trials/nct06777316/","status":"active","kind":"trial","cancerIcon":"cholangiocarcinoma","sub":"NCT06777316","facets":{"kind":["Trial"],"cancers":["Biliary tract cancer","Intrahepatic cholangiocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Intrahepatic cholangiocarcinoma","href":"/cancers/intrahepatic-cholangiocarcinoma/","tip":"Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and usually appears as a liver mass rather than causing jaundice. It is the biliary cancer with the most drug targets: FGFR2 fusions treated with pemigatinib or futibatinib, IDH1 mutations with ivosidenib, and for everyone chemotherapy with the immunotherapy durvalumab or pembrolizumab."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05094336","name":"A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)","tldr":"A phase 1/2 trial of Anvumetostat and Docetaxel in advanced solid tumours, run by Amgen, active and no longer recruiting.","route":"/trials/nct05094336/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05094336","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06669975","name":"A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors","tldr":"A phase 1/2 trial of AP402 (Part 1 Dose esclation) in advanced solid tumours, run by AP Biosciences Inc., now recruiting.","route":"/trials/nct06669975/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06669975","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01946204","name":"A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer","tldr":"A phase 3 trial of Apalutamide in prostate cancer, run by Aragon Pharmaceuticals, Inc., active and no longer recruiting.","route":"/trials/nct01946204/","status":"active","kind":"trial","cancerIcon":"prostate","sub":"NCT01946204","facets":{"kind":["Trial"],"cancers":["Prostate cancer","Non-metastatic castration-resistant prostate cancer"],"year":["2018"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Non-metastatic castration-resistant prostate cancer","href":"/cancers/prostate-nmcrpc/","tip":"Non-metastatic castration-resistant prostate cancer is a PSA that keeps rising on hormone therapy while scans still show nothing. Three androgen receptor blockers, apalutamide, enzalutamide and darolutamide, each delay metastasis by about two years and lengthen life, and darolutamide is the gentlest."}],"year":{"facet":"year","value":"2018"},"tags":[]},"sortKeys":{"year":2018}},{"id":"nct04325828","name":"A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma","tldr":"A phase 2 trial of Apalutamide in salivary gland cancers, run by Janssen Pharmaceutical K.K., active and no longer recruiting.","route":"/trials/nct04325828/","status":"active","kind":"trial","cancerIcon":"salivary-gland","sub":"NCT04325828","facets":{"kind":["Trial"],"cancers":["Salivary gland cancers","Salivary duct carcinoma"],"year":["2022"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Salivary gland cancers","href":"/cancers/salivary-gland/","tip":"Salivary gland cancers are a family of over 20 rare cancers, each with its own behaviour and often its own gene fusion. Surgery and radiation treat most; drug therapy is now chosen by the specific subtype, from anti-HER2 or anti-androgen drugs to NTRK inhibitors."},{"label":"Salivary duct carcinoma","href":"/cancers/salivary-duct-carcinoma/","tip":"Salivary duct carcinoma is an aggressive cancer of the parotid gland that behaves like a high-grade breast cancer and carries the same switches: most tumours run on the androgen receptor and about a third on HER2, so hormone blockers borrowed from prostate cancer and trastuzumab borrowed from breast cancer now shrink many of them."}],"year":{"facet":"year","value":"2022"},"tags":[]},"sortKeys":{"year":2022}},{"id":"nct03767244","name":"A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy","tldr":"A phase 3 trial of Apalutamide in prostate cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.","route":"/trials/nct03767244/","status":"active","kind":"trial","cancerIcon":"prostate","sub":"NCT03767244","facets":{"kind":["Trial"],"cancers":["Prostate cancer","Localised prostate cancer, high and very high risk"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Localised prostate cancer, high and very high risk","href":"/cancers/prostate-high-risk/","tip":"High-risk prostate cancer has Grade Group 4 or 5 disease, a PSA above 20 or a tumour growing beyond the gland. It is still curable, but needs radiotherapy with two to three years of hormone therapy, or surgery followed by radiotherapy, and adding abiraterone to hormone therapy now lengthens life in the highest-risk men."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00229203","name":"A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma","tldr":"A phase 2 trial of Plitidepsin in Multiple myeloma, run by PharmaMar, completed.","route":"/trials/nct00229203/","status":"completed","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT00229203","facets":{"kind":["Trial"],"cancers":["Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05867420","name":"A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.","tldr":"A phase 1/2 trial of Bevacizumab, Fruquintinib and Docetaxel in advanced solid tumours, run by AskGene Pharma, Inc., now recruiting.","route":"/trials/nct05867420/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05867420","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03182244","name":"A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation","tldr":"A phase 3 trial of Gilteritinib, Cytarabine, Mitoxantrone, Etoposide and Fludarabine in acute myeloid leukaemia, run by Astellas Pharma Inc, now completed.","route":"/trials/nct03182244/","status":"completed","kind":"trial","cancerIcon":"aml","sub":"NCT03182244","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia","FLT3-mutated acute myeloid leukaemia"],"year":["2025"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"FLT3-mutated acute myeloid leukaemia","href":"/cancers/aml-flt3/","tip":"FLT3-mutated acute myeloid leukaemia carries a mutation in a growth-signal receptor that makes the leukaemia relapse quickly. Adding a FLT3 blocker to chemotherapy, midostaurin or quizartinib, lengthens life, and gilteritinib is the standard when the disease comes back."}],"year":{"facet":"year","value":"2025"},"tags":[]},"sortKeys":{"year":2025}},{"id":"nct07287995","name":"A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors","tldr":"A phase 1/2 trial of Pembrolizumab, Enfortumab vedotin and Carboplatin in advanced solid tumours, run by Astellas Pharma Global Development, Inc., now recruiting.","route":"/trials/nct07287995/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07287995","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07730021","name":"A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors","tldr":"A phase 1/2 trial of Pembrolizumab, Carboplatin and Oxaliplatin in advanced solid tumours, run by Astellas Pharma Global Development, Inc., now recruiting.","route":"/trials/nct07730021/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07730021","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07488676","name":"A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors","tldr":"A phase 1/2 trial of ASP546C in gastric & gastro-oesophageal junction cancer and pancreatic ductal adenocarcinoma, run by Astellas Pharma Global Development, Inc., now recruiting.","route":"/trials/nct07488676/","status":"recruiting","kind":"trial","cancerIcon":"gastric","sub":"NCT07488676","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer","Pancreatic ductal adenocarcinoma","Claudin 18.2-positive gastric cancer","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Claudin 18.2-positive gastric cancer","href":"/cancers/gastric-cldn18-2-positive/","tip":"Claudin 18.2 is a tight-junction protein normally hidden inside stomach lining cells that becomes exposed on the surface of many stomach cancers. Zolbetuximab, an antibody against it, added to chemotherapy lengthens survival in tumours that express it strongly, and antibody-drug conjugates and CAR-T cells against the same target are in trials."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06977737","name":"A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours","tldr":"A phase 1/2 trial of ATTR-01 in advanced solid tumours, run by Accession Therapeutics Limited, now recruiting.","route":"/trials/nct06977737/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06977737","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06682572","name":"A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients","tldr":"A phase 2 trial of Avutometinib (VS-6766) + Defactinib (VS-6063) in ovarian cancer, run by Verastem, Inc., active and no longer recruiting.","route":"/trials/nct06682572/","status":"active","kind":"trial","cancerIcon":"ovarian","sub":"NCT06682572","facets":{"kind":["Trial"],"cancers":["Ovarian cancer","Low-grade serous ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Low-grade serous ovarian cancer","href":"/cancers/low-grade-serous-ovarian-cancer/","tip":"Low-grade serous cancer is the slow-growing, chemotherapy-resistant cousin of the common ovarian cancer. Surgery and hormone therapy are its mainstays, and MEK inhibitors, alone or combined with a FAK inhibitor, are the first drugs shown to shrink it reliably."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04995523","name":"A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC","tldr":"A phase 1/2 trial of Rilvegostomig in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct04995523/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT04995523","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06130553","name":"A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors","tldr":"A phase 1/2 trial of AZD3470 and Datopotamab deruxtecan in advanced solid tumours, run by AstraZeneca, now recruiting.","route":"/trials/nct06130553/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06130553","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06472076","name":"A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)","tldr":"A phase 3 trial of Dostarlimab and Pembrolizumab in non-small-cell lung cancer, run by GlaxoSmithKline, active and no longer recruiting.","route":"/trials/nct06472076/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT06472076","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","PD-L1-high non-small-cell lung cancer without a driver mutation"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"PD-L1-high non-small-cell lung cancer without a driver mutation","href":"/cancers/pdl1-high-nsclc/","tip":"Lung cancers that carry a lot of PD-L1 and no targetable mutation can be treated with an immunotherapy antibody alone instead of chemotherapy. Pembrolizumab keeps about a third of patients alive at five years, roughly double what chemotherapy achieved, and adding chemotherapy is reserved for those who need a fast response."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04586231","name":"A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)","tldr":"A phase 3 trial of Belzutifan, Lenvatinib and Cabozantinib in renal cell carcinoma, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","route":"/trials/nct04586231/","status":"active","kind":"trial","cancerIcon":"rcc","sub":"NCT04586231","facets":{"kind":["Trial"],"cancers":["Renal cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04489771","name":"A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)","tldr":"A phase 2 trial of Belzutifan in renal cell carcinoma, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","route":"/trials/nct04489771/","status":"active","kind":"trial","cancerIcon":"rcc","sub":"NCT04489771","facets":{"kind":["Trial"],"cancers":["Renal cell carcinoma"],"year":["2024"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."}],"year":{"facet":"year","value":"2024"},"tags":[]},"sortKeys":{"year":2024}},{"id":"nct03729245","name":"A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)","tldr":"A phase 3 trial of Bempegaldesleukin, Sunitinib, Nivolumab and Cabozantinib in Renal cell carcinoma, run by Nektar Therapeutics, recorded as terminated on the registry.","route":"/trials/nct03729245/","kind":"trial","cancerIcon":"rcc","sub":"NCT03729245","facets":{"kind":["Trial"],"cancers":["Renal cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04762069","name":"A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme","tldr":"A phase 2 trial of Berubicin in glioma & glioblastoma, run by CNS Pharmaceuticals, Inc., active and no longer recruiting.","route":"/trials/nct04762069/","status":"active","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT04762069","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04771130","name":"A Study of BGB-11417 in Participants With Myeloid Malignancies","tldr":"A phase 1/2 trial of Sonrotoclax and Azacitidine in acute myeloid leukaemia and myelodysplastic syndromes / neoplasms, run by BeOne Medicines, now recruiting.","route":"/trials/nct04771130/","status":"recruiting","kind":"trial","cancerIcon":"aml","sub":"NCT04771130","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia","Myelodysplastic syndromes / neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Myelodysplastic syndromes / neoplasms","href":"/cancers/mds/","tip":"Bone-marrow disorders where blood cells are made badly and too few reach the blood; a third progress to acute leukaemia. Treatment ranges from transfusions and growth factors to hypomethylating drugs and, for the fit, transplant."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06970743","name":"A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors","tldr":"A phase 3 trial of BGB-16673, Bendamustine, Rituximab, Chlorambucil and Obinutuzumab in chronic lymphocytic leukaemia, run by BeOne Medicines, active and no longer recruiting.","route":"/trials/nct06970743/","status":"active","kind":"trial","cancerIcon":"cll","sub":"NCT06970743","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia","Relapsed or refractory chronic lymphocytic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Relapsed or refractory chronic lymphocytic leukaemia","href":"/cancers/cll-relapsed/","tip":"When chronic lymphocytic leukaemia returns, the usual move is to switch drug class: venetoclax-based therapy after a BTK inhibitor, or a BTK inhibitor after venetoclax. Pirtobrutinib (BRUIN) works after the older BTK inhibitors fail, and CAR-T is approved for patients who have run out of both classes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04219254","name":"A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors","tldr":"A phase 1/2 trial of BI1206 in advanced solid tumours, run by BioInvent International AB, now recruiting.","route":"/trials/nct04219254/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04219254","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06405425","name":"A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma","tldr":"A phase 2 trial of BL-B01D1 in bladder & urothelial cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct06405425/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT06405425","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07554456","name":"A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)","tldr":"A phase 2/3 trial of Tislelizumab and Cisplatin in oesophageal cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07554456/","status":"recruiting","kind":"trial","cancerIcon":"esophageal","sub":"NCT07554456","facets":{"kind":["Trial"],"cancers":["Oesophageal cancer","Oesophageal squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."},{"label":"Oesophageal squamous cell carcinoma","href":"/cancers/oesophageal-squamous-cell-carcinoma/","tip":"Squamous cell carcinoma of the oesophagus, the world's commonest form, is linked to smoking, alcohol and very hot drinks and sits in the upper and middle gullet. It is treated with chemoradiation, with or without surgery, and immunotherapy has recently joined chemotherapy for advanced disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05785039","name":"A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors","tldr":"A phase 2 trial of BL-B01D1 in advanced solid tumours, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct05785039/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05785039","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05803018","name":"A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies","tldr":"A phase 1/2 trial of BL-B01D1 in advanced solid tumours, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct05803018/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05803018","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06598787","name":"A Study of BL-B01D1 in Patients With Recurrent Glioblastoma","tldr":"A phase 2 trial of BL-B01D1 for Injection in glioma & glioblastoma, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct06598787/","status":"recruiting","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT06598787","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06471205","name":"A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer","tldr":"A phase 2 trial of BL-B01D1 in triple-negative breast cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct06471205/","status":"recruiting","kind":"trial","cancerIcon":"tnbc","sub":"NCT06471205","facets":{"kind":["Trial"],"cancers":["Triple-negative breast cancer","Metastatic triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Metastatic triple-negative breast cancer","href":"/cancers/tnbc-metastatic/","tip":"Triple-negative breast cancer that has spread is not curable, but its treatment has been transformed since 2020. By PD-L1 score, first treatment is pembrolizumab with chemotherapy or with sacituzumab govitecan, or datopotamab deruxtecan or sacituzumab govitecan alone; BRCA carriers can take a PARP inhibitor tablet; and trastuzumab deruxtecan reaches the third of tumours with low HER2."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06978114","name":"A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer","tldr":"A phase 2 trial of Pembrolizumab in biliary tract cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct06978114/","status":"recruiting","kind":"trial","cancerIcon":"cholangiocarcinoma","sub":"NCT06978114","facets":{"kind":["Trial"],"cancers":["Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06962787","name":"A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer","tldr":"A phase 2 trial of Axitinib, Lenvatinib and Pembrolizumab in advanced solid tumours, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct06962787/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06962787","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05949619","name":"A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors","tldr":"A phase 1/2 trial of BL-M02D1 in non-small-cell lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.","route":"/trials/nct05949619/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT05949619","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06031584","name":"A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors","tldr":"A phase 1/2 trial of BL-M07D1 in advanced solid tumours, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct06031584/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06031584","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06131450","name":"A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies","tldr":"A phase 1/2 trial of BL-M07D1 in advanced solid tumours, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct06131450/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06131450","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06957886","name":"A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer","tldr":"A phase 3 trial of Capecitabine, Eribulin and Gemcitabine in HER2-positive breast cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct06957886/","status":"recruiting","kind":"trial","cancerIcon":"breast-her2-positive","sub":"NCT06957886","facets":{"kind":["Trial"],"cancers":["HER2-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07606599","name":"A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure","tldr":"A phase 3 trial of Oxaliplatin and Capecitabine in biliary tract cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07606599/","status":"recruiting","kind":"trial","cancerIcon":"cholangiocarcinoma","sub":"NCT07606599","facets":{"kind":["Trial"],"cancers":["Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07255872","name":"A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia","tldr":"A phase 2/3 trial of Cytarabine, Daunorubicin, Venetoclax and Azacitidine in acute myeloid leukaemia, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07255872/","status":"recruiting","kind":"trial","cancerIcon":"aml","sub":"NCT07255872","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05888831","name":"A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors","tldr":"A phase 1/2 trial of Nivolumab in advanced solid tumours, run by Bristol-Myers Squibb, active and no longer recruiting.","route":"/trials/nct05888831/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05888831","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06697197","name":"A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors","tldr":"A phase 1/2 trial of Nivolumab and Bevacizumab in advanced solid tumours, run by Bristol-Myers Squibb, now recruiting.","route":"/trials/nct06697197/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06697197","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06730750","name":"A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors","tldr":"A phase 1/2 trial of Bevacizumab in advanced solid tumours, run by Bristol-Myers Squibb, active and no longer recruiting.","route":"/trials/nct06730750/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06730750","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07492680","name":"A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)","tldr":"A phase 2 trial of Daraxonrasib, Nivolumab, Temozolomide, PM8002, Pemetrexed and Carboplatin in advanced solid tumours, run by Bristol-Myers Squibb, now recruiting.","route":"/trials/nct07492680/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07492680","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04752813","name":"A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)","tldr":"A phase 2 trial of Temozolomide in glioma & glioblastoma, run by BPGbio, active and no longer recruiting.","route":"/trials/nct04752813/","status":"active","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT04752813","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02972840","name":"A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL","tldr":"A phase 3 trial of Acalabrutinib, Bendamustine and Rituximab in mantle cell lymphoma, run by Acerta Pharma BV, active and no longer recruiting.","route":"/trials/nct02972840/","status":"active","kind":"trial","cancerIcon":"mantle-cell-lymphoma","sub":"NCT02972840","facets":{"kind":["Trial"],"cancers":["Mantle cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Mantle cell lymphoma","href":"/cancers/mantle-cell-lymphoma/","tip":"An uncommon B-cell lymphoma driven by cyclin D1 that used to behave badly in almost everyone. BTK inhibitors, CAR-T and now BCL2 drugs have changed it from chemotherapy-plus-transplant to targeted combinations."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02979522","name":"A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma","tldr":"A phase 1/2 trial of Brentuximab vedotin, Doxorubicin, Vinblastine and Dacarbazine in hodgkin lymphoma, run by Takeda, active and no longer recruiting.","route":"/trials/nct02979522/","status":"active","kind":"trial","cancerIcon":"hodgkin-lymphoma","sub":"NCT02979522","facets":{"kind":["Trial"],"cancers":["Hodgkin lymphoma","Advanced-stage classical Hodgkin lymphoma"],"year":["2021"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hodgkin lymphoma","href":"/cancers/hodgkin-lymphoma/","tip":"Hodgkin lymphoma is one of the most curable cancers, where the goal is now to cure with less toxicity, using brentuximab and, from 2026, first-line nivolumab."},{"label":"Advanced-stage classical Hodgkin lymphoma","href":"/cancers/advanced-stage-classical-hodgkin-lymphoma/","tip":"Advanced-stage classical Hodgkin lymphoma is Hodgkin lymphoma involving nodes on both sides of the diaphragm or organs such as the liver, lungs or bone marrow. It is treated with six cycles of combination chemotherapy, and two trials changed the standard: replacing bleomycin with brentuximab vedotin (ECHELON-1) and then with nivolumab (SWOG S1826), which cured more patients with less toxicity."}],"year":{"facet":"year","value":"2021"},"tags":[]},"sortKeys":{"year":2021}},{"id":"nct05673785","name":"A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)","tldr":"A phase 2 trial of Brentuximab vedotin, Cyclophosphamide, Doxorubicin and Prednisone in non-Hodgkin lymphoma, run by Takeda, active and no longer recruiting.","route":"/trials/nct05673785/","status":"active","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT05673785","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma","Peripheral T-cell lymphomas"],"year":["2026"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."},{"label":"Peripheral T-cell lymphomas","href":"/cancers/peripheral-t-cell-lymphoma/","tip":"Peripheral T-cell lymphomas are lymphomas of T cells rather than B cells. They are rarer, more varied and, apart from a few subtypes, harder to treat than B-cell lymphomas; several new drugs help only defined subtypes."}],"year":{"facet":"year","value":"2026"},"tags":[]},"sortKeys":{"year":2026}},{"id":"nct05521802","name":"A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma","tldr":"A phase 1/2 trial of B-cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR)-T cell in multiple myeloma, run by Shanghai AbelZeta Ltd., now recruiting.","route":"/trials/nct05521802/","status":"recruiting","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT05521802","facets":{"kind":["Trial"],"cancers":["Multiple myeloma","Relapsed or refractory multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."},{"label":"Relapsed or refractory multiple myeloma","href":"/cancers/myeloma-relapsed-refractory/","tip":"Myeloma almost always returns, and each return is harder to treat. Two kinds of immune therapy aimed at the BCMA protein on myeloma cells, CAR-T cells (KarMMa-3, CARTITUDE-4) and off-the-shelf bispecific antibodies (MajesTEC), now give deep remissions after other drugs fail, and a second target, GPRC5D, gives another option."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05774951","name":"A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy","tldr":"A phase 3 trial of Camizestrant, Tamoxifen and Exemestane in advanced solid tumours, run by AstraZeneca, now recruiting.","route":"/trials/nct05774951/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05774951","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05299424","name":"A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma","tldr":"A phase 1/2 trial of CM336_group 1 in multiple myeloma, run by Keymed Biosciences Co.Ltd, now recruiting.","route":"/trials/nct05299424/","status":"recruiting","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT05299424","facets":{"kind":["Trial"],"cancers":["Multiple myeloma","Relapsed or refractory multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."},{"label":"Relapsed or refractory multiple myeloma","href":"/cancers/myeloma-relapsed-refractory/","tip":"Myeloma almost always returns, and each return is harder to treat. Two kinds of immune therapy aimed at the BCMA protein on myeloma cells, CAR-T cells (KarMMa-3, CARTITUDE-4) and off-the-shelf bispecific antibodies (MajesTEC), now give deep remissions after other drugs fail, and a second target, GPRC5D, gives another option."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05263960","name":"A Study of CM350 in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of CM350 group1 in advanced solid tumours, run by Keymed Biosciences Co.Ltd, now recruiting.","route":"/trials/nct05263960/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05263960","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05759728","name":"A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer","tldr":"A phase 1/2 trial of CNA3103: 5 x 10^7 cells in colorectal cancer, run by Carina Biotech Limited, now recruiting.","route":"/trials/nct05759728/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT05759728","facets":{"kind":["Trial"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05667506","name":"A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)","tldr":"A phase 1/2 trial of single dose of CNCT19 in acute lymphoblastic leukaemia, run by Juventas Cell Therapy Ltd., now recruiting.","route":"/trials/nct05667506/","status":"recruiting","kind":"trial","cancerIcon":"all-leukemia","sub":"NCT05667506","facets":{"kind":["Trial"],"cancers":["Acute lymphoblastic leukaemia","Relapsed and refractory acute lymphoblastic leukaemia in children"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."},{"label":"Relapsed and refractory acute lymphoblastic leukaemia in children","href":"/cancers/all-paediatric-relapsed/","tip":"When childhood leukaemia comes back, chemotherapy alone cures fewer than half. Three immune treatments changed this: blinatumomab, which links the child's T-cells to leukaemia cells and beat chemotherapy in two trials; tisagenlecleucel, the first approved CAR T-cell therapy, which put over eight in ten pretreated children into remission; and the antibody-drug conjugate inotuzumab ozogamicin."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04538664","name":"A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions","tldr":"A phase 3 trial of Amivantamab, Pemetrexed and Carboplatin in non-small-cell lung cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.","route":"/trials/nct04538664/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT04538664","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","EGFR-mutated non-small-cell lung cancer"],"year":["2024"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"year":{"facet":"year","value":"2024"},"tags":[]},"sortKeys":{"year":2024}},{"id":"nct05908734","name":"A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer","tldr":"A phase 1/2 trial of Cetrelimab and Amivantamab in non-small-cell lung cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.","route":"/trials/nct05908734/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT05908734","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06246643","name":"A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies","tldr":"A phase 2 trial of Regorafenib in advanced solid tumours, run by Bayer, active and no longer recruiting.","route":"/trials/nct06246643/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06246643","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07070219","name":"A Study of CTD402 in T-ALL/LBL Patients","tldr":"A phase 1/2 trial of CTD402 CAR T Cell Injection in acute lymphoblastic leukaemia and non-Hodgkin lymphoma, run by Imviva Bio, now recruiting.","route":"/trials/nct07070219/","status":"recruiting","kind":"trial","cancerIcon":"all-leukemia","sub":"NCT07070219","facets":{"kind":["Trial"],"cancers":["Acute lymphoblastic leukaemia","Non-Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."},{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05732103","name":"A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes","tldr":"A phase 1/2 trial of CTX-712 in acute myeloid leukaemia and myelodysplastic syndromes / neoplasms, run by Chordia Therapeutics, Inc., now recruiting.","route":"/trials/nct05732103/","status":"recruiting","kind":"trial","cancerIcon":"aml","sub":"NCT05732103","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia","Myelodysplastic syndromes / neoplasms","Higher-risk myelodysplastic syndromes"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Myelodysplastic syndromes / neoplasms","href":"/cancers/mds/","tip":"Bone-marrow disorders where blood cells are made badly and too few reach the blood; a third progress to acute leukaemia. Treatment ranges from transfusions and growth factors to hypomethylating drugs and, for the fit, transplant."},{"label":"Higher-risk myelodysplastic syndromes","href":"/cancers/mds-higher-risk/","tip":"Higher-risk myelodysplastic syndromes behave like a slow leukaemia and often become one. Azacitidine lengthens life and a donor stem cell transplant is the only cure; every attempt to improve on azacitidine in a large trial, including the venetoclax combination tested in VERONA, has so far failed."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04023526","name":"A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy","tldr":"A phase 2 trial of Azacitidine and Cusatuzumab in acute myeloid leukaemia, run by OncoVerity, Inc., active and no longer recruiting.","route":"/trials/nct04023526/","status":"active","kind":"trial","cancerIcon":"aml","sub":"NCT04023526","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia"],"year":["2024"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"year":{"facet":"year","value":"2024"},"tags":[]},"sortKeys":{"year":2024}},{"id":"nct05410145","name":"A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation","tldr":"A phase 1/2 trial of Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed and Cetuximab in advanced solid tumours, run by D3 Bio (Wuxi) Co., Ltd, now recruiting.","route":"/trials/nct05410145/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05410145","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05460273","name":"A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)","tldr":"A phase 1/2 trial of Datopotamab deruxtecan in non-small-cell lung cancer and triple-negative breast cancer, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct05460273/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT05460273","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","Triple-negative breast cancer","Metastatic triple-negative breast cancer"],"year":["2025"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Metastatic triple-negative breast cancer","href":"/cancers/tnbc-metastatic/","tip":"Triple-negative breast cancer that has spread is not curable, but its treatment has been transformed since 2020. By PD-L1 score, first treatment is pembrolizumab with chemotherapy or with sacituzumab govitecan, or datopotamab deruxtecan or sacituzumab govitecan alone; BRCA carriers can take a PARP inhibitor tablet; and trastuzumab deruxtecan reaches the third of tumours with low HER2."}],"year":{"facet":"year","value":"2025"},"tags":[]},"sortKeys":{"year":2025}},{"id":"nct07205822","name":"A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer","tldr":"A phase 3 trial of Dato-DXd in HR-positive / HER2-negative breast cancer, run by AstraZeneca, now recruiting.","route":"/trials/nct07205822/","status":"recruiting","kind":"trial","cancerIcon":"breast-hr-positive","sub":"NCT07205822","facets":{"kind":["Trial"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05785741","name":"A Study of DB-1310 in Advanced/Metastatic Solid Tumors","tldr":"A phase 1/2 trial of Trastuzumab, Osimertinib and Capecitabine in advanced solid tumours, run by DualityBio Inc., now recruiting.","route":"/trials/nct05785741/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05785741","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07263594","name":"A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors","tldr":"A phase 1/2 trial of DB-1324 in advanced solid tumours, run by DualityBio Inc., now recruiting.","route":"/trials/nct07263594/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07263594","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06873555","name":"A Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors","tldr":"A phase 1/2 trial of DC05F01 in ovarian cancer and small-cell lung cancer, run by Heronova Pharmaceuticals, now recruiting.","route":"/trials/nct06873555/","status":"recruiting","kind":"trial","cancerIcon":"ovarian","sub":"NCT06873555","facets":{"kind":["Trial"],"cancers":["Ovarian cancer","Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05765812","name":"A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma","tldr":"A phase 1/2 trial of Temozolomide in glioma & glioblastoma, run by Debiopharm International SA, now recruiting.","route":"/trials/nct05765812/","status":"recruiting","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT05765812","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04879329","name":"A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2","tldr":"A phase 2 trial of Disitamab vedotin and Pembrolizumab in bladder & urothelial cancer, run by Seagen, a wholly owned subsidiary of Pfizer, now recruiting.","route":"/trials/nct04879329/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT04879329","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07315750","name":"A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.","tldr":"A phase 3 trial of Disitamab vedotin, Tislelizumab, Capecitabine, Oxaliplatin, Trastuzumab and Pembrolizumab in gastric & gastro-oesophageal junction cancer, run by RemeGen Co., Ltd., now recruiting.","route":"/trials/nct07315750/","status":"recruiting","kind":"trial","cancerIcon":"gastric","sub":"NCT07315750","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06966453","name":"A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer","tldr":"A phase 1/2 trial of Disitamab vedotin in advanced solid tumours, run by Pfizer, active and no longer recruiting.","route":"/trials/nct06966453/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06966453","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06003231","name":"A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2","tldr":"A phase 2 trial of Disitamab vedotin in non-small-cell lung cancer, ovarian cancer, endometrial cancer and head and neck squamous cell carcinoma, run by Seagen, a wholly owned subsidiary of Pfizer, active and no longer recruiting.","route":"/trials/nct06003231/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT06003231","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","Ovarian cancer","Endometrial cancer","Head and neck squamous cell carcinoma","HER2-mutant non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."},{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06157892","name":"A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors","tldr":"A phase 2 trial of Disitamab vedotin and Tucatinib in gastric & gastro-oesophageal junction cancer, HER2-positive breast cancer and triple-negative breast cancer, run by Seagen, a wholly owned subsidiary of Pfizer, active and no longer recruiting.","route":"/trials/nct06157892/","status":"active","kind":"trial","cancerIcon":"gastric","sub":"NCT06157892","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer","HER2-positive breast cancer","Triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."},{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06751329","name":"A Study of DM002 in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of DM002 in ovarian cancer, prostate cancer, endometrial cancer, colorectal cancer and pancreatic ductal adenocarcinoma, run by Xadcera Biopharmaceutical (Suzhou) Co., Ltd., now recruiting.","route":"/trials/nct06751329/","status":"recruiting","kind":"trial","cancerIcon":"ovarian","sub":"NCT06751329","facets":{"kind":["Trial"],"cancers":["Ovarian cancer","Prostate cancer","Endometrial cancer","Colorectal cancer","Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06515990","name":"A Study of DM005 in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of DM005 in non-small-cell lung cancer and head and neck squamous cell carcinoma, run by Doma Biopharmaceutical（Suzhou）Co., Ltd., now recruiting.","route":"/trials/nct06515990/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06515990","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07108270","name":"A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)","tldr":"A phase 2 trial of Dostarlimab and Carboplatin in endometrial cancer, run by GlaxoSmithKline, now recruiting.","route":"/trials/nct07108270/","status":"recruiting","kind":"trial","cancerIcon":"endometrial","sub":"NCT07108270","facets":{"kind":["Trial"],"cancers":["Endometrial cancer","Advanced or recurrent endometrial cancer","Mismatch-repair-deficient endometrial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."},{"label":"Advanced or recurrent endometrial cancer","href":"/cancers/advanced-recurrent-endometrial-cancer/","tip":"Advanced or recurrent endometrial cancer has spread beyond the uterus or come back after treatment. Chemotherapy plus an immune checkpoint antibody is now the first treatment for everyone, with the biggest gains in mismatch-repair-deficient tumours, and lenvatinib with pembrolizumab is the standard when platinum chemotherapy stops working."},{"label":"Mismatch-repair-deficient endometrial cancer","href":"/cancers/endometrial-mmr-deficient/","tip":"Mismatch-repair-deficient endometrial cancer has lost the machinery that corrects copying errors in DNA, so it accumulates thousands of mutations that make it visible to the immune system. Adding dostarlimab or pembrolizumab to chemotherapy in advanced disease cut the risk of progression by about seventy percent, and many patients remain in remission years later."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06317311","name":"A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer","tldr":"A phase 2 trial of Dostarlimab and Carboplatin in advanced solid tumours, run by GlaxoSmithKline, active and no longer recruiting.","route":"/trials/nct06317311/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06317311","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06640049","name":"A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China","tldr":"A phase 2 trial of Dostarlimab in colorectal cancer, run by GlaxoSmithKline, active and no longer recruiting.","route":"/trials/nct06640049/","status":"active","kind":"trial","cancerIcon":"colorectal","sub":"NCT06640049","facets":{"kind":["Trial"],"cancers":["Colorectal cancer","Mismatch-repair deficient (MSI-high) colorectal cancer","Rectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Mismatch-repair deficient (MSI-high) colorectal cancer","href":"/cancers/msi-high-colorectal/","tip":"Mismatch-repair deficient bowel cancer has lost its DNA spell-checker, so it carries thousands of mutations that the immune system can recognise. Immunotherapy alone controls most metastatic cases for years and makes most localised tumours disappear before surgery, sometimes so completely that no surgery is needed."},{"label":"Rectal cancer","href":"/cancers/rectal-cancer/","tip":"Rectal cancer is bowel cancer in the last part of the large intestine, where surgery can mean a permanent stoma. Treatment now usually gives all the chemotherapy and radiotherapy first, and about half of people whose tumour disappears completely can keep their rectum and avoid surgery altogether."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06256588","name":"A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma","tldr":"A phase 3 trial of Dostarlimab in head and neck squamous cell carcinoma, run by GlaxoSmithKline, now recruiting.","route":"/trials/nct06256588/","status":"recruiting","kind":"trial","cancerIcon":"head-and-neck","sub":"NCT06256588","facets":{"kind":["Trial"],"cancers":["Head and neck squamous cell carcinoma","HPV-negative head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"HPV-negative head and neck squamous cell carcinoma","href":"/cancers/hpv-negative-head-and-neck-cancer/","tip":"Head and neck cancers caused by tobacco and alcohol rather than HPV are harder to cure: surgery or cisplatin chemoradiation is the mainstay, immunotherapy given around surgery (KEYNOTE-689) or after it (NIVOPOSTOP) has begun to help, and pembrolizumab is the first treatment once the disease has spread."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05475925","name":"A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas","tldr":"A phase 1/2 trial of DR-01 in peripheral T-cell lymphomas, run by Dren Bio, now recruiting.","route":"/trials/nct05475925/","status":"recruiting","kind":"trial","cancerIcon":"peripheral-t-cell-lymphoma","sub":"NCT05475925","facets":{"kind":["Trial"],"cancers":["Peripheral T-cell lymphomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Peripheral T-cell lymphomas","href":"/cancers/peripheral-t-cell-lymphoma/","tip":"Peripheral T-cell lymphomas are lymphomas of T cells rather than B cells. They are rarer, more varied and, apart from a few subtypes, harder to treat than B-cell lymphomas; several new drugs help only defined subtypes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04458272","name":"A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma","tldr":"A phase 2 trial of Safusidenib in glioma & glioblastoma, run by Daiichi Sankyo Co., Ltd., active and no longer recruiting.","route":"/trials/nct04458272/","status":"active","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT04458272","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma","Astrocytoma, IDH-mutant"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."},{"label":"Astrocytoma, IDH-mutant","href":"/cancers/idh-mutant-astrocytoma/","tip":"IDH-mutant astrocytoma is the slow-growing form of adult glioma, defined by a mutation in the IDH1 or IDH2 gene that makes the tumour produce a chemical which rewires its own cells. Surgery first, and then either watchful waiting, the new pill vorasidenib, or radiotherapy with chemotherapy, depending on grade and how much tumour is left."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02671435","name":"A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors","tldr":"A phase 1/2 trial of Monalizumab, Durvalumab, Cetuximab, FOLFOX (5-FU, leucovorin, oxaliplatin) and Bevacizumab in advanced solid tumours, run by MedImmune LLC, active and no longer recruiting.","route":"/trials/nct02671435/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT02671435","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":["2023"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"year":{"facet":"year","value":"2023"},"tags":[]},"sortKeys":{"year":2023}},{"id":"nct03459846","name":"A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)","tldr":"A phase 2 trial of Durvalumab and Olaparib in bladder & urothelial cancer, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct03459846/","status":"active","kind":"trial","cancerIcon":"urothelial","sub":"NCT03459846","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":["2022"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"year":{"facet":"year","value":"2022"},"tags":[]},"sortKeys":{"year":2022}},{"id":"nct03706690","name":"A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients","tldr":"A phase 3 trial of Durvalumab in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct03706690/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT03706690","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","Unresectable stage III non-small-cell lung cancer"],"year":["2025"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Unresectable stage III non-small-cell lung cancer","href":"/cancers/stage-iii-unresectable-nsclc/","tip":"Stage III lung cancer that cannot be removed is treated with chemotherapy and radiotherapy together, aiming at cure. A year of the immunotherapy antibody durvalumab afterwards raised five-year survival from a third to over 40 percent, and for EGFR-mutated tumours osimertinib after chemoradiation holds the disease for years."}],"year":{"facet":"year","value":"2025"},"tags":[]},"sortKeys":{"year":2025}},{"id":"nct06522737","name":"A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype","tldr":"A phase 3 trial of Duvelisib, Gemcitabine and Bendamustine in non-Hodgkin lymphoma, run by SecuraBio, now recruiting.","route":"/trials/nct06522737/","status":"recruiting","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT06522737","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07154264","name":"A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)","tldr":"A phase 2 trial of DZD8586 and Venetoclax in chronic lymphocytic leukaemia, run by Dizal Pharmaceuticals, now recruiting.","route":"/trials/nct07154264/","status":"recruiting","kind":"trial","cancerIcon":"cll","sub":"NCT07154264","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04008797","name":"A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor","tldr":"A phase 1/2 trial of Lenvatinib and Doxorubicin in endometrial cancer, hepatocellular carcinoma and colorectal cancer, run by Eisai Inc., active and no longer recruiting.","route":"/trials/nct04008797/","status":"active","kind":"trial","cancerIcon":"endometrial","sub":"NCT04008797","facets":{"kind":["Trial"],"cancers":["Endometrial cancer","Hepatocellular carcinoma","Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."},{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04078295","name":"A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor","tldr":"A phase 1/2 trial of Nivolumab in advanced solid tumours, run by Eisai Co., Ltd., active and no longer recruiting.","route":"/trials/nct04078295/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04078295","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05845814","name":"A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)","tldr":"A phase 1/2 trial of Favezelimab and Pembrolizumab in bladder & urothelial cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","route":"/trials/nct05845814/","status":"active","kind":"trial","cancerIcon":"urothelial","sub":"NCT05845814","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06483334","name":"A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)","tldr":"A phase 1/2 trial of Sacituzumab tirumotecan, Enfortumab vedotin and Pembrolizumab in bladder & urothelial cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","route":"/trials/nct06483334/","status":"active","kind":"trial","cancerIcon":"urothelial","sub":"NCT06483334","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06492616","name":"A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence","tldr":"A phase 3 trial of Elacestrant, Exemestane and Tamoxifen in advanced solid tumours, run by Stemline Therapeutics, Inc., now recruiting.","route":"/trials/nct06492616/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06492616","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07271667","name":"A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies","tldr":"A phase 2 trial of Zanubrutinib in chronic lymphocytic leukaemia, run by Curis, Inc., now recruiting.","route":"/trials/nct07271667/","status":"recruiting","kind":"trial","cancerIcon":"cll","sub":"NCT07271667","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05377996","name":"A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors","tldr":"A phase 1/2 trial of Emi-Le in triple-negative breast cancer, endometrial cancer, ovarian cancer and salivary gland cancers, run by Day One Biopharmaceuticals, Inc., now recruiting.","route":"/trials/nct05377996/","status":"recruiting","kind":"trial","cancerIcon":"tnbc","sub":"NCT05377996","facets":{"kind":["Trial"],"cancers":["Triple-negative breast cancer","Endometrial cancer","Ovarian cancer","Salivary gland cancers","Mucoepidermoid carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."},{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Salivary gland cancers","href":"/cancers/salivary-gland/","tip":"Salivary gland cancers are a family of over 20 rare cancers, each with its own behaviour and often its own gene fusion. Surgery and radiation treat most; drug therapy is now chosen by the specific subtype, from anti-HER2 or anti-androgen drugs to NTRK inhibitors."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06099769","name":"A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer","tldr":"A phase 2 trial of Enzalutamide and Mifepristone in Breast cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting.","route":"/trials/nct06099769/","status":"recruiting","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT06099769","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05443126","name":"A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies","tldr":"A phase 1/2 trial of EP0031 and Pemetrexed in non-small-cell lung cancer, run by Ellipses Pharma, now recruiting.","route":"/trials/nct05443126/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT05443126","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","RET fusion-positive non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"RET fusion-positive non-small-cell lung cancer","href":"/cancers/ret-fusion-nsclc/","tip":"RET fusion lung cancer is a rare adenocarcinoma driven by a fused RET gene. The selective pill selpercatinib shrinks most tumours and more than doubles the time to progression compared with chemotherapy and immunotherapy, and pralsetinib is a second option."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03473743","name":"A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer","tldr":"A phase 1/2 trial of Erdafitinib, Cetrelimab, Cisplatin and Carboplatin in bladder & urothelial cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.","route":"/trials/nct03473743/","status":"active","kind":"trial","cancerIcon":"urothelial","sub":"NCT03473743","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":["2023"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"year":{"facet":"year","value":"2023"},"tags":[]},"sortKeys":{"year":2023}},{"id":"nct03980054","name":"A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer","tldr":"A phase 3 trial of Pyrotinib in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.","route":"/trials/nct03980054/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT03980054","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06782555","name":"A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab","tldr":"A phase 1/2 trial of Zalifrelimab and Balstilimab in prostate cancer, head and neck squamous cell carcinoma and pancreatic ductal adenocarcinoma, run by ImmunoGenesis, now recruiting.","route":"/trials/nct06782555/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT06782555","facets":{"kind":["Trial"],"cancers":["Prostate cancer","Head and neck squamous cell carcinoma","Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06499350","name":"A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors","tldr":"A phase 1/2 trial of Tislelizumab in advanced solid tumours, run by FindCure Biosciences (ZhongShan) Co., Ltd., now recruiting.","route":"/trials/nct06499350/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06499350","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06842498","name":"A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","tldr":"A phase 2 trial of FG-3246 in prostate cancer, run by Kyntra Bio, now recruiting.","route":"/trials/nct06842498/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT06842498","facets":{"kind":["Trial"],"cancers":["Prostate cancer","Metastatic castration-resistant prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Metastatic castration-resistant prostate cancer","href":"/cancers/prostate-mcrpc/","tip":"Metastatic castration-resistant prostate cancer is disease that grows despite castrate testosterone. Sequenced treatments now include androgen receptor inhibitors, docetaxel and cabazitaxel, PARP inhibitors for men with BRCA-type mutations, the radioligand 177Lu-PSMA-617 and radium-223 for bone-predominant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06119581","name":"A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer","tldr":"A phase 3 trial of Olomorasib, Pembrolizumab, Cisplatin, Carboplatin and Pemetrexed in non-small-cell lung cancer, run by Eli Lilly and Company, now recruiting.","route":"/trials/nct06119581/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06119581","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","KRAS G12C-mutant non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"KRAS G12C-mutant non-small-cell lung cancer","href":"/cancers/kras-g12c-nsclc/","tip":"KRAS G12C lung cancer carries a mutation that was thought impossible to drug for forty years. Sotorasib and adagrasib now shrink about four in ten tumours after chemotherapy and immunotherapy, though the benefit is measured in months, and newer inhibitors and first-line combinations with immunotherapy are in trials."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07131202","name":"A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors","tldr":"A phase 1/2 trial of FL115+PD-1 in advanced solid tumours, run by Suzhou Forlong Biotechnology Co., Ltd, now recruiting.","route":"/trials/nct07131202/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07131202","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06980480","name":"A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma","tldr":"A phase 3 trial of IGI, 10% in multiple myeloma, run by Takeda, now recruiting.","route":"/trials/nct06980480/","status":"recruiting","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT06980480","facets":{"kind":["Trial"],"cancers":["Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06375733","name":"A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL","tldr":"A phase 1/2 trial of Zanubrutinib in diffuse large B-cell lymphoma, run by Genfleet Therapeutics (Shanghai) Inc., now recruiting.","route":"/trials/nct06375733/","status":"recruiting","kind":"trial","cancerIcon":"dlbcl","sub":"NCT06375733","facets":{"kind":["Trial"],"cancers":["Diffuse large B-cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05934513","name":"A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)","tldr":"A phase 1/2 trial of GFH009 in peripheral T-cell lymphomas, run by Genfleet Therapeutics (Shanghai) Inc., now recruiting.","route":"/trials/nct05934513/","status":"recruiting","kind":"trial","cancerIcon":"peripheral-t-cell-lymphoma","sub":"NCT05934513","facets":{"kind":["Trial"],"cancers":["Peripheral T-cell lymphomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Peripheral T-cell lymphomas","href":"/cancers/peripheral-t-cell-lymphoma/","tip":"Peripheral T-cell lymphomas are lymphomas of T cells rather than B cells. They are rarer, more varied and, apart from a few subtypes, harder to treat than B-cell lymphomas; several new drugs help only defined subtypes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06500676","name":"A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations","tldr":"A phase 1/2 trial of GFH375 in advanced solid tumours, run by Genfleet Therapeutics (Shanghai) Inc., now recruiting.","route":"/trials/nct06500676/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06500676","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07172802","name":"A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors","tldr":"A phase 1/2 trial of GI-108 in non-small-cell lung cancer, head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma and renal cell carcinoma, run by GI Innovation, Inc., now recruiting.","route":"/trials/nct07172802/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07172802","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","Head and neck squamous cell carcinoma","Pancreatic ductal adenocarcinoma","Renal cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05520567","name":"A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia","tldr":"A phase 1/2 trial of Gilteritinib, Venetoclax and Azacitidine in acute myeloid leukaemia, run by Astellas Pharma Global Development, Inc., active and no longer recruiting.","route":"/trials/nct05520567/","status":"active","kind":"trial","cancerIcon":"aml","sub":"NCT05520567","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia","Acute myeloid leukaemia in older or unfit patients"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Acute myeloid leukaemia in older or unfit patients","href":"/cancers/aml-older-unfit/","tip":"Most people with acute myeloid leukaemia are over 65, and many cannot take intensive chemotherapy. Venetoclax with azacitidine, two gentler drugs, doubled remission rates and lengthened life in this group, replacing the old choice between supportive care and low-dose chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05944978","name":"A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies","tldr":"A phase 1/2 trial of GNC-035 in chronic lymphocytic leukaemia, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.","route":"/trials/nct05944978/","status":"active","kind":"trial","cancerIcon":"cll","sub":"NCT05944978","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia","Relapsed or refractory chronic lymphocytic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Relapsed or refractory chronic lymphocytic leukaemia","href":"/cancers/cll-relapsed/","tip":"When chronic lymphocytic leukaemia returns, the usual move is to switch drug class: venetoclax-based therapy after a BTK inhibitor, or a BTK inhibitor after venetoclax. Pirtobrutinib (BRUIN) works after the older BTK inhibitors fail, and CAR-T is approved for patients who have run out of both classes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06066203","name":"A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies","tldr":"A phase 1/2 trial of GNC-035 in non-Hodgkin lymphoma, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct06066203/","status":"recruiting","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT06066203","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05627856","name":"A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL","tldr":"A phase 1/2 trial of GNC-038 in peripheral T-cell lymphomas and non-Hodgkin lymphoma, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.","route":"/trials/nct05627856/","status":"active","kind":"trial","cancerIcon":"peripheral-t-cell-lymphoma","sub":"NCT05627856","facets":{"kind":["Trial"],"cancers":["Peripheral T-cell lymphomas","Non-Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Peripheral T-cell lymphomas","href":"/cancers/peripheral-t-cell-lymphoma/","tip":"Peripheral T-cell lymphomas are lymphomas of T cells rather than B cells. They are rarer, more varied and, apart from a few subtypes, harder to treat than B-cell lymphomas; several new drugs help only defined subtypes."},{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05623982","name":"A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","tldr":"A phase 1/2 trial of GNC-038 in non-Hodgkin lymphoma, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct05623982/","status":"recruiting","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT05623982","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05192486","name":"A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)","tldr":"A phase 1/2 trial of GNC-038 in diffuse large B-cell lymphoma, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.","route":"/trials/nct05192486/","status":"active","kind":"trial","cancerIcon":"dlbcl","sub":"NCT05192486","facets":{"kind":["Trial"],"cancers":["Diffuse large B-cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06464055","name":"A Study of GQ1010 in Subjects With Advanced Solid Tumors","tldr":"A phase 1/2 trial of Dose Escalation in advanced solid tumours, run by GeneQuantum Healthcare (Suzhou) Co., Ltd., now recruiting.","route":"/trials/nct06464055/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06464055","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07192588","name":"A Study of GR1014 Cutaneous Gel for the Prevention of Skin Reactions Caused by Radiation Therapy for Breast Cancer","tldr":"A phase 2 trial of GR1014-CG 2.4% in advanced solid tumours, run by Graegis Pharmaceuticals Ltd, active and no longer recruiting.","route":"/trials/nct07192588/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07192588","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06990880","name":"A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer","tldr":"A phase 1/2 trial of GSK5458514 in prostate cancer, run by GlaxoSmithKline, now recruiting.","route":"/trials/nct06990880/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT06990880","facets":{"kind":["Trial"],"cancers":["Prostate cancer","Metastatic castration-resistant prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Metastatic castration-resistant prostate cancer","href":"/cancers/prostate-mcrpc/","tip":"Metastatic castration-resistant prostate cancer is disease that grows despite castrate testosterone. Sequenced treatments now include androgen receptor inhibitors, docetaxel and cabazitaxel, PARP inhibitors for men with BRCA-type mutations, the radioligand 177Lu-PSMA-617 and radium-223 for bone-predominant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07099898","name":"A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)","tldr":"A phase 3 trial of Topotecan in small-cell lung cancer, run by GlaxoSmithKline, now recruiting.","route":"/trials/nct07099898/","status":"recruiting","kind":"trial","cancerIcon":"sclc","sub":"NCT07099898","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05669430","name":"A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies","tldr":"A phase 1/2 trial of Pembrolizumab in endometrial cancer, head and neck squamous cell carcinoma, melanoma and non-small-cell lung cancer, run by GV20 Therapeutics, now recruiting.","route":"/trials/nct05669430/","status":"recruiting","kind":"trial","cancerIcon":"endometrial","sub":"NCT05669430","facets":{"kind":["Trial"],"cancers":["Endometrial cancer","Head and neck squamous cell carcinoma","Melanoma","Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."},{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07678684","name":"A Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma","tldr":"A phase 2 trial of HF1K16 in glioma & glioblastoma, run by HighField Biopharmaceuticals Corporation, now recruiting.","route":"/trials/nct07678684/","status":"recruiting","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT07678684","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07140393","name":"A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor","tldr":"A phase 1/2 trial of Capecitabine, Trastuzumab, Pertuzumab and Trastuzumab rezetecan in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.","route":"/trials/nct07140393/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07140393","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06520488","name":"A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors","tldr":"A phase 1/2 trial of HRS-4642 in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.","route":"/trials/nct06520488/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06520488","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06385678","name":"A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","tldr":"A phase 1/2 trial of Adebrelimab, Carboplatin, Cisplatin, Pemetrexed and Cetuximab in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.","route":"/trials/nct06385678/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06385678","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07389733","name":"A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer","tldr":"A phase 1/2 trial of HRS-8080 and Fulvestrant in advanced solid tumours, run by Shandong Suncadia Medicine Co., Ltd., now recruiting.","route":"/trials/nct07389733/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07389733","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06147570","name":"A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer","tldr":"A phase 2 trial of HS-10365 capsules in non-small-cell lung cancer, run by Jiangsu Hansoh Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct06147570/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06147570","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","RET fusion-positive non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"RET fusion-positive non-small-cell lung cancer","href":"/cancers/ret-fusion-nsclc/","tip":"RET fusion lung cancer is a rare adenocarcinoma driven by a fused RET gene. The selective pill selpercatinib shrinks most tumours and more than doubles the time to progression compared with chemotherapy and immunotherapy, and pralsetinib is a second option."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07468851","name":"A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy","tldr":"A phase 1/2 trial of HS-10566 in bladder & urothelial cancer, run by Jiangsu Hansoh Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07468851/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT07468851","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Non-muscle-invasive bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Non-muscle-invasive bladder cancer","href":"/cancers/non-muscle-invasive-bladder-cancer/","tip":"Most bladder cancers are found while still confined to the lining. They are scraped out through the urethra and, when higher risk, treated with BCG instilled into the bladder; the challenge is the frequent recurrences and the patients whose tumours stop responding to BCG."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05662397","name":"A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody","tldr":"A phase 1/2 trial of Cemiplimab in advanced solid tumours, run by HotSpot Therapeutics, Inc, active and no longer recruiting.","route":"/trials/nct05662397/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05662397","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06083207","name":"A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma","tldr":"A phase 1/2 trial of IBI3003 in multiple myeloma, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.","route":"/trials/nct06083207/","status":"recruiting","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT06083207","facets":{"kind":["Trial"],"cancers":["Multiple myeloma","Relapsed or refractory multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."},{"label":"Relapsed or refractory multiple myeloma","href":"/cancers/myeloma-relapsed-refractory/","tip":"Myeloma almost always returns, and each return is harder to treat. Two kinds of immune therapy aimed at the BCMA protein on myeloma cells, CAR-T cells (KarMMa-3, CARTITUDE-4) and off-the-shelf bispecific antibodies (MajesTEC), now give deep remissions after other drugs fail, and a second target, GPRC5D, gives another option."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05678270","name":"A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma","tldr":"A phase 2 trial of ICP-192 in biliary tract cancer, run by Beijing InnoCare Pharma Tech Co., Ltd., now recruiting.","route":"/trials/nct05678270/","status":"recruiting","kind":"trial","cancerIcon":"cholangiocarcinoma","sub":"NCT05678270","facets":{"kind":["Trial"],"cancers":["Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07602842","name":"A Study of IDP-001 in Advanced or Metastatic Solid Tumors","tldr":"A phase 1/2 trial of IDP-001 in head and neck squamous cell carcinoma, cutaneous squamous cell carcinoma, cervical cancer, non-small-cell lung cancer and oesophageal cancer, run by InduPro, Inc., now recruiting.","route":"/trials/nct07602842/","status":"recruiting","kind":"trial","cancerIcon":"head-and-neck","sub":"NCT07602842","facets":{"kind":["Trial"],"cancers":["Head and neck squamous cell carcinoma","Cutaneous squamous cell carcinoma","Cervical cancer","Non-small-cell lung cancer","Oesophageal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Cutaneous squamous cell carcinoma","href":"/cancers/cutaneous-scc/","tip":"Cutaneous squamous cell carcinoma is a sun-related skin cancer with over a million US cases a year, almost all cured by removing them. The 2 to 5% that grow deep or spread respond to PD-1 immunotherapy (cemiplimab, pembrolizumab), which is now also given after surgery in high-risk cases; transplant recipients cannot safely receive it."},{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07630974","name":"A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)","tldr":"A phase 1/2 trial of Ifinatamab deruxtecan in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting.","route":"/trials/nct07630974/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07630974","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06644781","name":"A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)","tldr":"A phase 3 trial of Ifinatamab deruxtecan and Docetaxel in oesophageal cancer, run by Daiichi Sankyo, now recruiting.","route":"/trials/nct06644781/","status":"recruiting","kind":"trial","cancerIcon":"esophageal","sub":"NCT06644781","facets":{"kind":["Trial"],"cancers":["Oesophageal cancer","Oesophageal squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."},{"label":"Oesophageal squamous cell carcinoma","href":"/cancers/oesophageal-squamous-cell-carcinoma/","tip":"Squamous cell carcinoma of the oesophagus, the world's commonest form, is linked to smoking, alcohol and very hot drinks and sits in the upper and middle gullet. It is treated with chemoradiation, with or without surgery, and immunotherapy has recently joined chemotherapy for advanced disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06365840","name":"A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor","tldr":"A phase 2 trial of IMC-001 in advanced solid tumours, run by ImmuneOncia Therapeutics Inc., now recruiting.","route":"/trials/nct06365840/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06365840","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04414163","name":"A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type","tldr":"A phase 2 trial of IMC-001 in peripheral T-cell lymphomas, run by ImmuneOncia Therapeutics Inc., active and no longer recruiting.","route":"/trials/nct04414163/","status":"active","kind":"trial","cancerIcon":"peripheral-t-cell-lymphoma","sub":"NCT04414163","facets":{"kind":["Trial"],"cancers":["Peripheral T-cell lymphomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Peripheral T-cell lymphomas","href":"/cancers/peripheral-t-cell-lymphoma/","tip":"Peripheral T-cell lymphomas are lymphomas of T cells rather than B cells. They are rarer, more varied and, apart from a few subtypes, harder to treat than B-cell lymphomas; several new drugs help only defined subtypes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07287098","name":"A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer","tldr":"A phase 2 trial of Imlunestrant and Tamoxifen in HR-positive / HER2-negative breast cancer, run by Eli Lilly and Company, now recruiting.","route":"/trials/nct07287098/","status":"recruiting","kind":"trial","cancerIcon":"breast-hr-positive","sub":"NCT07287098","facets":{"kind":["Trial"],"cancers":["HR-positive / HER2-negative breast cancer","High-risk early HR-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"High-risk early HR-positive breast cancer","href":"/cancers/hr-positive-early-high-risk/","tip":"Most hormone-driven breast cancers are cured with surgery, radiotherapy and five to ten years of endocrine tablets. Women whose tumours are larger, higher grade or have reached the lymph nodes face a higher risk of relapse: two to three years of a CDK4/6 inhibitor added to endocrine therapy cuts recurrence, and genomic tests such as Oncotype DX and MammaPrint decide who also needs chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05514054","name":"A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer","tldr":"A phase 3 trial of Imlunestrant, Tamoxifen and Exemestane in advanced solid tumours, run by Eli Lilly and Company, active and no longer recruiting.","route":"/trials/nct05514054/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05514054","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05957367","name":"A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies","tldr":"A phase 1/2 trial of Ripretinib in advanced solid tumours, run by Deciphera Pharmaceuticals, LLC, now recruiting.","route":"/trials/nct05957367/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05957367","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02138734","name":"A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer","tldr":"A phase 1/2 trial of BCG (50mg/instillation) + N-803 (400 μg/instillation) in bladder & urothelial cancer, run by ImmunityBio, Inc., active and no longer recruiting.","route":"/trials/nct02138734/","status":"active","kind":"trial","cancerIcon":"urothelial","sub":"NCT02138734","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Non-muscle-invasive bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Non-muscle-invasive bladder cancer","href":"/cancers/non-muscle-invasive-bladder-cancer/","tip":"Most bladder cancers are found while still confined to the lining. They are scraped out through the urethra and, when higher risk, treated with BCG instilled into the bladder; the challenge is the frequent recurrences and the patients whose tumours stop responding to BCG."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07122414","name":"A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer","tldr":"A phase 1/2 trial of FL115 in bladder & urothelial cancer, run by Suzhou Forlong Biotechnology Co., Ltd, now recruiting.","route":"/trials/nct07122414/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT07122414","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Non-muscle-invasive bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Non-muscle-invasive bladder cancer","href":"/cancers/non-muscle-invasive-bladder-cancer/","tip":"Most bladder cancers are found while still confined to the lining. They are scraped out through the urethra and, when higher risk, treated with BCG instilled into the bladder; the challenge is the frequent recurrences and the patients whose tumours stop responding to BCG."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06780085","name":"A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)","tldr":"A phase 2 trial of Raludotatug deruxtecan and Ifinatamab deruxtecan in non-small-cell lung cancer, run by Merck Sharp & Dohme LLC, now recruiting.","route":"/trials/nct06780085/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06780085","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06827613","name":"A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors","tldr":"A phase 1/2 trial of Sacituzumab govitecan in advanced solid tumours, run by Marengo Therapeutics, Inc., now recruiting.","route":"/trials/nct06827613/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06827613","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07815665","name":"A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma","tldr":"A phase 2/3 trial of Ivonescimab, Enfortumab vedotin and Pembrolizumab in bladder & urothelial cancer, run by Summit Therapeutics, now recruiting.","route":"/trials/nct07815665/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT07815665","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00883116","name":"A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer","tldr":"A phase 3 trial of Ixabepilone, Doxorubicin and Paclitaxel / nab-paclitaxel in Endometrial cancer, run by R-Pharm, recorded as terminated on the registry.","route":"/trials/nct00883116/","kind":"trial","cancerIcon":"endometrial","sub":"NCT00883116","facets":{"kind":["Trial"],"cancers":["Endometrial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05009329","name":"A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China","tldr":"A phase 1/2 trial of Glecirasib in non-small-cell lung cancer, run by Allist Pharmaceuticals, Inc., active and no longer recruiting.","route":"/trials/nct05009329/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT05009329","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","KRAS G12C-mutant non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"KRAS G12C-mutant non-small-cell lung cancer","href":"/cancers/kras-g12c-nsclc/","tip":"KRAS G12C lung cancer carries a mutation that was thought impossible to drug for forty years. Sotorasib and adagrasib now shrink about four in ten tumours after chemotherapy and immunotherapy, though the benefit is measured in months, and newer inhibitors and first-line combinations with immunotherapy are in trials."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06868849","name":"A Study of JMT203 in Patients With Cancer Cachexia","tldr":"A phase 1/2 trial of JMT203 Injection in non-small-cell lung cancer, pancreatic ductal adenocarcinoma and colorectal cancer, run by Shanghai JMT-Bio Inc., now recruiting.","route":"/trials/nct06868849/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06868849","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","Pancreatic ductal adenocarcinoma","Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06667908","name":"A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)","tldr":"A phase 2 trial of JNJ-90301900, Durvalumab and Carboplatin in non-small-cell lung cancer, run by Johnson & Johnson Enterprise Innovation Inc., now recruiting.","route":"/trials/nct06667908/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06667908","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","Unresectable stage III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Unresectable stage III non-small-cell lung cancer","href":"/cancers/stage-iii-unresectable-nsclc/","tip":"Stage III lung cancer that cannot be removed is treated with chemotherapy and radiotherapy together, aiming at cure. A year of the immunotherapy antibody durvalumab afterwards raised five-year survival from a third to over 40 percent, and for EGFR-mutated tumours osimertinib after chemoradiation holds the disease for years."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07047118","name":"A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)","tldr":"A phase 2 trial of JSB462 in prostate cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.","route":"/trials/nct07047118/","status":"active","kind":"trial","cancerIcon":"prostate","sub":"NCT07047118","facets":{"kind":["Trial"],"cancers":["Prostate cancer","Metastatic castration-resistant prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Metastatic castration-resistant prostate cancer","href":"/cancers/prostate-mcrpc/","tip":"Metastatic castration-resistant prostate cancer is disease that grows despite castrate testosterone. Sequenced treatments now include androgen receptor inhibitors, docetaxel and cabazitaxel, PARP inhibitors for men with BRCA-type mutations, the radioligand 177Lu-PSMA-617 and radium-223 for bone-predominant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05683886","name":"A Study of KC1036 in Patients with Advanced Thymic Tumors","tldr":"A phase 2 trial of KC1036 in thymoma and thymic carcinoma, run by Beijing Konruns Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct05683886/","status":"recruiting","kind":"trial","cancerIcon":"thymic-epithelial","sub":"NCT05683886","facets":{"kind":["Trial"],"cancers":["Thymoma and thymic carcinoma","Thymoma","Thymic carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Thymoma and thymic carcinoma","href":"/cancers/thymic-epithelial/","tip":"Thymoma and thymic carcinoma are rare tumours of the thymus gland in the chest. Thymomas grow slowly, often cause autoimmune diseases such as myasthenia gravis, and are usually cured by surgery; thymic carcinomas behave like other aggressive cancers and have few effective drugs."},{"label":"Thymoma","href":"/cancers/thymoma/","tip":"Thymoma is the slower-growing kind of thymic epithelial tumour, an indolent cancer of the thymus gland behind the breastbone that often announces itself through the autoimmune disease myasthenia gravis. Complete surgical removal cures most patients, radiotherapy is added when the tumour has grown through its capsule, and chemotherapy is used to shrink large tumours or control spread in the chest."},{"label":"Thymic carcinoma","href":"/cancers/thymic-carcinoma/","tip":"Thymic carcinoma is the aggressive kind of thymic epithelial tumour, a cancer of the thymus that behaves like carcinoma elsewhere and has often spread when found. Surgery is attempted when possible, carboplatin with paclitaxel is the usual chemotherapy, and sunitinib, lenvatinib and the PD-1 antibody pembrolizumab have shown responses in trials, with lenvatinib approved in Japan."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05265091","name":"A Study of KL590586 in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of KL590586 Capsule in advanced solid tumours, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., active and no longer recruiting.","route":"/trials/nct05265091/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05265091","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07609823","name":"A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL","tldr":"A phase 2 trial of Lacutoclax in chronic lymphocytic leukaemia, run by Guangzhou Lupeng Pharmaceutical Company LTD., now recruiting.","route":"/trials/nct07609823/","status":"recruiting","kind":"trial","cancerIcon":"cll","sub":"NCT07609823","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia","Relapsed or refractory chronic lymphocytic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Relapsed or refractory chronic lymphocytic leukaemia","href":"/cancers/cll-relapsed/","tip":"When chronic lymphocytic leukaemia returns, the usual move is to switch drug class: venetoclax-based therapy after a BTK inhibitor, or a BTK inhibitor after venetoclax. Pirtobrutinib (BRUIN) works after the older BTK inhibitors fail, and CAR-T is approved for patients who have run out of both classes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07359820","name":"A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement","tldr":"A phase 2 trial of Lirafugratinib in advanced solid tumours, run by Elevar Therapeutics, now recruiting.","route":"/trials/nct07359820/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07359820","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05518045","name":"A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors","tldr":"A phase 1/2 trial of LM-108 and Toripalimab in advanced solid tumours, run by LaNova Medicines Limited, active and no longer recruiting.","route":"/trials/nct05518045/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05518045","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06868199","name":"A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours","tldr":"A phase 1/2 trial of Toripalimab in advanced solid tumours, run by LaNova Medicines Limited, now recruiting.","route":"/trials/nct06868199/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06868199","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07669415","name":"A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors","tldr":"A phase 2 trial of Tislelizumab and Docetaxel in advanced solid tumours, run by LaNova Medicines Limited, now recruiting.","route":"/trials/nct07669415/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07669415","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06187402","name":"A Study of LM-24C5 For Advanced Solid Tumors","tldr":"A phase 1/2 trial of LM-24C5 in advanced solid tumours, run by LaNova Medicines Limited, now recruiting.","route":"/trials/nct06187402/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06187402","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07112222","name":"A Study of LM-350 in Subjects With Advanced Solid Tumours","tldr":"A phase 1/2 trial of LM-350 for injection in advanced solid tumours, run by LaNova Medicines Limited, now recruiting.","route":"/trials/nct07112222/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07112222","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01387763","name":"A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms","tldr":"A phase 3 trial of Peginterferon alfa-2b and Hydroxyurea in Polycythaemia vera, Essential thrombocythaemia and Primary myelofibrosis, run by Thomas Stauffer Larsen, completed.","route":"/trials/nct01387763/","status":"completed","kind":"trial","cancerIcon":"polycythaemia-vera","sub":"NCT01387763","facets":{"kind":["Trial"],"cancers":["Polycythaemia vera","Essential thrombocythaemia","Primary myelofibrosis"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Polycythaemia vera","href":"/cancers/polycythaemia-vera/","tip":"Polycythaemia vera is a slow blood cancer in which a single faulty gene, JAK2, makes the bone marrow produce too many red cells. Thick blood causes clots, so treatment thins it (blood removal, aspirin) and, for higher-risk patients, calms the marrow with hydroxyurea, interferon or ruxolitinib; a hepcidin mimic, rusfertide, now controls red cell counts without regular blood removal."},{"label":"Essential thrombocythaemia","href":"/cancers/essential-thrombocythaemia/","tip":"Essential thrombocythaemia is a slow blood cancer in which the marrow makes too many platelets. Most people need only aspirin and monitoring; those at higher risk of clots take a drug to lower the platelet count, usually hydroxyurea or interferon, with anagrelide in reserve."},{"label":"Primary myelofibrosis","href":"/cancers/primary-myelofibrosis/","tip":"Primary myelofibrosis is a blood cancer in which the marrow scars over, the spleen swells and patients become anaemic and exhausted. JAK inhibitors, ruxolitinib first (COMFORT) and then fedratinib, pacritinib and momelotinib (MOMENTUM), shrink the spleen and relieve symptoms; only a donor stem cell transplant can cure it."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05456256","name":"A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma","tldr":"A phase 2 trial of Pemetrexed and Carboplatin in non-small-cell lung cancer, run by Lantern Pharma Inc., now recruiting.","route":"/trials/nct05456256/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT05456256","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01594723","name":"A Study of LY2784544 in Participants With Myeloproliferative Neoplasms","tldr":"A phase 2 trial of 120 mg LY2784544 in myeloproliferative neoplasms, run by Eli Lilly and Company, active and no longer recruiting.","route":"/trials/nct01594723/","status":"active","kind":"trial","cancerIcon":"myeloproliferative-neoplasms","sub":"NCT01594723","facets":{"kind":["Trial"],"cancers":["Myeloproliferative neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Myeloproliferative neoplasms","href":"/cancers/myeloproliferative-neoplasms/","tip":"Myeloproliferative neoplasms are slow-growing blood cancers in which the marrow overproduces red cells (polycythaemia vera), platelets (essential thrombocythaemia) or scar tissue (myelofibrosis). Almost all carry a mutation in JAK2, CALR or MPL; treatment aims to prevent clots and control symptoms, and only transplant cures myelofibrosis."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04274738","name":"A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4","tldr":"A phase 1 trial of Mavorixafor and Ibrutinib in Waldenström macroglobulinaemia, run by X4 Pharmaceuticals, completed.","route":"/trials/nct04274738/","status":"completed","kind":"trial","cancerIcon":"waldenstrom","sub":"NCT04274738","facets":{"kind":["Trial"],"cancers":["Waldenström macroglobulinaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Waldenström macroglobulinaemia","href":"/cancers/waldenstrom/","tip":"A slow lymphoma that makes an abnormal IgM antibody, causing thick blood, anaemia and nerve damage. Nearly all cases share one mutation (MYD88 L265P), and BTK inhibitors control it for years."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06232096","name":"A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.","tldr":"A phase 1/2 trial of MBS314 Injection in multiple myeloma, run by Beijing Mabworks Biotech Co., Ltd., now recruiting.","route":"/trials/nct06232096/","status":"recruiting","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT06232096","facets":{"kind":["Trial"],"cancers":["Multiple myeloma","Relapsed or refractory multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."},{"label":"Relapsed or refractory multiple myeloma","href":"/cancers/myeloma-relapsed-refractory/","tip":"Myeloma almost always returns, and each return is harder to treat. Two kinds of immune therapy aimed at the BCMA protein on myeloma cells, CAR-T cells (KarMMa-3, CARTITUDE-4) and off-the-shelf bispecific antibodies (MajesTEC), now give deep remissions after other drugs fail, and a second target, GPRC5D, gives another option."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02963493","name":"A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","tldr":"A phase 2 trial of Melphalan flufenamide and Dexamethasone in Multiple myeloma, run by Oncopeptides AB, completed.","route":"/trials/nct02963493/","status":"completed","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT02963493","facets":{"kind":["Trial"],"cancers":["Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03151811","name":"A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide","tldr":"A phase 3 trial of Melphalan flufenamide, Pomalidomide and Dexamethasone in Multiple myeloma, run by Oncopeptides AB, recorded as terminated on the registry.","route":"/trials/nct03151811/","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT03151811","facets":{"kind":["Trial"],"cancers":["Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06679829","name":"A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant","tldr":"A phase 2 trial of Siltuximab and Melphalan in Multiple myeloma, run by Memorial Sloan Kettering Cancer Center, now recruiting.","route":"/trials/nct06679829/","status":"recruiting","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT06679829","facets":{"kind":["Trial"],"cancers":["Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07326488","name":"A Study of MHB009C in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of MHB009C for Injection in advanced solid tumours, run by Minghui Pharmaceutical (Hangzhou) Ltd, now recruiting.","route":"/trials/nct07326488/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07326488","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07229599","name":"A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer","tldr":"A phase 1/2 trial of Furmonertinib and Carboplatin in advanced solid tumours, run by Minghui Pharmaceutical (Hangzhou) Ltd, now recruiting.","route":"/trials/nct07229599/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07229599","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07130383","name":"A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors","tldr":"A phase 2 trial of MHB036C for Injection in advanced solid tumours, run by Minghui Pharmaceutical (Hangzhou) Ltd, now recruiting.","route":"/trials/nct07130383/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07130383","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06373406","name":"A Study of MHB036C for Advanced Solid Tumor","tldr":"A phase 1/2 trial of MHB036C in advanced solid tumours, run by Minghui Pharmaceutical (Hangzhou) Ltd, active and no longer recruiting.","route":"/trials/nct06373406/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06373406","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06345482","name":"A Study of MHB039A for Advanced Solid Tumor","tldr":"A phase 1/2 trial of MHB039A in advanced solid tumours, run by Minghui Pharmaceutical (Hangzhou) Ltd, active and no longer recruiting.","route":"/trials/nct06345482/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06345482","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07192107","name":"A Study of MHB042C in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of MHB042C for Injection in advanced solid tumours, run by Minghui Pharmaceutical (Hangzhou) Ltd, now recruiting.","route":"/trials/nct07192107/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07192107","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06985355","name":"A Study of MHB046C Injection in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of MHB046C in advanced solid tumours, run by Minghui Pharmaceutical (Hangzhou) Ltd, now recruiting.","route":"/trials/nct06985355/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06985355","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07192120","name":"A Study of MHB048C in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of MHB048C for Injection in prostate cancer, run by Minghui Pharmaceutical (Hangzhou) Ltd, now recruiting.","route":"/trials/nct07192120/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT07192120","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07126665","name":"A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors","tldr":"A phase 1/2 trial of QLC5508 in advanced solid tumours, run by Minghui Pharmaceutical (Hangzhou) Ltd, now recruiting.","route":"/trials/nct07126665/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07126665","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06979596","name":"A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)","tldr":"A phase 2 trial of Opevesostat, Dexamethasone, Fulvestrant, Exemestane, Megestrol acetate and Tamoxifen in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting.","route":"/trials/nct06979596/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06979596","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06796907","name":"A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)","tldr":"A phase 1/2 trial of Dostarlimab and Bevacizumab in advanced solid tumours, run by GlaxoSmithKline, now recruiting.","route":"/trials/nct06796907/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06796907","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07701486","name":"A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer","tldr":"A phase 1/2 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by Theriva Biologics SL, now recruiting.","route":"/trials/nct07701486/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT07701486","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07208149","name":"A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)","tldr":"A phase 1/2 trial of MCLA-129 in triple-negative breast cancer, run by Shenzhen Majory Biotechnology Co., Ltd., now recruiting.","route":"/trials/nct07208149/","status":"recruiting","kind":"trial","cancerIcon":"tnbc","sub":"NCT07208149","facets":{"kind":["Trial"],"cancers":["Triple-negative breast cancer","Metastatic triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Metastatic triple-negative breast cancer","href":"/cancers/tnbc-metastatic/","tip":"Triple-negative breast cancer that has spread is not curable, but its treatment has been transformed since 2020. By PD-L1 score, first treatment is pembrolizumab with chemotherapy or with sacituzumab govitecan, or datopotamab deruxtecan or sacituzumab govitecan alone; BRCA carriers can take a PARP inhibitor tablet; and trastuzumab deruxtecan reaches the third of tumours with low HER2."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04492488","name":"A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer","tldr":"A phase 1/2 trial of MRG002 in gastric & gastro-oesophageal junction cancer, run by Shanghai Miracogen Inc., active and no longer recruiting.","route":"/trials/nct04492488/","status":"active","kind":"trial","cancerIcon":"gastric","sub":"NCT04492488","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer","HER2-positive gastric cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"HER2-positive gastric cancer","href":"/cancers/gastric-her2-positive/","tip":"HER2-positive gastric cancer overexpresses the HER2 growth receptor and is treated with trastuzumab added to chemotherapy, now usually with pembrolizumab as well. After progression the antibody-drug conjugate trastuzumab deruxtecan gives responses that plain chemotherapy cannot."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05688605","name":"A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors","tldr":"A phase 1/2 trial of MRG003+HX008 in advanced solid tumours, run by Lepu Biopharma Co., Ltd., now recruiting.","route":"/trials/nct05688605/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05688605","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07093970","name":"A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of MRG006A in advanced solid tumours, run by Lepu Biopharma Co., Ltd., now recruiting.","route":"/trials/nct07093970/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07093970","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07116616","name":"A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma","tldr":"A phase 1/2 trial of mRNA-2808 in multiple myeloma, run by ModernaTX, Inc., now recruiting.","route":"/trials/nct07116616/","status":"recruiting","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT07116616","facets":{"kind":["Trial"],"cancers":["Multiple myeloma","Relapsed or refractory multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."},{"label":"Relapsed or refractory multiple myeloma","href":"/cancers/myeloma-relapsed-refractory/","tip":"Myeloma almost always returns, and each return is harder to treat. Two kinds of immune therapy aimed at the BCMA protein on myeloma cells, CAR-T cells (KarMMa-3, CARTITUDE-4) and off-the-shelf bispecific antibodies (MajesTEC), now give deep remissions after other drugs fail, and a second target, GPRC5D, gives another option."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06943521","name":"A Study of MT-4561 in Patients With Various Advanced Solid Tumors","tldr":"A phase 1/2 trial of MT-4561 in head and neck squamous cell carcinoma, non-small-cell lung cancer, oesophageal cancer, gastric & gastro-oesophageal junction cancer, biliary tract cancer and pancreatic ductal adenocarcinoma, run by Tanabe Pharma America, Inc., now recruiting.","route":"/trials/nct06943521/","status":"recruiting","kind":"trial","cancerIcon":"head-and-neck","sub":"NCT06943521","facets":{"kind":["Trial"],"cancers":["Head and neck squamous cell carcinoma","Non-small-cell lung cancer","Oesophageal cancer","Gastric & gastro-oesophageal junction cancer","Biliary tract cancer","Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."},{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03862430","name":"A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM","tldr":"A phase 2 trial of NanO2TM in glioma & glioblastoma, run by NuvOx LLC, active and no longer recruiting.","route":"/trials/nct03862430/","status":"active","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT03862430","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07026279","name":"A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer","tldr":"A phase 1/2 trial of narmafotinib ascending doses in pancreatic ductal adenocarcinoma, run by Amplia Therapeutics Limited, active and no longer recruiting.","route":"/trials/nct07026279/","status":"active","kind":"trial","cancerIcon":"pancreatic","sub":"NCT07026279","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06855771","name":"A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)","tldr":"A phase 2 trial of BMS-986504 in non-small-cell lung cancer, run by Bristol-Myers Squibb, now recruiting.","route":"/trials/nct06855771/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06855771","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05947851","name":"A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).","tldr":"A phase 3 trial of Nemtabrutinib, Venetoclax and Rituximab in chronic lymphocytic leukaemia and non-Hodgkin lymphoma, run by Merck Sharp & Dohme LLC, now recruiting.","route":"/trials/nct05947851/","status":"recruiting","kind":"trial","cancerIcon":"cll","sub":"NCT05947851","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia","Non-Hodgkin lymphoma","Relapsed or refractory chronic lymphocytic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."},{"label":"Relapsed or refractory chronic lymphocytic leukaemia","href":"/cancers/cll-relapsed/","tip":"When chronic lymphocytic leukaemia returns, the usual move is to switch drug class: venetoclax-based therapy after a BTK inhibitor, or a BTK inhibitor after venetoclax. Pirtobrutinib (BRUIN) works after the older BTK inhibitors fail, and CAR-T is approved for patients who have run out of both classes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05624554","name":"A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)","tldr":"A phase 3 trial of Nemtabrutinib, Fludarabine, Cyclophosphamide, Bendamustine and Rituximab in chronic lymphocytic leukaemia, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","route":"/trials/nct05624554/","status":"active","kind":"trial","cancerIcon":"cll","sub":"NCT05624554","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia","Chronic lymphocytic leukaemia, first treatment"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Chronic lymphocytic leukaemia, first treatment","href":"/cancers/cll-treatment-naive/","tip":"Chronic lymphocytic leukaemia is treated only when it causes problems, and chemotherapy has gone. The first treatment is now either a BTK inhibitor taken indefinitely or a one-year course of venetoclax with obinutuzumab (CLL14), and the two can be combined for a fixed course."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07586202","name":"A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC","tldr":"A phase 2 trial of Amivantamab, Lazertinib, Carboplatin and Pemetrexed in non-small-cell lung cancer, run by Janssen Research & Development, LLC, now recruiting.","route":"/trials/nct07586202/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07586202","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","EGFR-mutated non-small-cell lung cancer","Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."},{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04025879","name":"A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer","tldr":"A phase 3 trial of Nivolumab, Carboplatin, Cisplatin, Pemetrexed and Docetaxel in non-small-cell lung cancer, run by Bristol-Myers Squibb, active and no longer recruiting.","route":"/trials/nct04025879/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT04025879","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","Resectable stage I to III non-small-cell lung cancer"],"year":["2024"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"year":{"facet":"year","value":"2024"},"tags":[]},"sortKeys":{"year":2024}},{"id":"nct06567782","name":"A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer","tldr":"A phase 2 trial of Dostarlimab in colorectal cancer, run by GlaxoSmithKline, now recruiting.","route":"/trials/nct06567782/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT06567782","facets":{"kind":["Trial"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06198751","name":"A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer","tldr":"A phase 2 trial of TQB2102 in HER2-positive breast cancer, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., active and no longer recruiting.","route":"/trials/nct06198751/","status":"active","kind":"trial","cancerIcon":"breast-her2-positive","sub":"NCT06198751","facets":{"kind":["Trial"],"cancers":["HER2-positive breast cancer","Early HER2-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."},{"label":"Early HER2-positive breast cancer","href":"/cancers/her2-positive-early-breast-cancer/","tip":"HER2-positive breast cancer caught early is usually cured. Chemotherapy with the antibodies trastuzumab and pertuzumab comes before surgery; if the tumour has gone by then, antibodies alone finish the year, and if cancer remains, trastuzumab emtansine or trastuzumab deruxtecan take over. Small tumours get a gentler regimen, and trials now ask how much treatment can be left out."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03431350","name":"A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer","tldr":"A phase 2 trial of Niraparib, Cetrelimab, Abiraterone acetate and Prednisone in prostate cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.","route":"/trials/nct03431350/","status":"active","kind":"trial","cancerIcon":"prostate","sub":"NCT03431350","facets":{"kind":["Trial"],"cancers":["Prostate cancer","Metastatic castration-resistant prostate cancer"],"year":["2023"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Metastatic castration-resistant prostate cancer","href":"/cancers/prostate-mcrpc/","tip":"Metastatic castration-resistant prostate cancer is disease that grows despite castrate testosterone. Sequenced treatments now include androgen receptor inhibitors, docetaxel and cabazitaxel, PARP inhibitors for men with BRCA-type mutations, the radioligand 177Lu-PSMA-617 and radium-223 for bone-predominant disease."}],"year":{"facet":"year","value":"2023"},"tags":[]},"sortKeys":{"year":2023}},{"id":"nct04497844","name":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)","tldr":"A phase 3 trial of Abiraterone acetate, Niraparib and Prednisone in prostate cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.","route":"/trials/nct04497844/","status":"active","kind":"trial","cancerIcon":"prostate","sub":"NCT04497844","facets":{"kind":["Trial"],"cancers":["Prostate cancer","Metastatic hormone-sensitive prostate cancer"],"year":["2026"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Metastatic hormone-sensitive prostate cancer","href":"/cancers/prostate-mhspc/","tip":"Metastatic hormone-sensitive prostate cancer is disease that has spread but still responds to lowering testosterone. Hormone therapy alone is no longer enough: adding an androgen receptor inhibitor, and docetaxel for high-volume disease, lengthens life by years."}],"year":{"facet":"year","value":"2026"},"tags":[]},"sortKeys":{"year":2026}},{"id":"nct03635983","name":"A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma","tldr":"A phase 3 trial of Bempegaldesleukin and Nivolumab in Melanoma, run by Bristol-Myers Squibb, completed.","route":"/trials/nct03635983/","status":"completed","kind":"trial","cancerIcon":"melanoma","sub":"NCT03635983","facets":{"kind":["Trial"],"cancers":["Melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07069712","name":"A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma","tldr":"A phase 2 trial of Sonesitatug vedotin, Rilvegostomig, Trastuzumab, Trastuzumab deruxtecan, Capecitabine and Fluorouracil (5-FU) in oesophageal cancer, run by AstraZeneca, now recruiting.","route":"/trials/nct07069712/","status":"recruiting","kind":"trial","cancerIcon":"esophageal","sub":"NCT07069712","facets":{"kind":["Trial"],"cancers":["Oesophageal cancer","Oesophageal and junctional adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."},{"label":"Oesophageal and junctional adenocarcinoma","href":"/cancers/oesophageal-adenocarcinoma/","tip":"Adenocarcinoma of the lower oesophagus and junction grows out of Barrett's oesophagus, the change in the lining caused by long-standing acid reflux. Chemotherapy or chemoradiation before surgery is standard, and HER2, PD-L1 and claudin 18.2 now guide drugs for advanced disease as they do in stomach cancer."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03742102","name":"A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer","tldr":"A phase 1/2 trial of Durvalumab, Capivasertib, Oleclumab, Trastuzumab deruxtecan and Datopotamab deruxtecan in triple-negative breast cancer, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct03742102/","status":"active","kind":"trial","cancerIcon":"tnbc","sub":"NCT03742102","facets":{"kind":["Trial"],"cancers":["Triple-negative breast cancer","Metastatic triple-negative breast cancer"],"year":["2026"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Metastatic triple-negative breast cancer","href":"/cancers/tnbc-metastatic/","tip":"Triple-negative breast cancer that has spread is not curable, but its treatment has been transformed since 2020. By PD-L1 score, first treatment is pembrolizumab with chemotherapy or with sacituzumab govitecan, or datopotamab deruxtecan or sacituzumab govitecan alone; BRCA carriers can take a PARP inhibitor tablet; and trastuzumab deruxtecan reaches the third of tumours with low HER2."}],"year":{"facet":"year","value":"2026"},"tags":[]},"sortKeys":{"year":2026}},{"id":"nct07450859","name":"A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","tldr":"A phase 2 trial of nuzefatide pevedotin (BT5528) in pancreatic ductal adenocarcinoma, run by BicycleTx Limited, now recruiting.","route":"/trials/nct07450859/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT07450859","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07221500","name":"A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)","tldr":"A phase 2 trial of Bexobrutideg in chronic lymphocytic leukaemia, run by Nurix Therapeutics, Inc., now recruiting.","route":"/trials/nct07221500/","status":"recruiting","kind":"trial","cancerIcon":"cll","sub":"NCT07221500","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia","Relapsed or refractory chronic lymphocytic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Relapsed or refractory chronic lymphocytic leukaemia","href":"/cancers/cll-relapsed/","tip":"When chronic lymphocytic leukaemia returns, the usual move is to switch drug class: venetoclax-based therapy after a BTK inhibitor, or a BTK inhibitor after venetoclax. Pirtobrutinib (BRUIN) works after the older BTK inhibitors fail, and CAR-T is approved for patients who have run out of both classes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07734116","name":"A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma.","tldr":"A phase 1/2 trial of ONO-4538HSC in epithelioid sarcoma, run by Ono Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07734116/","status":"recruiting","kind":"trial","cancerIcon":"epithelioid-sarcoma","sub":"NCT07734116","facets":{"kind":["Trial"],"cancers":["Epithelioid sarcoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Epithelioid sarcoma","href":"/cancers/epithelioid-sarcoma/","tip":"Epithelioid sarcoma is a rare soft tissue cancer that has lost a gene brake called SMARCB1, leaving it dependent on the enzyme EZH2. Surgery cures localised tumours. The EZH2 inhibitor tazemetostat, the first epigenetic drug approved for a solid tumour, was approved in 2020 and withdrawn worldwide in March 2026 after secondary blood cancers in a lymphoma trial, so there is no targeted drug today."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04971226","name":"A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP","tldr":"A phase 3 trial of Imatinib, Nilotinib, Bosutinib, Dasatinib and Asciminib in chronic myeloid leukaemia, run by Novartis Pharmaceuticals, active and no longer recruiting.","route":"/trials/nct04971226/","status":"active","kind":"trial","cancerIcon":"cml","sub":"NCT04971226","facets":{"kind":["Trial"],"cancers":["Chronic myeloid leukaemia","Chronic myeloid leukaemia, chronic phase"],"year":["2025"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic myeloid leukaemia","href":"/cancers/cml/","tip":"Chronic myeloid leukaemia is a blood cancer driven by a single fused gene, BCR-ABL1, and the model for oncogene-targeted treatment: imatinib in 2001 and the tyrosine kinase inhibitors that followed turned it into a condition most people live with long-term. About half of patients with a sustained deep molecular response can now stop treatment altogether."},{"label":"Chronic myeloid leukaemia, chronic phase","href":"/cancers/cml-chronic-phase/","tip":"Chronic-phase chronic myeloid leukaemia is the disease that imatinib turned from fatal into manageable: a daily pill blocks the BCR::ABL1 protein that drives it. Blood tests track the leukaemia gene to a millionth, newer pills such as asciminib (ASC4FIRST) reach deeper responses faster, and patients with years of undetectable disease can try stopping."}],"year":{"facet":"year","value":"2025"},"tags":[]},"sortKeys":{"year":2025}},{"id":"nct07266428","name":"A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of OTP-01 in advanced solid tumours, run by Ottimo Pharma Limited, now recruiting.","route":"/trials/nct07266428/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07266428","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00434161","name":"A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma","tldr":"A phase 3 trial of Palifermin in Multiple myeloma, run by Swedish Orphan Biovitrum, completed.","route":"/trials/nct00434161/","status":"completed","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT00434161","facets":{"kind":["Trial"],"cancers":["Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06395519","name":"A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies","tldr":"A phase 1/2 trial of ETX-19477 in ovarian cancer, prostate cancer, endometrial cancer, colorectal cancer and gastric & gastro-oesophageal junction cancer, run by 858 Therapeutics, Inc., now recruiting.","route":"/trials/nct06395519/","status":"recruiting","kind":"trial","cancerIcon":"ovarian","sub":"NCT06395519","facets":{"kind":["Trial"],"cancers":["Ovarian cancer","Prostate cancer","Endometrial cancer","Colorectal cancer","Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06987500","name":"A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment","tldr":"A phase 1/2 trial of XNW29016 in advanced solid tumours, run by Evopoint Biosciences Inc., now recruiting.","route":"/trials/nct06987500/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06987500","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06907043","name":"A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.","tldr":"A phase 1/2 trial of EIK1004-001 (IMP1707-001) in advanced solid tumours, run by Eikon Therapeutics, now recruiting.","route":"/trials/nct06907043/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06907043","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07225946","name":"A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer","tldr":"A phase 3 trial of Pasritamig, Docetaxel and Prednisone in prostate cancer, run by Janssen Research & Development, LLC, now recruiting.","route":"/trials/nct07225946/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT07225946","facets":{"kind":["Trial"],"cancers":["Prostate cancer","Metastatic castration-resistant prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Metastatic castration-resistant prostate cancer","href":"/cancers/prostate-mcrpc/","tip":"Metastatic castration-resistant prostate cancer is disease that grows despite castrate testosterone. Sequenced treatments now include androgen receptor inhibitors, docetaxel and cabazitaxel, PARP inhibitors for men with BRCA-type mutations, the radioligand 177Lu-PSMA-617 and radium-223 for bone-predominant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06941272","name":"A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)","tldr":"A phase 1/2 trial of Patritumab deruxtecan in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting.","route":"/trials/nct06941272/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06941272","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05334823","name":"A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents","tldr":"A phase 2 trial of pCAR-19B cells in acute lymphoblastic leukaemia and childhood cancers, run by Chongqing Precision Biotech Co., Ltd, now recruiting.","route":"/trials/nct05334823/","status":"recruiting","kind":"trial","cancerIcon":"all-leukemia","sub":"NCT05334823","facets":{"kind":["Trial"],"cancers":["Acute lymphoblastic leukaemia","Childhood cancers","Relapsed and refractory acute lymphoblastic leukaemia in children"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."},{"label":"Childhood cancers","href":"/cancers/childhood-cancers/","tip":"Cancer in children is rare and different from adult cancer: the common types are leukaemias, brain tumours, lymphomas and embryonal tumours such as neuroblastoma and Wilms tumour, most are curable in well-resourced health systems, and the great challenge is bringing the same cures to the majority of children who live where they are not available."},{"label":"Relapsed and refractory acute lymphoblastic leukaemia in children","href":"/cancers/all-paediatric-relapsed/","tip":"When childhood leukaemia comes back, chemotherapy alone cures fewer than half. Three immune treatments changed this: blinatumomab, which links the child's T-cells to leukaemia cells and beat chemotherapy in two trials; tisagenlecleucel, the first approved CAR T-cell therapy, which put over eight in ten pretreated children into remission; and the antibody-drug conjugate inotuzumab ozogamicin."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06041802","name":"A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)","tldr":"A phase 2 trial of Pembrolizumab in advanced solid tumours, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","route":"/trials/nct06041802/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06041802","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05899049","name":"A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study","tldr":"A phase 3 trial of Pembrolizumab, Belzutifan and Lenvatinib in renal cell carcinoma, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","route":"/trials/nct05899049/","status":"active","kind":"trial","cancerIcon":"rcc","sub":"NCT05899049","facets":{"kind":["Trial"],"cancers":["Renal cell carcinoma","Clear cell renal cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."},{"label":"Clear cell renal cell carcinoma","href":"/cancers/clear-cell-rcc/","tip":"Clear cell is the common kidney cancer, driven by loss of the VHL gene that leaves the tumour behaving as if starved of oxygen and flooding itself with blood vessels. That biology explains why anti-angiogenic drugs, immunotherapy and the HIF-2 alpha blocker belzutifan all work."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06623422","name":"A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)","tldr":"A phase 3 trial of Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Gemcitabine and Intismeran autogene in non-small-cell lung cancer, run by Merck Sharp & Dohme LLC, now recruiting.","route":"/trials/nct06623422/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06623422","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07302347","name":"A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)","tldr":"A phase 1/2 trial of Pembrolizumab in merkel cell carcinoma and non-Hodgkin lymphoma, run by Merck Sharp & Dohme LLC, now recruiting.","route":"/trials/nct07302347/","status":"recruiting","kind":"trial","cancerIcon":"merkel-cell-carcinoma","sub":"NCT07302347","facets":{"kind":["Trial"],"cancers":["Merkel cell carcinoma","Non-Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Merkel cell carcinoma","href":"/cancers/merkel-cell-carcinoma/","tip":"Merkel cell carcinoma is a rare, fast-growing skin cancer, usually caused by a common virus (Merkel cell polyomavirus) or by sun damage. It was almost untreatable once it spread; PD-1/PD-L1 immunotherapy now gives lasting responses in about half of patients."},{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05023980","name":"A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","tldr":"A phase 3 trial of Pirtobrutinib, Bendamustine and Rituximab in chronic lymphocytic leukaemia, run by Loxo Oncology, Inc., active and no longer recruiting.","route":"/trials/nct05023980/","status":"active","kind":"trial","cancerIcon":"cll","sub":"NCT05023980","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia","Chronic lymphocytic leukaemia, first treatment"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Chronic lymphocytic leukaemia, first treatment","href":"/cancers/cll-treatment-naive/","tip":"Chronic lymphocytic leukaemia is treated only when it causes problems, and chemotherapy has gone. The first treatment is now either a BTK inhibitor taken indefinitely or a one-year course of venetoclax with obinutuzumab (CLL14), and the two can be combined for a fixed course."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05254743","name":"A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","tldr":"A phase 3 trial of Pirtobrutinib and Ibrutinib in chronic lymphocytic leukaemia, run by Loxo Oncology, Inc., now recruiting.","route":"/trials/nct05254743/","status":"recruiting","kind":"trial","cancerIcon":"cll","sub":"NCT05254743","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05844150","name":"A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC","tldr":"A phase 2 trial of PM8002 and Etoposide in small-cell lung cancer, run by Biotheus Inc., active and no longer recruiting.","route":"/trials/nct05844150/","status":"active","kind":"trial","cancerIcon":"sclc","sub":"NCT05844150","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer","Extensive-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."},{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05879055","name":"A Study of PM8002 in Combination With Chemotherapy in Patients With NEN","tldr":"A phase 2 trial of PM8002 in neuroendocrine tumours, run by Biotheus Inc., active and no longer recruiting.","route":"/trials/nct05879055/","status":"active","kind":"trial","cancerIcon":"neuroendocrine","sub":"NCT05879055","facets":{"kind":["Trial"],"cancers":["Neuroendocrine tumours"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Neuroendocrine tumours","href":"/cancers/neuroendocrine/","tip":"A family of usually slow-growing tumours that start in hormone-producing cells of the gut, pancreas and lungs. They pioneered the idea of using the same molecule to see a tumour on a scan and then to treat it with radiation."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05879068","name":"A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC","tldr":"A phase 2 trial of PM8002 in small-cell lung cancer, run by Biotheus Inc., active and no longer recruiting.","route":"/trials/nct05879068/","status":"active","kind":"trial","cancerIcon":"sclc","sub":"NCT05879068","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05918133","name":"A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC","tldr":"A phase 1/2 trial of PM8002 in triple-negative breast cancer, run by Biotheus Inc., active and no longer recruiting.","route":"/trials/nct05918133/","status":"active","kind":"trial","cancerIcon":"tnbc","sub":"NCT05918133","facets":{"kind":["Trial"],"cancers":["Triple-negative breast cancer","Metastatic triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Metastatic triple-negative breast cancer","href":"/cancers/tnbc-metastatic/","tip":"Triple-negative breast cancer that has spread is not curable, but its treatment has been transformed since 2020. By PD-L1 score, first treatment is pembrolizumab with chemotherapy or with sacituzumab govitecan, or datopotamab deruxtecan or sacituzumab govitecan alone; BRCA carriers can take a PARP inhibitor tablet; and trastuzumab deruxtecan reaches the third of tumours with low HER2."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04172597","name":"A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies","tldr":"A phase 2 trial of Poziotinib in Breast cancer and Colorectal cancer, run by Spectrum Pharmaceuticals, Inc, recorded as terminated on the registry.","route":"/trials/nct04172597/","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT04172597","facets":{"kind":["Trial"],"cancers":["Breast cancer","Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06914128","name":"A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors","tldr":"A phase 1/2 trial of BAY 3713372 in advanced solid tumours, run by Bayer, now recruiting.","route":"/trials/nct06914128/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06914128","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03812874","name":"A Study of PTX-9908 Injection for Non-resectable HCC with TACE","tldr":"A phase 1/2 trial of PTX-9908 Injection in hepatocellular carcinoma, run by TCM Biotech International Corp., now recruiting.","route":"/trials/nct03812874/","status":"recruiting","kind":"trial","cancerIcon":"hcc","sub":"NCT03812874","facets":{"kind":["Trial"],"cancers":["Hepatocellular carcinoma","Intermediate hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."},{"label":"Intermediate hepatocellular carcinoma","href":"/cancers/hcc-intermediate/","tip":"Intermediate hepatocellular carcinoma is several tumours inside a working liver, too many to cut out but with no spread beyond it. The standard treatment for two decades has been chemoembolisation through the hepatic artery, and trials now show that adding immunotherapy and anti-angiogenic drugs to it delays progression."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06789796","name":"a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy","tldr":"A phase 3 trial of Iparomlimab and tuvonralimab in Small-cell lung cancer, run by Qilu Pharmaceutical Co., Ltd., not yet recruiting.","route":"/trials/nct06789796/","status":"planned","kind":"trial","cancerIcon":"sclc","sub":"NCT06789796","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07256782","name":"A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of QLC5508, QL1706, Carboplatin, Cisplatin, QL2107 and Fluorouracil (5-FU) in advanced solid tumours, run by Qilu Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07256782/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07256782","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06911827","name":"A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients","tldr":"A phase 1/2 trial of QL2107 in advanced solid tumours, run by Qilu Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct06911827/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06911827","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06504147","name":"A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery","tldr":"A phase 2 trial of Radspherin in ovarian cancer, run by Oncoinvent Solutions AS, now recruiting.","route":"/trials/nct06504147/","status":"recruiting","kind":"trial","cancerIcon":"ovarian","sub":"NCT06504147","facets":{"kind":["Trial"],"cancers":["Ovarian cancer","High-grade serous ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"High-grade serous ovarian cancer","href":"/cancers/high-grade-serous-ovarian-cancer/","tip":"High-grade serous cancer is the common, aggressive form of ovarian cancer, now known to start in the fallopian tube. It is treated with surgery and platinum chemotherapy, and maintenance PARP inhibitors have changed its course for the half of patients whose tumours cannot repair DNA properly."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06864169","name":"A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)","tldr":"A phase 2 trial of Raludotatug deruxtecan in advanced solid tumours, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","route":"/trials/nct06864169/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06864169","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06660654","name":"A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)","tldr":"A phase 2 trial of Raludotatug deruxtecan in advanced solid tumours, run by Daiichi Sankyo, active and no longer recruiting.","route":"/trials/nct06660654/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06660654","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05205850","name":"A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors","tldr":"A phase 1/2 trial of RC118-ADC in advanced solid tumours, run by RemeGen Co., Ltd., now recruiting.","route":"/trials/nct05205850/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05205850","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06038396","name":"A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors","tldr":"A phase 1/2 trial of RC118-ADC, Toripalimab and RC148 in advanced solid tumours, run by RemeGen Co., Ltd., now recruiting.","route":"/trials/nct06038396/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06038396","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06016062","name":"A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors","tldr":"A phase 1/2 trial of Docetaxel and Bevacizumab in advanced solid tumours, run by RemeGen Co., Ltd., now recruiting.","route":"/trials/nct06016062/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06016062","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05980481","name":"A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer","tldr":"A phase 2/3 trial of Trastuzumab, Toripalimab, Oxaliplatin and Capecitabine in gastric & gastro-oesophageal junction cancer, run by RemeGen Co., Ltd., active and no longer recruiting.","route":"/trials/nct05980481/","status":"active","kind":"trial","cancerIcon":"gastric","sub":"NCT05980481","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05302284","name":"A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma","tldr":"A phase 3 trial of Toripalimab, Gemcitabine, Cisplatin and Carboplatin in bladder & urothelial cancer, run by RemeGen Co., Ltd., now recruiting.","route":"/trials/nct05302284/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT05302284","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06678659","name":"A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer","tldr":"A phase 1/2 trial of REC-1245 in non-Hodgkin lymphoma, run by Recursion Pharmaceuticals Inc., now recruiting.","route":"/trials/nct06678659/","status":"recruiting","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT06678659","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04077099","name":"A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer","tldr":"A phase 1/2 trial of REGN5093 in non-small-cell lung cancer, run by Regeneron Pharmaceuticals, active and no longer recruiting.","route":"/trials/nct04077099/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT04077099","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","MET exon 14 and MET-amplified non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"MET exon 14 and MET-amplified non-small-cell lung cancer","href":"/cancers/met-altered-nsclc/","tip":"MET-driven lung cancer comes in three forms: an exon 14 skipping mutation treated with the pills capmatinib or tepotinib, MET amplification that often arises as an escape route from EGFR drugs, and high c-Met protein levels that the antibody-drug conjugate telisotuzumab vedotin targets."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03093116","name":"A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements","tldr":"A phase 1/2 trial of Repotrectinib in advanced solid tumours, run by Turning Point Therapeutics, Inc., now recruiting.","route":"/trials/nct03093116/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT03093116","facets":{"kind":["Trial"],"cancers":["Metastatic cancer","ROS1-positive non-small-cell lung cancer","NTRK fusion-positive non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."},{"label":"ROS1-positive non-small-cell lung cancer","href":"/cancers/ros1-positive-nsclc/","tip":"ROS1-positive lung cancer is a rare fusion-driven adenocarcinoma treated with a pill. Crizotinib was the first, and the newer drugs repotrectinib and taletrectinib control the disease for about three years, reach the brain and work against the resistance mutation that defeated the older drugs."},{"label":"NTRK fusion-positive non-small-cell lung cancer","href":"/cancers/ntrk-fusion-nsclc/","tip":"NTRK fusion lung cancer is very rare and is treated with the same TRK-blocking pills approved for any cancer with the fusion: larotrectinib, entrectinib or repotrectinib shrink most tumours, including in the brain, so the point is to test broadly enough to find it."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04094610","name":"A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations","tldr":"A phase 1/2 trial of Repotrectinib in non-Hodgkin lymphoma and brain and spinal cord tumours, run by Turning Point Therapeutics, Inc., now recruiting.","route":"/trials/nct04094610/","status":"recruiting","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT04094610","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma","Brain and spinal cord tumours"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."},{"label":"Brain and spinal cord tumours","href":"/cancers/brain-tumours/","tip":"Brain and spinal cord tumours range from slow-growing meningiomas and low-grade gliomas to glioblastoma, the commonest malignant brain tumour in adults, and a distinct set of childhood tumours such as medulloblastoma and diffuse midline glioma. Molecular markers now define them, and treatment is surgery, radiotherapy and, for some, drugs chosen by those markers."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06140836","name":"A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)","tldr":"A phase 3 trial of Repotrectinib and Crizotinib in non-small-cell lung cancer, run by Bristol-Myers Squibb, active and no longer recruiting.","route":"/trials/nct06140836/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT06140836","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","ROS1-positive non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"ROS1-positive non-small-cell lung cancer","href":"/cancers/ros1-positive-nsclc/","tip":"ROS1-positive lung cancer is a rare fusion-driven adenocarcinoma treated with a pill. Crizotinib was the first, and the newer drugs repotrectinib and taletrectinib control the disease for about three years, reach the brain and work against the resistance mutation that defeated the older drugs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07221253","name":"A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)","tldr":"A phase 3 trial of Rilvegostomig, Durvalumab and Gemcitabine + cisplatin in biliary tract cancer, run by AstraZeneca, now recruiting.","route":"/trials/nct07221253/","status":"recruiting","kind":"trial","cancerIcon":"cholangiocarcinoma","sub":"NCT07221253","facets":{"kind":["Trial"],"cancers":["Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03673501","name":"A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib","tldr":"A phase 3 trial of Ripretinib and Sunitinib in gastrointestinal stromal tumour, run by Deciphera Pharmaceuticals, LLC, active and no longer recruiting.","route":"/trials/nct03673501/","status":"active","kind":"trial","cancerIcon":"gist","sub":"NCT03673501","facets":{"kind":["Trial"],"cancers":["Gastrointestinal stromal tumour","Imatinib-resistant GIST"],"year":["2024"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastrointestinal stromal tumour","href":"/cancers/gist/","tip":"GIST is a sarcoma of the gut wall driven almost always by a KIT or PDGFRA mutation. It was the proof that a pill can control a solid tumour: imatinib turned a median survival of about a year into one of eight years or more, and the mutation now dictates which drug to use."},{"label":"Imatinib-resistant GIST","href":"/cancers/gist-imatinib-resistant/","tip":"Imatinib-resistant GIST is disease that has grown through the first drug, usually because the tumour has acquired a second KIT mutation that imatinib cannot block. Sunitinib, regorafenib and ripretinib are given in turn; ripretinib, in the INVICTUS trial, extended progression-free survival from 1 to 6 months in patients who had exhausted the other three."}],"year":{"facet":"year","value":"2024"},"tags":[]},"sortKeys":{"year":2024}},{"id":"nct05487170","name":"A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)","tldr":"A phase 1/2 trial of RNK05047 in advanced solid tumours, run by Ranok Therapeutics (Hangzhou) Co., Ltd., now recruiting.","route":"/trials/nct05487170/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05487170","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06667544","name":"A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation","tldr":"A phase 1/2 trial of RNK08954-01 in sarcomas, run by Ranok Therapeutics (Hangzhou) Co., Ltd., now recruiting.","route":"/trials/nct06667544/","status":"recruiting","kind":"trial","cancerIcon":"sarcoma","sub":"NCT06667544","facets":{"kind":["Trial"],"cancers":["Sarcomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Sarcomas","href":"/cancers/sarcoma/","tip":"Sarcomas are dozens of rare cancers of bone and connective tissue. GIST was the first solid tumour cured-in-practice by a targeted pill; synovial sarcoma got the first TCR-T therapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03033511","name":"A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)","tldr":"A phase 3 trial of Rovalpituzumab tesirine and Dexamethasone in Small-cell lung cancer, run by AbbVie, recorded as terminated on the registry.","route":"/trials/nct03033511/","kind":"trial","cancerIcon":"sclc","sub":"NCT03033511","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06149559","name":"A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis","tldr":"A phase 2/3 trial of rozanolixizumab in childhood cancers, run by UCB Biopharma SRL, active and no longer recruiting.","route":"/trials/nct06149559/","status":"active","kind":"trial","cancerIcon":"childhood-cancers","sub":"NCT06149559","facets":{"kind":["Trial"],"cancers":["Childhood cancers"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Childhood cancers","href":"/cancers/childhood-cancers/","tip":"Cancer in children is rare and different from adult cancer: the common types are leukaemias, brain tumours, lymphomas and embryonal tumours such as neuroblastoma and Wilms tumour, most are curable in well-resourced health systems, and the great challenge is bringing the same cures to the majority of children who live where they are not available."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07648030","name":"A Study of Rusfertide in Japanese Adults With Polycythemia Vera","tldr":"A phase 2 trial of Rusfertide in myeloproliferative neoplasms, run by Takeda, now recruiting.","route":"/trials/nct07648030/","status":"recruiting","kind":"trial","cancerIcon":"myeloproliferative-neoplasms","sub":"NCT07648030","facets":{"kind":["Trial"],"cancers":["Myeloproliferative neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Myeloproliferative neoplasms","href":"/cancers/myeloproliferative-neoplasms/","tip":"Myeloproliferative neoplasms are slow-growing blood cancers in which the marrow overproduces red cells (polycythaemia vera), platelets (essential thrombocythaemia) or scar tissue (myelofibrosis). Almost all carry a mutation in JAK2, CALR or MPL; treatment aims to prevent clots and control symptoms, and only transplant cures myelofibrosis."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06926920","name":"A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer","tldr":"A phase 1/2 trial of Sacituzumab govitecan in triple-negative breast cancer, run by Gilead Sciences, now recruiting.","route":"/trials/nct06926920/","status":"recruiting","kind":"trial","cancerIcon":"tnbc","sub":"NCT06926920","facets":{"kind":["Trial"],"cancers":["Triple-negative breast cancer","Metastatic triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Metastatic triple-negative breast cancer","href":"/cancers/tnbc-metastatic/","tip":"Triple-negative breast cancer that has spread is not curable, but its treatment has been transformed since 2020. By PD-L1 score, first treatment is pembrolizumab with chemotherapy or with sacituzumab govitecan, or datopotamab deruxtecan or sacituzumab govitecan alone; BRCA carriers can take a PARP inhibitor tablet; and trastuzumab deruxtecan reaches the third of tumours with low HER2."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06312176","name":"A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)","tldr":"A phase 3 trial of Sacituzumab tirumotecan, Pembrolizumab, Capecitabine and Doxorubicin in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting.","route":"/trials/nct06312176/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06312176","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06841354","name":"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)","tldr":"A phase 3 trial of Sacituzumab tirumotecan, Pembrolizumab, Gemcitabine and Carboplatin in triple-negative breast cancer, run by Merck Sharp & Dohme LLC, now recruiting.","route":"/trials/nct06841354/","status":"recruiting","kind":"trial","cancerIcon":"tnbc","sub":"NCT06841354","facets":{"kind":["Trial"],"cancers":["Triple-negative breast cancer","Metastatic triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Metastatic triple-negative breast cancer","href":"/cancers/tnbc-metastatic/","tip":"Triple-negative breast cancer that has spread is not curable, but its treatment has been transformed since 2020. By PD-L1 score, first treatment is pembrolizumab with chemotherapy or with sacituzumab govitecan, or datopotamab deruxtecan or sacituzumab govitecan alone; BRCA carriers can take a PARP inhibitor tablet; and trastuzumab deruxtecan reaches the third of tumours with low HER2."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07060989","name":"A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation","tldr":"A phase 1/2 trial of NTS071 in advanced solid tumours, run by Nutshell Therapeutics (Shanghai) Co., LTD., now recruiting.","route":"/trials/nct07060989/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07060989","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04819100","name":"A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)","tldr":"A phase 3 trial of Selpercatinib in non-small-cell lung cancer, run by Eli Lilly and Company, active and no longer recruiting.","route":"/trials/nct04819100/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT04819100","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","Resectable stage I to III non-small-cell lung cancer","RET fusion-positive non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."},{"label":"RET fusion-positive non-small-cell lung cancer","href":"/cancers/ret-fusion-nsclc/","tip":"RET fusion lung cancer is a rare adenocarcinoma driven by a fused RET gene. The selective pill selpercatinib shrinks most tumours and more than doubles the time to progression compared with chemotherapy and immunotherapy, and pralsetinib is a second option."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06012435","name":"A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer","tldr":"A phase 3 trial of Docetaxel in non-small-cell lung cancer, run by Seagen, a wholly owned subsidiary of Pfizer, active and no longer recruiting.","route":"/trials/nct06012435/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT06012435","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06703177","name":"A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors","tldr":"A phase 1/2 trial of SHR-8068, Bevacizumab, Leucovorin (folinic acid), Adebrelimab and Capecitabine in advanced solid tumours, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.","route":"/trials/nct06703177/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06703177","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06764628","name":"A Study of SHR-4375 in Subjects With Solid Tumors","tldr":"A phase 1/2 trial of SHR-4375 in advanced solid tumours, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.","route":"/trials/nct06764628/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06764628","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07298772","name":"A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors","tldr":"A phase 1/2 trial of SHR-4375 Injection in advanced solid tumours, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.","route":"/trials/nct07298772/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07298772","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07231211","name":"A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of Trastuzumab rezetecan in advanced solid tumours, run by Shanghai Shengdi Pharmaceutical Co., Ltd, now recruiting.","route":"/trials/nct07231211/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07231211","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07229586","name":"A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors","tldr":"A phase 1/2 trial of Adebrelimab and Gemcitabine in advanced solid tumours, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07229586/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07229586","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07450976","name":"A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer","tldr":"A phase 2 trial of SHR-A1904 for Injection in biliary tract cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.","route":"/trials/nct07450976/","status":"recruiting","kind":"trial","cancerIcon":"cholangiocarcinoma","sub":"NCT07450976","facets":{"kind":["Trial"],"cancers":["Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05668858","name":"A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma","tldr":"A phase 1/2 trial of SI-B001 in head and neck squamous cell carcinoma, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.","route":"/trials/nct05668858/","status":"active","kind":"trial","cancerIcon":"head-and-neck","sub":"NCT05668858","facets":{"kind":["Trial"],"cancers":["Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05965856","name":"A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors","tldr":"A phase 2 trial of BL-B01D1 in bladder & urothelial cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct05965856/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT05965856","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06042894","name":"A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer","tldr":"A phase 2 trial of BL-B01D1 in advanced solid tumours, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct06042894/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06042894","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07241936","name":"A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors","tldr":"A phase 1/2 trial of SYS6010 in advanced solid tumours, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., now recruiting.","route":"/trials/nct07241936/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07241936","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06279364","name":"A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer","tldr":"A phase 3 trial of Capecitabine, Eribulin and Carboplatin in triple-negative breast cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct06279364/","status":"recruiting","kind":"trial","cancerIcon":"tnbc","sub":"NCT06279364","facets":{"kind":["Trial"],"cancers":["Triple-negative breast cancer","Metastatic triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Metastatic triple-negative breast cancer","href":"/cancers/tnbc-metastatic/","tip":"Triple-negative breast cancer that has spread is not curable, but its treatment has been transformed since 2020. By PD-L1 score, first treatment is pembrolizumab with chemotherapy or with sacituzumab govitecan, or datopotamab deruxtecan or sacituzumab govitecan alone; BRCA carriers can take a PARP inhibitor tablet; and trastuzumab deruxtecan reaches the third of tumours with low HER2."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07071337","name":"A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy","tldr":"A phase 3 trial of Capecitabine in advanced solid tumours, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07071337/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07071337","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07448922","name":"A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors","tldr":"A phase 2 trial of Carboplatin and Bevacizumab in advanced solid tumours, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07448922/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07448922","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07019675","name":"A Study of SKB518 in Patients With Lung Cancer","tldr":"A phase 2 trial of Tislelizumab and Carboplatin in advanced solid tumours, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07019675/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07019675","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06359860","name":"A Study of ST-1898 for Unresectable or Metastatic Melanoma","tldr":"A phase 1/2 trial of ST-1898 tablets in melanoma, run by Beijing Scitech-Mq Pharmaceuticals Limited, now recruiting.","route":"/trials/nct06359860/","status":"recruiting","kind":"trial","cancerIcon":"melanoma","sub":"NCT06359860","facets":{"kind":["Trial"],"cancers":["Melanoma","Advanced melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"label":"Advanced melanoma","href":"/cancers/advanced-melanoma/","tip":"Advanced melanoma has spread beyond what surgery can remove, and it is the cancer in which immunotherapy first proved it could cure some people: about half of those given nivolumab with ipilimumab are alive ten years later. If immunotherapy fails, options include a cell therapy grown from the patient's own immune cells, a virus injected into the tumour, and targeted pills for BRAF-mutant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05710848","name":"A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer","tldr":"A phase 1/2 trial of STM-416 in bladder & urothelial cancer, run by SURGE Therapeutics, now recruiting.","route":"/trials/nct05710848/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT05710848","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04521231","name":"A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL","tldr":"A phase 1/2 trial of Blinatumomab in acute lymphoblastic leukaemia, run by Amgen, active and no longer recruiting.","route":"/trials/nct04521231/","status":"active","kind":"trial","cancerIcon":"all-leukemia","sub":"NCT04521231","facets":{"kind":["Trial"],"cancers":["Acute lymphoblastic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07134088","name":"A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia","tldr":"A phase 1/2 trial of Blinatumomab in acute lymphoblastic leukaemia, run by Amgen, active and no longer recruiting.","route":"/trials/nct07134088/","status":"active","kind":"trial","cancerIcon":"all-leukemia","sub":"NCT07134088","facets":{"kind":["Trial"],"cancers":["Acute lymphoblastic leukaemia","Relapsed and refractory acute lymphoblastic leukaemia in children"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."},{"label":"Relapsed and refractory acute lymphoblastic leukaemia in children","href":"/cancers/all-paediatric-relapsed/","tip":"When childhood leukaemia comes back, chemotherapy alone cures fewer than half. Three immune treatments changed this: blinatumomab, which links the child's T-cells to leukaemia cells and beat chemotherapy in two trials; tisagenlecleucel, the first approved CAR T-cell therapy, which put over eight in ten pretreated children into remission; and the antibody-drug conjugate inotuzumab ozogamicin."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06533644","name":"A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer","tldr":"A phase 2 trial of Partial Oncolysis in prostate cancer, run by Syncromune, Inc., now recruiting.","route":"/trials/nct06533644/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT06533644","facets":{"kind":["Trial"],"cancers":["Prostate cancer","Metastatic castration-resistant prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Metastatic castration-resistant prostate cancer","href":"/cancers/prostate-mcrpc/","tip":"Metastatic castration-resistant prostate cancer is disease that grows despite castrate testosterone. Sequenced treatments now include androgen receptor inhibitors, docetaxel and cabazitaxel, PARP inhibitors for men with BRCA-type mutations, the radioligand 177Lu-PSMA-617 and radium-223 for bone-predominant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06271837","name":"A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors","tldr":"A phase 2 trial of Trastuzumab deruxtecan and Bevacizumab in gastric & gastro-oesophageal junction cancer, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct06271837/","status":"active","kind":"trial","cancerIcon":"gastric","sub":"NCT06271837","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer","HER2-positive gastric cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"HER2-positive gastric cancer","href":"/cancers/gastric-her2-positive/","tip":"HER2-positive gastric cancer overexpresses the HER2 growth receptor and is treated with trastuzumab added to chemotherapy, now usually with pembrolizumab as well. After progression the antibody-drug conjugate trastuzumab deruxtecan gives responses that plain chemotherapy cannot."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06971614","name":"A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC","tldr":"A phase 2 trial of T3011 in bladder & urothelial cancer, run by ImmVira Pharma Co. Ltd, now recruiting.","route":"/trials/nct06971614/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT06971614","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Non-muscle-invasive bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Non-muscle-invasive bladder cancer","href":"/cancers/non-muscle-invasive-bladder-cancer/","tip":"Most bladder cancers are found while still confined to the lining. They are scraped out through the urethra and, when higher risk, treated with BCG instilled into the bladder; the challenge is the frequent recurrences and the patients whose tumours stop responding to BCG."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06846671","name":"A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors","tldr":"A phase 3 trial of Bendamustine, Idelalisib, Rituximab and Venetoclax in chronic lymphocytic leukaemia, run by BeOne Medicines, now recruiting.","route":"/trials/nct06846671/","status":"recruiting","kind":"trial","cancerIcon":"cll","sub":"NCT06846671","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06456463","name":"A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy","tldr":"A phase 2 trial of Tagraxofusp, Venetoclax and Azacitidine in acute myeloid leukaemia, run by Stemline Therapeutics, Inc., active and no longer recruiting.","route":"/trials/nct06456463/","status":"active","kind":"trial","cancerIcon":"aml","sub":"NCT06456463","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia","Acute myeloid leukaemia in older or unfit patients"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Acute myeloid leukaemia in older or unfit patients","href":"/cancers/aml-older-unfit/","tip":"Most people with acute myeloid leukaemia are over 65, and many cannot take intensive chemotherapy. Venetoclax with azacitidine, two gentler drugs, doubled remission rates and lengthened life in this group, replacing the old choice between supportive care and low-dose chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05020015","name":"A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)","tldr":"A phase 2 trial of TAK-007 in non-Hodgkin lymphoma, run by Takeda, active and no longer recruiting.","route":"/trials/nct05020015/","status":"active","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT05020015","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma"],"year":["2025"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"year":{"facet":"year","value":"2025"},"tags":[]},"sortKeys":{"year":2025}},{"id":"nct07205718","name":"A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors","tldr":"A phase 1/2 trial of TAK-188 in advanced solid tumours, run by Takeda, now recruiting.","route":"/trials/nct07205718/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07205718","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07436728","name":"A Study of TAK-505 in Adults With Solid Tumors","tldr":"A phase 1/2 trial of TAK-505 in advanced solid tumours, run by Takeda, now recruiting.","route":"/trials/nct07436728/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07436728","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02716116","name":"A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer","tldr":"A phase 1/2 trial of TAK-788 in non-small-cell lung cancer, run by Takeda, active and no longer recruiting.","route":"/trials/nct02716116/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT02716116","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","EGFR-mutated non-small-cell lung cancer","HER2-mutant non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."},{"label":"HER2-mutant non-small-cell lung cancer","href":"/cancers/her2-mutant-nsclc/","tip":"HER2-mutant lung cancer carries a mutation in the same receptor that drives HER2-positive breast cancer, but the breast cancer antibodies alone did little here. The antibody-drug conjugate trastuzumab deruxtecan shrinks about half of tumours after chemotherapy, and the pill zongertinib about seven in ten, and both are approved."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06211764","name":"A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)","tldr":"A phase 3 trial of Gemcitabine intravesical system (TAR-200), Mitomycin C and Gemcitabine in bladder & urothelial cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.","route":"/trials/nct06211764/","status":"active","kind":"trial","cancerIcon":"urothelial","sub":"NCT06211764","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Non-muscle-invasive bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Non-muscle-invasive bladder cancer","href":"/cancers/non-muscle-invasive-bladder-cancer/","tip":"Most bladder cancers are found while still confined to the lining. They are scraped out through the urethra and, when higher risk, treated with BCG instilled into the bladder; the challenge is the frequent recurrences and the patients whose tumours stop responding to BCG."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07259213","name":"A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC","tldr":"A phase 1/2 trial of 161Tb RAD402 in prostate cancer, run by Radiopharm Theranostics, Ltd, now recruiting.","route":"/trials/nct07259213/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT07259213","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05968326","name":"A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC","tldr":"A phase 2 trial of Autogene cevumeran and Atezolizumab in pancreatic ductal adenocarcinoma, run by Genentech, Inc., active and no longer recruiting.","route":"/trials/nct05968326/","status":"active","kind":"trial","cancerIcon":"pancreatic","sub":"NCT05968326","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07742215","name":"A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)","tldr":"A phase 3 trial of Daratumumab, Dexamethasone and Pomalidomide in multiple myeloma, run by Biocad, now recruiting.","route":"/trials/nct07742215/","status":"recruiting","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT07742215","facets":{"kind":["Trial"],"cancers":["Multiple myeloma","Relapsed or refractory multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."},{"label":"Relapsed or refractory multiple myeloma","href":"/cancers/myeloma-relapsed-refractory/","tip":"Myeloma almost always returns, and each return is harder to treat. Two kinds of immune therapy aimed at the BCMA protein on myeloma cells, CAR-T cells (KarMMa-3, CARTITUDE-4) and off-the-shelf bispecific antibodies (MajesTEC), now give deep remissions after other drugs fail, and a second target, GPRC5D, gives another option."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07015242","name":"A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma","tldr":"A phase 2 trial of Rituximab, Methotrexate, Procarbazine, Temozolomide, Lisocabtagene maraleucel and Fludarabine in non-Hodgkin lymphoma, run by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, now recruiting.","route":"/trials/nct07015242/","status":"recruiting","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT07015242","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma","Primary CNS lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."},{"label":"Primary CNS lymphoma","href":"/cancers/primary-cns-lymphoma/","tip":"Primary CNS lymphoma is a lymphoma confined to the brain, eyes and spinal fluid. Unlike most brain tumours it is chemo-sensitive: high-dose methotrexate-based treatment cures a substantial minority, and consolidation with a stem-cell transplant has replaced whole-brain radiation for the fit."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04488822","name":"A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT","tldr":"A phase 3 trial of Pexidartinib in tenosynovial giant cell tumour, run by Daiichi Sankyo Co., Ltd., active and no longer recruiting.","route":"/trials/nct04488822/","status":"active","kind":"trial","cancerIcon":"tenosynovial-giant-cell-tumour","sub":"NCT04488822","facets":{"kind":["Trial"],"cancers":["Tenosynovial giant cell tumour"],"year":["2023"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Tenosynovial giant cell tumour","href":"/cancers/tenosynovial-giant-cell-tumour/","tip":"TGCT is a benign but destructive tumour of the joint lining, classed with soft-tissue sarcomas, in which a few cells carrying a CSF1 gene fusion recruit a crowd of normal immune cells that eat away at the joint. Surgery cures most localised cases, and for diffuse or recurrent disease two pills that block the CSF1 receptor, pexidartinib and vimseltinib, shrink tumours and restore joint function."}],"year":{"facet":"year","value":"2023"},"tags":[]},"sortKeys":{"year":2023}},{"id":"nct05327530","name":"A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)","tldr":"A phase 2 trial of Avelumab and Sacituzumab govitecan in bladder & urothelial cancer, run by EMD Serono Research & Development Institute, Inc., active and no longer recruiting.","route":"/trials/nct05327530/","status":"active","kind":"trial","cancerIcon":"urothelial","sub":"NCT05327530","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":["2026"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"year":{"facet":"year","value":"2026"},"tags":[]},"sortKeys":{"year":2026}},{"id":"nct03933735","name":"A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma","tldr":"A phase 1/2 trial of TNB-383B in multiple myeloma, run by AbbVie, active and no longer recruiting.","route":"/trials/nct03933735/","status":"active","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT03933735","facets":{"kind":["Trial"],"cancers":["Multiple myeloma","Relapsed or refractory multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."},{"label":"Relapsed or refractory multiple myeloma","href":"/cancers/myeloma-relapsed-refractory/","tip":"Myeloma almost always returns, and each return is harder to treat. Two kinds of immune therapy aimed at the BCMA protein on myeloma cells, CAR-T cells (KarMMa-3, CARTITUDE-4) and off-the-shelf bispecific antibodies (MajesTEC), now give deep remissions after other drugs fail, and a second target, GPRC5D, gives another option."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05852691","name":"A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer","tldr":"A phase 2 trial of Pembrolizumab in triple-negative breast cancer, run by Hoffmann-La Roche, active and no longer recruiting.","route":"/trials/nct05852691/","status":"active","kind":"trial","cancerIcon":"tnbc","sub":"NCT05852691","facets":{"kind":["Trial"],"cancers":["Triple-negative breast cancer","Metastatic triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Metastatic triple-negative breast cancer","href":"/cancers/tnbc-metastatic/","tip":"Triple-negative breast cancer that has spread is not curable, but its treatment has been transformed since 2020. By PD-L1 score, first treatment is pembrolizumab with chemotherapy or with sacituzumab govitecan, or datopotamab deruxtecan or sacituzumab govitecan alone; BRCA carriers can take a PARP inhibitor tablet; and trastuzumab deruxtecan reaches the third of tumours with low HER2."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07439653","name":"A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma","tldr":"A phase 1/2 trial of TORL-5-700 in non-Hodgkin lymphoma, run by TORL Biotherapeutics, LLC, now recruiting.","route":"/trials/nct07439653/","status":"recruiting","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT07439653","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06431490","name":"A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer","tldr":"A phase 1/2 trial of TQB2102 in biliary tract cancer, run by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct06431490/","status":"recruiting","kind":"trial","cancerIcon":"cholangiocarcinoma","sub":"NCT06431490","facets":{"kind":["Trial"],"cancers":["Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06202261","name":"A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer","tldr":"A phase 1/2 trial of TQB2930, TQB3616, Fulvestrant, Capecitabine, Vinorelbine and Eribulin in advanced solid tumours, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting.","route":"/trials/nct06202261/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06202261","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07679360","name":"A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer","tldr":"A phase 3 trial of Trastuzumab, Trastuzumab rezetecan, Adebrelimab, Capecitabine and Pembrolizumab in triple-negative breast cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.","route":"/trials/nct07679360/","status":"recruiting","kind":"trial","cancerIcon":"tnbc","sub":"NCT07679360","facets":{"kind":["Trial"],"cancers":["Triple-negative breast cancer","Early triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Early triple-negative breast cancer","href":"/cancers/tnbc-early/","tip":"Early triple-negative breast cancer is treated to cure. For tumours over 2 cm or with node involvement, chemotherapy plus the immunotherapy pembrolizumab before and after surgery has raised cure rates; BRCA carriers with cancer left at surgery add a year of olaparib, and others with residual cancer are offered capecitabine. Whether the tumour has vanished by surgery guides what comes next."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07567521","name":"A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC","tldr":"A phase 1/2 trial of Radiopharmaceuticals in prostate cancer, run by C Ray Therapeutics, now recruiting.","route":"/trials/nct07567521/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT07567521","facets":{"kind":["Trial"],"cancers":["Prostate cancer","Metastatic castration-resistant prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Metastatic castration-resistant prostate cancer","href":"/cancers/prostate-mcrpc/","tip":"Metastatic castration-resistant prostate cancer is disease that grows despite castrate testosterone. Sequenced treatments now include androgen receptor inhibitors, docetaxel and cabazitaxel, PARP inhibitors for men with BRCA-type mutations, the radioligand 177Lu-PSMA-617 and radium-223 for bone-predominant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05382338","name":"A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss","tldr":"A phase 3 trial of Cisplatin, Cyclophosphamide, Lomustine, Sodium thiosulfate and Vincristine in Medulloblastoma, run by Children's Oncology Group, now recruiting.","route":"/trials/nct05382338/","status":"recruiting","kind":"trial","cancerIcon":"medulloblastoma","sub":"NCT05382338","facets":{"kind":["Trial"],"cancers":["Medulloblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Medulloblastoma","href":"/cancers/medulloblastoma/","tip":"Medulloblastoma is the most common malignant childhood brain tumour, arising in the cerebellum. Surgery, radiation to the whole brain and spine, and chemotherapy cure about 70%, at a heavy cost to thinking and growth; treatment is now being tailored to four molecular subgroups so that the low-risk children get less."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06038578","name":"A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer","tldr":"A phase 2 trial of TRK-950 and Ramucirumab in gastric & gastro-oesophageal junction cancer, run by Toray Industries, Inc, now recruiting.","route":"/trials/nct06038578/","status":"recruiting","kind":"trial","cancerIcon":"gastric","sub":"NCT06038578","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06385925","name":"A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","tldr":"A phase 1/2 trial of TSN1611 in advanced solid tumours, run by Tyligand Pharmaceuticals (Suzhou) Limited, now recruiting.","route":"/trials/nct06385925/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06385925","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04721977","name":"A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)","tldr":"A phase 2 trial of Tucatinib, Trastuzumab and Capecitabine in advanced solid tumours, run by Pfizer, active and no longer recruiting.","route":"/trials/nct04721977/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04721977","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":["2024"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"year":{"facet":"year","value":"2024"},"tags":[]},"sortKeys":{"year":2024}},{"id":"nct04014205","name":"A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies","tldr":"A phase 1/2 trial of Orelabrutinib in advanced solid tumours, run by Beijing InnoCare Pharma Tech Co., Ltd., active and no longer recruiting.","route":"/trials/nct04014205/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04014205","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06930794","name":"A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive","tldr":"A phase 3 trial of Vebreltinib in non-small-cell lung cancer, run by Beijing Pearl Biotechnology Limited Liability Company, now recruiting.","route":"/trials/nct06930794/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06930794","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","MET exon 14 and MET-amplified non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"MET exon 14 and MET-amplified non-small-cell lung cancer","href":"/cancers/met-altered-nsclc/","tip":"MET-driven lung cancer comes in three forms: an exon 14 skipping mutation treated with the pills capmatinib or tepotinib, MET amplification that often arises as an escape route from EGFR drugs, and high c-Met protein levels that the antibody-drug conjugate telisotuzumab vedotin targets."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07689201","name":"A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib","tldr":"A phase 2 trial of Velzatinib in advanced solid tumours, run by GlaxoSmithKline, now recruiting.","route":"/trials/nct07689201/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07689201","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02966756","name":"A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","tldr":"A phase 2 trial of Venetoclax in chronic lymphocytic leukaemia, run by AbbVie, active and no longer recruiting.","route":"/trials/nct02966756/","status":"active","kind":"trial","cancerIcon":"cll","sub":"NCT02966756","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia","Relapsed or refractory chronic lymphocytic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Relapsed or refractory chronic lymphocytic leukaemia","href":"/cancers/cll-relapsed/","tip":"When chronic lymphocytic leukaemia returns, the usual move is to switch drug class: venetoclax-based therapy after a BTK inhibitor, or a BTK inhibitor after venetoclax. Pirtobrutinib (BRUIN) works after the older BTK inhibitors fail, and CAR-T is approved for patients who have run out of both classes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06943833","name":"A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)","tldr":"A phase 2 trial of Volrustomig in cervical cancer, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct06943833/","status":"active","kind":"trial","cancerIcon":"cervical","sub":"NCT06943833","facets":{"kind":["Trial"],"cancers":["Cervical cancer","Locally advanced cervical cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."},{"label":"Locally advanced cervical cancer","href":"/cancers/locally-advanced-cervical-cancer/","tip":"Locally advanced cervical cancer has grown beyond the cervix or into the pelvic lymph nodes but not to distant organs. It is treated with cisplatin chemotherapy given alongside external radiotherapy and brachytherapy, and two recent trials have improved on that: adding pembrolizumab, and giving six weeks of chemotherapy before the radiotherapy starts."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07093814","name":"A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma","tldr":"A phase 1/2 trial of VRT106 in glioma & glioblastoma, run by Guangzhou Virotech Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07093814/","status":"recruiting","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT07093814","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07589257","name":"A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pontine Glioma","tldr":"A phase 2 trial of VRT106 for injection in glioma & glioblastoma and diffuse midline glioma, H3 K27-altered, run by Guangzhou Virotech Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07589257/","status":"recruiting","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT07589257","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma","Diffuse midline glioma, H3 K27-altered"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."},{"label":"Diffuse midline glioma, H3 K27-altered","href":"/cancers/dipg-dmg/","tip":"Diffuse midline glioma grows through the brainstem and cannot be removed surgically. A single change in a histone protein (H3 K27M) rewires how the tumour reads its DNA. Radiotherapy was long the only help; in 2025 the first drug aimed at this tumour, dordaviprone (ONC201), was approved after durable shrinkage in some patients, and GD2 CAR-T cells have produced striking early responses."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06117566","name":"A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of Toripalimab in advanced solid tumours, run by Shanghai Jiatan Pharmatech Co., Ltd, now recruiting.","route":"/trials/nct06117566/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06117566","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06117540","name":"A Study of WX390 in Patients With Advanced Solid Tumors","tldr":"A phase 2 trial of WX390 in advanced solid tumours, run by Shanghai Jiatan Pharmatech Co., Ltd, now recruiting.","route":"/trials/nct06117540/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06117540","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05032040","name":"A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies","tldr":"A phase 2 trial of vudalimab in ovarian cancer, endometrial cancer, cervical cancer and prostate cancer, run by Xencor, Inc., active and no longer recruiting.","route":"/trials/nct05032040/","status":"active","kind":"trial","cancerIcon":"ovarian","sub":"NCT05032040","facets":{"kind":["Trial"],"cancers":["Ovarian cancer","Endometrial cancer","Cervical cancer","Prostate cancer","Metastatic castration-resistant prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."},{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."},{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05257395","name":"A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer","tldr":"A phase 3 trial of XZP-3287 in advanced solid tumours, run by Xuanzhu Biopharmaceutical Co., Ltd., active and no longer recruiting.","route":"/trials/nct05257395/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05257395","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04996121","name":"A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors","tldr":"A phase 1/2 trial of XZP-5955 tablets in non-small-cell lung cancer, run by Xuanzhu Biopharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct04996121/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT04996121","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","NTRK fusion-positive non-small-cell lung cancer","ROS1-positive non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"NTRK fusion-positive non-small-cell lung cancer","href":"/cancers/ntrk-fusion-nsclc/","tip":"NTRK fusion lung cancer is very rare and is treated with the same TRK-blocking pills approved for any cancer with the fusion: larotrectinib, entrectinib or repotrectinib shrink most tumours, including in the brain, so the point is to test broadly enough to find it."},{"label":"ROS1-positive non-small-cell lung cancer","href":"/cancers/ros1-positive-nsclc/","tip":"ROS1-positive lung cancer is a rare fusion-driven adenocarcinoma treated with a pill. Crizotinib was the first, and the newer drugs repotrectinib and taletrectinib control the disease for about three years, reach the brain and work against the resistance mutation that defeated the older drugs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07407933","name":"A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of YL201 and Atezolizumab in small-cell lung cancer, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.","route":"/trials/nct07407933/","status":"recruiting","kind":"trial","cancerIcon":"sclc","sub":"NCT07407933","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05434234","name":"A Study of YL201 in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of YL201 and Atezolizumab in advanced solid tumours, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.","route":"/trials/nct05434234/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05434234","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06107686","name":"A Study of YL202 in Selected Patients With Advanced Solid Tumors","tldr":"A phase 2 trial of YL202 should be intravenously infused in non-small-cell lung cancer, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.","route":"/trials/nct06107686/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06107686","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07197827","name":"A Study of YL242 in Subjects With Advanced Solid Tumors","tldr":"A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.","route":"/trials/nct07197827/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07197827","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02912949","name":"A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)","tldr":"A phase 2 trial of Zenocutuzumab in non-small-cell lung cancer and pancreatic ductal adenocarcinoma, run by Partner Therapeutics, Inc., active and no longer recruiting.","route":"/trials/nct02912949/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT02912949","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","Pancreatic ductal adenocarcinoma","KRAS wild-type pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"KRAS wild-type pancreatic ductal adenocarcinoma","href":"/cancers/kras-wild-type-pdac/","tip":"KRAS wild-type pancreatic cancer is the one in ten pancreatic cancers without the KRAS mutation that drives the rest. Instead many carry a different switched-on gene, often a fusion involving NRG1, NTRK, ALK, ROS1, FGFR2 or RET, or a BRAF change, and several of these have approved pills or antibodies, so these tumours must be sequenced with a test that detects fusions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05118789","name":"A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)","tldr":"A phase 1/2 trial of Zidesamtinib in advanced solid tumours, run by Nuvalent Inc., now recruiting.","route":"/trials/nct05118789/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05118789","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05406401","name":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)","tldr":"A phase 2 trial of Zilovertamab vedotin, Cyclophosphamide, Doxorubicin, Rituximab and Prednisone in diffuse large B-cell lymphoma, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","route":"/trials/nct05406401/","status":"active","kind":"trial","cancerIcon":"dlbcl","sub":"NCT05406401","facets":{"kind":["Trial"],"cancers":["Diffuse large B-cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05967689","name":"A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.","tldr":"A phase 2 trial of TAS6417 in non-small-cell lung cancer, run by Taiho Oncology, Inc., now recruiting.","route":"/trials/nct05967689/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT05967689","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06885281","name":"A Study of ZL-1310 in Participants With Selected Solid Tumors","tldr":"A phase 1/2 trial of ZL-1310 in advanced solid tumours, run by Zai Lab (Shanghai) Co., Ltd., now recruiting.","route":"/trials/nct06885281/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06885281","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03505320","name":"A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer","tldr":"A phase 2 trial of Zolbetuximab, Oxaliplatin, Pembrolizumab, Leucovorin (folinic acid), Nivolumab and Docetaxel in gastric & gastro-oesophageal junction cancer, run by Astellas Pharma Global Development, Inc., active and no longer recruiting.","route":"/trials/nct03505320/","status":"active","kind":"trial","cancerIcon":"gastric","sub":"NCT03505320","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03816163","name":"A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer","tldr":"A phase 2 trial of Zolbetuximab and Gemcitabine in pancreatic ductal adenocarcinoma, run by Astellas Pharma Global Development, Inc., active and no longer recruiting.","route":"/trials/nct03816163/","status":"active","kind":"trial","cancerIcon":"pancreatic","sub":"NCT03816163","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06901531","name":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","tldr":"A phase 3 trial of Zolbetuximab, Pembrolizumab, Capecitabine, Oxaliplatin, Leucovorin (folinic acid) and Fluorouracil (5-FU) in gastric & gastro-oesophageal junction cancer, run by Astellas Pharma Global Development, Inc., now recruiting.","route":"/trials/nct06901531/","status":"recruiting","kind":"trial","cancerIcon":"gastric","sub":"NCT06901531","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer","PD-L1-high gastric cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"PD-L1-high gastric cancer","href":"/cancers/gastric-pdl1-high/","tip":"PD-L1-high gastric cancer expresses the immune checkpoint protein PD-L1 on tumour and immune cells, and this is the group in which nivolumab or pembrolizumab added to chemotherapy clearly extends life. The benefit shrinks as the score falls, so regulators now restrict the antibodies to tumours with at least some PD-L1 expression."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01517802","name":"A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate","tldr":"A phase 3 trial of Abiraterone acetate and Prednisone in Prostate cancer, run by Janssen Research & Development, LLC, completed.","route":"/trials/nct01517802/","status":"completed","kind":"trial","cancerIcon":"prostate","sub":"NCT01517802","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05485948","name":"A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU","tldr":"A phase 2 trial of Ropeginterferon alfa-2b in myeloproliferative neoplasms, run by PharmaEssentia, active and no longer recruiting.","route":"/trials/nct05485948/","status":"active","kind":"trial","cancerIcon":"myeloproliferative-neoplasms","sub":"NCT05485948","facets":{"kind":["Trial"],"cancers":["Myeloproliferative neoplasms","Polycythaemia vera"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Myeloproliferative neoplasms","href":"/cancers/myeloproliferative-neoplasms/","tip":"Myeloproliferative neoplasms are slow-growing blood cancers in which the marrow overproduces red cells (polycythaemia vera), platelets (essential thrombocythaemia) or scar tissue (myelofibrosis). Almost all carry a mutation in JAK2, CALR or MPL; treatment aims to prevent clots and control symptoms, and only transplant cures myelofibrosis."},{"label":"Polycythaemia vera","href":"/cancers/polycythaemia-vera/","tip":"Polycythaemia vera is a slow blood cancer in which a single faulty gene, JAK2, makes the bone marrow produce too many red cells. Thick blood causes clots, so treatment thins it (blood removal, aspirin) and, for higher-risk patients, calms the marrow with hydroxyurea, interferon or ruxolitinib; a hepcidin mimic, rusfertide, now controls red cell counts without regular blood removal."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03744715","name":"A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib","tldr":"A phase 2 trial of Poziotinib in Breast cancer, run by Spectrum Pharmaceuticals, Inc, recorded as terminated on the registry.","route":"/trials/nct03744715/","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT03744715","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06833008","name":"A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours","tldr":"A phase 1/2 trial of IPN01195 in advanced solid tumours, run by Ipsen, now recruiting.","route":"/trials/nct06833008/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06833008","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07196644","name":"A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan","tldr":"A phase 2 trial of Telisotuzumab adizutecan in advanced solid tumours, run by AbbVie, now recruiting.","route":"/trials/nct07196644/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07196644","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07581002","name":"A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)","tldr":"A phase 2/3 trial of Pivekimab sunirine, Venetoclax and Azacitidine in acute myeloid leukaemia, run by AbbVie, now recruiting.","route":"/trials/nct07581002/","status":"recruiting","kind":"trial","cancerIcon":"aml","sub":"NCT07581002","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05481151","name":"A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV","tldr":"A phase 3 trial of Ropeginterferon alfa-2b in myeloproliferative neoplasms, run by PharmaEssentia, active and no longer recruiting.","route":"/trials/nct05481151/","status":"active","kind":"trial","cancerIcon":"myeloproliferative-neoplasms","sub":"NCT05481151","facets":{"kind":["Trial"],"cancers":["Myeloproliferative neoplasms","Polycythaemia vera"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Myeloproliferative neoplasms","href":"/cancers/myeloproliferative-neoplasms/","tip":"Myeloproliferative neoplasms are slow-growing blood cancers in which the marrow overproduces red cells (polycythaemia vera), platelets (essential thrombocythaemia) or scar tissue (myelofibrosis). Almost all carry a mutation in JAK2, CALR or MPL; treatment aims to prevent clots and control symptoms, and only transplant cures myelofibrosis."},{"label":"Polycythaemia vera","href":"/cancers/polycythaemia-vera/","tip":"Polycythaemia vera is a slow blood cancer in which a single faulty gene, JAK2, makes the bone marrow produce too many red cells. Thick blood causes clots, so treatment thins it (blood removal, aspirin) and, for higher-risk patients, calms the marrow with hydroxyurea, interferon or ruxolitinib; a hepcidin mimic, rusfertide, now controls red cell counts without regular blood removal."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06305247","name":"A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours","tldr":"A phase 1/2 trial of IPN01194 in melanoma, head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma and colorectal cancer, run by Ipsen, active and no longer recruiting.","route":"/trials/nct06305247/","status":"active","kind":"trial","cancerIcon":"melanoma","sub":"NCT06305247","facets":{"kind":["Trial"],"cancers":["Melanoma","Head and neck squamous cell carcinoma","Pancreatic ductal adenocarcinoma","Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04452955","name":"A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors","tldr":"A phase 2 trial of PRL3-zumab in advanced solid tumours, run by Intra-IMMUSG Pte Ltd, active and no longer recruiting.","route":"/trials/nct04452955/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04452955","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05706129","name":"A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors","tldr":"A phase 1/2 trial of [68Ga]Ga-DPI-4452 in renal cell carcinoma, pancreatic ductal adenocarcinoma, colorectal cancer, bladder & urothelial cancer, head and neck squamous cell carcinoma and triple-negative breast cancer, run by Lumara Bio Oncologics GmbH, now recruiting.","route":"/trials/nct05706129/","status":"recruiting","kind":"trial","cancerIcon":"rcc","sub":"NCT05706129","facets":{"kind":["Trial"],"cancers":["Renal cell carcinoma","Pancreatic ductal adenocarcinoma","Colorectal cancer","Bladder & urothelial cancer","Head and neck squamous cell carcinoma","Triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05428969","name":"A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies","tldr":"A phase 1/2 trial of Azacitidine and Venetoclax in acute myeloid leukaemia, chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms and myelodysplastic syndromes / neoplasms, run by Faron Pharmaceuticals Ltd, active and no longer recruiting.","route":"/trials/nct05428969/","status":"active","kind":"trial","cancerIcon":"aml","sub":"NCT05428969","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia","Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms","Myelodysplastic syndromes / neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms","href":"/cancers/cmml/","tip":"Chronic myelomonocytic leukaemia and its relatives are bone-marrow cancers that behave partly like myelodysplasia (poorly made blood cells) and partly like a proliferative disease (an excess of monocytes or platelets). Hypomethylating agents produce responses in a minority and stabilise counts in more, transplant can cure the fit, and RAS-pathway and JAK inhibitors are in trials."},{"label":"Myelodysplastic syndromes / neoplasms","href":"/cancers/mds/","tip":"Bone-marrow disorders where blood cells are made badly and too few reach the blood; a third progress to acute leukaemia. Treatment ranges from transfusions and growth factors to hypomethylating drugs and, for the fit, transplant."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00718549","name":"A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)","tldr":"A phase 3 trial of Cladribine, Cyclophosphamide and Rituximab in Leukaemia, run by Hoffmann-La Roche, completed.","route":"/trials/nct00718549/","status":"completed","kind":"trial","cancerIcon":"leukaemia","sub":"NCT00718549","facets":{"kind":["Trial"],"cancers":["Leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Leukaemia","href":"/cancers/leukaemia/","tip":"Leukaemia means cancer of the blood-forming cells, but the four main types share little beyond the name: acute lymphoblastic and acute myeloid leukaemia are emergencies treated with intensive therapy, while chronic lymphocytic and chronic myeloid leukaemia are slow diseases controlled for years with pills. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05503797","name":"A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations","tldr":"A phase 2 trial of Plixorafenib in advanced solid tumours, run by Fore Biotherapeutics, now recruiting.","route":"/trials/nct05503797/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05503797","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06631989","name":"A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer","tldr":"A phase 1/2 trial of WSD0922-FU in non-small-cell lung cancer, run by Wayshine Biopharm, Inc., now recruiting.","route":"/trials/nct06631989/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06631989","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06868485","name":"A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer","tldr":"A phase 2 trial of WSD0922-FU Tablets, Dose level A in non-small-cell lung cancer, run by Wayshine Biopharm, Inc., now recruiting.","route":"/trials/nct06868485/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06868485","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04931654","name":"A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer","tldr":"A phase 1/2 trial of AZD7789 in non-small-cell lung cancer and gastric & gastro-oesophageal junction cancer, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct04931654/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT04931654","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02677922","name":"A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy","tldr":"A phase 1/2 trial of Azacitidine in acute myeloid leukaemia, run by Celgene, active and no longer recruiting.","route":"/trials/nct02677922/","status":"active","kind":"trial","cancerIcon":"aml","sub":"NCT02677922","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia","IDH1- and IDH2-mutated acute myeloid leukaemia"],"year":["2022"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"IDH1- and IDH2-mutated acute myeloid leukaemia","href":"/cancers/aml-idh/","tip":"IDH-mutated acute myeloid leukaemia has a faulty metabolic enzyme that floods cells with a chemical that blocks maturation. Pills that shut the enzyme off, ivosidenib for IDH1 and enasidenib or olutasidenib for IDH2 and IDH1, let the leukaemia cells mature, and ivosidenib with azacitidine tripled survival in older patients."}],"year":{"facet":"year","value":"2022"},"tags":[]},"sortKeys":{"year":2022}},{"id":"nct04817007","name":"A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)","tldr":"A phase 1/2 trial of Ruxolitinib and Fedratinib in myeloproliferative neoplasms, run by Bristol-Myers Squibb, active and no longer recruiting.","route":"/trials/nct04817007/","status":"active","kind":"trial","cancerIcon":"myeloproliferative-neoplasms","sub":"NCT04817007","facets":{"kind":["Trial"],"cancers":["Myeloproliferative neoplasms","Primary myelofibrosis"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Myeloproliferative neoplasms","href":"/cancers/myeloproliferative-neoplasms/","tip":"Myeloproliferative neoplasms are slow-growing blood cancers in which the marrow overproduces red cells (polycythaemia vera), platelets (essential thrombocythaemia) or scar tissue (myelofibrosis). Almost all carry a mutation in JAK2, CALR or MPL; treatment aims to prevent clots and control symptoms, and only transplant cures myelofibrosis."},{"label":"Primary myelofibrosis","href":"/cancers/primary-myelofibrosis/","tip":"Primary myelofibrosis is a blood cancer in which the marrow scars over, the spleen swells and patients become anaemic and exhausted. JAK inhibitors, ruxolitinib first (COMFORT) and then fedratinib, pacritinib and momelotinib (MOMENTUM), shrink the spleen and relieve symptoms; only a donor stem cell transplant can cure it."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06155084","name":"A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients","tldr":"A phase 1/2 trial of HP518 - Dose Escalation in prostate cancer, run by Hinova Pharmaceuticals Inc., now recruiting.","route":"/trials/nct06155084/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT06155084","facets":{"kind":["Trial"],"cancers":["Prostate cancer","Metastatic castration-resistant prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Metastatic castration-resistant prostate cancer","href":"/cancers/prostate-mcrpc/","tip":"Metastatic castration-resistant prostate cancer is disease that grows despite castrate testosterone. Sequenced treatments now include androgen receptor inhibitors, docetaxel and cabazitaxel, PARP inhibitors for men with BRCA-type mutations, the radioligand 177Lu-PSMA-617 and radium-223 for bone-predominant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06969430","name":"A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)","tldr":"A phase 1/2 trial of Debio 1562M in acute myeloid leukaemia, run by Debiopharm International SA, now recruiting.","route":"/trials/nct06969430/","status":"recruiting","kind":"trial","cancerIcon":"aml","sub":"NCT06969430","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06898450","name":"A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.","tldr":"A phase 1/2 trial of NDI-219216 in advanced solid tumours, run by Nimbus Wadjet, Inc., now recruiting.","route":"/trials/nct06898450/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06898450","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06035497","name":"A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)","tldr":"A phase 1/2 trial of BMS-986369 in peripheral T-cell lymphomas, run by Bristol-Myers Squibb, active and no longer recruiting.","route":"/trials/nct06035497/","status":"active","kind":"trial","cancerIcon":"peripheral-t-cell-lymphoma","sub":"NCT06035497","facets":{"kind":["Trial"],"cancers":["Peripheral T-cell lymphomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Peripheral T-cell lymphomas","href":"/cancers/peripheral-t-cell-lymphoma/","tip":"Peripheral T-cell lymphomas are lymphomas of T cells rather than B cells. They are rarer, more varied and, apart from a few subtypes, harder to treat than B-cell lymphomas; several new drugs help only defined subtypes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07213817","name":"A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours","tldr":"A phase 1/2 trial of IPN60300 in advanced solid tumours, run by Ipsen, now recruiting.","route":"/trials/nct07213817/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07213817","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07213830","name":"A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies","tldr":"A phase 1/2 trial of IPN01203 in advanced solid tumours, run by Ipsen, now recruiting.","route":"/trials/nct07213830/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07213830","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06939595","name":"A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer","tldr":"A phase 3 trial of Pembrolizumab in non-small-cell lung cancer, run by Celltrion, active and no longer recruiting.","route":"/trials/nct06939595/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT06939595","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04293562","name":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations","tldr":"A phase 3 trial of Crisantaspase, Asparaginase, Cytarabine, Daunorubicin, Dexrazoxane, Etoposide, Fludeoxyglucose F-18, Gemtuzumab ozogamicin, Gilteritinib, CPX-351, Methotrexate and Mitoxantrone in Acute myeloid leukaemia, run by Children's Oncology Group, now recruiting.","route":"/trials/nct04293562/","status":"recruiting","kind":"trial","cancerIcon":"aml","sub":"NCT04293562","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04603807","name":"A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases","tldr":"A phase 3 trial of Entrectinib and Crizotinib in non-small-cell lung cancer, run by Hoffmann-La Roche, active and no longer recruiting.","route":"/trials/nct04603807/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT04603807","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","ROS1-positive non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"ROS1-positive non-small-cell lung cancer","href":"/cancers/ros1-positive-nsclc/","tip":"ROS1-positive lung cancer is a rare fusion-driven adenocarcinoma treated with a pill. Crizotinib was the first, and the newer drugs repotrectinib and taletrectinib control the disease for about three years, reach the brain and work against the resistance mutation that defeated the older drugs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06022861","name":"A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma","tldr":"A phase 3 trial of Cisplatin and Nivolumab in oesophageal cancer, run by Shandong Boan Biotechnology Co., Ltd, now recruiting.","route":"/trials/nct06022861/","status":"recruiting","kind":"trial","cancerIcon":"esophageal","sub":"NCT06022861","facets":{"kind":["Trial"],"cancers":["Oesophageal cancer","Oesophageal squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."},{"label":"Oesophageal squamous cell carcinoma","href":"/cancers/oesophageal-squamous-cell-carcinoma/","tip":"Squamous cell carcinoma of the oesophagus, the world's commonest form, is linked to smoking, alcohol and very hot drinks and sits in the upper and middle gullet. It is treated with chemoradiation, with or without surgery, and immunotherapy has recently joined chemotherapy for advanced disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05197426","name":"A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission","tldr":"A phase 2 trial of Azacitidine in acute myeloid leukaemia, run by Bristol-Myers Squibb, active and no longer recruiting.","route":"/trials/nct05197426/","status":"active","kind":"trial","cancerIcon":"aml","sub":"NCT05197426","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia"],"year":["2026"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"year":{"facet":"year","value":"2026"},"tags":[]},"sortKeys":{"year":2026}},{"id":"nct05963074","name":"A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia","tldr":"A phase 2 trial of Ibrutinib and Venetoclax in chronic lymphocytic leukaemia, run by Janssen Research & Development, LLC, active and no longer recruiting.","route":"/trials/nct05963074/","status":"active","kind":"trial","cancerIcon":"cll","sub":"NCT05963074","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia","Chronic lymphocytic leukaemia, first treatment"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Chronic lymphocytic leukaemia, first treatment","href":"/cancers/cll-treatment-naive/","tip":"Chronic lymphocytic leukaemia is treated only when it causes problems, and chemotherapy has gone. The first treatment is now either a BTK inhibitor taken indefinitely or a one-year course of venetoclax with obinutuzumab (CLL14), and the two can be combined for a fixed course."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05944224","name":"A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.","tldr":"A phase 1/2 trial of SPH4336 and Cadonilimab in advanced solid tumours, run by Shanghai Pharmaceuticals Holding Co., Ltd, now recruiting.","route":"/trials/nct05944224/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05944224","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06196736","name":"A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer","tldr":"A phase 3 trial of 9MW2821 in bladder & urothelial cancer, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.","route":"/trials/nct06196736/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT06196736","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06692166","name":"A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer","tldr":"A phase 3 trial of 9MW2821 in cervical cancer, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.","route":"/trials/nct06692166/","status":"recruiting","kind":"trial","cancerIcon":"cervical","sub":"NCT06692166","facets":{"kind":["Trial"],"cancers":["Cervical cancer","Recurrent or metastatic cervical cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."},{"label":"Recurrent or metastatic cervical cancer","href":"/cancers/recurrent-metastatic-cervical-cancer/","tip":"Recurrent or metastatic cervical cancer has spread beyond the pelvis or come back where it cannot be cured by surgery or radiotherapy. Pembrolizumab added to chemotherapy and bevacizumab is the first treatment, and the antibody-drug conjugate tisotumab vedotin or the PD-1 antibody cemiplimab extend life when it progresses."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07749586","name":"A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors","tldr":"A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by Arvinas Inc., now recruiting.","route":"/trials/nct07749586/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07749586","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07023731","name":"A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation","tldr":"A phase 1/2 trial of ARV-806 in advanced solid tumours, run by Arvinas Inc., active and no longer recruiting.","route":"/trials/nct07023731/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07023731","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06590246","name":"A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)","tldr":"A phase 1/2 trial of Armored and GPC3-targeted autologous CAR T-cell in hepatocellular carcinoma, run by Shanghai AbelZeta Ltd., now recruiting.","route":"/trials/nct06590246/","status":"recruiting","kind":"trial","cancerIcon":"hcc","sub":"NCT06590246","facets":{"kind":["Trial"],"cancers":["Hepatocellular carcinoma","Advanced hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."},{"label":"Advanced hepatocellular carcinoma","href":"/cancers/hcc-advanced/","tip":"Advanced hepatocellular carcinoma has invaded the liver's veins or spread beyond it. Sorafenib was the only drug for a decade; now the combination of the immunotherapy atezolizumab with the anti-angiogenic antibody bevacizumab, or the two-antibody regimen durvalumab with tremelimumab, is standard first line, and several further drugs follow it."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07460375","name":"A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors","tldr":"A phase 1/2 trial of LCB02A in advanced solid tumours, run by LigaChem Biosciences, Inc., now recruiting.","route":"/trials/nct07460375/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07460375","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06065748","name":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)","tldr":"A phase 3 trial of Giredestrant, Fulvestrant, Abemaciclib, Palbociclib and Ribociclib in HR-positive / HER2-negative breast cancer, run by Hoffmann-La Roche, active and no longer recruiting.","route":"/trials/nct06065748/","status":"active","kind":"trial","cancerIcon":"breast-hr-positive","sub":"NCT06065748","facets":{"kind":["Trial"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07554521","name":"A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States","tldr":"A phase 2 trial of Tislelizumab, Capecitabine, Fluorouracil (5-FU) and Oxaliplatin in gastric & gastro-oesophageal junction cancer and oesophageal cancer, run by BeOne Medicines, now recruiting.","route":"/trials/nct07554521/","status":"recruiting","kind":"trial","cancerIcon":"gastric","sub":"NCT07554521","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer","Oesophageal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05645107","name":"A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma","tldr":"A phase 3 trial of Xembify in chronic lymphocytic leukaemia and non-Hodgkin lymphoma, run by Grifols Therapeutics LLC, now recruiting.","route":"/trials/nct05645107/","status":"recruiting","kind":"trial","cancerIcon":"cll","sub":"NCT05645107","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia","Non-Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04225117","name":"A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)","tldr":"A phase 2 trial of Enfortumab vedotin and Pembrolizumab in advanced solid tumours, run by Astellas Pharma Global Development, Inc., active and no longer recruiting.","route":"/trials/nct04225117/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04225117","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":["2026"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"year":{"facet":"year","value":"2026"},"tags":[]},"sortKeys":{"year":2026}},{"id":"nct06084936","name":"A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma","tldr":"A phase 3 trial of Obinutuzumab, Glofitamab, Rituximab, Bendamustine, Lenalidomide and Tocilizumab in non-Hodgkin lymphoma, run by Hoffmann-La Roche, now recruiting.","route":"/trials/nct06084936/","status":"recruiting","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT06084936","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma","Mantle cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."},{"label":"Mantle cell lymphoma","href":"/cancers/mantle-cell-lymphoma/","tip":"An uncommon B-cell lymphoma driven by cyclin D1 that used to behave badly in almost everyone. BTK inhibitors, CAR-T and now BCL2 drugs have changed it from chemotherapy-plus-transplant to targeted combinations."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07294508","name":"A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer","tldr":"A phase 2/3 trial of Pertuzumab in HER2-positive breast cancer, run by Shanghai Henlius Biotech, now recruiting.","route":"/trials/nct07294508/","status":"recruiting","kind":"trial","cancerIcon":"breast-her2-positive","sub":"NCT07294508","facets":{"kind":["Trial"],"cancers":["HER2-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05879822","name":"A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive","tldr":"A phase 2 trial of INCB099280 in advanced solid tumours, run by Incyte Corporation, active and no longer recruiting.","route":"/trials/nct05879822/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05879822","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05319730","name":"A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)","tldr":"A phase 1/2 trial of Pembrolizumab, Lenvatinib, Sacituzumab tirumotecan and Dexamethasone in oesophageal cancer, run by Merck Sharp & Dohme LLC, now recruiting.","route":"/trials/nct05319730/","status":"recruiting","kind":"trial","cancerIcon":"esophageal","sub":"NCT05319730","facets":{"kind":["Trial"],"cancers":["Oesophageal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06468358","name":"A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors","tldr":"A phase 1/2 trial of LB1410 and LB4330 in advanced solid tumours, run by L & L Bio Co., Ltd., Ningbo, China, now recruiting.","route":"/trials/nct06468358/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06468358","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06319963","name":"A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer","tldr":"A phase 1/2 trial of Two IM injections Lenti-HPV-07 in cervical cancer and head and neck squamous cell carcinoma, run by Theravectys S.A., now recruiting.","route":"/trials/nct06319963/","status":"recruiting","kind":"trial","cancerIcon":"cervical","sub":"NCT06319963","facets":{"kind":["Trial"],"cancers":["Cervical cancer","Head and neck squamous cell carcinoma","Oropharyngeal cancer","HPV-positive oropharyngeal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."},{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Oropharyngeal cancer","href":"/cancers/oropharyngeal-cancer/","tip":"Cancer of the tonsils and back of the tongue, a head and neck cancer, now comes mostly from HPV infection rather than smoking, and behaves like a different disease: it responds well to chemoradiation, most patients are cured, and the research question is how much treatment can safely be removed."},{"label":"HPV-positive oropharyngeal cancer","href":"/cancers/hpv-positive-oropharyngeal-cancer/","tip":"Throat cancers caused by HPV are usually cured with chemoradiation or robotic surgery, so trials now ask how much treatment can be taken away: swapping cisplatin for cetuximab failed, cutting the radiation dose has worked only after surgery so far, and blood tests for HPV DNA may pick out the patients who can safely have less."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04064060","name":"A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials","tldr":"A phase 3 trial of Luspatercept in myelodysplastic syndromes / neoplasms and myeloproliferative neoplasms, run by Celgene, now recruiting.","route":"/trials/nct04064060/","status":"recruiting","kind":"trial","cancerIcon":"mds","sub":"NCT04064060","facets":{"kind":["Trial"],"cancers":["Myelodysplastic syndromes / neoplasms","Myeloproliferative neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Myelodysplastic syndromes / neoplasms","href":"/cancers/mds/","tip":"Bone-marrow disorders where blood cells are made badly and too few reach the blood; a third progress to acute leukaemia. Treatment ranges from transfusions and growth factors to hypomethylating drugs and, for the fit, transplant."},{"label":"Myeloproliferative neoplasms","href":"/cancers/myeloproliferative-neoplasms/","tip":"Myeloproliferative neoplasms are slow-growing blood cancers in which the marrow overproduces red cells (polycythaemia vera), platelets (essential thrombocythaemia) or scar tissue (myelofibrosis). Almost all carry a mutation in JAK2, CALR or MPL; treatment aims to prevent clots and control symptoms, and only transplant cures myelofibrosis."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04170283","name":"A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib","tldr":"A phase 3 trial of Zanubrutinib and Tislelizumab in advanced solid tumours, run by BeOne Medicines, active and no longer recruiting.","route":"/trials/nct04170283/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04170283","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07169851","name":"A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer","tldr":"A phase 2 trial of LY3537021 in advanced solid tumours, run by Eli Lilly and Company, now recruiting.","route":"/trials/nct07169851/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07169851","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05053880","name":"A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme","tldr":"A phase 1/2 trial of Pembrolizumab in glioma & glioblastoma, run by Accendatech USA Inc., active and no longer recruiting.","route":"/trials/nct05053880/","status":"active","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT05053880","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06542250","name":"A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.","tldr":"A phase 1/2 trial of AZD5492 in advanced solid tumours, run by AstraZeneca, now recruiting.","route":"/trials/nct06542250/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06542250","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06055959","name":"A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis","tldr":"A phase 2/3 trial of Zilucoplan in childhood cancers, run by UCB Biopharma SRL, now recruiting.","route":"/trials/nct06055959/","status":"recruiting","kind":"trial","cancerIcon":"childhood-cancers","sub":"NCT06055959","facets":{"kind":["Trial"],"cancers":["Childhood cancers"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Childhood cancers","href":"/cancers/childhood-cancers/","tip":"Cancer in children is rare and different from adult cancer: the common types are leukaemias, brain tumours, lymphomas and embryonal tumours such as neuroblastoma and Wilms tumour, most are curable in well-resourced health systems, and the great challenge is bringing the same cures to the majority of children who live where they are not available."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04554914","name":"A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases","tldr":"A phase 2 trial of Tabelecleucel in brain and spinal cord tumours, sarcomas and uterine sarcoma, run by Pierre Fabre Medicament, active and no longer recruiting.","route":"/trials/nct04554914/","status":"active","kind":"trial","cancerIcon":"brain-tumours","sub":"NCT04554914","facets":{"kind":["Trial"],"cancers":["Brain and spinal cord tumours","Sarcomas","Uterine sarcoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Brain and spinal cord tumours","href":"/cancers/brain-tumours/","tip":"Brain and spinal cord tumours range from slow-growing meningiomas and low-grade gliomas to glioblastoma, the commonest malignant brain tumour in adults, and a distinct set of childhood tumours such as medulloblastoma and diffuse midline glioma. Molecular markers now define them, and treatment is surgery, radiotherapy and, for some, drugs chosen by those markers."},{"label":"Sarcomas","href":"/cancers/sarcoma/","tip":"Sarcomas are dozens of rare cancers of bone and connective tissue. GIST was the first solid tumour cured-in-practice by a targeted pill; synovial sarcoma got the first TCR-T therapy."},{"label":"Uterine sarcoma","href":"/cancers/uterine-sarcoma/","tip":"Uterine sarcomas are rare cancers of the muscle and supporting tissue of the womb, distinct from the far commoner endometrial cancer. Removing the uterus intact is the main treatment and is followed by observation for stage I disease; low-grade stromal sarcomas respond to hormone-blocking pills, while advanced leiomyosarcoma is treated with doxorubicin and trabectedin."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06319820","name":"A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer","tldr":"A phase 3 trial of TAR-210 and Gemcitabine in bladder & urothelial cancer, run by Janssen Research & Development, LLC, now recruiting.","route":"/trials/nct06319820/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT06319820","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Non-muscle-invasive bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Non-muscle-invasive bladder cancer","href":"/cancers/non-muscle-invasive-bladder-cancer/","tip":"Most bladder cancers are found while still confined to the lining. They are scraped out through the urethra and, when higher risk, treated with BCG instilled into the bladder; the challenge is the frequent recurrences and the patients whose tumours stop responding to BCG."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07100106","name":"A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer","tldr":"A phase 1/2 trial of Giredestrant and Abemaciclib in HR-positive / HER2-negative breast cancer, run by Genentech, Inc., now recruiting.","route":"/trials/nct07100106/","status":"recruiting","kind":"trial","cancerIcon":"breast-hr-positive","sub":"NCT07100106","facets":{"kind":["Trial"],"cancers":["HR-positive / HER2-negative breast cancer","HR-positive metastatic breast cancer after CDK4/6 inhibitors"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"HR-positive metastatic breast cancer after CDK4/6 inhibitors","href":"/cancers/hr-positive-metastatic-post-cdk46/","tip":"When hormone-positive breast cancer grows through a CDK4/6 inhibitor, a blood test picks the next drug. Tumours with an acquired ESR1 mutation respond to the oral degraders elacestrant, camizestrant and imlunestrant; tumours with PIK3CA, AKT1 or PTEN changes to capivasertib, inavolisib or alpelisib; and once endocrine options run out, antibody-drug conjugates come before chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06524375","name":"A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period","tldr":"A phase 2 trial of Venetoclax in chronic lymphocytic leukaemia, run by Genentech, Inc., active and no longer recruiting.","route":"/trials/nct06524375/","status":"active","kind":"trial","cancerIcon":"cll","sub":"NCT06524375","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia","Chronic lymphocytic leukaemia, first treatment"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Chronic lymphocytic leukaemia, first treatment","href":"/cancers/cll-treatment-naive/","tip":"Chronic lymphocytic leukaemia is treated only when it causes problems, and chemotherapy has gone. The first treatment is now either a BTK inhibitor taken indefinitely or a one-year course of venetoclax with obinutuzumab (CLL14), and the two can be combined for a fixed course."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05043922","name":"A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma","tldr":"A phase 2 trial of CYH33 in ovarian cancer, run by Haihe Biopharma Co., Ltd., active and no longer recruiting.","route":"/trials/nct05043922/","status":"active","kind":"trial","cancerIcon":"ovarian","sub":"NCT05043922","facets":{"kind":["Trial"],"cancers":["Ovarian cancer","Clear cell ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Clear cell ovarian cancer","href":"/cancers/clear-cell-ovarian-cancer/","tip":"Clear cell ovarian cancer grows out of endometriosis, is usually caught early and cured by surgery, but when advanced it resists platinum chemotherapy. Its distinct genetics, with ARID1A and PIK3CA mutations, are the focus of targeted and immune approaches."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05296798","name":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)","tldr":"A phase 3 trial of Giredestrant and Docetaxel in advanced solid tumours, run by Hoffmann-La Roche, active and no longer recruiting.","route":"/trials/nct05296798/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05296798","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06425302","name":"A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma","tldr":"A phase 2 trial of Golcadomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone in non-Hodgkin lymphoma, run by Celgene, active and no longer recruiting.","route":"/trials/nct06425302/","status":"active","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT06425302","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma","Follicular lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."},{"label":"Follicular lymphoma","href":"/cancers/follicular-lymphoma/","tip":"Follicular lymphoma is the most common slow-growing lymphoma, defined in about 85% of cases by a BCL2 translocation. Most people live with it for decades, treated only when it causes problems; it can be controlled repeatedly with anti-CD20 antibodies, chemotherapy, bispecifics or CAR-T but rarely cured, and a small share transform into an aggressive lymphoma each year."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06330064","name":"A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)","tldr":"A phase 1/2 trial of Ifinatamab deruxtecan in advanced solid tumours, run by Daiichi Sankyo, now recruiting.","route":"/trials/nct06330064/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06330064","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05894239","name":"A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer","tldr":"A phase 3 trial of Inavolisib in HER2-positive breast cancer, run by Hoffmann-La Roche, now recruiting.","route":"/trials/nct05894239/","status":"recruiting","kind":"trial","cancerIcon":"breast-her2-positive","sub":"NCT05894239","facets":{"kind":["Trial"],"cancers":["HER2-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03671044","name":"A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients","tldr":"A phase 3 trial of Docetaxel in triple-negative breast cancer, run by Jina Pharmaceuticals Inc., now recruiting.","route":"/trials/nct03671044/","status":"recruiting","kind":"trial","cancerIcon":"tnbc","sub":"NCT03671044","facets":{"kind":["Trial"],"cancers":["Triple-negative breast cancer","Metastatic triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Metastatic triple-negative breast cancer","href":"/cancers/tnbc-metastatic/","tip":"Triple-negative breast cancer that has spread is not curable, but its treatment has been transformed since 2020. By PD-L1 score, first treatment is pembrolizumab with chemotherapy or with sacituzumab govitecan, or datopotamab deruxtecan or sacituzumab govitecan alone; BRCA carriers can take a PARP inhibitor tablet; and trastuzumab deruxtecan reaches the third of tumours with low HER2."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05144854","name":"A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)","tldr":"A phase 3 trial of Ipilimumab, Oxaliplatin and Capecitabine in gastric & gastro-oesophageal junction cancer, run by Ono Pharmaceutical Co., Ltd., active and no longer recruiting.","route":"/trials/nct05144854/","status":"active","kind":"trial","cancerIcon":"gastric","sub":"NCT05144854","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06010329","name":"A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC","tldr":"A phase 2 trial of Sutetinib Maleate Capsule in non-small-cell lung cancer, run by Teligene US, now recruiting.","route":"/trials/nct06010329/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06010329","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06010342","name":"A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients","tldr":"A phase 2 trial of TL118 Capsule in advanced solid tumours, run by Teligene US, now recruiting.","route":"/trials/nct06010342/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06010342","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07811193","name":"A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum","tldr":"A phase 2 trial of Pembrolizumab in colorectal cancer, run by Vividion Therapeutics, Inc., now recruiting.","route":"/trials/nct07811193/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT07811193","facets":{"kind":["Trial"],"cancers":["Colorectal cancer","Mismatch-repair deficient (MSI-high) colorectal cancer","Rectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Mismatch-repair deficient (MSI-high) colorectal cancer","href":"/cancers/msi-high-colorectal/","tip":"Mismatch-repair deficient bowel cancer has lost its DNA spell-checker, so it carries thousands of mutations that the immune system can recognise. Immunotherapy alone controls most metastatic cases for years and makes most localised tumours disappear before surgery, sometimes so completely that no surgery is needed."},{"label":"Rectal cancer","href":"/cancers/rectal-cancer/","tip":"Rectal cancer is bowel cancer in the last part of the large intestine, where surgery can mean a permanent stoma. Treatment now usually gives all the chemotherapy and radiotherapy first, and about half of people whose tumour disappears completely can keep their rectum and avoid surgery altogether."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06041061","name":"A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years","tldr":"A phase 3 trial of Recombinant 14-Valent Human Papillomavirus Vaccine（Insect Cell） in advanced solid tumours, run by Sinocelltech Ltd., active and no longer recruiting.","route":"/trials/nct06041061/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06041061","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06828991","name":"A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP","tldr":"A phase 2 trial of Mosunetuzumab and clonoSEQ in Diffuse large B-cell lymphoma, run by Danielle Wallace, now recruiting.","route":"/trials/nct06828991/","status":"recruiting","kind":"trial","cancerIcon":"dlbcl","sub":"NCT06828991","facets":{"kind":["Trial"],"cancers":["Diffuse large B-cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06428019","name":"A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)","tldr":"A phase 3 trial of Venetoclax, Acalabrutinib and Obinutuzumab in chronic lymphocytic leukaemia, run by AbbVie, now recruiting.","route":"/trials/nct06428019/","status":"recruiting","kind":"trial","cancerIcon":"cll","sub":"NCT06428019","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia","Chronic lymphocytic leukaemia, first treatment"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Chronic lymphocytic leukaemia, first treatment","href":"/cancers/cll-treatment-naive/","tip":"Chronic lymphocytic leukaemia is treated only when it causes problems, and chemotherapy has gone. The first treatment is now either a BTK inhibitor taken indefinitely or a one-year course of venetoclax with obinutuzumab (CLL14), and the two can be combined for a fixed course."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07691775","name":"A Study to Evaluate the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Solid Tumors","tldr":"A phase 1/2 trial of F18 FBPA Injection in advanced solid tumours, run by Heron Neutron Medical Corp., now recruiting.","route":"/trials/nct07691775/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07691775","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06682793","name":"A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression","tldr":"A phase 1/2 trial of A2B395 in colorectal cancer, non-small-cell lung cancer, head and neck squamous cell carcinoma, renal cell carcinoma and triple-negative breast cancer, run by A2 Biotherapeutics Inc., now recruiting.","route":"/trials/nct06682793/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT06682793","facets":{"kind":["Trial"],"cancers":["Colorectal cancer","Non-small-cell lung cancer","Head and neck squamous cell carcinoma","Renal cell carcinoma","Triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05736731","name":"A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression","tldr":"A phase 1/2 trial of A2B530 in pancreatic ductal adenocarcinoma, non-small-cell lung cancer and colorectal cancer, run by A2 Biotherapeutics Inc., active and no longer recruiting.","route":"/trials/nct05736731/","status":"active","kind":"trial","cancerIcon":"pancreatic","sub":"NCT05736731","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Non-small-cell lung cancer","Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06166836","name":"a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors","tldr":"A phase 1/2 trial of IN10018 in advanced solid tumours, run by InxMed (Shanghai) Co., Ltd., active and no longer recruiting.","route":"/trials/nct06166836/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06166836","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04980222","name":"A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma","tldr":"A phase 2 trial of Glofitamab, Tocilizumab, Doxorubicin, Vincristine, Prednisone and Rituximab in non-Hodgkin lymphoma, run by Hoffmann-La Roche, active and no longer recruiting.","route":"/trials/nct04980222/","status":"active","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT04980222","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma","Diffuse large B-cell lymphoma"],"year":["2026"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."},{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."}],"year":{"facet":"year","value":"2026"},"tags":[]},"sortKeys":{"year":2026}},{"id":"nct06051695","name":"A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression","tldr":"A phase 1/2 trial of A2B694 in colorectal cancer, non-small-cell lung cancer, pancreatic ductal adenocarcinoma, ovarian cancer and mesothelioma, run by A2 Biotherapeutics Inc., now recruiting.","route":"/trials/nct06051695/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT06051695","facets":{"kind":["Trial"],"cancers":["Colorectal cancer","Non-small-cell lung cancer","Pancreatic ductal adenocarcinoma","Ovarian cancer","Mesothelioma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06818643","name":"A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)","tldr":"A phase 1/2 trial of MK-3120 in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting.","route":"/trials/nct06818643/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06818643","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06663137","name":"A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC","tldr":"A phase 2 trial of Docetaxel and Gemcitabine in bladder & urothelial cancer, run by Relmada Therapeutics, Inc., now recruiting.","route":"/trials/nct06663137/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT06663137","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Non-muscle-invasive bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Non-muscle-invasive bladder cancer","href":"/cancers/non-muscle-invasive-bladder-cancer/","tip":"Most bladder cancers are found while still confined to the lining. They are scraped out through the urethra and, when higher risk, treated with BCG instilled into the bladder; the challenge is the frequent recurrences and the patients whose tumours stop responding to BCG."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07221149","name":"A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)","tldr":"A phase 2/3 trial of PM8002 and Nivolumab in gastric & gastro-oesophageal junction cancer, run by Bristol-Myers Squibb, now recruiting.","route":"/trials/nct07221149/","status":"recruiting","kind":"trial","cancerIcon":"gastric","sub":"NCT07221149","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06973187","name":"A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","tldr":"A phase 3 trial of Pirtobrutinib in chronic lymphocytic leukaemia, run by BeOne Medicines, now recruiting.","route":"/trials/nct06973187/","status":"recruiting","kind":"trial","cancerIcon":"cll","sub":"NCT06973187","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia","Relapsed or refractory chronic lymphocytic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Relapsed or refractory chronic lymphocytic leukaemia","href":"/cancers/cll-relapsed/","tip":"When chronic lymphocytic leukaemia returns, the usual move is to switch drug class: venetoclax-based therapy after a BTK inhibitor, or a BTK inhibitor after venetoclax. Pirtobrutinib (BRUIN) works after the older BTK inhibitors fail, and CAR-T is approved for patients who have run out of both classes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04570423","name":"A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy","tldr":"A phase 2 trial of Eflapegrastim in non-Hodgkin lymphoma, run by Spectrum Pharmaceuticals, Inc, now recruiting.","route":"/trials/nct04570423/","status":"recruiting","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT04570423","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05804669","name":"A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome","tldr":"A phase 1/2 trial of atumelnant in pituitary tumours and pituitary carcinoma, run by Crinetics Pharmaceuticals Inc., active and no longer recruiting.","route":"/trials/nct05804669/","status":"active","kind":"trial","cancerIcon":"pituitary-tumours","sub":"NCT05804669","facets":{"kind":["Trial"],"cancers":["Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma","href":"/cancers/pituitary-tumours/","tip":"Pituitary tumours are usually benign growths of the hormone gland at the base of the brain that cause trouble by overproducing hormones or pressing on the optic nerves. Prolactin-producing tumours melt away with a tablet, most others are cured by surgery through the nose, and the rare aggressive ones respond to the chemotherapy drug temozolomide."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06116136","name":"A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.","tldr":"A phase 1/2 trial of Pembrolizumab in gastric & gastro-oesophageal junction cancer, run by Servier Bio-Innovation LLC, active and no longer recruiting.","route":"/trials/nct06116136/","status":"active","kind":"trial","cancerIcon":"gastric","sub":"NCT06116136","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer","Microsatellite-unstable (MSI-high) gastric cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Microsatellite-unstable (MSI-high) gastric cancer","href":"/cancers/gastric-msi-high/","tip":"Microsatellite-unstable gastric cancer has lost its DNA mismatch repair machinery, carries thousands of mutations and is unusually visible to the immune system. It responds strongly to checkpoint antibodies, may gain little from chemotherapy, and in early-stage disease immunotherapy before surgery is making many tumours disappear entirely."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06609005","name":"A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer","tldr":"A phase 1/2 trial of INV-9956 in prostate cancer, run by Shenzhen Ionova Life Sciences Co., Ltd., now recruiting.","route":"/trials/nct06609005/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT06609005","facets":{"kind":["Trial"],"cancers":["Prostate cancer","Metastatic castration-resistant prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Metastatic castration-resistant prostate cancer","href":"/cancers/prostate-mcrpc/","tip":"Metastatic castration-resistant prostate cancer is disease that grows despite castrate testosterone. Sequenced treatments now include androgen receptor inhibitors, docetaxel and cabazitaxel, PARP inhibitors for men with BRCA-type mutations, the radioligand 177Lu-PSMA-617 and radium-223 for bone-predominant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02908906","name":"A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers","tldr":"A phase 1/2 trial of Cetrelimab in advanced solid tumours, run by Janssen Research & Development, LLC, active and no longer recruiting.","route":"/trials/nct02908906/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT02908906","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07498725","name":"A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors","tldr":"A phase 1/2 trial of LRK-4189 escalation in advanced solid tumours, run by LARKSPUR BIOSCIENCES, INC., now recruiting.","route":"/trials/nct07498725/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07498725","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04300556","name":"A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types","tldr":"A phase 1/2 trial of Prednisone, Dexamethasone and Lenvatinib in advanced solid tumours, run by Eisai Inc., now recruiting.","route":"/trials/nct04300556/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04300556","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06618287","name":"A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors","tldr":"A phase 1/2 trial of Osimertinib, Pembrolizumab, Nivolumab and PM8002 in advanced solid tumours, run by Bristol-Myers Squibb, now recruiting.","route":"/trials/nct06618287/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06618287","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06656390","name":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors","tldr":"A phase 1/2 trial of ALK201 in advanced solid tumours, run by Shanghai Allink Biotherapeutics Co., Ltd., now recruiting.","route":"/trials/nct06656390/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06656390","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07612891","name":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor","tldr":"A phase 1/2 trial of INV-6452 in ovarian cancer, endometrial cancer and HR-positive / HER2-negative breast cancer, run by Shenzhen Ionova Life Sciences Co., Ltd., now recruiting.","route":"/trials/nct07612891/","status":"recruiting","kind":"trial","cancerIcon":"ovarian","sub":"NCT07612891","facets":{"kind":["Trial"],"cancers":["Ovarian cancer","Endometrial cancer","HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."},{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07610798","name":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations","tldr":"A phase 1/2 trial of INV-8989 in colorectal cancer, non-small-cell lung cancer, pancreatic ductal adenocarcinoma, ovarian cancer, endometrial cancer and biliary tract cancer, run by Shenzhen Ionova Life Sciences Co., Ltd., now recruiting.","route":"/trials/nct07610798/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT07610798","facets":{"kind":["Trial"],"cancers":["Colorectal cancer","Non-small-cell lung cancer","Pancreatic ductal adenocarcinoma","Ovarian cancer","Endometrial cancer","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05941507","name":"A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors","tldr":"A phase 1/2 trial of LCB84 in advanced solid tumours, run by LigaChem Biosciences, Inc., now recruiting.","route":"/trials/nct05941507/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05941507","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06349980","name":"A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.","tldr":"A phase 2 trial of Serplulimab in hepatocellular carcinoma, run by Shanghai Henlius Biotech, now recruiting.","route":"/trials/nct06349980/","status":"recruiting","kind":"trial","cancerIcon":"hcc","sub":"NCT06349980","facets":{"kind":["Trial"],"cancers":["Hepatocellular carcinoma","Advanced hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."},{"label":"Advanced hepatocellular carcinoma","href":"/cancers/hcc-advanced/","tip":"Advanced hepatocellular carcinoma has invaded the liver's veins or spread beyond it. Sorafenib was the only drug for a decade; now the combination of the immunotherapy atezolizumab with the anti-angiogenic antibody bevacizumab, or the two-antibody regimen durvalumab with tremelimumab, is standard first line, and several further drugs follow it."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07475806","name":"A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder","tldr":"A phase 2 trial of Enfortumab vedotin and Pembrolizumab in bladder & urothelial cancer, run by Astellas Pharma Global Development, Inc., now recruiting.","route":"/trials/nct07475806/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT07475806","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06747585","name":"A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors","tldr":"A phase 1/2 trial of ALE.P02 in non-small-cell lung cancer, head and neck squamous cell carcinoma and oesophageal cancer, run by Alentis Therapeutics AG, now recruiting.","route":"/trials/nct06747585/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06747585","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","Head and neck squamous cell carcinoma","Oesophageal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07169734","name":"A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors","tldr":"A phase 1/2 trial of ALE.P03 in non-small-cell lung cancer, colorectal cancer, biliary tract cancer and bladder & urothelial cancer, run by Alentis Therapeutics AG, now recruiting.","route":"/trials/nct07169734/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07169734","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","Colorectal cancer","Biliary tract cancer","Bladder & urothelial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07538804","name":"A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer","tldr":"A phase 1/2 trial of ANS02 in non-small-cell lung cancer, run by Avistone Biotechnology Co., Ltd., now recruiting.","route":"/trials/nct07538804/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07538804","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06399757","name":"A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors","tldr":"A phase 1/2 trial of APL-5125 in colorectal cancer, biliary tract cancer, appendiceal cancer and pseudomyxoma peritonei, pancreatic ductal adenocarcinoma, gastric & gastro-oesophageal junction cancer and endometrial cancer, run by Apollo Therapeutics Ltd, active and no longer recruiting.","route":"/trials/nct06399757/","status":"active","kind":"trial","cancerIcon":"colorectal","sub":"NCT06399757","facets":{"kind":["Trial"],"cancers":["Colorectal cancer","Biliary tract cancer","Appendiceal cancer and pseudomyxoma peritonei","Pancreatic ductal adenocarcinoma","Gastric & gastro-oesophageal junction cancer","Endometrial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Appendiceal cancer and pseudomyxoma peritonei","href":"/cancers/appendiceal/","tip":"Rare tumours of the appendix that range from slow mucin-producing growths that fill the abdomen (pseudomyxoma peritonei) to aggressive adenocarcinomas. The slow forms are treated by extensive surgery with heated chemotherapy in the abdomen; the fast ones like colon cancer."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05952037","name":"A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia","tldr":"A phase 2 trial of Sonrotoclax and Zanubrutinib in waldenström macroglobulinaemia, run by BeOne Medicines, active and no longer recruiting.","route":"/trials/nct05952037/","status":"active","kind":"trial","cancerIcon":"waldenstrom","sub":"NCT05952037","facets":{"kind":["Trial"],"cancers":["Waldenström macroglobulinaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Waldenström macroglobulinaemia","href":"/cancers/waldenstrom/","tip":"A slow lymphoma that makes an abnormal IgM antibody, causing thick blood, anaemia and nerve damage. Nearly all cases share one mutation (MYD88 L265P), and BTK inhibitors control it for years."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05941897","name":"A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy","tldr":"A phase 2 trial of Ceralasertib and Durvalumab in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct05941897/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT05941897","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04214288","name":"A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer","tldr":"A phase 2 trial of Camizestrant and Fulvestrant in HR-positive / HER2-negative breast cancer, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct04214288/","status":"active","kind":"trial","cancerIcon":"breast-hr-positive","sub":"NCT04214288","facets":{"kind":["Trial"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":["2023"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"year":{"facet":"year","value":"2023"},"tags":[]},"sortKeys":{"year":2023}},{"id":"nct07286331","name":"A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)","tldr":"A phase 3 trial of Doxorubicin in endometrial cancer, run by GlaxoSmithKline, now recruiting.","route":"/trials/nct07286331/","status":"recruiting","kind":"trial","cancerIcon":"endometrial","sub":"NCT07286331","facets":{"kind":["Trial"],"cancers":["Endometrial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07286266","name":"A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)","tldr":"A phase 3 trial of Doxorubicin, Pegylated liposomal doxorubicin, Topotecan, Gemcitabine, Pembrolizumab and Bevacizumab in ovarian cancer, run by GlaxoSmithKline, now recruiting.","route":"/trials/nct07286266/","status":"recruiting","kind":"trial","cancerIcon":"ovarian","sub":"NCT07286266","facets":{"kind":["Trial"],"cancers":["Ovarian cancer","Platinum-resistant ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Platinum-resistant ovarian cancer","href":"/cancers/platinum-resistant-ovarian-cancer/","tip":"Platinum-resistant ovarian cancer grows back within six months of platinum chemotherapy, or during it, and used to be treated with single chemotherapy drugs that shrink a tumour one time in ten. The antibody-drug conjugate mirvetuximab soravtansine, the cortisol-blocking drug relacorilant and pembrolizumab in PD-L1-positive tumours have each extended survival in phase 3 trials since 2023."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06943872","name":"A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)","tldr":"A phase 3 trial of Sonrotoclax, Obinutuzumab, Rituximab and Venetoclax in chronic lymphocytic leukaemia, run by BeOne Medicines, now recruiting.","route":"/trials/nct06943872/","status":"recruiting","kind":"trial","cancerIcon":"cll","sub":"NCT06943872","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia","Relapsed or refractory chronic lymphocytic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Relapsed or refractory chronic lymphocytic leukaemia","href":"/cancers/cll-relapsed/","tip":"When chronic lymphocytic leukaemia returns, the usual move is to switch drug class: venetoclax-based therapy after a BTK inhibitor, or a BTK inhibitor after venetoclax. Pirtobrutinib (BRUIN) works after the older BTK inhibitors fail, and CAR-T is approved for patients who have run out of both classes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07129252","name":"A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors","tldr":"A phase 1/2 trial of CRN09682 in neuroendocrine tumours, run by Crinetics Pharmaceuticals Inc., now recruiting.","route":"/trials/nct07129252/","status":"recruiting","kind":"trial","cancerIcon":"neuroendocrine","sub":"NCT07129252","facets":{"kind":["Trial"],"cancers":["Neuroendocrine tumours"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Neuroendocrine tumours","href":"/cancers/neuroendocrine/","tip":"A family of usually slow-growing tumours that start in hormone-producing cells of the gut, pancreas and lungs. They pioneered the idea of using the same molecule to see a tumour on a scan and then to treat it with radiation."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06634589","name":"A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies","tldr":"A phase 1/2 trial of Sonrotoclax, Zanubrutinib, Mosunetuzumab, Glofitamab and Obinutuzumab in non-Hodgkin lymphoma, run by BeOne Medicines, now recruiting.","route":"/trials/nct06634589/","status":"recruiting","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT06634589","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07055594","name":"A Study to Investigate Safety and Preliminary Efficacy of SOA101 in Adult Subjects With Advanced Solid Tumors","tldr":"A phase 1/2 trial of SOA101 in advanced solid tumours, run by Shine-On Biomedical Co., Ltd., now recruiting.","route":"/trials/nct07055594/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07055594","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07277231","name":"A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia","tldr":"A phase 3 trial of Sonrotoclax, Zanubrutinib, Acalabrutinib and Venetoclax in chronic lymphocytic leukaemia, run by BeOne Medicines, now recruiting.","route":"/trials/nct07277231/","status":"recruiting","kind":"trial","cancerIcon":"cll","sub":"NCT07277231","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia","Chronic lymphocytic leukaemia, first treatment"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Chronic lymphocytic leukaemia, first treatment","href":"/cancers/cll-treatment-naive/","tip":"Chronic lymphocytic leukaemia is treated only when it causes problems, and chemotherapy has gone. The first treatment is now either a BTK inhibitor taken indefinitely or a one-year course of venetoclax with obinutuzumab (CLL14), and the two can be combined for a fixed course."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06637501","name":"A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia","tldr":"A phase 2 trial of Sonrotoclax and Zanubrutinib in chronic lymphocytic leukaemia, run by BeOne Medicines, active and no longer recruiting.","route":"/trials/nct06637501/","status":"active","kind":"trial","cancerIcon":"cll","sub":"NCT06637501","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia","Chronic lymphocytic leukaemia, first treatment"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Chronic lymphocytic leukaemia, first treatment","href":"/cancers/cll-treatment-naive/","tip":"Chronic lymphocytic leukaemia is treated only when it causes problems, and chemotherapy has gone. The first treatment is now either a BTK inhibitor taken indefinitely or a one-year course of venetoclax with obinutuzumab (CLL14), and the two can be combined for a fixed course."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07143604","name":"A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2","tldr":"A phase 2 trial of AZD0901 in gastric & gastro-oesophageal junction cancer, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct07143604/","status":"active","kind":"trial","cancerIcon":"gastric","sub":"NCT07143604","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05361174","name":"A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer","tldr":"A phase 1/2 trial of IOV-4001 in melanoma and non-small-cell lung cancer, run by Iovance Biotherapeutics, Inc., now recruiting.","route":"/trials/nct05361174/","status":"recruiting","kind":"trial","cancerIcon":"melanoma","sub":"NCT05361174","facets":{"kind":["Trial"],"cancers":["Melanoma","Non-small-cell lung cancer","Advanced melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Advanced melanoma","href":"/cancers/advanced-melanoma/","tip":"Advanced melanoma has spread beyond what surgery can remove, and it is the cancer in which immunotherapy first proved it could cure some people: about half of those given nivolumab with ipilimumab are alive ten years later. If immunotherapy fails, options include a cell therapy grown from the patient's own immune cells, a virus injected into the tumour, and targeted pills for BRAF-mutant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06256328","name":"A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)","tldr":"A phase 2 trial of Oxaliplatin, Capecitabine and Nivolumab in gastric & gastro-oesophageal junction cancer, run by Ono Pharmaceutical Co., Ltd., active and no longer recruiting.","route":"/trials/nct06256328/","status":"active","kind":"trial","cancerIcon":"gastric","sub":"NCT06256328","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06008093","name":"A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS","tldr":"A phase 2 trial of Durvalumab, Tremelimumab, Pemetrexed, Pembrolizumab, Carboplatin and Cisplatin in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct06008093/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT06008093","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06940739","name":"A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel","tldr":"A phase 1/2 trial of IOV-3001 in melanoma and uveal melanoma, run by Iovance Biotherapeutics, Inc., now recruiting.","route":"/trials/nct06940739/","status":"recruiting","kind":"trial","cancerIcon":"melanoma","sub":"NCT06940739","facets":{"kind":["Trial"],"cancers":["Melanoma","Uveal melanoma","Advanced melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"label":"Uveal melanoma","href":"/cancers/uveal-melanoma/","tip":"A melanoma inside the eye that is biologically unrelated to skin melanoma: different mutations, no response to standard immunotherapy, and a tendency to spread to the liver years later. Tebentafusp is the first drug ever to extend survival in the metastatic disease."},{"label":"Advanced melanoma","href":"/cancers/advanced-melanoma/","tip":"Advanced melanoma has spread beyond what surgery can remove, and it is the cancer in which immunotherapy first proved it could cure some people: about half of those given nivolumab with ipilimumab are alive ten years later. If immunotherapy fails, options include a cell therapy grown from the patient's own immune cells, a virus injected into the tumour, and targeted pills for BRAF-mutant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07213609","name":"A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors","tldr":"A phase 1/2 trial of GSK5460025 in colorectal cancer, run by GlaxoSmithKline, now recruiting.","route":"/trials/nct07213609/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT07213609","facets":{"kind":["Trial"],"cancers":["Colorectal cancer","Mismatch-repair deficient (MSI-high) colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Mismatch-repair deficient (MSI-high) colorectal cancer","href":"/cancers/msi-high-colorectal/","tip":"Mismatch-repair deficient bowel cancer has lost its DNA spell-checker, so it carries thousands of mutations that the immune system can recognise. Immunotherapy alone controls most metastatic cases for years and makes most localised tumours disappear before surgery, sometimes so completely that no surgery is needed."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05473156","name":"A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies","tldr":"A phase 1/2 trial of AP203 in non-small-cell lung cancer, head and neck squamous cell carcinoma and oesophageal cancer, run by AP Biosciences Inc., now recruiting.","route":"/trials/nct05473156/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT05473156","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","Head and neck squamous cell carcinoma","Oesophageal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06710847","name":"A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors","tldr":"A phase 1/2 trial of GSK4418959 in colorectal cancer and endometrial cancer, run by GlaxoSmithKline, active and no longer recruiting.","route":"/trials/nct06710847/","status":"active","kind":"trial","cancerIcon":"colorectal","sub":"NCT06710847","facets":{"kind":["Trial"],"cancers":["Colorectal cancer","Endometrial cancer","Mismatch-repair deficient (MSI-high) colorectal cancer","Mismatch-repair-deficient endometrial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."},{"label":"Mismatch-repair deficient (MSI-high) colorectal cancer","href":"/cancers/msi-high-colorectal/","tip":"Mismatch-repair deficient bowel cancer has lost its DNA spell-checker, so it carries thousands of mutations that the immune system can recognise. Immunotherapy alone controls most metastatic cases for years and makes most localised tumours disappear before surgery, sometimes so completely that no surgery is needed."},{"label":"Mismatch-repair-deficient endometrial cancer","href":"/cancers/endometrial-mmr-deficient/","tip":"Mismatch-repair-deficient endometrial cancer has lost the machinery that corrects copying errors in DNA, so it accumulates thousands of mutations that make it visible to the immune system. Adding dostarlimab or pembrolizumab to chemotherapy in advanced disease cut the risk of progression by about seventy percent, and many patients remain in remission years later."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06077877","name":"A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors","tldr":"A phase 1/2 trial of Niraparib in advanced solid tumours, run by GlaxoSmithKline, active and no longer recruiting.","route":"/trials/nct06077877/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06077877","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05456191","name":"A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)","tldr":"A phase 3 trial of Asciminib and Nilotinib in chronic myeloid leukaemia, run by Novartis Pharmaceuticals, active and no longer recruiting.","route":"/trials/nct05456191/","status":"active","kind":"trial","cancerIcon":"cml","sub":"NCT05456191","facets":{"kind":["Trial"],"cancers":["Chronic myeloid leukaemia","Chronic myeloid leukaemia, chronic phase"],"year":["2026"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic myeloid leukaemia","href":"/cancers/cml/","tip":"Chronic myeloid leukaemia is a blood cancer driven by a single fused gene, BCR-ABL1, and the model for oncogene-targeted treatment: imatinib in 2001 and the tyrosine kinase inhibitors that followed turned it into a condition most people live with long-term. About half of patients with a sustained deep molecular response can now stop treatment altogether."},{"label":"Chronic myeloid leukaemia, chronic phase","href":"/cancers/cml-chronic-phase/","tip":"Chronic-phase chronic myeloid leukaemia is the disease that imatinib turned from fatal into manageable: a daily pill blocks the BCR::ABL1 protein that drives it. Blood tests track the leukaemia gene to a millionth, newer pills such as asciminib (ASC4FIRST) reach deeper responses faster, and patients with years of undetectable disease can try stopping."}],"year":{"facet":"year","value":"2026"},"tags":[]},"sortKeys":{"year":2026}},{"id":"nct07154290","name":"A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)","tldr":"A phase 2 trial of Ubamatamab and REGN7075 in non-small-cell lung cancer, run by Regeneron Pharmaceuticals, now recruiting.","route":"/trials/nct07154290/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07154290","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06989437","name":"A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue","tldr":"A phase 2/3 trial of ponsegromab in pancreatic ductal adenocarcinoma, run by Pfizer, now recruiting.","route":"/trials/nct06989437/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT06989437","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05262400","name":"A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors","tldr":"A phase 1/2 trial of Atirmociclib and Fulvestrant in advanced solid tumours, run by Pfizer, active and no longer recruiting.","route":"/trials/nct05262400/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05262400","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06206837","name":"A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.","tldr":"A phase 1/2 trial of Vepdegestrant and Atirmociclib in advanced solid tumours, run by Pfizer, active and no longer recruiting.","route":"/trials/nct06206837/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06206837","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05587296","name":"A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer","tldr":"A phase 3 trial of Elinzanetant (BAY3427080) in HR-positive / HER2-negative breast cancer, run by Bayer, active and no longer recruiting.","route":"/trials/nct05587296/","status":"active","kind":"trial","cancerIcon":"breast-hr-positive","sub":"NCT05587296","facets":{"kind":["Trial"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06760819","name":"A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)","tldr":"A phase 2 trial of BAY2927088 in advanced solid tumours, run by Bayer, now recruiting.","route":"/trials/nct06760819/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06760819","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05748171","name":"A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL","tldr":"A phase 2 trial of Inotuzumab ozogamicin in acute lymphoblastic leukaemia, run by Pfizer, now recruiting.","route":"/trials/nct05748171/","status":"recruiting","kind":"trial","cancerIcon":"all-leukemia","sub":"NCT05748171","facets":{"kind":["Trial"],"cancers":["Acute lymphoblastic leukaemia","Relapsed and refractory acute lymphoblastic leukaemia in children"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."},{"label":"Relapsed and refractory acute lymphoblastic leukaemia in children","href":"/cancers/all-paediatric-relapsed/","tip":"When childhood leukaemia comes back, chemotherapy alone cures fewer than half. Three immune treatments changed this: blinatumomab, which links the child's T-cells to leukaemia cells and beat chemotherapy in two trials; tisagenlecleucel, the first approved CAR T-cell therapy, which put over eight in ten pretreated children into remission; and the antibody-drug conjugate inotuzumab ozogamicin."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07265674","name":"A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer","tldr":"A phase 3 trial of Nanvuranlat in biliary tract cancer, run by J-Pharma Co., Ltd., now recruiting.","route":"/trials/nct07265674/","status":"recruiting","kind":"trial","cancerIcon":"cholangiocarcinoma","sub":"NCT07265674","facets":{"kind":["Trial"],"cancers":["Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07054190","name":"A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer","tldr":"A phase 2 trial of Inavolisib, Ribociclib and Giredestrant in advanced solid tumours, run by Hoffmann-La Roche, now recruiting.","route":"/trials/nct07054190/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07054190","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06619509","name":"A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine","tldr":"A phase 2 trial of Brigimadlin in advanced solid tumours, run by Boehringer Ingelheim, active and no longer recruiting.","route":"/trials/nct06619509/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06619509","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06885034","name":"A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)","tldr":"A phase 1/2 trial of Risvutatug Rezetecan in advanced solid tumours, run by GlaxoSmithKline, now recruiting.","route":"/trials/nct06885034/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06885034","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02637687","name":"A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children","tldr":"A phase 1/2 trial of Larotrectinib in advanced solid tumours, run by Bayer, active and no longer recruiting.","route":"/trials/nct02637687/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT02637687","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06336291","name":"A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence","tldr":"A phase 2 trial of L19TNF in glioma & glioblastoma, run by Philogen S.p.A., active and no longer recruiting.","route":"/trials/nct06336291/","status":"active","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT06336291","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06057922","name":"A Study YL201 in Patients With Selected Advanced Solid Tumors","tldr":"A phase 1/2 trial of YL201 for Injection in advanced solid tumours, run by MediLink Therapeutics (Suzhou) Co., Ltd., active and no longer recruiting.","route":"/trials/nct06057922/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06057922","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05562830","name":"A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)","tldr":"A phase 1/2 trial of Zilovertamab vedotin and Pembrolizumab in bladder & urothelial cancer, run by Merck Sharp & Dohme LLC, now recruiting.","route":"/trials/nct05562830/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT05562830","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02663908","name":"A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease","tldr":"A phase 3 trial of Degarelix in Prostate cancer, run by Ferring Pharmaceuticals, recorded as terminated on the registry.","route":"/trials/nct02663908/","kind":"trial","cancerIcon":"prostate","sub":"NCT02663908","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03851640","name":"A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).","tldr":"A phase 3 trial of HC-1119 in prostate cancer, run by Hinova Pharmaceuticals Inc., now recruiting.","route":"/trials/nct03851640/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT03851640","facets":{"kind":["Trial"],"cancers":["Prostate cancer","Metastatic castration-resistant prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Metastatic castration-resistant prostate cancer","href":"/cancers/prostate-mcrpc/","tip":"Metastatic castration-resistant prostate cancer is disease that grows despite castrate testosterone. Sequenced treatments now include androgen receptor inhibitors, docetaxel and cabazitaxel, PARP inhibitors for men with BRCA-type mutations, the radioligand 177Lu-PSMA-617 and radium-223 for bone-predominant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07110571","name":"A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer","tldr":"A phase 2 trial of Adebrelimab, Trastuzumab rezetecan and SHR-8068 in gastric & gastro-oesophageal junction cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.","route":"/trials/nct07110571/","status":"recruiting","kind":"trial","cancerIcon":"gastric","sub":"NCT07110571","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04980885","name":"A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia","tldr":"A phase 1/2 trial of AK117 and Azacitidine in acute myeloid leukaemia, run by Akeso, active and no longer recruiting.","route":"/trials/nct04980885/","status":"active","kind":"trial","cancerIcon":"aml","sub":"NCT04980885","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04503265","name":"A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies","tldr":"A phase 1/2 trial of AMXI-5001:Dose Escalation Phase I in ovarian cancer, prostate cancer and pancreatic ductal adenocarcinoma, run by AtlasMedx, Incorporated, now recruiting.","route":"/trials/nct04503265/","status":"recruiting","kind":"trial","cancerIcon":"ovarian","sub":"NCT04503265","facets":{"kind":["Trial"],"cancers":["Ovarian cancer","Prostate cancer","Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06679036","name":"A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients","tldr":"A phase 1/2 trial of HRS-8080 in advanced solid tumours, run by Shandong Suncadia Medicine Co., Ltd., now recruiting.","route":"/trials/nct06679036/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06679036","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07232849","name":"A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer","tldr":"A phase 2 trial of HRS-4508 tablet in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.","route":"/trials/nct07232849/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07232849","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07003321","name":"A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer","tldr":"A phase 2 trial of HRS-4508 tablet in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.","route":"/trials/nct07003321/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07003321","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06555068","name":"A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients","tldr":"A phase 1/2 trial of Fulvestrant and HRS-8080 in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.","route":"/trials/nct06555068/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06555068","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07070349","name":"A Trial of HRS-6213 in Healthy Subjects and Patients With Solid Tumors","tldr":"A phase 1/2 trial of HRS-6213 in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.","route":"/trials/nct07070349/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07070349","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06925581","name":"A Trial of HRS-6768 in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of HRS-6768 in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.","route":"/trials/nct06925581/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06925581","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07601048","name":"A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment","tldr":"A phase 3 trial of Fulzerasib, Garsorasib and Glecirasib in Non-small-cell lung cancer, run by Shandong Suncadia Medicine Co., Ltd., not yet recruiting.","route":"/trials/nct07601048/","status":"planned","kind":"trial","cancerIcon":"nsclc","sub":"NCT07601048","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05482568","name":"A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer","tldr":"A phase 1/2 trial of Adebrelimab, Pyrotinib and Trastuzumab rezetecan in non-small-cell lung cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.","route":"/trials/nct05482568/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT05482568","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","HER2-mutant non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"HER2-mutant non-small-cell lung cancer","href":"/cancers/her2-mutant-nsclc/","tip":"HER2-mutant lung cancer carries a mutation in the same receptor that drives HER2-positive breast cancer, but the breast cancer antibodies alone did little here. The antibody-drug conjugate trastuzumab deruxtecan shrinks about half of tumours after chemotherapy, and the pill zongertinib about seven in ten, and both are approved."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00880360","name":"A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer","tldr":"A phase 2 trial of Denileukin diftitox in Ovarian cancer, run by The University of Texas Health Science Center at San Antonio, completed.","route":"/trials/nct00880360/","status":"completed","kind":"trial","cancerIcon":"ovarian","sub":"NCT00880360","facets":{"kind":["Trial"],"cancers":["Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07281976","name":"A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer","tldr":"A phase 1/2 trial of Toripalimab in triple-negative breast cancer, run by Nanjing Leads Biolabs Co.,Ltd, now recruiting.","route":"/trials/nct07281976/","status":"recruiting","kind":"trial","cancerIcon":"tnbc","sub":"NCT07281976","facets":{"kind":["Trial"],"cancers":["Triple-negative breast cancer","Metastatic triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Metastatic triple-negative breast cancer","href":"/cancers/tnbc-metastatic/","tip":"Triple-negative breast cancer that has spread is not curable, but its treatment has been transformed since 2020. By PD-L1 score, first treatment is pembrolizumab with chemotherapy or with sacituzumab govitecan, or datopotamab deruxtecan or sacituzumab govitecan alone; BRCA carriers can take a PARP inhibitor tablet; and trastuzumab deruxtecan reaches the third of tumours with low HER2."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04965493","name":"A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)","tldr":"A phase 3 trial of Pirtobrutinib, Venetoclax and Rituximab in chronic lymphocytic leukaemia, run by Loxo Oncology, Inc., active and no longer recruiting.","route":"/trials/nct04965493/","status":"active","kind":"trial","cancerIcon":"cll","sub":"NCT04965493","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia","Relapsed or refractory chronic lymphocytic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Relapsed or refractory chronic lymphocytic leukaemia","href":"/cancers/cll-relapsed/","tip":"When chronic lymphocytic leukaemia returns, the usual move is to switch drug class: venetoclax-based therapy after a BTK inhibitor, or a BTK inhibitor after venetoclax. Pirtobrutinib (BRUIN) works after the older BTK inhibitors fail, and CAR-T is approved for patients who have run out of both classes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07028268","name":"A Trial of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors","tldr":"A phase 2 trial of Denosumab in advanced solid tumours, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.","route":"/trials/nct07028268/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07028268","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07028281","name":"A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors","tldr":"A phase 2 trial of Adebrelimab, Carboplatin, Cisplatin and SHR-8068 in advanced solid tumours, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.","route":"/trials/nct07028281/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07028281","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07268040","name":"A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors","tldr":"A phase 2 trial of Adebrelimab, Etoposide, Carboplatin and Cisplatin in advanced solid tumours, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07268040/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07268040","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06605222","name":"A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of SHR-7787 injection in advanced solid tumours, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct06605222/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06605222","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06015048","name":"A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.","tldr":"A phase 1/2 trial of Pyrotinib and Trastuzumab rezetecan in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.","route":"/trials/nct06015048/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06015048","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06654440","name":"A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy","tldr":"A phase 2 trial of SHR-A2102 in advanced solid tumours, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct06654440/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06654440","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07393542","name":"A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma","tldr":"A phase 3 trial of SHR-A2102, Adebrelimab, Gemcitabine, Carboplatin and Cisplatin in bladder & urothelial cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.","route":"/trials/nct07393542/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT07393542","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06474468","name":"A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer","tldr":"A phase 1/2 trial of Adebrelimab, Cisplatin and SHR-A2102 in oesophageal cancer, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct06474468/","status":"recruiting","kind":"trial","cancerIcon":"esophageal","sub":"NCT06474468","facets":{"kind":["Trial"],"cancers":["Oesophageal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06639347","name":"A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma","tldr":"A phase 1/2 trial of SHR-A2102, Adebrelimab and SHR-8068 in bladder & urothelial cancer, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct06639347/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT06639347","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06417554","name":"A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors","tldr":"A phase 1/2 trial of SHR-A2102, Adebrelimab and Disitamab vedotin in advanced solid tumours, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct06417554/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06417554","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06895928","name":"A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors","tldr":"A phase 2 trial of SHR-A2102, Bevacizumab and Osimertinib in advanced solid tumours, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct06895928/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06895928","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07497386","name":"A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer","tldr":"A phase 2 trial of Trastuzumab, Trastuzumab rezetecan and Trastuzumab deruxtecan in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.","route":"/trials/nct07497386/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07497386","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02346747","name":"A Trial of Vigil for Participants With Ovarian Cancer","tldr":"A phase 2 trial of Vigil in ovarian cancer, run by Gradalis, Inc., active and no longer recruiting.","route":"/trials/nct02346747/","status":"active","kind":"trial","cancerIcon":"ovarian","sub":"NCT02346747","facets":{"kind":["Trial"],"cancers":["Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06505395","name":"A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)","tldr":"A phase 2 trial of SYHX2008 injection in pancreatic ductal adenocarcinoma, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., now recruiting.","route":"/trials/nct06505395/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT06505395","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06545955","name":"A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer","tldr":"A phase 3 trial of Nadofaragene firadenovec, Gemcitabine, Docetaxel and Pembrolizumab in bladder & urothelial cancer, run by Ferring Pharmaceuticals, now recruiting.","route":"/trials/nct06545955/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT06545955","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Non-muscle-invasive bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Non-muscle-invasive bladder cancer","href":"/cancers/non-muscle-invasive-bladder-cancer/","tip":"Most bladder cancers are found while still confined to the lining. They are scraped out through the urethra and, when higher risk, treated with BCG instilled into the bladder; the challenge is the frequent recurrences and the patients whose tumours stop responding to BCG."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05277168","name":"A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS","tldr":"A phase 1/2 trial of SHR-A1904 in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.","route":"/trials/nct05277168/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05277168","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04626635","name":"A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers","tldr":"A phase 1/2 trial of REGN7075, Cemiplimab, Bevacizumab and Trifluridine/tipiracil in advanced solid tumours, run by Regeneron Pharmaceuticals, active and no longer recruiting.","route":"/trials/nct04626635/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04626635","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05125016","name":"A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer","tldr":"A phase 1/2 trial of REGN4336 in prostate cancer, run by Regeneron Pharmaceuticals, now recruiting.","route":"/trials/nct05125016/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT05125016","facets":{"kind":["Trial"],"cancers":["Prostate cancer","Metastatic castration-resistant prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Metastatic castration-resistant prostate cancer","href":"/cancers/prostate-mcrpc/","tip":"Metastatic castration-resistant prostate cancer is disease that grows despite castrate testosterone. Sequenced treatments now include androgen receptor inhibitors, docetaxel and cabazitaxel, PARP inhibitors for men with BRCA-type mutations, the radioligand 177Lu-PSMA-617 and radium-223 for bone-predominant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"a166","name":"A166","tldr":"A166 is an experimental antibody-drug conjugate from Sichuan Kelun-Biotech Biopharmaceutical in phase 3 trials for HER2-positive breast cancer, aimed at HER2.","route":"/drugs/a166/","status":"phase-3","kind":"drug","molecule":"a166","modality":"ADC","facets":{"kind":["Treatment"],"cancers":["HER2-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."}],"tags":[]},"sortKeys":{"year":0}},{"id":"aaa817","name":"AAA817","tldr":"AAA817 is an experimental radioligand therapy from Novartis Pharmaceuticals in phase 3 trials for prostate cancer, aimed at PSMA.","route":"/drugs/aaa817/","status":"phase-3","kind":"drug","molecule":"aaa817","modality":"radioligand","facets":{"kind":["Treatment"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06245915","name":"AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)","tldr":"A phase 1/2 trial of AB-2100 in renal cell carcinoma, run by Arsenal Biosciences, Inc., active and no longer recruiting.","route":"/trials/nct06245915/","status":"active","kind":"trial","cancerIcon":"rcc","sub":"NCT06245915","facets":{"kind":["Trial"],"cancers":["Renal cell carcinoma","Clear cell renal cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."},{"label":"Clear cell renal cell carcinoma","href":"/cancers/clear-cell-rcc/","tip":"Clear cell is the common kidney cancer, driven by loss of the VHL gene that leaves the tumour behaving as if starved of oxygen and flooding itself with blood vessels. That biology explains why anti-angiogenic drugs, immunotherapy and the HIF-2 alpha blocker belzutifan all work."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07285694","name":"AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)","tldr":"A phase 1/2 trial of AB-3028 in prostate cancer, run by Arsenal Biosciences, Inc., active and no longer recruiting.","route":"/trials/nct07285694/","status":"active","kind":"trial","cancerIcon":"prostate","sub":"NCT07285694","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05211570","name":"AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia","tldr":"A phase 1/2 trial of Venetoclax in acute myeloid leukaemia, run by AB Science, now recruiting.","route":"/trials/nct05211570/","status":"recruiting","kind":"trial","cancerIcon":"aml","sub":"NCT05211570","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00841113","name":"Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer","tldr":"A phase 3 trial of Abarelix in Prostate cancer, run by Speciality European Pharma Limited, completed.","route":"/trials/nct00841113/","status":"completed","kind":"trial","cancerIcon":"prostate","sub":"NCT00841113","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"abbv-706","name":"ABBV-706","tldr":"ABBV-706 is an experimental antibody-drug conjugate from AbbVie in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.","route":"/drugs/abbv-706/","status":"phase-3","kind":"drug","molecule":"abbv-706","modality":"ADC","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"abexinostat","name":"Abexinostat","tldr":"Abexinostat is an experimental small-molecule drug from Xynomic Pharmaceuticals in phase 3 trials for renal cell carcinoma, diffuse large B-cell lymphoma and follicular lymphoma, with its target not yet stated publicly.","route":"/drugs/abexinostat/","status":"phase-3","kind":"drug","molecule":"abexinostat","modality":"small molecule","sub":"PCI-24781","facets":{"kind":["Treatment"],"cancers":["Renal cell carcinoma","Diffuse large B-cell lymphoma","Follicular lymphoma","Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."},{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."},{"label":"Follicular lymphoma","href":"/cancers/follicular-lymphoma/","tip":"Follicular lymphoma is the most common slow-growing lymphoma, defined in about 85% of cases by a BCL2 translocation. Most people live with it for decades, treated only when it causes problems; it can be controlled repeatedly with anti-CD20 antibodies, chemotherapy, bispecifics or CAR-T but rarely cured, and a small share transform into an aggressive lymphoma each year."},{"label":"Hodgkin lymphoma","href":"/cancers/hodgkin-lymphoma/","tip":"Hodgkin lymphoma is one of the most curable cancers, where the goal is now to cure with less toxicity, using brentuximab and, from 2026, first-line nivolumab."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07158918","name":"ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors","tldr":"A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by ABL Bio, Inc., now recruiting.","route":"/trials/nct07158918/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07158918","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02788981","name":"Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer","tldr":"A phase 2 trial of Mifepristone and Paclitaxel / nab-paclitaxel in Breast cancer, run by University of Chicago, active and no longer recruiting.","route":"/trials/nct02788981/","status":"active","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT02788981","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07327034","name":"ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression","tldr":"A phase 2 trial of ABSK-011+BSC in hepatocellular carcinoma, run by Abbisko Therapeutics Co, Ltd, now recruiting.","route":"/trials/nct07327034/","status":"recruiting","kind":"trial","cancerIcon":"hcc","sub":"NCT07327034","facets":{"kind":["Trial"],"cancers":["Hepatocellular carcinoma","Advanced hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."},{"label":"Advanced hepatocellular carcinoma","href":"/cancers/hcc-advanced/","tip":"Advanced hepatocellular carcinoma has invaded the liver's veins or spread beyond it. Sorafenib was the only drug for a decade; now the combination of the immunotherapy atezolizumab with the anti-angiogenic antibody bevacizumab, or the two-antibody regimen durvalumab with tremelimumab, is standard first line, and several further drugs follow it."}],"tags":[]},"sortKeys":{"year":0}},{"id":"absk061","name":"ABSK061","tldr":"ABSK061 is an experimental small-molecule drug from Abbisko Therapeutics in phase 2 trials for gastric & gastro-oesophageal junction cancer, bladder & urothelial cancer and non-small-cell lung cancer, aimed at HER2 and FGFR2.","route":"/drugs/absk061/","status":"phase-2","kind":"drug","molecule":"absk061","modality":"small molecule (structure undisclosed or not yet in PubChem)","facets":{"kind":["Treatment"],"cancers":["Gastric & gastro-oesophageal junction cancer","Bladder & urothelial cancer","Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"abt-301","name":"ABT-301","tldr":"ABT-301 is an experimental small-molecule drug from Anbogen Therapeutics in phase 2 trials for colorectal cancer, aimed at Histone deacetylases (HDAC).","route":"/drugs/abt-301/","status":"phase-2","kind":"drug","molecule":"abt-301","modality":"small molecule","facets":{"kind":["Treatment"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03897543","name":"ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma","tldr":"A phase 1/2 trial of ABX196 in hepatocellular carcinoma, run by Abivax S.A., now recruiting.","route":"/trials/nct03897543/","status":"recruiting","kind":"trial","cancerIcon":"hcc","sub":"NCT03897543","facets":{"kind":["Trial"],"cancers":["Hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04624633","name":"Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL","tldr":"A phase 2 trial of Acalabrutinib and Umbralisib in Chronic lymphocytic leukaemia, run by Jennifer R. Brown, MD, PhD, active and no longer recruiting.","route":"/trials/nct04624633/","status":"active","kind":"trial","cancerIcon":"cll","sub":"NCT04624633","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."}],"tags":[]},"sortKeys":{"year":0}},{"id":"acasunlimab","name":"Acasunlimab","tldr":"Acasunlimab is an experimental bispecific antibody from Genmab in phase 3 trials for non-small-cell lung cancer, aimed at PD-L1.","route":"/drugs/acasunlimab/","status":"phase-3","kind":"drug","molecule":"acasunlimab","modality":"bispecific antibody","sub":"GEN1046","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00261313","name":"ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer","tldr":"A phase 2 trial of Pegfilgrastim and Darbepoetin alfa in Breast cancer, run by Amgen, completed.","route":"/trials/nct00261313/","status":"completed","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT00261313","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05355298","name":"ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer","tldr":"A phase 1/2 trial of AMP945 ascending doses in pancreatic ductal adenocarcinoma, run by Amplia Therapeutics Limited, active and no longer recruiting.","route":"/trials/nct05355298/","status":"active","kind":"trial","cancerIcon":"pancreatic","sub":"NCT05355298","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06850623","name":"Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer","tldr":"A phase 2 trial of Acoustic Cluster Therapy in pancreatic ductal adenocarcinoma, run by EXACT Therapeutics AS, now recruiting.","route":"/trials/nct06850623/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT06850623","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Locally advanced unresectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02029443","name":"ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia","tldr":"A phase 1/2 trial of Acalabrutinib in chronic lymphocytic leukaemia, run by Acerta Pharma BV, active and no longer recruiting.","route":"/trials/nct02029443/","status":"active","kind":"trial","cancerIcon":"cll","sub":"NCT02029443","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia","Richter transformation of chronic lymphocytic leukaemia"],"year":["2022"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Richter transformation of chronic lymphocytic leukaemia","href":"/cancers/richter-transformation-cll/","tip":"Richter transformation is the sudden change of slow chronic lymphocytic leukaemia into a fast-growing lymphoma, usually of the diffuse large B-cell type. It is treated with lymphoma chemotherapy followed by a donor transplant where possible, and newer drugs such as pirtobrutinib, venetoclax combinations and bispecific antibodies are being tested because standard chemotherapy rarely cures it."}],"year":{"facet":"year","value":"2022"},"tags":[]},"sortKeys":{"year":2022}},{"id":"nct03686124","name":"ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors","tldr":"A phase 1/2 trial of Nivolumab in advanced solid tumours, run by Immatics US, Inc., now recruiting.","route":"/trials/nct03686124/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT03686124","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06911333","name":"AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors","tldr":"A phase 1/2 trial of AD1208 in advanced solid tumours, run by Avelos Therapeutics Inc., now recruiting.","route":"/trials/nct06911333/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06911333","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"adagloxad-simolenin","name":"Adagloxad simolenin","tldr":"Adagloxad simolenin is OBI Pharma's vaccine against the tumour sugar Globo H, in the phase 3 GLORIA trial as adjuvant treatment for triple-negative breast cancer that expresses the antigen.","route":"/drugs/adagloxad-simolenin/","status":"phase-3","kind":"drug","molecule":"adagloxad-simolenin","modality":"Carbohydrate antigen vaccine (Globo H conjugate) with the adjuvant OBI-821","sub":"OBI-822","facets":{"kind":["Treatment"],"cancers":["Triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06246344","name":"Adaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer","tldr":"A phase 3 trial of Adaptive radiotherapy in Rectal cancer, run by Shandong Cancer Hospital and Institute, active and no longer recruiting.","route":"/trials/nct06246344/","status":"active","kind":"trial","cancerIcon":"rectal-cancer","sub":"NCT06246344","facets":{"kind":["Trial"],"cancers":["Rectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Rectal cancer","href":"/cancers/rectal-cancer/","tip":"Rectal cancer is bowel cancer in the last part of the large intestine, where surgery can mean a permanent stoma. Treatment now usually gives all the chemotherapy and radiotherapy first, and about half of people whose tumour disappears completely can keep their rectum and avoid surgery altogether."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07523555","name":"Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies","tldr":"A phase 1/2 trial of Autologous CD19/CD22 dual-target CAR-T module in acute lymphoblastic leukaemia, non-Hodgkin lymphoma, multiple myeloma, acute myeloid leukaemia and peripheral T-cell lymphomas, run by Beijing Biotech, now recruiting.","route":"/trials/nct07523555/","status":"recruiting","kind":"trial","cancerIcon":"all-leukemia","sub":"NCT07523555","facets":{"kind":["Trial"],"cancers":["Acute lymphoblastic leukaemia","Non-Hodgkin lymphoma","Multiple myeloma","Acute myeloid leukaemia","Peripheral T-cell lymphomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."},{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."},{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."},{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07744256","name":"Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)","tldr":"A phase 1/2 trial of EB-DART-NK01 in small-cell lung cancer, run by Beijing Biotech, now recruiting.","route":"/trials/nct07744256/","status":"recruiting","kind":"trial","cancerIcon":"sclc","sub":"NCT07744256","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07480213","name":"Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)","tldr":"A phase 1/2 trial of EB-DART-NK01 (DLL3/CD56 CAR-NK cells) in small-cell lung cancer, run by Beijing Biotech, now recruiting.","route":"/trials/nct07480213/","status":"recruiting","kind":"trial","cancerIcon":"sclc","sub":"NCT07480213","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[]},"sortKeys":{"year":0}},{"id":"adavosertib","name":"Adavosertib","tldr":"Adavosertib is an oral serine/threonine kinase inhibitor from AstraZeneca, in registered phase 2 trials for triple-negative breast cancer.","route":"/drugs/adavosertib/","status":"phase-2","kind":"drug","molecule":"adavosertib","modality":"Oral serine/threonine kinase inhibitor","facets":{"kind":["Treatment"],"cancers":["Triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct07802626","name":"Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing","tldr":"A phase 3 trial of Guardant Reveal in Breast cancer, run by SWOG Cancer Research Network, not yet recruiting.","route":"/trials/nct07802626/","status":"planned","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT07802626","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"adg126","name":"ADG126","tldr":"ADG126 is an experimental monoclonal antibody from Adagene in phase 2 trials for hepatocellular carcinoma, aimed at CTLA-4.","route":"/drugs/adg126/","status":"phase-2","kind":"drug","molecule":"adg126","modality":"monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05405595","name":"ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors","tldr":"A phase 1/2 trial of ADG126, Pembrolizumab, Bevacizumab, Trifluridine/tipiracil and Fruquintinib in advanced solid tumours, run by Adagene Inc, now recruiting.","route":"/trials/nct05405595/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05405595","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"adi-270","name":"ADI-270","tldr":"ADI-270 is an experimental CAR-T cell therapy from Adicet Therapeutics in phase 2 trials for renal cell carcinoma, aimed at CD70.","route":"/drugs/adi-270/","status":"phase-2","kind":"drug","molecule":"adi-270","modality":"CAR-T cell therapy","facets":{"kind":["Treatment"],"cancers":["Renal cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04587830","name":"ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme","tldr":"A phase 2 trial of Temozolomide in glioma & glioblastoma, run by Polaris Group, active and no longer recruiting.","route":"/trials/nct04587830/","status":"active","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT04587830","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"adi-peg20","name":"ADI-PEG20","tldr":"ADI-PEG20 is an experimental investigational agent whose form is not stated in the registry from Polaris in phase 3 trials for hepatocellular carcinoma, with its target not yet stated publicly.","route":"/drugs/adi-peg20/","status":"phase-3","kind":"drug","molecule":"adi-peg20","modality":"PEGylated enzyme (pegargiminase, arginine deiminase; INN stem -ase; form not stated in the registry record)","sub":"PEG20","facets":{"kind":["Treatment"],"cancers":["Hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04724980","name":"Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis","tldr":"A phase 1/2 trial of PRGN-2012 - Phase I; Dose Level 1 in rare cancers of childhood, run by Precigen, Inc, active and no longer recruiting.","route":"/trials/nct04724980/","status":"active","kind":"trial","cancerIcon":"rare-childhood-cancers","sub":"NCT04724980","facets":{"kind":["Trial"],"cancers":["Rare cancers of childhood"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Rare cancers of childhood","href":"/cancers/rare-childhood-cancers/","tip":"Some childhood cancers are so rare that no single hospital sees enough to learn from. The NCI groups them together: heart tumours, airway papillomas, cancers of the thyroid, adrenal, nose and throat, melanoma and carcinomas more typical of adults. The answer has been international registries and expert networks that pool every case, so treatment guidance exists even without trials."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07225621","name":"Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma","tldr":"A phase 2 trial of Aminolevulinic acid (topical, for photodynamic therapy) in glioma & glioblastoma, run by Alpheus Medical, Inc., now recruiting.","route":"/trials/nct07225621/","status":"recruiting","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT07225621","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02132390","name":"Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea","tldr":"A phase 3 trial of Goserelin / leuprolide and Toremifene in Breast cancer, run by Peking Union Medical College Hospital, with a status the registry has not verified recently.","route":"/trials/nct02132390/","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT02132390","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00576914","name":"Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer","tldr":"A phase 3 trial of Recombinant human endostatin in Non-small-cell lung cancer, run by Chinese Academy of Sciences, with a status the registry has not verified recently.","route":"/trials/nct00576914/","kind":"trial","cancerIcon":"nsclc","sub":"NCT00576914","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01124253","name":"Adjuvant Vinorelbine Plus Cisplatin(NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer(NSCLC)","tldr":"A phase 3 trial of Recombinant human endostatin in Non-small-cell lung cancer, run by Shanghai Jiao Tong University School of Medicine, completed.","route":"/trials/nct01124253/","status":"completed","kind":"trial","cancerIcon":"nsclc","sub":"NCT01124253","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00022282","name":"AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma","tldr":"A phase 2 trial of Shark cartilage in Multiple myeloma, run by AEterna Zentaris, completed.","route":"/trials/nct00022282/","status":"completed","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT00022282","facets":{"kind":["Trial"],"cancers":["Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[]},"sortKeys":{"year":0}},{"id":"aglatimagene-besadenovec","name":"Aglatimagene besadenovec","tldr":"Aglatimagene besadenovec is an experimental gene therapy from Candel Therapeutics in phase 3 trials for non-small-cell lung cancer and prostate cancer, with its target not yet stated publicly.","route":"/drugs/aglatimagene-besadenovec/","status":"phase-3","kind":"drug","molecule":"aglatimagene-besadenovec","modality":"gene therapy","sub":"CAN-2409","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ai-081","name":"AI-081","tldr":"AI-081 is an experimental bispecific antibody from OncoC4 in phase 2 trials, aimed at PD-1 and VEGF / VEGFR.","route":"/drugs/ai-081/","status":"phase-2","kind":"drug","molecule":"ai-081","modality":"bispecific antibody","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06600022","name":"Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours.","tldr":"A phase 1/2 trial of SCTB41 in advanced solid tumours, run by Sinocelltech Ltd., now recruiting.","route":"/trials/nct06600022/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06600022","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06951503","name":"AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer","tldr":"A phase 3 trial of Oxaliplatin and Bevacizumab in colorectal cancer, run by Akeso, now recruiting.","route":"/trials/nct06951503/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT06951503","facets":{"kind":["Trial"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06591520","name":"AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer","tldr":"A phase 3 trial of Cisplatin, Gemcitabine, Gemcitabine + cisplatin and Durvalumab in biliary tract cancer, run by Akeso, active and no longer recruiting.","route":"/trials/nct06591520/","status":"active","kind":"trial","cancerIcon":"cholangiocarcinoma","sub":"NCT06591520","facets":{"kind":["Trial"],"cancers":["Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ak117","name":"AK117","tldr":"AK117 is an experimental investigational agent whose form is not stated in the registry from Akeso in phase 3 trials for head and neck squamous cell carcinoma, colorectal cancer and non-small-cell lung cancer, with its target not yet stated publicly.","route":"/drugs/ak117/","status":"phase-3","kind":"drug","molecule":"ak117","modality":"monoclonal antibody (AK117 is ligufalimab; INN stem -mab; form not stated in the registry record)","facets":{"kind":["Treatment"],"cancers":["Head and neck squamous cell carcinoma","Colorectal cancer","Non-small-cell lung cancer","Acute myeloid leukaemia","Triple-negative breast cancer","Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ak119","name":"AK119","tldr":"AK119 is an experimental monoclonal antibody from Akeso in phase 2 trials for colorectal cancer, aimed at CD73 / adenosine axis.","route":"/drugs/ak119/","status":"phase-2","kind":"drug","molecule":"ak119","modality":"monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03386617","name":"AKY15-HK-301_NEPA Study","tldr":"A phase 2 trial of Netupitant and palonosetron in Breast cancer, run by Chinese University of Hong Kong, active and no longer recruiting.","route":"/trials/nct03386617/","status":"active","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT03386617","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"al2846","name":"AL2846","tldr":"AL2846 is an experimental small-molecule drug from Chia Tai Tianqing Pharmaceutical in phase 3 trials for thyroid cancer, aimed at MET and RET.","route":"/drugs/al2846/","status":"phase-3","kind":"drug","molecule":"al2846","modality":"small molecule (structure undisclosed or not yet in PubChem)","facets":{"kind":["Treatment"],"cancers":["Thyroid cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Thyroid cancer","href":"/cancers/thyroid/","tip":"Thyroid cancer is usually curable with surgery and radioactive iodine, the original theranostic. Rare aggressive forms respond to RET and BRAF inhibitors."}],"tags":[]},"sortKeys":{"year":0}},{"id":"al8326","name":"AL8326","tldr":"AL8326 is an experimental small-molecule drug from Advenchen Pharmaceuticals in phase 3 trials for small-cell lung cancer, non-small-cell lung cancer and renal cell carcinoma, with its target not yet stated publicly.","route":"/drugs/al8326/","status":"phase-3","kind":"drug","molecule":"al8326","modality":"small molecule (structure undisclosed or not yet in PubChem)","facets":{"kind":["Treatment"],"cancers":["Small-cell lung cancer","Non-small-cell lung cancer","Renal cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."}],"tags":[]},"sortKeys":{"year":0}},{"id":"alisertib","name":"Alisertib","tldr":"Alisertib is an oral serine/threonine kinase inhibitor from Puma Biotechnology, Inc., in registered phase 2 trials for small-cell lung cancer.","route":"/drugs/alisertib/","status":"phase-2","kind":"drug","molecule":"alisertib","modality":"Oral serine/threonine kinase inhibitor","facets":{"kind":["Treatment"],"cancers":["Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct01423500","name":"ALL-SCT BFM International- HSCT in Children and Adolescents With ALL","tldr":"A phase 3 trial of Fludarabine, Treosulfan and Thiotepa in Leukaemia, run by St. Anna Kinderkrebsforschung, with a status the registry has not verified recently.","route":"/trials/nct01423500/","kind":"trial","cancerIcon":"leukaemia","sub":"NCT01423500","facets":{"kind":["Trial"],"cancers":["Leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Leukaemia","href":"/cancers/leukaemia/","tip":"Leukaemia means cancer of the blood-forming cells, but the four main types share little beyond the name: acute lymphoblastic and acute myeloid leukaemia are emergencies treated with intensive therapy, while chronic lymphocytic and chronic myeloid leukaemia are slow diseases controlled for years with pills. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"allo-647","name":"ALLO-647","tldr":"ALLO-647 is an experimental monoclonal antibody from Allogene Therapeutics in phase 2 trials for diffuse large B-cell lymphoma, aimed at CD52.","route":"/drugs/allo-647/","status":"phase-2","kind":"drug","molecule":"allo-647","modality":"monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Diffuse large B-cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04616209","name":"Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients","tldr":"A phase 1/2 trial of donor-derived NK cell infusion in non-small-cell lung cancer, run by Precision Biotech Taiwan Corp., now recruiting.","route":"/trials/nct04616209/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT04616209","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05948943","name":"Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.","tldr":"A phase 2/3 trial of Alpelisib in childhood cancers, run by Novartis Pharmaceuticals, now recruiting.","route":"/trials/nct05948943/","status":"recruiting","kind":"trial","cancerIcon":"childhood-cancers","sub":"NCT05948943","facets":{"kind":["Trial"],"cancers":["Childhood cancers"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Childhood cancers","href":"/cancers/childhood-cancers/","tip":"Cancer in children is rare and different from adult cancer: the common types are leukaemias, brain tumours, lymphomas and embryonal tumours such as neuroblastoma and Wilms tumour, most are curable in well-resourced health systems, and the great challenge is bringing the same cures to the majority of children who live where they are not available."}],"tags":[]},"sortKeys":{"year":0}},{"id":"amo959","name":"AMO959","tldr":"AMO959 is a small-molecule inhibitor from Novartis Pharmaceuticals, in registered phase 2 trials for prostate cancer.","route":"/drugs/amo959/","status":"phase-2","kind":"drug","molecule":"amo959","modality":"Small-molecule inhibitor","sub":"AMO959","facets":{"kind":["Treatment"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"amrubicin","name":"Amrubicin","tldr":"Amrubicin is a Japanese anthracycline approved there in 2002 for small cell and non-small cell lung cancer, a standard second-line option for small cell lung cancer in Japan that failed to beat topotecan in a Western phase 3 trial and now serves as the comparator in global trials.","route":"/drugs/amrubicin/","status":"established","kind":"drug","molecule":"amrubicin","modality":"Synthetic anthracycline (topoisomerase II inhibitor), intravenous","facets":{"kind":["Treatment"],"cancers":["Small-cell lung cancer","Non-small-cell lung cancer"],"year":["2002"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"year":{"facet":"year","value":"2002"},"tags":[]},"sortKeys":{"year":2002}},{"id":"amt-116","name":"AMT-116","tldr":"AMT-116 is an antibody-drug conjugate from Multitude Therapeutics Inc., in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer.","route":"/drugs/amt-116/","status":"phase-2","kind":"drug","molecule":"amt-116","modality":"Antibody-drug conjugate","sub":"AMT-116","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct06782334","name":"AMT-116 in Patients with Solid Tumors","tldr":"A phase 1/2 trial of AMT-116 in advanced solid tumours, run by Multitude Therapeutics Inc., now recruiting.","route":"/trials/nct06782334/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06782334","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06209580","name":"AMT-253 in Patients With Advanced Solid Tumours","tldr":"A phase 1/2 trial of AMT-253 for injection in melanoma, run by Multitude Therapeutics Inc., now recruiting.","route":"/trials/nct06209580/","status":"recruiting","kind":"trial","cancerIcon":"melanoma","sub":"NCT06209580","facets":{"kind":["Trial"],"cancers":["Melanoma","Advanced melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"label":"Advanced melanoma","href":"/cancers/advanced-melanoma/","tip":"Advanced melanoma has spread beyond what surgery can remove, and it is the cancer in which immunotherapy first proved it could cure some people: about half of those given nivolumab with ipilimumab are alive ten years later. If immunotherapy fails, options include a cell therapy grown from the patient's own immune cells, a virus injected into the tumour, and targeted pills for BRAF-mutant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05876754","name":"An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma","tldr":"A phase 3 trial of Ivosidenib in biliary tract cancer, run by Servier Affaires Médicales, active and no longer recruiting.","route":"/trials/nct05876754/","status":"active","kind":"trial","cancerIcon":"cholangiocarcinoma","sub":"NCT05876754","facets":{"kind":["Trial"],"cancers":["Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07293754","name":"An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors","tldr":"A phase 1/2 trial of RPTR-1-201 in advanced solid tumours, run by Repertoire Immune Medicines, now recruiting.","route":"/trials/nct07293754/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07293754","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02257736","name":"An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)","tldr":"A phase 3 trial of Apalutamide, Abiraterone acetate and Prednisone in prostate cancer, run by Aragon Pharmaceuticals, Inc., active and no longer recruiting.","route":"/trials/nct02257736/","status":"active","kind":"trial","cancerIcon":"prostate","sub":"NCT02257736","facets":{"kind":["Trial"],"cancers":["Prostate cancer","Metastatic castration-resistant prostate cancer"],"year":["2021"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Metastatic castration-resistant prostate cancer","href":"/cancers/prostate-mcrpc/","tip":"Metastatic castration-resistant prostate cancer is disease that grows despite castrate testosterone. Sequenced treatments now include androgen receptor inhibitors, docetaxel and cabazitaxel, PARP inhibitors for men with BRCA-type mutations, the radioligand 177Lu-PSMA-617 and radium-223 for bone-predominant disease."}],"year":{"facet":"year","value":"2021"},"tags":[]},"sortKeys":{"year":2021}},{"id":"nct02365597","name":"An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer","tldr":"A phase 2 trial of Erdafitinib in bladder & urothelial cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.","route":"/trials/nct02365597/","status":"active","kind":"trial","cancerIcon":"urothelial","sub":"NCT02365597","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":["2023"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"year":{"facet":"year","value":"2023"},"tags":[]},"sortKeys":{"year":2023}},{"id":"nct02531516","name":"An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS","tldr":"A phase 3 trial of Apalutamide and Bicalutamide in prostate cancer, run by Aragon Pharmaceuticals, Inc., active and no longer recruiting.","route":"/trials/nct02531516/","status":"active","kind":"trial","cancerIcon":"prostate","sub":"NCT02531516","facets":{"kind":["Trial"],"cancers":["Prostate cancer","Localised prostate cancer, high and very high risk"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Localised prostate cancer, high and very high risk","href":"/cancers/prostate-high-risk/","tip":"High-risk prostate cancer has Grade Group 4 or 5 disease, a PSA above 20 or a tumour growing beyond the gland. It is still curable, but needs radiotherapy with two to three years of hormone therapy, or surgery followed by radiotherapy, and adding abiraterone to hormone therapy now lengthens life in the highest-risk men."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05413018","name":"An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission","tldr":"A phase 2 trial of CC-486 in acute myeloid leukaemia, run by Bristol-Myers Squibb, active and no longer recruiting.","route":"/trials/nct05413018/","status":"active","kind":"trial","cancerIcon":"aml","sub":"NCT05413018","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07033026","name":"An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.","tldr":"A phase 2 trial of NGM120 Q4W in colorectal cancer, run by NGM Biopharmaceuticals, Inc, now recruiting.","route":"/trials/nct07033026/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT07033026","facets":{"kind":["Trial"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01368276","name":"An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma","tldr":"A phase 3 trial of Talimogene laherparepvec in Melanoma, run by BioVex Limited, completed.","route":"/trials/nct01368276/","status":"completed","kind":"trial","cancerIcon":"melanoma","sub":"NCT01368276","facets":{"kind":["Trial"],"cancers":["Melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05112965","name":"An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)","tldr":"A phase 3 trial of Atezolizumab, Bevacizumab, Pemetrexed and Enzalutamide in advanced solid tumours, run by Hoffmann-La Roche, active and no longer recruiting.","route":"/trials/nct05112965/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05112965","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06447103","name":"An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer","tldr":"A phase 2 trial of CAIX PET in Clear cell renal cell carcinoma and Renal cell carcinoma, run by Jonsson Comprehensive Cancer Center, now recruiting.","route":"/trials/nct06447103/","status":"recruiting","kind":"trial","cancerIcon":"clear-cell-rcc","sub":"NCT06447103","facets":{"kind":["Trial"],"cancers":["Clear cell renal cell carcinoma","Renal cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Clear cell renal cell carcinoma","href":"/cancers/clear-cell-rcc/","tip":"Clear cell is the common kidney cancer, driven by loss of the VHL gene that leaves the tumour behaving as if starved of oxygen and flooding itself with blood vessels. That biology explains why anti-angiogenic drugs, immunotherapy and the HIF-2 alpha blocker belzutifan all work."},{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06634849","name":"An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1).","tldr":"A phase 1/2 trial of PTT-4256 in advanced solid tumours, run by Pathios Therapeutics Pty Ltd, now recruiting.","route":"/trials/nct06634849/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06634849","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06668792","name":"An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma","tldr":"A phase 2 trial of BCD-248 in multiple myeloma, run by Biocad, now recruiting.","route":"/trials/nct06668792/","status":"recruiting","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT06668792","facets":{"kind":["Trial"],"cancers":["Multiple myeloma","Relapsed or refractory multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."},{"label":"Relapsed or refractory multiple myeloma","href":"/cancers/myeloma-relapsed-refractory/","tip":"Myeloma almost always returns, and each return is harder to treat. Two kinds of immune therapy aimed at the BCMA protein on myeloma cells, CAR-T cells (KarMMa-3, CARTITUDE-4) and off-the-shelf bispecific antibodies (MajesTEC), now give deep remissions after other drugs fail, and a second target, GPRC5D, gives another option."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07206056","name":"An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)","tldr":"A phase 1/2 trial of Tulmimetostat DL1 QD in prostate cancer, run by Novartis Pharmaceuticals, now recruiting.","route":"/trials/nct07206056/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT07206056","facets":{"kind":["Trial"],"cancers":["Prostate cancer","Metastatic castration-resistant prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Metastatic castration-resistant prostate cancer","href":"/cancers/prostate-mcrpc/","tip":"Metastatic castration-resistant prostate cancer is disease that grows despite castrate testosterone. Sequenced treatments now include androgen receptor inhibitors, docetaxel and cabazitaxel, PARP inhibitors for men with BRCA-type mutations, the radioligand 177Lu-PSMA-617 and radium-223 for bone-predominant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05884255","name":"An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.","tldr":"A phase 3 trial of Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide in pancreatic ductal adenocarcinoma, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.","route":"/trials/nct05884255/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT05884255","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05907057","name":"An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.","tldr":"A phase 3 trial of Ivosidenib and Azacitidine in acute myeloid leukaemia, run by Servier Affaires Médicales, now recruiting.","route":"/trials/nct05907057/","status":"recruiting","kind":"trial","cancerIcon":"aml","sub":"NCT05907057","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia","Acute myeloid leukaemia in older or unfit patients"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Acute myeloid leukaemia in older or unfit patients","href":"/cancers/aml-older-unfit/","tip":"Most people with acute myeloid leukaemia are over 65, and many cannot take intensive chemotherapy. Venetoclax with azacitidine, two gentler drugs, doubled remission rates and lengthened life in this group, replacing the old choice between supportive care and low-dose chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03533283","name":"An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","tldr":"A phase 1/2 trial of Glofitamab, Atezolizumab, Obinutuzumab, Tocilizumab and Polatuzumab vedotin in hodgkin lymphoma, run by Hoffmann-La Roche, active and no longer recruiting.","route":"/trials/nct03533283/","status":"active","kind":"trial","cancerIcon":"hodgkin-lymphoma","sub":"NCT03533283","facets":{"kind":["Trial"],"cancers":["Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hodgkin lymphoma","href":"/cancers/hodgkin-lymphoma/","tip":"Hodgkin lymphoma is one of the most curable cancers, where the goal is now to cure with less toxicity, using brentuximab and, from 2026, first-line nivolumab."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07720284","name":"An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC","tldr":"A phase 3 trial of Rilvegostomig, Durvalumab, Nivolumab, Pembrolizumab and Enfortumab vedotin in bladder & urothelial cancer, run by AstraZeneca, now recruiting.","route":"/trials/nct07720284/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT07720284","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04305795","name":"An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors","tldr":"A phase 1/2 trial of Pembrolizumab and Cemiplimab in head and neck squamous cell carcinoma and cutaneous squamous cell carcinoma, run by Rakuten Medical, Inc., active and no longer recruiting.","route":"/trials/nct04305795/","status":"active","kind":"trial","cancerIcon":"head-and-neck","sub":"NCT04305795","facets":{"kind":["Trial"],"cancers":["Head and neck squamous cell carcinoma","Cutaneous squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Cutaneous squamous cell carcinoma","href":"/cancers/cutaneous-scc/","tip":"Cutaneous squamous cell carcinoma is a sun-related skin cancer with over a million US cases a year, almost all cured by removing them. The 2 to 5% that grow deep or spread respond to PD-1 immunotherapy (cemiplimab, pembrolizumab), which is now also given after surgery in high-risk cases; transplant recipients cannot safely receive it."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07359066","name":"An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of SRP1020 in advanced solid tumours, run by Shanghai SciBrunch Therapeutics Co., Ltd., now recruiting.","route":"/trials/nct07359066/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07359066","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07589569","name":"An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer","tldr":"A phase 2 trial of HRS-7058 in pancreatic ductal adenocarcinoma, run by Shandong Suncadia Medicine Co., Ltd., now recruiting.","route":"/trials/nct07589569/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT07589569","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma","KRAS G12C-mutant pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."},{"label":"KRAS G12C-mutant pancreatic ductal adenocarcinoma","href":"/cancers/kras-g12c-pdac/","tip":"KRAS G12C pancreatic cancer is the small slice of pancreatic cancer whose KRAS mutation happens to be the one that the first KRAS drugs were built for. Sotorasib and adagrasib, approved for lung cancer, shrink a share of these tumours after chemotherapy and are listed as options, and newer inhibitors such as elironrasib, olomorasib and the pan-RAS drug daraxonrasib are being tested in this group."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02180724","name":"An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia","tldr":"A phase 2 trial of Acalabrutinib in waldenström macroglobulinaemia, run by Acerta Pharma BV, active and no longer recruiting.","route":"/trials/nct02180724/","status":"active","kind":"trial","cancerIcon":"waldenstrom","sub":"NCT02180724","facets":{"kind":["Trial"],"cancers":["Waldenström macroglobulinaemia"],"year":["2020"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Waldenström macroglobulinaemia","href":"/cancers/waldenstrom/","tip":"A slow lymphoma that makes an abnormal IgM antibody, causing thick blood, anaemia and nerve damage. Nearly all cases share one mutation (MYD88 L265P), and BTK inhibitors control it for years."}],"year":{"facet":"year","value":"2020"},"tags":[]},"sortKeys":{"year":2020}},{"id":"nct07371663","name":"An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors","tldr":"A phase 1/2 trial of TCC1727 tablet 90mg in non-small-cell lung cancer, gastric & gastro-oesophageal junction cancer, endometrial cancer and melanoma, run by Beijing Tide Pharmaceutical Co., Ltd, now recruiting.","route":"/trials/nct07371663/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07371663","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","Gastric & gastro-oesophageal junction cancer","Endometrial cancer","Melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."},{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00532194","name":"An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer","tldr":"A phase 3 trial of Cediranib in Ovarian cancer, run by Medical Research Council, with a status the registry has not verified recently.","route":"/trials/nct00532194/","kind":"trial","cancerIcon":"ovarian","sub":"NCT00532194","facets":{"kind":["Trial"],"cancers":["Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07336732","name":"Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations","tldr":"A phase 2 trial of PLB1004 in non-small-cell lung cancer, run by Avistone Biotechnology Co., Ltd., now recruiting.","route":"/trials/nct07336732/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07336732","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07444541","name":"ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer","tldr":"A phase 1/2 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by Anova Innovation Limited, now recruiting.","route":"/trials/nct07444541/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT07444541","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00003456","name":"Antineoplaston Therapy in Treating Patients With Newly-diagnosed Glioblastoma Multiforme","tldr":"A phase 2 trial of Antineoplastons in Glioma & glioblastoma, run by Burzynski Research Institute, completed.","route":"/trials/nct00003456/","status":"completed","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT00003456","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00003475","name":"Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors","tldr":"A phase 2 trial of Antineoplastons in Brain and spinal cord tumours, run by Burzynski Research Institute, completed.","route":"/trials/nct00003475/","status":"completed","kind":"trial","cancerIcon":"brain-tumours","sub":"NCT00003475","facets":{"kind":["Trial"],"cancers":["Brain and spinal cord tumours"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Brain and spinal cord tumours","href":"/cancers/brain-tumours/","tip":"Brain and spinal cord tumours range from slow-growing meningiomas and low-grade gliomas to glioblastoma, the commonest malignant brain tumour in adults, and a distinct set of childhood tumours such as medulloblastoma and diffuse midline glioma. Molecular markers now define them, and treatment is surgery, radiotherapy and, for some, drugs chosen by those markers."}],"tags":[]},"sortKeys":{"year":0}},{"id":"anvumetostat","name":"Anvumetostat","tldr":"Anvumetostat is an experimental small-molecule drug from Amgen in phase 2 trials for non-small-cell lung cancer, aimed at PRMT5 (MTAP-deleted cancers).","route":"/drugs/anvumetostat/","status":"phase-2","kind":"drug","molecule":"anvumetostat","modality":"small molecule","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05701306","name":"APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors","tldr":"A phase 1/2 trial of APG-115 in neuroblastoma, run by Ascentage Pharma Group Inc., now recruiting.","route":"/trials/nct05701306/","status":"recruiting","kind":"trial","cancerIcon":"neuroblastoma","sub":"NCT05701306","facets":{"kind":["Trial"],"cancers":["Neuroblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Neuroblastoma","href":"/cancers/neuroblastoma/","tip":"Neuroblastoma is a childhood nerve-cell cancer where anti-GD2 antibodies and, recently, GD2 CAR-T have improved survival in high-risk disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04785196","name":"APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors","tldr":"A phase 1/2 trial of Toripalimab in sarcomas, run by Ascentage Pharma Group Inc., now recruiting.","route":"/trials/nct04785196/","status":"recruiting","kind":"trial","cancerIcon":"sarcoma","sub":"NCT04785196","facets":{"kind":["Trial"],"cancers":["Sarcomas","Liposarcoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Sarcomas","href":"/cancers/sarcoma/","tip":"Sarcomas are dozens of rare cancers of bone and connective tissue. GIST was the first solid tumour cured-in-practice by a targeted pill; synovial sarcoma got the first TCR-T therapy."},{"label":"Liposarcoma","href":"/cancers/liposarcoma/","tip":"Liposarcoma is a cancer of fat cells that comes in four different forms: two driven by extra copies of the MDM2 gene, one by a fusion gene that makes it unusually sensitive to radiotherapy and trabectedin, and one that behaves like other aggressive sarcomas. Surgery is the mainstay and MDM2 inhibitors are the most promising drugs in trials."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01102426","name":"Aplidin - Dexamethasone in Relapsed/Refractory Myeloma","tldr":"A phase 3 trial of Plitidepsin and Dexamethasone in Multiple myeloma, run by PharmaMar, completed.","route":"/trials/nct01102426/","status":"completed","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT01102426","facets":{"kind":["Trial"],"cancers":["Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05701436","name":"Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial","tldr":"A phase 3 trial of Oxaliplatin, Doxorubicin, Cisplatin and Raltitrexed in Hepatocellular carcinoma, run by Zhujiang Hospital, with a status the registry has not verified recently.","route":"/trials/nct05701436/","kind":"trial","cancerIcon":"hcc","sub":"NCT05701436","facets":{"kind":["Trial"],"cancers":["Hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05766605","name":"Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial","tldr":"A phase 3 trial of Oxaliplatin, Doxorubicin, Cisplatin and Raltitrexed in Hepatocellular carcinoma, run by Zhujiang Hospital, with a status the registry has not verified recently.","route":"/trials/nct05766605/","kind":"trial","cancerIcon":"hcc","sub":"NCT05766605","facets":{"kind":["Trial"],"cancers":["Hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01360554","name":"ARCHER 1009: A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer","tldr":"A phase 3 trial of Dacomitinib and Erlotinib in Non-small-cell lung cancer, run by Pfizer, completed.","route":"/trials/nct01360554/","status":"completed","kind":"trial","cancerIcon":"nsclc","sub":"NCT01360554","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01774721","name":"ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC","tldr":"A phase 3 trial of Dacomitinib and Gefitinib in Non-small-cell lung cancer, run by Pfizer, completed.","route":"/trials/nct01774721/","status":"completed","kind":"trial","cancerIcon":"nsclc","sub":"NCT01774721","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ard103","name":"ARD103","tldr":"ARD103 is a car-t cell therapy from ARCE Therapeutics, Inc., in registered phase 2 trials for acute myeloid leukaemia, myelodysplastic syndromes / neoplasms.","route":"/drugs/ard103/","status":"phase-2","kind":"drug","molecule":"ard103","modality":"CAR-T cell therapy","sub":"ARD103","facets":{"kind":["Treatment"],"cancers":["Acute myeloid leukaemia","Myelodysplastic syndromes / neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Myelodysplastic syndromes / neoplasms","href":"/cancers/mds/","tip":"Bone-marrow disorders where blood cells are made badly and too few reach the blood; a third progress to acute leukaemia. Treatment ranges from transfusions and growth factors to hypomethylating drugs and, for the fit, transplant."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"arlocabtagene-autoleucel","name":"Arlocabtagene Autoleucel","tldr":"Arlocabtagene Autoleucel is an experimental CAR-T cell therapy from Juno Therapeutics, a Bristol-Myers Squibb in phase 3 trials for multiple myeloma, aimed at GPRC5D.","route":"/drugs/arlocabtagene-autoleucel/","status":"phase-3","kind":"drug","molecule":"arlocabtagene-autoleucel","modality":"CAR-T cell therapy","sub":"CC-95266, BMS-986393","facets":{"kind":["Treatment"],"cancers":["Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04098744","name":"Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)","tldr":"A phase 2 trial of Artesunate vaginal insert in vaginal cancer, run by Frantz Viral Therapeutics, LLC, now recruiting.","route":"/trials/nct04098744/","status":"recruiting","kind":"trial","cancerIcon":"vaginal","sub":"NCT04098744","facets":{"kind":["Trial"],"cancers":["Vaginal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Vaginal cancer","href":"/cancers/vaginal/","tip":"Primary vaginal cancer is rare and mostly caused by HPV, the virus behind cervical cancer. It is treated like cervical cancer, with weekly cisplatin alongside external and internal radiotherapy, which controls most tumours while preserving the organ; HPV vaccination and cervical screening, which also detects vaginal precursors, are steadily reducing it."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04829604","name":"ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)","tldr":"A phase 2 trial of ARX788 in HER2-positive breast cancer, run by Ambrx, Inc., active and no longer recruiting.","route":"/trials/nct04829604/","status":"active","kind":"trial","cancerIcon":"breast-her2-positive","sub":"NCT04829604","facets":{"kind":["Trial"],"cancers":["HER2-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."}],"tags":[]},"sortKeys":{"year":0}},{"id":"asc40","name":"ASC40","tldr":"ASC40 is an experimental small-molecule drug from Ascletis Pharmaceuticals in phase 3 trials for glioma & glioblastoma, with its target not yet stated publicly.","route":"/drugs/asc40/","status":"phase-3","kind":"drug","molecule":"asc40","modality":"small molecule","sub":"TVB-2640","facets":{"kind":["Treatment"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05384587","name":"Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia","tldr":"A phase 2 trial of Asciminib in chronic myeloid leukaemia, run by Novartis Pharmaceuticals, active and no longer recruiting.","route":"/trials/nct05384587/","status":"active","kind":"trial","cancerIcon":"cml","sub":"NCT05384587","facets":{"kind":["Trial"],"cancers":["Chronic myeloid leukaemia","Chronic myeloid leukaemia, chronic phase"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic myeloid leukaemia","href":"/cancers/cml/","tip":"Chronic myeloid leukaemia is a blood cancer driven by a single fused gene, BCR-ABL1, and the model for oncogene-targeted treatment: imatinib in 2001 and the tyrosine kinase inhibitors that followed turned it into a condition most people live with long-term. About half of patients with a sustained deep molecular response can now stop treatment altogether."},{"label":"Chronic myeloid leukaemia, chronic phase","href":"/cancers/cml-chronic-phase/","tip":"Chronic-phase chronic myeloid leukaemia is the disease that imatinib turned from fatal into manageable: a daily pill blocks the BCR::ABL1 protein that drives it. Blood tests track the leukaemia gene to a millionth, newer pills such as asciminib (ASC4FIRST) reach deeper responses faster, and patients with years of undetectable disease can try stopping."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04639986","name":"Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)","tldr":"A phase 3 trial of Sacituzumab govitecan, Eribulin, Capecitabine, Gemcitabine and Vinorelbine in advanced solid tumours, run by Gilead Sciences, active and no longer recruiting.","route":"/trials/nct04639986/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04639986","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07109531","name":"ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy","tldr":"A phase 3 trial of Limertinib, Carboplatin, Cisplatin and Pemetrexed in non-small-cell lung cancer, run by Jiangsu Aosaikang Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07109531/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07109531","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","EGFR-mutated non-small-cell lung cancer","MET exon 14 and MET-amplified non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."},{"label":"MET exon 14 and MET-amplified non-small-cell lung cancer","href":"/cancers/met-altered-nsclc/","tip":"MET-driven lung cancer comes in three forms: an exon 14 skipping mutation treated with the pills capmatinib or tepotinib, MET amplification that often arises as an escape route from EGFR drugs, and high c-Met protein levels that the antibody-drug conjugate telisotuzumab vedotin targets."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03769506","name":"ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy","tldr":"A phase 3 trial of ASP-1929 Photoimmunotherapy in head and neck squamous cell carcinoma, run by Rakuten Medical, Inc., active and no longer recruiting.","route":"/trials/nct03769506/","status":"active","kind":"trial","cancerIcon":"head-and-neck","sub":"NCT03769506","facets":{"kind":["Trial"],"cancers":["Head and neck squamous cell carcinoma","Recurrent or metastatic head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Recurrent or metastatic head and neck squamous cell carcinoma","href":"/cancers/recurrent-metastatic-hnscc/","tip":"When head and neck cancer comes back where it cannot be removed, or spreads elsewhere, it is treated to extend life rather than cure: pembrolizumab, alone or with chemotherapy, is the first choice, cetuximab-based regimens and cheap oral chemotherapy are alternatives, and antibodies that hit two targets at once are in late-stage trials."}],"tags":[]},"sortKeys":{"year":0}},{"id":"asp2138","name":"ASP2138","tldr":"ASP2138 is an experimental bispecific antibody from Astellas Pharma Global Development in phase 3 trials for gastric & gastro-oesophageal junction cancer, aimed at Claudin 18.2 and CD3.","route":"/drugs/asp2138/","status":"phase-3","kind":"drug","molecule":"asp2138","modality":"bispecific antibody","facets":{"kind":["Treatment"],"cancers":["Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07007559","name":"ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer","tldr":"A phase 2 trial of Evorpacept, Trastuzumab, Capecitabine, Eribulin, Gemcitabine and Vinorelbine in HER2-positive breast cancer, run by ALX Oncology Inc., now recruiting.","route":"/trials/nct07007559/","status":"recruiting","kind":"trial","cancerIcon":"breast-her2-positive","sub":"NCT07007559","facets":{"kind":["Trial"],"cancers":["HER2-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07455903","name":"Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT","tldr":"A phase 2 trial of Leuprolide, Degarelix, Relugolix, Triptorelin, Bicalutamide and Flotufolastat F-18 in Prostate cancer, run by Baptist Health South Florida, now recruiting.","route":"/trials/nct07455903/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT07455903","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07496229","name":"Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)","tldr":"A phase 1/2 trial of Golidocitinib in peripheral T-cell lymphomas, run by Dizal Pharmaceuticals, now recruiting.","route":"/trials/nct07496229/","status":"recruiting","kind":"trial","cancerIcon":"peripheral-t-cell-lymphoma","sub":"NCT07496229","facets":{"kind":["Trial"],"cancers":["Peripheral T-cell lymphomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Peripheral T-cell lymphomas","href":"/cancers/peripheral-t-cell-lymphoma/","tip":"Peripheral T-cell lymphomas are lymphomas of T cells rather than B cells. They are rarer, more varied and, apart from a few subtypes, harder to treat than B-cell lymphomas; several new drugs help only defined subtypes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04270591","name":"Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer","tldr":"A phase 1/2 trial of Glumetinib in non-small-cell lung cancer, run by Haihe Biopharma Co., Ltd., now recruiting.","route":"/trials/nct04270591/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT04270591","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","MET exon 14 and MET-amplified non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"MET exon 14 and MET-amplified non-small-cell lung cancer","href":"/cancers/met-altered-nsclc/","tip":"MET-driven lung cancer comes in three forms: an exon 14 skipping mutation treated with the pills capmatinib or tepotinib, MET amplification that often arises as an escape route from EGFR drugs, and high c-Met protein levels that the antibody-drug conjugate telisotuzumab vedotin targets."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06220318","name":"Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors","tldr":"A phase 1/2 trial of Sintilimab in advanced solid tumours, run by Fujian Haixi Pharmaceuticals Co., Ltd., active and no longer recruiting.","route":"/trials/nct06220318/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06220318","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"at101","name":"AT101","tldr":"AT101 is an experimental CAR-T cell therapy from AbClon in phase 2 trials for hodgkin lymphoma, aimed at CD19.","route":"/drugs/at101/","status":"phase-2","kind":"drug","molecule":"at101","modality":"CAR-T cell therapy","facets":{"kind":["Treatment"],"cancers":["Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Hodgkin lymphoma","href":"/cancers/hodgkin-lymphoma/","tip":"Hodgkin lymphoma is one of the most curable cancers, where the goal is now to cure with less toxicity, using brentuximab and, from 2026, first-line nivolumab."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07374419","name":"Atamparib in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of atamparib escalation levels in non-small-cell lung cancer, run by Nerviano Medical Sciences (Shanghai) Ltd., now recruiting.","route":"/trials/nct07374419/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07374419","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"atebimetinib","name":"Atebimetinib","tldr":"Atebimetinib is an experimental small-molecule drug from Immuneering in phase 3 trials for pancreatic ductal adenocarcinoma, aimed at MEK1/2.","route":"/drugs/atebimetinib/","status":"phase-3","kind":"drug","molecule":"atebimetinib","modality":"small molecule","facets":{"kind":["Treatment"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"atigotatug","name":"Atigotatug","tldr":"Atigotatug is an experimental monoclonal antibody from Bristol-Myers Squibb in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.","route":"/drugs/atigotatug/","status":"phase-3","kind":"drug","molecule":"atigotatug","modality":"monoclonal antibody","sub":"BMS-986489","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"au-007","name":"AU-007","tldr":"AU-007 is a monoclonal antibody from Aulos Bioscience, Inc., in registered phase 2 trials for metastatic cancer, melanoma, non-small-cell lung cancer.","route":"/drugs/au-007/","status":"phase-2","kind":"drug","molecule":"au-007","modality":"Monoclonal antibody","sub":"AU-007","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer","Melanoma","Non-small-cell lung cancer","Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."},{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct04807257","name":"Auger Molecular Therapy (AMT) for Malignant Cutaneous Lesions Treatment","tldr":"A phase 1/2 trial of Auger Molecular Therapy (AMT) in advanced solid tumours, run by NanoRay Biotech Co., Ltd., now recruiting.","route":"/trials/nct04807257/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04807257","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05261750","name":"Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer","tldr":"A phase 1/2 trial of Auto-DC (Autologous Dendritic Cell as Adjuvant Therapy) in nasopharyngeal carcinoma, run by PT. Prodia Stem Cell Indonesia, active and no longer recruiting.","route":"/trials/nct05261750/","status":"active","kind":"trial","cancerIcon":"nasopharyngeal","sub":"NCT05261750","facets":{"kind":["Trial"],"cancers":["Nasopharyngeal carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Nasopharyngeal carcinoma","href":"/cancers/nasopharyngeal/","tip":"A cancer at the back of the nose caused largely by the Epstein-Barr virus and common in southern China and Southeast Asia. Radiation cures most early cases; adding chemotherapy and, recently, PD-1 immunotherapy has improved outcomes in advanced disease, and a blood test for viral DNA can detect it early."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04614103","name":"Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer","tldr":"A phase 2 trial of LN-145 in non-small-cell lung cancer, run by Iovance Biotherapeutics, Inc., now recruiting.","route":"/trials/nct04614103/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT04614103","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06241781","name":"Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer","tldr":"A phase 2 trial of Gemcitabine in cervical cancer, run by Grit Biotechnology, now recruiting.","route":"/trials/nct06241781/","status":"recruiting","kind":"trial","cancerIcon":"cervical","sub":"NCT06241781","facets":{"kind":["Trial"],"cancers":["Cervical cancer","Recurrent or metastatic cervical cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."},{"label":"Recurrent or metastatic cervical cancer","href":"/cancers/recurrent-metastatic-cervical-cancer/","tip":"Recurrent or metastatic cervical cancer has spread beyond the pelvis or come back where it cannot be cured by surgery or radiotherapy. Pembrolizumab added to chemotherapy and bevacizumab is the first treatment, and the antibody-drug conjugate tisotumab vedotin or the PD-1 antibody cemiplimab extend life when it progresses."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03815643","name":"Avelumab Program Rollover Study","tldr":"A phase 3 trial of Avelumab in advanced solid tumours, run by EMD Serono Research & Development Institute, Inc., active and no longer recruiting.","route":"/trials/nct03815643/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT03815643","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07038343","name":"AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)","tldr":"A phase 1/2 trial of AVZO-1418 in biliary tract cancer, bladder & urothelial cancer and nasopharyngeal carcinoma, run by Avenzo Therapeutics, Inc., now recruiting.","route":"/trials/nct07038343/","status":"recruiting","kind":"trial","cancerIcon":"cholangiocarcinoma","sub":"NCT07038343","facets":{"kind":["Trial"],"cancers":["Biliary tract cancer","Bladder & urothelial cancer","Nasopharyngeal carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Nasopharyngeal carcinoma","href":"/cancers/nasopharyngeal/","tip":"A cancer at the back of the nose caused largely by the Epstein-Barr virus and common in southern China and Southeast Asia. Radiation cures most early cases; adding chemotherapy and, recently, PD-1 immunotherapy has improved outcomes in advanced disease, and a blood test for viral DNA can detect it early."}],"tags":[]},"sortKeys":{"year":0}},{"id":"avzo-021","name":"AVZO-021","tldr":"AVZO-021 is an experimental small-molecule drug from Avenzo Therapeutics in phase 2 trials for HR-positive / HER2-negative breast cancer, ovarian cancer and endometrial cancer, aimed at HER2.","route":"/drugs/avzo-021/","status":"phase-2","kind":"drug","molecule":"avzo-021","modality":"small molecule (structure undisclosed or not yet in PubChem)","facets":{"kind":["Treatment"],"cancers":["HR-positive / HER2-negative breast cancer","Ovarian cancer","Endometrial cancer","Triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."},{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."}],"tags":[]},"sortKeys":{"year":0}},{"id":"avzo-023","name":"AVZO-023","tldr":"AVZO-023 is a small-molecule inhibitor from Avenzo Therapeutics, Inc., in registered phase 2 trials for metastatic cancer.","route":"/drugs/avzo-023/","status":"phase-2","kind":"drug","molecule":"avzo-023","modality":"Small-molecule inhibitor","sub":"AVZO-023","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"azd0120","name":"AZD0120","tldr":"AZD0120 is a car-t cell therapy from AstraZeneca, in registered phase 3 trials for multiple myeloma.","route":"/drugs/azd0120/","status":"phase-3","kind":"drug","molecule":"azd0120","modality":"CAR-T cell therapy","sub":"AZD0120","facets":{"kind":["Treatment"],"cancers":["Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct05850234","name":"AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)","tldr":"A phase 1/2 trial of AZD0120 in multiple myeloma, run by AstraZeneca, now recruiting.","route":"/trials/nct05850234/","status":"recruiting","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT05850234","facets":{"kind":["Trial"],"cancers":["Multiple myeloma","Relapsed or refractory multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."},{"label":"Relapsed or refractory multiple myeloma","href":"/cancers/myeloma-relapsed-refractory/","tip":"Myeloma almost always returns, and each return is harder to treat. Two kinds of immune therapy aimed at the BCMA protein on myeloma cells, CAR-T cells (KarMMa-3, CARTITUDE-4) and off-the-shelf bispecific antibodies (MajesTEC), now give deep remissions after other drugs fail, and a second target, GPRC5D, gives another option."}],"tags":[]},"sortKeys":{"year":0}},{"id":"azd0486","name":"AZD0486","tldr":"AZD0486 is an experimental bispecific antibody from AstraZeneca in phase 3 trials for diffuse large B-cell lymphoma, aimed at CD19 and CD3.","route":"/drugs/azd0486/","status":"phase-3","kind":"drug","molecule":"azd0486","modality":"bispecific antibody","sub":"TNB-486","facets":{"kind":["Treatment"],"cancers":["Diffuse large B-cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06137118","name":"AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia","tldr":"A phase 1/2 trial of Surovatamig in acute lymphoblastic leukaemia, run by AstraZeneca, now recruiting.","route":"/trials/nct06137118/","status":"recruiting","kind":"trial","cancerIcon":"all-leukemia","sub":"NCT06137118","facets":{"kind":["Trial"],"cancers":["Acute lymphoblastic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."}],"tags":[]},"sortKeys":{"year":0}},{"id":"azd3470","name":"AZD3470","tldr":"AZD3470 is an experimental small-molecule drug from AstraZeneca in phase 2 trials for hodgkin lymphoma and peripheral T-cell lymphomas, aimed at PRMT5 (MTAP-deleted cancers).","route":"/drugs/azd3470/","status":"phase-2","kind":"drug","molecule":"azd3470","modality":"small molecule","facets":{"kind":["Treatment"],"cancers":["Hodgkin lymphoma","Peripheral T-cell lymphomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Hodgkin lymphoma","href":"/cancers/hodgkin-lymphoma/","tip":"Hodgkin lymphoma is one of the most curable cancers, where the goal is now to cure with less toxicity, using brentuximab and, from 2026, first-line nivolumab."},{"label":"Peripheral T-cell lymphomas","href":"/cancers/peripheral-t-cell-lymphoma/","tip":"Peripheral T-cell lymphomas are lymphomas of T cells rather than B cells. They are rarer, more varied and, apart from a few subtypes, harder to treat than B-cell lymphomas; several new drugs help only defined subtypes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"azd4045","name":"AZD4045","tldr":"AZD4045 is an experimental CAR-T cell therapy from AstraZeneca in phase 2 trials for multiple myeloma, aimed at BCMA.","route":"/drugs/azd4045/","status":"phase-2","kind":"drug","molecule":"azd4045","modality":"CAR-T cell therapy","facets":{"kind":["Treatment"],"cancers":["Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[]},"sortKeys":{"year":0}},{"id":"azd4360","name":"AZD4360","tldr":"AZD4360 is an experimental antibody-drug conjugate from AstraZeneca in phase 2 trials for gastric & gastro-oesophageal junction cancer, biliary tract cancer and pancreatic ductal adenocarcinoma, aimed at Claudin 18.2.","route":"/drugs/azd4360/","status":"phase-2","kind":"drug","molecule":"azd4360","modality":"ADC","facets":{"kind":["Treatment"],"cancers":["Gastric & gastro-oesophageal junction cancer","Biliary tract cancer","Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"azd4512","name":"AZD4512","tldr":"AZD4512 is an experimental antibody-drug conjugate from AstraZeneca in phase 2 trials for hodgkin lymphoma, aimed at CD22.","route":"/drugs/azd4512/","status":"phase-2","kind":"drug","molecule":"azd4512","modality":"ADC","facets":{"kind":["Treatment"],"cancers":["Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Hodgkin lymphoma","href":"/cancers/hodgkin-lymphoma/","tip":"Hodgkin lymphoma is one of the most curable cancers, where the goal is now to cure with less toxicity, using brentuximab and, from 2026, first-line nivolumab."}],"tags":[]},"sortKeys":{"year":0}},{"id":"azd5335","name":"AZD5335","tldr":"AZD5335 is an experimental antibody-drug conjugate from AstraZeneca in phase 3 trials for ovarian cancer, with its target not yet stated publicly.","route":"/drugs/azd5335/","status":"phase-3","kind":"drug","molecule":"azd5335","modality":"ADC","facets":{"kind":["Treatment"],"cancers":["Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"azd5492","name":"AZD5492","tldr":"AZD5492 is an experimental T-cell engager from AstraZeneca in phase 2 trials, aimed at CD20.","route":"/drugs/azd5492/","status":"phase-2","kind":"drug","molecule":"azd5492","modality":"T-cell engager","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"azd5863","name":"AZD5863","tldr":"AZD5863 is an experimental bispecific antibody from AstraZeneca in phase 2 trials for gastric & gastro-oesophageal junction cancer, pancreatic ductal adenocarcinoma and oesophageal cancer, aimed at Claudin 18.2 and CD3.","route":"/drugs/azd5863/","status":"phase-2","kind":"drug","molecule":"azd5863","modality":"bispecific antibody","facets":{"kind":["Treatment"],"cancers":["Gastric & gastro-oesophageal junction cancer","Pancreatic ductal adenocarcinoma","Oesophageal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."}],"tags":[]},"sortKeys":{"year":0}},{"id":"azd6621","name":"AZD6621","tldr":"AZD6621 is an experimental T-cell engager from AstraZeneca in phase 2 trials for prostate cancer, aimed at CD3.","route":"/drugs/azd6621/","status":"phase-2","kind":"drug","molecule":"azd6621","modality":"T-cell engager","facets":{"kind":["Treatment"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"azd7789","name":"AZD7789","tldr":"AZD7789 is an experimental bispecific antibody from AstraZeneca in phase 2 trials for non-small-cell lung cancer and gastric & gastro-oesophageal junction cancer, aimed at PD-1 and TIM-3.","route":"/drugs/azd7789/","status":"phase-2","kind":"drug","molecule":"azd7789","modality":"bispecific antibody","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"azd8421","name":"AZD8421","tldr":"AZD8421 is a small-molecule inhibitor from AstraZeneca, in registered phase 2 trials for ovarian cancer.","route":"/drugs/azd8421/","status":"phase-2","kind":"drug","molecule":"azd8421","modality":"Small-molecule inhibitor","sub":"AZD8421","facets":{"kind":["Treatment"],"cancers":["Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"azd9750","name":"AZD9750","tldr":"AZD9750 is an experimental protein degrader from AstraZeneca in phase 2 trials for prostate cancer, aimed at Androgen receptor.","route":"/drugs/azd9750/","status":"phase-2","kind":"drug","molecule":"azd9750","modality":"protein degrader","facets":{"kind":["Treatment"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"azd9793","name":"AZD9793","tldr":"AZD9793 is an experimental T-cell engager from AstraZeneca in phase 2 trials for hepatocellular carcinoma, aimed at Glypican-3.","route":"/drugs/azd9793/","status":"phase-2","kind":"drug","molecule":"azd9793","modality":"T-cell engager","facets":{"kind":["Treatment"],"cancers":["Hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05986851","name":"Azeliragon in MGMT Unmethylated Glioblastoma","tldr":"A phase 2 trial of Azeliragon in glioma & glioblastoma, run by Cantex Pharmaceuticals, active and no longer recruiting.","route":"/trials/nct05986851/","status":"active","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT05986851","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"azenosertib","name":"Azenosertib","tldr":"Azenosertib is an experimental small-molecule drug from K-, Beta in phase 3 trials for ovarian cancer, aimed at WEE1.","route":"/drugs/azenosertib/","status":"phase-3","kind":"drug","molecule":"azenosertib","modality":"small molecule","facets":{"kind":["Treatment"],"cancers":["Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ba3071","name":"BA3071","tldr":"BA3071 is an experimental monoclonal antibody from BioAtla in phase 2 trials for non-small-cell lung cancer and melanoma, aimed at CTLA-4.","route":"/drugs/ba3071/","status":"phase-2","kind":"drug","molecule":"ba3071","modality":"monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."}],"tags":[]},"sortKeys":{"year":0}},{"id":"balstilimab","name":"Balstilimab","tldr":"Balstilimab is a monoclonal antibody from Agenus Inc., in registered phase 2 trials for colorectal cancer.","route":"/drugs/balstilimab/","status":"phase-2","kind":"drug","molecule":"balstilimab","modality":"Monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct04579380","name":"Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations","tldr":"A phase 2 trial of Tucatinib, Trastuzumab and Fulvestrant in endometrial cancer, cervical cancer, biliary tract cancer and non-small-cell lung cancer, run by Seagen, a wholly owned subsidiary of Pfizer, active and no longer recruiting.","route":"/trials/nct04579380/","status":"active","kind":"trial","cancerIcon":"endometrial","sub":"NCT04579380","facets":{"kind":["Trial"],"cancers":["Endometrial cancer","Cervical cancer","Biliary tract cancer","Non-small-cell lung cancer","HER2-mutant non-small-cell lung cancer"],"year":["2024"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."},{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"year":{"facet":"year","value":"2024"},"tags":[]},"sortKeys":{"year":2024}},{"id":"nct07469774","name":"BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors","tldr":"A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by Biocity Biopharmaceutics Co., Ltd., now recruiting.","route":"/trials/nct07469774/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07469774","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"bcb-276","name":"BCB-276","tldr":"BCB-276 is an experimental CAR-T cell therapy from BrainChild Bio in phase 2 trials for glioma & glioblastoma, aimed at B7-H3.","route":"/drugs/bcb-276/","status":"phase-2","kind":"drug","molecule":"bcb-276","modality":"CAR-T cell therapy","facets":{"kind":["Treatment"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"bcd-100","name":"BCD-100","tldr":"BCD-100 is an experimental investigational agent whose form is not stated in the registry from Biocad in phase 3 trials for melanoma, with its target not yet stated publicly.","route":"/drugs/bcd-100/","status":"phase-3","kind":"drug","molecule":"bcd-100","modality":"monoclonal antibody (prolgolimab; INN stem -mab; form not stated in the registry record)","facets":{"kind":["Treatment"],"cancers":["Melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."}],"tags":[]},"sortKeys":{"year":0}},{"id":"bcd-217","name":"BCD-217","tldr":"BCD-217 is an experimental investigational agent whose form is not stated in the registry from Biocad in phase 3 trials for melanoma, aimed at PD-1 and CTLA-4.","route":"/drugs/bcd-217/","status":"phase-3","kind":"drug","molecule":"bcd-217","modality":"antibody combination (nurulimab and prolgolimab; INN stem -mab; form not stated in the registry record)","facets":{"kind":["Treatment"],"cancers":["Melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07108309","name":"BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer","tldr":"A phase 2 trial of BCD-236 in triple-negative breast cancer, run by Biocad, now recruiting.","route":"/trials/nct07108309/","status":"recruiting","kind":"trial","cancerIcon":"tnbc","sub":"NCT07108309","facets":{"kind":["Trial"],"cancers":["Triple-negative breast cancer","Metastatic triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Metastatic triple-negative breast cancer","href":"/cancers/tnbc-metastatic/","tip":"Triple-negative breast cancer that has spread is not curable, but its treatment has been transformed since 2020. By PD-L1 score, first treatment is pembrolizumab with chemotherapy or with sacituzumab govitecan, or datopotamab deruxtecan or sacituzumab govitecan alone; BRCA carriers can take a PARP inhibitor tablet; and trastuzumab deruxtecan reaches the third of tumours with low HER2."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05943106","name":"BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants","tldr":"A phase 3 trial of Durvalumab in bladder & urothelial cancer, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct05943106/","status":"active","kind":"trial","cancerIcon":"urothelial","sub":"NCT05943106","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Non-muscle-invasive bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Non-muscle-invasive bladder cancer","href":"/cancers/non-muscle-invasive-bladder-cancer/","tip":"Most bladder cancers are found while still confined to the lining. They are scraped out through the urethra and, when higher risk, treated with BCG instilled into the bladder; the challenge is the frequent recurrences and the patients whose tumours stop responding to BCG."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04271644","name":"BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease","tldr":"A phase 1/2 trial of BCMA CAR-T cells in multiple myeloma, run by Chongqing Precision Biotech Co., Ltd, now recruiting.","route":"/trials/nct04271644/","status":"recruiting","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT04271644","facets":{"kind":["Trial"],"cancers":["Multiple myeloma","Relapsed or refractory multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."},{"label":"Relapsed or refractory multiple myeloma","href":"/cancers/myeloma-relapsed-refractory/","tip":"Myeloma almost always returns, and each return is harder to treat. Two kinds of immune therapy aimed at the BCMA protein on myeloma cells, CAR-T cells (KarMMa-3, CARTITUDE-4) and off-the-shelf bispecific antibodies (MajesTEC), now give deep remissions after other drugs fail, and a second target, GPRC5D, gives another option."}],"tags":[]},"sortKeys":{"year":0}},{"id":"bdc-4182","name":"BDC-4182","tldr":"BDC-4182 is an experimental monoclonal antibody from Bolt Biotherapeutics in phase 2 trials for gastric & gastro-oesophageal junction cancer, aimed at Claudin 18.2.","route":"/drugs/bdc-4182/","status":"phase-2","kind":"drug","molecule":"bdc-4182","modality":"monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07193511","name":"BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)","tldr":"A phase 1/2 trial of AVZO-103 in bladder & urothelial cancer, run by Avenzo Therapeutics, Inc., now recruiting.","route":"/trials/nct07193511/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT07193511","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07486817","name":"Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab","tldr":"A phase 2 trial of Zongertinib, Cisplatin, Carboplatin, Pemetrexed and Pembrolizumab in non-small-cell lung cancer, run by Boehringer Ingelheim, now recruiting.","route":"/trials/nct07486817/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07486817","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06151574","name":"Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment","tldr":"A phase 3 trial of Zongertinib, Pembrolizumab, Cisplatin, Carboplatin and Pemetrexed in non-small-cell lung cancer, run by Boehringer Ingelheim, active and no longer recruiting.","route":"/trials/nct06151574/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT06151574","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","HER2-mutant non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"HER2-mutant non-small-cell lung cancer","href":"/cancers/her2-mutant-nsclc/","tip":"HER2-mutant lung cancer carries a mutation in the same receptor that drives HER2-positive breast cancer, but the breast cancer antibodies alone did little here. The antibody-drug conjugate trastuzumab deruxtecan shrinks about half of tumours after chemotherapy, and the pill zongertinib about seven in ten, and both are approved."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06581432","name":"Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations","tldr":"A phase 2 trial of Zongertinib in advanced solid tumours, run by Boehringer Ingelheim, now recruiting.","route":"/trials/nct06581432/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06581432","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"bebt-209","name":"BEBT-209","tldr":"BEBT-209 is an experimental small-molecule drug from BeBetter Med in phase 3 trials for triple-negative breast cancer and HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.","route":"/drugs/bebt-209/","status":"phase-3","kind":"drug","molecule":"bebt-209","modality":"small molecule (structure undisclosed or not yet in PubChem)","sub":"KCBI-0191","facets":{"kind":["Treatment"],"cancers":["Triple-negative breast cancer","HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"befotertinib","name":"Befotertinib","tldr":"Befotertinib is an oral kinase inhibitor from Betta Pharmaceuticals Co., Ltd., in registered phase 2 trials for non-small-cell lung cancer.","route":"/drugs/befotertinib/","status":"phase-2","kind":"drug","molecule":"befotertinib","modality":"Oral kinase inhibitor","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct07195591","name":"Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care","tldr":"A phase 3 trial of Temozolomide in glioma & glioblastoma, run by GT Medical Technologies, Inc., now recruiting.","route":"/trials/nct07195591/","status":"recruiting","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT07195591","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"bexmarilimab","name":"Bexmarilimab","tldr":"Bexmarilimab is a monoclonal antibody from Faron Pharmaceuticals Ltd, in registered phase 2 trials for acute myeloid leukaemia, chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, myelodysplastic syndromes / neoplasms.","route":"/drugs/bexmarilimab/","status":"phase-2","kind":"drug","molecule":"bexmarilimab","modality":"Monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Acute myeloid leukaemia","Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms","Myelodysplastic syndromes / neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms","href":"/cancers/cmml/","tip":"Chronic myelomonocytic leukaemia and its relatives are bone-marrow cancers that behave partly like myelodysplasia (poorly made blood cells) and partly like a proliferative disease (an excess of monocytes or platelets). Hypomethylating agents produce responses in a minority and stabilise counts in more, transplant can cure the fit, and RAS-pathway and JAK inhibitors are in trials."},{"label":"Myelodysplastic syndromes / neoplasms","href":"/cancers/mds/","tip":"Bone-marrow disorders where blood cells are made badly and too few reach the blood; a third progress to acute leukaemia. Treatment ranges from transfusions and growth factors to hypomethylating drugs and, for the fit, transplant."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"bexobrutideg","name":"Bexobrutideg","tldr":"Bexobrutideg is an experimental protein degrader from Nurix Therapeutics in phase 3 trials for chronic lymphocytic leukaemia, aimed at BTK (Bruton tyrosine kinase).","route":"/drugs/bexobrutideg/","status":"phase-3","kind":"drug","molecule":"bexobrutideg","modality":"protein degrader","sub":"NX-5948","facets":{"kind":["Treatment"],"cancers":["Chronic lymphocytic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."}],"tags":[]},"sortKeys":{"year":0}},{"id":"bezuclastinib","name":"Bezuclastinib","tldr":"Bezuclastinib is an experimental small-molecule drug from Cogent Biosciences in phase 3 trials for gastrointestinal stromal tumour, aimed at KIT and MET.","route":"/drugs/bezuclastinib/","status":"phase-3","kind":"drug","molecule":"bezuclastinib","modality":"small molecule","sub":"CGT9486","facets":{"kind":["Treatment"],"cancers":["Gastrointestinal stromal tumour","Indolent and smouldering systemic mastocytosis","Advanced systemic mastocytosis"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Gastrointestinal stromal tumour","href":"/cancers/gist/","tip":"GIST is a sarcoma of the gut wall driven almost always by a KIT or PDGFRA mutation. It was the proof that a pill can control a solid tumour: imatinib turned a median survival of about a year into one of eight years or more, and the mutation now dictates which drug to use."},{"label":"Indolent and smouldering systemic mastocytosis","href":"/cancers/indolent-systemic-mastocytosis/","tip":"Indolent systemic mastocytosis is the common, slow form of this rare blood disorder, in which KIT-mutant mast cells build up in the marrow and skin and release histamine that causes flushing, itching, stomach pain, bone thinning and sometimes severe allergic reactions. Life expectancy is near normal, antihistamines and adrenaline control symptoms, and low-dose avapritinib was approved in 2023."},{"label":"Advanced systemic mastocytosis","href":"/cancers/advanced-systemic-mastocytosis/","tip":"Advanced systemic mastocytosis is the dangerous form of this rare blood cancer, in which KIT-mutant mast cells damage the marrow, liver, gut or bones, grow alongside a second blood cancer such as chronic myelomonocytic leukaemia, or flood the blood as mast cell leukaemia. The KIT-blocking tablets midostaurin and avapritinib have replaced older chemotherapy, and fit patients may have a transplant."}],"tags":[]},"sortKeys":{"year":0}},{"id":"bgb-43395","name":"BGB-43395","tldr":"BGB-43395 is an experimental small-molecule drug from BeOne Medicines in phase 3 trials for HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.","route":"/drugs/bgb-43395/","status":"phase-3","kind":"drug","molecule":"bgb-43395","modality":"small molecule (structure undisclosed or not yet in PubChem)","facets":{"kind":["Treatment"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02706691","name":"BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer","tldr":"A phase 2 trial of Infigratinib in Head and neck squamous cell carcinoma, run by University of Chicago, recorded as terminated on the registry.","route":"/trials/nct02706691/","kind":"trial","cancerIcon":"head-and-neck","sub":"NCT02706691","facets":{"kind":["Trial"],"cancers":["Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00513539","name":"Biliary Stenting With or Without Photodynamic Therapy in Treating Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors That Cannot Be Removed by Surgery","tldr":"A phase 3 trial of Porfimer sodium in Biliary tract cancer and Gallbladder cancer, run by University College, London, completed.","route":"/trials/nct00513539/","status":"completed","kind":"trial","cancerIcon":"cholangiocarcinoma","sub":"NCT00513539","facets":{"kind":["Trial"],"cancers":["Biliary tract cancer","Gallbladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer is a biliary tract cancer of the bile-storing sac under the liver, most often found by chance when the gallbladder is removed for stones. Caught early, a second operation to clear the liver bed and nodes can cure it; for advanced disease, chemotherapy now comes with an immunotherapy partner, and HER2-directed antibodies help the subset whose tumours over-express HER2."}],"tags":[]},"sortKeys":{"year":0}},{"id":"bio-106","name":"BIO-106","tldr":"BIO-106 is an experimental antibody-drug conjugate from BiOneCure Therapeutics in phase 2 trials, aimed at TROP2.","route":"/drugs/bio-106/","status":"phase-2","kind":"drug","molecule":"bio-106","modality":"ADC","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03444844","name":"Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer","tldr":"A phase 1/2 trial of Ga-68 P16-093 PET/CT scan in prostate cancer, run by Five Eleven Pharma, Inc., active and no longer recruiting.","route":"/trials/nct03444844/","status":"active","kind":"trial","cancerIcon":"prostate","sub":"NCT03444844","facets":{"kind":["Trial"],"cancers":["Prostate cancer","Biochemical recurrence of prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Biochemical recurrence of prostate cancer","href":"/cancers/prostate-bcr/","tip":"Biochemical recurrence of prostate cancer is a rising PSA after surgery or radiotherapy with nothing yet visible on scans. Salvage radiotherapy can still cure it after surgery, and for a fast-doubling PSA the EMBARK trial showed that enzalutamide with or without hormone therapy delays spread."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06062810","name":"Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms","tldr":"A phase 2/3 trial of Raloxifene in advanced solid tumours, run by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, active and no longer recruiting.","route":"/trials/nct06062810/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06062810","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07523529","name":"Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors","tldr":"A phase 1/2 trial of Fludarabine and Cyclophosphamide in advanced solid tumours, run by Beijing Biotech, now recruiting.","route":"/trials/nct07523529/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07523529","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00002872","name":"Bleomycin, Doxycycline, or Talc in Treating Patients With Malignant Pleural Effusions","tldr":"A phase 3 trial of Bleomycin and Talc in Metastatic cancer, run by Eastern Cooperative Oncology Group, completed.","route":"/trials/nct00002872/","status":"completed","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT00002872","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"bleximenib","name":"Bleximenib","tldr":"Bleximenib is an experimental small-molecule drug from Janssen Research & Development in phase 3 trials for acute myeloid leukaemia, with its target not yet stated publicly.","route":"/drugs/bleximenib/","status":"phase-3","kind":"drug","molecule":"bleximenib","modality":"small molecule","sub":"JNJ-75276617","facets":{"kind":["Treatment"],"cancers":["Acute myeloid leukaemia","NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia","href":"/cancers/aml-npm1-kmt2a/","tip":"NPM1-mutated and KMT2A-rearranged leukaemias depend on a protein called menin to keep leukaemia genes switched on. Menin inhibitors, revumenib and ziftomenib, are the first drugs to exploit this, and they produce remissions in patients whose leukaemia had come back after everything else."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05630209","name":"Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)","tldr":"A phase 1/2 trial of Doxorubicin in brain and spinal cord tumours, run by InSightec, active and no longer recruiting.","route":"/trials/nct05630209/","status":"active","kind":"trial","cancerIcon":"brain-tumours","sub":"NCT05630209","facets":{"kind":["Trial"],"cancers":["Brain and spinal cord tumours","Glioma & glioblastoma","Diffuse midline glioma, H3 K27-altered"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Brain and spinal cord tumours","href":"/cancers/brain-tumours/","tip":"Brain and spinal cord tumours range from slow-growing meningiomas and low-grade gliomas to glioblastoma, the commonest malignant brain tumour in adults, and a distinct set of childhood tumours such as medulloblastoma and diffuse midline glioma. Molecular markers now define them, and treatment is surgery, radiotherapy and, for some, drugs chosen by those markers."},{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."},{"label":"Diffuse midline glioma, H3 K27-altered","href":"/cancers/dipg-dmg/","tip":"Diffuse midline glioma grows through the brainstem and cannot be removed surgically. A single change in a histone protein (H3 K27M) rewires how the tumour reads its DNA. Radiotherapy was long the only help; in 2025 the first drug aimed at this tumour, dordaviprone (ONC201), was approved after durable shrinkage in some patients, and GD2 CAR-T cells have produced striking early responses."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05615623","name":"Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG","tldr":"A phase 1/2 trial of Doxorubicin in brain and spinal cord tumours, run by InSightec, active and no longer recruiting.","route":"/trials/nct05615623/","status":"active","kind":"trial","cancerIcon":"brain-tumours","sub":"NCT05615623","facets":{"kind":["Trial"],"cancers":["Brain and spinal cord tumours","Glioma & glioblastoma","Diffuse midline glioma, H3 K27-altered"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Brain and spinal cord tumours","href":"/cancers/brain-tumours/","tip":"Brain and spinal cord tumours range from slow-growing meningiomas and low-grade gliomas to glioblastoma, the commonest malignant brain tumour in adults, and a distinct set of childhood tumours such as medulloblastoma and diffuse midline glioma. Molecular markers now define them, and treatment is surgery, radiotherapy and, for some, drugs chosen by those markers."},{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."},{"label":"Diffuse midline glioma, H3 K27-altered","href":"/cancers/dipg-dmg/","tip":"Diffuse midline glioma grows through the brainstem and cannot be removed surgically. A single change in a histone protein (H3 K27M) rewires how the tumour reads its DNA. Radiotherapy was long the only help; in 2025 the first drug aimed at this tumour, dordaviprone (ONC201), was approved after durable shrinkage in some patients, and GD2 CAR-T cells have produced striking early responses."}],"tags":[]},"sortKeys":{"year":0}},{"id":"bms-986365","name":"BMS-986365","tldr":"BMS-986365 is an experimental protein degrader from Celgene in phase 3 trials for prostate cancer, aimed at Androgen receptor.","route":"/drugs/bms-986365/","status":"phase-3","kind":"drug","molecule":"bms-986365","modality":"protein degrader","facets":{"kind":["Treatment"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"bnt113","name":"BNT113","tldr":"BNT113 is an experimental investigational agent whose form is not stated in the registry from BioNTech SE in phase 3 trials for head and neck squamous cell carcinoma, with its target not yet stated publicly.","route":"/drugs/bnt113/","status":"phase-3","kind":"drug","molecule":"bnt113","modality":"mRNA vaccine (per the sponsor's pipeline page; form not stated in the registry record)","facets":{"kind":["Treatment"],"cancers":["Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[]},"sortKeys":{"year":0}},{"id":"bnt324","name":"BNT324","tldr":"BNT324 is an experimental antibody-drug conjugate from BioNTech SE in phase 3 trials for prostate cancer and non-small-cell lung cancer, aimed at B7-H3.","route":"/drugs/bnt324/","status":"phase-3","kind":"drug","molecule":"bnt324","modality":"ADC","sub":"DB-1311","facets":{"kind":["Treatment"],"cancers":["Prostate cancer","Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"bomedemstat","name":"Bomedemstat","tldr":"Bomedemstat is an experimental small-molecule drug from Merck Sharp & Dohme in phase 3 trials for myeloproliferative neoplasms, with its target not yet stated publicly.","route":"/drugs/bomedemstat/","status":"phase-3","kind":"drug","molecule":"bomedemstat","modality":"small molecule","sub":"MK-3543, IMG-7289","facets":{"kind":["Treatment"],"cancers":["Myeloproliferative neoplasms","Polycythaemia vera","Essential thrombocythaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Myeloproliferative neoplasms","href":"/cancers/myeloproliferative-neoplasms/","tip":"Myeloproliferative neoplasms are slow-growing blood cancers in which the marrow overproduces red cells (polycythaemia vera), platelets (essential thrombocythaemia) or scar tissue (myelofibrosis). Almost all carry a mutation in JAK2, CALR or MPL; treatment aims to prevent clots and control symptoms, and only transplant cures myelofibrosis."},{"label":"Polycythaemia vera","href":"/cancers/polycythaemia-vera/","tip":"Polycythaemia vera is a slow blood cancer in which a single faulty gene, JAK2, makes the bone marrow produce too many red cells. Thick blood causes clots, so treatment thins it (blood removal, aspirin) and, for higher-risk patients, calms the marrow with hydroxyurea, interferon or ruxolitinib; a hepcidin mimic, rusfertide, now controls red cell counts without regular blood removal."},{"label":"Essential thrombocythaemia","href":"/cancers/essential-thrombocythaemia/","tip":"Essential thrombocythaemia is a slow blood cancer in which the marrow makes too many platelets. Most people need only aspirin and monitoring; those at higher risk of clots take a drug to lower the platelet count, usually hydroxyurea or interferon, with anagrelide in reserve."}],"tags":[]},"sortKeys":{"year":0}},{"id":"boserolimab","name":"Boserolimab","tldr":"Boserolimab is a monoclonal antibody from Merck Sharp & Dohme LLC, in registered phase 2 trials for non-small-cell lung cancer.","route":"/drugs/boserolimab/","status":"phase-2","kind":"drug","molecule":"boserolimab","modality":"Monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"botensilimab","name":"Botensilimab","tldr":"Botensilimab is an experimental monoclonal antibody from Agenus in phase 2 trials for colorectal cancer, aimed at CTLA-4.","route":"/drugs/botensilimab/","status":"phase-2","kind":"drug","molecule":"botensilimab","modality":"monoclonal antibody","sub":"AGEN1181","facets":{"kind":["Treatment"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06968221","name":"Bovine Reinforcement in Stomach, Colorectal and Lung Operation","tldr":"A phase 3 trial of Bioabsorbable Staple Line Reinforcemen in colorectal cancer, run by Shanghai Cingularbio Co. Ltd, now recruiting.","route":"/trials/nct06968221/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT06968221","facets":{"kind":["Trial"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05120271","name":"BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors","tldr":"A phase 1/2 trial of CAR-GPC3 T Cells in hepatocellular carcinoma, non-small-cell lung cancer, merkel cell carcinoma and sarcomas, run by Sotio Biotech Inc., active and no longer recruiting.","route":"/trials/nct05120271/","status":"active","kind":"trial","cancerIcon":"hcc","sub":"NCT05120271","facets":{"kind":["Trial"],"cancers":["Hepatocellular carcinoma","Non-small-cell lung cancer","Merkel cell carcinoma","Sarcomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Merkel cell carcinoma","href":"/cancers/merkel-cell-carcinoma/","tip":"Merkel cell carcinoma is a rare, fast-growing skin cancer, usually caused by a common virus (Merkel cell polyomavirus) or by sun damage. It was almost untreatable once it spread; PD-1/PD-L1 immunotherapy now gives lasting responses in about half of patients."},{"label":"Sarcomas","href":"/cancers/sarcoma/","tip":"Sarcomas are dozens of rare cancers of bone and connective tissue. GIST was the first solid tumour cured-in-practice by a targeted pill; synovial sarcoma got the first TCR-T therapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01106040","name":"Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes","tldr":"A phase 3 trial of Technetium-99m tilmanocept in Breast cancer and Melanoma, run by Navidea Biopharmaceuticals, completed.","route":"/trials/nct01106040/","status":"completed","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT01106040","facets":{"kind":["Trial"],"cancers":["Breast cancer","Melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."},{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05498311","name":"Breast Cancer With Intraoperative Radiotherapy Followed by Hypofractionated External Beam Radiotherapy","tldr":"A phase 2 trial of Intraoperative radiotherapy in Breast cancer, run by Institut Català d'Oncologia, with a status the registry has not verified recently.","route":"/trials/nct05498311/","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT05498311","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"budigalimab","name":"Budigalimab","tldr":"Budigalimab is an experimental investigational agent whose form is not stated in the registry from AbbVie in phase 3 trials for hepatocellular carcinoma, non-small-cell lung cancer and bladder & urothelial cancer, with its target not yet stated publicly.","route":"/drugs/budigalimab/","status":"phase-3","kind":"drug","molecule":"budigalimab","modality":"antibody (INN stem -mab; form not stated in the registry record)","sub":"ABBV-181","facets":{"kind":["Treatment"],"cancers":["Hepatocellular carcinoma","Non-small-cell lung cancer","Bladder & urothelial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05322590","name":"BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma","tldr":"A phase 1/2 trial of BXQ-350 in colorectal cancer, run by Bexion Pharmaceuticals, Inc., active and no longer recruiting.","route":"/trials/nct05322590/","status":"active","kind":"trial","cancerIcon":"colorectal","sub":"NCT05322590","facets":{"kind":["Trial"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03328078","name":"CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)","tldr":"A phase 1/2 trial of Ibrutinib in brain and spinal cord tumours, run by Curis, Inc., now recruiting.","route":"/trials/nct03328078/","status":"recruiting","kind":"trial","cancerIcon":"brain-tumours","sub":"NCT03328078","facets":{"kind":["Trial"],"cancers":["Brain and spinal cord tumours","Primary CNS lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Brain and spinal cord tumours","href":"/cancers/brain-tumours/","tip":"Brain and spinal cord tumours range from slow-growing meningiomas and low-grade gliomas to glioblastoma, the commonest malignant brain tumour in adults, and a distinct set of childhood tumours such as medulloblastoma and diffuse midline glioma. Molecular markers now define them, and treatment is surgery, radiotherapy and, for some, drugs chosen by those markers."},{"label":"Primary CNS lymphoma","href":"/cancers/primary-cns-lymphoma/","tip":"Primary CNS lymphoma is a lymphoma confined to the brain, eyes and spinal fluid. Unlike most brain tumours it is chemo-sensitive: high-dose methotrexate-based treatment cures a substantial minority, and consolidation with a stem-cell transplant has replaced whole-brain radiation for the fit."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03271918","name":"Cabergoline in Nonfunctioning Pituitary Adenomas","tldr":"A phase 3 trial of Cabergoline in Pituitary tumours, run by University of Sao Paulo General Hospital, completed.","route":"/trials/nct03271918/","status":"completed","kind":"trial","cancerIcon":"pituitary-tumours","sub":"NCT03271918","facets":{"kind":["Trial"],"cancers":["Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma","href":"/cancers/pituitary-tumours/","tip":"Pituitary tumours are usually benign growths of the hormone gland at the base of the brain that cause trouble by overproducing hormones or pressing on the optic nerves. Prolactin-producing tumours melt away with a tablet, most others are cured by surgery through the nose, and the rare aggressive ones respond to the chemotherapy drug temozolomide."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00998738","name":"Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer","tldr":"A phase 3 trial of Ixabepilone in Breast cancer, run by Mayo Clinic, recorded as terminated on the registry.","route":"/trials/nct00998738/","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT00998738","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"calderasib","name":"Calderasib","tldr":"Calderasib is an experimental small-molecule drug from Merck Sharp & Dohme in phase 3 trials for non-small-cell lung cancer and colorectal cancer, aimed at KRAS.","route":"/drugs/calderasib/","status":"phase-3","kind":"drug","molecule":"calderasib","modality":"small molecule","sub":"MK-1084","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"cam2029","name":"CAM2029 (octreotide subcutaneous depot)","tldr":"CAM2029 is Camurus's monthly octreotide depot that patients can inject themselves, positive in the phase 3 SORENTO trial for gastroenteropancreatic neuroendocrine tumours against the standard depot formulations.","route":"/drugs/cam2029/","status":"phase-3","kind":"drug","molecule":"cam2029","modality":"Peptide somatostatin analogue (octreotide) in a long-acting subcutaneous depot","facets":{"kind":["Treatment"],"cancers":["Neuroendocrine tumours"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Neuroendocrine tumours","href":"/cancers/neuroendocrine/","tip":"A family of usually slow-growing tumours that start in hormone-producing cells of the gut, pancreas and lungs. They pioneered the idea of using the same molecule to see a tumour on a scan and then to treat it with radiation."}],"tags":[]},"sortKeys":{"year":0}},{"id":"camonsertib","name":"Camonsertib","tldr":"Camonsertib is an oral serine/threonine kinase inhibitor from Hoffmann-La Roche, in registered phase 2 trials for metastatic cancer.","route":"/drugs/camonsertib/","status":"phase-2","kind":"drug","molecule":"camonsertib","modality":"Oral serine/threonine kinase inhibitor","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct05440786","name":"CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma","tldr":"A phase 2 trial of Abemaciclib and Temozolomide in ewing sarcoma, run by Eli Lilly and Company, active and no longer recruiting.","route":"/trials/nct05440786/","status":"active","kind":"trial","cancerIcon":"ewing-sarcoma","sub":"NCT05440786","facets":{"kind":["Trial"],"cancers":["Ewing sarcoma"],"year":["2026"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ewing sarcoma","href":"/cancers/ewing-sarcoma/","tip":"Ewing sarcoma is a bone and soft-tissue cancer of teenagers driven by a single fusion gene, EWSR1-FLI1. Intensive chemotherapy with surgery or radiation cures most localised cases; disease that has spread at diagnosis, and relapse, remain hard to treat, and no drug against the fusion protein itself has yet succeeded."}],"year":{"facet":"year","value":"2026"},"tags":[]},"sortKeys":{"year":2026}},{"id":"nct04906993","name":"Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer","tldr":"A phase 3 trial of Camrelizumab in cervical cancer, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.","route":"/trials/nct04906993/","status":"active","kind":"trial","cancerIcon":"cervical","sub":"NCT04906993","facets":{"kind":["Trial"],"cancers":["Cervical cancer","Recurrent or metastatic cervical cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."},{"label":"Recurrent or metastatic cervical cancer","href":"/cancers/recurrent-metastatic-cervical-cancer/","tip":"Recurrent or metastatic cervical cancer has spread beyond the pelvis or come back where it cannot be cured by surgery or radiotherapy. Pembrolizumab added to chemotherapy and bevacizumab is the first treatment, and the antibody-drug conjugate tisotumab vedotin or the PD-1 antibody cemiplimab extend life when it progresses."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03949283","name":"Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer","tldr":"A phase 3 trial of Standard Chemotherapy in ovarian cancer, run by Cordgenics, LLC, active and no longer recruiting.","route":"/trials/nct03949283/","status":"active","kind":"trial","cancerIcon":"ovarian","sub":"NCT03949283","facets":{"kind":["Trial"],"cancers":["Ovarian cancer","Platinum-resistant ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Platinum-resistant ovarian cancer","href":"/cancers/platinum-resistant-ovarian-cancer/","tip":"Platinum-resistant ovarian cancer grows back within six months of platinum chemotherapy, or during it, and used to be treated with single chemotherapy drugs that shrink a tumour one time in ten. The antibody-drug conjugate mirvetuximab soravtansine, the cortisol-blocking drug relacorilant and pembrolizumab in PD-L1-positive tumours have each extended survival in phase 3 trials since 2023."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00602082","name":"Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors","tldr":"A phase 2 trial of Capecitabine, Cisplatin and Streptozocin in Pancreatic neuroendocrine tumours, run by Cambridge University Hospitals NHS Foundation Trust, completed.","route":"/trials/nct00602082/","status":"completed","kind":"trial","cancerIcon":"pancreatic-net","sub":"NCT00602082","facets":{"kind":["Trial"],"cancers":["Pancreatic neuroendocrine tumours"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic neuroendocrine tumours","href":"/cancers/pancreatic-net/","tip":"Pancreatic neuroendocrine tumours arise from the hormone-producing islet cells of the pancreas and behave very differently from ordinary pancreatic cancer, often growing for years. Surgery cures localised tumours; advanced disease is treated in sequence with somatostatin analogues, lutetium-177 dotatate, targeted tablets and oral chemotherapy, and a minority secrete insulin or gastrin."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04862663","name":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)","tldr":"A phase 3 trial of Capivasertib, Fulvestrant, Palbociclib, Ribociclib and Abemaciclib in advanced solid tumours, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct04862663/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04862663","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06635447","name":"Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients","tldr":"A phase 3 trial of Capivasertib and Fulvestrant in advanced solid tumours, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct06635447/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06635447","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03997123","name":"Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC","tldr":"A phase 3 trial of Capivasertib in triple-negative breast cancer, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct03997123/","status":"active","kind":"trial","cancerIcon":"tnbc","sub":"NCT03997123","facets":{"kind":["Trial"],"cancers":["Triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06179524","name":"CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL","tldr":"A phase 2 trial of CAR-T-19 cell injection in acute lymphoblastic leukaemia, run by Beijing Yongtai Ruike Biotechnology Company Ltd, now recruiting.","route":"/trials/nct06179524/","status":"recruiting","kind":"trial","cancerIcon":"all-leukemia","sub":"NCT06179524","facets":{"kind":["Trial"],"cancers":["Acute lymphoblastic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07087054","name":"Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen","tldr":"A phase 3 trial of Paltusotine in neuroendocrine tumours and pancreatic ductal adenocarcinoma, run by Crinetics Pharmaceuticals Inc., now recruiting.","route":"/trials/nct07087054/","status":"recruiting","kind":"trial","cancerIcon":"neuroendocrine","sub":"NCT07087054","facets":{"kind":["Trial"],"cancers":["Neuroendocrine tumours","Pancreatic ductal adenocarcinoma","Small intestinal neuroendocrine tumours"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Neuroendocrine tumours","href":"/cancers/neuroendocrine/","tip":"A family of usually slow-growing tumours that start in hormone-producing cells of the gut, pancreas and lungs. They pioneered the idea of using the same molecule to see a tumour on a scan and then to treat it with radiation."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Small intestinal neuroendocrine tumours","href":"/cancers/small-intestinal-net/","tip":"Small intestinal neuroendocrine tumours are slow-growing hormone-producing tumours of the ileum and jejunum, often found only after they have spread to lymph nodes and the liver. Monthly somatostatin analogue injections control symptoms and growth, lutetium-177 dotatate is the main second treatment, and everolimus, cabozantinib and surgery fill in."}],"tags":[]},"sortKeys":{"year":0}},{"id":"cart84","name":"CART84","tldr":"CART84 is an experimental CAR-T cell therapy from Gyala Therapeutics in phase 2 trials for acute myeloid leukaemia, aimed at CD3.","route":"/drugs/cart84/","status":"phase-2","kind":"drug","molecule":"cart84","modality":"CAR-T cell therapy","facets":{"kind":["Treatment"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[]},"sortKeys":{"year":0}},{"id":"cd19-t-hank","name":"CD19 t-haNK","tldr":"CD19 t-haNK is an experimental cell therapy whose type is not stated from ImmunityBio in phase 2 trials for hodgkin lymphoma, aimed at CD19.","route":"/drugs/cd19-t-hank/","status":"phase-2","kind":"drug","molecule":"cd19-t-hank","modality":"cell therapy (type not stated)","facets":{"kind":["Treatment"],"cancers":["Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Hodgkin lymphoma","href":"/cancers/hodgkin-lymphoma/","tip":"Hodgkin lymphoma is one of the most curable cancers, where the goal is now to cure with less toxicity, using brentuximab and, from 2026, first-line nivolumab."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04718883","name":"CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma","tldr":"A phase 2 trial of CD19-targeted Chimeric Antigen Receptor (CAR) T Cells in mantle cell lymphoma, run by Shanghai Ming Ju Biotechnology Co., Ltd., active and no longer recruiting.","route":"/trials/nct04718883/","status":"active","kind":"trial","cancerIcon":"mantle-cell-lymphoma","sub":"NCT04718883","facets":{"kind":["Trial"],"cancers":["Mantle cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Mantle cell lymphoma","href":"/cancers/mantle-cell-lymphoma/","tip":"An uncommon B-cell lymphoma driven by cyclin D1 that used to behave badly in almost everyone. BTK inhibitors, CAR-T and now BCL2 drugs have changed it from chemotherapy-plus-transplant to targeted combinations."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06538857","name":"CEB-01 in Locally Resectable Pancreatic Cancer","tldr":"A phase 2 trial of Standard surgery in pancreatic ductal adenocarcinoma, run by CEBIOTEX, now recruiting.","route":"/trials/nct06538857/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT06538857","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06986811","name":"CEB-01 in Paediatrics With Locally Resectable Abdominal Tumours","tldr":"A phase 2 trial of Standard surgery in childhood cancers, run by CEBIOTEX, now recruiting.","route":"/trials/nct06986811/","status":"recruiting","kind":"trial","cancerIcon":"childhood-cancers","sub":"NCT06986811","facets":{"kind":["Trial"],"cancers":["Childhood cancers"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Childhood cancers","href":"/cancers/childhood-cancers/","tip":"Cancer in children is rare and different from adult cancer: the common types are leukaemias, brain tumours, lymphomas and embryonal tumours such as neuroblastoma and Wilms tumour, most are curable in well-resourced health systems, and the great challenge is bringing the same cures to the majority of children who live where they are not available."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00399035","name":"Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer","tldr":"A phase 3 trial of Cediranib, FOLFOX, Leucovorin, Oxaliplatin, Fluorouracil and CAPOX in Colorectal cancer, run by AstraZeneca, completed.","route":"/trials/nct00399035/","status":"completed","kind":"trial","cancerIcon":"colorectal","sub":"NCT00399035","facets":{"kind":["Trial"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00777153","name":"Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma","tldr":"A phase 3 trial of Cediranib in Glioma & glioblastoma, run by AstraZeneca, completed.","route":"/trials/nct00777153/","status":"completed","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT00777153","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ceralasertib","name":"Ceralasertib","tldr":"Ceralasertib is an experimental small-molecule drug from AstraZeneca in phase 3 trials for non-small-cell lung cancer, melanoma and triple-negative breast cancer, aimed at ATR.","route":"/drugs/ceralasertib/","status":"phase-3","kind":"drug","molecule":"ceralasertib","modality":"small molecule","sub":"AZD6738","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Melanoma","Triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."}],"tags":[]},"sortKeys":{"year":0}},{"id":"cetrelimab","name":"Cetrelimab","tldr":"Cetrelimab is an experimental investigational agent whose form is not stated in the registry from Janssen Research & Development in phase 3 trials for bladder & urothelial cancer, prostate cancer and non-small-cell lung cancer, with its target not yet stated publicly.","route":"/drugs/cetrelimab/","status":"phase-3","kind":"drug","molecule":"cetrelimab","modality":"antibody (INN stem -mab; form not stated in the registry record)","sub":"JNJ-63723283","facets":{"kind":["Treatment"],"cancers":["Bladder & urothelial cancer","Prostate cancer","Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"cevostamab","name":"Cevostamab","tldr":"Cevostamab is an experimental investigational agent whose form is not stated in the registry from Hoffmann-La Roche in phase 3 trials for multiple myeloma, with its target not yet stated publicly.","route":"/drugs/cevostamab/","status":"phase-3","kind":"drug","molecule":"cevostamab","modality":"antibody (INN stem -mab; form not stated in the registry record)","facets":{"kind":["Treatment"],"cancers":["Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05251714","name":"CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer","tldr":"A phase 1/2 trial of Fulvestrant in advanced solid tumours, run by Treadwell Therapeutics, Inc, active and no longer recruiting.","route":"/trials/nct05251714/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05251714","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"cgt4859","name":"CGT4859","tldr":"CGT4859 is an experimental small-molecule drug from Cogent Biosciences in phase 2 trials for biliary tract cancer, aimed at FGFR2.","route":"/drugs/cgt4859/","status":"phase-2","kind":"drug","molecule":"cgt4859","modality":"small molecule (structure undisclosed or not yet in PubChem)","facets":{"kind":["Treatment"],"cancers":["Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07125391","name":"Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer","tldr":"A phase 2 trial of Propranolol, Paclitaxel / nab-paclitaxel and Carboplatin in Ovarian cancer, run by Bai-Rong Xia, now recruiting.","route":"/trials/nct07125391/","status":"recruiting","kind":"trial","cancerIcon":"ovarian","sub":"NCT07125391","facets":{"kind":["Trial"],"cancers":["Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00024167","name":"Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer","tldr":"A phase 3 trial of Docetaxel, Doxorubicin, Estramustine, Prednisone, Vinblastine and Dexamethasone in Prostate cancer, run by M.D. Anderson Cancer Center, recorded as terminated on the registry.","route":"/trials/nct00024167/","kind":"trial","cancerIcon":"prostate","sub":"NCT00024167","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01275677","name":"Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer","tldr":"A phase 3 trial of Cyclophosphamide, Docetaxel, Doxorubicin, Paclitaxel / nab-paclitaxel, Trastuzumab and Trastuzumab biosimilars in Breast cancer, run by National Cancer Institute (NCI), completed.","route":"/trials/nct01275677/","status":"completed","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT01275677","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"chiauranib","name":"Chiauranib","tldr":"Chiauranib is an experimental small-molecule drug from Chipscreen Biosciences in phase 3 trials for ovarian cancer, aimed at VEGF / VEGFR and KIT.","route":"/drugs/chiauranib/","status":"phase-3","kind":"drug","molecule":"chiauranib","modality":"small molecule","sub":"CS2164","facets":{"kind":["Treatment"],"cancers":["Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05833724","name":"Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)","tldr":"A phase 2 trial of Tucidinostat (chidamide) in peripheral T-cell lymphomas, run by Great Novel Therapeutics Biotech & Medicals Corporation, now recruiting.","route":"/trials/nct05833724/","status":"recruiting","kind":"trial","cancerIcon":"peripheral-t-cell-lymphoma","sub":"NCT05833724","facets":{"kind":["Trial"],"cancers":["Peripheral T-cell lymphomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Peripheral T-cell lymphomas","href":"/cancers/peripheral-t-cell-lymphoma/","tip":"Peripheral T-cell lymphomas are lymphomas of T cells rather than B cells. They are rarer, more varied and, apart from a few subtypes, harder to treat than B-cell lymphomas; several new drugs help only defined subtypes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01054079","name":"Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer","tldr":"A phase 2 trial of Cinacalcet in Prostate cancer, run by Wake Forest University Health Sciences, completed.","route":"/trials/nct01054079/","status":"completed","kind":"trial","cancerIcon":"prostate","sub":"NCT01054079","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"cinrebafusp-alfa","name":"Cinrebafusp alfa","tldr":"Cinrebafusp alfa is an experimental fusion protein from Pieris Pharmaceuticals in phase 2 trials for gastric & gastro-oesophageal junction cancer, aimed at HER2.","route":"/drugs/cinrebafusp-alfa/","status":"phase-2","kind":"drug","molecule":"cinrebafusp-alfa","modality":"fusion protein","sub":"PRS-343","facets":{"kind":["Treatment"],"cancers":["Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05190445","name":"Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma","tldr":"A phase 2 trial of Cinrebafusp alfa, Ramucirumab and Tucatinib in gastric & gastro-oesophageal junction cancer, run by Pieris Pharmaceuticals, Inc., active and no longer recruiting.","route":"/trials/nct05190445/","status":"active","kind":"trial","cancerIcon":"gastric","sub":"NCT05190445","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06896890","name":"Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer","tldr":"A phase 1/2 trial of CIS-DPI in non-small-cell lung cancer, run by Inhatarget Therapeutics, now recruiting.","route":"/trials/nct06896890/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06896890","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00652132","name":"Cisplatin With or Without Sodium Thiosulfate in Treating Young Patients With Stage I, II, or III Childhood Liver Cancer","tldr":"A phase 3 trial of Cisplatin and Sodium thiosulfate in Hepatocellular carcinoma, run by University of Birmingham, completed.","route":"/trials/nct00652132/","status":"completed","kind":"trial","cancerIcon":"hcc","sub":"NCT00652132","facets":{"kind":["Trial"],"cancers":["Hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04404595","name":"Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers","tldr":"A phase 1/2 trial of CT041 in gastric & gastro-oesophageal junction cancer and pancreatic ductal adenocarcinoma, run by CARsgen Therapeutics Co., Ltd., active and no longer recruiting.","route":"/trials/nct04404595/","status":"active","kind":"trial","cancerIcon":"gastric","sub":"NCT04404595","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer","Pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma","Claudin 18.2-positive gastric cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."},{"label":"Claudin 18.2-positive gastric cancer","href":"/cancers/gastric-cldn18-2-positive/","tip":"Claudin 18.2 is a tight-junction protein normally hidden inside stomach lining cells that becomes exposed on the surface of many stomach cancers. Zolbetuximab, an antibody against it, added to chemotherapy lengthens survival in tumours that express it strongly, and antibody-drug conjugates and CAR-T cells against the same target are in trials."}],"tags":[]},"sortKeys":{"year":0}},{"id":"clifutinib","name":"Clifutinib","tldr":"Clifutinib is an experimental small-molecule drug from Sunshine Lake Pharma in phase 3 trials for acute myeloid leukaemia, with its target not yet stated publicly.","route":"/drugs/clifutinib/","status":"phase-3","kind":"drug","molecule":"clifutinib","modality":"small molecule","sub":"HEC73543","facets":{"kind":["Treatment"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00822393","name":"Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)","tldr":"A phase 3 trial of Busulfan and Treosulfan in Acute myeloid leukaemia, run by medac GmbH, completed.","route":"/trials/nct00822393/","status":"completed","kind":"trial","cancerIcon":"aml","sub":"NCT00822393","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06825494","name":"Clinical Studies for the Treatment of Advanced Solid Tumors","tldr":"A phase 1/2 trial of Capecitabine, Oxaliplatin, Penpulimab and Tislelizumab in advanced solid tumours, run by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct06825494/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06825494","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07512583","name":"Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors","tldr":"A phase 1/2 trial of TQB2102 and TQB2930 in advanced solid tumours, run by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07512583/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07512583","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06821503","name":"Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C","tldr":"A phase 1/2 trial of Penpulimab and Gemcitabine in pancreatic ductal adenocarcinoma, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting.","route":"/trials/nct06821503/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT06821503","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07522151","name":"Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer","tldr":"A phase 3 trial of Adebrelimab and Oxaliplatin in gastric & gastro-oesophageal junction cancer, run by Shanghai Shengdi Pharmaceutical Co., Ltd, now recruiting.","route":"/trials/nct07522151/","status":"recruiting","kind":"trial","cancerIcon":"gastric","sub":"NCT07522151","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06680752","name":"Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS","tldr":"A phase 1/2 trial of Cyclophosphamide and Fludarabine in acute myeloid leukaemia and myelodysplastic syndromes / neoplasms, run by ARCE Therapeutics, Inc., now recruiting.","route":"/trials/nct06680752/","status":"recruiting","kind":"trial","cancerIcon":"aml","sub":"NCT06680752","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia","Myelodysplastic syndromes / neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Myelodysplastic syndromes / neoplasms","href":"/cancers/mds/","tip":"Bone-marrow disorders where blood cells are made badly and too few reach the blood; a third progress to acute leukaemia. Treatment ranges from transfusions and growth factors to hypomethylating drugs and, for the fit, transplant."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06167694","name":"Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer","tldr":"A phase 1/2 trial of Dalpiciclib and HRS-8080 in advanced solid tumours, run by Shandong Suncadia Medicine Co., Ltd., now recruiting.","route":"/trials/nct06167694/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06167694","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04668690","name":"Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL","tldr":"A phase 3 trial of Mitoxantrone and Tucidinostat (chidamide) in peripheral T-cell lymphomas, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., active and no longer recruiting.","route":"/trials/nct04668690/","status":"active","kind":"trial","cancerIcon":"peripheral-t-cell-lymphoma","sub":"NCT04668690","facets":{"kind":["Trial"],"cancers":["Peripheral T-cell lymphomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Peripheral T-cell lymphomas","href":"/cancers/peripheral-t-cell-lymphoma/","tip":"Peripheral T-cell lymphomas are lymphomas of T cells rather than B cells. They are rarer, more varied and, apart from a few subtypes, harder to treat than B-cell lymphomas; several new drugs help only defined subtypes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05802225","name":"Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer","tldr":"A phase 3 trial of Pertuzumab in HER2-positive breast cancer, run by Biocad, active and no longer recruiting.","route":"/trials/nct05802225/","status":"active","kind":"trial","cancerIcon":"breast-her2-positive","sub":"NCT05802225","facets":{"kind":["Trial"],"cancers":["HER2-positive breast cancer","Early HER2-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."},{"label":"Early HER2-positive breast cancer","href":"/cancers/her2-positive-early-breast-cancer/","tip":"HER2-positive breast cancer caught early is usually cured. Chemotherapy with the antibodies trastuzumab and pertuzumab comes before surgery; if the tumour has gone by then, antibodies alone finish the year, and if cancer remains, trastuzumab emtansine or trastuzumab deruxtecan take over. Small tumours get a gentler regimen, and trials now ask how much treatment can be left out."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02628665","name":"Clinical Study of Time Optimizing of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer","tldr":"A phase 3 trial of Porfimer sodium in Oesophageal and junctional adenocarcinoma and Oesophageal squamous cell carcinoma, run by The First Affiliated Hospital of Henan University of Science and Technology, with a status the registry has not verified recently.","route":"/trials/nct02628665/","kind":"trial","cancerIcon":"oesophageal-adenocarcinoma","sub":"NCT02628665","facets":{"kind":["Trial"],"cancers":["Oesophageal and junctional adenocarcinoma","Oesophageal squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Oesophageal and junctional adenocarcinoma","href":"/cancers/oesophageal-adenocarcinoma/","tip":"Adenocarcinoma of the lower oesophagus and junction grows out of Barrett's oesophagus, the change in the lining caused by long-standing acid reflux. Chemotherapy or chemoradiation before surgery is standard, and HER2, PD-L1 and claudin 18.2 now guide drugs for advanced disease as they do in stomach cancer."},{"label":"Oesophageal squamous cell carcinoma","href":"/cancers/oesophageal-squamous-cell-carcinoma/","tip":"Squamous cell carcinoma of the oesophagus, the world's commonest form, is linked to smoking, alcohol and very hot drinks and sits in the upper and middle gullet. It is treated with chemoradiation, with or without surgery, and immunotherapy has recently joined chemotherapy for advanced disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06767813","name":"Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms","tldr":"A phase 2 trial of Gemcitabine and Anlotinib in pancreatic ductal adenocarcinoma, run by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct06767813/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT06767813","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05653453","name":"Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer","tldr":"A phase 3 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by Jiangsu Healthy Life Innovation Medical Technology Co., Ltd, now recruiting.","route":"/trials/nct05653453/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT05653453","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Locally advanced unresectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05768529","name":"Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","tldr":"A phase 1/2 trial of U16 in non-Hodgkin lymphoma, run by Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, now recruiting.","route":"/trials/nct05768529/","status":"recruiting","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT05768529","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07036250","name":"Clinical Study of U32 in Patients With Acute Myeloid Leukemia","tldr":"A phase 1/2 trial of U32 CAR-T in acute myeloid leukaemia, run by Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, now recruiting.","route":"/trials/nct07036250/","status":"recruiting","kind":"trial","cancerIcon":"aml","sub":"NCT07036250","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06126510","name":"Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma","tldr":"A phase 2 trial of Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell) in sarcomas, run by CNBG-Virogin Biotech (Shanghai) Ltd., now recruiting.","route":"/trials/nct06126510/","status":"recruiting","kind":"trial","cancerIcon":"sarcoma","sub":"NCT06126510","facets":{"kind":["Trial"],"cancers":["Sarcomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Sarcomas","href":"/cancers/sarcoma/","tip":"Sarcomas are dozens of rare cancers of bone and connective tissue. GIST was the first solid tumour cured-in-practice by a targeted pill; synovial sarcoma got the first TCR-T therapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06879145","name":"Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)","tldr":"A phase 2/3 trial of Adebrelimab and SHR-A2102 in bladder & urothelial cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.","route":"/trials/nct06879145/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT06879145","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03067051","name":"Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System","tldr":"A phase 1/2 trial of Verteporfin in prostate cancer, run by SpectraCure AB, now recruiting.","route":"/trials/nct03067051/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT03067051","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07122063","name":"Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors","tldr":"A phase 1/2 trial of SYS6045 in advanced solid tumours, run by CSPC Megalith Biopharmaceutical Co.,Ltd., active and no longer recruiting.","route":"/trials/nct07122063/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07122063","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07367516","name":"Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer","tldr":"A phase 1/2 trial of TQB6411 in oesophageal cancer, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting.","route":"/trials/nct07367516/","status":"recruiting","kind":"trial","cancerIcon":"esophageal","sub":"NCT07367516","facets":{"kind":["Trial"],"cancers":["Oesophageal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05230810","name":"Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.","tldr":"A phase 1/2 trial of Alpelisib, Tucatinib and Fulvestrant in HER2-positive breast cancer, run by Criterium, Inc., active and no longer recruiting.","route":"/trials/nct05230810/","status":"active","kind":"trial","cancerIcon":"breast-her2-positive","sub":"NCT05230810","facets":{"kind":["Trial"],"cancers":["HER2-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02781883","name":"Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML","tldr":"A phase 2 trial of Decitabine in acute myeloid leukaemia, run by Bio-Path Holdings, Inc., now recruiting.","route":"/trials/nct02781883/","status":"recruiting","kind":"trial","cancerIcon":"aml","sub":"NCT02781883","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia","Acute myeloid leukaemia in older or unfit patients"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Acute myeloid leukaemia in older or unfit patients","href":"/cancers/aml-older-unfit/","tip":"Most people with acute myeloid leukaemia are over 65, and many cannot take intensive chemotherapy. Venetoclax with azacitidine, two gentler drugs, doubled remission rates and lengthened life in this group, replacing the old choice between supportive care and low-dose chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04684147","name":"Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia","tldr":"A phase 2 trial of single dose of CNCT19 in acute lymphoblastic leukaemia, run by Juventas Cell Therapy Ltd., now recruiting.","route":"/trials/nct04684147/","status":"recruiting","kind":"trial","cancerIcon":"all-leukemia","sub":"NCT04684147","facets":{"kind":["Trial"],"cancers":["Acute lymphoblastic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06781567","name":"Clinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma","tldr":"A phase 2 trial of HG146 in salivary gland cancers and head and neck squamous cell carcinoma, run by HitGen Inc., now recruiting.","route":"/trials/nct06781567/","status":"recruiting","kind":"trial","cancerIcon":"salivary-gland","sub":"NCT06781567","facets":{"kind":["Trial"],"cancers":["Salivary gland cancers","Head and neck squamous cell carcinoma","Adenoid cystic carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Salivary gland cancers","href":"/cancers/salivary-gland/","tip":"Salivary gland cancers are a family of over 20 rare cancers, each with its own behaviour and often its own gene fusion. Surgery and radiation treat most; drug therapy is now chosen by the specific subtype, from anti-HER2 or anti-androgen drugs to NTRK inhibitors."},{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Adenoid cystic carcinoma","href":"/cancers/adenoid-cystic-carcinoma/","tip":"Adenoid cystic carcinoma is a slow but relentless cancer of the salivary glands that creeps along nerves and comes back years later, often in the lungs. Surgery with radiotherapy is the only cure, chemotherapy barely works, and the tablets lenvatinib and axitinib can hold spreading disease still for months rather than shrink it."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06745908","name":"Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In","tldr":"A phase 3 trial of Nogapendekin alfa inbakicept, Tislelizumab and Docetaxel in non-small-cell lung cancer, run by ImmunityBio, Inc., now recruiting.","route":"/trials/nct06745908/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06745908","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06854445","name":"Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma","tldr":"A phase 2 trial of Gemcitabine, Oxaliplatin and TQB2825 in non-Hodgkin lymphoma, run by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd., now recruiting.","route":"/trials/nct06854445/","status":"recruiting","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT06854445","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma","Diffuse large B-cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."},{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07299747","name":"Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors","tldr":"A phase 1/2 trial of VBC103 in advanced solid tumours, run by VelaVigo Bio Inc, now recruiting.","route":"/trials/nct07299747/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07299747","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06975410","name":"Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors","tldr":"A phase 1/2 trial of YH32364 in advanced solid tumours, run by Yuhan Corporation, now recruiting.","route":"/trials/nct06975410/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06975410","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05523947","name":"Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor","tldr":"A phase 1/2 trial of YH32367 in advanced solid tumours, run by Yuhan Corporation, now recruiting.","route":"/trials/nct05523947/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05523947","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06422936","name":"Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC)","tldr":"A phase 2 trial of BO-112 in basal cell carcinoma, run by Highlight Therapeutics, active and no longer recruiting.","route":"/trials/nct06422936/","status":"active","kind":"trial","cancerIcon":"basal-cell-carcinoma","sub":"NCT06422936","facets":{"kind":["Trial"],"cancers":["Basal cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Basal cell carcinoma","href":"/cancers/basal-cell-carcinoma/","tip":"Basal cell carcinoma is a skin cancer and the most common cancer of all, caused by sun exposure and almost never life-threatening. Nearly all are removed surgically; the rare advanced cases are treated with drugs that block the hedgehog signalling pathway, and with immunotherapy if those fail."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03850574","name":"Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia","tldr":"A phase 1/2 trial of Venetoclax and Azacitidine in myelodysplastic syndromes / neoplasms and chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, run by Aptose Biosciences Inc., now recruiting.","route":"/trials/nct03850574/","status":"recruiting","kind":"trial","cancerIcon":"mds","sub":"NCT03850574","facets":{"kind":["Trial"],"cancers":["Myelodysplastic syndromes / neoplasms","Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Myelodysplastic syndromes / neoplasms","href":"/cancers/mds/","tip":"Bone-marrow disorders where blood cells are made badly and too few reach the blood; a third progress to acute leukaemia. Treatment ranges from transfusions and growth factors to hypomethylating drugs and, for the fit, transplant."},{"label":"Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms","href":"/cancers/cmml/","tip":"Chronic myelomonocytic leukaemia and its relatives are bone-marrow cancers that behave partly like myelodysplasia (poorly made blood cells) and partly like a proliferative disease (an excess of monocytes or platelets). Hypomethylating agents produce responses in a minority and stabilise counts in more, transplant can cure the fit, and RAS-pathway and JAK inhibitors are in trials."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06293651","name":"Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors","tldr":"A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by Dong-A ST Co., Ltd., now recruiting.","route":"/trials/nct06293651/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06293651","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07548177","name":"Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma","tldr":"A phase 2 trial of Anlotinib in sarcomas, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting.","route":"/trials/nct07548177/","status":"recruiting","kind":"trial","cancerIcon":"sarcoma","sub":"NCT07548177","facets":{"kind":["Trial"],"cancers":["Sarcomas","Alveolar soft part sarcoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Sarcomas","href":"/cancers/sarcoma/","tip":"Sarcomas are dozens of rare cancers of bone and connective tissue. GIST was the first solid tumour cured-in-practice by a targeted pill; synovial sarcoma got the first TCR-T therapy."},{"label":"Alveolar soft part sarcoma","href":"/cancers/alveolar-soft-part-sarcoma/","tip":"Alveolar soft part sarcoma is a rare, slow-growing cancer of young adults driven by a single fusion gene, ASPSCR1-TFE3, that switches on blood vessel growth. Chemotherapy does not work, but drugs that block the tumour's blood supply shrink it, and in 2023 the immunotherapy atezolizumab became the first drug approved for it."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00703820","name":"Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia","tldr":"A phase 3 trial of Cytarabine, Daunorubicin, Etoposide and Clofarabine in Acute myeloid leukaemia, run by St. Jude Children's Research Hospital, completed.","route":"/trials/nct00703820/","status":"completed","kind":"trial","cancerIcon":"aml","sub":"NCT00703820","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[]},"sortKeys":{"year":0}},{"id":"cobolimab","name":"Cobolimab","tldr":"Cobolimab is an experimental investigational agent whose form is not stated in the registry from GlaxoSmithKline in phase 3 trials for non-small-cell lung cancer, melanoma and hodgkin lymphoma, with its target not yet stated publicly.","route":"/drugs/cobolimab/","status":"phase-3","kind":"drug","molecule":"cobolimab","modality":"antibody (INN stem -mab; form not stated in the registry record)","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Melanoma","Hodgkin lymphoma","Glioma & glioblastoma","Osteosarcoma","Hepatocellular carcinoma","Rhabdomyosarcoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"label":"Hodgkin lymphoma","href":"/cancers/hodgkin-lymphoma/","tip":"Hodgkin lymphoma is one of the most curable cancers, where the goal is now to cure with less toxicity, using brentuximab and, from 2026, first-line nivolumab."},{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01091974","name":"Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy","tldr":"A phase 2 trial of Cognitive behavioural therapy for insomnia in Breast cancer, run by University of Rochester, completed.","route":"/trials/nct01091974/","status":"completed","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT01091974","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00083382","name":"Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide","tldr":"A phase 2 trial of Pamidronate, Thalidomide and Zoledronic acid in Multiple myeloma, run by University of Arkansas, completed.","route":"/trials/nct00083382/","status":"completed","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT00083382","facets":{"kind":["Trial"],"cancers":["Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00628810","name":"Combination Chemotherapy and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer","tldr":"A phase 2 trial of UGT1A1 genotyping before irinotecan in Colorectal cancer, run by Federation Francophone de Cancerologie Digestive, completed.","route":"/trials/nct00628810/","status":"completed","kind":"trial","cancerIcon":"colorectal","sub":"NCT00628810","facets":{"kind":["Trial"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02883049","name":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","tldr":"A phase 3 trial of Clofarabine, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin, Dexamethasone, Doxorubicin, Etoposide, Leucovorin, Mercaptopurine, Methotrexate, Asparaginase, Prednisone, Thioguanine and Vincristine in Acute lymphoblastic leukaemia and Leukaemia, run by National Cancer Institute (NCI), completed.","route":"/trials/nct02883049/","status":"completed","kind":"trial","cancerIcon":"all-leukemia","sub":"NCT02883049","facets":{"kind":["Trial"],"cancers":["Acute lymphoblastic leukaemia","Leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."},{"label":"Leukaemia","href":"/cancers/leukaemia/","tip":"Leukaemia means cancer of the blood-forming cells, but the four main types share little beyond the name: acute lymphoblastic and acute myeloid leukaemia are emergencies treated with intensive therapy, while chronic lymphocytic and chronic myeloid leukaemia are slow diseases controlled for years with pills. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00005838","name":"Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery","tldr":"A phase 3 trial of Shark cartilage in Lung cancer and Non-small-cell lung cancer, run by National Cancer Institute (NCI), completed.","route":"/trials/nct00005838/","status":"completed","kind":"trial","cancerIcon":"lung-cancer","sub":"NCT00005838","facets":{"kind":["Trial"],"cancers":["Lung cancer","Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Lung cancer","href":"/cancers/lung-cancer/","tip":"Lung cancer splits into non-small-cell (about 85 percent) and small-cell (about 15 percent) disease, which behave and are treated very differently. The subtype pages carry the detail; this page covers screening, staging and what the types share."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00003436","name":"Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia","tldr":"A phase 3 trial of Amsacrine, Asparaginase, Cytarabine, Daunorubicin, Etoposide, Methotrexate and Mitoxantrone in Leukaemia and Myelodysplastic syndromes / neoplasms, run by Medical Research Council, completed.","route":"/trials/nct00003436/","status":"completed","kind":"trial","cancerIcon":"leukaemia","sub":"NCT00003436","facets":{"kind":["Trial"],"cancers":["Leukaemia","Myelodysplastic syndromes / neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Leukaemia","href":"/cancers/leukaemia/","tip":"Leukaemia means cancer of the blood-forming cells, but the four main types share little beyond the name: acute lymphoblastic and acute myeloid leukaemia are emergencies treated with intensive therapy, while chronic lymphocytic and chronic myeloid leukaemia are slow diseases controlled for years with pills. Each has its own page."},{"label":"Myelodysplastic syndromes / neoplasms","href":"/cancers/mds/","tip":"Bone-marrow disorders where blood cells are made badly and too few reach the blood; a third progress to acute leukaemia. Treatment ranges from transfusions and growth factors to hypomethylating drugs and, for the fit, transplant."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00002719","name":"Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia","tldr":"A phase 3 trial of Filgrastim, Amsacrine, Carmustine, Cytarabine, Etoposide, Idarubicin and Mitoxantrone in Leukaemia, run by European Organisation for Research and Treatment of Cancer - EORTC, completed.","route":"/trials/nct00002719/","status":"completed","kind":"trial","cancerIcon":"leukaemia","sub":"NCT00002719","facets":{"kind":["Trial"],"cancers":["Leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Leukaemia","href":"/cancers/leukaemia/","tip":"Leukaemia means cancer of the blood-forming cells, but the four main types share little beyond the name: acute lymphoblastic and acute myeloid leukaemia are emergencies treated with intensive therapy, while chronic lymphocytic and chronic myeloid leukaemia are slow diseases controlled for years with pills. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00557193","name":"Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","tldr":"A phase 3 trial of Asparaginase, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Etoposide, Filgrastim, Leucovorin, Mercaptopurine, Methotrexate, Prednisone and Vincristine in Acute lymphoblastic leukaemia and Leukaemia, run by Children's Oncology Group, completed.","route":"/trials/nct00557193/","status":"completed","kind":"trial","cancerIcon":"all-leukemia","sub":"NCT00557193","facets":{"kind":["Trial"],"cancers":["Acute lymphoblastic leukaemia","Leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."},{"label":"Leukaemia","href":"/cancers/leukaemia/","tip":"Leukaemia means cancer of the blood-forming cells, but the four main types share little beyond the name: acute lymphoblastic and acute myeloid leukaemia are emergencies treated with intensive therapy, while chronic lymphocytic and chronic myeloid leukaemia are slow diseases controlled for years with pills. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00002658","name":"Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia","tldr":"A phase 3 trial of Filgrastim, Amsacrine, Cyclophosphamide, Cytarabine, Daunorubicin, Etoposide, Idarubicin, Mitoxantrone, Thioguanine and Tretinoin in Leukaemia, run by Medical Research Council, with a status the registry has not verified recently.","route":"/trials/nct00002658/","kind":"trial","cancerIcon":"leukaemia","sub":"NCT00002658","facets":{"kind":["Trial"],"cancers":["Leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Leukaemia","href":"/cancers/leukaemia/","tip":"Leukaemia means cancer of the blood-forming cells, but the four main types share little beyond the name: acute lymphoblastic and acute myeloid leukaemia are emergencies treated with intensive therapy, while chronic lymphocytic and chronic myeloid leukaemia are slow diseases controlled for years with pills. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00016276","name":"Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer","tldr":"A phase 3 trial of Dexrazoxane, Doxorubicin, Cyclophosphamide, Paclitaxel / nab-paclitaxel, Trastuzumab and Tamoxifen in Inflammatory breast cancer and Breast cancer, run by National Cancer Institute (NCI), recorded as terminated on the registry.","route":"/trials/nct00016276/","kind":"trial","cancerIcon":"inflammatory-breast-cancer","sub":"NCT00016276","facets":{"kind":["Trial"],"cancers":["Inflammatory breast cancer","Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Inflammatory breast cancer","href":"/cancers/inflammatory-breast-cancer/","tip":"Inflammatory breast cancer does not usually form a lump. The breast becomes red, swollen, warm and heavy over weeks, with skin thickened like orange peel, because cancer cells have blocked the lymph channels in the skin. It is often mistaken for infection, is always at least stage III, and needs chemotherapy first, then mastectomy and radiotherapy, with HER2 or immune drugs added by subtype."},{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04390399","name":"Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer","tldr":"A phase 2 trial of Nogapendekin alfa inbakicept, Aldoxorubicin, Gemcitabine and Cyclophosphamide in pancreatic ductal adenocarcinoma, run by ImmunityBio, Inc., active and no longer recruiting.","route":"/trials/nct04390399/","status":"active","kind":"trial","cancerIcon":"pancreatic","sub":"NCT04390399","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04082364","name":"Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer","tldr":"A phase 2/3 trial of Margetuximab, Retifanlimab and Trastuzumab in HER2-positive gastric cancer, run by MacroGenics, completed.","route":"/trials/nct04082364/","status":"completed","kind":"trial","cancerIcon":"gastric-her2-positive","sub":"NCT04082364","facets":{"kind":["Trial"],"cancers":["HER2-positive gastric cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HER2-positive gastric cancer","href":"/cancers/gastric-her2-positive/","tip":"HER2-positive gastric cancer overexpresses the HER2 growth receptor and is treated with trastuzumab added to chemotherapy, now usually with pembrolizumab as well. After progression the antibody-drug conjugate trastuzumab deruxtecan gives responses that plain chemotherapy cannot."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01886105","name":"Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma","tldr":"A phase 2 trial of Samarium-153 lexidronam in Osteosarcoma, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, recorded as terminated on the registry.","route":"/trials/nct01886105/","kind":"trial","cancerIcon":"osteosarcoma","sub":"NCT01886105","facets":{"kind":["Trial"],"cancers":["Osteosarcoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Osteosarcoma","href":"/cancers/osteosarcoma/","tip":"Osteosarcoma is the most common bone cancer, mostly in teenagers. Chemotherapy plus surgery cures about two-thirds when it has not spread; because no new drug has beaten that chemotherapy in a large trial in 30 years, the next gains are being sought in cellular therapy against GD2, HER2 and B7-H3."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05874414","name":"Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma","tldr":"A phase 1/2 trial of Trametinib in biliary tract cancer, run by Genfit, now recruiting.","route":"/trials/nct05874414/","status":"recruiting","kind":"trial","cancerIcon":"cholangiocarcinoma","sub":"NCT05874414","facets":{"kind":["Trial"],"cancers":["Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05609578","name":"Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation","tldr":"A phase 2 trial of Adagrasib, Pembrolizumab, Pemetrexed, Carboplatin and Cisplatin in non-small-cell lung cancer, run by Mirati Therapeutics Inc., active and no longer recruiting.","route":"/trials/nct05609578/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT05609578","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","KRAS G12C-mutant non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"KRAS G12C-mutant non-small-cell lung cancer","href":"/cancers/kras-g12c-nsclc/","tip":"KRAS G12C lung cancer carries a mutation that was thought impossible to drug for forty years. Sotorasib and adagrasib now shrink about four in ten tumours after chemotherapy and immunotherapy, though the benefit is measured in months, and newer inhibitors and first-line combinations with immunotherapy are in trials."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06312670","name":"Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer","tldr":"A phase 2 trial of Masofaniten and Enzalutamide in Metastatic hormone-sensitive prostate cancer and Prostate cancer, run by Pedro Barata, MD, MSc, completed.","route":"/trials/nct06312670/","status":"completed","kind":"trial","cancerIcon":"prostate-mhspc","sub":"NCT06312670","facets":{"kind":["Trial"],"cancers":["Metastatic hormone-sensitive prostate cancer","Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic hormone-sensitive prostate cancer","href":"/cancers/prostate-mhspc/","tip":"Metastatic hormone-sensitive prostate cancer is disease that has spread but still responds to lowering testosterone. Hormone therapy alone is no longer enough: adding an androgen receptor inhibitor, and docetaxel for high-volume disease, lengthens life by years."},{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03711877","name":"Comparative Study of Scalp Cooling System and Chemical Cold Cap (COHAIR Study)","tldr":"A phase 3 trial of Scalp cooling in Breast cancer, run by Tao OUYANG, with a status the registry has not verified recently.","route":"/trials/nct03711877/","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT03711877","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04333537","name":"Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer","tldr":"A phase 2/3 trial of Fludeoxyglucose F-18 in Oral cavity cancer, run by NRG Oncology, now recruiting.","route":"/trials/nct04333537/","status":"recruiting","kind":"trial","cancerIcon":"oral-cavity-cancer","sub":"NCT04333537","facets":{"kind":["Trial"],"cancers":["Oral cavity cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Oral cavity cancer","href":"/cancers/oral-cavity-cancer/","tip":"Cancer of the mouth and tongue, a head and neck cancer, is caused mainly by tobacco, alcohol and betel quid and is usually visible or feelable early, yet often diagnosed late. Surgery is the mainstay, with radiotherapy or chemoradiation after operation for higher-risk disease, and reconstruction to restore speech and swallowing."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00099437","name":"Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.","tldr":"A phase 3 trial of Fulvestrant in HR-positive / HER2-negative breast cancer, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct00099437/","status":"active","kind":"trial","cancerIcon":"breast-hr-positive","sub":"NCT00099437","facets":{"kind":["Trial"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":["2010"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"year":{"facet":"year","value":"2010"},"tags":[]},"sortKeys":{"year":2010}},{"id":"nct02739594","name":"Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma","tldr":"A phase 3 trial of Ibandronic acid and Zoledronic acid in Multiple myeloma, run by Hoffmann-La Roche, recorded as terminated on the registry.","route":"/trials/nct02739594/","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT02739594","facets":{"kind":["Trial"],"cancers":["Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04971473","name":"Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal","tldr":"A phase 3 trial of Thyrotropin alfa in Thyroid cancer, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, completed.","route":"/trials/nct04971473/","status":"completed","kind":"trial","cancerIcon":"thyroid","sub":"NCT04971473","facets":{"kind":["Trial"],"cancers":["Thyroid cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Thyroid cancer","href":"/cancers/thyroid/","tip":"Thyroid cancer is usually curable with surgery and radioactive iodine, the original theranostic. Rare aggressive forms respond to RET and BRAF inhibitors."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04275986","name":"Concurrent Chemoradiotherapy After Endoscopic Resection for Stage I Esophageal Carcinoma","tldr":"A phase 2 trial of Endoscopic resection in Oesophageal squamous cell carcinoma, run by Chinese Academy of Medical Sciences, with a status the registry has not verified recently.","route":"/trials/nct04275986/","kind":"trial","cancerIcon":"oesophageal-squamous-cell-carcinoma","sub":"NCT04275986","facets":{"kind":["Trial"],"cancers":["Oesophageal squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Oesophageal squamous cell carcinoma","href":"/cancers/oesophageal-squamous-cell-carcinoma/","tip":"Squamous cell carcinoma of the oesophagus, the world's commonest form, is linked to smoking, alcohol and very hot drinks and sits in the upper and middle gullet. It is treated with chemoradiation, with or without surgery, and immunotherapy has recently joined chemotherapy for advanced disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06470451","name":"Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL","tldr":"A phase 3 trial of Synthetic hypericin in Cutaneous T-cell lymphoma and Peripheral T-cell lymphomas, run by Soligenix, recorded as terminated on the registry.","route":"/trials/nct06470451/","kind":"trial","cancerIcon":"cutaneous-t-cell-lymphoma","sub":"NCT06470451","facets":{"kind":["Trial"],"cancers":["Cutaneous T-cell lymphoma","Peripheral T-cell lymphomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Cutaneous T-cell lymphoma","href":"/cancers/cutaneous-t-cell-lymphoma/","tip":"Mycosis fungoides is a lymphoma that lives in the skin, looking like eczema or psoriasis for years before it is diagnosed. It is treated with creams, light and skin-directed radiotherapy for as long as possible, then with antibodies such as mogamulizumab and brentuximab vedotin when it spreads to the blood or lymph nodes."},{"label":"Peripheral T-cell lymphomas","href":"/cancers/peripheral-t-cell-lymphoma/","tip":"Peripheral T-cell lymphomas are lymphomas of T cells rather than B cells. They are rarer, more varied and, apart from a few subtypes, harder to treat than B-cell lymphomas; several new drugs help only defined subtypes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06500273","name":"Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL","tldr":"A phase 2 trial of Fludarabine and Cyclophosphamide in diffuse large B-cell lymphoma, run by Allogene Therapeutics, now recruiting.","route":"/trials/nct06500273/","status":"recruiting","kind":"trial","cancerIcon":"dlbcl","sub":"NCT06500273","facets":{"kind":["Trial"],"cancers":["Diffuse large B-cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04842604","name":"Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML","tldr":"A phase 3 trial of Glasdegib and Azacitidine in Acute myeloid leukaemia and Leukaemia, run by Pfizer, completed.","route":"/trials/nct04842604/","status":"completed","kind":"trial","cancerIcon":"aml","sub":"NCT04842604","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia","Leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Leukaemia","href":"/cancers/leukaemia/","tip":"Leukaemia means cancer of the blood-forming cells, but the four main types share little beyond the name: acute lymphoblastic and acute myeloid leukaemia are emergencies treated with intensive therapy, while chronic lymphocytic and chronic myeloid leukaemia are slow diseases controlled for years with pills. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06311695","name":"Contrast-Enhanced Spectral Mammography (CESM)","tldr":"A phase 2 trial of Contrast-enhanced mammography in Breast cancer, run by European Institute of Oncology, with a status the registry has not verified recently.","route":"/trials/nct06311695/","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT06311695","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03777982","name":"Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT","tldr":"A phase 3 trial of Prednisone and Apalutamide and Abiraterone acetate in Prostate cancer, run by Dana-Farber Cancer Institute, recorded as terminated on the registry.","route":"/trials/nct03777982/","kind":"trial","cancerIcon":"prostate","sub":"NCT03777982","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06235151","name":"Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer","tldr":"A phase 3 trial of Copper Cu 64 PSMA I&T in prostate cancer, run by Curium US LLC, active and no longer recruiting.","route":"/trials/nct06235151/","status":"active","kind":"trial","cancerIcon":"prostate","sub":"NCT06235151","facets":{"kind":["Trial"],"cancers":["Prostate cancer","Localised prostate cancer, high and very high risk"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Localised prostate cancer, high and very high risk","href":"/cancers/prostate-high-risk/","tip":"High-risk prostate cancer has Grade Group 4 or 5 disease, a PSA above 20 or a tumour growing beyond the gland. It is still curable, but needs radiotherapy with two to three years of hormone therapy, or surgery followed by radiotherapy, and adding abiraterone to hormone therapy now lengthens life in the highest-risk men."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07398339","name":"Cosiporfin Sodium for Injection Photodynamic Therapy","tldr":"A phase 2 trial of Gemcitabine and Cisplatin in biliary tract cancer, run by Shanghai Guangsheng Biopharmaceutical Co., Ltd, now recruiting.","route":"/trials/nct07398339/","status":"recruiting","kind":"trial","cancerIcon":"cholangiocarcinoma","sub":"NCT07398339","facets":{"kind":["Trial"],"cancers":["Biliary tract cancer","Extrahepatic cholangiocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07335497","name":"CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors","tldr":"A phase 1/2 trial of CR-001 in advanced solid tumours, run by Crescent Biopharma, Inc., now recruiting.","route":"/trials/nct07335497/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07335497","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"crb-701","name":"CRB-701","tldr":"CRB-701 is an experimental antibody-drug conjugate from Corbus Pharmaceuticals in phase 2 trials, aimed at Nectin-4.","route":"/drugs/crb-701/","status":"phase-2","kind":"drug","molecule":"crb-701","modality":"ADC","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"crc01","name":"CRC01","tldr":"CRC01 is an experimental CAR-T cell therapy from Curocell in phase 2 trials for diffuse large B-cell lymphoma, follicular lymphoma and acute lymphoblastic leukaemia, aimed at CD19.","route":"/drugs/crc01/","status":"phase-2","kind":"drug","molecule":"crc01","modality":"CAR-T cell therapy","facets":{"kind":["Treatment"],"cancers":["Diffuse large B-cell lymphoma","Follicular lymphoma","Acute lymphoblastic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."},{"label":"Follicular lymphoma","href":"/cancers/follicular-lymphoma/","tip":"Follicular lymphoma is the most common slow-growing lymphoma, defined in about 85% of cases by a BCL2 translocation. Most people live with it for decades, treated only when it causes problems; it can be controlled repeatedly with anti-CD20 antibodies, chemotherapy, bispecifics or CAR-T but rarely cured, and a small share transform into an aggressive lymphoma each year."},{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07483996","name":"Cryoablation Versus Lumpectomy in Early-Stage Breast Cancer","tldr":"A phase 3 trial of Thermal ablation in Breast cancer, run by Franciscus Gasthuis & Vlietland (Hospital), not yet recruiting.","route":"/trials/nct07483996/","status":"planned","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT07483996","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ct3001","name":"CT3001","tldr":"CT3001 is a small-molecule inhibitor from Crossignal Therapeutics, Inc., in registered phase 2 trials for colorectal cancer, pancreatic ductal adenocarcinoma.","route":"/drugs/ct3001/","status":"phase-2","kind":"drug","molecule":"ct3001","modality":"Small-molecule inhibitor","sub":"CT3001","facets":{"kind":["Treatment"],"cancers":["Colorectal cancer","Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"ctx112","name":"CTX112","tldr":"CTX112 is an experimental CAR-T cell therapy from CRISPR Therapeutics in phase 2 trials for hodgkin lymphoma, chronic lymphocytic leukaemia and follicular lymphoma, aimed at CD19.","route":"/drugs/ctx112/","status":"phase-2","kind":"drug","molecule":"ctx112","modality":"CAR-T cell therapy","facets":{"kind":["Treatment"],"cancers":["Hodgkin lymphoma","Chronic lymphocytic leukaemia","Follicular lymphoma","Mantle cell lymphoma","Diffuse large B-cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Hodgkin lymphoma","href":"/cancers/hodgkin-lymphoma/","tip":"Hodgkin lymphoma is one of the most curable cancers, where the goal is now to cure with less toxicity, using brentuximab and, from 2026, first-line nivolumab."},{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Follicular lymphoma","href":"/cancers/follicular-lymphoma/","tip":"Follicular lymphoma is the most common slow-growing lymphoma, defined in about 85% of cases by a BCL2 translocation. Most people live with it for decades, treated only when it causes problems; it can be controlled repeatedly with anti-CD20 antibodies, chemotherapy, bispecifics or CAR-T but rarely cured, and a small share transform into an aggressive lymphoma each year."},{"label":"Mantle cell lymphoma","href":"/cancers/mantle-cell-lymphoma/","tip":"An uncommon B-cell lymphoma driven by cyclin D1 that used to behave badly in almost everyone. BTK inhibitors, CAR-T and now BCL2 drugs have changed it from chemotherapy-plus-transplant to targeted combinations."}],"tags":[]},"sortKeys":{"year":0}},{"id":"cusatuzumab","name":"Cusatuzumab","tldr":"Cusatuzumab is an experimental monoclonal antibody from OncoVerity in phase 2 trials for acute myeloid leukaemia, aimed at CD70.","route":"/drugs/cusatuzumab/","status":"phase-2","kind":"drug","molecule":"cusatuzumab","modality":"monoclonal antibody","sub":"OV-1001, JNJ-74494550, ARGX-110","facets":{"kind":["Treatment"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07664150","name":"CW-301 FIH Study of CAN016","tldr":"A phase 1/2 trial of CAN016 in advanced solid tumours, run by Canwell Biotech Limited, now recruiting.","route":"/trials/nct07664150/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07664150","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"cyh33","name":"CYH33","tldr":"CYH33 is a small-molecule inhibitor from Haihe Biopharma Co., Ltd., in registered phase 2 trials for ovarian cancer.","route":"/drugs/cyh33/","status":"phase-2","kind":"drug","molecule":"cyh33","modality":"Small-molecule inhibitor","sub":"CYH33","facets":{"kind":["Treatment"],"cancers":["Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct06434909","name":"CYTALUX™for the Intraoperative Imaging of Prostate Cancer","tldr":"A phase 2 trial of Pafolacianine in Prostate cancer, run by Indiana University, completed.","route":"/trials/nct06434909/","status":"completed","kind":"trial","cancerIcon":"prostate","sub":"NCT06434909","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"d-0502","name":"D-0502","tldr":"D-0502 is an experimental small-molecule drug from InventisBio in phase 3 trials for HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.","route":"/drugs/d-0502/","status":"phase-3","kind":"drug","molecule":"d-0502","modality":"small molecule","facets":{"kind":["Treatment"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"d07001","name":"D07001","tldr":"D07001 is an experimental small-molecule drug from InnoPharmax in phase 3 trials for biliary tract cancer, with its target not yet stated publicly.","route":"/drugs/d07001/","status":"phase-3","kind":"drug","molecule":"d07001","modality":"small molecule (structure undisclosed or not yet in PubChem)","facets":{"kind":["Treatment"],"cancers":["Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07544654","name":"DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy","tldr":"A phase 3 trial of Carboplatin and Etoposide in neuroendocrine tumours, run by Boehringer Ingelheim, now recruiting.","route":"/trials/nct07544654/","status":"recruiting","kind":"trial","cancerIcon":"neuroendocrine","sub":"NCT07544654","facets":{"kind":["Trial"],"cancers":["Neuroendocrine tumours","Extrapulmonary neuroendocrine carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Neuroendocrine tumours","href":"/cancers/neuroendocrine/","tip":"A family of usually slow-growing tumours that start in hormone-producing cells of the gut, pancreas and lungs. They pioneered the idea of using the same molecule to see a tumour on a scan and then to treat it with radiation."},{"label":"Extrapulmonary neuroendocrine carcinoma","href":"/cancers/extrapulmonary-nec/","tip":"Extrapulmonary neuroendocrine carcinoma is the fast-growing, poorly differentiated form of neuroendocrine cancer arising outside the lung, most often in the bowel, oesophagus, stomach or pancreas. It behaves like small-cell lung cancer and is treated the same way, with platinum and etoposide chemotherapy, and drugs against the DLL3 protein are now in phase 3 trials."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05882058","name":"DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers","tldr":"A phase 2 trial of BI 764532, dose 1 in small-cell lung cancer and neuroendocrine tumours, run by Boehringer Ingelheim, now recruiting.","route":"/trials/nct05882058/","status":"recruiting","kind":"trial","cancerIcon":"sclc","sub":"NCT05882058","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer","Neuroendocrine tumours","Extrapulmonary neuroendocrine carcinoma","Extensive-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."},{"label":"Neuroendocrine tumours","href":"/cancers/neuroendocrine/","tip":"A family of usually slow-growing tumours that start in hormone-producing cells of the gut, pancreas and lungs. They pioneered the idea of using the same molecule to see a tumour on a scan and then to treat it with radiation."},{"label":"Extrapulmonary neuroendocrine carcinoma","href":"/cancers/extrapulmonary-nec/","tip":"Extrapulmonary neuroendocrine carcinoma is the fast-growing, poorly differentiated form of neuroendocrine cancer arising outside the lung, most often in the bowel, oesophagus, stomach or pancreas. It behaves like small-cell lung cancer and is treated the same way, with platinum and etoposide chemotherapy, and drugs against the DLL3 protein are now in phase 3 trials."},{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"tags":[]},"sortKeys":{"year":0}},{"id":"darovasertib","name":"Darovasertib","tldr":"Darovasertib is an experimental small-molecule drug from IDEAYA Biosciences in phase 3 trials for uveal melanoma and melanoma, with its target not yet stated publicly.","route":"/drugs/darovasertib/","status":"phase-3","kind":"drug","molecule":"darovasertib","modality":"small molecule","sub":"IDE196, LXS196","facets":{"kind":["Treatment"],"cancers":["Uveal melanoma","Melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Uveal melanoma","href":"/cancers/uveal-melanoma/","tip":"A melanoma inside the eye that is biologically unrelated to skin melanoma: different mutations, no response to standard immunotherapy, and a tendency to spread to the liver years later. Tebentafusp is the first drug ever to extend survival in the metastatic disease."},{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05566795","name":"DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)","tldr":"A phase 3 trial of Tovorafenib in glioma & glioblastoma, run by Day One Biopharmaceuticals, Inc., active and no longer recruiting.","route":"/trials/nct05566795/","status":"active","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT05566795","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma","Paediatric low-grade glioma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."},{"label":"Paediatric low-grade glioma","href":"/cancers/paediatric-low-grade-glioma/","tip":"Paediatric low-grade gliomas are slow-growing brain tumours driven almost always by a single overactive signal, the MAPK pathway, most often through a BRAF gene change. Because the switch is known, pills that block it (dabrafenib with trametinib, and tovorafenib) now shrink tumours far more often than chemotherapy, and children are increasingly spared radiation to the developing brain."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06953089","name":"DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors","tldr":"A phase 2 trial of BNT324 and PM8002 in advanced solid tumours, run by DualityBio Inc., now recruiting.","route":"/trials/nct06953089/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06953089","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00112463","name":"Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma","tldr":"A phase 2 trial of Romidepsin in Alveolar soft part sarcoma, Angiosarcoma, Epithelioid sarcoma, Chondrosarcoma, Osteosarcoma and Leiomyosarcoma, run by National Cancer Institute (NCI), completed.","route":"/trials/nct00112463/","status":"completed","kind":"trial","cancerIcon":"alveolar-soft-part-sarcoma","sub":"NCT00112463","facets":{"kind":["Trial"],"cancers":["Alveolar soft part sarcoma","Angiosarcoma","Epithelioid sarcoma","Chondrosarcoma","Osteosarcoma","Leiomyosarcoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Alveolar soft part sarcoma","href":"/cancers/alveolar-soft-part-sarcoma/","tip":"Alveolar soft part sarcoma is a rare, slow-growing cancer of young adults driven by a single fusion gene, ASPSCR1-TFE3, that switches on blood vessel growth. Chemotherapy does not work, but drugs that block the tumour's blood supply shrink it, and in 2023 the immunotherapy atezolizumab became the first drug approved for it."},{"label":"Angiosarcoma","href":"/cancers/angiosarcoma/","tip":"Angiosarcoma is an aggressive vascular tumour, a cancer of the cells that line blood and lymph vessels. It grows as bruise-like patches on the scalp of older people, in breasts treated years earlier with radiotherapy, or inside organs. Surgery and radiotherapy are used where possible, weekly paclitaxel is the most active drug, and immunotherapy helps a minority with the sun-damaged scalp form."},{"label":"Epithelioid sarcoma","href":"/cancers/epithelioid-sarcoma/","tip":"Epithelioid sarcoma is a rare soft tissue cancer that has lost a gene brake called SMARCB1, leaving it dependent on the enzyme EZH2. Surgery cures localised tumours. The EZH2 inhibitor tazemetostat, the first epigenetic drug approved for a solid tumour, was approved in 2020 and withdrawn worldwide in March 2026 after secondary blood cancers in a lymphoma trial, so there is no targeted drug today."},{"label":"Chondrosarcoma","href":"/cancers/chondrosarcoma/","tip":"Chondrosarcoma is a cancer of cartilage-forming cells in bone. It is nearly immune to chemotherapy and radiotherapy, so complete surgery is the treatment, with proton or carbon-ion beams for skull base and spine tumours that cannot be fully removed. Half of conventional tumours carry an IDH mutation, and the IDH1 blocker ivosidenib is in a phase 3 trial."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00033332","name":"Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma","tldr":"A phase 3 trial of Dexamethasone, Pamidronate, Thalidomide and Zoledronic acid in Multiple myeloma, run by National Cancer Institute (NCI), completed.","route":"/trials/nct00033332/","status":"completed","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT00033332","facets":{"kind":["Trial"],"cancers":["Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00316927","name":"Dexamethasone, Aspirin, and Diethylstilbestrol in Treating Patients With Locally Advanced or Metastatic Prostate Cancer","tldr":"A phase 3 trial of Aspirin, Dexamethasone and Diethylstilbestrol in Prostate cancer, run by St. Bartholomew's Hospital, completed.","route":"/trials/nct00316927/","status":"completed","kind":"trial","cancerIcon":"prostate","sub":"NCT00316927","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06382168","name":"DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia","tldr":"A phase 1/2 trial of Venetoclax in acute myeloid leukaemia, run by Delta-Fly Pharma, Inc., now recruiting.","route":"/trials/nct06382168/","status":"recruiting","kind":"trial","cancerIcon":"aml","sub":"NCT06382168","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01986569","name":"Diagnostic Accuracy and Safety Study of FES PET/CT in Assessment of ER Status of Recurrent or Metastatic Breast Cancer","tldr":"A phase 3 trial of FES PET in Breast cancer, run by Asan Medical Center, completed.","route":"/trials/nct01986569/","status":"completed","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT01986569","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07285057","name":"Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance","tldr":"A phase 2 trial of Flotufolastat F-18 in Prostate cancer, run by Icahn School of Medicine at Mount Sinai, now recruiting.","route":"/trials/nct07285057/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT07285057","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05911295","name":"Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2","tldr":"A phase 3 trial of Disitamab vedotin, Pembrolizumab, Gemcitabine, Cisplatin and Carboplatin in bladder & urothelial cancer, run by Seagen, a wholly owned subsidiary of Pfizer, active and no longer recruiting.","route":"/trials/nct05911295/","status":"active","kind":"trial","cancerIcon":"urothelial","sub":"NCT05911295","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"dji136","name":"DJI136","tldr":"DJI136 is an experimental CAR-T cell therapy from Novartis Pharmaceuticals in phase 2 trials for non-small-cell lung cancer, aimed at DLL3.","route":"/drugs/dji136/","status":"phase-2","kind":"drug","molecule":"dji136","modality":"CAR-T cell therapy","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04567420","name":"DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)","tldr":"A phase 2 trial of Palbociclib and Fulvestrant in HR-positive / HER2-negative breast cancer, run by Criterium, Inc., active and no longer recruiting.","route":"/trials/nct04567420/","status":"active","kind":"trial","cancerIcon":"breast-hr-positive","sub":"NCT04567420","facets":{"kind":["Trial"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"doc1021","name":"DOC1021","tldr":"DOC1021 is a cancer vaccine from Diakonos Oncology Corporation, in registered phase 2 trials for glioma & glioblastoma, melanoma.","route":"/drugs/doc1021/","status":"phase-2","kind":"drug","molecule":"doc1021","modality":"Cancer vaccine","sub":"DOC1021","facets":{"kind":["Treatment"],"cancers":["Glioma & glioblastoma","Melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."},{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct07288112","name":"DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma","tldr":"A phase 1/2 trial of DOC1021 in melanoma, run by Diakonos Oncology Corporation, now recruiting.","route":"/trials/nct07288112/","status":"recruiting","kind":"trial","cancerIcon":"melanoma","sub":"NCT07288112","facets":{"kind":["Trial"],"cancers":["Melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06805305","name":"DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)","tldr":"A phase 2 trial of Temozolomide in glioma & glioblastoma, run by Diakonos Oncology Corporation, now recruiting.","route":"/trials/nct06805305/","status":"recruiting","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT06805305","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00077311","name":"Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer","tldr":"A phase 2 trial of Darbepoetin alfa, Pegfilgrastim, Cisplatin and Docetaxel in Lung cancer, run by Alliance for Clinical Trials in Oncology, completed.","route":"/trials/nct00077311/","status":"completed","kind":"trial","cancerIcon":"lung-cancer","sub":"NCT00077311","facets":{"kind":["Trial"],"cancers":["Lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Lung cancer","href":"/cancers/lung-cancer/","tip":"Lung cancer splits into non-small-cell (about 85 percent) and small-cell (about 15 percent) disease, which behave and are treated very differently. The subtype pages carry the detail; this page covers screening, staging and what the types share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02003209","name":"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer","tldr":"A phase 3 trial of Carboplatin, Docetaxel, Goserelin / leuprolide, Pertuzumab, HLX11, Trastuzumab and Trastuzumab biosimilars in Breast cancer, run by National Cancer Institute (NCI), completed.","route":"/trials/nct02003209/","status":"completed","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT02003209","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"domvanalimab","name":"Domvanalimab","tldr":"Domvanalimab is an experimental monoclonal antibody from Gilead Sciences in phase 3 trials for non-small-cell lung cancer, bladder & urothelial cancer and head and neck squamous cell carcinoma, with its target not yet stated publicly.","route":"/drugs/domvanalimab/","status":"phase-3","kind":"drug","molecule":"domvanalimab","modality":"monoclonal antibody","sub":"AB154, GS-0154","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Bladder & urothelial cancer","Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06239194","name":"Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of MDX2001 in biliary tract cancer, cervical cancer, colorectal cancer, endometrial cancer, oesophageal cancer and gastric & gastro-oesophageal junction cancer, run by ModeX Therapeutics, An OPKO Health Company, now recruiting.","route":"/trials/nct06239194/","status":"recruiting","kind":"trial","cancerIcon":"cholangiocarcinoma","sub":"NCT06239194","facets":{"kind":["Trial"],"cancers":["Biliary tract cancer","Cervical cancer","Colorectal cancer","Endometrial cancer","Oesophageal cancer","Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07249905","name":"Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma","tldr":"A phase 1/2 trial of MDX2003 in non-Hodgkin lymphoma, waldenström macroglobulinaemia, diffuse large B-cell lymphoma and follicular lymphoma, run by ModeX Therapeutics, An OPKO Health Company, now recruiting.","route":"/trials/nct07249905/","status":"recruiting","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT07249905","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma","Waldenström macroglobulinaemia","Diffuse large B-cell lymphoma","Follicular lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."},{"label":"Waldenström macroglobulinaemia","href":"/cancers/waldenstrom/","tip":"A slow lymphoma that makes an abnormal IgM antibody, causing thick blood, anaemia and nerve damage. Nearly all cases share one mutation (MYD88 L265P), and BTK inhibitors control it for years."},{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."},{"label":"Follicular lymphoma","href":"/cancers/follicular-lymphoma/","tip":"Follicular lymphoma is the most common slow-growing lymphoma, defined in about 85% of cases by a BCL2 translocation. Most people live with it for decades, treated only when it causes problems; it can be controlled repeatedly with anti-CD20 antibodies, chemotherapy, bispecifics or CAR-T but rarely cured, and a small share transform into an aggressive lymphoma each year."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04140500","name":"Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors","tldr":"A phase 1/2 trial of RO7247669 in melanoma, non-small-cell lung cancer and oesophageal cancer, run by Hoffmann-La Roche, active and no longer recruiting.","route":"/trials/nct04140500/","status":"active","kind":"trial","cancerIcon":"melanoma","sub":"NCT04140500","facets":{"kind":["Trial"],"cancers":["Melanoma","Non-small-cell lung cancer","Oesophageal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06440057","name":"Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.","tldr":"A phase 1/2 trial of ZG006 in neuroendocrine tumours, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, now recruiting.","route":"/trials/nct06440057/","status":"recruiting","kind":"trial","cancerIcon":"neuroendocrine","sub":"NCT06440057","facets":{"kind":["Trial"],"cancers":["Neuroendocrine tumours"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Neuroendocrine tumours","href":"/cancers/neuroendocrine/","tip":"A family of usually slow-growing tumours that start in hormone-producing cells of the gut, pancreas and lungs. They pioneered the idea of using the same molecule to see a tumour on a scan and then to treat it with radiation."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02174549","name":"Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer","tldr":"A phase 1/2 trial of Tirapazamine in hepatocellular carcinoma and neuroendocrine tumours, run by Teclison Ltd., now recruiting.","route":"/trials/nct02174549/","status":"recruiting","kind":"trial","cancerIcon":"hcc","sub":"NCT02174549","facets":{"kind":["Trial"],"cancers":["Hepatocellular carcinoma","Neuroendocrine tumours"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."},{"label":"Neuroendocrine tumours","href":"/cancers/neuroendocrine/","tip":"A family of usually slow-growing tumours that start in hormone-producing cells of the gut, pancreas and lungs. They pioneered the idea of using the same molecule to see a tumour on a scan and then to treat it with radiation."}],"tags":[]},"sortKeys":{"year":0}},{"id":"dr-01","name":"DR-01","tldr":"DR-01 is a monoclonal antibody from Dren Bio, in registered phase 2 trials for peripheral T-cell lymphomas.","route":"/drugs/dr-01/","status":"phase-2","kind":"drug","molecule":"dr-01","modality":"Monoclonal antibody","sub":"DR-01","facets":{"kind":["Treatment"],"cancers":["Peripheral T-cell lymphomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Peripheral T-cell lymphomas","href":"/cancers/peripheral-t-cell-lymphoma/","tip":"Peripheral T-cell lymphomas are lymphomas of T cells rather than B cells. They are rarer, more varied and, apart from a few subtypes, harder to treat than B-cell lymphomas; several new drugs help only defined subtypes."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct05709171","name":"Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms","tldr":"A phase 2 trial of Somatostatin receptor PET in Neuroendocrine tumours, run by Rigshospitalet, Denmark, with a status the registry has not verified recently.","route":"/trials/nct05709171/","kind":"trial","cancerIcon":"neuroendocrine","sub":"NCT05709171","facets":{"kind":["Trial"],"cancers":["Neuroendocrine tumours"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Neuroendocrine tumours","href":"/cancers/neuroendocrine/","tip":"A family of usually slow-growing tumours that start in hormone-producing cells of the gut, pancreas and lungs. They pioneered the idea of using the same molecule to see a tumour on a scan and then to treat it with radiation."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07467863","name":"Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC","tldr":"A phase 1/2 trial of Dual-target CAR-NK cells in non-small-cell lung cancer, run by Beijing Biotech, now recruiting.","route":"/trials/nct07467863/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07467863","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07510802","name":"Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC","tldr":"A phase 1/2 trial of Dual-target CAR-NK cells in HER2-positive breast cancer and triple-negative breast cancer, run by Beijing Biotech, now recruiting.","route":"/trials/nct07510802/","status":"recruiting","kind":"trial","cancerIcon":"breast-her2-positive","sub":"NCT07510802","facets":{"kind":["Trial"],"cancers":["HER2-positive breast cancer","Triple-negative breast cancer","Metastatic triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."},{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Metastatic triple-negative breast cancer","href":"/cancers/tnbc-metastatic/","tip":"Triple-negative breast cancer that has spread is not curable, but its treatment has been transformed since 2020. By PD-L1 score, first treatment is pembrolizumab with chemotherapy or with sacituzumab govitecan, or datopotamab deruxtecan or sacituzumab govitecan alone; BRCA carriers can take a PARP inhibitor tablet; and trastuzumab deruxtecan reaches the third of tumours with low HER2."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07462650","name":"Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer","tldr":"A phase 1/2 trial of EB-DUO-CAR-NK-CEA/GCC (IV) in colorectal cancer, run by Beijing Biotech, now recruiting.","route":"/trials/nct07462650/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT07462650","facets":{"kind":["Trial"],"cancers":["Colorectal cancer","HER2-amplified colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"HER2-amplified colorectal cancer","href":"/cancers/her2-amplified-colorectal/","tip":"A few bowel cancers make too much of the HER2 protein, the same target as in HER2-positive breast cancer. Two HER2 drugs together, tucatinib and trastuzumab, shrink about four in ten of these tumours after chemotherapy has failed, and the antibody-drug conjugate trastuzumab deruxtecan works even when other HER2 drugs have stopped."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07641023","name":"Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC","tldr":"A phase 1/2 trial of Dual-target CAR-NK cells in non-small-cell lung cancer, run by Beijing Biotech, now recruiting.","route":"/trials/nct07641023/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07641023","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07551362","name":"Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer","tldr":"A phase 1/2 trial of Fludarabine and Cyclophosphamide in gastric & gastro-oesophageal junction cancer, run by Beijing Biotech, now recruiting.","route":"/trials/nct07551362/","status":"recruiting","kind":"trial","cancerIcon":"gastric","sub":"NCT07551362","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07502287","name":"Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma","tldr":"A phase 1/2 trial of Fludarabine and Cyclophosphamide in neuroblastoma, run by Beijing Biotech, now recruiting.","route":"/trials/nct07502287/","status":"recruiting","kind":"trial","cancerIcon":"neuroblastoma","sub":"NCT07502287","facets":{"kind":["Trial"],"cancers":["Neuroblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Neuroblastoma","href":"/cancers/neuroblastoma/","tip":"Neuroblastoma is a childhood nerve-cell cancer where anti-GD2 antibodies and, recently, GD2 CAR-T have improved survival in high-risk disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07480954","name":"Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)","tldr":"A phase 1/2 trial of Dual-target CAR-NK cell product in ovarian cancer, run by Beijing Biotech, now recruiting.","route":"/trials/nct07480954/","status":"recruiting","kind":"trial","cancerIcon":"ovarian","sub":"NCT07480954","facets":{"kind":["Trial"],"cancers":["Ovarian cancer","High-grade serous ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"High-grade serous ovarian cancer","href":"/cancers/high-grade-serous-ovarian-cancer/","tip":"High-grade serous cancer is the common, aggressive form of ovarian cancer, now known to start in the fallopian tube. It is treated with surgery and platinum chemotherapy, and maintenance PARP inhibitors have changed its course for the half of patients whose tumours cannot repair DNA properly."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07589517","name":"Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer","tldr":"A phase 1/2 trial of EB-DUO-CAR-NK-CEA/GCC in colorectal cancer, run by Beijing Biotech, now recruiting.","route":"/trials/nct07589517/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT07589517","facets":{"kind":["Trial"],"cancers":["Colorectal cancer","HER2-amplified colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"HER2-amplified colorectal cancer","href":"/cancers/her2-amplified-colorectal/","tip":"A few bowel cancers make too much of the HER2 protein, the same target as in HER2-positive breast cancer. Two HER2 drugs together, tucatinib and trastuzumab, shrink about four in ten of these tumours after chemotherapy has failed, and the antibody-drug conjugate trastuzumab deruxtecan works even when other HER2 drugs have stopped."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06992609","name":"Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.","tldr":"A phase 3 trial of Durvalumab in small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct06992609/","status":"active","kind":"trial","cancerIcon":"sclc","sub":"NCT06992609","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer","Limited-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."},{"label":"Limited-stage small-cell lung cancer","href":"/cancers/limited-stage-sclc/","tip":"Small-cell lung cancer that is still confined to one side of the chest is treated to cure with chemotherapy and radiotherapy given together. Adding two years of the immunotherapy antibody durvalumab afterwards lengthened median survival from under three years to over four and a half, the first improvement in this disease in decades."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03837899","name":"Durvalumab and Tremelimumab for Pediatric Malignancies","tldr":"A phase 1/2 trial of Durvalumab and Tremelimumab in childhood cancers, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct03837899/","status":"active","kind":"trial","cancerIcon":"childhood-cancers","sub":"NCT03837899","facets":{"kind":["Trial"],"cancers":["Childhood cancers"],"year":["2024"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Childhood cancers","href":"/cancers/childhood-cancers/","tip":"Cancer in children is rare and different from adult cancer: the common types are leukaemias, brain tumours, lymphomas and embryonal tumours such as neuroblastoma and Wilms tumour, most are curable in well-resourced health systems, and the great challenge is bringing the same cures to the majority of children who live where they are not available."}],"year":{"facet":"year","value":"2024"},"tags":[]},"sortKeys":{"year":2024}},{"id":"nct05771480","name":"Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)","tldr":"A phase 3 trial of Durvalumab, Gemcitabine, Gemcitabine + cisplatin, Oxaliplatin, Carboplatin and Cisplatin in biliary tract cancer, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct05771480/","status":"active","kind":"trial","cancerIcon":"cholangiocarcinoma","sub":"NCT05771480","facets":{"kind":["Trial"],"cancers":["Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03833154","name":"Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation","tldr":"A phase 3 trial of Durvalumab and Osimertinib in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct03833154/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT03833154","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","EGFR-mutated non-small-cell lung cancer","Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."},{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06221748","name":"DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy","tldr":"A phase 2/3 trial of Disitamab vedotin and Cadonilimab in gastric & gastro-oesophageal junction cancer, run by RemeGen Co., Ltd., now recruiting.","route":"/trials/nct06221748/","status":"recruiting","kind":"trial","cancerIcon":"gastric","sub":"NCT06221748","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer","HER2-positive gastric cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"HER2-positive gastric cancer","href":"/cancers/gastric-her2-positive/","tip":"HER2-positive gastric cancer overexpresses the HER2 growth receptor and is treated with trastuzumab added to chemotherapy, now usually with pembrolizumab as well. After progression the antibody-drug conjugate trastuzumab deruxtecan gives responses that plain chemotherapy cannot."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06178159","name":"DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer","tldr":"A phase 2 trial of Disitamab vedotin, Pertuzumab and Toripalimab in HER2-positive breast cancer, run by RemeGen Co., Ltd., now recruiting.","route":"/trials/nct06178159/","status":"recruiting","kind":"trial","cancerIcon":"breast-her2-positive","sub":"NCT06178159","facets":{"kind":["Trial"],"cancers":["HER2-positive breast cancer","Early HER2-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."},{"label":"Early HER2-positive breast cancer","href":"/cancers/her2-positive-early-breast-cancer/","tip":"HER2-positive breast cancer caught early is usually cured. Chemotherapy with the antibodies trastuzumab and pertuzumab comes before surgery; if the tumour has gone by then, antibodies alone finish the year, and if cancer remains, trastuzumab emtansine or trastuzumab deruxtecan take over. Small tumours get a gentler regimen, and trials now ask how much treatment can be left out."}],"tags":[]},"sortKeys":{"year":0}},{"id":"dzd8586","name":"DZD8586","tldr":"DZD8586 is an experimental small-molecule drug from Dizal Pharmaceuticals in phase 3 trials for chronic lymphocytic leukaemia and diffuse large B-cell lymphoma, with its target not yet stated publicly.","route":"/drugs/dzd8586/","status":"phase-3","kind":"drug","molecule":"dzd8586","modality":"small molecule","facets":{"kind":["Treatment"],"cancers":["Chronic lymphocytic leukaemia","Diffuse large B-cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06539182","name":"DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)","tldr":"A phase 2 trial of DZD8586 in chronic lymphocytic leukaemia, run by Dizal Pharmaceuticals, now recruiting.","route":"/trials/nct06539182/","status":"recruiting","kind":"trial","cancerIcon":"cll","sub":"NCT06539182","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia","Relapsed or refractory chronic lymphocytic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Relapsed or refractory chronic lymphocytic leukaemia","href":"/cancers/cll-relapsed/","tip":"When chronic lymphocytic leukaemia returns, the usual move is to switch drug class: venetoclax-based therapy after a BTK inhibitor, or a BTK inhibitor after venetoclax. Pirtobrutinib (BRUIN) works after the older BTK inhibitors fail, and CAR-T is approved for patients who have run out of both classes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06276283","name":"DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)","tldr":"A phase 2 trial of Sunvozertinib and Bevacizumab in non-small-cell lung cancer, run by Dizal Pharmaceuticals, now recruiting.","route":"/trials/nct06276283/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06276283","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"e-edv-d682","name":"E-EDV-D682","tldr":"E-EDV-D682 is an experimental EDV nanocell (bacterial minicell) drug conjugate from Engeneic Pty in phase 2 trials for pancreatic ductal adenocarcinoma, aimed at EGFR.","route":"/drugs/e-edv-d682/","status":"phase-2","kind":"drug","molecule":"e-edv-d682","modality":"EDV nanocell (bacterial minicell) drug conjugate","sub":"EDV-D682","facets":{"kind":["Treatment"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06926075","name":"Early Phase Study of KESONOTIDE™in Participants With Solid Tumours","tldr":"A phase 1/2 trial of A novel hGIIA-Vimentin Inhibitor in prostate cancer, ovarian cancer, glioma & glioblastoma, pancreatic ductal adenocarcinoma and skin cancer, run by Filamon LTD, now recruiting.","route":"/trials/nct06926075/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT06926075","facets":{"kind":["Trial"],"cancers":["Prostate cancer","Ovarian cancer","Glioma & glioblastoma","Pancreatic ductal adenocarcinoma","Skin cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07455734","name":"Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors","tldr":"A phase 1/2 trial of BNT3214 in advanced solid tumours, run by BioNTech SE, now recruiting.","route":"/trials/nct07455734/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07455734","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"eb-car30-nk","name":"EB-CAR30-NK","tldr":"EB-CAR30-NK is an experimental CAR-NK cell therapy from Beijing Biotech in phase 2 trials for thymoma and thymic carcinoma, aimed at CD30.","route":"/drugs/eb-car30-nk/","status":"phase-2","kind":"drug","molecule":"eb-car30-nk","modality":"CAR-NK cell therapy","facets":{"kind":["Treatment"],"cancers":["Thymoma and thymic carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Thymoma and thymic carcinoma","href":"/cancers/thymic-epithelial/","tip":"Thymoma and thymic carcinoma are rare tumours of the thymus gland in the chest. Thymomas grow slowly, often cause autoimmune diseases such as myasthenia gravis, and are usually cured by surgery; thymic carcinomas behave like other aggressive cancers and have few effective drugs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"eb-mf-car-nk-01","name":"EB-MF-CAR-NK-01","tldr":"EB-MF-CAR-NK-01 is an experimental bispecific antibody from Beijing Biotech in phase 2 trials for mesothelioma, aimed at Mesothelin and FAP.","route":"/drugs/eb-mf-car-nk-01/","status":"phase-2","kind":"drug","molecule":"eb-mf-car-nk-01","modality":"bispecific antibody","facets":{"kind":["Treatment"],"cancers":["Mesothelioma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Mesothelioma","href":"/cancers/mesothelioma/","tip":"An asbestos-caused cancer of the lung lining. Immunotherapy doublets replaced chemotherapy in 2020, and mesothelin CAR-T is under study."}],"tags":[]},"sortKeys":{"year":0}},{"id":"eb-nk-301","name":"EB-NK-301","tldr":"EB-NK-301 is an experimental CAR-NK cell therapy from Beijing Biotech in phase 2 trials, aimed at TROP2.","route":"/drugs/eb-nk-301/","status":"phase-2","kind":"drug","molecule":"eb-nk-301","modality":"CAR-NK cell therapy","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06556563","name":"EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma","tldr":"A phase 3 trial of Temozolomide and Pembrolizumab in glioma & glioblastoma, run by NovoCure GmbH, now recruiting.","route":"/trials/nct06556563/","status":"recruiting","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT06556563","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01020448","name":"Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer","tldr":"A phase 3 trial of Triptorelin in Prostate cancer, run by Ipsen, completed.","route":"/trials/nct01020448/","status":"completed","kind":"trial","cancerIcon":"prostate","sub":"NCT01020448","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04915755","name":"Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease","tldr":"A phase 3 trial of Niraparib in triple-negative breast cancer, run by GlaxoSmithKline, active and no longer recruiting.","route":"/trials/nct04915755/","status":"active","kind":"trial","cancerIcon":"tnbc","sub":"NCT04915755","facets":{"kind":["Trial"],"cancers":["Triple-negative breast cancer"],"year":["2025"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."}],"year":{"facet":"year","value":"2025"},"tags":[]},"sortKeys":{"year":2025}},{"id":"nct02697734","name":"Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease","tldr":"A phase 3 trial of Osilodrostat in Pituitary tumours, run by Novartis Pharmaceuticals, completed.","route":"/trials/nct02697734/","status":"completed","kind":"trial","cancerIcon":"pituitary-tumours","sub":"NCT02697734","facets":{"kind":["Trial"],"cancers":["Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma","href":"/cancers/pituitary-tumours/","tip":"Pituitary tumours are usually benign growths of the hormone gland at the base of the brain that cause trouble by overproducing hormones or pressing on the optic nerves. Prolactin-producing tumours melt away with a tablet, most others are cured by surgery through the nose, and the rare aggressive ones respond to the chemotherapy drug temozolomide."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06959082","name":"Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer","tldr":"A phase 2 trial of Cisplatin in head and neck squamous cell carcinoma, run by VSPharmTech Co.,Ltd., now recruiting.","route":"/trials/nct06959082/","status":"recruiting","kind":"trial","cancerIcon":"head-and-neck","sub":"NCT06959082","facets":{"kind":["Trial"],"cancers":["Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07276789","name":"Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer","tldr":"A phase 2 trial of LS301-IT 0.1 mg/kg in non-small-cell lung cancer, run by Integro Theranostics, now recruiting.","route":"/trials/nct07276789/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07276789","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05304481","name":"Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma","tldr":"A phase 2 trial of ATL administration in hepatocellular carcinoma, run by Lukas Biomedical Inc., now recruiting.","route":"/trials/nct05304481/","status":"recruiting","kind":"trial","cancerIcon":"hcc","sub":"NCT05304481","facets":{"kind":["Trial"],"cancers":["Hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05466149","name":"Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion","tldr":"A phase 2 trial of Furmonertinib in non-small-cell lung cancer, run by Allist Pharmaceuticals, Inc., active and no longer recruiting.","route":"/trials/nct05466149/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT05466149","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06224257","name":"Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia","tldr":"A phase 2 trial of Linperlisib in Leukaemia, run by Institute of Hematology & Blood Diseases Hospital, China, now recruiting.","route":"/trials/nct06224257/","status":"recruiting","kind":"trial","cancerIcon":"leukaemia","sub":"NCT06224257","facets":{"kind":["Trial"],"cancers":["Leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Leukaemia","href":"/cancers/leukaemia/","tip":"Leukaemia means cancer of the blood-forming cells, but the four main types share little beyond the name: acute lymphoblastic and acute myeloid leukaemia are emergencies treated with intensive therapy, while chronic lymphocytic and chronic myeloid leukaemia are slow diseases controlled for years with pills. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03742895","name":"Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)","tldr":"A phase 2 trial of Olaparib in advanced solid tumours, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","route":"/trials/nct03742895/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT03742895","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":["2026"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"year":{"facet":"year","value":"2026"},"tags":[]},"sortKeys":{"year":2026}},{"id":"nct06082102","name":"Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma","tldr":"A phase 3 trial of Orelabrutinib, Rituximab and Lenalidomide in non-Hodgkin lymphoma, run by Beijing InnoCare Pharma Tech Co., Ltd., now recruiting.","route":"/trials/nct06082102/","status":"recruiting","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT06082102","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma","Marginal zone lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."},{"label":"Marginal zone lymphoma","href":"/cancers/marginal-zone-lymphoma/","tip":"Marginal zone lymphoma is a slow B-cell lymphoma that often grows where the body has been fighting a chronic infection: the stomach with Helicobacter pylori, the eye, the skin or the spleen. Curing the infection cures many early cases; the rest are treated with rituximab, chemotherapy or BTK inhibitors."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00880269","name":"Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)","tldr":"A phase 2 trial of Panobinostat in Leukaemia, run by Novartis Pharmaceuticals, completed.","route":"/trials/nct00880269/","status":"completed","kind":"trial","cancerIcon":"leukaemia","sub":"NCT00880269","facets":{"kind":["Trial"],"cancers":["Leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Leukaemia","href":"/cancers/leukaemia/","tip":"Leukaemia means cancer of the blood-forming cells, but the four main types share little beyond the name: acute lymphoblastic and acute myeloid leukaemia are emergencies treated with intensive therapy, while chronic lymphocytic and chronic myeloid leukaemia are slow diseases controlled for years with pills. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01137682","name":"Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly","tldr":"A phase 3 trial of Pasireotide in Pituitary tumours, run by Novartis Pharmaceuticals, completed.","route":"/trials/nct01137682/","status":"completed","kind":"trial","cancerIcon":"pituitary-tumours","sub":"NCT01137682","facets":{"kind":["Trial"],"cancers":["Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma","href":"/cancers/pituitary-tumours/","tip":"Pituitary tumours are usually benign growths of the hormone gland at the base of the brain that cause trouble by overproducing hormones or pressing on the optic nerves. Prolactin-producing tumours melt away with a tablet, most others are cured by surgery through the nose, and the rare aggressive ones respond to the chemotherapy drug temozolomide."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06050122","name":"Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome","tldr":"A phase 3 trial of Patidegib Topical Gel in basal cell carcinoma, run by Sol-Gel Technologies, Ltd., now completed.","route":"/trials/nct06050122/","status":"completed","kind":"trial","cancerIcon":"basal-cell-carcinoma","sub":"NCT06050122","facets":{"kind":["Trial"],"cancers":["Basal cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Basal cell carcinoma","href":"/cancers/basal-cell-carcinoma/","tip":"Basal cell carcinoma is a skin cancer and the most common cancer of all, caused by sun exposure and almost never life-threatening. Nearly all are removed surgically; the rare advanced cases are treated with drugs that block the hedgehog signalling pathway, and with immunotherapy if those fail."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03711032","name":"Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)","tldr":"A phase 3 trial of Pembrolizumab in bladder & urothelial cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","route":"/trials/nct03711032/","status":"active","kind":"trial","cancerIcon":"urothelial","sub":"NCT03711032","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Non-muscle-invasive bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Non-muscle-invasive bladder cancer","href":"/cancers/non-muscle-invasive-bladder-cancer/","tip":"Most bladder cancers are found while still confined to the lining. They are scraped out through the urethra and, when higher risk, treated with BCG instilled into the bladder; the challenge is the frequent recurrences and the patients whose tumours stop responding to BCG."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04241185","name":"Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)","tldr":"A phase 3 trial of Pembrolizumab, Cisplatin, Fluorouracil (5-FU), Mitomycin C and Gemcitabine in bladder & urothelial cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","route":"/trials/nct04241185/","status":"active","kind":"trial","cancerIcon":"urothelial","sub":"NCT04241185","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01876043","name":"Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial","tldr":"A phase 2 trial of Plitidepsin in Liposarcoma, run by Institut Bergonié, recorded as terminated on the registry.","route":"/trials/nct01876043/","kind":"trial","cancerIcon":"liposarcoma","sub":"NCT01876043","facets":{"kind":["Trial"],"cancers":["Liposarcoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Liposarcoma","href":"/cancers/liposarcoma/","tip":"Liposarcoma is a cancer of fat cells that comes in four different forms: two driven by extra copies of the MDM2 gene, one by a fusion gene that makes it unusually sensitive to radiotherapy and trabectedin, and one that behaves like other aggressive sarcomas. Surgery is the mainstay and MDM2 inhibitors are the most promising drugs in trials."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05872347","name":"Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.","tldr":"A phase 2 trial of SPH4336 in brain and spinal cord tumours, run by Shanghai Pharmaceuticals Holding Co., Ltd, now recruiting.","route":"/trials/nct05872347/","status":"recruiting","kind":"trial","cancerIcon":"brain-tumours","sub":"NCT05872347","facets":{"kind":["Trial"],"cancers":["Brain and spinal cord tumours","Brain metastases"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Brain and spinal cord tumours","href":"/cancers/brain-tumours/","tip":"Brain and spinal cord tumours range from slow-growing meningiomas and low-grade gliomas to glioblastoma, the commonest malignant brain tumour in adults, and a distinct set of childhood tumours such as medulloblastoma and diffuse midline glioma. Molecular markers now define them, and treatment is surgery, radiotherapy and, for some, drugs chosen by those markers."},{"label":"Brain metastases","href":"/cancers/secondary-brain-tumours/","tip":"Brain metastases are cancers that have spread to the brain from elsewhere, most often from the lung, breast or skin. Focused radiation aimed at each spot (radiosurgery) has largely replaced radiation to the whole brain, and for some cancers modern targeted drugs and immunotherapy reach the brain well enough to shrink the deposits on their own."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06189209","name":"Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)","tldr":"A phase 2 trial of Tenalisib in triple-negative breast cancer, run by Rhizen Pharmaceuticals SA, now recruiting.","route":"/trials/nct06189209/","status":"recruiting","kind":"trial","cancerIcon":"tnbc","sub":"NCT06189209","facets":{"kind":["Trial"],"cancers":["Triple-negative breast cancer","Metastatic triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Metastatic triple-negative breast cancer","href":"/cancers/tnbc-metastatic/","tip":"Triple-negative breast cancer that has spread is not curable, but its treatment has been transformed since 2020. By PD-L1 score, first treatment is pembrolizumab with chemotherapy or with sacituzumab govitecan, or datopotamab deruxtecan or sacituzumab govitecan alone; BRCA carriers can take a PARP inhibitor tablet; and trastuzumab deruxtecan reaches the third of tumours with low HER2."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07498478","name":"Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment","tldr":"A phase 2 trial of Fulvestrant and Tinengotinib in HR-positive / HER2-negative breast cancer, run by TransThera Sciences (Nanjing), Inc., now recruiting.","route":"/trials/nct07498478/","status":"recruiting","kind":"trial","cancerIcon":"breast-hr-positive","sub":"NCT07498478","facets":{"kind":["Trial"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06995677","name":"Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer","tldr":"A phase 2 trial of TYRA-300 in bladder & urothelial cancer, run by Tyra Biosciences, Inc, now recruiting.","route":"/trials/nct06995677/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT06995677","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Non-muscle-invasive bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Non-muscle-invasive bladder cancer","href":"/cancers/non-muscle-invasive-bladder-cancer/","tip":"Most bladder cancers are found while still confined to the lining. They are scraped out through the urethra and, when higher risk, treated with BCG instilled into the bladder; the challenge is the frequent recurrences and the patients whose tumours stop responding to BCG."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06642545","name":"Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer","tldr":"A phase 2 trial of Disitamab vedotin, RC148 and Toripalimab in HER2-positive breast cancer, run by RemeGen Co., Ltd., now recruiting.","route":"/trials/nct06642545/","status":"recruiting","kind":"trial","cancerIcon":"breast-her2-positive","sub":"NCT06642545","facets":{"kind":["Trial"],"cancers":["HER2-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05374915","name":"Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)","tldr":"A phase 2 trial of REM-001 photodynamic therapy in advanced solid tumours, run by Kintara Therapeutics, Inc., active and no longer recruiting.","route":"/trials/nct05374915/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05374915","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00769704","name":"Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma","tldr":"A phase 3 trial of Talimogene laherparepvec and Sargramostim in Melanoma, run by BioVex Limited, completed.","route":"/trials/nct00769704/","status":"completed","kind":"trial","cancerIcon":"melanoma","sub":"NCT00769704","facets":{"kind":["Trial"],"cancers":["Melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03485209","name":"Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors","tldr":"A phase 2 trial of Tisotumab vedotin, Pembrolizumab, Carboplatin and Cisplatin in colorectal cancer, non-small-cell lung cancer, pancreatic ductal adenocarcinoma and head and neck squamous cell carcinoma, run by Seagen, a wholly owned subsidiary of Pfizer, active and no longer recruiting.","route":"/trials/nct03485209/","status":"active","kind":"trial","cancerIcon":"colorectal","sub":"NCT03485209","facets":{"kind":["Trial"],"cancers":["Colorectal cancer","Non-small-cell lung cancer","Pancreatic ductal adenocarcinoma","Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01310894","name":"Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance","tldr":"A phase 3 trial of Padeliporfin in Prostate cancer, run by Steba Biotech S.A., completed.","route":"/trials/nct01310894/","status":"completed","kind":"trial","cancerIcon":"prostate","sub":"NCT01310894","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03937141","name":"Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer","tldr":"A phase 2 trial of ADU-S100 in Head and neck squamous cell carcinoma, run by Chinook Therapeutics, Inc. (formerly Aduro), recorded as terminated on the registry.","route":"/trials/nct03937141/","kind":"trial","cancerIcon":"head-and-neck","sub":"NCT03937141","facets":{"kind":["Trial"],"cancers":["Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03567889","name":"Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients","tldr":"A phase 3 trial of Daromun in melanoma, run by Philogen S.p.A., now recruiting.","route":"/trials/nct03567889/","status":"recruiting","kind":"trial","cancerIcon":"melanoma","sub":"NCT03567889","facets":{"kind":["Trial"],"cancers":["Melanoma","Stage III melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"label":"Stage III melanoma","href":"/cancers/stage-iii-melanoma/","tip":"Stage III melanoma has spread to nearby lymph nodes but not further, and after surgery a year of immunotherapy, or of targeted pills if the cancer has a BRAF mutation, roughly halves the chance of it coming back. The newest trials show that giving immunotherapy before the operation instead of after works even better and lets most people stop treatment early."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03351062","name":"Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer","tldr":"A phase 3 trial of Tamoxifen and Toremifene in Breast cancer, run by Chinese Anti-Cancer Association, with a status the registry has not verified recently.","route":"/trials/nct03351062/","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT03351062","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01875393","name":"Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer","tldr":"A phase 3 trial of Padeliporfin in Prostate cancer, run by Steba Biotech S.A., completed.","route":"/trials/nct01875393/","status":"completed","kind":"trial","cancerIcon":"prostate","sub":"NCT01875393","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06486142","name":"EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study","tldr":"A phase 3 trial of Afatinib, Dacomitinib and Osimertinib in Non-small-cell lung cancer, run by Region Skane, now recruiting.","route":"/trials/nct06486142/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06486142","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"eik1001","name":"EIK1001","tldr":"EIK1001 is an experimental investigational agent whose form is not stated in the registry from Eikon Therapeutics in phase 3 trials for melanoma and non-small-cell lung cancer, with its target not yet stated publicly.","route":"/drugs/eik1001/","status":"phase-3","kind":"drug","molecule":"eik1001","modality":"small molecule (structure undisclosed or not yet in PubChem)","facets":{"kind":["Treatment"],"cancers":["Melanoma","Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"eik1005","name":"EIK1005","tldr":"EIK1005 is a small-molecule inhibitor from Eikon Therapeutics, in registered phase 2 trials for colorectal cancer, endometrial cancer.","route":"/drugs/eik1005/","status":"phase-2","kind":"drug","molecule":"eik1005","modality":"Small-molecule inhibitor","sub":"EIK1005","facets":{"kind":["Treatment"],"cancers":["Colorectal cancer","Endometrial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct06525298","name":"EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors","tldr":"A phase 1/2 trial of Olaparib and Trastuzumab deruxtecan in advanced solid tumours, run by Eisbach Bio GmbH, now recruiting.","route":"/trials/nct06525298/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06525298","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05596409","name":"ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study","tldr":"A phase 2 trial of Elacestrant in HR-positive / HER2-negative breast cancer, run by Stemline Therapeutics, Inc., active and no longer recruiting.","route":"/trials/nct05596409/","status":"active","kind":"trial","cancerIcon":"breast-hr-positive","sub":"NCT05596409","facets":{"kind":["Trial"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00744653","name":"Electrochemotherapy for Chest Wall Recurrence af Breast Cancer: Present Challenges and Future Prospects","tldr":"A phase 2 trial of Electrochemotherapy in Breast cancer, run by Copenhagen University Hospital at Herlev, recorded as terminated on the registry.","route":"/trials/nct00744653/","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT00744653","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07443475","name":"Electrochemotherapy for Recurrent Vulvar Cancer","tldr":"A phase 2 trial of Electrochemotherapy in Vulvar cancer, run by Institute of Oncology Ljubljana, now recruiting.","route":"/trials/nct07443475/","status":"recruiting","kind":"trial","cancerIcon":"vulvar","sub":"NCT07443475","facets":{"kind":["Trial"],"cancers":["Vulvar cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Vulvar cancer","href":"/cancers/vulvar/","tip":"An uncommon cancer of the external genitalia with two distinct causes: HPV infection in younger women and chronic skin inflammation in older women. Surgery is the mainstay, and sentinel-node biopsy has made it far less mutilating."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05395962","name":"Electrochemotherapy With Carboplatinum Plus Bleomycin Versus Bleomycin Alone in Vulvar Cancer","tldr":"A phase 2 trial of Electrochemotherapy in Vulvar cancer, run by IRCCS Azienda Ospedaliero-Universitaria di Bologna, now recruiting.","route":"/trials/nct05395962/","status":"recruiting","kind":"trial","cancerIcon":"vulvar","sub":"NCT05395962","facets":{"kind":["Trial"],"cancers":["Vulvar cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Vulvar cancer","href":"/cancers/vulvar/","tip":"An uncommon cancer of the external genitalia with two distinct causes: HPV infection in younger women and chronic skin inflammation in older women. Surgery is the mainstay, and sentinel-node biopsy has made it far less mutilating."}],"tags":[]},"sortKeys":{"year":0}},{"id":"elenestinib","name":"Elenestinib","tldr":"Elenestinib is an experimental small-molecule drug from Blueprint Medicines in phase 3 trials for systemic mastocytosis, with its target not yet stated publicly.","route":"/drugs/elenestinib/","status":"phase-3","kind":"drug","molecule":"elenestinib","modality":"small molecule","sub":"BLU-263","facets":{"kind":["Treatment"],"cancers":["Systemic mastocytosis","Indolent and smouldering systemic mastocytosis"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Systemic mastocytosis","href":"/cancers/systemic-mastocytosis/","tip":"Systemic mastocytosis is a clonal disease of mast cells, the immune cells that release histamine; almost every case is driven by a single mutation in the KIT gene. Precise KIT-blocking pills now shrink the mast cell burden, ease symptoms and, in the aggressive forms, prolong life. Most patients have the indolent form, where the goal is controlling symptoms and preventing anaphylaxis."},{"label":"Indolent and smouldering systemic mastocytosis","href":"/cancers/indolent-systemic-mastocytosis/","tip":"Indolent systemic mastocytosis is the common, slow form of this rare blood disorder, in which KIT-mutant mast cells build up in the marrow and skin and release histamine that causes flushing, itching, stomach pain, bone thinning and sometimes severe allergic reactions. Life expectancy is near normal, antihistamines and adrenaline control symptoms, and low-dose avapritinib was approved in 2023."}],"tags":[]},"sortKeys":{"year":0}},{"id":"elritercept","name":"Elritercept","tldr":"Elritercept is Keros and Takeda's ligand trap for the anaemia of myelodysplastic syndromes, a relative of luspatercept, in phase 3 trials.","route":"/drugs/elritercept/","status":"phase-3","kind":"drug","molecule":"elritercept","modality":"Activin receptor type IIA ligand trap (fusion protein), subcutaneous","sub":"KER-050","facets":{"kind":["Treatment"],"cancers":["Myelodysplastic syndromes / neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Myelodysplastic syndromes / neoplasms","href":"/cancers/mds/","tip":"Bone-marrow disorders where blood cells are made badly and too few reach the blood; a third progress to acute leukaemia. Treatment ranges from transfusions and growth factors to hypomethylating drugs and, for the fit, transplant."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04241315","name":"ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting","tldr":"A phase 3 trial of Pafolacianine in Lung cancer, run by On Target Laboratories, LLC, completed.","route":"/trials/nct04241315/","status":"completed","kind":"trial","cancerIcon":"lung-cancer","sub":"NCT04241315","facets":{"kind":["Trial"],"cancers":["Lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Lung cancer","href":"/cancers/lung-cancer/","tip":"Lung cancer splits into non-small-cell (about 85 percent) and small-cell (about 15 percent) disease, which behave and are treated very differently. The subtype pages carry the detail; this page covers screening, staging and what the types share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"emactuzumab","name":"Emactuzumab","tldr":"Emactuzumab is an experimental monoclonal antibody from SynOx Therapeutics in phase 3 trials for tenosynovial giant cell tumour, aimed at CSF1R.","route":"/drugs/emactuzumab/","status":"phase-3","kind":"drug","molecule":"emactuzumab","modality":"monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Tenosynovial giant cell tumour"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Tenosynovial giant cell tumour","href":"/cancers/tenosynovial-giant-cell-tumour/","tip":"TGCT is a benign but destructive tumour of the joint lining, classed with soft-tissue sarcomas, in which a few cells carrying a CSF1 gene fusion recruit a crowd of normal immune cells that eat away at the joint. Surgery cures most localised cases, and for diffuse or recurrent disease two pills that block the CSF1 receptor, pexidartinib and vimseltinib, shrink tumours and restore joint function."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06550141","name":"Emapalumab Prevention of CAR-T Cell Associated Toxicities","tldr":"A phase 2 trial of Emapalumab, Cyclophosphamide, Fludarabine and Axicabtagene ciloleucel in Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma, Primary mediastinal and Follicular lymphoma, run by Marcela V. Maus, M.D.,Ph.D., now recruiting.","route":"/trials/nct06550141/","status":"recruiting","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT06550141","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma","Diffuse large B-cell lymphoma","Primary mediastinal (thymic) large B-cell lymphoma","Follicular lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."},{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."},{"label":"Primary mediastinal (thymic) large B-cell lymphoma","href":"/cancers/primary-mediastinal-b-cell-lymphoma/","tip":"Primary mediastinal B-cell lymphoma is a fast-growing lymphoma of the thymus behind the breastbone that mostly affects young women. Immunochemotherapy cures about nine in ten, radiotherapy can now be skipped when the end-of-treatment scan is clear, and PD-1 antibodies and CAR-T cells rescue many of those who relapse."},{"label":"Follicular lymphoma","href":"/cancers/follicular-lymphoma/","tip":"Follicular lymphoma is the most common slow-growing lymphoma, defined in about 85% of cases by a BCL2 translocation. Most people live with it for decades, treated only when it causes problems; it can be controlled repeatedly with anti-CD20 antibodies, chemotherapy, bispecifics or CAR-T but rarely cured, and a small share transform into an aggressive lymphoma each year."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07567014","name":"Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS","tldr":"A phase 2 trial of Emapalumab in Multiple myeloma, run by NYU Langone Health, not yet recruiting.","route":"/trials/nct07567014/","status":"planned","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT07567014","facets":{"kind":["Trial"],"cancers":["Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[]},"sortKeys":{"year":0}},{"id":"emavusertib","name":"Emavusertib","tldr":"Emavusertib is an oral serine/threonine kinase inhibitor from Curis, Inc., in registered phase 2 trials for chronic lymphocytic leukaemia, brain and spinal cord tumours.","route":"/drugs/emavusertib/","status":"phase-2","kind":"drug","molecule":"emavusertib","modality":"Oral serine/threonine kinase inhibitor","facets":{"kind":["Treatment"],"cancers":["Chronic lymphocytic leukaemia","Brain and spinal cord tumours"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Brain and spinal cord tumours","href":"/cancers/brain-tumours/","tip":"Brain and spinal cord tumours range from slow-growing meningiomas and low-grade gliomas to glioblastoma, the commonest malignant brain tumour in adults, and a distinct set of childhood tumours such as medulloblastoma and diffuse midline glioma. Molecular markers now define them, and treatment is surgery, radiotherapy and, for some, drugs chosen by those markers."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"enb003","name":"ENB003","tldr":"ENB003 is a small-molecule antagonist from ENB Therapeutics, Inc, in registered phase 2 trials for melanoma.","route":"/drugs/enb003/","status":"phase-2","kind":"drug","molecule":"enb003","modality":"Small-molecule antagonist","sub":"ENB003","facets":{"kind":["Treatment"],"cancers":["Melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct02971345","name":"Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus","tldr":"A phase 3 trial of Epirubicin and Ethiodized oil in Hepatocellular carcinoma, run by Shanghai Zhongshan Hospital, with a status the registry has not verified recently.","route":"/trials/nct02971345/","kind":"trial","cancerIcon":"hcc","sub":"NCT02971345","facets":{"kind":["Trial"],"cancers":["Hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07566156","name":"Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)","tldr":"A phase 3 trial of Enfortumab vedotin, Cisplatin, Mitomycin C, Gemcitabine and Pembrolizumab in bladder & urothelial cancer, run by Astellas Pharma Global Development, Inc., now recruiting.","route":"/trials/nct07566156/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT07566156","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"englumafusp-alfa","name":"Englumafusp alfa","tldr":"Englumafusp alfa is an experimental fusion protein from Hoffmann-La Roche in phase 2 trials for hodgkin lymphoma, aimed at CD19.","route":"/drugs/englumafusp-alfa/","status":"phase-2","kind":"drug","molecule":"englumafusp-alfa","modality":"fusion protein","sub":"RO7227166","facets":{"kind":["Treatment"],"cancers":["Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Hodgkin lymphoma","href":"/cancers/hodgkin-lymphoma/","tip":"Hodgkin lymphoma is one of the most curable cancers, where the goal is now to cure with less toxicity, using brentuximab and, from 2026, first-line nivolumab."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06120140","name":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib","tldr":"A phase 2 trial of Amivantamab and Lazertinib in non-small-cell lung cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.","route":"/trials/nct06120140/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT06120140","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"env-501","name":"ENV-501","tldr":"ENV-501 is an experimental antibody-drug conjugate from Hummingbird Bioscience in phase 2 trials for melanoma, non-small-cell lung cancer and HR-positive / HER2-negative breast cancer, aimed at HER3.","route":"/drugs/env-501/","status":"phase-2","kind":"drug","molecule":"env-501","modality":"ADC","facets":{"kind":["Treatment"],"cancers":["Melanoma","Non-small-cell lung cancer","HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04891198","name":"ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors","tldr":"A phase 2 trial of Envafolimab in advanced solid tumours, run by 3D Medicines (Sichuan) Co., Ltd., now recruiting.","route":"/trials/nct04891198/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04891198","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ep0031","name":"EP0031","tldr":"EP0031 is an experimental small-molecule drug from Ellipses Pharma in phase 2 trials for non-small-cell lung cancer, aimed at RET.","route":"/drugs/ep0031/","status":"phase-2","kind":"drug","molecule":"ep0031","modality":"small molecule (structure undisclosed or not yet in PubChem)","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ep0062","name":"EP0062","tldr":"EP0062 is an experimental small-molecule drug from Ellipses Pharma in phase 2 trials for HR-positive / HER2-negative breast cancer, aimed at Androgen receptor.","route":"/drugs/ep0062/","status":"phase-2","kind":"drug","molecule":"ep0062","modality":"small molecule","facets":{"kind":["Treatment"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02890602","name":"Erythropoietin for Management of Anemia Caused by Chemotherapy","tldr":"A phase 2 trial of Darbepoetin alfa, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone in Diffuse large B-cell lymphoma, run by Kosin University Gospel Hospital, completed.","route":"/trials/nct02890602/","status":"completed","kind":"trial","cancerIcon":"dlbcl","sub":"NCT02890602","facets":{"kind":["Trial"],"cancers":["Diffuse large B-cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."}],"tags":[]},"sortKeys":{"year":0}},{"id":"esg401","name":"ESG401","tldr":"ESG401 is an experimental investigational agent whose form is not stated in the registry from Qilu Pharmaceutical in phase 3 trials for triple-negative breast cancer and HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.","route":"/drugs/esg401/","status":"phase-3","kind":"drug","molecule":"esg401","modality":"antibody-drug conjugate (ADC), per the sponsor's pipeline page; form not stated in the registry record","facets":{"kind":["Treatment"],"cancers":["Triple-negative breast cancer","HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04634357","name":"ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma","tldr":"A phase 1/2 trial of ET140203 T Cells in hepatoblastoma and hepatocellular carcinoma, run by Eureka Therapeutics Inc., now recruiting.","route":"/trials/nct04634357/","status":"recruiting","kind":"trial","cancerIcon":"hepatoblastoma","sub":"NCT04634357","facets":{"kind":["Trial"],"cancers":["Hepatoblastoma","Hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hepatoblastoma","href":"/cancers/hepatoblastoma/","tip":"Hepatoblastoma is a childhood liver cancer, mostly of toddlers, cured in most standard-risk cases with cisplatin chemotherapy and surgery, including liver transplant when the tumour cannot be cut out. Sodium thiosulfate given after cisplatin halves the permanent hearing loss cisplatin causes, and became the first approved otoprotectant in 2022."},{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06806033","name":"Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL","tldr":"A phase 2 trial of Obinutuzumab, Glofitamab, Gemcitabine and Oxaliplatin in hodgkin lymphoma, run by Hoffmann-La Roche, now recruiting.","route":"/trials/nct06806033/","status":"recruiting","kind":"trial","cancerIcon":"hodgkin-lymphoma","sub":"NCT06806033","facets":{"kind":["Trial"],"cancers":["Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hodgkin lymphoma","href":"/cancers/hodgkin-lymphoma/","tip":"Hodgkin lymphoma is one of the most curable cancers, where the goal is now to cure with less toxicity, using brentuximab and, from 2026, first-line nivolumab."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04390737","name":"Evaluate the Safety and Clinical Activity of HH2853","tldr":"A phase 1/2 trial of HH2853 Tablets in non-Hodgkin lymphoma, epithelioid sarcoma and peripheral T-cell lymphomas, run by Haihe Biopharma Co., Ltd., now recruiting.","route":"/trials/nct04390737/","status":"recruiting","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT04390737","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma","Epithelioid sarcoma","Peripheral T-cell lymphomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."},{"label":"Epithelioid sarcoma","href":"/cancers/epithelioid-sarcoma/","tip":"Epithelioid sarcoma is a rare soft tissue cancer that has lost a gene brake called SMARCB1, leaving it dependent on the enzyme EZH2. Surgery cures localised tumours. The EZH2 inhibitor tazemetostat, the first epigenetic drug approved for a solid tumour, was approved in 2020 and withdrawn worldwide in March 2026 after secondary blood cancers in a lymphoma trial, so there is no targeted drug today."},{"label":"Peripheral T-cell lymphomas","href":"/cancers/peripheral-t-cell-lymphoma/","tip":"Peripheral T-cell lymphomas are lymphomas of T cells rather than B cells. They are rarer, more varied and, apart from a few subtypes, harder to treat than B-cell lymphomas; several new drugs help only defined subtypes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07095868","name":"Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors","tldr":"A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by Everest Medicines (Beijing) Co., Ltd., now recruiting.","route":"/trials/nct07095868/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07095868","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00542542","name":"Evaluate the Use of Paravertebral Block in Reconstructive Breast Surgery","tldr":"A phase 3 trial of Fentanyl in Breast cancer, run by M.D. Anderson Cancer Center, completed.","route":"/trials/nct00542542/","status":"completed","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT00542542","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05037279","name":"Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)","tldr":"A phase 3 trial of Bacillus Calmette-Guerin: Strain Russian BCG-I in bladder & urothelial cancer, run by Verity Pharmaceuticals Inc., now recruiting.","route":"/trials/nct05037279/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT05037279","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Non-muscle-invasive bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Non-muscle-invasive bladder cancer","href":"/cancers/non-muscle-invasive-bladder-cancer/","tip":"Most bladder cancers are found while still confined to the lining. They are scraped out through the urethra and, when higher risk, treated with BCG instilled into the bladder; the challenge is the frequent recurrences and the patients whose tumours stop responding to BCG."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01377220","name":"Evaluation of 11 C-Choline PET-CT for Detection of Hepatocellular Carcinoma","tldr":"A phase 2 trial of Choline C-11 in Hepatocellular carcinoma, run by Commissariat A L'energie Atomique, with a status the registry has not verified recently.","route":"/trials/nct01377220/","kind":"trial","cancerIcon":"hcc","sub":"NCT01377220","facets":{"kind":["Trial"],"cancers":["Hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06262139","name":"Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients","tldr":"A phase 1/2 trial of MT218 injection in prostate cancer, run by Songqi Gao, now recruiting.","route":"/trials/nct06262139/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT06262139","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06612281","name":"Evaluation of Gixam's Performance in a FIT Negative Population","tldr":"A phase 2 trial of colorectal cancer (CRC) screening in colorectal cancer, run by Jubaan Ltd., now recruiting.","route":"/trials/nct06612281/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT06612281","facets":{"kind":["Trial"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07617493","name":"Evaluation of ICP-B208 in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of ICP-B208 in advanced solid tumours, run by Beijing InnoCare Pharma Tech Co., Ltd., now recruiting.","route":"/trials/nct07617493/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07617493","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05696626","name":"Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation","tldr":"A phase 3 trial of Abemaciclib and Fulvestrant in advanced solid tumours, run by LeonaBio, now recruiting.","route":"/trials/nct05696626/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05696626","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07669519","name":"Evaluation of NuvastaticTM in Reducing Cancer-Related Fatigue in Colon Cancer Patients Undergoing First-Line Chemotherapy","tldr":"A phase 3 trial of Nuvastatic™ in colorectal cancer, run by Natureceuticals Sdn Bhd, now recruiting.","route":"/trials/nct07669519/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT07669519","facets":{"kind":["Trial"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01767714","name":"Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation","tldr":"A phase 3 trial of Filgrastim and Plerixafor in Non-Hodgkin lymphoma, run by Sanofi, completed.","route":"/trials/nct01767714/","status":"completed","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT01767714","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06824064","name":"Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer","tldr":"A phase 2 trial of RBS2418 in colorectal cancer, run by Riboscience, LLC., now recruiting.","route":"/trials/nct06824064/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT06824064","facets":{"kind":["Trial"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03579836","name":"Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer","tldr":"A phase 1/2 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by BeyondBio Inc., now recruiting.","route":"/trials/nct03579836/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT03579836","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00911326","name":"Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma","tldr":"A phase 3 trial of Technetium-99m tilmanocept in Head and neck squamous cell carcinoma, run by Navidea Biopharmaceuticals, recorded as terminated on the registry.","route":"/trials/nct00911326/","kind":"trial","cancerIcon":"head-and-neck","sub":"NCT00911326","facets":{"kind":["Trial"],"cancers":["Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07056777","name":"Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer","tldr":"A phase 1/2 trial of Oxaliplatin, Capecitabine and Leucovorin (folinic acid) in advanced solid tumours, run by Zhejiang Doer Biologics Co., Ltd., now recruiting.","route":"/trials/nct07056777/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07056777","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07499674","name":"Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung","tldr":"A phase 3 trial of Abenacianine in advanced solid tumours, run by Vergent Bioscience, Inc., now recruiting.","route":"/trials/nct07499674/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07499674","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07787429","name":"Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma","tldr":"A phase 2 trial of Mifamurtide and Sorafenib in Osteosarcoma, run by Anna Raciborska, now recruiting.","route":"/trials/nct07787429/","status":"recruiting","kind":"trial","cancerIcon":"osteosarcoma","sub":"NCT07787429","facets":{"kind":["Trial"],"cancers":["Osteosarcoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Osteosarcoma","href":"/cancers/osteosarcoma/","tip":"Osteosarcoma is the most common bone cancer, mostly in teenagers. Chemotherapy plus surgery cures about two-thirds when it has not spread; because no new drug has beaten that chemotherapy in a large trial in 30 years, the next gains are being sought in cellular therapy against GD2, HER2 and B7-H3."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07136181","name":"Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma","tldr":"A phase 1/2 trial of NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers. in uveal melanoma, run by Novelwise Pharmaceutical Corporation, now recruiting.","route":"/trials/nct07136181/","status":"recruiting","kind":"trial","cancerIcon":"uveal-melanoma","sub":"NCT07136181","facets":{"kind":["Trial"],"cancers":["Uveal melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Uveal melanoma","href":"/cancers/uveal-melanoma/","tip":"A melanoma inside the eye that is biologically unrelated to skin melanoma: different mutations, no response to standard immunotherapy, and a tendency to spread to the liver years later. Tebentafusp is the first drug ever to extend survival in the metastatic disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06702618","name":"Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer","tldr":"A phase 2 trial of Fulvestrant and TQB3616 in advanced solid tumours, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., active and no longer recruiting.","route":"/trials/nct06702618/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06702618","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06824168","name":"Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission","tldr":"A phase 2 trial of Quizartinib in acute myeloid leukaemia, run by Daiichi Sankyo, now recruiting.","route":"/trials/nct06824168/","status":"recruiting","kind":"trial","cancerIcon":"aml","sub":"NCT06824168","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[]},"sortKeys":{"year":0}},{"id":"evexomostat","name":"Evexomostat","tldr":"Evexomostat is a small-molecule inhibitor from SynDevRx, Inc., in registered phase 2 trials for metastatic cancer.","route":"/drugs/evexomostat/","status":"phase-2","kind":"drug","molecule":"evexomostat","modality":"Small-molecule inhibitor","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct05455619","name":"Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer","tldr":"A phase 1/2 trial of Evexomostat in advanced solid tumours, run by SynDevRx, Inc., now recruiting.","route":"/trials/nct05455619/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05455619","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"evm14","name":"EVM14","tldr":"EVM14 is a cancer vaccine from Everest Medicines (Beijing) Co., Ltd., in registered phase 2 trials for metastatic cancer.","route":"/drugs/evm14/","status":"phase-2","kind":"drug","molecule":"evm14","modality":"Cancer vaccine","sub":"EVM14","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"evorpacept","name":"Evorpacept","tldr":"Evorpacept is an experimental immune checkpoint modulator from ALX Oncology in phase 3 trials for gastric & gastro-oesophageal junction cancer, HR-positive / HER2-negative breast cancer and HER2-positive breast cancer, with its target not yet stated publicly.","route":"/drugs/evorpacept/","status":"phase-3","kind":"drug","molecule":"evorpacept","modality":"immune checkpoint modulator","sub":"ALX148","facets":{"kind":["Treatment"],"cancers":["Gastric & gastro-oesophageal junction cancer","HR-positive / HER2-negative breast cancer","HER2-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02260817","name":"Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer","tldr":"A phase 3 trial of Choline C-11 in Prostate cancer, run by Global Isotopes, LLC d/b/a Zevacor Molecular, completed.","route":"/trials/nct02260817/","status":"completed","kind":"trial","cancerIcon":"prostate","sub":"NCT02260817","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07146672","name":"Exploratory Study of Super DC Cell Injection in Preventing Recurrence After Radical Surgery for Tumors","tldr":"A phase 1/2 trial of Super DC Vaccine in advanced solid tumours, run by Shanghai Cell Therapy Group Co.,Ltd, now recruiting.","route":"/trials/nct07146672/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07146672","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03441113","name":"Extended Access of Momelotinib in Adults With Myelofibrosis","tldr":"A phase 2 trial of MMB in myeloproliferative neoplasms, run by GlaxoSmithKline, active and no longer recruiting.","route":"/trials/nct03441113/","status":"active","kind":"trial","cancerIcon":"myeloproliferative-neoplasms","sub":"NCT03441113","facets":{"kind":["Trial"],"cancers":["Myeloproliferative neoplasms","Primary myelofibrosis"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Myeloproliferative neoplasms","href":"/cancers/myeloproliferative-neoplasms/","tip":"Myeloproliferative neoplasms are slow-growing blood cancers in which the marrow overproduces red cells (polycythaemia vera), platelets (essential thrombocythaemia) or scar tissue (myelofibrosis). Almost all carry a mutation in JAK2, CALR or MPL; treatment aims to prevent clots and control symptoms, and only transplant cures myelofibrosis."},{"label":"Primary myelofibrosis","href":"/cancers/primary-myelofibrosis/","tip":"Primary myelofibrosis is a blood cancer in which the marrow scars over, the spleen swells and patients become anaemic and exhausted. JAK inhibitors, ruxolitinib first (COMFORT) and then fedratinib, pacritinib and momelotinib (MOMENTUM), shrink the spleen and relieve symptoms; only a donor stem cell transplant can cure it."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07405164","name":"Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)","tldr":"A phase 3 trial of Belzutifan, Nivolumab, Lenvatinib and Cabozantinib in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting.","route":"/trials/nct07405164/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07405164","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04655092","name":"Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients","tldr":"A phase 3 trial of Ropeginterferon alfa-2b in myeloproliferative neoplasms, run by PharmaEssentia Japan K.K., now recruiting.","route":"/trials/nct04655092/","status":"recruiting","kind":"trial","cancerIcon":"myeloproliferative-neoplasms","sub":"NCT04655092","facets":{"kind":["Trial"],"cancers":["Myeloproliferative neoplasms","Essential thrombocythaemia","Polycythaemia vera"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Myeloproliferative neoplasms","href":"/cancers/myeloproliferative-neoplasms/","tip":"Myeloproliferative neoplasms are slow-growing blood cancers in which the marrow overproduces red cells (polycythaemia vera), platelets (essential thrombocythaemia) or scar tissue (myelofibrosis). Almost all carry a mutation in JAK2, CALR or MPL; treatment aims to prevent clots and control symptoms, and only transplant cures myelofibrosis."},{"label":"Essential thrombocythaemia","href":"/cancers/essential-thrombocythaemia/","tip":"Essential thrombocythaemia is a slow blood cancer in which the marrow makes too many platelets. Most people need only aspirin and monitoring; those at higher risk of clots take a drug to lower the platelet count, usually hydroxyurea or interferon, with anagrelide in reserve."},{"label":"Polycythaemia vera","href":"/cancers/polycythaemia-vera/","tip":"Polycythaemia vera is a slow blood cancer in which a single faulty gene, JAK2, makes the bone marrow produce too many red cells. Thick blood causes clots, so treatment thins it (blood removal, aspirin) and, for higher-risk patients, calms the marrow with hydroxyurea, interferon or ruxolitinib; a hepcidin mimic, rusfertide, now controls red cell counts without regular blood removal."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06465433","name":"Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab","tldr":"A phase 2 trial of Tafasitamab in advanced solid tumours, run by Incyte Corporation, now recruiting.","route":"/trials/nct06465433/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06465433","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04930653","name":"Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma","tldr":"A phase 2 trial of Methoxsalen and Mogamulizumab in Cutaneous T-cell lymphoma, Peripheral T-cell lymphomas and Non-Hodgkin lymphoma, run by City of Hope Medical Center, now recruiting.","route":"/trials/nct04930653/","status":"recruiting","kind":"trial","cancerIcon":"cutaneous-t-cell-lymphoma","sub":"NCT04930653","facets":{"kind":["Trial"],"cancers":["Cutaneous T-cell lymphoma","Peripheral T-cell lymphomas","Non-Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Cutaneous T-cell lymphoma","href":"/cancers/cutaneous-t-cell-lymphoma/","tip":"Mycosis fungoides is a lymphoma that lives in the skin, looking like eczema or psoriasis for years before it is diagnosed. It is treated with creams, light and skin-directed radiotherapy for as long as possible, then with antibodies such as mogamulizumab and brentuximab vedotin when it spreads to the blood or lymph nodes."},{"label":"Peripheral T-cell lymphomas","href":"/cancers/peripheral-t-cell-lymphoma/","tip":"Peripheral T-cell lymphomas are lymphomas of T cells rather than B cells. They are rarer, more varied and, apart from a few subtypes, harder to treat than B-cell lymphomas; several new drugs help only defined subtypes."},{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"f182112","name":"F182112","tldr":"F182112 is an experimental investigational agent whose form is not stated in the registry from Shandong New Time Pharmaceutical in phase 3 trials for multiple myeloma, with its target not yet stated publicly.","route":"/drugs/f182112/","status":"phase-3","kind":"drug","molecule":"f182112","modality":"not stated (registered as a drug or biological on ClinicalTrials.gov)","facets":{"kind":["Treatment"],"cancers":["Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[]},"sortKeys":{"year":0}},{"id":"farletuzumab-ecteribulin","name":"Farletuzumab ecteribulin","tldr":"Farletuzumab ecteribulin is an antibody-drug conjugate from Eisai Inc., in registered phase 2 trials for metastatic cancer.","route":"/drugs/farletuzumab-ecteribulin/","status":"phase-2","kind":"drug","molecule":"farletuzumab-ecteribulin","modality":"Antibody-drug conjugate","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"farletuzumab-exatecan","name":"Farletuzumab-exatecan","tldr":"Farletuzumab-exatecan is an experimental antibody-drug conjugate from CSPC Megalith Biopharmaceutical in phase 2 trials, aimed at Folate receptor alpha.","route":"/drugs/farletuzumab-exatecan/","status":"phase-2","kind":"drug","molecule":"farletuzumab-exatecan","modality":"ADC","sub":"SYS6041","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"favezelimab","name":"Favezelimab","tldr":"Favezelimab is Merck's LAG-3 antibody, tested with pembrolizumab in phase 3 trials in colorectal cancer and classical Hodgkin lymphoma; the colorectal trial did not succeed.","route":"/drugs/favezelimab/","status":"phase-3","kind":"drug","molecule":"favezelimab","modality":"Anti-LAG-3 monoclonal antibody, intravenous, also coformulated with pembrolizumab (MK-4280A)","sub":"MK-4280","facets":{"kind":["Treatment"],"cancers":["Colorectal cancer","Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Hodgkin lymphoma","href":"/cancers/hodgkin-lymphoma/","tip":"Hodgkin lymphoma is one of the most curable cancers, where the goal is now to cure with less toxicity, using brentuximab and, from 2026, first-line nivolumab."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06858618","name":"FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms","tldr":"A phase 2 trial of Azacitidine in advanced solid tumours, run by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., active and no longer recruiting.","route":"/trials/nct06858618/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06858618","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"fda018-adc","name":"FDA018-ADC","tldr":"FDA018-ADC is an experimental antibody-drug conjugate from Shanghai Fudan-Zhangjiang Bio-Pharmaceutical in phase 3 trials for triple-negative breast cancer, with its target not yet stated publicly.","route":"/drugs/fda018-adc/","status":"phase-3","kind":"drug","molecule":"fda018-adc","modality":"ADC","sub":"FDA018","facets":{"kind":["Treatment"],"cancers":["Triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02584244","name":"Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers","tldr":"A phase 1/2 trial of LUM015 in colorectal cancer, pancreatic ductal adenocarcinoma, oesophageal cancer and gastric & gastro-oesophageal junction cancer, run by Lumicell, Inc., now recruiting.","route":"/trials/nct02584244/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT02584244","facets":{"kind":["Trial"],"cancers":["Colorectal cancer","Pancreatic ductal adenocarcinoma","Oesophageal cancer","Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."},{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03290534","name":"Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®","tldr":"A phase 2 trial of CivaSheet in advanced solid tumours, run by CivaTech Oncology, now recruiting.","route":"/trials/nct03290534/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT03290534","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"feladilimab","name":"Feladilimab","tldr":"Feladilimab is a monoclonal antibody from GlaxoSmithKline, in registered phase 2 trials for multiple myeloma.","route":"/drugs/feladilimab/","status":"phase-2","kind":"drug","molecule":"feladilimab","modality":"Monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct02398773","name":"FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy","tldr":"A phase 2 trial of Fluoroestradiol F-18 in Breast cancer, run by National Cancer Institute (NCI), active and no longer recruiting.","route":"/trials/nct02398773/","status":"active","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT02398773","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ficlatuzumab","name":"Ficlatuzumab","tldr":"Ficlatuzumab is an experimental monoclonal antibody from AVEO Pharmaceuticals in phase 3 trials for head and neck squamous cell carcinoma, with its target not yet stated publicly.","route":"/drugs/ficlatuzumab/","status":"phase-3","kind":"drug","molecule":"ficlatuzumab","modality":"monoclonal antibody","sub":"AV-299","facets":{"kind":["Treatment"],"cancers":["Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06332092","name":"FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma","tldr":"A phase 2 trial of FID007 in head and neck squamous cell carcinoma, run by Fulgent Pharma LLC., active and no longer recruiting.","route":"/trials/nct06332092/","status":"active","kind":"trial","cancerIcon":"head-and-neck","sub":"NCT06332092","facets":{"kind":["Trial"],"cancers":["Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06303505","name":"FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC","tldr":"A phase 1/2 trial of TUB-040 in ovarian cancer and non-small-cell lung cancer, run by Tubulis GmbH, now recruiting.","route":"/trials/nct06303505/","status":"recruiting","kind":"trial","cancerIcon":"ovarian","sub":"NCT06303505","facets":{"kind":["Trial"],"cancers":["Ovarian cancer","Non-small-cell lung cancer","Platinum-resistant ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Platinum-resistant ovarian cancer","href":"/cancers/platinum-resistant-ovarian-cancer/","tip":"Platinum-resistant ovarian cancer grows back within six months of platinum chemotherapy, or during it, and used to be treated with single chemotherapy drugs that shrink a tumour one time in ten. The antibody-drug conjugate mirvetuximab soravtansine, the cortisol-blocking drug relacorilant and pembrolizumab in PD-L1-positive tumours have each extended survival in phase 3 trials since 2023."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06669117","name":"FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations","tldr":"A phase 1/2 trial of VERT-002 in advanced solid tumours, run by Pierre Fabre Medicament, now recruiting.","route":"/trials/nct06669117/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06669117","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06154291","name":"FIH XON7 in Advanced/Metastatic Solid Tumors","tldr":"A phase 1/2 trial of XON7 in advanced solid tumours, run by Xenothera SAS, now recruiting.","route":"/trials/nct06154291/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06154291","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01301963","name":"Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide","tldr":"A phase 3 trial of Plerixafor and Filgrastim in Multiple myeloma, run by Case Comprehensive Cancer Center, recorded as terminated on the registry.","route":"/trials/nct01301963/","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT01301963","facets":{"kind":["Trial"],"cancers":["Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05141149","name":"First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer","tldr":"A phase 1/2 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by Prestige Biopharma Limited, active and no longer recruiting.","route":"/trials/nct05141149/","status":"active","kind":"trial","cancerIcon":"pancreatic","sub":"NCT05141149","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05647122","name":"First in Human Study of AZD9592 in Solid Tumors","tldr":"A phase 1 trial of Tilatamig samrotecan, Osimertinib, Fluorouracil and Leucovorin in Head and neck squamous cell carcinoma, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct05647122/","status":"active","kind":"trial","cancerIcon":"head-and-neck","sub":"NCT05647122","facets":{"kind":["Trial"],"cancers":["Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05120596","name":"First in Human Study of T3P-Y058-739 (T3P)","tldr":"A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by T3 Pharmaceuticals AG, now recruiting.","route":"/trials/nct05120596/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05120596","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06657222","name":"First in Human Study of TUB-030 in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of TUB-030 in small-cell lung cancer, non-small-cell lung cancer and triple-negative breast cancer, run by Tubulis GmbH, now recruiting.","route":"/trials/nct06657222/","status":"recruiting","kind":"trial","cancerIcon":"sclc","sub":"NCT06657222","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer","Non-small-cell lung cancer","Triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06795022","name":"First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours","tldr":"A phase 1/2 trial of AZD9793 in hepatocellular carcinoma, run by AstraZeneca, now recruiting.","route":"/trials/nct06795022/","status":"recruiting","kind":"trial","cancerIcon":"hcc","sub":"NCT06795022","facets":{"kind":["Trial"],"cancers":["Hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06877650","name":"First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors","tldr":"A phase 1/2 trial of Pembrolizumab and Ivonescimab in advanced solid tumours, run by Shanghai JMT-Bio Inc., now recruiting.","route":"/trials/nct06877650/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06877650","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05601726","name":"First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients","tldr":"A phase 1/2 trial of ABD-3001 in acute myeloid leukaemia and myelodysplastic syndromes / neoplasms, run by Advanced BioDesign, now recruiting.","route":"/trials/nct05601726/","status":"recruiting","kind":"trial","cancerIcon":"aml","sub":"NCT05601726","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia","Myelodysplastic syndromes / neoplasms","Acute myeloid leukaemia in older or unfit patients","Higher-risk myelodysplastic syndromes"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Myelodysplastic syndromes / neoplasms","href":"/cancers/mds/","tip":"Bone-marrow disorders where blood cells are made badly and too few reach the blood; a third progress to acute leukaemia. Treatment ranges from transfusions and growth factors to hypomethylating drugs and, for the fit, transplant."},{"label":"Acute myeloid leukaemia in older or unfit patients","href":"/cancers/aml-older-unfit/","tip":"Most people with acute myeloid leukaemia are over 65, and many cannot take intensive chemotherapy. Venetoclax with azacitidine, two gentler drugs, doubled remission rates and lengthened life in this group, replacing the old choice between supportive care and low-dose chemotherapy."},{"label":"Higher-risk myelodysplastic syndromes","href":"/cancers/mds-higher-risk/","tip":"Higher-risk myelodysplastic syndromes behave like a slow leukaemia and often become one. Azacitidine lengthens life and a donor stem cell transplant is the only cure; every attempt to improve on azacitidine in a large trial, including the venetoclax combination tested in VERONA, has so far failed."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07216560","name":"First-in-human Study of 7MW4911 in GI Cancer","tldr":"A phase 1/2 trial of 7MW4911 in advanced solid tumours, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.","route":"/trials/nct07216560/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07216560","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07265622","name":"First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of 7MW4911 in advanced solid tumours, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.","route":"/trials/nct07265622/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07265622","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06797999","name":"First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma","tldr":"A phase 1/2 trial of Antibody-drug conjugate (ADC) in sarcomas, run by Adcendo ApS, now recruiting.","route":"/trials/nct06797999/","status":"recruiting","kind":"trial","cancerIcon":"sarcoma","sub":"NCT06797999","facets":{"kind":["Trial"],"cancers":["Sarcomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Sarcomas","href":"/cancers/sarcoma/","tip":"Sarcomas are dozens of rare cancers of bone and connective tissue. GIST was the first solid tumour cured-in-practice by a targeted pill; synovial sarcoma got the first TCR-T therapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05920135","name":"First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI","tldr":"A phase 1/2 trial of BBT-207 in non-small-cell lung cancer, run by Bridge Biotherapeutics, Inc., active and no longer recruiting.","route":"/trials/nct05920135/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT05920135","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06603844","name":"First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.","tldr":"A phase 1/2 trial of CRB-601 monoclonal antibody in advanced solid tumours, run by Corbus Pharmaceuticals Inc., now recruiting.","route":"/trials/nct06603844/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06603844","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05438329","name":"First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors","tldr":"A phase 1/2 trial of Pembrolizumab and PM8002 in advanced solid tumours, run by DualityBio Inc., active and no longer recruiting.","route":"/trials/nct05438329/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05438329","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06554795","name":"First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors","tldr":"A phase 1/2 trial of DB-1419 in advanced solid tumours, run by DualityBio Inc., now recruiting.","route":"/trials/nct06554795/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06554795","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05875168","name":"First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors","tldr":"A phase 1/2 trial of DS-3939a in advanced solid tumours, run by Daiichi Sankyo, now recruiting.","route":"/trials/nct05875168/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05875168","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04243499","name":"First-in-Human Study of ICT01 in Patients With Advanced Cancer","tldr":"A phase 1/2 trial of IV ICT01 in advanced solid tumours, run by ImCheck Therapeutics, an Ipsen company, active and no longer recruiting.","route":"/trials/nct04243499/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04243499","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06043817","name":"First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations","tldr":"A phase 1/2 trial of STX-721/PFL-721 (Escalated) in non-small-cell lung cancer, run by Pierre Fabre Medicament, now recruiting.","route":"/trials/nct06043817/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06043817","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","EGFR-mutated non-small-cell lung cancer","HER2-mutant non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."},{"label":"HER2-mutant non-small-cell lung cancer","href":"/cancers/her2-mutant-nsclc/","tip":"HER2-mutant lung cancer carries a mutation in the same receptor that drives HER2-positive breast cancer, but the breast cancer antibodies alone did little here. The antibody-drug conjugate trastuzumab deruxtecan shrinks about half of tumours after chemotherapy, and the pill zongertinib about seven in ten, and both are approved."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05768139","name":"First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors","tldr":"A phase 1/2 trial of Fulvestrant, Ribociclib, Palbociclib, Exemestane, Tamoxifen and Abemaciclib in advanced solid tumours, run by Eli Lilly and Company, now recruiting.","route":"/trials/nct05768139/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05768139","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04725474","name":"First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)","tldr":"A phase 1/2 trial of Visugromab and Nivolumab in advanced solid tumours, run by CatalYm GmbH, active and no longer recruiting.","route":"/trials/nct04725474/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04725474","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03319628","name":"First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b","tldr":"A phase 1/2 trial of upifitamab rilsodotin in ovarian cancer and non-small-cell lung cancer, run by Mersana Therapeutics, active and no longer recruiting.","route":"/trials/nct03319628/","status":"active","kind":"trial","cancerIcon":"ovarian","sub":"NCT03319628","facets":{"kind":["Trial"],"cancers":["Ovarian cancer","Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07529717","name":"First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer","tldr":"A phase 1/2 trial of AZD8359 in prostate cancer, run by AstraZeneca, now recruiting.","route":"/trials/nct07529717/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT07529717","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06622486","name":"First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors","tldr":"A phase 1/2 trial of EGL-001 in advanced solid tumours, run by Egle Therapeutics, now recruiting.","route":"/trials/nct06622486/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06622486","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06934538","name":"First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer","tldr":"A phase 1/2 trial of STC-1010 + IS regimen + SOC therapy in colorectal cancer, run by Brenus Pharma, now recruiting.","route":"/trials/nct06934538/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT06934538","facets":{"kind":["Trial"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07136779","name":"First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies","tldr":"A phase 1/2 trial of VBC101 in advanced solid tumours, run by VelaVigo Bio Inc, now recruiting.","route":"/trials/nct07136779/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07136779","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07700160","name":"First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors","tldr":"A phase 1/2 trial of VBC108 in advanced solid tumours, run by VelaVigo Bio Inc, now recruiting.","route":"/trials/nct07700160/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07700160","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07332455","name":"First-Time-in-Human Study of GSK5471713 in Adults With mCRPC","tldr":"A phase 1/2 trial of GSK5471713 in prostate cancer, run by GlaxoSmithKline, now recruiting.","route":"/trials/nct07332455/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT07332455","facets":{"kind":["Trial"],"cancers":["Prostate cancer","Metastatic castration-resistant prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Metastatic castration-resistant prostate cancer","href":"/cancers/prostate-mcrpc/","tip":"Metastatic castration-resistant prostate cancer is disease that grows despite castrate testosterone. Sequenced treatments now include androgen receptor inhibitors, docetaxel and cabazitaxel, PARP inhibitors for men with BRCA-type mutations, the radioligand 177Lu-PSMA-617 and radium-223 for bone-predominant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06636682","name":"FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer","tldr":"A phase 2 trial of FK-PC101 in prostate cancer, run by Cellvax Therapeutics Inc, now recruiting.","route":"/trials/nct06636682/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT06636682","facets":{"kind":["Trial"],"cancers":["Prostate cancer","Localised prostate cancer, high and very high risk"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Localised prostate cancer, high and very high risk","href":"/cancers/prostate-high-risk/","tip":"High-risk prostate cancer has Grade Group 4 or 5 disease, a PSA above 20 or a tumour growing beyond the gland. It is still curable, but needs radiotherapy with two to three years of hormone therapy, or surgery followed by radiotherapy, and adding abiraterone to hormone therapy now lengthens life in the highest-risk men."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02448381","name":"FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)","tldr":"A phase 3 trial of Synthetic hypericin in Cutaneous T-cell lymphoma, run by Soligenix, completed.","route":"/trials/nct02448381/","status":"completed","kind":"trial","cancerIcon":"cutaneous-t-cell-lymphoma","sub":"NCT02448381","facets":{"kind":["Trial"],"cancers":["Cutaneous T-cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Cutaneous T-cell lymphoma","href":"/cancers/cutaneous-t-cell-lymphoma/","tip":"Mycosis fungoides is a lymphoma that lives in the skin, looking like eczema or psoriasis for years before it is diagnosed. It is treated with creams, light and skin-directed radiotherapy for as long as possible, then with antibodies such as mogamulizumab and brentuximab vedotin when it spreads to the blood or lymph nodes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07455331","name":"Flash Radiotherapy for Skin Cancer","tldr":"A phase 2 trial of FLASH radiotherapy in Cutaneous squamous cell carcinoma and Basal cell carcinoma, run by Jules Bordet Institute, not yet recruiting.","route":"/trials/nct07455331/","status":"planned","kind":"trial","cancerIcon":"cutaneous-scc","sub":"NCT07455331","facets":{"kind":["Trial"],"cancers":["Cutaneous squamous cell carcinoma","Basal cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Cutaneous squamous cell carcinoma","href":"/cancers/cutaneous-scc/","tip":"Cutaneous squamous cell carcinoma is a sun-related skin cancer with over a million US cases a year, almost all cured by removing them. The 2 to 5% that grow deep or spread respond to PD-1 immunotherapy (cemiplimab, pembrolizumab), which is now also given after surgery in high-risk cases; transplant recipients cannot safely receive it."},{"label":"Basal cell carcinoma","href":"/cancers/basal-cell-carcinoma/","tip":"Basal cell carcinoma is a skin cancer and the most common cancer of all, caused by sun exposure and almost never life-threatening. Nearly all are removed surgically; the rare advanced cases are treated with drugs that block the hedgehog signalling pathway, and with immunotherapy if those fail."}],"tags":[]},"sortKeys":{"year":0}},{"id":"flonoltinib","name":"Flonoltinib","tldr":"Flonoltinib is an oral kinase inhibitor from Chengdu Zenitar Biomedical Technology Co., Ltd, in registered phase 2 trials for myeloproliferative neoplasms.","route":"/drugs/flonoltinib/","status":"phase-2","kind":"drug","molecule":"flonoltinib","modality":"Oral kinase inhibitor","facets":{"kind":["Treatment"],"cancers":["Myeloproliferative neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Myeloproliferative neoplasms","href":"/cancers/myeloproliferative-neoplasms/","tip":"Myeloproliferative neoplasms are slow-growing blood cancers in which the marrow overproduces red cells (polycythaemia vera), platelets (essential thrombocythaemia) or scar tissue (myelofibrosis). Almost all carry a mutation in JAK2, CALR or MPL; treatment aims to prevent clots and control symptoms, and only transplant cures myelofibrosis."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"florastamin-f18","name":"Florastamin F-18","tldr":"Florastamin is FutureChem's fluorine-18 PSMA PET tracer from South Korea, in phase 3 trials for staging high-risk and recurrent prostate cancer alongside the established PSMA agents.","route":"/drugs/florastamin-f18/","status":"phase-3","kind":"drug","molecule":"florastamin-f18","modality":"PSMA-targeted PET radiotracer, fluorine-18","sub":"FC303","facets":{"kind":["Treatment"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00254163","name":"Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients","tldr":"A phase 3 trial of Fludarabine, Cyclophosphamide, Rituximab and Pentostatin in Chronic lymphocytic leukaemia, run by US Oncology Research, completed.","route":"/trials/nct00254163/","status":"completed","kind":"trial","cancerIcon":"cll","sub":"NCT00254163","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00002881","name":"Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer","tldr":"A phase 3 trial of Flutamide, Goserelin / leuprolide and Leuprolide in Prostate cancer, run by Eastern Cooperative Oncology Group, completed.","route":"/trials/nct00002881/","status":"completed","kind":"trial","cancerIcon":"prostate","sub":"NCT00002881","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"fluzoparib","name":"Fluzoparib","tldr":"Fluzoparib is an oral parp inhibitor from Risen (Suzhou) Pharma Tech Co., Ltd., in registered phase 2 trials for metastatic cancer.","route":"/drugs/fluzoparib/","status":"phase-2","kind":"drug","molecule":"fluzoparib","modality":"Oral PARP inhibitor","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct01883128","name":"FOcal RECurrent Assessment and Salvage Treatment","tldr":"A phase 2 trial of Whole-body MRI in Prostate cancer, run by University College London Hospitals, with a status the registry has not verified recently.","route":"/trials/nct01883128/","kind":"trial","cancerIcon":"prostate","sub":"NCT01883128","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05466799","name":"FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma","tldr":"A phase 2 trial of FOLFIRINOX chemotherapy in pancreatic ductal adenocarcinoma, run by OncoSil Medical Limited, active and no longer recruiting.","route":"/trials/nct05466799/","status":"active","kind":"trial","cancerIcon":"pancreatic","sub":"NCT05466799","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Locally advanced unresectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01086488","name":"Foscan®-Mediated Photodynamic Therapy Versus Brachytherapy in Patients With Nasopharyngeal Carcinoma","tldr":"A phase 2 trial of Temoporfin in Nasopharyngeal carcinoma, run by Ministry of Health, Malaysia, with a status the registry has not verified recently.","route":"/trials/nct01086488/","kind":"trial","cancerIcon":"nasopharyngeal","sub":"NCT01086488","facets":{"kind":["Trial"],"cancers":["Nasopharyngeal carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Nasopharyngeal carcinoma","href":"/cancers/nasopharyngeal/","tip":"A cancer at the back of the nose caused largely by the Epstein-Barr virus and common in southern China and Southeast Asia. Radiation cures most early cases; adding chemotherapy and, recently, PD-1 immunotherapy has improved outcomes in advanced disease, and a blood test for viral DNA can detect it early."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04543279","name":"Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia","tldr":"A phase 2 trial of Fostamatinib and Ruxolitinib in Primary myelofibrosis, run by Washington University School of Medicine, recorded as terminated on the registry.","route":"/trials/nct04543279/","kind":"trial","cancerIcon":"primary-myelofibrosis","sub":"NCT04543279","facets":{"kind":["Trial"],"cancers":["Primary myelofibrosis"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Primary myelofibrosis","href":"/cancers/primary-myelofibrosis/","tip":"Primary myelofibrosis is a blood cancer in which the marrow scars over, the spleen swells and patients become anaemic and exhausted. JAK inhibitors, ruxolitinib first (COMFORT) and then fedratinib, pacritinib and momelotinib (MOMENTUM), shrink the spleen and relieve symptoms; only a donor stem cell transplant can cure it."}],"tags":[]},"sortKeys":{"year":0}},{"id":"fpi-2265","name":"FPI-2265","tldr":"FPI-2265 is an experimental radioligand therapy from Fusion Pharmaceuticals in phase 2 trials for prostate cancer, aimed at PSMA.","route":"/drugs/fpi-2265/","status":"phase-2","kind":"drug","molecule":"fpi-2265","modality":"radioligand","facets":{"kind":["Treatment"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03678428","name":"FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM","tldr":"A phase 3 trial of Irinotecan, Floxuridine, Leucovorin, Fluorouracil and Oxaliplatin in Colorectal cancer, run by Sun Yat-sen University, recorded as terminated on the registry.","route":"/trials/nct03678428/","kind":"trial","cancerIcon":"colorectal","sub":"NCT03678428","facets":{"kind":["Trial"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07710885","name":"Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer","tldr":"A phase 3 trial of Futibatinib, Zimberelimab, Durvalumab, Pembrolizumab, Gemcitabine and Cisplatin in biliary tract cancer, run by Taiho Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07710885/","status":"recruiting","kind":"trial","cancerIcon":"cholangiocarcinoma","sub":"NCT07710885","facets":{"kind":["Trial"],"cancers":["Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00541125","name":"G-CSF in Preventing Neutropenia During First-Line Treatment With Chemotherapy and Bevacizumab in Patients With Metastatic Colorectal Cancer","tldr":"A phase 2 trial of UGT1A1 genotyping before irinotecan in Colorectal cancer, run by Federation Francophone de Cancerologie Digestive, completed.","route":"/trials/nct00541125/","status":"completed","kind":"trial","cancerIcon":"colorectal","sub":"NCT00541125","facets":{"kind":["Trial"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04229979","name":"Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2","tldr":"A phase 3 trial of Azacitidine, Venetoclax, Decitabine and Cytarabine in acute myeloid leukaemia, run by Sellas Life Sciences Group, active and no longer recruiting.","route":"/trials/nct04229979/","status":"active","kind":"trial","cancerIcon":"aml","sub":"NCT04229979","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[]},"sortKeys":{"year":0}},{"id":"gc012f","name":"GC012F","tldr":"GC012F is an experimental CAR-T cell therapy from Gracell Biotechnologies (Shanghai) in phase 2 trials for multiple myeloma, aimed at CD19 and BCMA.","route":"/drugs/gc012f/","status":"phase-2","kind":"drug","molecule":"gc012f","modality":"CAR-T cell therapy","facets":{"kind":["Treatment"],"cancers":["Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[]},"sortKeys":{"year":0}},{"id":"gc101-til","name":"GC101 TIL","tldr":"GC101 TIL is an experimental tumour-infiltrating lymphocyte therapy from Shanghai Juncell Therapeutics in phase 2 trials for melanoma, aimed at PD-1 and BRAF.","route":"/drugs/gc101-til/","status":"phase-2","kind":"drug","molecule":"gc101-til","modality":"TIL therapy","sub":"GC101","facets":{"kind":["Treatment"],"cancers":["Melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."}],"tags":[]},"sortKeys":{"year":0}},{"id":"gecacitinib","name":"Gecacitinib","tldr":"Gecacitinib is an oral kinase inhibitor from Suzhou Zelgen Biopharmaceuticals Co.,Ltd, in registered phase 2 trials for cervical cancer.","route":"/drugs/gecacitinib/","status":"phase-2","kind":"drug","molecule":"gecacitinib","modality":"Oral kinase inhibitor","facets":{"kind":["Treatment"],"cancers":["Cervical cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct05501886","name":"Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)","tldr":"A phase 3 trial of Gedatolisib, Palbociclib, Fulvestrant and Alpelisib in advanced solid tumours, run by Celcuity Inc, active and no longer recruiting.","route":"/trials/nct05501886/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05501886","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04093505","name":"Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)","tldr":"A phase 3 trial of Glasdegib in Acute myeloid leukaemia, run by University Hospital Heidelberg, recorded as terminated on the registry.","route":"/trials/nct04093505/","kind":"trial","cancerIcon":"aml","sub":"NCT04093505","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06533579","name":"Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)","tldr":"A phase 1/2 trial of Dose Level 1, VNX-101 in acute lymphoblastic leukaemia, diffuse large B-cell lymphoma, chronic lymphocytic leukaemia, non-Hodgkin lymphoma, follicular lymphoma and mantle cell lymphoma, run by Vironexis Biotherapeutics Inc., now recruiting.","route":"/trials/nct06533579/","status":"recruiting","kind":"trial","cancerIcon":"all-leukemia","sub":"NCT06533579","facets":{"kind":["Trial"],"cancers":["Acute lymphoblastic leukaemia","Diffuse large B-cell lymphoma","Chronic lymphocytic leukaemia","Non-Hodgkin lymphoma","Follicular lymphoma","Mantle cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."},{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."},{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07192432","name":"Gene Therapy for HER-Positive Cancer (SENTRY-HER2)","tldr":"A phase 1/2 trial of Dose Level 1, VNX-202 in advanced solid tumours, run by Vironexis Biotherapeutics Inc., now recruiting.","route":"/trials/nct07192432/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07192432","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06052826","name":"Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study","tldr":"A phase 2 trial of Geriatric assessment in Non-Hodgkin lymphoma and Multiple myeloma, run by City of Hope Medical Center, now recruiting.","route":"/trials/nct06052826/","status":"recruiting","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT06052826","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma","Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."},{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[]},"sortKeys":{"year":0}},{"id":"gfh375","name":"GFH375","tldr":"GFH375 is an experimental small-molecule drug from Genfleet Therapeutics (Shanghai) in phase 3 trials for pancreatic ductal adenocarcinoma and non-small-cell lung cancer, aimed at KRAS.","route":"/drugs/gfh375/","status":"phase-3","kind":"drug","molecule":"gfh375","modality":"small molecule (structure undisclosed or not yet in PubChem)","facets":{"kind":["Treatment"],"cancers":["Pancreatic ductal adenocarcinoma","Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"givinostat","name":"Givinostat","tldr":"Givinostat is an experimental small-molecule drug from Italfarmaco in phase 3 trials for myeloproliferative neoplasms, with its target not yet stated publicly.","route":"/drugs/givinostat/","status":"phase-3","kind":"drug","molecule":"givinostat","modality":"small molecule","sub":"ITF2357","facets":{"kind":["Treatment"],"cancers":["Myeloproliferative neoplasms","Polycythaemia vera"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Myeloproliferative neoplasms","href":"/cancers/myeloproliferative-neoplasms/","tip":"Myeloproliferative neoplasms are slow-growing blood cancers in which the marrow overproduces red cells (polycythaemia vera), platelets (essential thrombocythaemia) or scar tissue (myelofibrosis). Almost all carry a mutation in JAK2, CALR or MPL; treatment aims to prevent clots and control symptoms, and only transplant cures myelofibrosis."},{"label":"Polycythaemia vera","href":"/cancers/polycythaemia-vera/","tip":"Polycythaemia vera is a slow blood cancer in which a single faulty gene, JAK2, makes the bone marrow produce too many red cells. Thick blood causes clots, so treatment thins it (blood removal, aspirin) and, for higher-risk patients, calms the marrow with hydroxyurea, interferon or ruxolitinib; a hepcidin mimic, rusfertide, now controls red cell counts without regular blood removal."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07209813","name":"GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma","tldr":"A phase 2 trial of GKL-006 Injection in hepatocellular carcinoma, run by Beijing Gene Key Life Technology Co., Ltd, now recruiting.","route":"/trials/nct07209813/","status":"recruiting","kind":"trial","cancerIcon":"hcc","sub":"NCT07209813","facets":{"kind":["Trial"],"cancers":["Hepatocellular carcinoma","Intermediate hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."},{"label":"Intermediate hepatocellular carcinoma","href":"/cancers/hcc-intermediate/","tip":"Intermediate hepatocellular carcinoma is several tumours inside a working liver, too many to cut out but with no spread beyond it. The standard treatment for two decades has been chemoembolisation through the hepatic artery, and trials now show that adding immunotherapy and anti-angiogenic drugs to it delays progression."}],"tags":[]},"sortKeys":{"year":0}},{"id":"glecirasib","name":"Glecirasib","tldr":"Glecirasib is Jacobio's KRAS G12C inhibitor, approved in China in 2024 for previously treated non-small cell lung cancer with that mutation, and in a phase 3 trial against docetaxel.","route":"/drugs/glecirasib/","status":"approved","kind":"drug","molecule":"glecirasib","modality":"Oral covalent KRAS G12C inhibitor","sub":"JAB-21822","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","KRAS G12C-mutant non-small-cell lung cancer"],"year":["2024"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"KRAS G12C-mutant non-small-cell lung cancer","href":"/cancers/kras-g12c-nsclc/","tip":"KRAS G12C lung cancer carries a mutation that was thought impossible to drug for forty years. Sotorasib and adagrasib now shrink about four in ten tumours after chemotherapy and immunotherapy, though the benefit is measured in months, and newer inhibitors and first-line combinations with immunotherapy are in trials."}],"year":{"facet":"year","value":"2024"},"tags":[]},"sortKeys":{"year":2024}},{"id":"nct04121455","name":"Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients","tldr":"A phase 1/2 trial of Bevacizumab, Pembrolizumab and Temozolomide in glioma & glioblastoma, run by TME Pharma AG, active and no longer recruiting.","route":"/trials/nct04121455/","status":"active","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT04121455","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06252675","name":"Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma","tldr":"A phase 2 trial of Obinutuzumab, Glofitamab, Pirtobrutinib and clonoSEQ in Mantle cell lymphoma, run by University of California, San Francisco, now recruiting.","route":"/trials/nct06252675/","status":"recruiting","kind":"trial","cancerIcon":"mantle-cell-lymphoma","sub":"NCT06252675","facets":{"kind":["Trial"],"cancers":["Mantle cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Mantle cell lymphoma","href":"/cancers/mantle-cell-lymphoma/","tip":"An uncommon B-cell lymphoma driven by cyclin D1 that used to behave badly in almost everyone. BTK inhibitors, CAR-T and now BCL2 drugs have changed it from chemotherapy-plus-transplant to targeted combinations."}],"tags":[]},"sortKeys":{"year":0}},{"id":"glsi-100","name":"GLSI-100","tldr":"GLSI-100 is an experimental cancer vaccine from Greenwich LifeSciences in phase 3 trials for HR-positive / HER2-negative breast cancer, aimed at HER2.","route":"/drugs/glsi-100/","status":"phase-3","kind":"drug","molecule":"glsi-100","modality":"vaccine","facets":{"kind":["Treatment"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01305655","name":"Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL","tldr":"A phase 3 trial of Glucarpidase in Acute lymphoblastic leukaemia, run by Nordic Society for Pediatric Hematology and Oncology, completed.","route":"/trials/nct01305655/","status":"completed","kind":"trial","cancerIcon":"all-leukemia","sub":"NCT01305655","facets":{"kind":["Trial"],"cancers":["Acute lymphoblastic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01954992","name":"Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer","tldr":"A phase 3 trial of Glufosfamide in pancreatic ductal adenocarcinoma, run by Eleison Pharmaceuticals LLC., now recruiting.","route":"/trials/nct01954992/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT01954992","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"glumetinib","name":"Glumetinib","tldr":"Glumetinib is a Chinese MET inhibitor approved in 2023 for lung cancers with MET exon 14 skipping, one of three such drugs approved in China and now in a phase 3 trial in gastric cancer.","route":"/drugs/glumetinib/","status":"approved","kind":"drug","molecule":"glumetinib","modality":"Oral selective MET tyrosine kinase inhibitor","sub":"SCC244","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Gastric & gastro-oesophageal junction cancer","Small-cell lung cancer"],"year":["2023"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"year":{"facet":"year","value":"2023"},"tags":[]},"sortKeys":{"year":2023}},{"id":"nct06994507","name":"GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer","tldr":"A phase 3 trial of GM1 in advanced solid tumours, run by Qilu Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct06994507/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06994507","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"golidocitinib","name":"Golidocitinib","tldr":"Golidocitinib is Dizal's JAK1 inhibitor, approved in China in 2024 as the first JAK inhibitor for relapsed peripheral T-cell lymphoma, a cancer with few options after first-line chemotherapy.","route":"/drugs/golidocitinib/","status":"approved","kind":"drug","molecule":"golidocitinib","modality":"Oral selective JAK1 inhibitor","sub":"DZD4205","facets":{"kind":["Treatment"],"cancers":["Peripheral T-cell lymphomas"],"year":["2024"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Peripheral T-cell lymphomas","href":"/cancers/peripheral-t-cell-lymphoma/","tip":"Peripheral T-cell lymphomas are lymphomas of T cells rather than B cells. They are rarer, more varied and, apart from a few subtypes, harder to treat than B-cell lymphomas; several new drugs help only defined subtypes."}],"year":{"facet":"year","value":"2024"},"tags":[]},"sortKeys":{"year":2024}},{"id":"gotistobart","name":"Gotistobart","tldr":"Gotistobart is an experimental monoclonal antibody from OncoC4 in phase 3 trials for non-small-cell lung cancer, melanoma and head and neck squamous cell carcinoma, aimed at CTLA-4.","route":"/drugs/gotistobart/","status":"phase-3","kind":"drug","molecule":"gotistobart","modality":"monoclonal antibody","sub":"ONC-392, BNT316","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Melanoma","Head and neck squamous cell carcinoma","Renal cell carcinoma","Colorectal cancer","Sarcomas","Prostate cancer","Ovarian cancer","HR-positive / HER2-negative breast cancer","Pancreatic ductal adenocarcinoma","Gastric & gastro-oesophageal junction cancer","Oesophageal cancer","Cervical cancer","Salivary gland cancers","Mucoepidermoid carcinoma","Bladder & urothelial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04864054","name":"GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC","tldr":"A phase 1/2 trial of ECT204 T cells in hepatocellular carcinoma, run by Eureka Therapeutics Inc., now recruiting.","route":"/trials/nct04864054/","status":"recruiting","kind":"trial","cancerIcon":"hcc","sub":"NCT04864054","facets":{"kind":["Trial"],"cancers":["Hepatocellular carcinoma","Advanced hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."},{"label":"Advanced hepatocellular carcinoma","href":"/cancers/hcc-advanced/","tip":"Advanced hepatocellular carcinoma has invaded the liver's veins or spread beyond it. Sorafenib was the only drug for a decade; now the combination of the immunotherapy atezolizumab with the anti-angiogenic antibody bevacizumab, or the two-antibody regimen durvalumab with tremelimumab, is standard first line, and several further drugs follow it."}],"tags":[]},"sortKeys":{"year":0}},{"id":"gq1005","name":"GQ1005","tldr":"GQ1005 is an experimental antibody-drug conjugate from GeneQuantum Healthcare (Suzhou) in phase 3 trials for HER2-positive breast cancer, aimed at HER2.","route":"/drugs/gq1005/","status":"phase-3","kind":"drug","molecule":"gq1005","modality":"ADC","facets":{"kind":["Treatment"],"cancers":["HER2-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."}],"tags":[]},"sortKeys":{"year":0}},{"id":"gr1803","name":"GR1803","tldr":"GR1803 is an experimental investigational agent whose form is not stated in the registry from Genrix (Shanghai) Biopharmaceutical in phase 3 trials for multiple myeloma, with its target not yet stated publicly.","route":"/drugs/gr1803/","status":"phase-3","kind":"drug","molecule":"gr1803","modality":"bispecific antibody (BCMA x CD3, per the sponsor's pipeline page; form not stated in the registry record)","facets":{"kind":["Treatment"],"cancers":["Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[]},"sortKeys":{"year":0}},{"id":"grt-c901","name":"GRT-C901","tldr":"GRT-C901 is an experimental cancer vaccine from Seattle Project in phase 3 trials for colorectal cancer, with its target not yet stated publicly.","route":"/drugs/grt-c901/","status":"phase-3","kind":"drug","molecule":"grt-c901","modality":"vaccine","facets":{"kind":["Treatment"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"grt-r902","name":"GRT-R902","tldr":"GRT-R902 is an experimental cancer vaccine from Seattle Project in phase 3 trials for colorectal cancer, with its target not yet stated publicly.","route":"/drugs/grt-r902/","status":"phase-3","kind":"drug","molecule":"grt-r902","modality":"vaccine","facets":{"kind":["Treatment"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06948981","name":"GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies","tldr":"A phase 1/2 trial of GT719 Injection in non-Hodgkin lymphoma, run by Grit Biotechnology, now recruiting.","route":"/trials/nct06948981/","status":"recruiting","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT06948981","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04652076","name":"GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab","tldr":"A phase 1/2 trial of Pembrolizumab and Carboplatin in endometrial cancer and cervical cancer, run by NETRIS Pharma, active and no longer recruiting.","route":"/trials/nct04652076/","status":"active","kind":"trial","cancerIcon":"endometrial","sub":"NCT04652076","facets":{"kind":["Trial"],"cancers":["Endometrial cancer","Cervical cancer","Advanced or recurrent endometrial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."},{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."},{"label":"Advanced or recurrent endometrial cancer","href":"/cancers/advanced-recurrent-endometrial-cancer/","tip":"Advanced or recurrent endometrial cancer has spread beyond the uterus or come back after treatment. Chemotherapy plus an immune checkpoint antibody is now the first treatment for everyone, with the biggest gains in mismatch-repair-deficient tumours, and lenvatinib with pembrolizumab is the standard when platinum chemotherapy stops working."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07398664","name":"H101 Plus TACE for r/m HNSCC","tldr":"A phase 2 trial of H101 oncolytic adenovirus in Head and neck squamous cell carcinoma, run by West China Hospital, now recruiting.","route":"/trials/nct07398664/","status":"recruiting","kind":"trial","cancerIcon":"head-and-neck","sub":"NCT07398664","facets":{"kind":["Trial"],"cancers":["Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03780049","name":"HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B","tldr":"A phase 3 trial of H101 oncolytic adenovirus in Hepatocellular carcinoma, run by Sun Yat-sen University, with a status the registry has not verified recently.","route":"/trials/nct03780049/","kind":"trial","cancerIcon":"hcc","sub":"NCT03780049","facets":{"kind":["Trial"],"cancers":["Hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."}],"tags":[]},"sortKeys":{"year":0}},{"id":"hb0036","name":"HB0036","tldr":"HB0036 is an experimental investigational agent whose form is not stated in the registry from Shanghai Huaota Biopharmaceutical in phase 2 trials for non-small-cell lung cancer, aimed at PD-L1 and TIGIT.","route":"/drugs/hb0036/","status":"phase-2","kind":"drug","molecule":"hb0036","modality":"bifunctional antibody (anti-PD-L1/anti-TIGIT, per the sponsor's description; form not stated in the registry record)","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"hb1801","name":"HB1801","tldr":"HB1801 is an experimental investigational agent whose form is not stated in the registry from Shanghai JMT-Bio in phase 3 trials for HER2-positive breast cancer, with its target not yet stated publicly.","route":"/drugs/hb1801/","status":"phase-3","kind":"drug","molecule":"hb1801","modality":"not stated (registered as a drug or biological on ClinicalTrials.gov)","facets":{"kind":["Treatment"],"cancers":["HER2-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07169552","name":"HC010 in First-line PD-L1 Positive Advanced NSCLC Patients","tldr":"A phase 2 trial of HC010 in non-small-cell lung cancer, run by HC Biopharma Inc., now recruiting.","route":"/trials/nct07169552/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07169552","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"hdm2017","name":"HDM2017","tldr":"HDM2017 is an experimental investigational agent whose form is not stated in the registry from Hangzhou Zhongmei Huadong Pharmaceutical in phase 2 trials for colorectal cancer, aimed at MET.","route":"/drugs/hdm2017/","status":"phase-2","kind":"drug","molecule":"hdm2017","modality":"not stated (registered as a drug or biological on ClinicalTrials.gov)","facets":{"kind":["Treatment"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05451602","name":"HEC169096 in Participants With Advanced Solid Tumors","tldr":"A phase 1/2 trial of HEC169096 in advanced solid tumours, run by Sunshine Lake Pharma Co., Ltd., now recruiting.","route":"/trials/nct05451602/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05451602","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06369831","name":"HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011","tldr":"A phase 2 trial of an investigational treatment in advanced solid tumours, run by Abscint NV/SA, now recruiting.","route":"/trials/nct06369831/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06369831","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05864014","name":"Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.","tldr":"A phase 3 trial of Hetrombopag in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.","route":"/trials/nct05864014/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05864014","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00634322","name":"High Dose Methotrexate With Leucovorin Rescue With or Without Glucarpidase in Osteosarcoma","tldr":"A phase 2 trial of Glucarpidase and Leucovorin in Osteosarcoma, run by BTG International Inc., recorded as terminated on the registry.","route":"/trials/nct00634322/","kind":"trial","cancerIcon":"osteosarcoma","sub":"NCT00634322","facets":{"kind":["Trial"],"cancers":["Osteosarcoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Osteosarcoma","href":"/cancers/osteosarcoma/","tip":"Osteosarcoma is the most common bone cancer, mostly in teenagers. Chemotherapy plus surgery cures about two-thirds when it has not spread; because no new drug has beaten that chemotherapy in a large trial in 30 years, the next gains are being sought in cellular therapy against GD2, HER2 and B7-H3."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03329183","name":"High-dose FOLFIRI in Advanced Colorectal Cancer Patients With Wild-type UGT1A1*6 and *28","tldr":"A phase 2 trial of UGT1A1 genotyping before irinotecan in Colorectal cancer, run by Shanghai Changzheng Hospital, with a status the registry has not verified recently.","route":"/trials/nct03329183/","kind":"trial","cancerIcon":"colorectal","sub":"NCT03329183","facets":{"kind":["Trial"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04221035","name":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)","tldr":"A phase 3 trial of Vincristine, Carboplatin, Etoposide, Vindesine, Dacarbazine, Ifosfamide, Doxorubicin, Busulfan, Melphalan, Thiotepa, Dinutuximab, Cisplatin and Irinotecan in High-risk neuroblastoma, run by Gustave Roussy, Cancer Campus, Grand Paris, now recruiting.","route":"/trials/nct04221035/","status":"recruiting","kind":"trial","cancerIcon":"neuroblastoma-high-risk","sub":"NCT04221035","facets":{"kind":["Trial"],"cancers":["High-risk neuroblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"High-risk neuroblastoma","href":"/cancers/neuroblastoma-high-risk/","tip":"High-risk neuroblastoma has spread widely in a child over 18 months old or carries extra copies of the MYCN gene. Treatment lasts about 18 months and uses every tool: chemotherapy, surgery, high-dose chemotherapy with stem cell rescue, radiotherapy, and the anti-GD2 antibody dinutuximab, which raised survival in ANBL0032; eflornithine, given afterwards, was approved in 2023 to lower relapse."}],"tags":[]},"sortKeys":{"year":0}},{"id":"hlx11","name":"HLX11","tldr":"HLX11 is an experimental monoclonal antibody from Shanghai Henlius Biotech in phase 3 trials for HR-positive / HER2-negative breast cancer and HER2-positive breast cancer, aimed at HER2.","route":"/drugs/hlx11/","status":"phase-3","kind":"drug","molecule":"hlx11","modality":"monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["HR-positive / HER2-negative breast cancer","HER2-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."}],"tags":[]},"sortKeys":{"year":0}},{"id":"hlx22","name":"HLX22","tldr":"HLX22 is an experimental monoclonal antibody from Shanghai Henlius Biotech in phase 3 trials for gastric & gastro-oesophageal junction cancer and HR-positive / HER2-negative breast cancer, aimed at HER2.","route":"/drugs/hlx22/","status":"phase-3","kind":"drug","molecule":"hlx22","modality":"monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Gastric & gastro-oesophageal junction cancer","HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"hlx26","name":"HLX26","tldr":"HLX26 is an experimental monoclonal antibody from Shanghai Henlius Biotech in phase 2 trials for non-small-cell lung cancer, aimed at LAG-3.","route":"/drugs/hlx26/","status":"phase-2","kind":"drug","molecule":"hlx26","modality":"monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"hlx43","name":"HLX43","tldr":"HLX43 is an experimental antibody-drug conjugate from Shanghai Henlius Biotech in phase 3 trials for non-small-cell lung cancer, cervical cancer and ovarian cancer, aimed at PD-L1 and EGFR.","route":"/drugs/hlx43/","status":"phase-3","kind":"drug","molecule":"hlx43","modality":"ADC","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Cervical cancer","Ovarian cancer","Oesophageal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."},{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."}],"tags":[]},"sortKeys":{"year":0}},{"id":"hmbd-001","name":"HMBD-001","tldr":"HMBD-001 is an experimental monoclonal antibody from Hummingbird Bioscience in phase 2 trials for non-small-cell lung cancer, head and neck squamous cell carcinoma and oesophageal cancer, aimed at HER3 and EGFR.","route":"/drugs/hmbd-001/","status":"phase-2","kind":"drug","molecule":"hmbd-001","modality":"monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Head and neck squamous cell carcinoma","Oesophageal cancer","Cervical cancer","Cutaneous squamous cell carcinoma","Nasopharyngeal carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."},{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."}],"tags":[]},"sortKeys":{"year":0}},{"id":"hmpl-306","name":"HMPL-306","tldr":"HMPL-306 is an experimental small-molecule drug from Hutchmed in phase 3 trials for acute myeloid leukaemia, aimed at IDH1 / IDH2.","route":"/drugs/hmpl-306/","status":"phase-3","kind":"drug","molecule":"hmpl-306","modality":"small molecule","facets":{"kind":["Treatment"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[]},"sortKeys":{"year":0}},{"id":"hmpl-453","name":"HMPL-453","tldr":"HMPL-453 is an experimental small-molecule drug from Hutchmed in phase 3 trials for biliary tract cancer, aimed at FGFR2.","route":"/drugs/hmpl-453/","status":"phase-3","kind":"drug","molecule":"hmpl-453","modality":"small molecule (structure undisclosed or not yet in PubChem)","facets":{"kind":["Treatment"],"cancers":["Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"hmpl-760","name":"HMPL-760","tldr":"HMPL-760 is an experimental small-molecule drug from Hutchmed in phase 3 trials for diffuse large B-cell lymphoma, with its target not yet stated publicly.","route":"/drugs/hmpl-760/","status":"phase-3","kind":"drug","molecule":"hmpl-760","modality":"small molecule (structure undisclosed or not yet in PubChem)","facets":{"kind":["Treatment"],"cancers":["Diffuse large B-cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07396584","name":"HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor","tldr":"A phase 1/2 trial of HMPL-A580 in advanced solid tumours, run by Hutchmed, now recruiting.","route":"/trials/nct07396584/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07396584","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00412022","name":"HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer","tldr":"A phase 3 trial of Tamoxifen, Triptorelin, Letrozole and Zoledronic acid in Breast cancer, run by National Cancer Institute, Naples, with a status the registry has not verified recently.","route":"/trials/nct00412022/","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT00412022","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00003653","name":"Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer","tldr":"A phase 3 trial of Bicalutamide, Buserelin, Flutamide, Goserelin / leuprolide, Leuprolide and Nilutamide in Prostate cancer, run by NCIC Clinical Trials Group, completed.","route":"/trials/nct00003653/","status":"completed","kind":"trial","cancerIcon":"prostate","sub":"NCT00003653","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00004054","name":"Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer","tldr":"A phase 3 trial of Bicalutamide, Estramustine, Etoposide, Flutamide and Paclitaxel / nab-paclitaxel in Prostate cancer, run by Radiation Therapy Oncology Group, completed.","route":"/trials/nct00004054/","status":"completed","kind":"trial","cancerIcon":"prostate","sub":"NCT00004054","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00055731","name":"Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse","tldr":"A phase 3 trial of Bicalutamide, Goserelin / leuprolide, Docetaxel, Estramustine and Aspirin in Prostate cancer, run by UNICANCER, completed.","route":"/trials/nct00055731/","status":"completed","kind":"trial","cancerIcon":"prostate","sub":"NCT00055731","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00002633","name":"Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer","tldr":"A phase 3 trial of Bicalutamide, Buserelin, Flutamide, Goserelin / leuprolide, Leuprolide and Nilutamide in Prostate cancer, run by NCIC Clinical Trials Group, completed.","route":"/trials/nct00002633/","status":"completed","kind":"trial","cancerIcon":"prostate","sub":"NCT00002633","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"hr070803","name":"HR070803","tldr":"HR070803 is an experimental small-molecule drug from Jiangsu HengRui Medicine in phase 3 trials for colorectal cancer, with its target not yet stated publicly.","route":"/drugs/hr070803/","status":"phase-3","kind":"drug","molecule":"hr070803","modality":"small molecule","facets":{"kind":["Treatment"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07232875","name":"HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer","tldr":"A phase 3 trial of HRS-4642 + AG in pancreatic ductal adenocarcinoma, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.","route":"/trials/nct07232875/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT07232875","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"hrs-4357","name":"HRS-4357","tldr":"HRS-4357 is an experimental investigational agent whose form is not stated in the registry from Jiangsu HengRui Medicine in phase 3 trials for prostate cancer, aimed at PSMA.","route":"/drugs/hrs-4357/","status":"phase-3","kind":"drug","molecule":"hrs-4357","modality":"not stated (registered as a drug or biological on ClinicalTrials.gov)","facets":{"kind":["Treatment"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07296341","name":"HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors","tldr":"A phase 1/2 trial of Adebrelimab and Gemcitabine in pancreatic ductal adenocarcinoma, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07296341/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT07296341","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"hrs-8080","name":"HRS-8080","tldr":"HRS-8080 is an experimental small-molecule drug from Shandong Suncadia Medicine in phase 3 trials for HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.","route":"/drugs/hrs-8080/","status":"phase-3","kind":"drug","molecule":"hrs-8080","modality":"small molecule (structure undisclosed or not yet in PubChem)","facets":{"kind":["Treatment"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"hs-20089","name":"HS-20089","tldr":"HS-20089 is an experimental antibody-drug conjugate from Hansoh BioMedical R&D in phase 3 trials for ovarian cancer and endometrial cancer, with its target not yet stated publicly.","route":"/drugs/hs-20089/","status":"phase-3","kind":"drug","molecule":"hs-20089","modality":"ADC","facets":{"kind":["Treatment"],"cancers":["Ovarian cancer","Endometrial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."}],"tags":[]},"sortKeys":{"year":0}},{"id":"hs-20093","name":"HS-20093","tldr":"HS-20093 is an experimental investigational agent whose form is not stated in the registry from Hansoh BioMedical R&D in phase 3 trials for osteosarcoma, non-small-cell lung cancer and sarcomas, with its target not yet stated publicly.","route":"/drugs/hs-20093/","status":"phase-3","kind":"drug","molecule":"hs-20093","modality":"antibody-drug conjugate (ADC), per the sponsor's pipeline page; form not stated in the registry record","facets":{"kind":["Treatment"],"cancers":["Osteosarcoma","Non-small-cell lung cancer","Sarcomas","Prostate cancer","Head and neck squamous cell carcinoma","Oesophageal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Osteosarcoma","href":"/cancers/osteosarcoma/","tip":"Osteosarcoma is the most common bone cancer, mostly in teenagers. Chemotherapy plus surgery cures about two-thirds when it has not spread; because no new drug has beaten that chemotherapy in a large trial in 30 years, the next gains are being sought in cellular therapy against GD2, HER2 and B7-H3."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Sarcomas","href":"/cancers/sarcoma/","tip":"Sarcomas are dozens of rare cancers of bone and connective tissue. GIST was the first solid tumour cured-in-practice by a targeted pill; synovial sarcoma got the first TCR-T therapy."},{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06112704","name":"HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors","tldr":"A phase 2 trial of HS-20093 in advanced solid tumours, run by Hansoh BioMedical R&D Company, now recruiting.","route":"/trials/nct06112704/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06112704","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"hs-20117","name":"HS-20117","tldr":"HS-20117 is an experimental bispecific antibody from Hansoh BioMedical R&D in phase 3 trials for non-small-cell lung cancer, aimed at EGFR and MET.","route":"/drugs/hs-20117/","status":"phase-3","kind":"drug","molecule":"hs-20117","modality":"bispecific antibody","sub":"PM1080","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"hst-1011","name":"HST-1011","tldr":"HST-1011 is a small-molecule inhibitor from HotSpot Therapeutics, Inc, in registered phase 2 trials for metastatic cancer.","route":"/drugs/hst-1011/","status":"phase-2","kind":"drug","molecule":"hst-1011","modality":"Small-molecule inhibitor","sub":"HST-1011","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct05594797","name":"Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM","tldr":"A phase 2 trial of Human BCMA Targeted T Cells Injection in multiple myeloma, run by Hrain Biotechnology Co., Ltd., now recruiting.","route":"/trials/nct05594797/","status":"recruiting","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT05594797","facets":{"kind":["Trial"],"cancers":["Multiple myeloma","Relapsed or refractory multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."},{"label":"Relapsed or refractory multiple myeloma","href":"/cancers/myeloma-relapsed-refractory/","tip":"Myeloma almost always returns, and each return is harder to treat. Two kinds of immune therapy aimed at the BCMA protein on myeloma cells, CAR-T cells (KarMMa-3, CARTITUDE-4) and off-the-shelf bispecific antibodies (MajesTEC), now give deep remissions after other drugs fail, and a second target, GPRC5D, gives another option."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06649708","name":"HX044,FIH Study in Patients with Advanced Solid Tumor Malignancies","tldr":"A phase 1/2 trial of HX044 in advanced solid tumours, run by Hanx Biopharmaceuticals (Wuhan) Co., Ltd., now recruiting.","route":"/trials/nct06649708/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06649708","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06149247","name":"HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL","tldr":"A phase 2 trial of Synthetic hypericin in Cutaneous T-cell lymphoma and Peripheral T-cell lymphomas, run by Soligenix, completed.","route":"/trials/nct06149247/","status":"completed","kind":"trial","cancerIcon":"cutaneous-t-cell-lymphoma","sub":"NCT06149247","facets":{"kind":["Trial"],"cancers":["Cutaneous T-cell lymphoma","Peripheral T-cell lymphomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Cutaneous T-cell lymphoma","href":"/cancers/cutaneous-t-cell-lymphoma/","tip":"Mycosis fungoides is a lymphoma that lives in the skin, looking like eczema or psoriasis for years before it is diagnosed. It is treated with creams, light and skin-directed radiotherapy for as long as possible, then with antibodies such as mogamulizumab and brentuximab vedotin when it spreads to the blood or lymph nodes."},{"label":"Peripheral T-cell lymphomas","href":"/cancers/peripheral-t-cell-lymphoma/","tip":"Peripheral T-cell lymphomas are lymphomas of T cells rather than B cells. They are rarer, more varied and, apart from a few subtypes, harder to treat than B-cell lymphomas; several new drugs help only defined subtypes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"iah0968","name":"IAH0968","tldr":"IAH0968 is an experimental small-molecule drug from SUNHO（China）BioPharmaceutical CO. in phase 3 trials for gastric & gastro-oesophageal junction cancer, aimed at HER2.","route":"/drugs/iah0968/","status":"phase-3","kind":"drug","molecule":"iah0968","modality":"monoclonal antibody (anti-HER2, per the sponsor's pipeline page; registered as a drug on ClinicalTrials.gov)","facets":{"kind":["Treatment"],"cancers":["Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00326820","name":"Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer","tldr":"A phase 3 trial of Ibandronic acid and Zoledronic acid in Breast cancer and Metastatic cancer, run by Wales Cancer Trials Unit, with a status the registry has not verified recently.","route":"/trials/nct00326820/","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT00326820","facets":{"kind":["Trial"],"cancers":["Breast cancer","Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."},{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06974812","name":"IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors","tldr":"A phase 1/2 trial of IBI3014 in advanced solid tumours, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.","route":"/trials/nct06974812/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06974812","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ibi310","name":"IBI310","tldr":"IBI310 is an experimental investigational agent whose form is not stated in the registry from Innovent Biopharmaceutical Technology (Hangzhou) in phase 3 trials for hepatocellular carcinoma, with its target not yet stated publicly.","route":"/drugs/ibi310/","status":"phase-3","kind":"drug","molecule":"ibi310","modality":"monoclonal antibody (anti-CTLA-4, per the sponsor's pipeline page; form not stated in the registry record)","facets":{"kind":["Treatment"],"cancers":["Hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ibi343","name":"IBI343","tldr":"IBI343 is an experimental investigational agent whose form is not stated in the registry from Innovent Biologics (Suzhou) in phase 3 trials for pancreatic ductal adenocarcinoma, aimed at Claudin 18.2.","route":"/drugs/ibi343/","status":"phase-3","kind":"drug","molecule":"ibi343","modality":"antibody-drug conjugate (ADC), per the sponsor's pipeline page; form not stated in the registry record","facets":{"kind":["Treatment"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ibi354","name":"IBI354","tldr":"IBI354 is an experimental antibody-drug conjugate from Innovent Biologics (Suzhou) in phase 3 trials for HER2-positive breast cancer and ovarian cancer, aimed at HER2.","route":"/drugs/ibi354/","status":"phase-3","kind":"drug","molecule":"ibi354","modality":"ADC","facets":{"kind":["Treatment"],"cancers":["HER2-positive breast cancer","Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."},{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ibi363","name":"IBI363","tldr":"IBI363 is an experimental fusion protein from Innovent Biologics (Suzhou) in phase 2 trials for melanoma, non-small-cell lung cancer and colorectal cancer, aimed at PD-1.","route":"/drugs/ibi363/","status":"phase-2","kind":"drug","molecule":"ibi363","modality":"fusion protein","facets":{"kind":["Treatment"],"cancers":["Melanoma","Non-small-cell lung cancer","Colorectal cancer","Renal cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00582166","name":"Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance","tldr":"A phase 2 trial of Ibritumomab tiuxetan and Rituximab in Non-Hodgkin lymphoma, run by University of Wisconsin, Madison, recorded as terminated on the registry.","route":"/trials/nct00582166/","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT00582166","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"icp-248","name":"ICP-248","tldr":"ICP-248 is an experimental small-molecule drug from Beijing InnoCare Pharma Tech in phase 3 trials for mantle cell lymphoma and chronic lymphocytic leukaemia, with its target not yet stated publicly.","route":"/drugs/icp-248/","status":"phase-3","kind":"drug","molecule":"icp-248","modality":"small molecule (structure undisclosed or not yet in PubChem)","facets":{"kind":["Treatment"],"cancers":["Mantle cell lymphoma","Chronic lymphocytic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Mantle cell lymphoma","href":"/cancers/mantle-cell-lymphoma/","tip":"An uncommon B-cell lymphoma driven by cyclin D1 that used to behave badly in almost everyone. BTK inhibitors, CAR-T and now BCL2 drugs have changed it from chemotherapy-plus-transplant to targeted combinations."},{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."}],"tags":[]},"sortKeys":{"year":0}},{"id":"idrx-42","name":"IDRX-42","tldr":"IDRX-42 is an experimental small-molecule drug from GlaxoSmithKline in phase 3 trials for gastrointestinal stromal tumour, with its target not yet stated publicly.","route":"/drugs/idrx-42/","status":"phase-3","kind":"drug","molecule":"idrx-42","modality":"small molecule","facets":{"kind":["Treatment"],"cancers":["Gastrointestinal stromal tumour"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Gastrointestinal stromal tumour","href":"/cancers/gist/","tip":"GIST is a sarcoma of the gut wall driven almost always by a KIT or PDGFRA mutation. It was the proof that a pill can control a solid tumour: imatinib turned a median survival of about a year into one of eight years or more, and the mutation now dictates which drug to use."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ifupinostat","name":"Ifupinostat","tldr":"Ifupinostat is an experimental investigational agent whose form is not stated in the registry from BeBetter Med in phase 3 trials for diffuse large B-cell lymphoma, with its target not yet stated publicly.","route":"/drugs/ifupinostat/","status":"phase-3","kind":"drug","molecule":"ifupinostat","modality":"not stated (registered as a drug or biological on ClinicalTrials.gov)","sub":"BEBT-908, CUDC-908","facets":{"kind":["Treatment"],"cancers":["Diffuse large B-cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ima203","name":"IMA203","tldr":"IMA203 is an experimental TCR-T cell therapy from Immatics US in phase 3 trials for melanoma, aimed at PRAME.","route":"/drugs/ima203/","status":"phase-3","kind":"drug","molecule":"ima203","modality":"TCR-T cell therapy","facets":{"kind":["Treatment"],"cancers":["Melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05958121","name":"IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors","tldr":"A phase 1/2 trial of IMA402 in advanced solid tumours, run by Immatics Biotechnologies GmbH, now recruiting.","route":"/trials/nct05958121/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05958121","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06107374","name":"Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG","tldr":"A phase 2 trial of [18F]F-AraG in non-small-cell lung cancer, run by CellSight Technologies, Inc., now recruiting.","route":"/trials/nct06107374/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06107374","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03673943","name":"Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE","tldr":"A phase 3 trial of Somatostatin receptor PET in Neuroendocrine tumours, run by Radiomedix, Inc., completed.","route":"/trials/nct03673943/","status":"completed","kind":"trial","cancerIcon":"neuroendocrine","sub":"NCT03673943","facets":{"kind":["Trial"],"cancers":["Neuroendocrine tumours"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Neuroendocrine tumours","href":"/cancers/neuroendocrine/","tip":"A family of usually slow-growing tumours that start in hormone-producing cells of the gut, pancreas and lungs. They pioneered the idea of using the same molecule to see a tumour on a scan and then to treat it with radiation."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02815033","name":"Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide","tldr":"A phase 2 trial of Whole-body MRI in Prostate cancer, run by The European Uro-Oncology Group, completed.","route":"/trials/nct02815033/","status":"completed","kind":"trial","cancerIcon":"prostate","sub":"NCT02815033","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04086264","name":"IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia","tldr":"A phase 1/2 trial of Azacitidine, Pivekimab sunirine and Venetoclax in acute myeloid leukaemia, run by AbbVie, active and no longer recruiting.","route":"/trials/nct04086264/","status":"active","kind":"trial","cancerIcon":"aml","sub":"NCT04086264","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05909436","name":"Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors","tldr":"A phase 1/2 trial of Zimberelimab in advanced solid tumours, run by Guangzhou Gloria Biosciences Co., Ltd., now recruiting.","route":"/trials/nct05909436/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05909436","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05027776","name":"Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years","tldr":"A phase 3 trial of 2-doses Group among 9-14 years in cervical cancer and vaginal cancer, run by Shanghai Bovax Biotechnology Co., Ltd., now recruiting.","route":"/trials/nct05027776/","status":"recruiting","kind":"trial","cancerIcon":"cervical","sub":"NCT05027776","facets":{"kind":["Trial"],"cancers":["Cervical cancer","Vaginal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."},{"label":"Vaginal cancer","href":"/cancers/vaginal/","tip":"Primary vaginal cancer is rare and mostly caused by HPV, the virus behind cervical cancer. It is treated like cervical cancer, with weekly cisplatin alongside external and internal radiotherapy, which controls most tumours while preserving the organ; HPV vaccination and cervical screening, which also detects vaginal precursors, are steadily reducing it."}],"tags":[]},"sortKeys":{"year":0}},{"id":"imp1734","name":"IMP1734","tldr":"IMP1734 is a small-molecule inhibitor from Eikon Therapeutics, in registered phase 2 trials for metastatic cancer.","route":"/drugs/imp1734/","status":"phase-2","kind":"drug","molecule":"imp1734","modality":"Small-molecule inhibitor","sub":"IMP1734","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"imp4927","name":"IMP4927","tldr":"IMP4927 is an experimental small-molecule drug from Impact Therapeutics in phase 3 trials for ovarian cancer, with its target not yet stated publicly.","route":"/drugs/imp4927/","status":"phase-3","kind":"drug","molecule":"imp4927","modality":"small molecule","facets":{"kind":["Treatment"],"cancers":["Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06044623","name":"Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients","tldr":"A phase 3 trial of Geriatric assessment in Breast cancer, run by Region Örebro County, now recruiting.","route":"/trials/nct06044623/","status":"recruiting","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT06044623","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"in10018","name":"IN10018","tldr":"IN10018 is an experimental small-molecule drug from InxMed (Shanghai) in phase 3 trials for non-small-cell lung cancer, pancreatic ductal adenocarcinoma and ovarian cancer, with its target not yet stated publicly.","route":"/drugs/in10018/","status":"phase-3","kind":"drug","molecule":"in10018","modality":"small molecule","sub":"BI853520","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Pancreatic ductal adenocarcinoma","Ovarian cancer","Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05994131","name":"IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC","tldr":"A phase 1/2 trial of IN10018 and Furmonertinib in non-small-cell lung cancer, run by InxMed (Shanghai) Co., Ltd., now recruiting.","route":"/trials/nct05994131/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT05994131","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07441174","name":"IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors","tldr":"A phase 1/2 trial of IN10018 in advanced solid tumours, run by InxMed (Shanghai) Co., Ltd., now recruiting.","route":"/trials/nct07441174/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07441174","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05827796","name":"IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer","tldr":"A phase 1/2 trial of IN10018 and Gemcitabine in pancreatic ductal adenocarcinoma, run by InxMed (Shanghai) Co., Ltd., now recruiting.","route":"/trials/nct05827796/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT05827796","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"inbrx-106","name":"INBRX-106","tldr":"INBRX-106 is an experimental monoclonal antibody from Inhibrx Biosciences in phase 3 trials for head and neck squamous cell carcinoma, with its target not yet stated publicly.","route":"/drugs/inbrx-106/","status":"phase-3","kind":"drug","molecule":"inbrx-106","modality":"monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[]},"sortKeys":{"year":0}},{"id":"inca33890","name":"INCA33890","tldr":"INCA33890 is an experimental investigational agent whose form is not stated in the registry from Incyte in phase 3 trials for colorectal cancer, with its target not yet stated publicly.","route":"/drugs/inca33890/","status":"phase-3","kind":"drug","molecule":"inca33890","modality":"bispecific antibody (TGF-beta receptor II x PD-1, per the sponsor's pipeline page; form not stated in the registry record)","facets":{"kind":["Treatment"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"incb123667","name":"INCB123667","tldr":"INCB123667 is an experimental small-molecule drug from Incyte in phase 3 trials for ovarian cancer, with its target not yet stated publicly.","route":"/drugs/incb123667/","status":"phase-3","kind":"drug","molecule":"incb123667","modality":"small molecule (structure undisclosed or not yet in PubChem)","facets":{"kind":["Treatment"],"cancers":["Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"incb161734","name":"INCB161734","tldr":"INCB161734 is an experimental small-molecule drug from Incyte in phase 3 trials for pancreatic ductal adenocarcinoma, aimed at KRAS.","route":"/drugs/incb161734/","status":"phase-3","kind":"drug","molecule":"incb161734","modality":"small molecule (structure undisclosed or not yet in PubChem)","facets":{"kind":["Treatment"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04736589","name":"Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway","tldr":"A phase 3 trial of Inetetamab, Sirolimus protein-bound particles and Pyrotinib in Breast cancer, run by Peking Union Medical College, not yet recruiting.","route":"/trials/nct04736589/","status":"planned","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT04736589","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02843945","name":"Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source","tldr":"A phase 1/2 trial of Directional Brachytherapy Source Implant in pancreatic ductal adenocarcinoma, run by CivaTech Oncology, now recruiting.","route":"/trials/nct02843945/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT02843945","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Borderline resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Borderline resectable pancreatic ductal adenocarcinoma","href":"/cancers/borderline-resectable-pdac/","tip":"Borderline resectable pancreatic cancer touches the big blood vessels behind the pancreas, so an operation straight away would probably leave cancer behind. Chemotherapy first, usually FOLFIRINOX for several months and sometimes radiotherapy, shrinks the edge of the tumour, and patients whose disease has not spread go on to surgery with a better chance of a clean removal."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06687681","name":"Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas","tldr":"A phase 2 trial of NK cell therapy in glioma & glioblastoma, run by Marzieh Ebrahimi, now recruiting.","route":"/trials/nct06687681/","status":"recruiting","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT06687681","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"inlexisertib","name":"Inlexisertib","tldr":"Inlexisertib is an oral serine/threonine kinase inhibitor from Deciphera Pharmaceuticals, LLC, in registered phase 2 trials for metastatic cancer.","route":"/drugs/inlexisertib/","status":"phase-2","kind":"drug","molecule":"inlexisertib","modality":"Oral serine/threonine kinase inhibitor","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"ino-5401","name":"INO-5401","tldr":"INO-5401 is an experimental cancer vaccine from Inovio Pharmaceuticals in phase 2 trials for glioma & glioblastoma, aimed at PSMA.","route":"/drugs/ino-5401/","status":"phase-2","kind":"drug","molecule":"ino-5401","modality":"vaccine","facets":{"kind":["Treatment"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03491683","name":"INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)","tldr":"A phase 1/2 trial of INO-5401, Cemiplimab and Temozolomide in glioma & glioblastoma, run by Inovio Pharmaceuticals, active and no longer recruiting.","route":"/trials/nct03491683/","status":"active","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT03491683","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03150693","name":"Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia","tldr":"A phase 3 trial of Cytarabine, Daunorubicin, Vincristine, Dexamethasone, Methotrexate, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine and Inotuzumab ozogamicin in Acute lymphoblastic leukaemia, run by Alliance for Clinical Trials in Oncology, now recruiting.","route":"/trials/nct03150693/","status":"recruiting","kind":"trial","cancerIcon":"all-leukemia","sub":"NCT03150693","facets":{"kind":["Trial"],"cancers":["Acute lymphoblastic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."}],"tags":[]},"sortKeys":{"year":0}},{"id":"int230-6","name":"INT230-6","tldr":"INT230-6 is an experimental investigational agent whose form is not stated in the registry from Intensity Therapeutics in phase 3 trials for sarcomas, with its target not yet stated publicly.","route":"/drugs/int230-6/","status":"phase-3","kind":"drug","molecule":"int230-6","modality":"not stated (registered as a drug or biological on ClinicalTrials.gov)","facets":{"kind":["Treatment"],"cancers":["Sarcomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Sarcomas","href":"/cancers/sarcoma/","tip":"Sarcomas are dozens of rare cancers of bone and connective tissue. GIST was the first solid tumour cured-in-practice by a targeted pill; synovial sarcoma got the first TCR-T therapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00493181","name":"Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients","tldr":"A phase 2 trial of Oprelvekin in Leukaemia and Chronic myeloid leukaemia, run by M.D. Anderson Cancer Center, completed.","route":"/trials/nct00493181/","status":"completed","kind":"trial","cancerIcon":"leukaemia","sub":"NCT00493181","facets":{"kind":["Trial"],"cancers":["Leukaemia","Chronic myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Leukaemia","href":"/cancers/leukaemia/","tip":"Leukaemia means cancer of the blood-forming cells, but the four main types share little beyond the name: acute lymphoblastic and acute myeloid leukaemia are emergencies treated with intensive therapy, while chronic lymphocytic and chronic myeloid leukaemia are slow diseases controlled for years with pills. Each has its own page."},{"label":"Chronic myeloid leukaemia","href":"/cancers/cml/","tip":"Chronic myeloid leukaemia is a blood cancer driven by a single fused gene, BCR-ABL1, and the model for oncogene-targeted treatment: imatinib in 2001 and the tyrosine kinase inhibitors that followed turned it into a condition most people live with long-term. About half of patients with a sustained deep molecular response can now stop treatment altogether."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00004157","name":"Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors","tldr":"A phase 2 trial of Filgrastim and Oprelvekin in Breast cancer, Neuroblastoma and Ovarian cancer, run by Fred Hutchinson Cancer Center, completed.","route":"/trials/nct00004157/","status":"completed","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT00004157","facets":{"kind":["Trial"],"cancers":["Breast cancer","Neuroblastoma","Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."},{"label":"Neuroblastoma","href":"/cancers/neuroblastoma/","tip":"Neuroblastoma is a childhood nerve-cell cancer where anti-GD2 antibodies and, recently, GD2 CAR-T have improved survival in high-risk disease."},{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01117441","name":"International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia","tldr":"A phase 3 trial of Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Etoposide, Ifosfamide, Mercaptopurine, Methotrexate, Prednisone, Thioguanine, Vincristine, Vindesine and Fludarabine in Leukaemia, run by University Hospital Schleswig-Holstein, completed.","route":"/trials/nct01117441/","status":"completed","kind":"trial","cancerIcon":"leukaemia","sub":"NCT01117441","facets":{"kind":["Trial"],"cancers":["Leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Leukaemia","href":"/cancers/leukaemia/","tip":"Leukaemia means cancer of the blood-forming cells, but the four main types share little beyond the name: acute lymphoblastic and acute myeloid leukaemia are emergencies treated with intensive therapy, while chronic lymphocytic and chronic myeloid leukaemia are slow diseases controlled for years with pills. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01415986","name":"Interstitial Photodynamic Therapy (PDT) With Temoporfin for Advanced Head and Neck Cancers","tldr":"A phase 2 trial of Temoporfin in Head and neck squamous cell carcinoma, run by University of Arkansas, recorded as terminated on the registry.","route":"/trials/nct01415986/","kind":"trial","cancerIcon":"head-and-neck","sub":"NCT01415986","facets":{"kind":["Trial"],"cancers":["Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03257033","name":"Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC","tldr":"A phase 3 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by RenovoRx, now recruiting.","route":"/trials/nct03257033/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT03257033","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Locally advanced unresectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02213991","name":"Intraoperative Radiotherapy for Korean Patients With Breast Cancer","tldr":"A phase 2 trial of Intraoperative radiotherapy in Breast cancer, run by Gangnam Severance Hospital, with a status the registry has not verified recently.","route":"/trials/nct02213991/","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT02213991","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02685605","name":"Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme","tldr":"A phase 3 trial of Intraoperative radiotherapy in Glioma & glioblastoma, run by Universitätsmedizin Mannheim, active and no longer recruiting.","route":"/trials/nct02685605/","status":"active","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT02685605","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05688280","name":"Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS","tldr":"A phase 1/2 trial of 1.0% IP-001 for Injection in colorectal cancer, non-small-cell lung cancer and sarcomas, run by Immunophotonics, Inc., active and no longer recruiting.","route":"/trials/nct05688280/","status":"active","kind":"trial","cancerIcon":"colorectal","sub":"NCT05688280","facets":{"kind":["Trial"],"cancers":["Colorectal cancer","Non-small-cell lung cancer","Sarcomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Sarcomas","href":"/cancers/sarcoma/","tip":"Sarcomas are dozens of rare cancers of bone and connective tissue. GIST was the first solid tumour cured-in-practice by a targeted pill; synovial sarcoma got the first TCR-T therapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07339176","name":"Intratumoral N17350 in Advanced Solid Tumors","tldr":"A phase 1/2 trial of N17350 in melanoma, head and neck squamous cell carcinoma and non-small-cell lung cancer, run by Onchilles Pharma Inc, now recruiting.","route":"/trials/nct07339176/","status":"recruiting","kind":"trial","cancerIcon":"melanoma","sub":"NCT07339176","facets":{"kind":["Trial"],"cancers":["Melanoma","Head and neck squamous cell carcinoma","Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06898970","name":"Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma","tldr":"A phase 2 trial of Vusolimogene oderparepvec and Pembrolizumab in Angiosarcoma, run by Varun Monga, MBBS, now recruiting.","route":"/trials/nct06898970/","status":"recruiting","kind":"trial","cancerIcon":"angiosarcoma","sub":"NCT06898970","facets":{"kind":["Trial"],"cancers":["Angiosarcoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Angiosarcoma","href":"/cancers/angiosarcoma/","tip":"Angiosarcoma is an aggressive vascular tumour, a cancer of the cells that line blood and lymph vessels. It grows as bruise-like patches on the scalp of older people, in breasts treated years earlier with radiotherapy, or inside organs. Surgery and radiotherapy are used where possible, weekly paclitaxel is the most active drug, and immunotherapy helps a minority with the sun-damaged scalp form."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03945162","name":"Intravesical Photodynamic Therapy (\"PDT\") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Patients","tldr":"A phase 2 trial of Ruvidar® (TLD-1433) bladder infusion and PDT in bladder & urothelial cancer, run by Theralase® Technologies Inc., now recruiting.","route":"/trials/nct03945162/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT03945162","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Non-muscle-invasive bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Non-muscle-invasive bladder cancer","href":"/cancers/non-muscle-invasive-bladder-cancer/","tip":"Most bladder cancers are found while still confined to the lining. They are scraped out through the urethra and, when higher risk, treated with BCG instilled into the bladder; the challenge is the frequent recurrences and the patients whose tumours stop responding to BCG."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07429266","name":"INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)","tldr":"A phase 3 trial of Sapablursen in myeloproliferative neoplasms, run by Ono Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07429266/","status":"recruiting","kind":"trial","cancerIcon":"myeloproliferative-neoplasms","sub":"NCT07429266","facets":{"kind":["Trial"],"cancers":["Myeloproliferative neoplasms","Polycythaemia vera"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Myeloproliferative neoplasms","href":"/cancers/myeloproliferative-neoplasms/","tip":"Myeloproliferative neoplasms are slow-growing blood cancers in which the marrow overproduces red cells (polycythaemia vera), platelets (essential thrombocythaemia) or scar tissue (myelofibrosis). Almost all carry a mutation in JAK2, CALR or MPL; treatment aims to prevent clots and control symptoms, and only transplant cures myelofibrosis."},{"label":"Polycythaemia vera","href":"/cancers/polycythaemia-vera/","tip":"Polycythaemia vera is a slow blood cancer in which a single faulty gene, JAK2, makes the bone marrow produce too many red cells. Thick blood causes clots, so treatment thins it (blood removal, aspirin) and, for higher-risk patients, calms the marrow with hydroxyurea, interferon or ruxolitinib; a hepcidin mimic, rusfertide, now controls red cell counts without regular blood removal."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05016349","name":"Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer","tldr":"A phase 3 trial of Tretinoin, Mifepristone, Alitretinoin and Tamoxifen in Breast cancer, run by Mahmoud Ramadan mohamed Elkazzaz, with a status the registry has not verified recently.","route":"/trials/nct05016349/","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT05016349","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07615101","name":"Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.","tldr":"A phase 3 trial of 68-Ga-NYM032 in prostate cancer, run by Norroy Bioscience Co., LTD, now recruiting.","route":"/trials/nct07615101/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT07615101","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03096093","name":"Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer","tldr":"A phase 1/2 trial of ACIT-1 in advanced solid tumours, run by Cancer Vaccines Limited, active and no longer recruiting.","route":"/trials/nct03096093/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT03096093","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04851717","name":"Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures","tldr":"A phase 2/3 trial of Remimazolam in childhood cancers, run by Acacia Pharma Ltd, active and no longer recruiting.","route":"/trials/nct04851717/","status":"active","kind":"trial","cancerIcon":"childhood-cancers","sub":"NCT04851717","facets":{"kind":["Trial"],"cancers":["Childhood cancers"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Childhood cancers","href":"/cancers/childhood-cancers/","tip":"Cancer in children is rare and different from adult cancer: the common types are leukaemias, brain tumours, lymphomas and embryonal tumours such as neuroblastoma and Wilms tumour, most are curable in well-resourced health systems, and the great challenge is bringing the same cures to the majority of children who live where they are not available."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03878849","name":"Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer","tldr":"A phase 2 trial of 2X-121 in ovarian cancer, run by Allarity Therapeutics, now recruiting.","route":"/trials/nct03878849/","status":"recruiting","kind":"trial","cancerIcon":"ovarian","sub":"NCT03878849","facets":{"kind":["Trial"],"cancers":["Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00884273","name":"Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients","tldr":"A phase 3 trial of Degarelix, Goserelin / leuprolide and Bicalutamide in Prostate cancer, run by Ferring Pharmaceuticals, completed.","route":"/trials/nct00884273/","status":"completed","kind":"trial","cancerIcon":"prostate","sub":"NCT00884273","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"io102-io103","name":"IO102-IO103","tldr":"IO102-IO103 is an experimental peptide (immunotherapeutic vaccine) from IO Biotech in phase 3 trials for melanoma and head and neck squamous cell carcinoma, aimed at PD-L1.","route":"/drugs/io102-io103/","status":"phase-3","kind":"drug","molecule":"io102-io103","modality":"peptide (immunotherapeutic vaccine)","sub":"IO102, IO103","facets":{"kind":["Treatment"],"cancers":["Melanoma","Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[]},"sortKeys":{"year":0}},{"id":"iomab-b","name":"Iomab-B","tldr":"Iomab-B is Actinium's radioactive antibody that clears the bone marrow before a transplant for older patients with active relapsed acute myeloid leukaemia; the phase 3 SIERRA trial met its primary endpoint but the FDA asked for another study.","route":"/drugs/iomab-b/","status":"phase-3","kind":"drug","molecule":"iomab-b","modality":"Radioimmunotherapy conditioning agent (anti-CD45 antibody labelled with iodine-131)","facets":{"kind":["Treatment"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07447570","name":"Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC","tldr":"A phase 2 trial of Iparomlimab and tuvonralimab in Head and neck squamous cell carcinoma, run by Second Affiliated Hospital, Zhejiang University, School of Medicine, now recruiting.","route":"/trials/nct07447570/","status":"recruiting","kind":"trial","cancerIcon":"head-and-neck","sub":"NCT07447570","facets":{"kind":["Trial"],"cancers":["Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ipatasertib","name":"Ipatasertib","tldr":"Ipatasertib is an experimental small-molecule drug from Hoffmann-La Roche in phase 3 trials for HR-positive / HER2-negative breast cancer and ovarian cancer, aimed at AKT.","route":"/drugs/ipatasertib/","status":"phase-3","kind":"drug","molecule":"ipatasertib","modality":"small molecule","sub":"GDC-0068, RO5532961, RG7440","facets":{"kind":["Treatment"],"cancers":["HR-positive / HER2-negative breast cancer","Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ipg1094","name":"IPG1094","tldr":"IPG1094 is a small-molecule inhibitor from Nanjing Immunophage Biotech Co., Ltd, in registered phase 2 trials for metastatic cancer.","route":"/drugs/ipg1094/","status":"phase-2","kind":"drug","molecule":"ipg1094","modality":"Small-molecule inhibitor","sub":"IPG1094","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct07508761","name":"IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors","tldr":"A phase 1/2 trial of Toripalimab in advanced solid tumours, run by Nanjing Immunophage Biotech Co., Ltd, now recruiting.","route":"/trials/nct07508761/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07508761","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07238283","name":"Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer","tldr":"A phase 3 trial of Leucovorin (folinic acid), Oxaliplatin and Gemcitabine in pancreatic ductal adenocarcinoma, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.","route":"/trials/nct07238283/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT07238283","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07356973","name":"Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma","tldr":"A phase 2 trial of irinotecan-ChemoSeed implementation into the resection cavity after surgical resection of GBM in glioma & glioblastoma, run by CRISM Therapeutics LTD, now recruiting.","route":"/trials/nct07356973/","status":"recruiting","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT07356973","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05946603","name":"IS-002 Phase 2 Prostate Cancer Study","tldr":"A phase 2 trial of Intraoperative fluorescence and Cerenkov imaging systems in Prostate cancer, run by Intuitive Surgical, completed.","route":"/trials/nct05946603/","status":"completed","kind":"trial","cancerIcon":"prostate","sub":"NCT05946603","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04270409","name":"Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma","tldr":"A phase 3 trial of Isatuximab, Lenalidomide and Dexamethasone in multiple myeloma, run by Sanofi, active and no longer recruiting.","route":"/trials/nct04270409/","status":"active","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT04270409","facets":{"kind":["Trial"],"cancers":["Multiple myeloma","Smouldering multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."},{"label":"Smouldering multiple myeloma","href":"/cancers/smouldering-myeloma/","tip":"Smouldering myeloma is myeloma that has not yet damaged bones, kidneys or blood counts. Most people are watched, but those at high risk of progressing can now be treated: the AQUILA trial showed daratumumab alone delays active myeloma, and it was approved for this use in 2025."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06634875","name":"Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)","tldr":"A phase 2 trial of isunakinra in colorectal cancer, run by Buzzard Pharmaceuticals, now recruiting.","route":"/trials/nct06634875/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT06634875","facets":{"kind":["Trial"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06127407","name":"Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen","tldr":"A phase 3 trial of Ivosidenib in sarcomas, run by Servier Bio-Innovation LLC, now recruiting.","route":"/trials/nct06127407/","status":"recruiting","kind":"trial","cancerIcon":"sarcoma","sub":"NCT06127407","facets":{"kind":["Trial"],"cancers":["Sarcomas","Chondrosarcoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Sarcomas","href":"/cancers/sarcoma/","tip":"Sarcomas are dozens of rare cancers of bone and connective tissue. GIST was the first solid tumour cured-in-practice by a targeted pill; synovial sarcoma got the first TCR-T therapy."},{"label":"Chondrosarcoma","href":"/cancers/chondrosarcoma/","tip":"Chondrosarcoma is a cancer of cartilage-forming cells in bone. It is nearly immune to chemotherapy and radiotherapy, so complete surgery is the treatment, with proton or carbon-ion beams for skull base and spine tumours that cannot be fully removed. Half of conventional tumours carry an IDH mutation, and the IDH1 blocker ivosidenib is in a phase 3 trial."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ivospemin","name":"Ivospemin","tldr":"Ivospemin is an experimental small-molecule drug from Panbela Therapeutics in phase 3 trials for pancreatic ductal adenocarcinoma, with its target not yet stated publicly.","route":"/drugs/ivospemin/","status":"phase-3","kind":"drug","molecule":"ivospemin","modality":"small molecule","sub":"SBP-101","facets":{"kind":["Treatment"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06549946","name":"Ixovex-1 Single Agent and Combination Therapy","tldr":"A phase 1/2 trial of Pembrolizumab in head and neck squamous cell carcinoma, run by Psivac Ltd, now recruiting.","route":"/trials/nct06549946/","status":"recruiting","kind":"trial","cancerIcon":"head-and-neck","sub":"NCT06549946","facets":{"kind":["Trial"],"cancers":["Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06973564","name":"JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration","tldr":"A phase 1/2 trial of JAB-23E73 in advanced solid tumours, run by Jacobio Pharmaceuticals Co., Ltd., now recruiting.","route":"/trials/nct06973564/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06973564","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05490472","name":"JAB-2485 Activity in Adult Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of JAB-2485 (Aurora A inhibitor) in triple-negative breast cancer and small-cell lung cancer, run by Jacobio Pharmaceuticals Co., Ltd., now recruiting.","route":"/trials/nct05490472/","status":"recruiting","kind":"trial","cancerIcon":"tnbc","sub":"NCT05490472","facets":{"kind":["Trial"],"cancers":["Triple-negative breast cancer","Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06386146","name":"JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation","tldr":"A phase 1/2 trial of JAB-30355 in advanced solid tumours, run by Jacobio Pharmaceuticals Co., Ltd., now recruiting.","route":"/trials/nct06386146/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06386146","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"jbi-802","name":"JBI-802","tldr":"JBI-802 is a small-molecule inhibitor from Jubilant Therapeutics Inc., in registered phase 2 trials for myeloproliferative neoplasms, chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms.","route":"/drugs/jbi-802/","status":"phase-2","kind":"drug","molecule":"jbi-802","modality":"Small-molecule inhibitor","sub":"JBI-802","facets":{"kind":["Treatment"],"cancers":["Myeloproliferative neoplasms","Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Myeloproliferative neoplasms","href":"/cancers/myeloproliferative-neoplasms/","tip":"Myeloproliferative neoplasms are slow-growing blood cancers in which the marrow overproduces red cells (polycythaemia vera), platelets (essential thrombocythaemia) or scar tissue (myelofibrosis). Almost all carry a mutation in JAK2, CALR or MPL; treatment aims to prevent clots and control symptoms, and only transplant cures myelofibrosis."},{"label":"Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms","href":"/cancers/cmml/","tip":"Chronic myelomonocytic leukaemia and its relatives are bone-marrow cancers that behave partly like myelodysplasia (poorly made blood cells) and partly like a proliferative disease (an excess of monocytes or platelets). Hypomethylating agents produce responses in a minority and stabilise counts in more, transplant can cure the fit, and RAS-pathway and JAK inhibitors are in trials."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"jdq443","name":"JDQ443","tldr":"JDQ443 is an experimental small-molecule drug from Novartis Pharmaceuticals in phase 3 trials for non-small-cell lung cancer and colorectal cancer, aimed at KRAS.","route":"/drugs/jdq443/","status":"phase-3","kind":"drug","molecule":"jdq443","modality":"small molecule","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06595186","name":"JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)","tldr":"A phase 2 trial of Temozolomide in glioma & glioblastoma, run by JenKem Technology Co., Ltd., now recruiting.","route":"/trials/nct06595186/","status":"recruiting","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT06595186","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"jk08","name":"JK08","tldr":"JK08 is an experimental fusion protein or cytokine from Salubris Biotherapeutics in phase 2 trials for melanoma, colorectal cancer and non-small-cell lung cancer, aimed at CTLA-4.","route":"/drugs/jk08/","status":"phase-2","kind":"drug","molecule":"jk08","modality":"fusion protein or cytokine","facets":{"kind":["Treatment"],"cancers":["Melanoma","Colorectal cancer","Non-small-cell lung cancer","Bladder & urothelial cancer","Head and neck squamous cell carcinoma","HR-positive / HER2-negative breast cancer","Triple-negative breast cancer","Renal cell carcinoma","Gastric & gastro-oesophageal junction cancer","Pancreatic ductal adenocarcinoma","Hepatocellular carcinoma","Ovarian cancer","Thyroid cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."}],"tags":[]},"sortKeys":{"year":0}},{"id":"jmt101","name":"JMT101","tldr":"JMT101 is an experimental monoclonal antibody from Shanghai JMT-Bio in phase 3 trials for non-small-cell lung cancer, aimed at EGFR.","route":"/drugs/jmt101/","status":"phase-3","kind":"drug","molecule":"jmt101","modality":"monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06391944","name":"JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations","tldr":"A phase 2 trial of Osimertinib in non-small-cell lung cancer, run by Shanghai JMT-Bio Inc., active and no longer recruiting.","route":"/trials/nct06391944/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT06391944","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"jmt203","name":"JMT203","tldr":"JMT203 is a monoclonal antibody from Shanghai JMT-Bio Inc., in registered phase 2 trials for non-small-cell lung cancer, pancreatic ductal adenocarcinoma, colorectal cancer.","route":"/drugs/jmt203/","status":"phase-2","kind":"drug","molecule":"jmt203","modality":"Monoclonal antibody","sub":"JMT203","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Pancreatic ductal adenocarcinoma","Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"jnj-79635322","name":"JNJ-79635322","tldr":"JNJ-79635322 is an experimental investigational agent whose form is not stated in the registry from Janssen Research & Development in phase 3 trials for multiple myeloma, with its target not yet stated publicly.","route":"/drugs/jnj-79635322/","status":"phase-3","kind":"drug","molecule":"jnj-79635322","modality":"trispecific antibody (BCMA x GPRC5D x CD3, per the sponsor's pipeline page; form not stated in the registry record)","facets":{"kind":["Treatment"],"cancers":["Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[]},"sortKeys":{"year":0}},{"id":"jnj-87189401","name":"JNJ-87189401","tldr":"JNJ-87189401 is an experimental costimulatory agent from Janssen Research & Development in phase 3 trials for prostate cancer, aimed at PSMA.","route":"/drugs/jnj-87189401/","status":"phase-3","kind":"drug","molecule":"jnj-87189401","modality":"costimulatory bispecific antibody (PSMA x CD28, per the sponsor's pipeline page)","facets":{"kind":["Treatment"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"jnj-90014496","name":"JNJ-90014496","tldr":"JNJ-90014496 is an experimental CAR-T cell therapy from Janssen Research & Development in phase 2 trials for hodgkin lymphoma and diffuse large B-cell lymphoma, aimed at CD19 and CD20.","route":"/drugs/jnj-90014496/","status":"phase-2","kind":"drug","molecule":"jnj-90014496","modality":"CAR-T cell therapy","facets":{"kind":["Treatment"],"cancers":["Hodgkin lymphoma","Diffuse large B-cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Hodgkin lymphoma","href":"/cancers/hodgkin-lymphoma/","tip":"Hodgkin lymphoma is one of the most curable cancers, where the goal is now to cure with less toxicity, using brentuximab and, from 2026, first-line nivolumab."},{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."}],"tags":[]},"sortKeys":{"year":0}},{"id":"jnj-90301900","name":"JNJ-90301900","tldr":"JNJ-90301900 is an experimental radioenhancer nanoparticle from Johnson & Johnson Enterprise Innovation in phase 3 trials for head and neck squamous cell carcinoma, with its target not yet stated publicly.","route":"/drugs/jnj-90301900/","status":"phase-3","kind":"drug","molecule":"jnj-90301900","modality":"radioenhancer nanoparticle","facets":{"kind":["Treatment"],"cancers":["Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[]},"sortKeys":{"year":0}},{"id":"js105","name":"JS105","tldr":"JS105 is an experimental small-molecule drug from Risen (Suzhou) Pharma Tech in phase 3 trials for HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.","route":"/drugs/js105/","status":"phase-3","kind":"drug","molecule":"js105","modality":"small molecule (structure undisclosed or not yet in PubChem)","facets":{"kind":["Treatment"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"js111","name":"JS111","tldr":"JS111 is an experimental small-molecule drug from Suzhou Junjing BioSciences in phase 2 trials for non-small-cell lung cancer, aimed at EGFR and MET.","route":"/drugs/js111/","status":"phase-2","kind":"drug","molecule":"js111","modality":"small molecule (structure undisclosed or not yet in PubChem)","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06940401","name":"JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations","tldr":"A phase 1/2 trial of JS111 capsules (AP-L1898) in non-small-cell lung cancer, run by Suzhou Junjing BioSciences Co., Ltd., active and no longer recruiting.","route":"/trials/nct06940401/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT06940401","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"jskn003","name":"JSKN003","tldr":"JSKN003 is an experimental investigational agent whose form is not stated in the registry from Jiangsu Alphamab Biopharmaceuticals in phase 3 trials for HR-positive / HER2-negative breast cancer and HER2-positive breast cancer, with its target not yet stated publicly.","route":"/drugs/jskn003/","status":"phase-3","kind":"drug","molecule":"jskn003","modality":"antibody-drug conjugate (ADC), per the sponsor's pipeline page; form not stated in the registry record","facets":{"kind":["Treatment"],"cancers":["HR-positive / HER2-negative breast cancer","HER2-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."}],"tags":[]},"sortKeys":{"year":0}},{"id":"jskn016","name":"JSKN016","tldr":"JSKN016 is an experimental investigational agent whose form is not stated in the registry from Jiangsu Alphamab Biopharmaceuticals in phase 3 trials for triple-negative breast cancer and HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.","route":"/drugs/jskn016/","status":"phase-3","kind":"drug","molecule":"jskn016","modality":"antibody-drug conjugate (ADC), per the sponsor's pipeline page; form not stated in the registry record","facets":{"kind":["Treatment"],"cancers":["Triple-negative breast cancer","HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"jyp0015","name":"JYP0015","tldr":"JYP0015 is an experimental small-molecule drug from Guangzhou JOYO Pharma in phase 2 trials for pancreatic ductal adenocarcinoma, non-small-cell lung cancer and colorectal cancer, aimed at KRAS.","route":"/drugs/jyp0015/","status":"phase-2","kind":"drug","molecule":"jyp0015","modality":"small molecule (structure undisclosed or not yet in PubChem)","facets":{"kind":["Treatment"],"cancers":["Pancreatic ductal adenocarcinoma","Non-small-cell lung cancer","Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"kc1036","name":"KC1036","tldr":"KC1036 is an experimental small-molecule drug from Beijing Konruns Pharmaceutical in phase 3 trials for oesophageal cancer, ewing sarcoma and thymoma and thymic carcinoma, with its target not yet stated publicly.","route":"/drugs/kc1036/","status":"phase-3","kind":"drug","molecule":"kc1036","modality":"small molecule (structure undisclosed or not yet in PubChem)","facets":{"kind":["Treatment"],"cancers":["Oesophageal cancer","Ewing sarcoma","Thymoma and thymic carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."},{"label":"Ewing sarcoma","href":"/cancers/ewing-sarcoma/","tip":"Ewing sarcoma is a bone and soft-tissue cancer of teenagers driven by a single fusion gene, EWSR1-FLI1. Intensive chemotherapy with surgery or radiation cures most localised cases; disease that has spread at diagnosis, and relapse, remain hard to treat, and no drug against the fusion protein itself has yet succeeded."},{"label":"Thymoma and thymic carcinoma","href":"/cancers/thymic-epithelial/","tip":"Thymoma and thymic carcinoma are rare tumours of the thymus gland in the chest. Thymomas grow slowly, often cause autoimmune diseases such as myasthenia gravis, and are usually cured by surgery; thymic carcinomas behave like other aggressive cancers and have few effective drugs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07481058","name":"KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer","tldr":"A phase 2 trial of KC1036, Toripalimab and Cisplatin in oesophageal cancer, run by Beijing Konruns Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07481058/","status":"recruiting","kind":"trial","cancerIcon":"esophageal","sub":"NCT07481058","facets":{"kind":["Trial"],"cancers":["Oesophageal cancer","Oesophageal squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."},{"label":"Oesophageal squamous cell carcinoma","href":"/cancers/oesophageal-squamous-cell-carcinoma/","tip":"Squamous cell carcinoma of the oesophagus, the world's commonest form, is linked to smoking, alcohol and very hot drinks and sits in the upper and middle gullet. It is treated with chemoradiation, with or without surgery, and immunotherapy has recently joined chemotherapy for advanced disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04165070","name":"KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)","tldr":"A phase 1/2 trial of Pembrolizumab, Carboplatin, Pemetrexed and Ifinatamab deruxtecan in non-small-cell lung cancer, run by Merck Sharp & Dohme LLC, now recruiting.","route":"/trials/nct04165070/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT04165070","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07252739","name":"KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)","tldr":"A phase 2 trial of Calderasib, Pembrolizumab, Cetuximab and Sacituzumab tirumotecan in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting.","route":"/trials/nct07252739/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07252739","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07232602","name":"KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)","tldr":"A phase 1/2 trial of Pembrolizumab in bladder & urothelial cancer, run by Merck Sharp & Dohme LLC, now recruiting.","route":"/trials/nct07232602/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT07232602","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"kl-a167","name":"KL-A167","tldr":"KL-A167 is an experimental investigational agent whose form is not stated in the registry from Sichuan Kelun-Biotech Biopharmaceutical in phase 3 trials for nasopharyngeal carcinoma and non-small-cell lung cancer, with its target not yet stated publicly.","route":"/drugs/kl-a167/","status":"phase-3","kind":"drug","molecule":"kl-a167","modality":"monoclonal antibody (KL-A167 is tagitanlimab; INN stem -mab; form not stated in the registry record)","facets":{"kind":["Treatment"],"cancers":["Nasopharyngeal carcinoma","Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Nasopharyngeal carcinoma","href":"/cancers/nasopharyngeal/","tip":"A cancer at the back of the nose caused largely by the Epstein-Barr virus and common in southern China and Southeast Asia. Radiation cures most early cases; adding chemotherapy and, recently, PD-1 immunotherapy has improved outcomes in advanced disease, and a blood test for viral DNA can detect it early."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"kn026","name":"KN026","tldr":"KN026 is an experimental monoclonal antibody from Shanghai JMT-Bio in phase 3 trials for HER2-positive breast cancer and HR-positive / HER2-negative breast cancer, aimed at HER2.","route":"/drugs/kn026/","status":"phase-3","kind":"drug","molecule":"kn026","modality":"monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["HER2-positive breast cancer","HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."},{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05427383","name":"KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy","tldr":"A phase 2/3 trial of Docetaxel in gastric & gastro-oesophageal junction cancer, run by Shanghai JMT-Bio Inc., now recruiting.","route":"/trials/nct05427383/","status":"recruiting","kind":"trial","cancerIcon":"gastric","sub":"NCT05427383","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer","HER2-positive gastric cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"HER2-positive gastric cancer","href":"/cancers/gastric-her2-positive/","tip":"HER2-positive gastric cancer overexpresses the HER2 growth receptor and is treated with trastuzumab added to chemotherapy, now usually with pembrolizumab as well. After progression the antibody-drug conjugate trastuzumab deruxtecan gives responses that plain chemotherapy cannot."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03667170","name":"KN035 for dMMR/MSI-H Advanced Solid Tumors","tldr":"A phase 2 trial of Envafolimab in advanced solid tumours, run by 3D Medicines (Sichuan) Co., Ltd., now recruiting.","route":"/trials/nct03667170/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT03667170","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"krt-232","name":"KRT-232","tldr":"KRT-232 is an experimental small-molecule drug from Kartos Therapeutics in phase 2 trials for myeloproliferative neoplasms, diffuse large B-cell lymphoma and chronic lymphocytic leukaemia, aimed at MDM2 and TP53.","route":"/drugs/krt-232/","status":"phase-2","kind":"drug","molecule":"krt-232","modality":"small molecule","facets":{"kind":["Treatment"],"cancers":["Myeloproliferative neoplasms","Diffuse large B-cell lymphoma","Chronic lymphocytic leukaemia","Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Myeloproliferative neoplasms","href":"/cancers/myeloproliferative-neoplasms/","tip":"Myeloproliferative neoplasms are slow-growing blood cancers in which the marrow overproduces red cells (polycythaemia vera), platelets (essential thrombocythaemia) or scar tissue (myelofibrosis). Almost all carry a mutation in JAK2, CALR or MPL; treatment aims to prevent clots and control symptoms, and only transplant cures myelofibrosis."},{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."},{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Hodgkin lymphoma","href":"/cancers/hodgkin-lymphoma/","tip":"Hodgkin lymphoma is one of the most curable cancers, where the goal is now to cure with less toxicity, using brentuximab and, from 2026, first-line nivolumab."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03669965","name":"KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera","tldr":"A phase 2 trial of KRT-232 and Ruxolitinib in myeloproliferative neoplasms, run by Kartos Therapeutics, Inc., active and no longer recruiting.","route":"/trials/nct03669965/","status":"active","kind":"trial","cancerIcon":"myeloproliferative-neoplasms","sub":"NCT03669965","facets":{"kind":["Trial"],"cancers":["Myeloproliferative neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Myeloproliferative neoplasms","href":"/cancers/myeloproliferative-neoplasms/","tip":"Myeloproliferative neoplasms are slow-growing blood cancers in which the marrow overproduces red cells (polycythaemia vera), platelets (essential thrombocythaemia) or scar tissue (myelofibrosis). Almost all carry a mutation in JAK2, CALR or MPL; treatment aims to prevent clots and control symptoms, and only transplant cures myelofibrosis."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07227350","name":"L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)","tldr":"A phase 2 trial of L19IL2 in basal cell carcinoma, run by Philogen S.p.A., now recruiting.","route":"/trials/nct07227350/","status":"recruiting","kind":"trial","cancerIcon":"basal-cell-carcinoma","sub":"NCT07227350","facets":{"kind":["Trial"],"cancers":["Basal cell carcinoma","Locally advanced and metastatic basal cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Basal cell carcinoma","href":"/cancers/basal-cell-carcinoma/","tip":"Basal cell carcinoma is a skin cancer and the most common cancer of all, caused by sun exposure and almost never life-threatening. Nearly all are removed surgically; the rare advanced cases are treated with drugs that block the hedgehog signalling pathway, and with immunotherapy if those fail."},{"label":"Locally advanced and metastatic basal cell carcinoma","href":"/cancers/locally-advanced-bcc/","tip":"Locally advanced basal cell carcinoma is a skin cancer that has grown so large or deep, usually on the face, that surgery or radiotherapy can no longer remove it without unacceptable damage. Almost all these tumours depend on the hedgehog growth pathway, and the pills vismodegib and sonidegib shrink about four in ten of them; cemiplimab is used when the pills fail or cannot be tolerated."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07227870","name":"L19IL2/TNF in Patients With Basal Cell Carcinoma","tldr":"A phase 2 trial of L19IL2/L19TNF in basal cell carcinoma, run by Philogen S.p.A., now recruiting.","route":"/trials/nct07227870/","status":"recruiting","kind":"trial","cancerIcon":"basal-cell-carcinoma","sub":"NCT07227870","facets":{"kind":["Trial"],"cancers":["Basal cell carcinoma","Locally advanced and metastatic basal cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Basal cell carcinoma","href":"/cancers/basal-cell-carcinoma/","tip":"Basal cell carcinoma is a skin cancer and the most common cancer of all, caused by sun exposure and almost never life-threatening. Nearly all are removed surgically; the rare advanced cases are treated with drugs that block the hedgehog signalling pathway, and with immunotherapy if those fail."},{"label":"Locally advanced and metastatic basal cell carcinoma","href":"/cancers/locally-advanced-bcc/","tip":"Locally advanced basal cell carcinoma is a skin cancer that has grown so large or deep, usually on the face, that surgery or radiotherapy can no longer remove it without unacceptable damage. Almost all these tumours depend on the hedgehog growth pathway, and the pills vismodegib and sonidegib shrink about four in ten of them; cemiplimab is used when the pills fail or cannot be tolerated."}],"tags":[]},"sortKeys":{"year":0}},{"id":"lam561","name":"LAM561","tldr":"LAM561 is an experimental small-molecule drug from Laminar Pharmaceuticals in phase 3 trials for glioma & glioblastoma, aimed at MET.","route":"/drugs/lam561/","status":"phase-3","kind":"drug","molecule":"lam561","modality":"small molecule","facets":{"kind":["Treatment"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00383708","name":"Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients","tldr":"A phase 3 trial of Somatostatin analogues and Pegvisomant in Pituitary tumours, run by Ipsen, completed.","route":"/trials/nct00383708/","status":"completed","kind":"trial","cancerIcon":"pituitary-tumours","sub":"NCT00383708","facets":{"kind":["Trial"],"cancers":["Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma","href":"/cancers/pituitary-tumours/","tip":"Pituitary tumours are usually benign growths of the hormone gland at the base of the brain that cause trouble by overproducing hormones or pressing on the optic nerves. Prolactin-producing tumours melt away with a tablet, most others are cured by surgery through the nose, and the rare aggressive ones respond to the chemotherapy drug temozolomide."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07620548","name":"Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas","tldr":"A phase 2 trial of Laser interstitial thermal therapy systems in Glioma & glioblastoma, run by Washington University School of Medicine, not yet recruiting.","route":"/trials/nct07620548/","status":"planned","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT07620548","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"lb1410","name":"LB1410","tldr":"LB1410 is an experimental bispecific antibody from L & L Bio, Ningbo, China in phase 2 trials, aimed at PD-1 and TIM-3.","route":"/drugs/lb1410/","status":"phase-2","kind":"drug","molecule":"lb1410","modality":"bispecific antibody","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"lb4330","name":"LB4330","tldr":"LB4330 is an experimental fusion protein from L & L Bio, Ningbo, China in phase 2 trials, aimed at Claudin 18.2.","route":"/drugs/lb4330/","status":"phase-2","kind":"drug","molecule":"lb4330","modality":"fusion protein","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"lcb02a","name":"LCB02A","tldr":"LCB02A is an experimental monoclonal antibody from LigaChem Biosciences in phase 2 trials, aimed at Claudin 18.2.","route":"/drugs/lcb02a/","status":"phase-2","kind":"drug","molecule":"lcb02a","modality":"monoclonal antibody","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"lcb84","name":"LCB84","tldr":"LCB84 is an experimental monoclonal antibody from LigaChem Biosciences in phase 2 trials, aimed at TROP2.","route":"/drugs/lcb84/","status":"phase-2","kind":"drug","molecule":"lcb84","modality":"monoclonal antibody","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02205762","name":"LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis","tldr":"A phase 2/3 trial of Prednisone, Vinblastine, Mercaptopurine, Methotrexate, Cytarabine, Cladribine and Human normal immunoglobulin in Langerhans cell histiocytosis, run by North American Consortium for Histiocytosis, active and no longer recruiting.","route":"/trials/nct02205762/","status":"active","kind":"trial","cancerIcon":"langerhans-cell-histiocytosis","sub":"NCT02205762","facets":{"kind":["Trial"],"cancers":["Langerhans cell histiocytosis"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Langerhans cell histiocytosis","href":"/cancers/langerhans-cell-histiocytosis/","tip":"Langerhans cell histiocytosis is a disorder in which a small group of immune cells with a faulty growth signal (most often a BRAF mutation) pile up in bone, skin, pituitary or organs. It ranges from a single bone lesion that heals after biopsy to a life-threatening disease of infants. A year of gentle chemotherapy cures most children, and BRAF or MEK inhibitors rescue those with resistant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01828112","name":"LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib","tldr":"A phase 3 trial of Ceritinib, Pemetrexed and Docetaxel in Non-small-cell lung cancer, run by Novartis Pharmaceuticals, completed.","route":"/trials/nct01828112/","status":"completed","kind":"trial","cancerIcon":"nsclc","sub":"NCT01828112","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01828099","name":"LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer","tldr":"A phase 3 trial of Ceritinib, Pemetrexed, Cisplatin and Carboplatin in Non-small-cell lung cancer, run by Novartis Pharmaceuticals, completed.","route":"/trials/nct01828099/","status":"completed","kind":"trial","cancerIcon":"nsclc","sub":"NCT01828099","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06710756","name":"Lead-212 PSV359 Therapy for Patients With Solid Tumors","tldr":"A phase 1/2 trial of [203Pb]Pb-PSV359 in pancreatic ductal adenocarcinoma, gastric & gastro-oesophageal junction cancer, oesophageal cancer, colorectal cancer, ovarian cancer and head and neck squamous cell carcinoma, run by Perspective Therapeutics, now recruiting.","route":"/trials/nct06710756/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT06710756","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Gastric & gastro-oesophageal junction cancer","Oesophageal cancer","Colorectal cancer","Ovarian cancer","Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04752722","name":"LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve","tldr":"A phase 1/2 trial of EG-70 (phase 1) in bladder & urothelial cancer, run by enGene, Inc., now recruiting.","route":"/trials/nct04752722/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT04752722","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Non-muscle-invasive bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Non-muscle-invasive bladder cancer","href":"/cancers/non-muscle-invasive-bladder-cancer/","tip":"Most bladder cancers are found while still confined to the lining. They are scraped out through the urethra and, when higher risk, treated with BCG instilled into the bladder; the challenge is the frequent recurrences and the patients whose tumours stop responding to BCG."}],"tags":[]},"sortKeys":{"year":0}},{"id":"lerociclib","name":"Lerociclib","tldr":"Lerociclib is a CDK4/6 inhibitor from G1 Therapeutics developed in China by Genor Biopharma, in a phase 3 trial with letrozole for hormone receptor-positive breast cancer.","route":"/drugs/lerociclib/","status":"phase-3","kind":"drug","molecule":"lerociclib","modality":"Oral CDK4/6 inhibitor","sub":"GB491","facets":{"kind":["Treatment"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"lerotinib","name":"Lerotinib","tldr":"Lerotinib is an experimental small-molecule drug from Sunshine Lake Pharma in phase 3 trials for oesophageal cancer, with its target not yet stated publicly.","route":"/drugs/lerotinib/","status":"phase-3","kind":"drug","molecule":"lerotinib","modality":"small molecule (structure undisclosed or not yet in PubChem)","facets":{"kind":["Treatment"],"cancers":["Oesophageal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04592653","name":"Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)","tldr":"A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by Mural Oncology, Inc, active and no longer recruiting.","route":"/trials/nct04592653/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04592653","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06193902","name":"LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.","tldr":"A phase 1/2 trial of LEU011 in advanced solid tumours, run by Leucid Bio, now recruiting.","route":"/trials/nct06193902/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06193902","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02159066","name":"LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma","tldr":"A phase 2 trial of Infigratinib and Capmatinib in Melanoma, run by Pfizer, completed.","route":"/trials/nct02159066/","status":"completed","kind":"trial","cancerIcon":"melanoma","sub":"NCT02159066","facets":{"kind":["Trial"],"cancers":["Melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."}],"tags":[]},"sortKeys":{"year":0}},{"id":"limertinib","name":"Limertinib","tldr":"Limertinib is Aosaikang's third-generation EGFR inhibitor, approved in China in 2024 for lung cancer with the T790M resistance mutation after earlier EGFR drugs, and in phase 3 trials for first-line use.","route":"/drugs/limertinib/","status":"approved","kind":"drug","molecule":"limertinib","modality":"Oral third-generation EGFR tyrosine kinase inhibitor","sub":"ASK120067","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":["2024"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"year":{"facet":"year","value":"2024"},"tags":[]},"sortKeys":{"year":2024}},{"id":"lirafugratinib","name":"Lirafugratinib","tldr":"Lirafugratinib is an experimental small-molecule drug from Elevar Therapeutics in phase 2 trials, aimed at FGFR2.","route":"/drugs/lirafugratinib/","status":"phase-2","kind":"drug","molecule":"lirafugratinib","modality":"small molecule","sub":"RLY-4008","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02755311","name":"Liver Resection Versus Transarterial Chemoembolization for the Treatment of Intermediate-stage Hepatocellular Carcinoma","tldr":"A phase 3 trial of Carboplatin and Ethiodized oil in Hepatocellular carcinoma, run by Sun Yat-sen University, with a status the registry has not verified recently.","route":"/trials/nct02755311/","kind":"trial","cancerIcon":"hcc","sub":"NCT02755311","facets":{"kind":["Trial"],"cancers":["Hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."}],"tags":[]},"sortKeys":{"year":0}},{"id":"livmoniplimab","name":"Livmoniplimab","tldr":"Livmoniplimab is an experimental investigational agent whose form is not stated in the registry from AbbVie in phase 3 trials for hepatocellular carcinoma, non-small-cell lung cancer and bladder & urothelial cancer, with its target not yet stated publicly.","route":"/drugs/livmoniplimab/","status":"phase-3","kind":"drug","molecule":"livmoniplimab","modality":"antibody (INN stem -mab; form not stated in the registry record)","sub":"ABBV-151","facets":{"kind":["Treatment"],"cancers":["Hepatocellular carcinoma","Non-small-cell lung cancer","Bladder & urothelial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."}],"tags":[]},"sortKeys":{"year":0}},{"id":"lm-108","name":"LM-108","tldr":"LM-108 is an experimental monoclonal antibody from Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical in phase 3 trials for pancreatic ductal adenocarcinoma and gastric & gastro-oesophageal junction cancer, with its target not yet stated publicly.","route":"/drugs/lm-108/","status":"phase-3","kind":"drug","molecule":"lm-108","modality":"monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Pancreatic ductal adenocarcinoma","Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"lm-302","name":"LM-302","tldr":"LM-302 is an experimental antibody-drug conjugate from LaNova Medicines Zhejiang in phase 3 trials for gastric & gastro-oesophageal junction cancer, aimed at Claudin 18.2.","route":"/drugs/lm-302/","status":"phase-3","kind":"drug","molecule":"lm-302","modality":"ADC","facets":{"kind":["Treatment"],"cancers":["Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"lns8801","name":"LNS8801","tldr":"LNS8801 is an experimental investigational agent whose form is not stated in the registry from Linnaeus Therapeutics in phase 3 trials for melanoma, aimed at Estrogen receptor (ERα).","route":"/drugs/lns8801/","status":"phase-3","kind":"drug","molecule":"lns8801","modality":"not stated (registered as a drug or biological on ClinicalTrials.gov)","facets":{"kind":["Treatment"],"cancers":["Melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00143416","name":"Long Term Study With B2036-PEG","tldr":"A phase 3 trial of Pegvisomant in Pituitary tumours, run by Pfizer, completed.","route":"/trials/nct00143416/","status":"completed","kind":"trial","cancerIcon":"pituitary-tumours","sub":"NCT00143416","facets":{"kind":["Trial"],"cancers":["Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma","href":"/cancers/pituitary-tumours/","tip":"Pituitary tumours are usually benign growths of the hormone gland at the base of the brain that cause trouble by overproducing hormones or pressing on the optic nerves. Prolactin-producing tumours melt away with a tablet, most others are cured by surgery through the nose, and the rare aggressive ones respond to the chemotherapy drug temozolomide."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06652633","name":"Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies","tldr":"A phase 3 trial of GLPG CAR T-cell therapy in advanced solid tumours, run by Lakefront Biotherapeutics NV, now recruiting.","route":"/trials/nct06652633/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06652633","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03435796","name":"Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells","tldr":"A phase 2/3 trial of Gene-modified (GM) T cell therapy in advanced solid tumours, run by Celgene, now recruiting.","route":"/trials/nct03435796/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT03435796","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01761968","name":"Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms","tldr":"A phase 2 trial of Givinostat in myeloproliferative neoplasms, run by Italfarmaco, active and no longer recruiting.","route":"/trials/nct01761968/","status":"active","kind":"trial","cancerIcon":"myeloproliferative-neoplasms","sub":"NCT01761968","facets":{"kind":["Trial"],"cancers":["Myeloproliferative neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Myeloproliferative neoplasms","href":"/cancers/myeloproliferative-neoplasms/","tip":"Myeloproliferative neoplasms are slow-growing blood cancers in which the marrow overproduces red cells (polycythaemia vera), platelets (essential thrombocythaemia) or scar tissue (myelofibrosis). Almost all carry a mutation in JAK2, CALR or MPL; treatment aims to prevent clots and control symptoms, and only transplant cures myelofibrosis."}],"tags":[]},"sortKeys":{"year":0}},{"id":"lorigerlimab","name":"Lorigerlimab","tldr":"Lorigerlimab is an experimental bispecific antibody from MacroGenics in phase 2 trials for ovarian cancer, vulvar cancer and cervical cancer, aimed at PD-1 and CTLA-4.","route":"/drugs/lorigerlimab/","status":"phase-2","kind":"drug","molecule":"lorigerlimab","modality":"bispecific antibody","sub":"MGD019","facets":{"kind":["Treatment"],"cancers":["Ovarian cancer","Vulvar cancer","Cervical cancer","Endometrial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Vulvar cancer","href":"/cancers/vulvar/","tip":"An uncommon cancer of the external genitalia with two distinct causes: HPV infection in younger women and chronic skin inflammation in older women. Surgery is the mainstay, and sentinel-node biopsy has made it far less mutilating."},{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."},{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."}],"tags":[]},"sortKeys":{"year":0}},{"id":"lp-184","name":"LP-184","tldr":"LP-184 is a small-molecule inhibitor from Lantern Pharma Inc., in registered phase 2 trials for triple-negative breast cancer, non-small-cell lung cancer, pancreatic ductal adenocarcinoma.","route":"/drugs/lp-184/","status":"phase-2","kind":"drug","molecule":"lp-184","modality":"Small-molecule inhibitor","sub":"LP-184","facets":{"kind":["Treatment"],"cancers":["Triple-negative breast cancer","Non-small-cell lung cancer","Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct07357519","name":"Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)","tldr":"A phase 1/2 trial of LNTH2403 Phase 1 dose in osteosarcoma, run by Lantheus Medical Imaging, now recruiting.","route":"/trials/nct07357519/","status":"recruiting","kind":"trial","cancerIcon":"osteosarcoma","sub":"NCT07357519","facets":{"kind":["Trial"],"cancers":["Osteosarcoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Osteosarcoma","href":"/cancers/osteosarcoma/","tip":"Osteosarcoma is the most common bone cancer, mostly in teenagers. Chemotherapy plus surgery cures about two-thirds when it has not spread; because no new drug has beaten that chemotherapy in a large trial in 30 years, the next gains are being sought in cellular therapy against GD2, HER2 and B7-H3."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04919226","name":"Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE","tldr":"A phase 3 trial of 177Lu-edotreotide, Temozolomide, Capecitabine, Everolimus, Leucovorin (folinic acid) and Oxaliplatin in neuroendocrine tumours, run by ITM Solucin GmbH, active and no longer recruiting.","route":"/trials/nct04919226/","status":"active","kind":"trial","cancerIcon":"neuroendocrine","sub":"NCT04919226","facets":{"kind":["Trial"],"cancers":["Neuroendocrine tumours","Grade 3 well-differentiated neuroendocrine tumour","Pancreatic neuroendocrine tumours","Small intestinal neuroendocrine tumours"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Neuroendocrine tumours","href":"/cancers/neuroendocrine/","tip":"A family of usually slow-growing tumours that start in hormone-producing cells of the gut, pancreas and lungs. They pioneered the idea of using the same molecule to see a tumour on a scan and then to treat it with radiation."},{"label":"Grade 3 well-differentiated neuroendocrine tumour","href":"/cancers/grade-3-net/","tip":"Grade 3 well-differentiated neuroendocrine tumours divide fast enough to be called grade 3 yet still look and behave like their slower relatives rather than like neuroendocrine carcinoma. Recognised as separate since 2017, they keep the somatostatin receptor, respond less well to platinum chemotherapy, and in the NETTER-2 trial were among the first treated with lutetium-177 dotatate up front."},{"label":"Pancreatic neuroendocrine tumours","href":"/cancers/pancreatic-net/","tip":"Pancreatic neuroendocrine tumours arise from the hormone-producing islet cells of the pancreas and behave very differently from ordinary pancreatic cancer, often growing for years. Surgery cures localised tumours; advanced disease is treated in sequence with somatostatin analogues, lutetium-177 dotatate, targeted tablets and oral chemotherapy, and a minority secrete insulin or gastrin."},{"label":"Small intestinal neuroendocrine tumours","href":"/cancers/small-intestinal-net/","tip":"Small intestinal neuroendocrine tumours are slow-growing hormone-producing tumours of the ileum and jejunum, often found only after they have spread to lymph nodes and the liver. Monthly somatostatin analogue injections control symptoms and growth, lutetium-177 dotatate is the main second treatment, and everolimus, cabozantinib and surgery fill in."}],"tags":[]},"sortKeys":{"year":0}},{"id":"lvgn6051","name":"LVGN6051","tldr":"LVGN6051 is a monoclonal antibody from Lyvgen Biopharma Holdings Limited, in registered phase 2 trials for head and neck squamous cell carcinoma.","route":"/drugs/lvgn6051/","status":"phase-2","kind":"drug","molecule":"lvgn6051","modality":"Monoclonal antibody","sub":"LVGN6051","facets":{"kind":["Treatment"],"cancers":["Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct05319314","name":"LYL273 for Patients With Relapsed or Refractory mCRC","tldr":"A phase 1/2 trial of LYL273 in colorectal cancer, run by Lyell Immunopharma, Inc., now recruiting.","route":"/trials/nct05319314/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT05319314","facets":{"kind":["Trial"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"m108","name":"M108","tldr":"M108 is an experimental monoclonal antibody from FutureGen Biopharmaceutical (Beijing) in phase 3 trials for gastric & gastro-oesophageal junction cancer, aimed at Claudin 18.2.","route":"/drugs/m108/","status":"phase-3","kind":"drug","molecule":"m108","modality":"monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"m701","name":"M701","tldr":"M701 is Wuhan YZY Biopharma's EpCAM-CD3 bispecific antibody infused into the abdomen to control malignant ascites, in a phase 3 trial in China.","route":"/drugs/m701/","status":"phase-3","kind":"drug","molecule":"m701","modality":"Bispecific antibody (EpCAM x CD3), intraperitoneal","facets":{"kind":["Treatment"],"cancers":["Ovarian cancer","Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02219529","name":"Magnetic-controlled Capsule Endoscopy vs. Gastroscopy for Detection of Gastric Diseases","tldr":"A phase 3 trial of Capsule endoscopy in Early gastric cancer, run by Changhai Hospital, completed.","route":"/trials/nct02219529/","status":"completed","kind":"trial","cancerIcon":"early-gastric-cancer","sub":"NCT02219529","facets":{"kind":["Trial"],"cancers":["Early gastric cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Early gastric cancer","href":"/cancers/early-gastric-cancer/","tip":"Early gastric cancer has not grown beyond the submucosa, whatever the lymph nodes show. In Japan and Korea, where screening endoscopy finds most stomach cancers at this stage, many are removed through the endoscope without an operation, and the rest are cured by gastrectomy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04313881","name":"Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)","tldr":"A phase 3 trial of Magrolimab and Azacitidine in Myelodysplastic syndromes / neoplasms, run by Gilead Sciences, recorded as terminated on the registry.","route":"/trials/nct04313881/","kind":"trial","cancerIcon":"mds","sub":"NCT04313881","facets":{"kind":["Trial"],"cancers":["Myelodysplastic syndromes / neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Myelodysplastic syndromes / neoplasms","href":"/cancers/mds/","tip":"Bone-marrow disorders where blood cells are made badly and too few reach the blood; a third progress to acute leukaemia. Treatment ranges from transfusions and growth factors to hypomethylating drugs and, for the fit, transplant."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03519230","name":"Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer","tldr":"A phase 3 trial of Pamiparib capsule in ovarian cancer, run by BeiGene, active and no longer recruiting.","route":"/trials/nct03519230/","status":"active","kind":"trial","cancerIcon":"ovarian","sub":"NCT03519230","facets":{"kind":["Trial"],"cancers":["Ovarian cancer","Platinum-sensitive ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Platinum-sensitive ovarian cancer","href":"/cancers/platinum-sensitive-ovarian-cancer/","tip":"Platinum-sensitive ovarian cancer is disease that responded to carboplatin and either has not relapsed or relapses more than six months after the last dose. It is treated with further platinum chemotherapy, sometimes repeat surgery, and above all with maintenance PARP inhibitors, which keep BRCA-mutant tumours away for years and have raised long-term survival."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04425018","name":"MARGetuximab Or Trastuzumab (MARGOT)","tldr":"A phase 2 trial of Paclitaxel / nab-paclitaxel, Pertuzumab, Margetuximab, Trastuzumab and Trastuzumab biosimilars in Breast cancer and HER2-positive breast cancer, run by Dana-Farber Cancer Institute, active and no longer recruiting.","route":"/trials/nct04425018/","status":"active","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT04425018","facets":{"kind":["Trial"],"cancers":["Breast cancer","HER2-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."},{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02492711","name":"Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer","tldr":"A phase 3 trial of Margetuximab and Trastuzumab in Breast cancer, run by MacroGenics, completed.","route":"/trials/nct02492711/","status":"completed","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT02492711","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"mavrostobart","name":"Mavrostobart","tldr":"Mavrostobart is an experimental monoclonal antibody from Phanes Therapeutics in phase 2 trials for non-small-cell lung cancer and pancreatic ductal adenocarcinoma, aimed at CD73 / adenosine axis.","route":"/drugs/mavrostobart/","status":"phase-2","kind":"drug","molecule":"mavrostobart","modality":"monoclonal antibody","sub":"PT199","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01906385","name":"Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)","tldr":"A phase 1/2 trial of Rhenium Liposome Treatment in glioma & glioblastoma, run by Cerenome, now recruiting.","route":"/trials/nct01906385/","status":"recruiting","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT01906385","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06534060","name":"MB-105 in Patients With CD5 Positive T-cell Lymphoma","tldr":"A phase 2 trial of Genetic: MB-105 in non-Hodgkin lymphoma, run by March Biosciences Inc, now recruiting.","route":"/trials/nct06534060/","status":"recruiting","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT06534060","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma","Peripheral T-cell lymphomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."},{"label":"Peripheral T-cell lymphomas","href":"/cancers/peripheral-t-cell-lymphoma/","tip":"Peripheral T-cell lymphomas are lymphomas of T cells rather than B cells. They are rarer, more varied and, apart from a few subtypes, harder to treat than B-cell lymphomas; several new drugs help only defined subtypes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"mcla-129","name":"MCLA-129","tldr":"MCLA-129 is an experimental bispecific antibody from Betta Pharmaceuticals in phase 2 trials for non-small-cell lung cancer, head and neck squamous cell carcinoma and colorectal cancer, aimed at EGFR and MET.","route":"/drugs/mcla-129/","status":"phase-2","kind":"drug","molecule":"mcla-129","modality":"bispecific antibody","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Head and neck squamous cell carcinoma","Colorectal cancer","Gastric & gastro-oesophageal junction cancer","Oesophageal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06483100","name":"Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance","tldr":"A phase 2 trial of clonoSEQ in Multiple myeloma, run by Washington University School of Medicine, now recruiting.","route":"/trials/nct06483100/","status":"recruiting","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT06483100","facets":{"kind":["Trial"],"cancers":["Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05463601","name":"Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer","tldr":"A phase 2 trial of Mecapegfilgrastim and Dalpiciclib in Breast cancer, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, active and no longer recruiting.","route":"/trials/nct05463601/","status":"active","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT05463601","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"men1703","name":"MEN1703","tldr":"MEN1703 is an experimental small molecule (kinase inhibitor) from Ryvu Therapeutics in phase 2 trials for hodgkin lymphoma, aimed at FLT3.","route":"/drugs/men1703/","status":"phase-2","kind":"drug","molecule":"men1703","modality":"small molecule (kinase inhibitor)","sub":"SEL24","facets":{"kind":["Treatment"],"cancers":["Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Hodgkin lymphoma","href":"/cancers/hodgkin-lymphoma/","tip":"Hodgkin lymphoma is one of the most curable cancers, where the goal is now to cure with less toxicity, using brentuximab and, from 2026, first-line nivolumab."}],"tags":[]},"sortKeys":{"year":0}},{"id":"merestinib","name":"Merestinib","tldr":"Merestinib is an oral kinase inhibitor from Eli Lilly and Company, in registered phase 2 trials for metastatic cancer.","route":"/drugs/merestinib/","status":"phase-2","kind":"drug","molecule":"merestinib","modality":"Oral kinase inhibitor","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct03223662","name":"Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy","tldr":"A phase 2 trial of BH3 profiling in Oesophageal cancer and Oesophageal and junctional adenocarcinoma, run by National Cancer Institute (NCI), recorded as terminated on the registry.","route":"/trials/nct03223662/","kind":"trial","cancerIcon":"esophageal","sub":"NCT03223662","facets":{"kind":["Trial"],"cancers":["Oesophageal cancer","Oesophageal and junctional adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."},{"label":"Oesophageal and junctional adenocarcinoma","href":"/cancers/oesophageal-adenocarcinoma/","tip":"Adenocarcinoma of the lower oesophagus and junction grows out of Barrett's oesophagus, the change in the lining caused by long-standing acid reflux. Chemotherapy or chemoradiation before surgery is standard, and HER2, PD-L1 and claudin 18.2 now guide drugs for advanced disease as they do in stomach cancer."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01188798","name":"Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies","tldr":"A phase 3 trial of Methotrexate and Pentostatin in Acute lymphoblastic leukaemia and Leukaemia, run by St. Jude Children's Research Hospital, completed.","route":"/trials/nct01188798/","status":"completed","kind":"trial","cancerIcon":"all-leukemia","sub":"NCT01188798","facets":{"kind":["Trial"],"cancers":["Acute lymphoblastic leukaemia","Leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."},{"label":"Leukaemia","href":"/cancers/leukaemia/","tip":"Leukaemia means cancer of the blood-forming cells, but the four main types share little beyond the name: acute lymphoblastic and acute myeloid leukaemia are emergencies treated with intensive therapy, while chronic lymphocytic and chronic myeloid leukaemia are slow diseases controlled for years with pills. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"mhb036c","name":"MHB036C","tldr":"MHB036C is an antibody-drug conjugate from Minghui Pharmaceutical (Hangzhou) Ltd, in registered phase 2 trials for metastatic cancer.","route":"/drugs/mhb036c/","status":"phase-2","kind":"drug","molecule":"mhb036c","modality":"Antibody-drug conjugate","sub":"MHB036C","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"mhb039a","name":"MHB039A","tldr":"MHB039A is a bispecific antibody from Minghui Pharmaceutical (Hangzhou) Ltd, in registered phase 2 trials for metastatic cancer.","route":"/drugs/mhb039a/","status":"phase-2","kind":"drug","molecule":"mhb039a","modality":"Bispecific antibody","sub":"MHB039A","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct03643133","name":"Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients","tldr":"A phase 2 trial of Mifamurtide in Osteosarcoma, run by UNICANCER, active and no longer recruiting.","route":"/trials/nct03643133/","status":"active","kind":"trial","cancerIcon":"osteosarcoma","sub":"NCT03643133","facets":{"kind":["Trial"],"cancers":["Osteosarcoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Osteosarcoma","href":"/cancers/osteosarcoma/","tip":"Osteosarcoma is the most common bone cancer, mostly in teenagers. Chemotherapy plus surgery cures about two-thirds when it has not spread; because no new drug has beaten that chemotherapy in a large trial in 30 years, the next gains are being sought in cellular therapy against GD2, HER2 and B7-H3."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04834024","name":"MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma","tldr":"A phase 3 trial of Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide in follicular lymphoma, run by Beijing Mabworks Biotech Co., Ltd., now recruiting.","route":"/trials/nct04834024/","status":"recruiting","kind":"trial","cancerIcon":"follicular-lymphoma","sub":"NCT04834024","facets":{"kind":["Trial"],"cancers":["Follicular lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Follicular lymphoma","href":"/cancers/follicular-lymphoma/","tip":"Follicular lymphoma is the most common slow-growing lymphoma, defined in about 85% of cases by a BCL2 translocation. Most people live with it for decades, treated only when it causes problems; it can be controlled repeatedly with anti-CD20 antibodies, chemotherapy, bispecifics or CAR-T but rarely cured, and a small share transform into an aggressive lymphoma each year."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06153173","name":"Mirdametinib in Histiocytic Disorders","tldr":"A phase 2 trial of Mirdametinib in Langerhans cell histiocytosis and Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms, run by Children's Hospital Medical Center, Cincinnati, now recruiting.","route":"/trials/nct06153173/","status":"recruiting","kind":"trial","cancerIcon":"langerhans-cell-histiocytosis","sub":"NCT06153173","facets":{"kind":["Trial"],"cancers":["Langerhans cell histiocytosis","Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Langerhans cell histiocytosis","href":"/cancers/langerhans-cell-histiocytosis/","tip":"Langerhans cell histiocytosis is a disorder in which a small group of immune cells with a faulty growth signal (most often a BRAF mutation) pile up in bone, skin, pituitary or organs. It ranges from a single bone lesion that heals after biopsy to a life-threatening disease of infants. A year of gentle chemotherapy cures most children, and BRAF or MEK inhibitors rescue those with resistant disease."},{"label":"Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms","href":"/cancers/histiocytoses/","tip":"Histiocytoses are diseases in which immune scavenger cells build up in bone, heart, brain, kidneys and skin. They used to be treated as inflammatory conditions with steroids and interferon. The discovery that most carry mutations in the same growth pathway as melanoma turned them into targetable cancers: BRAF and MEK inhibitor pills now produce responses in nearly every treated patient."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07237100","name":"Mirdametinib in Patients With Advanced NF1-mutant Melanoma","tldr":"A phase 2 trial of Mirdametinib in Advanced melanoma, run by Kevin Kim, MD, now recruiting.","route":"/trials/nct07237100/","status":"recruiting","kind":"trial","cancerIcon":"advanced-melanoma","sub":"NCT07237100","facets":{"kind":["Trial"],"cancers":["Advanced melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Advanced melanoma","href":"/cancers/advanced-melanoma/","tip":"Advanced melanoma has spread beyond what surgery can remove, and it is the cancer in which immunotherapy first proved it could cure some people: about half of those given nivolumab with ipilimumab are alive ten years later. If immunotherapy fails, options include a cell therapy grown from the patient's own immune cells, a virus injected into the tumour, and targeted pills for BRAF-mutant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02990728","name":"Mirena® ± Metformin as Fertility-preserving Treatment for Young Asian Women With Early Endometrial Cancer","tldr":"A phase 2 trial of Progestins in Endometrial cancer, run by Chang Gung Memorial Hospital, with a status the registry has not verified recently.","route":"/trials/nct02990728/","kind":"trial","cancerIcon":"endometrial","sub":"NCT02990728","facets":{"kind":["Trial"],"cancers":["Endometrial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04274426","name":"Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer","tldr":"A phase 2 trial of Carboplatin, Doxorubicin, Pegylated liposomal doxorubicin, Gemcitabine and Mirvetuximab soravtansine in ovarian cancer, run by AGO Research GmbH, active and no longer recruiting.","route":"/trials/nct04274426/","status":"active","kind":"trial","cancerIcon":"ovarian","sub":"NCT04274426","facets":{"kind":["Trial"],"cancers":["Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04651634","name":"MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients","tldr":"A phase 2 trial of MIT-001 plus CCRT in head and neck squamous cell carcinoma, run by MitoImmune Therapeutics, active and no longer recruiting.","route":"/trials/nct04651634/","status":"active","kind":"trial","cancerIcon":"head-and-neck","sub":"NCT04651634","facets":{"kind":["Trial"],"cancers":["Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[]},"sortKeys":{"year":0}},{"id":"mitazalimab","name":"Mitazalimab","tldr":"Mitazalimab is an antibody-drug conjugate from Alligator Bioscience AB, in registered phase 2 trials for pancreatic ductal adenocarcinoma.","route":"/drugs/mitazalimab/","status":"phase-2","kind":"drug","molecule":"mitazalimab","modality":"Antibody-drug conjugate","facets":{"kind":["Treatment"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct01624090","name":"Mithramycin for Lung, Esophagus, and Other Chest Cancers","tldr":"A phase 2 trial of Plicamycin in Lung cancer, Oesophageal cancer, Mesothelioma and Breast cancer, run by National Cancer Institute (NCI), recorded as terminated on the registry.","route":"/trials/nct01624090/","kind":"trial","cancerIcon":"lung-cancer","sub":"NCT01624090","facets":{"kind":["Trial"],"cancers":["Lung cancer","Oesophageal cancer","Mesothelioma","Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Lung cancer","href":"/cancers/lung-cancer/","tip":"Lung cancer splits into non-small-cell (about 85 percent) and small-cell (about 15 percent) disease, which behave and are treated very differently. The subtype pages carry the detail; this page covers screening, staging and what the types share."},{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."},{"label":"Mesothelioma","href":"/cancers/mesothelioma/","tip":"An asbestos-caused cancer of the lung lining. Immunotherapy doublets replaced chemotherapy in 2020, and mesothelin CAR-T is under study."},{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"mk-1045","name":"MK-1045","tldr":"MK-1045 is an experimental investigational agent whose form is not stated in the registry from Merck Sharp & Dohme in phase 3 trials for acute lymphoblastic leukaemia, follicular lymphoma and hodgkin lymphoma, aimed at CD19.","route":"/drugs/mk-1045/","status":"phase-3","kind":"drug","molecule":"mk-1045","modality":"bispecific antibody (CD3 x CD19, per the sponsor's description; form not stated in the registry record)","sub":"CN-201, CN201","facets":{"kind":["Treatment"],"cancers":["Acute lymphoblastic leukaemia","Follicular lymphoma","Hodgkin lymphoma","Diffuse large B-cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."},{"label":"Follicular lymphoma","href":"/cancers/follicular-lymphoma/","tip":"Follicular lymphoma is the most common slow-growing lymphoma, defined in about 85% of cases by a BCL2 translocation. Most people live with it for decades, treated only when it causes problems; it can be controlled repeatedly with anti-CD20 antibodies, chemotherapy, bispecifics or CAR-T but rarely cured, and a small share transform into an aggressive lymphoma each year."},{"label":"Hodgkin lymphoma","href":"/cancers/hodgkin-lymphoma/","tip":"Hodgkin lymphoma is one of the most curable cancers, where the goal is now to cure with less toxicity, using brentuximab and, from 2026, first-line nivolumab."},{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00103662","name":"Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients","tldr":"A phase 3 trial of Plerixafor in Multiple myeloma, run by Genzyme, a Sanofi Company, completed.","route":"/trials/nct00103662/","status":"completed","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT00103662","facets":{"kind":["Trial"],"cancers":["Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05429632","name":"Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT","tldr":"A phase 3 trial of mocravimod in acute myeloid leukaemia, run by Priothera SAS, now recruiting.","route":"/trials/nct05429632/","status":"recruiting","kind":"trial","cancerIcon":"aml","sub":"NCT05429632","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06641635","name":"Moderated Hypofractionated Online Adaptive Radiotherapy in Cervical Cancer","tldr":"A phase 3 trial of Adaptive radiotherapy in Cervical cancer, run by Peking Union Medical College Hospital, now recruiting.","route":"/trials/nct06641635/","status":"recruiting","kind":"trial","cancerIcon":"cervical","sub":"NCT06641635","facets":{"kind":["Trial"],"cancers":["Cervical cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05329532","name":"Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer","tldr":"A phase 1/2 trial of Pembrolizumab in triple-negative breast cancer, renal cell carcinoma, ovarian cancer and head and neck squamous cell carcinoma, run by Scancell Ltd, now recruiting.","route":"/trials/nct05329532/","status":"recruiting","kind":"trial","cancerIcon":"tnbc","sub":"NCT05329532","facets":{"kind":["Trial"],"cancers":["Triple-negative breast cancer","Renal cell carcinoma","Ovarian cancer","Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."},{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06493552","name":"Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors","tldr":"A phase 2/3 trial of Pembrolizumab, Gemcitabine, Cisplatin and Enfortumab vedotin in bladder & urothelial cancer, run by Vasgene Therapeutics, Inc, now recruiting.","route":"/trials/nct06493552/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT06493552","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03784014","name":"Molecular Profiling of Advanced Soft-tissue Sarcomas","tldr":"A phase 3 trial of Nilotinib, Ceritinib, Capmatinib, Lapatinib, Trametinib, Olaparib, Palbociclib and Glasdegib in Sarcomas, run by Institut National de la Santé Et de la Recherche Médicale, France, completed.","route":"/trials/nct03784014/","status":"completed","kind":"trial","cancerIcon":"sarcoma","sub":"NCT03784014","facets":{"kind":["Trial"],"cancers":["Sarcomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Sarcomas","href":"/cancers/sarcoma/","tip":"Sarcomas are dozens of rare cancers of bone and connective tissue. GIST was the first solid tumour cured-in-practice by a targeted pill; synovial sarcoma got the first TCR-T therapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"monalizumab","name":"Monalizumab","tldr":"Monalizumab is an experimental investigational agent whose form is not stated in the registry from AstraZeneca in phase 3 trials for non-small-cell lung cancer and head and neck squamous cell carcinoma, with its target not yet stated publicly.","route":"/drugs/monalizumab/","status":"phase-3","kind":"drug","molecule":"monalizumab","modality":"antibody (INN stem -mab; form not stated in the registry record)","sub":"IPH2201","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02338050","name":"Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation","tldr":"A phase 2 trial of Moxetumomab pasudotox in Acute lymphoblastic leukaemia, run by Center for International Blood and Marrow Transplant Research, recorded as terminated on the registry.","route":"/trials/nct02338050/","kind":"trial","cancerIcon":"all-leukemia","sub":"NCT02338050","facets":{"kind":["Trial"],"cancers":["Acute lymphoblastic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01829711","name":"Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia","tldr":"A phase 3 trial of Moxetumomab pasudotox in Leukaemia, run by MedImmune LLC, completed.","route":"/trials/nct01829711/","status":"completed","kind":"trial","cancerIcon":"leukaemia","sub":"NCT01829711","facets":{"kind":["Trial"],"cancers":["Leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Leukaemia","href":"/cancers/leukaemia/","tip":"Leukaemia means cancer of the blood-forming cells, but the four main types share little beyond the name: acute lymphoblastic and acute myeloid leukaemia are emergencies treated with intensive therapy, while chronic lymphocytic and chronic myeloid leukaemia are slow diseases controlled for years with pills. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01377753","name":"MR Image Guided Therapy in Prostate Cancer","tldr":"A phase 2 trial of Laser interstitial thermal therapy systems in Prostate cancer, run by National Cancer Institute (NCI), completed.","route":"/trials/nct01377753/","status":"completed","kind":"trial","cancerIcon":"prostate","sub":"NCT01377753","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06840665","name":"MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer","tldr":"A phase 2 trial of MR-guided adaptive radiotherapy in Rectal cancer, run by Fudan University, now recruiting.","route":"/trials/nct06840665/","status":"recruiting","kind":"trial","cancerIcon":"rectal-cancer","sub":"NCT06840665","facets":{"kind":["Trial"],"cancers":["Rectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Rectal cancer","href":"/cancers/rectal-cancer/","tip":"Rectal cancer is bowel cancer in the last part of the large intestine, where surgery can mean a permanent stoma. Treatment now usually gives all the chemotherapy and radiotherapy first, and about half of people whose tumour disappears completely can keep their rectum and avoid surgery altogether."}],"tags":[]},"sortKeys":{"year":0}},{"id":"mrg002","name":"MRG002","tldr":"MRG002 is an experimental investigational agent whose form is not stated in the registry from Shanghai Miracogen in phase 3 trials for gastric & gastro-oesophageal junction cancer and bladder & urothelial cancer, with its target not yet stated publicly.","route":"/drugs/mrg002/","status":"phase-3","kind":"drug","molecule":"mrg002","modality":"antibody-drug conjugate (ADC), per the sponsor's pipeline page; form not stated in the registry record","facets":{"kind":["Treatment"],"cancers":["Gastric & gastro-oesophageal junction cancer","Bladder & urothelial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."}],"tags":[]},"sortKeys":{"year":0}},{"id":"mrg003","name":"MRG003","tldr":"MRG003 is an experimental antibody-drug conjugate from Lepu Biopharma in phase 3 trials for head and neck squamous cell carcinoma and nasopharyngeal carcinoma, with its target not yet stated publicly.","route":"/drugs/mrg003/","status":"phase-3","kind":"drug","molecule":"mrg003","modality":"ADC","facets":{"kind":["Treatment"],"cancers":["Head and neck squamous cell carcinoma","Nasopharyngeal carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Nasopharyngeal carcinoma","href":"/cancers/nasopharyngeal/","tip":"A cancer at the back of the nose caused largely by the Epstein-Barr virus and common in southern China and Southeast Asia. Radiation cures most early cases; adding chemotherapy and, recently, PD-1 immunotherapy has improved outcomes in advanced disease, and a blood test for viral DNA can detect it early."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01310803","name":"Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder","tldr":"A phase 3 trial of Valrubicin in Non-muscle-invasive bladder cancer, run by Endo USA Inc., a Keenova Therapeutics Company, recorded as terminated on the registry.","route":"/trials/nct01310803/","kind":"trial","cancerIcon":"non-muscle-invasive-bladder-cancer","sub":"NCT01310803","facets":{"kind":["Trial"],"cancers":["Non-muscle-invasive bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-muscle-invasive bladder cancer","href":"/cancers/non-muscle-invasive-bladder-cancer/","tip":"Most bladder cancers are found while still confined to the lining. They are scraped out through the urethra and, when higher risk, treated with BCG instilled into the bladder; the challenge is the frequent recurrences and the patients whose tumours stop responding to BCG."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03439709","name":"Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma","tldr":"A phase 3 trial of Gamma Knife in Pituitary tumours, run by Samsung Medical Center, with a status the registry has not verified recently.","route":"/trials/nct03439709/","kind":"trial","cancerIcon":"pituitary-tumours","sub":"NCT03439709","facets":{"kind":["Trial"],"cancers":["Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma","href":"/cancers/pituitary-tumours/","tip":"Pituitary tumours are usually benign growths of the hormone gland at the base of the brain that cause trouble by overproducing hormones or pressing on the optic nerves. Prolactin-producing tumours melt away with a tablet, most others are cured by surgery through the nose, and the rare aggressive ones respond to the chemotherapy drug temozolomide."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07639450","name":"N-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors","tldr":"A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by Hefei Xinzhu Biological Technology Co., Ltd., now recruiting.","route":"/trials/nct07639450/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07639450","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06061809","name":"N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma","tldr":"A phase 2 trial of Bevacizumab and Nogapendekin alfa inbakicept in glioma & glioblastoma, run by ImmunityBio, Inc., active and no longer recruiting.","route":"/trials/nct06061809/","status":"active","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT06061809","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02802540","name":"Nabilone Effect on the Attenuation of Anorexia, Nutritional Status and Quality of Life in Lung Cancer Patients","tldr":"A phase 2/3 trial of Nabilone in Non-small-cell lung cancer, run by Instituto Nacional de Cancerologia de Mexico, with a status the registry has not verified recently.","route":"/trials/nct02802540/","kind":"trial","cancerIcon":"nsclc","sub":"NCT02802540","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05201404","name":"Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis","tldr":"A phase 3 trial of Namodenoson in hepatocellular carcinoma, run by Can-Fite BioPharma, now recruiting.","route":"/trials/nct05201404/","status":"recruiting","kind":"trial","cancerIcon":"hcc","sub":"NCT05201404","facets":{"kind":["Trial"],"cancers":["Hepatocellular carcinoma","Advanced hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."},{"label":"Advanced hepatocellular carcinoma","href":"/cancers/hcc-advanced/","tip":"Advanced hepatocellular carcinoma has invaded the liver's veins or spread beyond it. Sorafenib was the only drug for a decade; now the combination of the immunotherapy atezolizumab with the anti-angiogenic antibody bevacizumab, or the two-antibody regimen durvalumab with tremelimumab, is standard first line, and several further drugs follow it."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06387342","name":"Namodenoson Treatment of Advanced Pancreatic Cancer","tldr":"A phase 2 trial of Namodenoson 25mg in pancreatic ductal adenocarcinoma, run by Can-Fite BioPharma, now recruiting.","route":"/trials/nct06387342/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT06387342","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07150663","name":"Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer","tldr":"A phase 3 trial of Megestrol acetate in non-small-cell lung cancer, run by Changchun GeneScience Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07150663/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07150663","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"naporafenib","name":"Naporafenib","tldr":"Naporafenib is an experimental small-molecule drug from Erasca in phase 3 trials for melanoma, with its target not yet stated publicly.","route":"/drugs/naporafenib/","status":"phase-3","kind":"drug","molecule":"naporafenib","modality":"small molecule","sub":"ERAS-254, LXH254","facets":{"kind":["Treatment"],"cancers":["Melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."}],"tags":[]},"sortKeys":{"year":0}},{"id":"navitoclax","name":"Navitoclax","tldr":"Navitoclax is an experimental small-molecule drug from AbbVie in phase 3 trials for myeloproliferative neoplasms, with its target not yet stated publicly.","route":"/drugs/navitoclax/","status":"phase-3","kind":"drug","molecule":"navitoclax","modality":"small molecule","facets":{"kind":["Treatment"],"cancers":["Myeloproliferative neoplasms","Primary myelofibrosis"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Myeloproliferative neoplasms","href":"/cancers/myeloproliferative-neoplasms/","tip":"Myeloproliferative neoplasms are slow-growing blood cancers in which the marrow overproduces red cells (polycythaemia vera), platelets (essential thrombocythaemia) or scar tissue (myelofibrosis). Almost all carry a mutation in JAK2, CALR or MPL; treatment aims to prevent clots and control symptoms, and only transplant cures myelofibrosis."},{"label":"Primary myelofibrosis","href":"/cancers/primary-myelofibrosis/","tip":"Primary myelofibrosis is a blood cancer in which the marrow scars over, the spleen swells and patients become anaemic and exhausted. JAK inhibitors, ruxolitinib first (COMFORT) and then fedratinib, pacritinib and momelotinib (MOMENTUM), shrink the spleen and relieve symptoms; only a donor stem cell transplant can cure it."}],"tags":[]},"sortKeys":{"year":0}},{"id":"navlimetostat","name":"Navlimetostat","tldr":"Navlimetostat is an experimental small-molecule drug from Bristol-Myers Squibb in phase 3 trials for non-small-cell lung cancer and pancreatic ductal adenocarcinoma, aimed at PRMT5 (MTAP-deleted cancers).","route":"/drugs/navlimetostat/","status":"phase-3","kind":"drug","molecule":"navlimetostat","modality":"small molecule","sub":"BMS-986504, MRTX1719","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nb003","name":"NB003","tldr":"NB003 is an experimental small-molecule drug from Ningbo Newbay Technology Development in phase 3 trials for gastrointestinal stromal tumour, with its target not yet stated publicly.","route":"/drugs/nb003/","status":"phase-3","kind":"drug","molecule":"nb003","modality":"small molecule (structure undisclosed or not yet in PubChem)","facets":{"kind":["Treatment"],"cancers":["Gastrointestinal stromal tumour"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Gastrointestinal stromal tumour","href":"/cancers/gist/","tip":"GIST is a sarcoma of the gut wall driven almost always by a KIT or PDGFRA mutation. It was the proof that a pill can control a solid tumour: imatinib turned a median survival of about a year into one of eight years or more, and the mutation now dictates which drug to use."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06012695","name":"NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma","tldr":"A phase 1/2 trial of Temozolomide in advanced solid tumours, run by Novelwise Pharmaceutical Corporation, now recruiting.","route":"/trials/nct06012695/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06012695","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07765667","name":"NCT + PD1 + Ketogenic Diet and/or Vitamin C for LARC","tldr":"A phase 2 trial of High-dose intravenous vitamin C in Rectal cancer, run by Sixth Affiliated Hospital, Sun Yat-sen University, not yet recruiting.","route":"/trials/nct07765667/","status":"planned","kind":"trial","cancerIcon":"rectal-cancer","sub":"NCT07765667","facets":{"kind":["Trial"],"cancers":["Rectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Rectal cancer","href":"/cancers/rectal-cancer/","tip":"Rectal cancer is bowel cancer in the last part of the large intestine, where surgery can mean a permanent stoma. Treatment now usually gives all the chemotherapy and radiotherapy first, and about half of people whose tumour disappears completely can keep their rectum and avoid surgery altogether."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ndi-219216","name":"NDI-219216","tldr":"NDI-219216 is an experimental small-molecule drug from Nimbus Wadjet in phase 2 trials, aimed at WRN helicase (MSI-high cancers).","route":"/drugs/ndi-219216/","status":"phase-2","kind":"drug","molecule":"ndi-219216","modality":"small molecule (structure undisclosed or not yet in PubChem)","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02938299","name":"Neoadjuvant L19IL2/L19TNF- Pivotal Study","tldr":"A phase 3 trial of L19IL2 + L19TNF in melanoma, run by Philogen S.p.A., active and no longer recruiting.","route":"/trials/nct02938299/","status":"active","kind":"trial","cancerIcon":"melanoma","sub":"NCT02938299","facets":{"kind":["Trial"],"cancers":["Melanoma","Stage III melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"label":"Stage III melanoma","href":"/cancers/stage-iii-melanoma/","tip":"Stage III melanoma has spread to nearby lymph nodes but not further, and after surgery a year of immunotherapy, or of targeted pills if the cancer has a BRAF mutation, roughly halves the chance of it coming back. The newest trials show that giving immunotherapy before the operation instead of after works even better and lets most people stop treatment early."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00833248","name":"Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer","tldr":"A phase 3 trial of Degarelix, Goserelin / leuprolide and Bicalutamide in Prostate cancer, run by Ferring Pharmaceuticals, completed.","route":"/trials/nct00833248/","status":"completed","kind":"trial","cancerIcon":"prostate","sub":"NCT00833248","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06227117","name":"Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer","tldr":"A phase 2 trial of Disitamab vedotin, Toripalimab, Carboplatin and Epirubicin in HER2-positive breast cancer, run by RemeGen Co., Ltd., now recruiting.","route":"/trials/nct06227117/","status":"recruiting","kind":"trial","cancerIcon":"breast-her2-positive","sub":"NCT06227117","facets":{"kind":["Trial"],"cancers":["HER2-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07581912","name":"Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases","tldr":"A phase 2 trial of Fulzerasib in Colorectal cancer, run by Zhejiang University, now recruiting.","route":"/trials/nct07581912/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT07581912","facets":{"kind":["Trial"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05765877","name":"Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer","tldr":"A phase 2 trial of Iruplinalkib in Non-small-cell lung cancer, run by Pingping Song, now recruiting.","route":"/trials/nct05765877/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT05765877","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03252431","name":"Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy","tldr":"A phase 3 trial of Efbemalenograstim alfa and Pegfilgrastim in Breast cancer, run by EVIVE Biotechnology, completed.","route":"/trials/nct03252431/","status":"completed","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT03252431","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03348904","name":"Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer","tldr":"A phase 3 trial of Nivolumab, Epacadostat, Carboplatin, Cisplatin, Gemcitabine, Paclitaxel / nab-paclitaxel and Pemetrexed in Lung cancer, run by Incyte Corporation, recorded as terminated on the registry.","route":"/trials/nct03348904/","kind":"trial","cancerIcon":"lung-cancer","sub":"NCT03348904","facets":{"kind":["Trial"],"cancers":["Lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Lung cancer","href":"/cancers/lung-cancer/","tip":"Lung cancer splits into non-small-cell (about 85 percent) and small-cell (about 15 percent) disease, which behave and are treated very differently. The subtype pages carry the detail; this page covers screening, staging and what the types share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04041310","name":"Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors","tldr":"A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by Nouscom SRL, active and no longer recruiting.","route":"/trials/nct04041310/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04041310","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05702229","name":"Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","tldr":"A phase 2 trial of Rilvegostomig, CAPOX (capecitabine, oxaliplatin) and Capecitabine in gastric & gastro-oesophageal junction cancer, run by AstraZeneca, now recruiting.","route":"/trials/nct05702229/","status":"recruiting","kind":"trial","cancerIcon":"gastric","sub":"NCT05702229","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05023486","name":"NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies","tldr":"A phase 1/2 trial of NP-G2-044 Monotherapy in advanced solid tumours, run by Novita Pharmaceuticals, Inc., active and no longer recruiting.","route":"/trials/nct05023486/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05023486","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"np137","name":"NP137","tldr":"NP137 is a monoclonal antibody from NETRIS Pharma, in registered phase 2 trials for endometrial cancer, cervical cancer.","route":"/drugs/np137/","status":"phase-2","kind":"drug","molecule":"np137","modality":"Monoclonal antibody","sub":"NP137","facets":{"kind":["Treatment"],"cancers":["Endometrial cancer","Cervical cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."},{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nuv-1511","name":"NUV-1511","tldr":"NUV-1511 is a small-molecule inhibitor from Nuvation Bio Inc., in registered phase 2 trials for prostate cancer, pancreatic ductal adenocarcinoma, ovarian cancer.","route":"/drugs/nuv-1511/","status":"phase-2","kind":"drug","molecule":"nuv-1511","modality":"Small-molecule inhibitor","sub":"NUV-1511","facets":{"kind":["Treatment"],"cancers":["Prostate cancer","Pancreatic ductal adenocarcinoma","Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct07669467","name":"Nuvastatic® Phase III Trial for Fatigue in Triple-Negative Breast Cancer","tldr":"A phase 3 trial of Nuvastatic 300 in triple-negative breast cancer, run by Natureceuticals Sdn Bhd, now recruiting.","route":"/trials/nct07669467/","status":"recruiting","kind":"trial","cancerIcon":"tnbc","sub":"NCT07669467","facets":{"kind":["Trial"],"cancers":["Triple-negative breast cancer","Metastatic triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Metastatic triple-negative breast cancer","href":"/cancers/tnbc-metastatic/","tip":"Triple-negative breast cancer that has spread is not curable, but its treatment has been transformed since 2020. By PD-L1 score, first treatment is pembrolizumab with chemotherapy or with sacituzumab govitecan, or datopotamab deruxtecan or sacituzumab govitecan alone; BRCA carriers can take a PARP inhibitor tablet; and trastuzumab deruxtecan reaches the third of tumours with low HER2."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07324304","name":"NWRD06 DNA Plasmid for HCC After Curative Resection.","tldr":"A phase 2 trial of NWRD06 administered by electroporation in hepatocellular carcinoma, run by Newish Technology (Beijing) Co., Ltd., now recruiting.","route":"/trials/nct07324304/","status":"recruiting","kind":"trial","cancerIcon":"hcc","sub":"NCT07324304","facets":{"kind":["Trial"],"cancers":["Hepatocellular carcinoma","Early hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."},{"label":"Early hepatocellular carcinoma","href":"/cancers/hcc-early/","tip":"Early hepatocellular carcinoma means a single tumour, or up to three small ones, in a liver that still works, without spread or vein invasion. It is treated to cure: cutting out the tumour, destroying it with heat through a needle, or replacing the liver by transplant, chosen by tumour size, liver function and portal pressure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nxc-201-car-t","name":"NXC-201 CAR-T","tldr":"NXC-201 CAR-T is an experimental CAR-T cell therapy from Nexcella in phase 2 trials, aimed at BCMA.","route":"/drugs/nxc-201-car-t/","status":"phase-2","kind":"drug","molecule":"nxc-201-car-t","modality":"CAR-T cell therapy","sub":"NXC-201, HBI0101","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"obi-902","name":"OBI-902","tldr":"OBI-902 is an antibody-drug conjugate from OBI Pharma, Inc, in registered phase 2 trials for metastatic cancer.","route":"/drugs/obi-902/","status":"phase-2","kind":"drug","molecule":"obi-902","modality":"Antibody-drug conjugate","sub":"OBI-902","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"obi-992","name":"OBI-992","tldr":"OBI-992 is an antibody-drug conjugate from OBI Pharma, Inc, in registered phase 2 trials for metastatic cancer.","route":"/drugs/obi-992/","status":"phase-2","kind":"drug","molecule":"obi-992","modality":"Antibody-drug conjugate","sub":"OBI-992","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct07382531","name":"OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors","tldr":"A phase 1/2 trial of OH2+BS006 in advanced solid tumours, run by Binhui Biopharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07382531/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07382531","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05868707","name":"OH2 Injection in Melanoma","tldr":"A phase 3 trial of OH2 in melanoma, run by Binhui Biopharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct05868707/","status":"recruiting","kind":"trial","cancerIcon":"melanoma","sub":"NCT05868707","facets":{"kind":["Trial"],"cancers":["Melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03866525","name":"OH2 Oncolytic Viral Therapy in Solid Tumors","tldr":"A phase 1/2 trial of OH2 injection, with or without irinotecan or HX008 in advanced solid tumours, run by Binhui Biopharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct03866525/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT03866525","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01874353","name":"Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy","tldr":"A phase 3 trial of Olaparib in ovarian cancer, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct01874353/","status":"active","kind":"trial","cancerIcon":"ovarian","sub":"NCT01874353","facets":{"kind":["Trial"],"cancers":["Ovarian cancer","Platinum-sensitive ovarian cancer"],"year":["2018"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Platinum-sensitive ovarian cancer","href":"/cancers/platinum-sensitive-ovarian-cancer/","tip":"Platinum-sensitive ovarian cancer is disease that responded to carboplatin and either has not relapsed or relapses more than six months after the last dose. It is treated with further platinum chemotherapy, sometimes repeat surgery, and above all with maintenance PARP inhibitors, which keep BRCA-mutant tumours away for years and have raised long-term survival."}],"year":{"facet":"year","value":"2018"},"tags":[]},"sortKeys":{"year":2018}},{"id":"oleclumab","name":"Oleclumab","tldr":"Oleclumab is an experimental investigational agent whose form is not stated in the registry from AstraZeneca in phase 3 trials for non-small-cell lung cancer, triple-negative breast cancer and colorectal cancer, with its target not yet stated publicly.","route":"/drugs/oleclumab/","status":"phase-3","kind":"drug","molecule":"oleclumab","modality":"antibody (INN stem -mab; form not stated in the registry record)","sub":"MEDI9447","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Triple-negative breast cancer","Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03381274","name":"Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study","tldr":"A phase 1/2 trial of Oleclumab and Osimertinib in non-small-cell lung cancer, run by MedImmune LLC, active and no longer recruiting.","route":"/trials/nct03381274/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT03381274","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":["2022"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"year":{"facet":"year","value":"2022"},"tags":[]},"sortKeys":{"year":2022}},{"id":"nct03228277","name":"Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA","tldr":"A phase 2 trial of Olmutinib in Non-small-cell lung cancer, run by Konkuk University Medical Center, completed.","route":"/trials/nct03228277/","status":"completed","kind":"trial","cancerIcon":"nsclc","sub":"NCT03228277","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"olverembatinib","name":"Olverembatinib","tldr":"Olverembatinib is Ascentage Pharma's third-generation BCR-ABL inhibitor, approved in China in 2021 for chronic myeloid leukaemia carrying the T315I mutation, and now in global phase 3 trials against the established drugs; it was the one China-only approval OnCo found missing from the headline list.","route":"/drugs/olverembatinib/","status":"approved","kind":"drug","molecule":"olverembatinib","modality":"Oral third-generation BCR-ABL tyrosine kinase inhibitor","sub":"HQP1351","facets":{"kind":["Treatment"],"cancers":["Chronic myeloid leukaemia","Acute lymphoblastic leukaemia","Chronic myeloid leukaemia, accelerated and blast phase"],"year":["2021"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Chronic myeloid leukaemia","href":"/cancers/cml/","tip":"Chronic myeloid leukaemia is a blood cancer driven by a single fused gene, BCR-ABL1, and the model for oncogene-targeted treatment: imatinib in 2001 and the tyrosine kinase inhibitors that followed turned it into a condition most people live with long-term. About half of patients with a sustained deep molecular response can now stop treatment altogether."},{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."},{"label":"Chronic myeloid leukaemia, accelerated and blast phase","href":"/cancers/cml-advanced-phase/","tip":"Chronic myeloid leukaemia can accelerate and then transform into an acute leukaemia called blast crisis. Tyrosine kinase inhibitors are given at full strength, combined with acute leukaemia chemotherapy in blast phase, to bring the disease back to chronic phase quickly enough for a donor stem cell transplant, the only treatment that cures it."}],"year":{"facet":"year","value":"2021"},"tags":[]},"sortKeys":{"year":2021}},{"id":"olvimulogene-nanivacirepvec","name":"Olvimulogene nanivacirepvec","tldr":"Olvimulogene nanivacirepvec is an experimental oncolytic virus from Genelux in phase 3 trials for ovarian cancer and non-small-cell lung cancer, with its target not yet stated publicly.","route":"/drugs/olvimulogene-nanivacirepvec/","status":"phase-3","kind":"drug","molecule":"olvimulogene-nanivacirepvec","modality":"oncolytic virus","facets":{"kind":["Treatment"],"cancers":["Ovarian cancer","Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"onvansertib","name":"Onvansertib","tldr":"Onvansertib is an oral serine/threonine kinase inhibitor from Cardiff Oncology, in registered phase 2 trials for colorectal cancer.","route":"/drugs/onvansertib/","status":"phase-2","kind":"drug","molecule":"onvansertib","modality":"Oral serine/threonine kinase inhibitor","facets":{"kind":["Treatment"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct06016738","name":"OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer","tldr":"A phase 3 trial of Fulvestrant and Exemestane in HR-positive / HER2-negative breast cancer, run by Olema Pharmaceuticals, Inc., active and no longer recruiting.","route":"/trials/nct06016738/","status":"active","kind":"trial","cancerIcon":"breast-hr-positive","sub":"NCT06016738","facets":{"kind":["Trial"],"cancers":["HR-positive / HER2-negative breast cancer","HR-positive metastatic breast cancer after CDK4/6 inhibitors"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"HR-positive metastatic breast cancer after CDK4/6 inhibitors","href":"/cancers/hr-positive-metastatic-post-cdk46/","tip":"When hormone-positive breast cancer grows through a CDK4/6 inhibitor, a blood test picks the next drug. Tumours with an acquired ESR1 mutation respond to the oral degraders elacestrant, camizestrant and imlunestrant; tumours with PIK3CA, AKT1 or PTEN changes to capivasertib, inavolisib or alpelisib; and once endocrine options run out, antibody-drug conjugates come before chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04724369","name":"Open-Label Study of 18F-mFBG for Imaging Neuroblastoma","tldr":"A phase 3 trial of 18F-MFBG in neuroblastoma, run by Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC), now completed.","route":"/trials/nct04724369/","status":"completed","kind":"trial","cancerIcon":"neuroblastoma","sub":"NCT04724369","facets":{"kind":["Trial"],"cancers":["Neuroblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Neuroblastoma","href":"/cancers/neuroblastoma/","tip":"Neuroblastoma is a childhood nerve-cell cancer where anti-GD2 antibodies and, recently, GD2 CAR-T have improved survival in high-risk disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06514534","name":"Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.","tldr":"A phase 2 trial of Asciminib in chronic myeloid leukaemia, run by Novartis Pharmaceuticals, now recruiting.","route":"/trials/nct06514534/","status":"recruiting","kind":"trial","cancerIcon":"cml","sub":"NCT06514534","facets":{"kind":["Trial"],"cancers":["Chronic myeloid leukaemia","Chronic myeloid leukaemia, accelerated and blast phase"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic myeloid leukaemia","href":"/cancers/cml/","tip":"Chronic myeloid leukaemia is a blood cancer driven by a single fused gene, BCR-ABL1, and the model for oncogene-targeted treatment: imatinib in 2001 and the tyrosine kinase inhibitors that followed turned it into a condition most people live with long-term. About half of patients with a sustained deep molecular response can now stop treatment altogether."},{"label":"Chronic myeloid leukaemia, accelerated and blast phase","href":"/cancers/cml-advanced-phase/","tip":"Chronic myeloid leukaemia can accelerate and then transform into an acute leukaemia called blast crisis. Tyrosine kinase inhibitors are given at full strength, combined with acute leukaemia chemotherapy in blast phase, to bring the disease back to chronic phase quickly enough for a donor stem cell transplant, the only treatment that cures it."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05563220","name":"Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer","tldr":"A phase 1/2 trial of Elacestrant, Alpelisib, Everolimus, Ribociclib, Palbociclib and Capivasertib in advanced solid tumours, run by Stemline Therapeutics, Inc., active and no longer recruiting.","route":"/trials/nct05563220/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05563220","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05491525","name":"Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC","tldr":"A phase 2/3 trial of Vibegron in childhood cancers, run by Urovant Sciences GmbH, now recruiting.","route":"/trials/nct05491525/","status":"recruiting","kind":"trial","cancerIcon":"childhood-cancers","sub":"NCT05491525","facets":{"kind":["Trial"],"cancers":["Childhood cancers"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Childhood cancers","href":"/cancers/childhood-cancers/","tip":"Cancer in children is rare and different from adult cancer: the common types are leukaemias, brain tumours, lymphomas and embryonal tumours such as neuroblastoma and Wilms tumour, most are curable in well-resourced health systems, and the great challenge is bringing the same cures to the majority of children who live where they are not available."}],"tags":[]},"sortKeys":{"year":0}},{"id":"opevesostat","name":"Opevesostat","tldr":"Opevesostat is an experimental small-molecule drug from Merck Sharp & Dohme in phase 3 trials for prostate cancer, with its target not yet stated publicly.","route":"/drugs/opevesostat/","status":"phase-3","kind":"drug","molecule":"opevesostat","modality":"small molecule","sub":"MK-5684, ODM-208","facets":{"kind":["Treatment"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07527806","name":"Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging","tldr":"A phase 2 trial of HER2 PET in Breast cancer, run by Peking University Cancer Hospital & Institute, not yet recruiting.","route":"/trials/nct07527806/","status":"planned","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT07527806","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06558214","name":"OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial","tldr":"A phase 2 trial of Laser interstitial thermal therapy systems in Glioma & glioblastoma, run by University of Florida, now recruiting.","route":"/trials/nct06558214/","status":"recruiting","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT06558214","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"or502","name":"OR502","tldr":"OR502 is a monoclonal antibody from OncoResponse, Inc., in registered phase 2 trials for metastatic cancer, melanoma, non-small-cell lung cancer.","route":"/drugs/or502/","status":"phase-2","kind":"drug","molecule":"or502","modality":"Monoclonal antibody","sub":"OR502","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer","Melanoma","Non-small-cell lung cancer","Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."},{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct03315364","name":"Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy","tldr":"A phase 2/3 trial of Oral paclitaxel in advanced solid tumours, run by Daehwa Pharmaceutical Co., Ltd., active and no longer recruiting.","route":"/trials/nct03315364/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT03315364","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"oregovomab","name":"Oregovomab","tldr":"Oregovomab is an experimental monoclonal antibody from CanariaBio in phase 3 trials for ovarian cancer, with its target not yet stated publicly.","route":"/drugs/oregovomab/","status":"phase-3","kind":"drug","molecule":"oregovomab","modality":"monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07337876","name":"Organ Preservation in Rectal Cancer by Dose Escalated MR Guided Adaptive Radiotherapy","tldr":"A phase 2 trial of MR-guided adaptive radiotherapy in Rectal cancer, run by University Hospital Tuebingen, now recruiting.","route":"/trials/nct07337876/","status":"recruiting","kind":"trial","cancerIcon":"rectal-cancer","sub":"NCT07337876","facets":{"kind":["Trial"],"cancers":["Rectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Rectal cancer","href":"/cancers/rectal-cancer/","tip":"Rectal cancer is bowel cancer in the last part of the large intestine, where surgery can mean a permanent stoma. Treatment now usually gives all the chemotherapy and radiotherapy first, and about half of people whose tumour disappears completely can keep their rectum and avoid surgery altogether."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05652920","name":"Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC","tldr":"A phase 1/2 trial of Ori-C101 in hepatocellular carcinoma, run by OriCell Therapeutics Co., Ltd., now recruiting.","route":"/trials/nct05652920/","status":"recruiting","kind":"trial","cancerIcon":"hcc","sub":"NCT05652920","facets":{"kind":["Trial"],"cancers":["Hepatocellular carcinoma","Advanced hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."},{"label":"Advanced hepatocellular carcinoma","href":"/cancers/hcc-advanced/","tip":"Advanced hepatocellular carcinoma has invaded the liver's veins or spread beyond it. Sorafenib was the only drug for a decade; now the combination of the immunotherapy atezolizumab with the anti-angiogenic antibody bevacizumab, or the two-antibody regimen durvalumab with tremelimumab, is standard first line, and several further drugs follow it."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06998407","name":"ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors","tldr":"A phase 1/2 trial of AVZO-021 and Fulvestrant in advanced solid tumours, run by Avenzo Therapeutics, Inc., now recruiting.","route":"/trials/nct06998407/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06998407","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ose2101","name":"OSE2101","tldr":"OSE2101 is an experimental cancer vaccine from OSE Immunotherapeutics in phase 3 trials for non-small-cell lung cancer, aimed at HER2 and CEACAM5.","route":"/drugs/ose2101/","status":"phase-3","kind":"drug","molecule":"ose2101","modality":"vaccine","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07295821","name":"Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study","tldr":"A phase 2 trial of Osimertinib in advanced solid tumours, run by AstraZeneca, now recruiting.","route":"/trials/nct07295821/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07295821","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03778229","name":"Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib","tldr":"A phase 2 trial of Osimertinib and Savolitinib in advanced solid tumours, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct03778229/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT03778229","facets":{"kind":["Trial"],"cancers":["Metastatic cancer","EGFR-mutated non-small-cell lung cancer","MET exon 14 and MET-amplified non-small-cell lung cancer"],"year":["2026"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."},{"label":"MET exon 14 and MET-amplified non-small-cell lung cancer","href":"/cancers/met-altered-nsclc/","tip":"MET-driven lung cancer comes in three forms: an exon 14 skipping mutation treated with the pills capmatinib or tepotinib, MET amplification that often arises as an escape route from EGFR drugs, and high c-Met protein levels that the antibody-drug conjugate telisotuzumab vedotin targets."}],"year":{"facet":"year","value":"2026"},"tags":[]},"sortKeys":{"year":2026}},{"id":"nct04974008","name":"Osteosarcoma Maintenance Therapy With OST31-164","tldr":"A phase 2 trial of OST31-164 in advanced solid tumours, run by Emerald Clinical Inc., active and no longer recruiting.","route":"/trials/nct04974008/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04974008","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04906395","name":"Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer","tldr":"A phase 3 trial of Tamoxifen and Exemestane in advanced solid tumours, run by Tolmar Inc., active and no longer recruiting.","route":"/trials/nct04906395/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04906395","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00268463","name":"Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal Cancer","tldr":"A phase 3 trial of Capecitabine, Floxuridine and Oxaliplatin in Colorectal cancer and Metastatic cancer, run by NSABP Foundation Inc, recorded as terminated on the registry.","route":"/trials/nct00268463/","kind":"trial","cancerIcon":"colorectal","sub":"NCT00268463","facets":{"kind":["Trial"],"cancers":["Colorectal cancer","Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03268382","name":"p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246","tldr":"A phase 2 trial of Eprenetapopt and Pegylated liposomal doxorubicin in Ovarian cancer, run by Aprea Therapeutics, completed.","route":"/trials/nct03268382/","status":"completed","kind":"trial","cancerIcon":"ovarian","sub":"NCT03268382","facets":{"kind":["Trial"],"cancers":["Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07033598","name":"Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia","tldr":"A phase 2 trial of Pacritinib in chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, run by Theradex, now recruiting.","route":"/trials/nct07033598/","status":"recruiting","kind":"trial","cancerIcon":"cmml","sub":"NCT07033598","facets":{"kind":["Trial"],"cancers":["Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms","href":"/cancers/cmml/","tip":"Chronic myelomonocytic leukaemia and its relatives are bone-marrow cancers that behave partly like myelodysplasia (poorly made blood cells) and partly like a proliferative disease (an excess of monocytes or platelets). Hypomethylating agents produce responses in a minority and stabilise counts in more, transplant can cure the fit, and RAS-pathway and JAK inhibitors are in trials."}],"tags":[]},"sortKeys":{"year":0}},{"id":"palacaparib","name":"Palacaparib","tldr":"Palacaparib is an experimental small-molecule drug from AstraZeneca in phase 2 trials for ovarian cancer, non-small-cell lung cancer and endometrial cancer, aimed at PARP.","route":"/drugs/palacaparib/","status":"phase-2","kind":"drug","molecule":"palacaparib","modality":"small molecule","sub":"AZD9574","facets":{"kind":["Treatment"],"cancers":["Ovarian cancer","Non-small-cell lung cancer","Endometrial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07085767","name":"Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer","tldr":"A phase 3 trial of Ribociclib in HR-positive / HER2-negative breast cancer, run by Olema Pharmaceuticals, Inc., now recruiting.","route":"/trials/nct07085767/","status":"recruiting","kind":"trial","cancerIcon":"breast-hr-positive","sub":"NCT07085767","facets":{"kind":["Trial"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00101582","name":"Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer","tldr":"A phase 3 trial of Palifermin in Head and neck squamous cell carcinoma, run by Swedish Orphan Biovitrum, completed.","route":"/trials/nct00101582/","status":"completed","kind":"trial","cancerIcon":"head-and-neck","sub":"NCT00101582","facets":{"kind":["Trial"],"cancers":["Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00109031","name":"Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)","tldr":"A phase 3 trial of Palifermin, Cyclophosphamide and Etoposide in Leukaemia, run by Swedish Orphan Biovitrum, completed.","route":"/trials/nct00109031/","status":"completed","kind":"trial","cancerIcon":"leukaemia","sub":"NCT00109031","facets":{"kind":["Trial"],"cancers":["Leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Leukaemia","href":"/cancers/leukaemia/","tip":"Leukaemia means cancer of the blood-forming cells, but the four main types share little beyond the name: acute lymphoblastic and acute myeloid leukaemia are emergencies treated with intensive therapy, while chronic lymphocytic and chronic myeloid leukaemia are slow diseases controlled for years with pills. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00002893","name":"Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer","tldr":"A phase 3 trial of Fluorouracil, Leucovorin and Raltitrexed in Colorectal cancer, run by Medical Research Council, with a status the registry has not verified recently.","route":"/trials/nct00002893/","kind":"trial","cancerIcon":"colorectal","sub":"NCT00002893","facets":{"kind":["Trial"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00376883","name":"Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month","tldr":"A phase 3 trial of Pamidronate in Multiple myeloma, run by Nordic Myeloma Study Group, completed.","route":"/trials/nct00376883/","status":"completed","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT00376883","facets":{"kind":["Trial"],"cancers":["Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[]},"sortKeys":{"year":0}},{"id":"pamiparib","name":"Pamiparib","tldr":"Pamiparib is an oral parp inhibitor from BeiGene, in registered phase 3 trials for ovarian cancer.","route":"/drugs/pamiparib/","status":"phase-3","kind":"drug","molecule":"pamiparib","modality":"Oral PARP inhibitor","facets":{"kind":["Treatment"],"cancers":["Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct03899155","name":"Pan Tumor Rollover Study","tldr":"A phase 2 trial of Nivolumab, Ipilimumab, Cabozantinib, Trametinib, Capecitabine and Bevacizumab in advanced solid tumours, run by Bristol-Myers Squibb, now recruiting.","route":"/trials/nct03899155/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT03899155","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02506959","name":"Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma","tldr":"A phase 2 trial of Busulfan, Gemcitabine, Melphalan and Panobinostat in Plasma cell leukaemia, run by M.D. Anderson Cancer Center, completed.","route":"/trials/nct02506959/","status":"completed","kind":"trial","cancerIcon":"plasma-cell-leukaemia","sub":"NCT02506959","facets":{"kind":["Trial"],"cancers":["Plasma cell leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Plasma cell leukaemia","href":"/cancers/plasma-cell-leukaemia/","tip":"Plasma cell leukaemia is myeloma in which the cancerous plasma cells spill into the bloodstream in large numbers. It is the most aggressive plasma cell cancer and is treated urgently with several myeloma drugs at once followed by a stem cell transplant."}],"tags":[]},"sortKeys":{"year":0}},{"id":"parsaclisib","name":"Parsaclisib","tldr":"Parsaclisib is an oral pi3k inhibitor from Incyte Corporation, in registered phase 2 trials for diffuse large B-cell lymphoma.","route":"/drugs/parsaclisib/","status":"phase-2","kind":"drug","molecule":"parsaclisib","modality":"Oral PI3K inhibitor","facets":{"kind":["Treatment"],"cancers":["Diffuse large B-cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"pbp1510","name":"PBP1510","tldr":"PBP1510 is a monoclonal antibody from Prestige Biopharma Limited, in registered phase 2 trials for pancreatic ductal adenocarcinoma.","route":"/drugs/pbp1510/","status":"phase-2","kind":"drug","molecule":"pbp1510","modality":"Monoclonal antibody","sub":"PBP1510","facets":{"kind":["Treatment"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct07761533","name":"PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS","tldr":"A phase 1/2 trial of PBSS1113 in acute myeloid leukaemia and myelodysplastic syndromes / neoplasms, run by Chaser Therapeutics, Inc., now recruiting.","route":"/trials/nct07761533/","status":"recruiting","kind":"trial","cancerIcon":"aml","sub":"NCT07761533","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia","Myelodysplastic syndromes / neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Myelodysplastic syndromes / neoplasms","href":"/cancers/mds/","tip":"Bone-marrow disorders where blood cells are made badly and too few reach the blood; a third progress to acute leukaemia. Treatment ranges from transfusions and growth factors to hypomethylating drugs and, for the fit, transplant."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05801237","name":"PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor","tldr":"A phase 1/2 trial of PE0116&PE0105 in advanced solid tumours, run by Shanghai HyaMab Biotech Co.,Ltd., now recruiting.","route":"/trials/nct05801237/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05801237","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"pelabresib","name":"Pelabresib","tldr":"Pelabresib is an experimental small-molecule drug from Novartis Pharmaceuticals in phase 3 trials, with its target not yet stated publicly.","route":"/drugs/pelabresib/","status":"phase-3","kind":"drug","molecule":"pelabresib","modality":"small molecule","sub":"CPI-0610","facets":{"kind":["Treatment"],"cancers":["Primary myelofibrosis"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Primary myelofibrosis","href":"/cancers/primary-myelofibrosis/","tip":"Primary myelofibrosis is a blood cancer in which the marrow scars over, the spleen swells and patients become anaemic and exhausted. JAK inhibitors, ruxolitinib first (COMFORT) and then fedratinib, pacritinib and momelotinib (MOMENTUM), shrink the spleen and relieve symptoms; only a donor stem cell transplant can cure it."}],"tags":[]},"sortKeys":{"year":0}},{"id":"peluntamig","name":"Peluntamig","tldr":"Peluntamig is an experimental bispecific antibody from Phanes Therapeutics in phase 2 trials for non-small-cell lung cancer and neuroendocrine tumours, aimed at CD47 and DLL3.","route":"/drugs/peluntamig/","status":"phase-2","kind":"drug","molecule":"peluntamig","modality":"bispecific antibody","sub":"PT217","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Neuroendocrine tumours","Extrapulmonary neuroendocrine carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Neuroendocrine tumours","href":"/cancers/neuroendocrine/","tip":"A family of usually slow-growing tumours that start in hormone-producing cells of the gut, pancreas and lungs. They pioneered the idea of using the same molecule to see a tumour on a scan and then to treat it with radiation."},{"label":"Extrapulmonary neuroendocrine carcinoma","href":"/cancers/extrapulmonary-nec/","tip":"Extrapulmonary neuroendocrine carcinoma is the fast-growing, poorly differentiated form of neuroendocrine cancer arising outside the lung, most often in the bowel, oesophagus, stomach or pancreas. It behaves like small-cell lung cancer and is treated the same way, with platinum and etoposide chemotherapy, and drugs against the DLL3 protein are now in phase 3 trials."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03260894","name":"Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)","tldr":"A phase 3 trial of Pembrolizumab, Epacadostat, Sunitinib and Pazopanib in Renal cell carcinoma, run by Incyte Corporation, completed.","route":"/trials/nct03260894/","status":"completed","kind":"trial","cancerIcon":"rcc","sub":"NCT03260894","facets":{"kind":["Trial"],"cancers":["Renal cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06788912","name":"Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)","tldr":"A phase 2 trial of Pembrolizumab, Cisplatin, Gemcitabine, Pemetrexed, Sacituzumab tirumotecan and Dexamethasone in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting.","route":"/trials/nct06788912/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06788912","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03358472","name":"Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)","tldr":"A phase 3 trial of Pembrolizumab, Epacadostat, Cetuximab, Cisplatin and Carboplatin in Head and neck squamous cell carcinoma, run by Incyte Corporation, completed.","route":"/trials/nct03358472/","status":"completed","kind":"trial","cancerIcon":"head-and-neck","sub":"NCT03358472","facets":{"kind":["Trial"],"cancers":["Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04976634","name":"Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)","tldr":"A phase 2 trial of Pembrolizumab, Belzutifan and Lenvatinib in advanced solid tumours, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","route":"/trials/nct04976634/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04976634","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02263508","name":"Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma","tldr":"A phase 3 trial of Talimogene laherparepvec and Pembrolizumab in Melanoma, run by Amgen, recorded as terminated on the registry.","route":"/trials/nct02263508/","kind":"trial","cancerIcon":"melanoma","sub":"NCT02263508","facets":{"kind":["Trial"],"cancers":["Melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05224141","name":"Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)","tldr":"A phase 3 trial of Pembrolizumab, Etoposide, Cisplatin, Atezolizumab and Carboplatin in small-cell lung cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","route":"/trials/nct05224141/","status":"active","kind":"trial","cancerIcon":"sclc","sub":"NCT05224141","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer","Extensive-stage small-cell lung cancer"],"year":["2025"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."},{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"year":{"facet":"year","value":"2025"},"tags":[]},"sortKeys":{"year":2025}},{"id":"nct02678572","name":"Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma","tldr":"A phase 3 trial of Percutaneous hepatic perfusion in Uveal melanoma, run by Delcath Systems Inc., completed.","route":"/trials/nct02678572/","status":"completed","kind":"trial","cancerIcon":"uveal-melanoma","sub":"NCT02678572","facets":{"kind":["Trial"],"cancers":["Uveal melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Uveal melanoma","href":"/cancers/uveal-melanoma/","tip":"A melanoma inside the eye that is biologically unrelated to skin melanoma: different mutations, no response to standard immunotherapy, and a tendency to spread to the liver years later. Tebentafusp is the first drug ever to extend survival in the metastatic disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06155383","name":"Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.","tldr":"A phase 2 trial of Capecitabine, Oxaliplatin, Disitamab vedotin and Toripalimab in gastric & gastro-oesophageal junction cancer, run by RemeGen Co., Ltd., now recruiting.","route":"/trials/nct06155383/","status":"recruiting","kind":"trial","cancerIcon":"gastric","sub":"NCT06155383","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer","HER2-positive gastric cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"HER2-positive gastric cancer","href":"/cancers/gastric-her2-positive/","tip":"HER2-positive gastric cancer overexpresses the HER2 growth receptor and is treated with trastuzumab added to chemotherapy, now usually with pembrolizumab as well. After progression the antibody-drug conjugate trastuzumab deruxtecan gives responses that plain chemotherapy cannot."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06960577","name":"Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)","tldr":"A phase 3 trial of Durvalumab, Methotrexate, Vinblastine, Doxorubicin, Cisplatin and Gemcitabine in bladder & urothelial cancer, run by AstraZeneca, now recruiting.","route":"/trials/nct06960577/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT06960577","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06631079","name":"Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors","tldr":"A phase 1/2 trial of NECVAX-NEO1 in advanced solid tumours, run by NEC Bio B.V, active and no longer recruiting.","route":"/trials/nct06631079/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06631079","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06631092","name":"Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer","tldr":"A phase 1/2 trial of Oral DNA Vaccine in triple-negative breast cancer, run by NEC Bio B.V, now recruiting.","route":"/trials/nct06631092/","status":"recruiting","kind":"trial","cancerIcon":"tnbc","sub":"NCT06631092","facets":{"kind":["Trial"],"cancers":["Triple-negative breast cancer","Early triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Early triple-negative breast cancer","href":"/cancers/tnbc-early/","tip":"Early triple-negative breast cancer is treated to cure. For tumours over 2 cm or with node involvement, chemotherapy plus the immunotherapy pembrolizumab before and after surgery has raised cure rates; BRCA carriers with cancer left at surgery add a year of olaparib, and others with residual cancer are offered capecitabine. Whether the tumour has vanished by surgery guides what comes next."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07121595","name":"Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial","tldr":"A phase 2 trial of Carboplatin, Cisplatin, Paclitaxel / nab-paclitaxel, Technetium-99m tilmanocept and Technetium Tc-99m sulfur colloid in Oral cavity cancer, run by University of Michigan Rogel Cancer Center, now recruiting.","route":"/trials/nct07121595/","status":"recruiting","kind":"trial","cancerIcon":"oral-cavity-cancer","sub":"NCT07121595","facets":{"kind":["Trial"],"cancers":["Oral cavity cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Oral cavity cancer","href":"/cancers/oral-cavity-cancer/","tip":"Cancer of the mouth and tongue, a head and neck cancer, is caused mainly by tobacco, alcohol and betel quid and is usually visible or feelable early, yet often diagnosed late. Surgery is the mainstay, with radiotherapy or chemoradiation after operation for higher-risk disease, and reconstruction to restore speech and swallowing."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07002203","name":"Personalized Neoantigen Peptide Vaccines for Solid Tumors","tldr":"A phase 1/2 trial of Personalized Neoantigen Peptide Vaccine in advanced solid tumours, run by Seqker Biosciences, Inc., now recruiting.","route":"/trials/nct07002203/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07002203","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06617481","name":"PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence","tldr":"A phase 2 trial of Flotufolastat F-18 in Prostate cancer, run by AdventHealth, now recruiting.","route":"/trials/nct06617481/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT06617481","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02814968","name":"PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide","tldr":"A phase 2 trial of Whole-body MRI in Prostate cancer, run by The European Uro-Oncology Group, completed.","route":"/trials/nct02814968/","status":"completed","kind":"trial","cancerIcon":"prostate","sub":"NCT02814968","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03268954","name":"Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)","tldr":"A phase 3 trial of Azacitidine and Pevonedistat in Leukaemia, run by Takeda, completed.","route":"/trials/nct03268954/","status":"completed","kind":"trial","cancerIcon":"leukaemia","sub":"NCT03268954","facets":{"kind":["Trial"],"cancers":["Leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Leukaemia","href":"/cancers/leukaemia/","tip":"Leukaemia means cancer of the blood-forming cells, but the four main types share little beyond the name: acute lymphoblastic and acute myeloid leukaemia are emergencies treated with intensive therapy, while chronic lymphocytic and chronic myeloid leukaemia are slow diseases controlled for years with pills. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"pf-07248144","name":"PF-07248144","tldr":"PF-07248144 is an experimental small-molecule drug from Pfizer in phase 3 trials for HR-positive / HER2-negative breast cancer, prostate cancer and non-small-cell lung cancer, with its target not yet stated publicly.","route":"/drugs/pf-07248144/","status":"phase-3","kind":"drug","molecule":"pf-07248144","modality":"small molecule","facets":{"kind":["Treatment"],"cancers":["HR-positive / HER2-negative breast cancer","Prostate cancer","Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"pf-08046054","name":"PF-08046054","tldr":"PF-08046054 is an experimental antibody-drug conjugate from Pfizer in phase 3 trials for non-small-cell lung cancer, aimed at PD-L1.","route":"/drugs/pf-08046054/","status":"phase-3","kind":"drug","molecule":"pf-08046054","modality":"ADC","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"pf-08634404","name":"PF-08634404","tldr":"PF-08634404 is an experimental investigational agent whose form is not stated in the registry from Pfizer in phase 3 trials for colorectal cancer, gastric & gastro-oesophageal junction cancer and oesophageal cancer, with its target not yet stated publicly.","route":"/drugs/pf-08634404/","status":"phase-3","kind":"drug","molecule":"pf-08634404","modality":"bispecific antibody (PD-1 x VEGF, per the sponsor's pipeline page; form not stated in the registry record)","sub":"SSGJ-707","facets":{"kind":["Treatment"],"cancers":["Colorectal cancer","Gastric & gastro-oesophageal junction cancer","Oesophageal cancer","Non-small-cell lung cancer","Bladder & urothelial cancer","Hepatocellular carcinoma","Renal cell carcinoma","Small-cell lung cancer","Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04910022","name":"Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma","tldr":"A phase 1/2 trial of Temozolomide in glioma & glioblastoma, run by Nerviano Medical Sciences, active and no longer recruiting.","route":"/trials/nct04910022/","status":"active","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT04910022","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05671822","name":"Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer","tldr":"A phase 2 trial of Trastuzumab rezetecan, Retlirafusp alfa, Capecitabine, Adebrelimab and Oxaliplatin in gastric & gastro-oesophageal junction cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.","route":"/trials/nct05671822/","status":"recruiting","kind":"trial","cancerIcon":"gastric","sub":"NCT05671822","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer","HER2-positive gastric cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"HER2-positive gastric cancer","href":"/cancers/gastric-her2-positive/","tip":"HER2-positive gastric cancer overexpresses the HER2 growth receptor and is treated with trastuzumab added to chemotherapy, now usually with pembrolizumab as well. After progression the antibody-drug conjugate trastuzumab deruxtecan gives responses that plain chemotherapy cannot."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04379596","name":"Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)","tldr":"A phase 2 trial of Fluorouracil (5-FU), Capecitabine, Durvalumab, Oxaliplatin, Trastuzumab and Trastuzumab deruxtecan in gastric & gastro-oesophageal junction cancer, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct04379596/","status":"active","kind":"trial","cancerIcon":"gastric","sub":"NCT04379596","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer","HER2-positive gastric cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"HER2-positive gastric cancer","href":"/cancers/gastric-her2-positive/","tip":"HER2-positive gastric cancer overexpresses the HER2 growth receptor and is treated with trastuzumab added to chemotherapy, now usually with pembrolizumab as well. After progression the antibody-drug conjugate trastuzumab deruxtecan gives responses that plain chemotherapy cannot."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01064466","name":"Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms","tldr":"A phase 2/3 trial of Etoposide in small-cell lung cancer, run by Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair, active and no longer recruiting.","route":"/trials/nct01064466/","status":"active","kind":"trial","cancerIcon":"sclc","sub":"NCT01064466","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07145333","name":"Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms","tldr":"A phase 2/3 trial of Topotecan in small-cell lung cancer, run by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, active and no longer recruiting.","route":"/trials/nct07145333/","status":"active","kind":"trial","cancerIcon":"sclc","sub":"NCT07145333","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03348670","name":"Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms","tldr":"A phase 2/3 trial of Abiraterone - Usual in prostate cancer, run by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, active and no longer recruiting.","route":"/trials/nct03348670/","status":"active","kind":"trial","cancerIcon":"prostate","sub":"NCT03348670","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05987956","name":"Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms","tldr":"A phase 2/3 trial of Alectinib in non-small-cell lung cancer, run by Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair, active and no longer recruiting.","route":"/trials/nct05987956/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT05987956","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02503423","name":"Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas","tldr":"A phase 1/2 trial of ASTX660 in non-Hodgkin lymphoma, run by Taiho Oncology, Inc., active and no longer recruiting.","route":"/trials/nct02503423/","status":"active","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT02503423","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07612280","name":"Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis","tldr":"A phase 1/2 trial of JBI-802 in myeloproliferative neoplasms and chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, run by Jubilant Therapeutics Inc., now recruiting.","route":"/trials/nct07612280/","status":"recruiting","kind":"trial","cancerIcon":"myeloproliferative-neoplasms","sub":"NCT07612280","facets":{"kind":["Trial"],"cancers":["Myeloproliferative neoplasms","Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Myeloproliferative neoplasms","href":"/cancers/myeloproliferative-neoplasms/","tip":"Myeloproliferative neoplasms are slow-growing blood cancers in which the marrow overproduces red cells (polycythaemia vera), platelets (essential thrombocythaemia) or scar tissue (myelofibrosis). Almost all carry a mutation in JAK2, CALR or MPL; treatment aims to prevent clots and control symptoms, and only transplant cures myelofibrosis."},{"label":"Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms","href":"/cancers/cmml/","tip":"Chronic myelomonocytic leukaemia and its relatives are bone-marrow cancers that behave partly like myelodysplasia (poorly made blood cells) and partly like a proliferative disease (an excess of monocytes or platelets). Hypomethylating agents produce responses in a minority and stabilise counts in more, transplant can cure the fit, and RAS-pathway and JAK inhibitors are in trials."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04115306","name":"Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer","tldr":"A phase 1/2 trial of Fulvestrant in advanced solid tumours, run by Phoenix Molecular Designs, active and no longer recruiting.","route":"/trials/nct04115306/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04115306","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06639256","name":"Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of Test Product HY07121 in advanced solid tumours, run by Sichuan Huiyu Pharmaceutical Co., Ltd, now recruiting.","route":"/trials/nct06639256/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06639256","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06139575","name":"Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer","tldr":"A phase 1/2 trial of Lutetium Lu 177 JH020002 Injection in prostate cancer, run by Bivision Pharmaceuticals, Inc., now recruiting.","route":"/trials/nct06139575/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT06139575","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07145255","name":"Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors","tldr":"A phase 1/2 trial of ADC in prostate cancer, colorectal cancer and pancreatic ductal adenocarcinoma, run by MBrace Therapeutics, now recruiting.","route":"/trials/nct07145255/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT07145255","facets":{"kind":["Trial"],"cancers":["Prostate cancer","Colorectal cancer","Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07529808","name":"Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma","tldr":"A phase 1/2 trial of BHB810 in gastric & gastro-oesophageal junction cancer, oesophageal cancer, colorectal cancer and pancreatic ductal adenocarcinoma, run by BigHat Biosciences, Inc., now recruiting.","route":"/trials/nct07529808/","status":"recruiting","kind":"trial","cancerIcon":"gastric","sub":"NCT07529808","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer","Oesophageal cancer","Colorectal cancer","Pancreatic ductal adenocarcinoma","Oesophageal and junctional adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05326243","name":"Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma","tldr":"A phase 1/2 trial of CD19-targeted chimeric antigen receptor T-cell in diffuse large B-cell lymphoma and follicular lymphoma, run by Pell Bio-Med Technology Co., Ltd., now recruiting.","route":"/trials/nct05326243/","status":"recruiting","kind":"trial","cancerIcon":"dlbcl","sub":"NCT05326243","facets":{"kind":["Trial"],"cancers":["Diffuse large B-cell lymphoma","Follicular lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."},{"label":"Follicular lymphoma","href":"/cancers/follicular-lymphoma/","tip":"Follicular lymphoma is the most common slow-growing lymphoma, defined in about 85% of cases by a BCL2 translocation. Most people live with it for decades, treated only when it causes problems; it can be controlled repeatedly with anti-CD20 antibodies, chemotherapy, bispecifics or CAR-T but rarely cured, and a small share transform into an aggressive lymphoma each year."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07589530","name":"Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors","tldr":"A phase 1/2 trial of EB-NK-301 and Fludarabine in advanced solid tumours, run by Beijing Biotech, now recruiting.","route":"/trials/nct07589530/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07589530","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06993844","name":"Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors","tldr":"A phase 1/2 trial of Fulvestrant in advanced solid tumours, run by Ensem Therapeutics, now recruiting.","route":"/trials/nct06993844/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06993844","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05367778","name":"Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors","tldr":"A phase 1/2 trial of HS-10370 in advanced solid tumours, run by Jiangsu Hansoh Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct05367778/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05367778","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05435248","name":"Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)","tldr":"A phase 1/2 trial of HS-10375 in non-small-cell lung cancer, run by Jiangsu Hansoh Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct05435248/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT05435248","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06243354","name":"Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation","tldr":"A phase 1/2 trial of Test product: HYP-2090PTSA in advanced solid tumours, run by Sichuan Huiyu Pharmaceutical Co., Ltd, now recruiting.","route":"/trials/nct06243354/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06243354","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06840119","name":"Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers","tldr":"A phase 1/2 trial of IMC-R117C in advanced solid tumours, run by Immunocore Ltd, now recruiting.","route":"/trials/nct06840119/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06840119","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06249048","name":"Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab","tldr":"A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by Strand Therapeutics Inc., now recruiting.","route":"/trials/nct06249048/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06249048","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07751042","name":"Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab","tldr":"A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by Strand Therapeutics Inc., now recruiting.","route":"/trials/nct07751042/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07751042","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06795412","name":"Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors","tldr":"A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by Pyxis Oncology, Inc, now recruiting.","route":"/trials/nct06795412/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06795412","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05204862","name":"Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of TU2218 in advanced solid tumours, run by TiumBio Co., Ltd., now recruiting.","route":"/trials/nct05204862/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05204862","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04150497","name":"Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)","tldr":"A phase 1/2 trial of UCART22 in acute lymphoblastic leukaemia, run by Cellectis S.A., now recruiting.","route":"/trials/nct04150497/","status":"recruiting","kind":"trial","cancerIcon":"all-leukemia","sub":"NCT04150497","facets":{"kind":["Trial"],"cancers":["Acute lymphoblastic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07605962","name":"Phase 1/2 Study of UI-102 in Selected Advanced Cancers","tldr":"A phase 1/2 trial of UI-102 in advanced solid tumours, run by United Immunity, co., Ltd., now recruiting.","route":"/trials/nct07605962/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07605962","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05573126","name":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer","tldr":"A phase 1/2 trial of EP0062, Elacestrant, Everolimus, Abemaciclib, Fulvestrant and Exemestane in HR-positive / HER2-negative breast cancer, run by Ellipses Pharma, now recruiting.","route":"/trials/nct05573126/","status":"recruiting","kind":"trial","cancerIcon":"breast-hr-positive","sub":"NCT05573126","facets":{"kind":["Trial"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07151040","name":"Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors","tldr":"A phase 1/2 trial of TH9619 in colorectal cancer, head and neck squamous cell carcinoma, non-small-cell lung cancer and gastric & gastro-oesophageal junction cancer, run by One-carbon Therapeutics AB, now recruiting.","route":"/trials/nct07151040/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT07151040","facets":{"kind":["Trial"],"cancers":["Colorectal cancer","Head and neck squamous cell carcinoma","Non-small-cell lung cancer","Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04643418","name":"Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of MPB-1734 in advanced solid tumours, run by MegaPro Biomedical Co. Ltd., now recruiting.","route":"/trials/nct04643418/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04643418","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07148128","name":"Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.","tldr":"A phase 1/2 trial of WEF-001 in pancreatic ductal adenocarcinoma, colorectal cancer and non-small-cell lung cancer, run by Auricula Biosciences Inc., now recruiting.","route":"/trials/nct07148128/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT07148128","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Colorectal cancer","Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07415863","name":"Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors","tldr":"A phase 1/2 trial of SYS6043 in advanced solid tumours, run by CSPC Megalith Biopharmaceutical Co.,Ltd., now recruiting.","route":"/trials/nct07415863/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07415863","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05532696","name":"Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients","tldr":"A phase 1/2 trial of ABT-101 in non-small-cell lung cancer, run by Anbogen Therapeutics, Inc., now recruiting.","route":"/trials/nct05532696/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT05532696","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","HER2-mutant non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"HER2-mutant non-small-cell lung cancer","href":"/cancers/her2-mutant-nsclc/","tip":"HER2-mutant lung cancer carries a mutation in the same receptor that drives HER2-positive breast cancer, but the breast cancer antibodies alone did little here. The antibody-drug conjugate trastuzumab deruxtecan shrinks about half of tumours after chemotherapy, and the pill zongertinib about seven in ten, and both are approved."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06938867","name":"Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant","tldr":"A phase 1/2 trial of SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coli in advanced solid tumours, run by SNIPR Biome Aps., now recruiting.","route":"/trials/nct06938867/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06938867","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07168226","name":"Phase 2 Cachexia Clinical Trial to Evaluate the Efficacy and Safety of ASCA101","tldr":"A phase 2 trial of Active Comparator in advanced solid tumours, run by MetaFines, now recruiting.","route":"/trials/nct07168226/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07168226","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05945823","name":"Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors","tldr":"A phase 2 trial of Futibatinib, Pembrolizumab, Cisplatin and Oxaliplatin in oesophageal cancer and pancreatic ductal adenocarcinoma, run by Taiho Oncology, Inc., active and no longer recruiting.","route":"/trials/nct05945823/","status":"active","kind":"trial","cancerIcon":"esophageal","sub":"NCT05945823","facets":{"kind":["Trial"],"cancers":["Oesophageal cancer","Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05363280","name":"Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment","tldr":"A phase 2 trial of AL8326 40 mg in small-cell lung cancer, renal cell carcinoma and non-small-cell lung cancer, run by Advenchen Pharmaceuticals, LLC., now recruiting.","route":"/trials/nct05363280/","status":"recruiting","kind":"trial","cancerIcon":"sclc","sub":"NCT05363280","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer","Renal cell carcinoma","Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."},{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07024706","name":"Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab","tldr":"A phase 2 trial of Acalabrutinib and Venetoclax in chronic lymphocytic leukaemia, run by AstraZeneca, now recruiting.","route":"/trials/nct07024706/","status":"recruiting","kind":"trial","cancerIcon":"cll","sub":"NCT07024706","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06567743","name":"Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC","tldr":"A phase 2 trial of Cretostimogene grenadenorepvec in bladder & urothelial cancer, run by CG Oncology, Inc., now recruiting.","route":"/trials/nct06567743/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT06567743","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Non-muscle-invasive bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Non-muscle-invasive bladder cancer","href":"/cancers/non-muscle-invasive-bladder-cancer/","tip":"Most bladder cancers are found while still confined to the lining. They are scraped out through the urethra and, when higher risk, treated with BCG instilled into the bladder; the challenge is the frequent recurrences and the patients whose tumours stop responding to BCG."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00186628","name":"Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD","tldr":"A phase 2 trial of Rituximab, Filgrastim and Granisetron in Leukaemia and Mantle cell lymphoma, run by Stanford University, completed.","route":"/trials/nct00186628/","status":"completed","kind":"trial","cancerIcon":"leukaemia","sub":"NCT00186628","facets":{"kind":["Trial"],"cancers":["Leukaemia","Mantle cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Leukaemia","href":"/cancers/leukaemia/","tip":"Leukaemia means cancer of the blood-forming cells, but the four main types share little beyond the name: acute lymphoblastic and acute myeloid leukaemia are emergencies treated with intensive therapy, while chronic lymphocytic and chronic myeloid leukaemia are slow diseases controlled for years with pills. Each has its own page."},{"label":"Mantle cell lymphoma","href":"/cancers/mantle-cell-lymphoma/","tip":"An uncommon B-cell lymphoma driven by cyclin D1 that used to behave badly in almost everyone. BTK inhibitors, CAR-T and now BCL2 drugs have changed it from chemotherapy-plus-transplant to targeted combinations."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07106762","name":"Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy","tldr":"A phase 2/3 trial of Cisplatin, Gemcitabine and Carboplatin in bladder & urothelial cancer, run by Bristol-Myers Squibb, now recruiting.","route":"/trials/nct07106762/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT07106762","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05864534","name":"Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma","tldr":"A phase 2 trial of Transcranial focused ultrasound systems in Glioma & glioblastoma, run by Northwestern University, now recruiting.","route":"/trials/nct05864534/","status":"recruiting","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT05864534","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06777433","name":"Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases","tldr":"A phase 2 trial of RAD101 (18F-FPIA) in brain and spinal cord tumours, run by Radiopharm Theranostics, Ltd, active and no longer recruiting.","route":"/trials/nct06777433/","status":"active","kind":"trial","cancerIcon":"brain-tumours","sub":"NCT06777433","facets":{"kind":["Trial"],"cancers":["Brain and spinal cord tumours","Brain metastases"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Brain and spinal cord tumours","href":"/cancers/brain-tumours/","tip":"Brain and spinal cord tumours range from slow-growing meningiomas and low-grade gliomas to glioblastoma, the commonest malignant brain tumour in adults, and a distinct set of childhood tumours such as medulloblastoma and diffuse midline glioma. Molecular markers now define them, and treatment is surgery, radiotherapy and, for some, drugs chosen by those markers."},{"label":"Brain metastases","href":"/cancers/secondary-brain-tumours/","tip":"Brain metastases are cancers that have spread to the brain from elsewhere, most often from the lung, breast or skin. Focused radiation aimed at each spot (radiosurgery) has largely replaced radiation to the whole brain, and for some cancers modern targeted drugs and immunotherapy reach the brain well enough to shrink the deposits on their own."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06757634","name":"Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)","tldr":"A phase 3 trial of Fulvestrant, Gedatolisib, Palbociclib and Ribociclib in HR-positive / HER2-negative breast cancer, run by Celcuity Inc, now recruiting.","route":"/trials/nct06757634/","status":"recruiting","kind":"trial","cancerIcon":"breast-hr-positive","sub":"NCT06757634","facets":{"kind":["Trial"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06467357","name":"Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer","tldr":"A phase 3 trial of Gemcitabine, Cisplatin, Durvalumab, Trastuzumab deruxtecan and Rilvegostomig in biliary tract cancer, run by AstraZeneca, now recruiting.","route":"/trials/nct06467357/","status":"recruiting","kind":"trial","cancerIcon":"cholangiocarcinoma","sub":"NCT06467357","facets":{"kind":["Trial"],"cancers":["Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07197580","name":"Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC","tldr":"A phase 3 trial of 177Lu-TLX250 in renal cell carcinoma, run by Telix Pharmaceuticals (Innovations) Pty Limited, now recruiting.","route":"/trials/nct07197580/","status":"recruiting","kind":"trial","cancerIcon":"rcc","sub":"NCT07197580","facets":{"kind":["Trial"],"cancers":["Renal cell carcinoma","Clear cell renal cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."},{"label":"Clear cell renal cell carcinoma","href":"/cancers/clear-cell-rcc/","tip":"Clear cell is the common kidney cancer, driven by loss of the VHL gene that leaves the tumour behaving as if starved of oxygen and flooding itself with blood vessels. That biology explains why anti-angiogenic drugs, immunotherapy and the HIF-2 alpha blocker belzutifan all work."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06118788","name":"Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","tldr":"A phase 1/2 trial of BG1805 in acute myeloid leukaemia, run by Guangzhou Bio-gene Technology Co., Ltd, now recruiting.","route":"/trials/nct06118788/","status":"recruiting","kind":"trial","cancerIcon":"aml","sub":"NCT06118788","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06105021","name":"Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor","tldr":"A phase 1/2 trial of AFNT-211 in pancreatic ductal adenocarcinoma, non-small-cell lung cancer and colorectal cancer, run by Affini-T Therapeutics, Inc., active and no longer recruiting.","route":"/trials/nct06105021/","status":"active","kind":"trial","cancerIcon":"pancreatic","sub":"NCT06105021","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Non-small-cell lung cancer","Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07008703","name":"Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain","tldr":"A phase 1/2 trial of Injection of humanized nerve growth factor (NGF) antibody in advanced solid tumours, run by Shenyang Sunshine Pharmaceutical Co., LTD., now recruiting.","route":"/trials/nct07008703/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07008703","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05700084","name":"Phase I-II Clinical Trial of Utidelone Capsule in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of Capecitabine in advanced solid tumours, run by Beijing Biostar Pharmaceuticals Co., Ltd., active and no longer recruiting.","route":"/trials/nct05700084/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05700084","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06735144","name":"Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors","tldr":"A phase 1/2 trial of FH-006 in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.","route":"/trials/nct06735144/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06735144","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06144671","name":"Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors","tldr":"A phase 1/2 trial of GT201 in advanced solid tumours, run by Grit Biotechnology, now recruiting.","route":"/trials/nct06144671/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06144671","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07280832","name":"Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors","tldr":"A phase 1/2 trial of JMT108 in melanoma, run by Shanghai JMT-Bio Inc., now recruiting.","route":"/trials/nct07280832/","status":"recruiting","kind":"trial","cancerIcon":"melanoma","sub":"NCT07280832","facets":{"kind":["Trial"],"cancers":["Melanoma","Advanced melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"label":"Advanced melanoma","href":"/cancers/advanced-melanoma/","tip":"Advanced melanoma has spread beyond what surgery can remove, and it is the cancer in which immunotherapy first proved it could cure some people: about half of those given nivolumab with ipilimumab are alive ten years later. If immunotherapy fails, options include a cell therapy grown from the patient's own immune cells, a virus injected into the tumour, and targeted pills for BRAF-mutant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07073534","name":"Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors","tldr":"A phase 1/2 trial of Adebrelimab and SHR-1501 in advanced solid tumours, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07073534/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07073534","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06088004","name":"Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors","tldr":"A phase 1/2 trial of Toripalimab in advanced solid tumours, run by Suzhou Abogen Biosciences Co., Ltd., now recruiting.","route":"/trials/nct06088004/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06088004","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06819215","name":"Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of VB15010 in ovarian cancer, prostate cancer, pancreatic ductal adenocarcinoma, biliary tract cancer and colorectal cancer, run by Zhejiang Yangli Pharmaceutical Technology Co., Ltd., now recruiting.","route":"/trials/nct06819215/","status":"recruiting","kind":"trial","cancerIcon":"ovarian","sub":"NCT06819215","facets":{"kind":["Trial"],"cancers":["Ovarian cancer","Prostate cancer","Pancreatic ductal adenocarcinoma","Biliary tract cancer","Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05990452","name":"Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of 9MW2921 in advanced solid tumours, run by Mabwell (Shanghai) Bioscience Co., Ltd., active and no longer recruiting.","route":"/trials/nct05990452/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05990452","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06212076","name":"Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients","tldr":"A phase 1/2 trial of IPG1094 in advanced solid tumours, run by Nanjing Immunophage Biotech Co., Ltd, now recruiting.","route":"/trials/nct06212076/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06212076","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07050641","name":"Phase I/II Study of SCTB39-1 in Advanced Solid Tumours","tldr":"A phase 1/2 trial of SCTB39-1 in advanced solid tumours, run by Sinocelltech Ltd., now recruiting.","route":"/trials/nct07050641/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07050641","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06730009","name":"Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients","tldr":"A phase 1/2 trial of SLOG + Allogeneic NK cell in pancreatic ductal adenocarcinoma and biliary tract cancer, run by Medigen Biotechnology Corporation, now recruiting.","route":"/trials/nct06730009/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT06730009","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07235176","name":"Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients","tldr":"A phase 1/2 trial of Fulvestrant in advanced solid tumours, run by Qilu Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07235176/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07235176","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05720130","name":"Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).","tldr":"A phase 1/2 trial of [²¹²Pb]Pb-ADVC001 (Phase 1b) in prostate cancer, run by AdvanCell Pty Limited, now recruiting.","route":"/trials/nct05720130/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT05720130","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06413745","name":"Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer","tldr":"A phase 2 trial of Trastuzumab rezetecan in biliary tract cancer, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.","route":"/trials/nct06413745/","status":"active","kind":"trial","cancerIcon":"cholangiocarcinoma","sub":"NCT06413745","facets":{"kind":["Trial"],"cancers":["Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04586478","name":"Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma","tldr":"A phase 2 trial of single dose of CNCT19 in non-Hodgkin lymphoma, run by Juventas Cell Therapy Ltd., now recruiting.","route":"/trials/nct04586478/","status":"recruiting","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT04586478","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00539591","name":"Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma","tldr":"A phase 2 trial of Peginterferon alfa-2b and Temozolomide in Melanoma, run by St. Jude Children's Research Hospital, active and no longer recruiting.","route":"/trials/nct00539591/","status":"active","kind":"trial","cancerIcon":"melanoma","sub":"NCT00539591","facets":{"kind":["Trial"],"cancers":["Melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06075264","name":"Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)","tldr":"A phase 2 trial of Artesunate ointment in vulvar cancer, run by Frantz Viral Therapeutics, LLC, now recruiting.","route":"/trials/nct06075264/","status":"recruiting","kind":"trial","cancerIcon":"vulvar","sub":"NCT06075264","facets":{"kind":["Trial"],"cancers":["Vulvar cancer","HPV-associated vulvar squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Vulvar cancer","href":"/cancers/vulvar/","tip":"An uncommon cancer of the external genitalia with two distinct causes: HPV infection in younger women and chronic skin inflammation in older women. Surgery is the mainstay, and sentinel-node biopsy has made it far less mutilating."},{"label":"HPV-associated vulvar squamous cell carcinoma","href":"/cancers/hpv-associated-vulvar-cancer/","tip":"HPV-associated vulvar cancer is the type of vulvar squamous cell cancer caused by persistent HPV infection, growing out of the precancer called usual-type VIN and marked by the p16 protein. It tends to affect younger women, responds better to radiotherapy and recurs less often than the HPV-independent type, and it is preventable by HPV vaccination."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00004688","name":"Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms","tldr":"A phase 2 trial of Carmustine, Mercaptopurine and Streptozocin in Oligodendroglioma, IDH-mutant and 1p/19q-codeleted and Glioma & glioblastoma, run by Emory University, completed.","route":"/trials/nct00004688/","status":"completed","kind":"trial","cancerIcon":"oligodendroglioma","sub":"NCT00004688","facets":{"kind":["Trial"],"cancers":["Oligodendroglioma, IDH-mutant and 1p/19q-codeleted","Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Oligodendroglioma, IDH-mutant and 1p/19q-codeleted","href":"/cancers/oligodendroglioma/","tip":"Oligodendroglioma is the adult brain tumour most responsive to chemotherapy. It is recognised by an IDH mutation together with loss of parts of chromosomes 1 and 19, and after surgery it is treated with radiotherapy plus the PCV drug combination, or, for small grade 2 tumours, with vorasidenib or watchful waiting."},{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07572396","name":"Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities","tldr":"A phase 2 trial of EGCG and Quinine Sulfate Vaginal Suppository in vaginal cancer, run by Amplexd Therapeutics, Inc., now recruiting.","route":"/trials/nct07572396/","status":"recruiting","kind":"trial","cancerIcon":"vaginal","sub":"NCT07572396","facets":{"kind":["Trial"],"cancers":["Vaginal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Vaginal cancer","href":"/cancers/vaginal/","tip":"Primary vaginal cancer is rare and mostly caused by HPV, the virus behind cervical cancer. It is treated like cervical cancer, with weekly cisplatin alongside external and internal radiotherapy, which controls most tumours while preserving the organ; HPV vaccination and cervical screening, which also detects vaginal precursors, are steadily reducing it."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07314294","name":"Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients","tldr":"A phase 2 trial of EMB-01 1600 mg administered once weekly throughout the study in colorectal cancer, run by Shanghai EpimAb Biotherapeutics Co., Ltd., now recruiting.","route":"/trials/nct07314294/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT07314294","facets":{"kind":["Trial"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00582075","name":"Phase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases","tldr":"A phase 2 trial of Gamma Knife in Brain metastases, run by University of Alabama at Birmingham, completed.","route":"/trials/nct00582075/","status":"completed","kind":"trial","cancerIcon":"secondary-brain-tumours","sub":"NCT00582075","facets":{"kind":["Trial"],"cancers":["Brain metastases"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Brain metastases","href":"/cancers/secondary-brain-tumours/","tip":"Brain metastases are cancers that have spread to the brain from elsewhere, most often from the lung, breast or skin. Focused radiation aimed at each spot (radiosurgery) has largely replaced radiation to the whole brain, and for some cancers modern targeted drugs and immunotherapy reach the brain well enough to shrink the deposits on their own."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01772420","name":"Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia","tldr":"A phase 2 trial of Eltrombopag and Lenalidomide in Leukaemia, run by Albert Einstein College of Medicine, completed.","route":"/trials/nct01772420/","status":"completed","kind":"trial","cancerIcon":"leukaemia","sub":"NCT01772420","facets":{"kind":["Trial"],"cancers":["Leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Leukaemia","href":"/cancers/leukaemia/","tip":"Leukaemia means cancer of the blood-forming cells, but the four main types share little beyond the name: acute lymphoblastic and acute myeloid leukaemia are emergencies treated with intensive therapy, while chronic lymphocytic and chronic myeloid leukaemia are slow diseases controlled for years with pills. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07387081","name":"Phase II Study of LM-24C5","tldr":"A phase 2 trial of LM-24C5 in advanced solid tumours, run by LaNova Medicines Limited, now recruiting.","route":"/trials/nct07387081/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07387081","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00742027","name":"Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma","tldr":"A phase 2 trial of Panobinostat in Hodgkin lymphoma, run by Novartis Pharmaceuticals, completed.","route":"/trials/nct00742027/","status":"completed","kind":"trial","cancerIcon":"hodgkin-lymphoma","sub":"NCT00742027","facets":{"kind":["Trial"],"cancers":["Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hodgkin lymphoma","href":"/cancers/hodgkin-lymphoma/","tip":"Hodgkin lymphoma is one of the most curable cancers, where the goal is now to cure with less toxicity, using brentuximab and, from 2026, first-line nivolumab."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07724756","name":"Phase II Study of QLC2519 in Pediatric Solid Tumor Participants","tldr":"A phase 2 trial of Albipagrastim alf in childhood cancers, run by Qilu Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07724756/","status":"recruiting","kind":"trial","cancerIcon":"childhood-cancers","sub":"NCT07724756","facets":{"kind":["Trial"],"cancers":["Childhood cancers"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Childhood cancers","href":"/cancers/childhood-cancers/","tip":"Cancer in children is rare and different from adult cancer: the common types are leukaemias, brain tumours, lymphomas and embryonal tumours such as neuroblastoma and Wilms tumour, most are curable in well-resourced health systems, and the great challenge is bringing the same cures to the majority of children who live where they are not available."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00563836","name":"Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer","tldr":"A phase 2 trial of Catumaxomab in Ovarian cancer, run by Neovii Biotech, completed.","route":"/trials/nct00563836/","status":"completed","kind":"trial","cancerIcon":"ovarian","sub":"NCT00563836","facets":{"kind":["Trial"],"cancers":["Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02485652","name":"Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung","tldr":"A phase 2 trial of Olmutinib in Non-small-cell lung cancer, run by Hanmi Pharmaceutical Company Limited, recorded as terminated on the registry.","route":"/trials/nct02485652/","kind":"trial","cancerIcon":"nsclc","sub":"NCT02485652","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00299689","name":"Phase II Trial of Ontak With Metastatic Melanoma","tldr":"A phase 2 trial of Denileukin diftitox in Melanoma, run by James Graham Brown Cancer Center, completed.","route":"/trials/nct00299689/","status":"completed","kind":"trial","cancerIcon":"melanoma","sub":"NCT00299689","facets":{"kind":["Trial"],"cancers":["Melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02444819","name":"Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy","tldr":"A phase 2 trial of Olmutinib in Non-small-cell lung cancer, run by Hanmi Pharmaceutical Company Limited, completed.","route":"/trials/nct02444819/","status":"completed","kind":"trial","cancerIcon":"nsclc","sub":"NCT02444819","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07106892","name":"Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer","tldr":"A phase 2 trial of HLX43 Dose 1; in colorectal cancer, run by Shanghai Henlius Biotech, now recruiting.","route":"/trials/nct07106892/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT07106892","facets":{"kind":["Trial"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07290088","name":"Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor Patients","tldr":"A phase 2/3 trial of PRL3-ZUMAB in advanced solid tumours, run by Intra-IMMUSG Pte Ltd, now recruiting.","route":"/trials/nct07290088/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07290088","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07232290","name":"Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera","tldr":"A phase 2 trial of Flonoltinib 75mg in myeloproliferative neoplasms, run by Chengdu Zenitar Biomedical Technology Co., Ltd, now recruiting.","route":"/trials/nct07232290/","status":"recruiting","kind":"trial","cancerIcon":"myeloproliferative-neoplasms","sub":"NCT07232290","facets":{"kind":["Trial"],"cancers":["Myeloproliferative neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Myeloproliferative neoplasms","href":"/cancers/myeloproliferative-neoplasms/","tip":"Myeloproliferative neoplasms are slow-growing blood cancers in which the marrow overproduces red cells (polycythaemia vera), platelets (essential thrombocythaemia) or scar tissue (myelofibrosis). Almost all carry a mutation in JAK2, CALR or MPL; treatment aims to prevent clots and control symptoms, and only transplant cures myelofibrosis."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02453282","name":"Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)","tldr":"A phase 3 trial of Durvalumab, Tremelimumab, Carboplatin, Gemcitabine + cisplatin, Gemcitabine and Cisplatin in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct02453282/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT02453282","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":["2019"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"year":{"facet":"year","value":"2019"},"tags":[]},"sortKeys":{"year":2019}},{"id":"nct06123754","name":"Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC","tldr":"A phase 3 trial of Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection in non-small-cell lung cancer, run by 3D Medicines (Sichuan) Co., Ltd., now recruiting.","route":"/trials/nct06123754/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06123754","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05687266","name":"Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations","tldr":"A phase 3 trial of Datopotamab deruxtecan, Durvalumab, Carboplatin, Pembrolizumab, Cisplatin and Pemetrexed in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct05687266/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT05687266","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06632912","name":"Phase IIIb Clinical Trial of Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) for Age/Immunization Schedule Bridging","tldr":"A phase 3 trial of 2 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in advanced solid tumours, run by National Vaccine and Serum Institute, China, active and no longer recruiting.","route":"/trials/nct06632912/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06632912","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05827081","name":"Phase IIIb Study of Ribociclib + ET in Early Breast Cancer","tldr":"A phase 3 trial of Ribociclib and Exemestane in advanced solid tumours, run by Novartis Pharmaceuticals, now recruiting.","route":"/trials/nct05827081/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05827081","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00248287","name":"PhII ICb With/Without Erbitux in MBC Pts","tldr":"A phase 2 trial of Carboplatin and Cetuximab in advanced solid tumours, run by US Oncology Research, active and no longer recruiting.","route":"/trials/nct00248287/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT00248287","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":["2016"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"year":{"facet":"year","value":"2016"},"tags":[]},"sortKeys":{"year":2016}},{"id":"nct07619898","name":"PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure","tldr":"A phase 2 trial of Methoxsalen in Skin cancer and Melanoma, run by Therakos LLC, not yet recruiting.","route":"/trials/nct07619898/","status":"planned","kind":"trial","cancerIcon":"skin-cancer","sub":"NCT07619898","facets":{"kind":["Trial"],"cancers":["Skin cancer","Melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Skin cancer","href":"/cancers/skin-cancer/","tip":"Skin cancer covers the very common and rarely dangerous basal cell and squamous cell carcinomas, the less common but more serious melanoma, and rarer tumours such as Merkel cell carcinoma and Kaposi sarcoma. Almost all of it is caused by ultraviolet light and most of it is found and cured by simple surgery."},{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06807359","name":"Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System","tldr":"A phase 1/2 trial of Photodynamic Therapy (PDT) in prostate cancer, run by SpectraCure AB, now recruiting.","route":"/trials/nct06807359/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT06807359","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06519266","name":"PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases","tldr":"A phase 3 trial of Percutaneous hepatic perfusion in Uveal melanoma, run by Vastra Gotaland Region, now recruiting.","route":"/trials/nct06519266/","status":"recruiting","kind":"trial","cancerIcon":"uveal-melanoma","sub":"NCT06519266","facets":{"kind":["Trial"],"cancers":["Uveal melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Uveal melanoma","href":"/cancers/uveal-melanoma/","tip":"A melanoma inside the eye that is biologically unrelated to skin melanoma: different mutations, no response to standard immunotherapy, and a tendency to spread to the liver years later. Tebentafusp is the first drug ever to extend survival in the metastatic disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06731894","name":"Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors","tldr":"A phase 2 trial of Dronabinol in Breast cancer, run by City of Hope Medical Center, now recruiting.","route":"/trials/nct06731894/","status":"recruiting","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT06731894","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00003139","name":"Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer","tldr":"A phase 3 trial of Pilocarpine in Head and neck squamous cell carcinoma, run by Radiation Therapy Oncology Group, completed.","route":"/trials/nct00003139/","status":"completed","kind":"trial","cancerIcon":"head-and-neck","sub":"NCT00003139","facets":{"kind":["Trial"],"cancers":["Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00343382","name":"Pilocarpine in Treating Vaginal Dryness in Patients With Breast Cancer","tldr":"A phase 3 trial of Pilocarpine in Breast cancer, run by Alliance for Clinical Trials in Oncology, completed.","route":"/trials/nct00343382/","status":"completed","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT00343382","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00626444","name":"Pilot Trial of Intravenous Vitamin C in Refractory Non-Hodgkin Lymphoma (NHL)","tldr":"A phase 2 trial of High-dose intravenous vitamin C in Non-Hodgkin lymphoma, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, recorded as terminated on the registry.","route":"/trials/nct00626444/","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT00626444","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"pimicotinib","name":"Pimicotinib","tldr":"Pimicotinib is an oral kinase inhibitor from Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, in registered phase 2 trials for tenosynovial giant cell tumour.","route":"/drugs/pimicotinib/","status":"phase-2","kind":"drug","molecule":"pimicotinib","modality":"Oral kinase inhibitor","facets":{"kind":["Treatment"],"cancers":["Tenosynovial giant cell tumour"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Tenosynovial giant cell tumour","href":"/cancers/tenosynovial-giant-cell-tumour/","tip":"TGCT is a benign but destructive tumour of the joint lining, classed with soft-tissue sarcomas, in which a few cells carrying a CSF1 gene fusion recruit a crowd of normal immune cells that eat away at the joint. Surgery cures most localised cases, and for diffuse or recurrent disease two pills that block the CSF1 receptor, pexidartinib and vimseltinib, shrink tumours and restore joint function."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"pirarubicin","name":"Pirarubicin","tldr":"Pirarubicin is a doxorubicin relative developed in Japan and used there and in China for breast cancer, lymphoma, bladder cancer and other tumours, including instillation into the bladder after tumour resection.","route":"/drugs/pirarubicin/","status":"established","kind":"drug","molecule":"pirarubicin","modality":"Anthracycline (topoisomerase II inhibitor), intravenous or intravesical","facets":{"kind":["Treatment"],"cancers":["Bladder & urothelial cancer","HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01086605","name":"Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer","tldr":"A phase 2 trial of Pixantrone in Breast cancer, run by Alliance for Clinical Trials in Oncology, completed.","route":"/trials/nct01086605/","status":"completed","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT01086605","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04928222","name":"Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)","tldr":"A phase 1/2 trial of Doxorubicin in basal cell carcinoma, run by SkinJect, Inc., active and no longer recruiting.","route":"/trials/nct04928222/","status":"active","kind":"trial","cancerIcon":"basal-cell-carcinoma","sub":"NCT04928222","facets":{"kind":["Trial"],"cancers":["Basal cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Basal cell carcinoma","href":"/cancers/basal-cell-carcinoma/","tip":"Basal cell carcinoma is a skin cancer and the most common cancer of all, caused by sun exposure and almost never life-threatening. Nearly all are removed surgically; the rare advanced cases are treated with drugs that block the hedgehog signalling pathway, and with immunotherapy if those fail."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02872103","name":"Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy","tldr":"A phase 3 trial of Efbemalenograstim alfa in Breast cancer, run by EVIVE Biotechnology, completed.","route":"/trials/nct02872103/","status":"completed","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT02872103","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04165590","name":"Plasmodium Immunotherapy for Advanced Malignant Solid Tumors","tldr":"A phase 1/2 trial of an investigational treatment in advanced solid tumours, run by CAS Lamvac Biotech Co., Ltd., now recruiting.","route":"/trials/nct04165590/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04165590","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"pm8002","name":"PM8002","tldr":"PM8002 is an experimental bispecific antibody from Biotheus in phase 3 trials for small-cell lung cancer, triple-negative breast cancer and neuroendocrine tumours, aimed at PD-L1 and VEGF / VEGFR.","route":"/drugs/pm8002/","status":"phase-3","kind":"drug","molecule":"pm8002","modality":"bispecific antibody","sub":"BNT327","facets":{"kind":["Treatment"],"cancers":["Small-cell lung cancer","Triple-negative breast cancer","Neuroendocrine tumours","Colorectal cancer","Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."},{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Neuroendocrine tumours","href":"/cancers/neuroendocrine/","tip":"A family of usually slow-growing tumours that start in hormone-producing cells of the gut, pancreas and lungs. They pioneered the idea of using the same molecule to see a tumour on a scan and then to treat it with radiation."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05918445","name":"PM8002 in the Treatment of Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of PM8002 in advanced solid tumours, run by Biotheus Inc., now recruiting.","route":"/trials/nct05918445/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05918445","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06752811","name":"Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer","tldr":"A phase 3 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by Shanghai Yizhong Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct06752811/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT06752811","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ponsegromab","name":"Ponsegromab","tldr":"Ponsegromab is a monoclonal antibody from Pfizer, in registered phase 3 trials for pancreatic ductal adenocarcinoma.","route":"/drugs/ponsegromab/","status":"phase-3","kind":"drug","molecule":"ponsegromab","modality":"Monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct06056830","name":"Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy","tldr":"A phase 3 trial of 64Cu-SAR-bisPSMA in prostate cancer, run by Clarity Pharmaceuticals Ltd, now recruiting.","route":"/trials/nct06056830/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT06056830","facets":{"kind":["Trial"],"cancers":["Prostate cancer","Localised prostate cancer, high and very high risk"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Localised prostate cancer, high and very high risk","href":"/cancers/prostate-high-risk/","tip":"High-risk prostate cancer has Grade Group 4 or 5 disease, a PSA above 20 or a tumour growing beyond the gland. It is still curable, but needs radiotherapy with two to three years of hormone therapy, or surgery followed by radiotherapy, and adding abiraterone to hormone therapy now lengthens life in the highest-risk men."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04365374","name":"Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)","tldr":"A phase 3 trial of Gamma Tile-Surgically Targeted Radiation Therapy (STaRT) in brain and spinal cord tumours, run by GT Medical Technologies, Inc., active and no longer recruiting.","route":"/trials/nct04365374/","status":"active","kind":"trial","cancerIcon":"brain-tumours","sub":"NCT04365374","facets":{"kind":["Trial"],"cancers":["Brain and spinal cord tumours"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Brain and spinal cord tumours","href":"/cancers/brain-tumours/","tip":"Brain and spinal cord tumours range from slow-growing meningiomas and low-grade gliomas to glioblastoma, the commonest malignant brain tumour in adults, and a distinct set of childhood tumours such as medulloblastoma and diffuse midline glioma. Molecular markers now define them, and treatment is surgery, radiotherapy and, for some, drugs chosen by those markers."}],"tags":[]},"sortKeys":{"year":0}},{"id":"precemtabart-tocentecan","name":"Precemtabart tocentecan","tldr":"Precemtabart tocentecan is an experimental antibody-drug conjugate from EMD Serono Research & Development Institute in phase 3 trials for colorectal cancer, aimed at CEACAM5.","route":"/drugs/precemtabart-tocentecan/","status":"phase-3","kind":"drug","molecule":"precemtabart-tocentecan","modality":"ADC","facets":{"kind":["Treatment"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06227065","name":"Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived Organoids","tldr":"A phase 2 trial of Patient-derived organoids in Non-muscle-invasive bladder cancer, run by Hospital Centre Biel/Bienne, not yet recruiting.","route":"/trials/nct06227065/","status":"planned","kind":"trial","cancerIcon":"non-muscle-invasive-bladder-cancer","sub":"NCT06227065","facets":{"kind":["Trial"],"cancers":["Non-muscle-invasive bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-muscle-invasive bladder cancer","href":"/cancers/non-muscle-invasive-bladder-cancer/","tip":"Most bladder cancers are found while still confined to the lining. They are scraped out through the urethra and, when higher risk, treated with BCG instilled into the bladder; the challenge is the frequent recurrences and the patients whose tumours stop responding to BCG."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05316701","name":"Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies","tldr":"A phase 3 trial of Orca-T in acute myeloid leukaemia and myelodysplastic syndromes / neoplasms, run by Orca Biosystems, Inc., active and no longer recruiting.","route":"/trials/nct05316701/","status":"active","kind":"trial","cancerIcon":"aml","sub":"NCT05316701","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia","Myelodysplastic syndromes / neoplasms"],"year":["2025"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Myelodysplastic syndromes / neoplasms","href":"/cancers/mds/","tip":"Bone-marrow disorders where blood cells are made badly and too few reach the blood; a third progress to acute leukaemia. Treatment ranges from transfusions and growth factors to hypomethylating drugs and, for the fit, transplant."}],"year":{"facet":"year","value":"2025"},"tags":[]},"sortKeys":{"year":2025}},{"id":"nct05663866","name":"Premedication to Reduce Amivantamab Associated Infusion Related Reactions","tldr":"A phase 2 trial of Dexamethasone, Methotrexate, Amivantamab and Lazertinib in non-small-cell lung cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.","route":"/trials/nct05663866/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT05663866","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","EGFR-mutated non-small-cell lung cancer"],"year":["2025"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"year":{"facet":"year","value":"2025"},"tags":[]},"sortKeys":{"year":2025}},{"id":"nct04801511","name":"Preoperative IMRT With Concurrent High-dose Vitamin C and mFOLFOX6 in Locally Advanced Rectal Cancer","tldr":"A phase 2 trial of High-dose intravenous vitamin C in Rectal cancer, run by Zhou Fuxiang, with a status the registry has not verified recently.","route":"/trials/nct04801511/","kind":"trial","cancerIcon":"rectal-cancer","sub":"NCT04801511","facets":{"kind":["Trial"],"cancers":["Rectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Rectal cancer","href":"/cancers/rectal-cancer/","tip":"Rectal cancer is bowel cancer in the last part of the large intestine, where surgery can mean a permanent stoma. Treatment now usually gives all the chemotherapy and radiotherapy first, and about half of people whose tumour disappears completely can keep their rectum and avoid surgery altogether."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06220032","name":"Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma","tldr":"A phase 3 trial of Dexrazoxane, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Lenalidomide and Pegfilgrastim in Diffuse large B-cell lymphoma, run by Stichting Hemato-Oncologie voor Volwassenen Nederland, now recruiting.","route":"/trials/nct06220032/","status":"recruiting","kind":"trial","cancerIcon":"dlbcl","sub":"NCT06220032","facets":{"kind":["Trial"],"cancers":["Diffuse large B-cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03172299","name":"Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated with Proton Therapy for a Large Choroidal Melanoma","tldr":"A phase 3 trial of Ziv-aflibercept in Uveal melanoma, run by Centre Hospitalier Universitaire de Nice, completed.","route":"/trials/nct03172299/","status":"completed","kind":"trial","cancerIcon":"uveal-melanoma","sub":"NCT03172299","facets":{"kind":["Trial"],"cancers":["Uveal melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Uveal melanoma","href":"/cancers/uveal-melanoma/","tip":"A melanoma inside the eye that is biologically unrelated to skin melanoma: different mutations, no response to standard immunotherapy, and a tendency to spread to the liver years later. Tebentafusp is the first drug ever to extend survival in the metastatic disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00515762","name":"Prevention of Persistent Alopecia Following Docetaxel by Means of Scalp Cooling","tldr":"A phase 2 trial of Scalp cooling in Breast cancer, run by Hospital San Carlos, Madrid, completed.","route":"/trials/nct00515762/","status":"completed","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT00515762","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06157151","name":"PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer","tldr":"A phase 2 trial of Pembrolizumab in cervical cancer, run by Precigen, Inc, now recruiting.","route":"/trials/nct06157151/","status":"recruiting","kind":"trial","cancerIcon":"cervical","sub":"NCT06157151","facets":{"kind":["Trial"],"cancers":["Cervical cancer","Recurrent or metastatic cervical cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."},{"label":"Recurrent or metastatic cervical cancer","href":"/cancers/recurrent-metastatic-cervical-cancer/","tip":"Recurrent or metastatic cervical cancer has spread beyond the pelvis or come back where it cannot be cured by surgery or radiotherapy. Pembrolizumab added to chemotherapy and bevacizumab is the first treatment, and the antibody-drug conjugate tisotumab vedotin or the PD-1 antibody cemiplimab extend life when it progresses."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07510828","name":"PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors","tldr":"A phase 1/2 trial of EB-PT-CAR-NK-S in advanced solid tumours, run by Beijing Biotech, now recruiting.","route":"/trials/nct07510828/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07510828","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07541001","name":"PRL3-Zumab in Patients With Advanced Solid Tumors","tldr":"A phase 2 trial of PRL3-ZUMAB in advanced solid tumours, run by Intra-IMMUSG Pte Ltd, active and no longer recruiting.","route":"/trials/nct07541001/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07541001","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06460298","name":"ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer","tldr":"A phase 1/2 trial of ProAgio Dose Levels (DL) 1,2,3,4 in triple-negative breast cancer, run by ProDa BioTech, LLC, now recruiting.","route":"/trials/nct06460298/","status":"recruiting","kind":"trial","cancerIcon":"tnbc","sub":"NCT06460298","facets":{"kind":["Trial"],"cancers":["Triple-negative breast cancer","Metastatic triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Metastatic triple-negative breast cancer","href":"/cancers/tnbc-metastatic/","tip":"Triple-negative breast cancer that has spread is not curable, but its treatment has been transformed since 2020. By PD-L1 score, first treatment is pembrolizumab with chemotherapy or with sacituzumab govitecan, or datopotamab deruxtecan or sacituzumab govitecan alone; BRCA carriers can take a PARP inhibitor tablet; and trastuzumab deruxtecan reaches the third of tumours with low HER2."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07605728","name":"Probiotics for Abemaciclib-Induced Abdominal Discomfort.","tldr":"A phase 2 trial of an investigational treatment in advanced solid tumours, run by Leeuwenhoek Laboratories Co. Ltd., now recruiting.","route":"/trials/nct07605728/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07605728","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03478488","name":"Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC","tldr":"A phase 3 trial of Envafolimab, Gemcitabine and Oxaliplatin in biliary tract cancer, run by 3D Medicines (Sichuan) Co., Ltd., active and no longer recruiting.","route":"/trials/nct03478488/","status":"active","kind":"trial","cancerIcon":"cholangiocarcinoma","sub":"NCT03478488","facets":{"kind":["Trial"],"cancers":["Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05741164","name":"Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer","tldr":"A phase 2 trial of Pembrolizumab and Propranolol in Breast cancer, run by Emory University, now recruiting.","route":"/trials/nct05741164/","status":"recruiting","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT05741164","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00567580","name":"Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer","tldr":"A phase 3 trial of Flutamide, Bicalutamide, Goserelin / leuprolide, Buserelin and Triptorelin in Prostate cancer, run by Radiation Therapy Oncology Group, with a status the registry has not verified recently.","route":"/trials/nct00567580/","kind":"trial","cancerIcon":"prostate","sub":"NCT00567580","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"prtx007","name":"PRTX007","tldr":"PRTX007 is a small-molecule inhibitor from Primmune Therapeutics, Inc., in registered phase 2 trials for melanoma.","route":"/drugs/prtx007/","status":"phase-2","kind":"drug","molecule":"prtx007","modality":"Small-molecule inhibitor","sub":"PRTX007","facets":{"kind":["Treatment"],"cancers":["Melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct07072728","name":"Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder","tldr":"A phase 2 trial of Psilocybin therapy in endometrial cancer, prostate cancer, gastric & gastro-oesophageal junction cancer, melanoma and pancreatic ductal adenocarcinoma, run by Psyence Australia Pty Ltd, now recruiting.","route":"/trials/nct07072728/","status":"recruiting","kind":"trial","cancerIcon":"endometrial","sub":"NCT07072728","facets":{"kind":["Trial"],"cancers":["Endometrial cancer","Prostate cancer","Gastric & gastro-oesophageal junction cancer","Melanoma","Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."},{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."}],"tags":[]},"sortKeys":{"year":0}},{"id":"psma-1007-f18","name":"PSMA-1007 F-18","tldr":"PSMA-1007 is a fluorine-18 PSMA PET tracer from ABX in Germany, widely used in Europe for prostate cancer staging because little of it reaches the bladder, and in a phase 3 trial registered by its maker.","route":"/drugs/psma-1007-f18/","status":"phase-3","kind":"drug","molecule":"psma-1007-f18","modality":"PSMA-targeted PET radiotracer, fluorine-18","facets":{"kind":["Treatment"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05381103","name":"PSMA-PET to Guide Prostatectomy","tldr":"A phase 2/3 trial of an investigational treatment in prostate cancer, run by Five Eleven Pharma, Inc., now recruiting.","route":"/trials/nct05381103/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT05381103","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06244992","name":"PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors","tldr":"A phase 1/2 trial of PTT-936 in advanced solid tumours, run by Pyrotech Therapeutics, Inc., now recruiting.","route":"/trials/nct06244992/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06244992","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"pucotenlimab","name":"Pucotenlimab","tldr":"Pucotenlimab is Lepu Biopharma's PD-1 antibody, approved in China in 2022 for mismatch-repair-deficient solid tumours and for melanoma, and in a phase 3 trial in colorectal cancer.","route":"/drugs/pucotenlimab/","status":"approved","kind":"drug","molecule":"pucotenlimab","modality":"Anti-PD-1 monoclonal antibody, intravenous","sub":"HX008","facets":{"kind":["Treatment"],"cancers":["Melanoma","Colorectal cancer"],"year":["2022"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"year":{"facet":"year","value":"2022"},"tags":[]},"sortKeys":{"year":2022}},{"id":"nct06665100","name":"PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)","tldr":"A phase 2 trial of PUL-042 in advanced solid tumours, run by Pulmotect, Inc., now recruiting.","route":"/trials/nct06665100/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06665100","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"purinostat","name":"Purinostat","tldr":"Purinostat is an experimental investigational agent whose form is not stated in the registry from Chengdu Zenitar Biomedical Technology in phase 3 trials for diffuse large B-cell lymphoma and multiple myeloma, with its target not yet stated publicly.","route":"/drugs/purinostat/","status":"phase-3","kind":"drug","molecule":"purinostat","modality":"not stated (registered as a drug or biological on ClinicalTrials.gov)","facets":{"kind":["Treatment"],"cancers":["Diffuse large B-cell lymphoma","Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."},{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06484829","name":"Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","tldr":"A phase 1/2 trial of Purinostat in multiple myeloma, run by Chengdu Zenitar Biomedical Technology Co., Ltd, now recruiting.","route":"/trials/nct06484829/","status":"recruiting","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT06484829","facets":{"kind":["Trial"],"cancers":["Multiple myeloma","Relapsed or refractory multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."},{"label":"Relapsed or refractory multiple myeloma","href":"/cancers/myeloma-relapsed-refractory/","tip":"Myeloma almost always returns, and each return is harder to treat. Two kinds of immune therapy aimed at the BCMA protein on myeloma cells, CAR-T cells (KarMMa-3, CARTITUDE-4) and off-the-shelf bispecific antibodies (MajesTEC), now give deep remissions after other drugs fail, and a second target, GPRC5D, gives another option."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01686594","name":"PUVA Maintenance Therapy in Mycosis Fungoides","tldr":"A phase 3 trial of Methoxsalen in Cutaneous T-cell lymphoma and Peripheral T-cell lymphomas, run by Medical University of Graz, completed.","route":"/trials/nct01686594/","status":"completed","kind":"trial","cancerIcon":"cutaneous-t-cell-lymphoma","sub":"NCT01686594","facets":{"kind":["Trial"],"cancers":["Cutaneous T-cell lymphoma","Peripheral T-cell lymphomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Cutaneous T-cell lymphoma","href":"/cancers/cutaneous-t-cell-lymphoma/","tip":"Mycosis fungoides is a lymphoma that lives in the skin, looking like eczema or psoriasis for years before it is diagnosed. It is treated with creams, light and skin-directed radiotherapy for as long as possible, then with antibodies such as mogamulizumab and brentuximab vedotin when it spreads to the blood or lymph nodes."},{"label":"Peripheral T-cell lymphomas","href":"/cancers/peripheral-t-cell-lymphoma/","tip":"Peripheral T-cell lymphomas are lymphomas of T cells rather than B cells. They are rarer, more varied and, apart from a few subtypes, harder to treat than B-cell lymphomas; several new drugs help only defined subtypes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04963595","name":"Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer","tldr":"A phase 2 trial of Pyrotinib, Vinorelbine and Inetetamab in Breast cancer, run by Zhiyong Yu, with a status the registry has not verified recently.","route":"/trials/nct04963595/","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT04963595","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ql1706","name":"QL1706","tldr":"QL1706 is an experimental small-molecule drug from Qilu Pharmaceutical in phase 3 trials for non-small-cell lung cancer and colorectal cancer, with its target not yet stated publicly.","route":"/drugs/ql1706/","status":"phase-3","kind":"drug","molecule":"ql1706","modality":"bifunctional antibody mixture (iparomlimab and tuvonralimab; INN stem -mab)","sub":"PSB205","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ql2107","name":"QL2107","tldr":"QL2107 is an experimental investigational agent whose form is not stated in the registry from Qilu Pharmaceutical in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.","route":"/drugs/ql2107/","status":"phase-3","kind":"drug","molecule":"ql2107","modality":"not stated (registered as a drug or biological on ClinicalTrials.gov)","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"qlc5508","name":"QLC5508","tldr":"QLC5508 is an experimental antibody-drug conjugate from Qilu Pharmaceutical in phase 3 trials for oesophageal cancer, prostate cancer and non-small-cell lung cancer, aimed at B7-H3.","route":"/drugs/qlc5508/","status":"phase-3","kind":"drug","molecule":"qlc5508","modality":"ADC","sub":"MHB088C","facets":{"kind":["Treatment"],"cancers":["Oesophageal cancer","Prostate cancer","Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."},{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"qlh12016","name":"QLH12016","tldr":"QLH12016 is an experimental protein degrader from Qilu Pharmaceutical in phase 2 trials for prostate cancer, aimed at Androgen receptor.","route":"/drugs/qlh12016/","status":"phase-2","kind":"drug","molecule":"qlh12016","modality":"protein degrader","facets":{"kind":["Treatment"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"qls31905","name":"QLS31905","tldr":"QLS31905 is an experimental investigational agent whose form is not stated in the registry from Qilu Pharmaceutical in phase 3 trials for pancreatic ductal adenocarcinoma, with its target not yet stated publicly.","route":"/drugs/qls31905/","status":"phase-3","kind":"drug","molecule":"qls31905","modality":"not stated (registered as a drug or biological on ClinicalTrials.gov)","facets":{"kind":["Treatment"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"qls32015","name":"QLS32015","tldr":"QLS32015 is an experimental investigational agent whose form is not stated in the registry from Qilu Pharmaceutical in phase 3 trials for multiple myeloma, with its target not yet stated publicly.","route":"/drugs/qls32015/","status":"phase-3","kind":"drug","molecule":"qls32015","modality":"not stated (registered as a drug or biological on ClinicalTrials.gov)","facets":{"kind":["Treatment"],"cancers":["Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04486833","name":"Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib","tldr":"A phase 1/2 trial of Osimertinib in non-small-cell lung cancer, run by Genprex, Inc., now recruiting.","route":"/trials/nct04486833/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT04486833","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"quemliclustat","name":"Quemliclustat","tldr":"Quemliclustat is an experimental investigational agent whose form is not stated in the registry from Arcus Biosciences in phase 3 trials for pancreatic ductal adenocarcinoma and non-small-cell lung cancer, with its target not yet stated publicly.","route":"/drugs/quemliclustat/","status":"phase-3","kind":"drug","molecule":"quemliclustat","modality":"not stated (registered as a drug or biological on ClinicalTrials.gov)","facets":{"kind":["Treatment"],"cancers":["Pancreatic ductal adenocarcinoma","Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00936390","name":"Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer","tldr":"A phase 3 trial of Bicalutamide, Flutamide, Goserelin / leuprolide, Buserelin, Triptorelin and Degarelix in Prostate cancer, run by Radiation Therapy Oncology Group, completed.","route":"/trials/nct00936390/","status":"completed","kind":"trial","cancerIcon":"prostate","sub":"NCT00936390","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00769379","name":"Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy","tldr":"A phase 3 trial of Trastuzumab and Trastuzumab biosimilars in Ductal carcinoma in situ, run by National Cancer Institute (NCI), completed.","route":"/trials/nct00769379/","status":"completed","kind":"trial","cancerIcon":"ductal-carcinoma-in-situ","sub":"NCT00769379","facets":{"kind":["Trial"],"cancers":["Ductal carcinoma in situ"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ductal carcinoma in situ","href":"/cancers/ductal-carcinoma-in-situ/","tip":"DCIS is abnormal cells confined to the milk ducts of the breast; it is not yet invasive cancer and cannot spread, but some would become invasive if left. Lumpectomy with radiotherapy, or mastectomy, halves local recurrence, so the live question is which low-risk DCIS can safely be watched: the COMET trial (2024) found active monitoring no worse at two years."}],"tags":[]},"sortKeys":{"year":0}},{"id":"radotinib","name":"Radotinib","tldr":"Radotinib is an oral kinase inhibitor from Il-Yang Pharm. Co., Ltd., in registered phase 3 trials for chronic myeloid leukaemia.","route":"/drugs/radotinib/","status":"phase-3","kind":"drug","molecule":"radotinib","modality":"Oral kinase inhibitor","facets":{"kind":["Treatment"],"cancers":["Chronic myeloid leukaemia","Chronic myeloid leukaemia, chronic phase"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Chronic myeloid leukaemia","href":"/cancers/cml/","tip":"Chronic myeloid leukaemia is a blood cancer driven by a single fused gene, BCR-ABL1, and the model for oncogene-targeted treatment: imatinib in 2001 and the tyrosine kinase inhibitors that followed turned it into a condition most people live with long-term. About half of patients with a sustained deep molecular response can now stop treatment altogether."},{"label":"Chronic myeloid leukaemia, chronic phase","href":"/cancers/cml-chronic-phase/","tip":"Chronic-phase chronic myeloid leukaemia is the disease that imatinib turned from fatal into manageable: a daily pill blocks the BCR::ABL1 protein that drives it. Blood tests track the leukaemia gene to a millionth, newer pills such as asciminib (ASC4FIRST) reach deeper responses faster, and patients with years of undetectable disease can try stopping."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct06867705","name":"Randomized Controlled Trial of Remote Symptoms Monitoring With Resilience PRO Compared to Care As Usual Only","tldr":"A phase 3 trial of Resilience PRO in advanced solid tumours, run by Resilience, now recruiting.","route":"/trials/nct06867705/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06867705","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03722420","name":"Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)","tldr":"A phase 3 trial of Imatinib in chronic myeloid leukaemia, run by Il-Yang Pharm. Co., Ltd., active and no longer recruiting.","route":"/trials/nct03722420/","status":"active","kind":"trial","cancerIcon":"cml","sub":"NCT03722420","facets":{"kind":["Trial"],"cancers":["Chronic myeloid leukaemia","Chronic myeloid leukaemia, chronic phase"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic myeloid leukaemia","href":"/cancers/cml/","tip":"Chronic myeloid leukaemia is a blood cancer driven by a single fused gene, BCR-ABL1, and the model for oncogene-targeted treatment: imatinib in 2001 and the tyrosine kinase inhibitors that followed turned it into a condition most people live with long-term. About half of patients with a sustained deep molecular response can now stop treatment altogether."},{"label":"Chronic myeloid leukaemia, chronic phase","href":"/cancers/cml-chronic-phase/","tip":"Chronic-phase chronic myeloid leukaemia is the disease that imatinib turned from fatal into manageable: a daily pill blocks the BCR::ABL1 protein that drives it. Blood tests track the leukaemia gene to a millionth, newer pills such as asciminib (ASC4FIRST) reach deeper responses faster, and patients with years of undetectable disease can try stopping."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01059786","name":"Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia","tldr":"A phase 2 trial of Pentostatin, Rituximab and Bendamustine in Hairy cell leukaemia, run by National Cancer Institute (NCI), active and no longer recruiting.","route":"/trials/nct01059786/","status":"active","kind":"trial","cancerIcon":"hairy-cell-leukemia","sub":"NCT01059786","facets":{"kind":["Trial"],"cancers":["Hairy cell leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hairy cell leukaemia","href":"/cancers/hairy-cell-leukemia/","tip":"Hairy cell leukaemia is a rare, slow B-cell leukaemia with a single defining mutation (BRAF V600E) that is unusually curable: one week of a purine analogue puts most people into remission for years, and BRAF drugs rescue those who relapse."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04747236","name":"Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL","tldr":"A phase 2 trial of Azacitidine, Romidepsin, Belinostat, Pralatrexate and Gemcitabine in Peripheral T-cell lymphomas, run by University of Virginia, now recruiting.","route":"/trials/nct04747236/","status":"recruiting","kind":"trial","cancerIcon":"peripheral-t-cell-lymphoma","sub":"NCT04747236","facets":{"kind":["Trial"],"cancers":["Peripheral T-cell lymphomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Peripheral T-cell lymphomas","href":"/cancers/peripheral-t-cell-lymphoma/","tip":"Peripheral T-cell lymphomas are lymphomas of T cells rather than B cells. They are rarer, more varied and, apart from a few subtypes, harder to treat than B-cell lymphomas; several new drugs help only defined subtypes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00431080","name":"Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer","tldr":"A phase 3 trial of Docetaxel, Paclitaxel / nab-paclitaxel, Epirubicin, Cyclophosphamide, Fluorouracil, Lenograstim and Pegfilgrastim in Breast cancer, run by Hellenic Oncology Research Group, completed.","route":"/trials/nct00431080/","status":"completed","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT00431080","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04457245","name":"Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer","tldr":"A phase 3 trial of Piflufolastat F-18 / Pylarify TruVu in Prostate cancer, run by Jonsson Comprehensive Cancer Center, recorded as terminated on the registry.","route":"/trials/nct04457245/","kind":"trial","cancerIcon":"prostate","sub":"NCT04457245","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00189345","name":"Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients","tldr":"A phase 2 trial of Catumaxomab in Ovarian cancer, run by AGO Study Group, completed.","route":"/trials/nct00189345/","status":"completed","kind":"trial","cancerIcon":"ovarian","sub":"NCT00189345","facets":{"kind":["Trial"],"cancers":["Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01200485","name":"Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2","tldr":"A phase 2 trial of Rasburicase in Leukaemia, run by M.D. Anderson Cancer Center, completed.","route":"/trials/nct01200485/","status":"completed","kind":"trial","cancerIcon":"leukaemia","sub":"NCT01200485","facets":{"kind":["Trial"],"cancers":["Leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Leukaemia","href":"/cancers/leukaemia/","tip":"Leukaemia means cancer of the blood-forming cells, but the four main types share little beyond the name: acute lymphoblastic and acute myeloid leukaemia are emergencies treated with intensive therapy, while chronic lymphocytic and chronic myeloid leukaemia are slow diseases controlled for years with pills. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"rc118-adc","name":"RC118-ADC","tldr":"RC118-ADC is an experimental antibody-drug conjugate from RemeGen in phase 2 trials, aimed at Claudin 18.2.","route":"/drugs/rc118-adc/","status":"phase-2","kind":"drug","molecule":"rc118-adc","modality":"ADC","sub":"RC118","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"rc148","name":"RC148","tldr":"RC148 is an experimental investigational agent whose form is not stated in the registry from RemeGen in phase 3 trials for non-small-cell lung cancer and HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.","route":"/drugs/rc148/","status":"phase-3","kind":"drug","molecule":"rc148","modality":"bispecific antibody (PD-1 x VEGF, per the sponsor's pipeline page; form not stated in the registry record)","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07366840","name":"RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure","tldr":"A phase 2/3 trial of Disitamab vedotin, Gemcitabine, Capecitabine, Trastuzumab and Inetetamab in HER2-positive breast cancer and Breast cancer, run by Fudan University, not yet recruiting.","route":"/trials/nct07366840/","status":"planned","kind":"trial","cancerIcon":"breast-her2-positive","sub":"NCT07366840","facets":{"kind":["Trial"],"cancers":["HER2-positive breast cancer","Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."},{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07006077","name":"Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer","tldr":"A phase 2 trial of Recombinant human IL-21-expressing oncolytic vaccinia virus injection in pancreatic ductal adenocarcinoma, run by Hangzhou Converd Co., Ltd., now recruiting.","route":"/trials/nct07006077/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT07006077","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05870748","name":"REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1","tldr":"A phase 2/3 trial of Luveltamab tazevibulin, Pegfilgrastim, Gemcitabine, Paclitaxel / nab-paclitaxel, Pegylated liposomal doxorubicin and Topotecan in Ovarian cancer and Platinum-resistant ovarian cancer, run by Sutro Biopharma, Inc., recorded as terminated on the registry.","route":"/trials/nct05870748/","kind":"trial","cancerIcon":"ovarian","sub":"NCT05870748","facets":{"kind":["Trial"],"cancers":["Ovarian cancer","Platinum-resistant ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Platinum-resistant ovarian cancer","href":"/cancers/platinum-resistant-ovarian-cancer/","tip":"Platinum-resistant ovarian cancer grows back within six months of platinum chemotherapy, or during it, and used to be treated with single chemotherapy drugs that shrink a tumour one time in ten. The antibody-drug conjugate mirvetuximab soravtansine, the cortisol-blocking drug relacorilant and pembrolizumab in PD-L1-positive tumours have each extended survival in phase 3 trials since 2023."}],"tags":[]},"sortKeys":{"year":0}},{"id":"regn7075","name":"REGN7075","tldr":"REGN7075 is a bispecific antibody from Regeneron Pharmaceuticals, in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer.","route":"/drugs/regn7075/","status":"phase-2","kind":"drug","molecule":"regn7075","modality":"Bispecific antibody","sub":"REGN7075","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct06906341","name":"Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers","tldr":"A phase 2 trial of Relacorilant and Bevacizumab in ovarian cancer and endometrial cancer, run by Corcept Therapeutics, now recruiting.","route":"/trials/nct06906341/","status":"recruiting","kind":"trial","cancerIcon":"ovarian","sub":"NCT06906341","facets":{"kind":["Trial"],"cancers":["Ovarian cancer","Endometrial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07259317","name":"Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma","tldr":"A phase 2 trial of Relacorilant and Gemcitabine in pancreatic ductal adenocarcinoma, run by Corcept Therapeutics, now recruiting.","route":"/trials/nct07259317/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT07259317","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"rem-422","name":"REM-422","tldr":"REM-422 is a small-molecule inhibitor from Remix Therapeutics, in registered phase 2 trials for salivary gland cancers.","route":"/drugs/rem-422/","status":"phase-2","kind":"drug","molecule":"rem-422","modality":"Small-molecule inhibitor","sub":"REM-422","facets":{"kind":["Treatment"],"cancers":["Salivary gland cancers","Adenoid cystic carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Salivary gland cancers","href":"/cancers/salivary-gland/","tip":"Salivary gland cancers are a family of over 20 rare cancers, each with its own behaviour and often its own gene fusion. Surgery and radiation treat most; drug therapy is now chosen by the specific subtype, from anti-HER2 or anti-androgen drugs to NTRK inhibitors."},{"label":"Adenoid cystic carcinoma","href":"/cancers/adenoid-cystic-carcinoma/","tip":"Adenoid cystic carcinoma is a slow but relentless cancer of the salivary glands that creeps along nerves and comes back years later, often in the lungs. Surgery with radiotherapy is the only cure, chemotherapy barely works, and the tablets lenvatinib and axitinib can hold spreading disease still for months rather than shrink it."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct05796375","name":"Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance","tldr":"A phase 2 trial of Bladder EpiCheck urine methylation test in Non-muscle-invasive bladder cancer, run by White River Junction Veterans Affairs Medical Center, now recruiting.","route":"/trials/nct05796375/","status":"recruiting","kind":"trial","cancerIcon":"non-muscle-invasive-bladder-cancer","sub":"NCT05796375","facets":{"kind":["Trial"],"cancers":["Non-muscle-invasive bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-muscle-invasive bladder cancer","href":"/cancers/non-muscle-invasive-bladder-cancer/","tip":"Most bladder cancers are found while still confined to the lining. They are scraped out through the urethra and, when higher risk, treated with BCG instilled into the bladder; the challenge is the frequent recurrences and the patients whose tumours stop responding to BCG."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01037478","name":"Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma","tldr":"A phase 2 trial of Resminostat in Hodgkin lymphoma, run by 4SC AG, completed.","route":"/trials/nct01037478/","status":"completed","kind":"trial","cancerIcon":"hodgkin-lymphoma","sub":"NCT01037478","facets":{"kind":["Trial"],"cancers":["Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hodgkin lymphoma","href":"/cancers/hodgkin-lymphoma/","tip":"Hodgkin lymphoma is one of the most curable cancers, where the goal is now to cure with less toxicity, using brentuximab and, from 2026, first-line nivolumab."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02953301","name":"Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)","tldr":"A phase 2 trial of Resminostat in Cutaneous T-cell lymphoma and Peripheral T-cell lymphomas, run by 4SC AG, completed.","route":"/trials/nct02953301/","status":"completed","kind":"trial","cancerIcon":"cutaneous-t-cell-lymphoma","sub":"NCT02953301","facets":{"kind":["Trial"],"cancers":["Cutaneous T-cell lymphoma","Peripheral T-cell lymphomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Cutaneous T-cell lymphoma","href":"/cancers/cutaneous-t-cell-lymphoma/","tip":"Mycosis fungoides is a lymphoma that lives in the skin, looking like eczema or psoriasis for years before it is diagnosed. It is treated with creams, light and skin-directed radiotherapy for as long as possible, then with antibodies such as mogamulizumab and brentuximab vedotin when it spreads to the blood or lymph nodes."},{"label":"Peripheral T-cell lymphomas","href":"/cancers/peripheral-t-cell-lymphoma/","tip":"Peripheral T-cell lymphomas are lymphomas of T cells rather than B cells. They are rarer, more varied and, apart from a few subtypes, harder to treat than B-cell lymphomas; several new drugs help only defined subtypes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06345287","name":"Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC","tldr":"A phase 2 trial of Adaptive radiotherapy in Head and neck squamous cell carcinoma, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, now recruiting.","route":"/trials/nct06345287/","status":"recruiting","kind":"trial","cancerIcon":"head-and-neck","sub":"NCT06345287","facets":{"kind":["Trial"],"cancers":["Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02521493","name":"Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome","tldr":"A phase 3 trial of Asparaginase, Crisantaspase, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone and Thioguanine in Acute myeloid leukaemia and Leukaemia, run by Children's Oncology Group, active and no longer recruiting.","route":"/trials/nct02521493/","status":"active","kind":"trial","cancerIcon":"aml","sub":"NCT02521493","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia","Leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Leukaemia","href":"/cancers/leukaemia/","tip":"Leukaemia means cancer of the blood-forming cells, but the four main types share little beyond the name: acute lymphoblastic and acute myeloid leukaemia are emergencies treated with intensive therapy, while chronic lymphocytic and chronic myeloid leukaemia are slow diseases controlled for years with pills. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06679634","name":"Retinoblastoma Phase II Expanded Access Clinical Trial","tldr":"A phase 2 trial of Topotecan in retinoblastoma, run by Targeted Therapy Technologies, LLC, now recruiting.","route":"/trials/nct06679634/","status":"recruiting","kind":"trial","cancerIcon":"retinoblastoma","sub":"NCT06679634","facets":{"kind":["Trial"],"cancers":["Retinoblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Retinoblastoma","href":"/cancers/retinoblastoma/","tip":"An eye cancer of infants caused by loss of the RB1 gene, the first tumour-suppressor gene ever found. In rich countries almost every child survives and most eyes are saved by chemotherapy delivered through the eye's artery; in low-income countries, where most cases occur, survival depends on finding it early, and that is the global gap."}],"tags":[]},"sortKeys":{"year":0}},{"id":"retlirafusp-alfa","name":"Retlirafusp alfa","tldr":"Retlirafusp alfa is Hengrui's PD-L1 and TGF-beta bifunctional antibody, in phase 3 trials with chemotherapy in gastric cancer after the Western class leader bintrafusp alfa failed.","route":"/drugs/retlirafusp-alfa/","status":"phase-3","kind":"drug","molecule":"retlirafusp-alfa","modality":"Bifunctional fusion protein (anti-PD-L1 antibody fused to a TGF-beta receptor II trap), intravenous","sub":"SHR-1701","facets":{"kind":["Treatment"],"cancers":["Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05076682","name":"Reverse Triple Negative Immune Resistant Breast Cancer","tldr":"A phase 2 trial of Trastuzumab rezetecan, SHR-A2102, Adebrelimab and Mecapegfilgrastim in Triple-negative breast cancer, run by Fudan University, now recruiting.","route":"/trials/nct05076682/","status":"recruiting","kind":"trial","cancerIcon":"tnbc","sub":"NCT05076682","facets":{"kind":["Trial"],"cancers":["Triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."}],"tags":[]},"sortKeys":{"year":0}},{"id":"rezvilutamide","name":"Rezvilutamide","tldr":"Rezvilutamide is Hengrui's androgen receptor blocker, approved in China in 2022 for high-volume metastatic hormone-sensitive prostate cancer on the CHART trial, where it improved survival over bicalutamide.","route":"/drugs/rezvilutamide/","status":"approved","kind":"drug","molecule":"rezvilutamide","modality":"Oral androgen receptor antagonist","sub":"SHR3680","facets":{"kind":["Treatment"],"cancers":["Prostate cancer"],"year":["2022"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"year":{"facet":"year","value":"2022"},"tags":[]},"sortKeys":{"year":2022}},{"id":"nct04964284","name":"rhTSH for Radioactive Iodine Remnant Ablation in Participants With Differentiated Thyroid Cancer (DTC)","tldr":"A phase 3 trial of Thyrotropin alfa in Thyroid cancer, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, completed.","route":"/trials/nct04964284/","status":"completed","kind":"trial","cancerIcon":"thyroid","sub":"NCT04964284","facets":{"kind":["Trial"],"cancers":["Thyroid cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Thyroid cancer","href":"/cancers/thyroid/","tip":"Thyroid cancer is usually curable with surgery and radioactive iodine, the original theranostic. Rare aggressive forms respond to RET and BRAF inhibitors."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02934568","name":"Ribociclib (LEE011) Rollover Study for Continued Access","tldr":"A phase 2 trial of LEE011 in advanced solid tumours, run by Novartis Pharmaceuticals, active and no longer recruiting.","route":"/trials/nct02934568/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT02934568","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"rilvegostomig","name":"Rilvegostomig","tldr":"Rilvegostomig is an experimental bispecific antibody from AstraZeneca in phase 2 trials for non-small-cell lung cancer, aimed at PD-1 and TIGIT.","route":"/drugs/rilvegostomig/","status":"phase-2","kind":"drug","molecule":"rilvegostomig","modality":"bispecific antibody","sub":"AZD2936","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06109779","name":"Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)","tldr":"A phase 3 trial of Rilvegostomig, Capecitabine and Gemcitabine + cisplatin in biliary tract cancer, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct06109779/","status":"active","kind":"trial","cancerIcon":"cholangiocarcinoma","sub":"NCT06109779","facets":{"kind":["Trial"],"cancers":["Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"rinzimetostat","name":"Rinzimetostat","tldr":"Rinzimetostat is an experimental small-molecule drug from ORIC Pharmaceuticals in phase 3 trials for prostate cancer, with its target not yet stated publicly.","route":"/drugs/rinzimetostat/","status":"phase-3","kind":"drug","molecule":"rinzimetostat","modality":"small molecule","sub":"ORIC-944","facets":{"kind":["Treatment"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00057811","name":"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma","tldr":"A phase 2 trial of Doxorubicin, Cyclophosphamide, Methotrexate, Rasburicase, Leucovorin, Prednisone, Filgrastim, Rituximab, Cytarabine, Etoposide and Vincristine in Burkitt lymphoma and Acute lymphoblastic leukaemia, run by Children's Oncology Group, completed.","route":"/trials/nct00057811/","status":"completed","kind":"trial","cancerIcon":"burkitt-lymphoma","sub":"NCT00057811","facets":{"kind":["Trial"],"cancers":["Burkitt lymphoma","Acute lymphoblastic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Burkitt lymphoma","href":"/cancers/burkitt-lymphoma/","tip":"Burkitt lymphoma is the fastest-growing human tumour, driven by a single rearrangement that switches on the MYC gene. That speed makes it exquisitely sensitive to chemotherapy: short, intense courses, now with the antibody rituximab, cure the great majority of children in well-resourced settings. The remaining task is to bring the same cure to the African children who make up most cases."},{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."}],"tags":[]},"sortKeys":{"year":0}},{"id":"rnk05047","name":"RNK05047","tldr":"RNK05047 is a targeted protein degrader from Ranok Therapeutics (Hangzhou) Co., Ltd., in registered phase 2 trials for metastatic cancer.","route":"/drugs/rnk05047/","status":"phase-2","kind":"drug","molecule":"rnk05047","modality":"Targeted protein degrader","sub":"RNK05047","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"ro7771950","name":"RO7771950","tldr":"RO7771950 is an experimental small-molecule drug from Hoffmann-La Roche in phase 3 trials for HER2-positive breast cancer and HR-positive / HER2-negative breast cancer, aimed at HER2.","route":"/drugs/ro7771950/","status":"phase-3","kind":"drug","molecule":"ro7771950","modality":"small molecule","sub":"A-1041, RG6596","facets":{"kind":["Treatment"],"cancers":["HER2-positive breast cancer","HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."},{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"rocbrutinib","name":"Rocbrutinib","tldr":"Rocbrutinib is an experimental small-molecule drug from Guangzhou Lupeng Pharmaceutical in phase 3 trials for mantle cell lymphoma, chronic lymphocytic leukaemia and diffuse large B-cell lymphoma, with its target not yet stated publicly.","route":"/drugs/rocbrutinib/","status":"phase-3","kind":"drug","molecule":"rocbrutinib","modality":"small molecule","sub":"NWP-775, LP-168","facets":{"kind":["Treatment"],"cancers":["Mantle cell lymphoma","Chronic lymphocytic leukaemia","Diffuse large B-cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Mantle cell lymphoma","href":"/cancers/mantle-cell-lymphoma/","tip":"An uncommon B-cell lymphoma driven by cyclin D1 that used to behave badly in almost everyone. BTK inhibitors, CAR-T and now BCL2 drugs have changed it from chemotherapy-plus-transplant to targeted combinations."},{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."}],"tags":[]},"sortKeys":{"year":0}},{"id":"roginolisib","name":"Roginolisib","tldr":"Roginolisib is an oral pi3k inhibitor from iOnctura, in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer.","route":"/drugs/roginolisib/","status":"phase-2","kind":"drug","molecule":"roginolisib","modality":"Oral PI3K inhibitor","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct02072811","name":"Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia","tldr":"A phase 3 trial of Cladribine, Daunorubicin and Mitoxantrone in Acute myeloid leukaemia, run by dr hab. n. med. Agnieszka Wierzbowska, with a status the registry has not verified recently.","route":"/trials/nct02072811/","kind":"trial","cancerIcon":"aml","sub":"NCT02072811","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05629234","name":"Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)","tldr":"A phase 3 trial of Osimertinib in advanced solid tumours, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct05629234/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05629234","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05201066","name":"Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.","tldr":"A phase 2 trial of Decitabine, Azacitidine and Venetoclax in myelodysplastic syndromes / neoplasms, run by Novartis Pharmaceuticals, active and no longer recruiting.","route":"/trials/nct05201066/","status":"active","kind":"trial","cancerIcon":"mds","sub":"NCT05201066","facets":{"kind":["Trial"],"cancers":["Myelodysplastic syndromes / neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Myelodysplastic syndromes / neoplasms","href":"/cancers/mds/","tip":"Bone-marrow disorders where blood cells are made badly and too few reach the blood; a third progress to acute leukaemia. Treatment ranges from transfusions and growth factors to hypomethylating drugs and, for the fit, transplant."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04509700","name":"Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)","tldr":"A phase 2 trial of Parsaclisib, Ruxolitinib and Ibrutinib in advanced solid tumours, run by Incyte Corporation, active and no longer recruiting.","route":"/trials/nct04509700/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04509700","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"rondecabtagene-autoleucel","name":"Rondecabtagene autoleucel","tldr":"Rondecabtagene autoleucel is an experimental CAR-T cell therapy from Lyell Immunopharma in phase 3 trials for diffuse large B-cell lymphoma and hodgkin lymphoma, aimed at CD19 and CD20.","route":"/drugs/rondecabtagene-autoleucel/","status":"phase-3","kind":"drug","molecule":"rondecabtagene-autoleucel","modality":"CAR-T cell therapy","sub":"LYL314","facets":{"kind":["Treatment"],"cancers":["Diffuse large B-cell lymphoma","Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."},{"label":"Hodgkin lymphoma","href":"/cancers/hodgkin-lymphoma/","tip":"Hodgkin lymphoma is one of the most curable cancers, where the goal is now to cure with less toxicity, using brentuximab and, from 2026, first-line nivolumab."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04285086","name":"Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance","tldr":"A phase 3 trial of Ropeginterferon alfa-2b and Anagrelide in myeloproliferative neoplasms, run by PharmaEssentia, active and no longer recruiting.","route":"/trials/nct04285086/","status":"active","kind":"trial","cancerIcon":"myeloproliferative-neoplasms","sub":"NCT04285086","facets":{"kind":["Trial"],"cancers":["Myeloproliferative neoplasms","Essential thrombocythaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Myeloproliferative neoplasms","href":"/cancers/myeloproliferative-neoplasms/","tip":"Myeloproliferative neoplasms are slow-growing blood cancers in which the marrow overproduces red cells (polycythaemia vera), platelets (essential thrombocythaemia) or scar tissue (myelofibrosis). Almost all carry a mutation in JAK2, CALR or MPL; treatment aims to prevent clots and control symptoms, and only transplant cures myelofibrosis."},{"label":"Essential thrombocythaemia","href":"/cancers/essential-thrombocythaemia/","tip":"Essential thrombocythaemia is a slow blood cancer in which the marrow makes too many platelets. Most people need only aspirin and monitoring; those at higher risk of clots take a drug to lower the platelet count, usually hydroxyurea or interferon, with anagrelide in reserve."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07173751","name":"ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer","tldr":"A phase 3 trial of PM8002, Gemcitabine, Carboplatin and Eribulin in triple-negative breast cancer, run by BioNTech SE, now recruiting.","route":"/trials/nct07173751/","status":"recruiting","kind":"trial","cancerIcon":"tnbc","sub":"NCT07173751","facets":{"kind":["Trial"],"cancers":["Triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."}],"tags":[]},"sortKeys":{"year":0}},{"id":"rph-051","name":"RPH-051","tldr":"RPH-051 is an experimental monoclonal antibody from R-Pharm in phase 3 trials for HR-positive / HER2-negative breast cancer and HER2-positive breast cancer, aimed at HER2.","route":"/drugs/rph-051/","status":"phase-3","kind":"drug","molecule":"rph-051","modality":"monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["HR-positive / HER2-negative breast cancer","HER2-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05966194","name":"RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer","tldr":"A phase 2 trial of Cisplatin in head and neck squamous cell carcinoma, run by EpicentRx, Inc., active and no longer recruiting.","route":"/trials/nct05966194/","status":"active","kind":"trial","cancerIcon":"head-and-neck","sub":"NCT05966194","facets":{"kind":["Trial"],"cancers":["Head and neck squamous cell carcinoma","Oral cavity cancer","Oropharyngeal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Oral cavity cancer","href":"/cancers/oral-cavity-cancer/","tip":"Cancer of the mouth and tongue, a head and neck cancer, is caused mainly by tobacco, alcohol and betel quid and is usually visible or feelable early, yet often diagnosed late. Surgery is the mainstay, with radiotherapy or chemoradiation after operation for higher-risk disease, and reconstruction to restore speech and swallowing."},{"label":"Oropharyngeal cancer","href":"/cancers/oropharyngeal-cancer/","tip":"Cancer of the tonsils and back of the tongue, a head and neck cancer, now comes mostly from HPV infection rather than smoking, and behaves like a different disease: it responds well to chemoradiation, most patients are cured, and the research question is how much treatment can safely be removed."}],"tags":[]},"sortKeys":{"year":0}},{"id":"rv001v","name":"RV001V","tldr":"RV001V is a cancer vaccine from RhoVac APS, in registered phase 2 trials for prostate cancer.","route":"/drugs/rv001v/","status":"phase-2","kind":"drug","molecule":"rv001v","modality":"Cancer vaccine","sub":"RV001V","facets":{"kind":["Treatment"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"rvu120","name":"RVU120","tldr":"RVU120 is a small-molecule inhibitor from Ryvu Therapeutics SA, in registered phase 2 trials for acute myeloid leukaemia.","route":"/drugs/rvu120/","status":"phase-2","kind":"drug","molecule":"rvu120","modality":"Small-molecule inhibitor","sub":"RVU120","facets":{"kind":["Treatment"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct06243458","name":"RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms","tldr":"A phase 2 trial of RVU120 (SEL120) in myelodysplastic syndromes / neoplasms, run by GCP-Service International West GmbH, active and no longer recruiting.","route":"/trials/nct06243458/","status":"active","kind":"trial","cancerIcon":"mds","sub":"NCT06243458","facets":{"kind":["Trial"],"cancers":["Myelodysplastic syndromes / neoplasms","Lower-risk myelodysplastic syndromes"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Myelodysplastic syndromes / neoplasms","href":"/cancers/mds/","tip":"Bone-marrow disorders where blood cells are made badly and too few reach the blood; a third progress to acute leukaemia. Treatment ranges from transfusions and growth factors to hypomethylating drugs and, for the fit, transplant."},{"label":"Lower-risk myelodysplastic syndromes","href":"/cancers/mds-lower-risk/","tip":"Lower-risk myelodysplastic syndromes rarely turn into leukaemia quickly; the problem is anaemia and the transfusions it demands. Erythropoietin, then luspatercept (COMMANDS) and the telomerase blocker imetelstat (IMerge), free many patients from transfusions for months or years, and lenalidomide does the same for the del(5q) subtype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05101070","name":"S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors","tldr":"A phase 1/2 trial of Pembrolizumab and Bevacizumab in advanced solid tumours, run by Shionogi, now recruiting.","route":"/trials/nct05101070/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05101070","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06188702","name":"S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP","tldr":"A phase 1/2 trial of TNG462 in advanced solid tumours, run by Servier Bio-Innovation LLC, active and no longer recruiting.","route":"/trials/nct06188702/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06188702","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"sabatolimab","name":"Sabatolimab","tldr":"Sabatolimab is a monoclonal antibody from Novartis Pharmaceuticals, in registered phase 2 trials for myelodysplastic syndromes / neoplasms.","route":"/drugs/sabatolimab/","status":"phase-2","kind":"drug","molecule":"sabatolimab","modality":"Monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Myelodysplastic syndromes / neoplasms","Higher-risk myelodysplastic syndromes"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Myelodysplastic syndromes / neoplasms","href":"/cancers/mds/","tip":"Bone-marrow disorders where blood cells are made badly and too few reach the blood; a third progress to acute leukaemia. Treatment ranges from transfusions and growth factors to hypomethylating drugs and, for the fit, transplant."},{"label":"Higher-risk myelodysplastic syndromes","href":"/cancers/mds-higher-risk/","tip":"Higher-risk myelodysplastic syndromes behave like a slow leukaemia and often become one. Azacitidine lengthens life and a donor stem cell transplant is the only cure; every attempt to improve on azacitidine in a large trial, including the venetoclax combination tested in VERONA, has so far failed."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct06393374","name":"Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)","tldr":"A phase 3 trial of Pembrolizumab, Sacituzumab tirumotecan and Capecitabine in triple-negative breast cancer, run by Merck Sharp & Dohme LLC, now recruiting.","route":"/trials/nct06393374/","status":"recruiting","kind":"trial","cancerIcon":"tnbc","sub":"NCT06393374","facets":{"kind":["Trial"],"cancers":["Triple-negative breast cancer","Early triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Early triple-negative breast cancer","href":"/cancers/tnbc-early/","tip":"Early triple-negative breast cancer is treated to cure. For tumours over 2 cm or with node involvement, chemotherapy plus the immunotherapy pembrolizumab before and after surgery has raised cure rates; BRCA carriers with cancer left at surgery add a year of olaparib, and others with residual cancer are offered capecitabine. Whether the tumour has vanished by surgery guides what comes next."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07324629","name":"Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma","tldr":"A phase 2 trial of Sacituzumab tirumotecan in thymoma and thymic carcinoma, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07324629/","status":"recruiting","kind":"trial","cancerIcon":"thymic-epithelial","sub":"NCT07324629","facets":{"kind":["Trial"],"cancers":["Thymoma and thymic carcinoma","Thymic carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Thymoma and thymic carcinoma","href":"/cancers/thymic-epithelial/","tip":"Thymoma and thymic carcinoma are rare tumours of the thymus gland in the chest. Thymomas grow slowly, often cause autoimmune diseases such as myasthenia gravis, and are usually cured by surgery; thymic carcinomas behave like other aggressive cancers and have few effective drugs."},{"label":"Thymic carcinoma","href":"/cancers/thymic-carcinoma/","tip":"Thymic carcinoma is the aggressive kind of thymic epithelial tumour, a cancer of the thymus that behaves like carcinoma elsewhere and has often spread when found. Surgery is attempted when possible, carboplatin with paclitaxel is the usual chemotherapy, and sunitinib, lenvatinib and the PD-1 antibody pembrolizumab have shown responses in trials, with lenvatinib approved in Japan."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06937177","name":"Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy","tldr":"A phase 2 trial of TCMCB07 in colorectal cancer, run by Endevica Bio, now recruiting.","route":"/trials/nct06937177/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT06937177","facets":{"kind":["Trial"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03668639","name":"Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin","tldr":"A phase 2/3 trial of Netupitant and palonosetron and Dexamethasone in Cervical cancer, run by Christina Ruhlmann, with a status the registry has not verified recently.","route":"/trials/nct03668639/","kind":"trial","cancerIcon":"cervical","sub":"NCT03668639","facets":{"kind":["Trial"],"cancers":["Cervical cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06474806","name":"Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer","tldr":"A phase 2 trial of 64Cu-DOTA-AE105 in prostate cancer, run by Curasight, now recruiting.","route":"/trials/nct06474806/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT06474806","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00630032","name":"Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer","tldr":"A phase 3 trial of Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil and Ixabepilone in Breast cancer, run by UNICANCER, completed.","route":"/trials/nct00630032/","status":"completed","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT00630032","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05558007","name":"Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients","tldr":"A phase 2 trial of Tadalafil 5mg in prostate cancer, run by Biozeus Biopharmaceutical S.A., now recruiting.","route":"/trials/nct05558007/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT05558007","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04416984","name":"Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)","tldr":"A phase 1/2 trial of ALLO-647, Fludarabine and Cyclophosphamide in chronic lymphocytic leukaemia, run by Allogene Therapeutics, active and no longer recruiting.","route":"/trials/nct04416984/","status":"active","kind":"trial","cancerIcon":"cll","sub":"NCT04416984","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia","Relapsed or refractory chronic lymphocytic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Relapsed or refractory chronic lymphocytic leukaemia","href":"/cancers/cll-relapsed/","tip":"When chronic lymphocytic leukaemia returns, the usual move is to switch drug class: venetoclax-based therapy after a BTK inhibitor, or a BTK inhibitor after venetoclax. Pirtobrutinib (BRUIN) works after the older BTK inhibitors fail, and CAR-T is approved for patients who have run out of both classes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05312710","name":"Safety and Efficacy of APG-157 in Head and Neck Cancer","tldr":"A phase 2 trial of APG-157 in head and neck squamous cell carcinoma, run by Aveta Biomics, Inc., active and no longer recruiting.","route":"/trials/nct05312710/","status":"active","kind":"trial","cancerIcon":"head-and-neck","sub":"NCT05312710","facets":{"kind":["Trial"],"cancers":["Head and neck squamous cell carcinoma","Oral cavity cancer","Oropharyngeal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Oral cavity cancer","href":"/cancers/oral-cavity-cancer/","tip":"Cancer of the mouth and tongue, a head and neck cancer, is caused mainly by tobacco, alcohol and betel quid and is usually visible or feelable early, yet often diagnosed late. Surgery is the mainstay, with radiotherapy or chemoradiation after operation for higher-risk disease, and reconstruction to restore speech and swallowing."},{"label":"Oropharyngeal cancer","href":"/cancers/oropharyngeal-cancer/","tip":"Cancer of the tonsils and back of the tongue, a head and neck cancer, now comes mostly from HPV infection rather than smoking, and behaves like a different disease: it responds well to chemoradiation, most patients are cured, and the research question is how much treatment can safely be removed."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07387926","name":"Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)","tldr":"A phase 1/2 trial of Asciminib, Dexamethasone, Vincristine, Blinatumomab, Methotrexate and Cytarabine in acute lymphoblastic leukaemia, run by Novartis Pharmaceuticals, now recruiting.","route":"/trials/nct07387926/","status":"recruiting","kind":"trial","cancerIcon":"all-leukemia","sub":"NCT07387926","facets":{"kind":["Trial"],"cancers":["Acute lymphoblastic leukaemia","Relapsed and refractory acute lymphoblastic leukaemia in children","Philadelphia chromosome-like acute lymphoblastic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."},{"label":"Relapsed and refractory acute lymphoblastic leukaemia in children","href":"/cancers/all-paediatric-relapsed/","tip":"When childhood leukaemia comes back, chemotherapy alone cures fewer than half. Three immune treatments changed this: blinatumomab, which links the child's T-cells to leukaemia cells and beat chemotherapy in two trials; tisagenlecleucel, the first approved CAR T-cell therapy, which put over eight in ten pretreated children into remission; and the antibody-drug conjugate inotuzumab ozogamicin."},{"label":"Philadelphia chromosome-like acute lymphoblastic leukaemia","href":"/cancers/all-ph-like/","tip":"Ph-like leukaemia behaves like Philadelphia chromosome-positive leukaemia, with the same kind of overactive growth signalling, but lacks the BCR::ABL1 gene itself. It is caused by a scattered set of gene fusions and mutations, many of them blockable by existing kinase pills such as dasatinib or ruxolitinib, and it is now screened for at diagnosis so those drugs can be tried."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00434148","name":"Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease","tldr":"A phase 3 trial of Pasireotide in Pituitary tumours, run by Novartis Pharmaceuticals, completed.","route":"/trials/nct00434148/","status":"completed","kind":"trial","cancerIcon":"pituitary-tumours","sub":"NCT00434148","facets":{"kind":["Trial"],"cancers":["Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma","href":"/cancers/pituitary-tumours/","tip":"Pituitary tumours are usually benign growths of the hormone gland at the base of the brain that cause trouble by overproducing hormones or pressing on the optic nerves. Prolactin-producing tumours melt away with a tablet, most others are cured by surgery through the nose, and the rare aggressive ones respond to the chemotherapy drug temozolomide."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05704244","name":"Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)","tldr":"A phase 3 trial of FE 999326 in bladder & urothelial cancer, run by Ferring Pharmaceuticals, active and no longer recruiting.","route":"/trials/nct05704244/","status":"active","kind":"trial","cancerIcon":"urothelial","sub":"NCT05704244","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Non-muscle-invasive bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Non-muscle-invasive bladder cancer","href":"/cancers/non-muscle-invasive-bladder-cancer/","tip":"Most bladder cancers are found while still confined to the lining. They are scraped out through the urethra and, when higher risk, treated with BCG instilled into the bladder; the challenge is the frequent recurrences and the patients whose tumours stop responding to BCG."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06947291","name":"Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors","tldr":"A phase 2 trial of Glumetinib and Docetaxel in gastric & gastro-oesophageal junction cancer, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., now recruiting.","route":"/trials/nct06947291/","status":"recruiting","kind":"trial","cancerIcon":"gastric","sub":"NCT06947291","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07471789","name":"Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).","tldr":"A phase 1/2 trial of CART84 in acute myeloid leukaemia, run by Gyala Therapeutics, now recruiting.","route":"/trials/nct07471789/","status":"recruiting","kind":"trial","cancerIcon":"aml","sub":"NCT07471789","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06771622","name":"Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of Trastuzumab, Pertuzumab, Oxaliplatin, Capecitabine, Ramucirumab and Bevacizumab in advanced solid tumours, run by FBD Biologics Limited, active and no longer recruiting.","route":"/trials/nct06771622/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06771622","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04262466","name":"Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors","tldr":"A phase 1/2 trial of Brenetafusp, Pembrolizumab, Tebentafusp and Bevacizumab in advanced solid tumours, run by Immunocore Ltd, active and no longer recruiting.","route":"/trials/nct04262466/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04262466","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06506643","name":"Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms","tldr":"A phase 1/2 trial of Zinc-64 Aspartate in advanced solid tumours, run by Vector Vitale LLC, now recruiting.","route":"/trials/nct06506643/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06506643","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04443010","name":"Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma","tldr":"A phase 1/2 trial of Temozolomide in glioma & glioblastoma, run by Philogen S.p.A., now recruiting.","route":"/trials/nct04443010/","status":"recruiting","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT04443010","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01331239","name":"Safety and Efficacy of LCI699 in Cushing's Disease Patients","tldr":"A phase 2 trial of Osilodrostat in Pituitary tumours, run by Novartis Pharmaceuticals, completed.","route":"/trials/nct01331239/","status":"completed","kind":"trial","cancerIcon":"pituitary-tumours","sub":"NCT01331239","facets":{"kind":["Trial"],"cancers":["Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma","href":"/cancers/pituitary-tumours/","tip":"Pituitary tumours are usually benign growths of the hormone gland at the base of the brain that cause trouble by overproducing hormones or pressing on the optic nerves. Prolactin-producing tumours melt away with a tablet, most others are cured by surgery through the nose, and the rare aggressive ones respond to the chemotherapy drug temozolomide."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04888312","name":"Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients","tldr":"A phase 1/2 trial of CD40 agonist mitazalimab in combination with chemotherapy in pancreatic ductal adenocarcinoma, run by Alligator Bioscience AB, active and no longer recruiting.","route":"/trials/nct04888312/","status":"active","kind":"trial","cancerIcon":"pancreatic","sub":"NCT04888312","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06060613","name":"Safety and Efficacy of OBX-115 in Advanced Solid Tumors","tldr":"A phase 1/2 trial of OBX-115 in melanoma and non-small-cell lung cancer, run by Obsidian Therapeutics, Inc., now recruiting.","route":"/trials/nct06060613/","status":"recruiting","kind":"trial","cancerIcon":"melanoma","sub":"NCT06060613","facets":{"kind":["Trial"],"cancers":["Melanoma","Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00600886","name":"Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly","tldr":"A phase 3 trial of Pasireotide and Somatostatin analogues in Pituitary tumours, run by Novartis Pharmaceuticals, completed.","route":"/trials/nct00600886/","status":"completed","kind":"trial","cancerIcon":"pituitary-tumours","sub":"NCT00600886","facets":{"kind":["Trial"],"cancers":["Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma","href":"/cancers/pituitary-tumours/","tip":"Pituitary tumours are usually benign growths of the hormone gland at the base of the brain that cause trouble by overproducing hormones or pressing on the optic nerves. Prolactin-producing tumours melt away with a tablet, most others are cured by surgery through the nose, and the rare aggressive ones respond to the chemotherapy drug temozolomide."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03934372","name":"Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors","tldr":"A phase 1/2 trial of Ponatinib in acute myeloid leukaemia, chronic myeloid leukaemia, acute lymphoblastic leukaemia and non-Hodgkin lymphoma, run by Incyte Biosciences International Sàrl, now recruiting.","route":"/trials/nct03934372/","status":"recruiting","kind":"trial","cancerIcon":"aml","sub":"NCT03934372","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia","Chronic myeloid leukaemia","Acute lymphoblastic leukaemia","Non-Hodgkin lymphoma","Relapsed and refractory acute lymphoblastic leukaemia in children","Acute myeloid leukaemia in children"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Chronic myeloid leukaemia","href":"/cancers/cml/","tip":"Chronic myeloid leukaemia is a blood cancer driven by a single fused gene, BCR-ABL1, and the model for oncogene-targeted treatment: imatinib in 2001 and the tyrosine kinase inhibitors that followed turned it into a condition most people live with long-term. About half of patients with a sustained deep molecular response can now stop treatment altogether."},{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."},{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03793478","name":"Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood","tldr":"A phase 1/2 trial of Quizartinib, Fludarabine, Cytarabine and Etoposide in acute myeloid leukaemia, run by Daiichi Sankyo, active and no longer recruiting.","route":"/trials/nct03793478/","status":"active","kind":"trial","cancerIcon":"aml","sub":"NCT03793478","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia","FLT3-mutated acute myeloid leukaemia","Acute myeloid leukaemia in children"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"FLT3-mutated acute myeloid leukaemia","href":"/cancers/aml-flt3/","tip":"FLT3-mutated acute myeloid leukaemia carries a mutation in a growth-signal receptor that makes the leukaemia relapse quickly. Adding a FLT3 blocker to chemotherapy, midostaurin or quizartinib, lengthens life, and gilteritinib is the standard when the disease comes back."},{"label":"Acute myeloid leukaemia in children","href":"/cancers/aml-paediatric/","tip":"Acute myeloid leukaemia in children carries gene fusions rather than the mutations of ageing, is treated with four or five intensive courses of chemotherapy, and cures around two thirds of children. Adding gemtuzumab ozogamicin lowered relapse in the AAML0531 trial, and the menin inhibitor revumenib is the first targeted drug approved for the KMT2A-rearranged form common in young children."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06191263","name":"Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML","tldr":"A phase 2 trial of Venetoclax in acute myeloid leukaemia, run by Ryvu Therapeutics SA, now recruiting.","route":"/trials/nct06191263/","status":"recruiting","kind":"trial","cancerIcon":"aml","sub":"NCT06191263","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07102901","name":"Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma","tldr":"A phase 2 trial of Trastuzumab rezetecan and Retlirafusp alfa in gastric & gastro-oesophageal junction cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.","route":"/trials/nct07102901/","status":"recruiting","kind":"trial","cancerIcon":"gastric","sub":"NCT07102901","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04959903","name":"Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT","tldr":"A phase 1/2 trial of Allogeneic T cell progenitors, cultured ex-vivo in advanced solid tumours, run by Smart Immune SAS, now recruiting.","route":"/trials/nct04959903/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04959903","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06016920","name":"Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma","tldr":"A phase 1/2 trial of Pembrolizumab in head and neck squamous cell carcinoma, run by Nykode Therapeutics ASA, now recruiting.","route":"/trials/nct06016920/","status":"recruiting","kind":"trial","cancerIcon":"head-and-neck","sub":"NCT06016920","facets":{"kind":["Trial"],"cancers":["Head and neck squamous cell carcinoma","Recurrent or metastatic head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Recurrent or metastatic head and neck squamous cell carcinoma","href":"/cancers/recurrent-metastatic-hnscc/","tip":"When head and neck cancer comes back where it cannot be removed, or spreads elsewhere, it is treated to extend life rather than cure: pembrolizumab, alone or with chemotherapy, is the first choice, cetuximab-based regimens and cheap oral chemotherapy are alternatives, and antibodies that hit two targets at once are in late-stage trials."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02144077","name":"Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy","tldr":"A phase 3 trial of Aminolevulinic acid and Methyl aminolevulinate in Basal cell carcinoma, run by Biofrontera Bioscience GmbH, completed.","route":"/trials/nct02144077/","status":"completed","kind":"trial","cancerIcon":"basal-cell-carcinoma","sub":"NCT02144077","facets":{"kind":["Trial"],"cancers":["Basal cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Basal cell carcinoma","href":"/cancers/basal-cell-carcinoma/","tip":"Basal cell carcinoma is a skin cancer and the most common cancer of all, caused by sun exposure and almost never life-threatening. Nearly all are removed surgically; the rare advanced cases are treated with drugs that block the hedgehog signalling pathway, and with immunotherapy if those fail."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02704858","name":"Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma","tldr":"A phase 1/2 trial of Perillyl alcohol in glioma & glioblastoma, run by Neonc Technologies, Inc., active and no longer recruiting.","route":"/trials/nct02704858/","status":"active","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT02704858","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma","Astrocytoma, IDH-mutant"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."},{"label":"Astrocytoma, IDH-mutant","href":"/cancers/idh-mutant-astrocytoma/","tip":"IDH-mutant astrocytoma is the slow-growing form of adult glioma, defined by a mutation in the IDH1 or IDH2 gene that makes the tumour produce a chemical which rewires its own cells. Surgery first, and then either watchful waiting, the new pill vorasidenib, or radiotherapy with chemotherapy, depending on grade and how much tumour is left."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00377429","name":"Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy","tldr":"A phase 2 trial of Catumaxomab in Ovarian cancer, run by Neovii Biotech, completed.","route":"/trials/nct00377429/","status":"completed","kind":"trial","cancerIcon":"ovarian","sub":"NCT00377429","facets":{"kind":["Trial"],"cancers":["Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04521413","name":"Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies","tldr":"A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by Treadwell Therapeutics, Inc, active and no longer recruiting.","route":"/trials/nct04521413/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04521413","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04623541","name":"Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome","tldr":"A phase 1/2 trial of Epcoritamab, Prednisone, Cyclophosphamide, Doxorubicin, Rituximab and Vincristine in chronic lymphocytic leukaemia, run by Genmab, active and no longer recruiting.","route":"/trials/nct04623541/","status":"active","kind":"trial","cancerIcon":"cll","sub":"NCT04623541","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia","Richter transformation of chronic lymphocytic leukaemia","Relapsed or refractory chronic lymphocytic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Richter transformation of chronic lymphocytic leukaemia","href":"/cancers/richter-transformation-cll/","tip":"Richter transformation is the sudden change of slow chronic lymphocytic leukaemia into a fast-growing lymphoma, usually of the diffuse large B-cell type. It is treated with lymphoma chemotherapy followed by a donor transplant where possible, and newer drugs such as pirtobrutinib, venetoclax combinations and bispecific antibodies are being tested because standard chemotherapy rarely cures it."},{"label":"Relapsed or refractory chronic lymphocytic leukaemia","href":"/cancers/cll-relapsed/","tip":"When chronic lymphocytic leukaemia returns, the usual move is to switch drug class: venetoclax-based therapy after a BTK inhibitor, or a BTK inhibitor after venetoclax. Pirtobrutinib (BRUIN) works after the older BTK inhibitors fail, and CAR-T is approved for patients who have run out of both classes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05951179","name":"Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer","tldr":"A phase 2 trial of TARA-002 in bladder & urothelial cancer, run by Protara Therapeutics, now recruiting.","route":"/trials/nct05951179/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT05951179","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Non-muscle-invasive bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Non-muscle-invasive bladder cancer","href":"/cancers/non-muscle-invasive-bladder-cancer/","tip":"Most bladder cancers are found while still confined to the lining. They are scraped out through the urethra and, when higher risk, treated with BCG instilled into the bladder; the challenge is the frequent recurrences and the patients whose tumours stop responding to BCG."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04938817","name":"Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)","tldr":"A phase 1/2 trial of Pembrolizumab, Lenvatinib and Favezelimab in small-cell lung cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","route":"/trials/nct04938817/","status":"active","kind":"trial","cancerIcon":"sclc","sub":"NCT04938817","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer","Extensive-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."},{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06334432","name":"Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of NUV-1511 in prostate cancer, pancreatic ductal adenocarcinoma and ovarian cancer, run by Nuvation Bio Inc., active and no longer recruiting.","route":"/trials/nct06334432/","status":"active","kind":"trial","cancerIcon":"prostate","sub":"NCT06334432","facets":{"kind":["Trial"],"cancers":["Prostate cancer","Pancreatic ductal adenocarcinoma","Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06508931","name":"Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms","tldr":"A phase 2 trial of Zamtocabtagene autoleucel in advanced solid tumours, run by Miltenyi Biomedicine GmbH, now recruiting.","route":"/trials/nct06508931/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06508931","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07575191","name":"Safety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer","tldr":"A phase 1/2 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by Smartwise Sweden AB, now recruiting.","route":"/trials/nct07575191/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT07575191","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Locally advanced unresectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07463235","name":"Safety and Potency of a High Cabergoline Dosage in Microprolactinomas","tldr":"A phase 3 trial of Cabergoline in Pituitary tumours, run by University of Sao Paulo General Hospital, now recruiting.","route":"/trials/nct07463235/","status":"recruiting","kind":"trial","cancerIcon":"pituitary-tumours","sub":"NCT07463235","facets":{"kind":["Trial"],"cancers":["Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma","href":"/cancers/pituitary-tumours/","tip":"Pituitary tumours are usually benign growths of the hormone gland at the base of the brain that cause trouble by overproducing hormones or pressing on the optic nerves. Prolactin-producing tumours melt away with a tablet, most others are cured by surgery through the nose, and the rare aggressive ones respond to the chemotherapy drug temozolomide."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05544552","name":"Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations","tldr":"A phase 1/2 trial of TYRA-300 in bladder & urothelial cancer, run by Tyra Biosciences, Inc, active and no longer recruiting.","route":"/trials/nct05544552/","status":"active","kind":"trial","cancerIcon":"urothelial","sub":"NCT05544552","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06750185","name":"Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors","tldr":"A phase 1/2 trial of BNT317 DL1 in advanced solid tumours, run by BioNTech SE, now recruiting.","route":"/trials/nct06750185/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06750185","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06449222","name":"Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy","tldr":"A phase 2 trial of Carboplatin, Gemcitabine and Eribulin in triple-negative breast cancer, run by BioNTech SE, active and no longer recruiting.","route":"/trials/nct06449222/","status":"active","kind":"trial","cancerIcon":"tnbc","sub":"NCT06449222","facets":{"kind":["Trial"],"cancers":["Triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06578624","name":"Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors","tldr":"A phase 1/2 trial of SA53-OS (phase 1) in advanced solid tumours, run by Lamassu Bio Inc, now recruiting.","route":"/trials/nct06578624/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06578624","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05744427","name":"Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors","tldr":"A phase 1/2 trial of JSKN003 in advanced solid tumours, run by Jiangsu Alphamab Biopharmaceuticals Co., Ltd, active and no longer recruiting.","route":"/trials/nct05744427/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05744427","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05732831","name":"Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors","tldr":"A phase 1/2 trial of TNG462 and Pembrolizumab in advanced solid tumours, run by Tango Therapeutics, Inc., now recruiting.","route":"/trials/nct05732831/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05732831","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06028074","name":"Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies","tldr":"A phase 1/2 trial of GIM122 in advanced solid tumours, run by Georgiamune Inc, now recruiting.","route":"/trials/nct06028074/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06028074","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06425926","name":"Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors","tldr":"A phase 1/2 trial of GIM-531 in melanoma, run by Georgiamune Inc, now recruiting.","route":"/trials/nct06425926/","status":"recruiting","kind":"trial","cancerIcon":"melanoma","sub":"NCT06425926","facets":{"kind":["Trial"],"cancers":["Melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03003065","name":"Safety and Tumoricidal Effect of Low Dose Foscan PDT in Patients With Inoperable Bile Duct Cancers","tldr":"A phase 2 trial of Temoporfin in Extrahepatic cholangiocarcinoma, run by Chinese University of Hong Kong, completed.","route":"/trials/nct03003065/","status":"completed","kind":"trial","cancerIcon":"extrahepatic-cholangiocarcinoma","sub":"NCT03003065","facets":{"kind":["Trial"],"cancers":["Extrahepatic cholangiocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Extrahepatic cholangiocarcinoma","href":"/cancers/extrahepatic-cholangiocarcinoma/","tip":"Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01744223","name":"Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant","tldr":"A phase 1/2 trial of BPX-501 dose 1 in acute lymphoblastic leukaemia, non-Hodgkin lymphoma and myelodysplastic syndromes / neoplasms, run by Bellicum Pharmaceuticals, active and no longer recruiting.","route":"/trials/nct01744223/","status":"active","kind":"trial","cancerIcon":"all-leukemia","sub":"NCT01744223","facets":{"kind":["Trial"],"cancers":["Acute lymphoblastic leukaemia","Non-Hodgkin lymphoma","Myelodysplastic syndromes / neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."},{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."},{"label":"Myelodysplastic syndromes / neoplasms","href":"/cancers/mds/","tip":"Bone-marrow disorders where blood cells are made badly and too few reach the blood; a third progress to acute leukaemia. Treatment ranges from transfusions and growth factors to hypomethylating drugs and, for the fit, transplant."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04999969","name":"Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours","tldr":"A phase 2 trial of Durvalumab and Gemcitabine in advanced solid tumours, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct04999969/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04999969","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":["2025"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"year":{"facet":"year","value":"2025"},"tags":[]},"sortKeys":{"year":2025}},{"id":"nct06635785","name":"Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors","tldr":"A phase 1/2 trial of AI-081 in advanced solid tumours, run by OncoC4, Inc., now recruiting.","route":"/trials/nct06635785/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06635785","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06014658","name":"Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors","tldr":"A phase 1/2 trial of Antibody-Drug Conjugate in advanced solid tumours, run by MBrace Therapeutics, now recruiting.","route":"/trials/nct06014658/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06014658","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06732531","name":"Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer","tldr":"A phase 1/2 trial of BH011 in bladder & urothelial cancer, run by Zhuhai Beihai Biotech Co., Ltd, now recruiting.","route":"/trials/nct06732531/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT06732531","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Non-muscle-invasive bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Non-muscle-invasive bladder cancer","href":"/cancers/non-muscle-invasive-bladder-cancer/","tip":"Most bladder cancers are found while still confined to the lining. They are scraped out through the urethra and, when higher risk, treated with BCG instilled into the bladder; the challenge is the frequent recurrences and the patients whose tumours stop responding to BCG."}],"tags":[]},"sortKeys":{"year":0}},{"id":"safusidenib","name":"Safusidenib","tldr":"Safusidenib is an experimental small molecule inhibitor from Nuvation Bio in phase 3 trials for glioma & glioblastoma, aimed at IDH1 / IDH2.","route":"/drugs/safusidenib/","status":"phase-3","kind":"drug","molecule":"safusidenib","modality":"small molecule inhibitor","sub":"AB-218","facets":{"kind":["Treatment"],"cancers":["Glioma & glioblastoma","Astrocytoma, IDH-mutant","Oligodendroglioma, IDH-mutant and 1p/19q-codeleted"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."},{"label":"Astrocytoma, IDH-mutant","href":"/cancers/idh-mutant-astrocytoma/","tip":"IDH-mutant astrocytoma is the slow-growing form of adult glioma, defined by a mutation in the IDH1 or IDH2 gene that makes the tumour produce a chemical which rewires its own cells. Surgery first, and then either watchful waiting, the new pill vorasidenib, or radiotherapy with chemotherapy, depending on grade and how much tumour is left."},{"label":"Oligodendroglioma, IDH-mutant and 1p/19q-codeleted","href":"/cancers/oligodendroglioma/","tip":"Oligodendroglioma is the adult brain tumour most responsive to chemotherapy. It is recognised by an IDH mutation together with loss of parts of chromosomes 1 and 19, and after surgery it is treated with radiotherapy plus the PCV drug combination, or, for small grade 2 tumours, with vorasidenib or watchful waiting."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06737081","name":"SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies","tldr":"A phase 2 trial of SAL-0951 tablets 4mg in advanced solid tumours, run by Shenzhen Salubris Pharmaceuticals Co., Ltd., now recruiting.","route":"/trials/nct06737081/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06737081","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04589234","name":"Saltikva for Metastatic Pancreatic Cancer","tldr":"A phase 2 trial of Gemcitabine and Gemcitabine + nab-paclitaxel in pancreatic ductal adenocarcinoma, run by Salspera LLC, active and no longer recruiting.","route":"/trials/nct04589234/","status":"active","kind":"trial","cancerIcon":"pancreatic","sub":"NCT04589234","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00551525","name":"Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer","tldr":"A phase 2 trial of Samarium-153 lexidronam in Prostate cancer, run by Radiation Therapy Oncology Group, completed.","route":"/trials/nct00551525/","status":"completed","kind":"trial","cancerIcon":"prostate","sub":"NCT00551525","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"samuraciclib","name":"Samuraciclib","tldr":"Samuraciclib is an oral cdk inhibitor from Pfizer, in registered phase 2 trials for metastatic cancer, HR-positive / HER2-negative breast cancer.","route":"/drugs/samuraciclib/","status":"phase-2","kind":"drug","molecule":"samuraciclib","modality":"Oral CDK inhibitor","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer","HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."},{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"sapanisertib","name":"Sapanisertib","tldr":"Sapanisertib is an experimental small-molecule drug from Faeth Therapeutics in phase 2 trials for HR-positive / HER2-negative breast cancer and endometrial cancer, aimed at mTOR.","route":"/drugs/sapanisertib/","status":"phase-2","kind":"drug","molecule":"sapanisertib","modality":"small molecule","sub":"FTH-003, MLN0128","facets":{"kind":["Treatment"],"cancers":["HR-positive / HER2-negative breast cancer","Endometrial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07558733","name":"Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer","tldr":"A phase 1/2 trial of Serabelisib, Sapanisertib and Fulvestrant in advanced solid tumours, run by Faeth Therapeutics, now recruiting.","route":"/trials/nct07558733/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07558733","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04154956","name":"SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients","tldr":"A phase 3 trial of Tusamitamab ravtansine and Docetaxel in Non-small-cell lung cancer, run by Sanofi, recorded as terminated on the registry.","route":"/trials/nct04154956/","kind":"trial","cancerIcon":"nsclc","sub":"NCT04154956","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04977024","name":"SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer","tldr":"A phase 2 trial of COVID-19 Vaccine in non-Hodgkin lymphoma and multiple myeloma, run by GeoVax, Inc., active and no longer recruiting.","route":"/trials/nct04977024/","status":"active","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT04977024","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma","Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."},{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[]},"sortKeys":{"year":0}},{"id":"saruparib","name":"Saruparib","tldr":"Saruparib is an experimental small-molecule drug from AstraZeneca in phase 3 trials for prostate cancer, ovarian cancer and non-small-cell lung cancer, aimed at PARP.","route":"/drugs/saruparib/","status":"phase-3","kind":"drug","molecule":"saruparib","modality":"small molecule","sub":"AZD5305","facets":{"kind":["Treatment"],"cancers":["Prostate cancer","Ovarian cancer","Non-small-cell lung cancer","Endometrial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06380751","name":"Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer","tldr":"A phase 3 trial of Saruparib, Camizestrant, Abemaciclib, Ribociclib, Palbociclib and Fulvestrant in HR-positive / HER2-negative breast cancer, run by AstraZeneca, now recruiting.","route":"/trials/nct06380751/","status":"recruiting","kind":"trial","cancerIcon":"breast-hr-positive","sub":"NCT06380751","facets":{"kind":["Trial"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"sasanlimab","name":"Sasanlimab","tldr":"Sasanlimab is an experimental monoclonal antibody from Pfizer in phase 3 trials for bladder & urothelial cancer, aimed at PD-1 and PD-L1.","route":"/drugs/sasanlimab/","status":"phase-3","kind":"drug","molecule":"sasanlimab","modality":"monoclonal antibody","sub":"PF-06801591","facets":{"kind":["Treatment"],"cancers":["Bladder & urothelial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05374603","name":"Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC","tldr":"A phase 2 trial of Savolitinib and Durvalumab in advanced solid tumours, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct05374603/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05374603","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05261399","name":"Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment","tldr":"A phase 3 trial of Savolitinib, Osimertinib, Pemetrexed, Cisplatin and Carboplatin in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct05261399/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT05261399","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","EGFR-mutated non-small-cell lung cancer","MET exon 14 and MET-amplified non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."},{"label":"MET exon 14 and MET-amplified non-small-cell lung cancer","href":"/cancers/met-altered-nsclc/","tip":"MET-driven lung cancer comes in three forms: an exon 14 skipping mutation treated with the pills capmatinib or tepotinib, MET amplification that often arises as an escape route from EGFR drugs, and high c-Met protein levels that the antibody-drug conjugate telisotuzumab vedotin targets."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03091192","name":"Savolitinib vs. Sunitinib in MET-driven PRCC.","tldr":"A phase 3 trial of Savolitinib and Sunitinib in renal cell carcinoma, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct03091192/","status":"active","kind":"trial","cancerIcon":"rcc","sub":"NCT03091192","facets":{"kind":["Trial"],"cancers":["Renal cell carcinoma","Papillary renal cell carcinoma"],"year":["2020"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."},{"label":"Papillary renal cell carcinoma","href":"/cancers/papillary-rcc/","tip":"Papillary kidney cancer is the second commonest type and does not share the VHL biology of clear cell cancer, so the drugs work differently: the MET-targeting drug cabozantinib beat sunitinib in the first trial run just for this disease, and two hereditary syndromes account for some cases."}],"year":{"facet":"year","value":"2020"},"tags":[]},"sortKeys":{"year":2020}},{"id":"nct04986579","name":"Scalp Cooling in MBC","tldr":"A phase 2 trial of Scalp cooling in Breast cancer, run by Dana-Farber Cancer Institute, now recruiting.","route":"/trials/nct04986579/","status":"recruiting","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT04986579","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04079166","name":"SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)","tldr":"A phase 2 trial of SCIB1 or iSCIB1+ DNA vaccine in melanoma, run by Scancell Ltd, active and no longer recruiting.","route":"/trials/nct04079166/","status":"active","kind":"trial","cancerIcon":"melanoma","sub":"NCT04079166","facets":{"kind":["Trial"],"cancers":["Melanoma","Advanced melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"label":"Advanced melanoma","href":"/cancers/advanced-melanoma/","tip":"Advanced melanoma has spread beyond what surgery can remove, and it is the cancer in which immunotherapy first proved it could cure some people: about half of those given nivolumab with ipilimumab are alive ten years later. If immunotherapy fails, options include a cell therapy grown from the patient's own immune cells, a virus injected into the tumour, and targeted pills for BRAF-mutant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"sctb14","name":"SCTB14","tldr":"SCTB14 is an experimental investigational agent whose form is not stated in the registry from Sinocelltech in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.","route":"/drugs/sctb14/","status":"phase-3","kind":"drug","molecule":"sctb14","modality":"not stated (registered as a drug or biological on ClinicalTrials.gov)","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"sctb35","name":"SCTB35","tldr":"SCTB35 is an experimental investigational agent whose form is not stated in the registry from Sinocelltech in phase 3 trials for diffuse large B-cell lymphoma and follicular lymphoma, with its target not yet stated publicly.","route":"/drugs/sctb35/","status":"phase-3","kind":"drug","molecule":"sctb35","modality":"not stated (registered as a drug or biological on ClinicalTrials.gov)","facets":{"kind":["Treatment"],"cancers":["Diffuse large B-cell lymphoma","Follicular lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."},{"label":"Follicular lymphoma","href":"/cancers/follicular-lymphoma/","tip":"Follicular lymphoma is the most common slow-growing lymphoma, defined in about 85% of cases by a BCL2 translocation. Most people live with it for decades, treated only when it causes problems; it can be controlled repeatedly with anti-CD20 antibodies, chemotherapy, bispecifics or CAR-T but rarely cured, and a small share transform into an aggressive lymphoma each year."}],"tags":[]},"sortKeys":{"year":0}},{"id":"sctb41","name":"SCTB41","tldr":"SCTB41 is an experimental investigational agent whose form is not stated in the registry from Sinocelltech in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.","route":"/drugs/sctb41/","status":"phase-3","kind":"drug","molecule":"sctb41","modality":"not stated (registered as a drug or biological on ClinicalTrials.gov)","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"sctc21c","name":"SCTC21C","tldr":"SCTC21C is an experimental investigational agent whose form is not stated in the registry from Sinocelltech in phase 3 trials for multiple myeloma, with its target not yet stated publicly.","route":"/drugs/sctc21c/","status":"phase-3","kind":"drug","molecule":"sctc21c","modality":"not stated (registered as a drug or biological on ClinicalTrials.gov)","facets":{"kind":["Treatment"],"cancers":["Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[]},"sortKeys":{"year":0}},{"id":"selicrelumab","name":"Selicrelumab","tldr":"Selicrelumab is a monoclonal antibody from Hoffmann-La Roche, in registered phase 2 trials for metastatic cancer.","route":"/drugs/selicrelumab/","status":"phase-2","kind":"drug","molecule":"selicrelumab","modality":"Monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct01276054","name":"Sentinel and/or Axillary Lymph Node Biopsy With or Without Axillary Reverse Mapping in Reducing Incidence and Severity of Arm Lymphedema in Stage 0-2 Patients","tldr":"A phase 2 trial of Technetium Tc-99m sulfur colloid in Breast cancer, run by University of Southern California, recorded as terminated on the registry.","route":"/trials/nct01276054/","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT01276054","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05263583","name":"Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma","tldr":"A phase 2 trial of Sepantronium Bromide in non-Hodgkin lymphoma, burkitt lymphoma and diffuse large B-cell lymphoma, run by Cothera Bioscience, Inc, active and no longer recruiting.","route":"/trials/nct05263583/","status":"active","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT05263583","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma","Burkitt lymphoma","Diffuse large B-cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."},{"label":"Burkitt lymphoma","href":"/cancers/burkitt-lymphoma/","tip":"Burkitt lymphoma is the fastest-growing human tumour, driven by a single rearrangement that switches on the MYC gene. That speed makes it exquisitely sensitive to chemotherapy: short, intense courses, now with the antibody rituximab, cure the great majority of children in well-resourced settings. The remaining task is to bring the same cure to the African children who make up most cases."},{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01985724","name":"Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer","tldr":"A phase 3 trial of Docetaxel, Epirubicin, Cyclophosphamide, Fluorouracil, Lenograstim and Pegfilgrastim in Breast cancer, run by Hellenic Oncology Research Group, completed.","route":"/trials/nct01985724/","status":"completed","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT01985724","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07181499","name":"Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI","tldr":"A phase 2 trial of Carboplatin and Pemetrexed in non-small-cell lung cancer, run by Betta Pharmaceuticals Co., Ltd., now recruiting.","route":"/trials/nct07181499/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07181499","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"serabelisib","name":"Serabelisib","tldr":"Serabelisib is an experimental small-molecule drug from Faeth Therapeutics in phase 2 trials for HR-positive / HER2-negative breast cancer and endometrial cancer, aimed at PIK3CA / PI3K-alpha.","route":"/drugs/serabelisib/","status":"phase-2","kind":"drug","molecule":"serabelisib","modality":"small molecule","sub":"FTH-001, MLN1117","facets":{"kind":["Treatment"],"cancers":["HR-positive / HER2-negative breast cancer","Endometrial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04692103","name":"Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy","tldr":"A phase 2 trial of Fluoroestradiol F-18 and Fludeoxyglucose F-18 in Breast cancer, run by University of Washington, active and no longer recruiting.","route":"/trials/nct04692103/","status":"active","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT04692103","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"setidegrasib","name":"Setidegrasib","tldr":"Setidegrasib is an experimental investigational agent whose form is not stated in the registry from Astellas Pharma Global Development in phase 3 trials for pancreatic ductal adenocarcinoma and non-small-cell lung cancer, aimed at KRAS.","route":"/drugs/setidegrasib/","status":"phase-3","kind":"drug","molecule":"setidegrasib","modality":"not stated (registered as a drug or biological on ClinicalTrials.gov)","sub":"ASP3082","facets":{"kind":["Treatment"],"cancers":["Pancreatic ductal adenocarcinoma","Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"sg301","name":"SG301","tldr":"SG301 is an experimental investigational agent whose form is not stated in the registry from Hangzhou Sumgen Biotech in phase 3 trials for multiple myeloma, aimed at CD38.","route":"/drugs/sg301/","status":"phase-3","kind":"drug","molecule":"sg301","modality":"monoclonal antibody (humanised anti-CD38, per the sponsor's description; form not stated in the registry record)","facets":{"kind":["Treatment"],"cancers":["Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[]},"sortKeys":{"year":0}},{"id":"sgm-101","name":"SGM-101","tldr":"SGM-101 is an experimental monoclonal antibody from Surgimab in phase 3 trials for colorectal cancer, aimed at CEACAM5.","route":"/drugs/sgm-101/","status":"phase-3","kind":"drug","molecule":"sgm-101","modality":"monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06080776","name":"SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations","tldr":"A phase 3 trial of SH-1028 tablets in non-small-cell lung cancer, run by Nanjing Sanhome Pharmaceutical, Co., Ltd., now recruiting.","route":"/trials/nct06080776/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06080776","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","EGFR-mutated non-small-cell lung cancer","Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."},{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00026117","name":"Shark Cartilage in Treating Patients With Advanced Colorectal or Breast Cancer","tldr":"A phase 3 trial of Shark cartilage in Breast cancer and Colorectal cancer, run by Alliance for Clinical Trials in Oncology, completed.","route":"/trials/nct00026117/","status":"completed","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT00026117","facets":{"kind":["Trial"],"cancers":["Breast cancer","Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"shr-1501","name":"SHR-1501","tldr":"SHR-1501 is an experimental investigational agent whose form is not stated in the registry from Suzhou Suncadia Biopharmaceuticals in phase 3 trials for bladder & urothelial cancer, with its target not yet stated publicly.","route":"/drugs/shr-1501/","status":"phase-3","kind":"drug","molecule":"shr-1501","modality":"not stated (registered as a drug or biological on ClinicalTrials.gov)","facets":{"kind":["Treatment"],"cancers":["Bladder & urothelial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05300269","name":"SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer","tldr":"A phase 2 trial of Capecitabine, Oxaliplatin and Retlirafusp alfa in colorectal cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.","route":"/trials/nct05300269/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT05300269","facets":{"kind":["Trial"],"cancers":["Colorectal cancer","Rectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Rectal cancer","href":"/cancers/rectal-cancer/","tip":"Rectal cancer is bowel cancer in the last part of the large intestine, where surgery can mean a permanent stoma. Treatment now usually gives all the chemotherapy and radiotherapy first, and about half of people whose tumour disappears completely can keep their rectum and avoid surgery altogether."}],"tags":[]},"sortKeys":{"year":0}},{"id":"shr-8068","name":"SHR-8068","tldr":"SHR-8068 is an experimental investigational agent whose form is not stated in the registry from Suzhou Suncadia Biopharmaceuticals in phase 3 trials for biliary tract cancer, non-small-cell lung cancer and cervical cancer, with its target not yet stated publicly.","route":"/drugs/shr-8068/","status":"phase-3","kind":"drug","molecule":"shr-8068","modality":"monoclonal antibody (anti-CTLA-4, per the sponsor's pipeline page; form not stated in the registry record)","facets":{"kind":["Treatment"],"cancers":["Biliary tract cancer","Non-small-cell lung cancer","Cervical cancer","Gastric & gastro-oesophageal junction cancer","Bladder & urothelial cancer","Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."},{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06465563","name":"SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer","tldr":"A phase 2 trial of SHR-8068, Adebrelimab, Cisplatin, Gemcitabine and Bevacizumab in biliary tract cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., active and no longer recruiting.","route":"/trials/nct06465563/","status":"active","kind":"trial","cancerIcon":"cholangiocarcinoma","sub":"NCT06465563","facets":{"kind":["Trial"],"cancers":["Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06123494","name":"SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen","tldr":"A phase 3 trial of Trastuzumab rezetecan, Docetaxel and Ramucirumab in gastric & gastro-oesophageal junction cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.","route":"/trials/nct06123494/","status":"recruiting","kind":"trial","cancerIcon":"gastric","sub":"NCT06123494","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer","HER2-positive gastric cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"HER2-positive gastric cancer","href":"/cancers/gastric-her2-positive/","tip":"HER2-positive gastric cancer overexpresses the HER2 growth receptor and is treated with trastuzumab added to chemotherapy, now usually with pembrolizumab as well. After progression the antibody-drug conjugate trastuzumab deruxtecan gives responses that plain chemotherapy cannot."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05814354","name":"SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial","tldr":"A phase 3 trial of Trastuzumab rezetecan, Capecitabine, Eribulin, Gemcitabine and Paclitaxel / nab-paclitaxel in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.","route":"/trials/nct05814354/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05814354","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"shr-a1912","name":"SHR-A1912","tldr":"SHR-A1912 is an experimental investigational agent whose form is not stated in the registry from Suzhou Suncadia Biopharmaceuticals in phase 3 trials for diffuse large B-cell lymphoma, with its target not yet stated publicly.","route":"/drugs/shr-a1912/","status":"phase-3","kind":"drug","molecule":"shr-a1912","modality":"antibody-drug conjugate (ADC), per the sponsor's pipeline page; form not stated in the registry record","facets":{"kind":["Treatment"],"cancers":["Diffuse large B-cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."}],"tags":[]},"sortKeys":{"year":0}},{"id":"shr-a1921","name":"SHR-A1921","tldr":"SHR-A1921 is an experimental investigational agent whose form is not stated in the registry from Suzhou Suncadia Biopharmaceuticals in phase 3 trials for ovarian cancer, with its target not yet stated publicly.","route":"/drugs/shr-a1921/","status":"phase-3","kind":"drug","molecule":"shr-a1921","modality":"antibody-drug conjugate (ADC), per the sponsor's pipeline page; form not stated in the registry record","facets":{"kind":["Treatment"],"cancers":["Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"shr-a2009","name":"SHR-A2009","tldr":"SHR-A2009 is an experimental investigational agent whose form is not stated in the registry from Shanghai Hengrui Pharmaceutical in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.","route":"/drugs/shr-a2009/","status":"phase-3","kind":"drug","molecule":"shr-a2009","modality":"antibody-drug conjugate (ADC), per the sponsor's pipeline page; form not stated in the registry record","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"shr-a2102","name":"SHR-A2102","tldr":"SHR-A2102 is an experimental investigational agent whose form is not stated in the registry from Shanghai Hengrui Pharmaceutical in phase 3 trials for cervical cancer, non-small-cell lung cancer and head and neck squamous cell carcinoma, with its target not yet stated publicly.","route":"/drugs/shr-a2102/","status":"phase-3","kind":"drug","molecule":"shr-a2102","modality":"antibody-drug conjugate (ADC), per the sponsor's pipeline page; form not stated in the registry record","facets":{"kind":["Treatment"],"cancers":["Cervical cancer","Non-small-cell lung cancer","Head and neck squamous cell carcinoma","Bladder & urothelial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."}],"tags":[]},"sortKeys":{"year":0}},{"id":"si-b001","name":"SI-B001","tldr":"SI-B001 is an experimental investigational agent whose form is not stated in the registry from Sichuan Baili Pharmaceutical in phase 3 trials for non-small-cell lung cancer and head and neck squamous cell carcinoma, with its target not yet stated publicly.","route":"/drugs/si-b001/","status":"phase-3","kind":"drug","molecule":"si-b001","modality":"bispecific antibody (SI-B001 is izalontamab, EGFR x HER3; INN stem -mab; form not stated in the registry record)","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[]},"sortKeys":{"year":0}},{"id":"silevertinib","name":"Silevertinib","tldr":"Silevertinib is an experimental small-molecule drug from Black Diamond Therapeutics in phase 2 trials for non-small-cell lung cancer, aimed at EGFR.","route":"/drugs/silevertinib/","status":"phase-2","kind":"drug","molecule":"silevertinib","modality":"small molecule","sub":"BDTX-1535","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03315026","name":"Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis","tldr":"A phase 2 trial of Siltuximab in Multiple myeloma, run by Memorial Sloan Kettering Cancer Center, active and no longer recruiting.","route":"/trials/nct03315026/","status":"active","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT03315026","facets":{"kind":["Trial"],"cancers":["Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[]},"sortKeys":{"year":0}},{"id":"sim0270","name":"SIM0270","tldr":"SIM0270 is an experimental investigational agent whose form is not stated in the registry from Jiangsu Simcere Pharmaceutical in phase 3 trials for HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.","route":"/drugs/sim0270/","status":"phase-3","kind":"drug","molecule":"sim0270","modality":"small molecule (structure undisclosed or not yet in PubChem)","facets":{"kind":["Treatment"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07039526","name":"Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer","tldr":"A phase 2 trial of Pafolacianine in Oesophageal cancer, run by John Waters, now recruiting.","route":"/trials/nct07039526/","status":"recruiting","kind":"trial","cancerIcon":"esophageal","sub":"NCT07039526","facets":{"kind":["Trial"],"cancers":["Oesophageal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07648264","name":"Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies","tldr":"A phase 3 trial of IgPro20 in advanced solid tumours, run by CSL Behring, now recruiting.","route":"/trials/nct07648264/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07648264","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00082927","name":"Single-Dose Local Radiation Therapy Compared With Ibandronate in Treating Patients With Localized Metastatic Bone Pain","tldr":"A phase 3 trial of Ibandronic acid in Metastatic cancer and Prostate cancer, run by Cancer Research UK, completed.","route":"/trials/nct00082927/","status":"completed","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT00082927","facets":{"kind":["Trial"],"cancers":["Metastatic cancer","Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."},{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07165886","name":"Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors","tldr":"A phase 2/3 trial of Everolimus in pancreatic ductal adenocarcinoma, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., now recruiting.","route":"/trials/nct07165886/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT07165886","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06957379","name":"Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy","tldr":"A phase 2 trial of Exemestane and Fulvestrant in advanced solid tumours, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., active and no longer recruiting.","route":"/trials/nct06957379/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06957379","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"sitneprotafib","name":"Sitneprotafib","tldr":"Sitneprotafib is an experimental small-molecule drug from Allist Pharmaceuticals in phase 3 trials for non-small-cell lung cancer, colorectal cancer and pancreatic ductal adenocarcinoma, with its target not yet stated publicly.","route":"/drugs/sitneprotafib/","status":"phase-3","kind":"drug","molecule":"sitneprotafib","modality":"small molecule","sub":"JAB-3312","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Colorectal cancer","Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00615602","name":"Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer","tldr":"A phase 3 trial of Docetaxel, Trastuzumab, Epirubicin, Cyclophosphamide, Fluorouracil, Lenograstim and Pegfilgrastim in Breast cancer, run by Hellenic Oncology Research Group, completed.","route":"/trials/nct00615602/","status":"completed","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT00615602","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07459998","name":"SKB103 for Injection in Advanced Solid Tumors","tldr":"A phase 1/2 trial of SKB103 for injection monotherapy in advanced solid tumours, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07459998/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07459998","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"skb105","name":"SKB105","tldr":"SKB105 is an antibody-drug conjugate from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., in registered phase 2 trials for metastatic cancer.","route":"/drugs/skb105/","status":"phase-2","kind":"drug","molecule":"skb105","modality":"Antibody-drug conjugate","sub":"SKB105","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct07380386","name":"SKB105 for Injection in Advanced Solid Tumors","tldr":"A phase 1/2 trial of SKB105 for injection Monotherapy in advanced solid tumours, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07380386/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07380386","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07586943","name":"SKB118 Injection in Advanced Solid Tumors","tldr":"A phase 1/2 trial of SKB118 Injection in advanced solid tumours, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07586943/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07586943","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05642780","name":"SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors","tldr":"A phase 2 trial of Pembrolizumab in advanced solid tumours, run by Klus Pharma Inc., active and no longer recruiting.","route":"/trials/nct05642780/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05642780","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07697586","name":"SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer","tldr":"A phase 2 trial of SKB264+SKB118 in non-small-cell lung cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07697586/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07697586","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05347134","name":"SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer","tldr":"A phase 3 trial of SKB264 in triple-negative breast cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., active and no longer recruiting.","route":"/trials/nct05347134/","status":"active","kind":"trial","cancerIcon":"tnbc","sub":"NCT05347134","facets":{"kind":["Trial"],"cancers":["Triple-negative breast cancer","Metastatic triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Metastatic triple-negative breast cancer","href":"/cancers/tnbc-metastatic/","tip":"Triple-negative breast cancer that has spread is not curable, but its treatment has been transformed since 2020. By PD-L1 score, first treatment is pembrolizumab with chemotherapy or with sacituzumab govitecan, or datopotamab deruxtecan or sacituzumab govitecan alone; BRCA carriers can take a PARP inhibitor tablet; and trastuzumab deruxtecan reaches the third of tumours with low HER2."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05631262","name":"SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors","tldr":"A phase 2 trial of Docetaxel in advanced solid tumours, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., active and no longer recruiting.","route":"/trials/nct05631262/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05631262","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07700667","name":"SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma","tldr":"A phase 2 trial of Tislelizumab and Cisplatin in oesophageal cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07700667/","status":"recruiting","kind":"trial","cancerIcon":"esophageal","sub":"NCT07700667","facets":{"kind":["Trial"],"cancers":["Oesophageal cancer","Oesophageal squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."},{"label":"Oesophageal squamous cell carcinoma","href":"/cancers/oesophageal-squamous-cell-carcinoma/","tip":"Squamous cell carcinoma of the oesophagus, the world's commonest form, is linked to smoking, alcohol and very hot drinks and sits in the upper and middle gullet. It is treated with chemoradiation, with or without surgery, and immunotherapy has recently joined chemotherapy for advanced disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07545265","name":"SKB565 for Injection in Advanced Solid Tumors","tldr":"A phase 1/2 trial of SKB565 in advanced solid tumours, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07545265/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07545265","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07341737","name":"SL-28 for Advanced Solid Tumours","tldr":"A phase 1/2 trial of SL-28 in pancreatic ductal adenocarcinoma, non-small-cell lung cancer, oesophageal cancer, gastric & gastro-oesophageal junction cancer, hepatocellular carcinoma and bladder & urothelial cancer, run by Second Life Therapeutics, now recruiting.","route":"/trials/nct07341737/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT07341737","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Non-small-cell lung cancer","Oesophageal cancer","Gastric & gastro-oesophageal junction cancer","Hepatocellular carcinoma","Bladder & urothelial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."},{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06526819","name":"SMP-3124LP in Adults With Advanced Solid Tumors","tldr":"A phase 1/2 trial of SMP3124LP in advanced solid tumours, run by Sumitomo Pharma America, Inc., now recruiting.","route":"/trials/nct06526819/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06526819","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07391813","name":"SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer","tldr":"A phase 1/2 trial of SNB-101 in small-cell lung cancer, run by SN BioScience, now recruiting.","route":"/trials/nct07391813/","status":"recruiting","kind":"trial","cancerIcon":"sclc","sub":"NCT07391813","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer","Extensive-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."},{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06736704","name":"SNV4818 in Participants With Advanced Solid Tumors","tldr":"A phase 1/2 trial of Fulvestrant and Palbociclib in advanced solid tumours, run by Pikavation Therapeutics, Inc., now recruiting.","route":"/trials/nct06736704/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06736704","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"socazolimab","name":"Socazolimab","tldr":"Socazolimab is Lee's Pharmaceutical's PD-L1 antibody, in phase 3 trials in China for extensive-stage small cell lung cancer and recurrent cervical cancer.","route":"/drugs/socazolimab/","status":"phase-3","kind":"drug","molecule":"socazolimab","modality":"Anti-PD-L1 monoclonal antibody, intravenous","sub":"ZKAB001","facets":{"kind":["Treatment"],"cancers":["Cervical cancer","Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00716976","name":"Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy","tldr":"A phase 3 trial of Sodium thiosulfate in Extragonadal germ cell tumour, Hepatocellular carcinoma, Neuroblastoma and Ovarian cancer, run by Children's Oncology Group, completed.","route":"/trials/nct00716976/","status":"completed","kind":"trial","cancerIcon":"extragonadal-germ-cell-tumour","sub":"NCT00716976","facets":{"kind":["Trial"],"cancers":["Extragonadal germ cell tumour","Hepatocellular carcinoma","Neuroblastoma","Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Extragonadal germ cell tumour","href":"/cancers/extragonadal-germ-cell-tumour/","tip":"Extragonadal germ cell tumours are the same cancers as testicular germ cell tumours but arising in the midline of the body, most often the chest or the back of the abdomen. Seminomas are highly curable with chemotherapy; non-seminomas of the chest are the hardest germ cell tumours to cure and are treated with intensive chemotherapy followed by surgery."},{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."},{"label":"Neuroblastoma","href":"/cancers/neuroblastoma/","tip":"Neuroblastoma is a childhood nerve-cell cancer where anti-GD2 antibodies and, recently, GD2 CAR-T have improved survival in high-risk disease."},{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"sofetabart-mipitecan","name":"Sofetabart Mipitecan","tldr":"Sofetabart Mipitecan is an experimental antibody-drug conjugate from Eli Lilly and in phase 3 trials for ovarian cancer, aimed at Folate receptor alpha.","route":"/drugs/sofetabart-mipitecan/","status":"phase-3","kind":"drug","molecule":"sofetabart-mipitecan","modality":"ADC","sub":"LY4170156","facets":{"kind":["Treatment"],"cancers":["Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07431281","name":"Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2","tldr":"A phase 3 trial of Sonesitatug vedotin, Rilvegostomig, Nivolumab, Capecitabine, Oxaliplatin and Zolbetuximab in gastric & gastro-oesophageal junction cancer and oesophageal cancer, run by AstraZeneca, now recruiting.","route":"/trials/nct07431281/","status":"recruiting","kind":"trial","cancerIcon":"gastric","sub":"NCT07431281","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer","Oesophageal cancer","Oesophageal and junctional adenocarcinoma","Claudin 18.2-positive gastric cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."},{"label":"Oesophageal and junctional adenocarcinoma","href":"/cancers/oesophageal-adenocarcinoma/","tip":"Adenocarcinoma of the lower oesophagus and junction grows out of Barrett's oesophagus, the change in the lining caused by long-standing acid reflux. Chemotherapy or chemoradiation before surgery is standard, and HER2, PD-L1 and claudin 18.2 now guide drugs for advanced disease as they do in stomach cancer."},{"label":"Claudin 18.2-positive gastric cancer","href":"/cancers/gastric-cldn18-2-positive/","tip":"Claudin 18.2 is a tight-junction protein normally hidden inside stomach lining cells that becomes exposed on the surface of many stomach cancers. Zolbetuximab, an antibody against it, added to chemotherapy lengthens survival in tumours that express it strongly, and antibody-drug conjugates and CAR-T cells against the same target are in trials."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05902169","name":"Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM","tldr":"A phase 3 trial of Carboplatin and Temozolomide in glioma & glioblastoma, run by CarThera, now recruiting.","route":"/trials/nct05902169/","status":"recruiting","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT05902169","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"soquelitinib","name":"Soquelitinib","tldr":"Soquelitinib is an experimental small-molecule drug from Corvus Pharmaceuticals in phase 3 trials for peripheral T-cell lymphomas, with its target not yet stated publicly.","route":"/drugs/soquelitinib/","status":"phase-3","kind":"drug","molecule":"soquelitinib","modality":"small molecule","sub":"CPI-818","facets":{"kind":["Treatment"],"cancers":["Peripheral T-cell lymphomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Peripheral T-cell lymphomas","href":"/cancers/peripheral-t-cell-lymphoma/","tip":"Peripheral T-cell lymphomas are lymphomas of T cells rather than B cells. They are rarer, more varied and, apart from a few subtypes, harder to treat than B-cell lymphomas; several new drugs help only defined subtypes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"sotevtamab","name":"Sotevtamab","tldr":"Sotevtamab is a monoclonal antibody from Alethia Biotherapeutics, in registered phase 2 trials for colorectal cancer.","route":"/drugs/sotevtamab/","status":"phase-2","kind":"drug","molecule":"sotevtamab","modality":"Monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct03448549","name":"SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients","tldr":"A phase 3 trial of Oxaliplatin, Tegafur, gimeracil and oteracil and Capecitabine in Colorectal cancer, run by Peking University Cancer Hospital & Institute, with a status the registry has not verified recently.","route":"/trials/nct03448549/","kind":"trial","cancerIcon":"colorectal","sub":"NCT03448549","facets":{"kind":["Trial"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"spartalizumab","name":"Spartalizumab","tldr":"Spartalizumab is a monoclonal antibody from Novartis Pharmaceuticals, in registered phase 2 trials for myelodysplastic syndromes / neoplasms.","route":"/drugs/spartalizumab/","status":"phase-2","kind":"drug","molecule":"spartalizumab","modality":"Monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Myelodysplastic syndromes / neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Myelodysplastic syndromes / neoplasms","href":"/cancers/mds/","tip":"Bone-marrow disorders where blood cells are made badly and too few reach the blood; a third progress to acute leukaemia. Treatment ranges from transfusions and growth factors to hypomethylating drugs and, for the fit, transplant."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct04044768","name":"Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma","tldr":"A phase 2 trial of Afamitresgene autoleucel in sarcomas, run by USWM CT, LLC, active and no longer recruiting.","route":"/trials/nct04044768/","status":"active","kind":"trial","cancerIcon":"sarcoma","sub":"NCT04044768","facets":{"kind":["Trial"],"cancers":["Sarcomas","Liposarcoma","Synovial sarcoma"],"year":["2025"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Sarcomas","href":"/cancers/sarcoma/","tip":"Sarcomas are dozens of rare cancers of bone and connective tissue. GIST was the first solid tumour cured-in-practice by a targeted pill; synovial sarcoma got the first TCR-T therapy."},{"label":"Liposarcoma","href":"/cancers/liposarcoma/","tip":"Liposarcoma is a cancer of fat cells that comes in four different forms: two driven by extra copies of the MDM2 gene, one by a fusion gene that makes it unusually sensitive to radiotherapy and trabectedin, and one that behaves like other aggressive sarcomas. Surgery is the mainstay and MDM2 inhibitors are the most promising drugs in trials."},{"label":"Synovial sarcoma","href":"/cancers/synovial-sarcoma/","tip":"Synovial sarcoma is a young person's sarcoma driven by a single fusion gene, SS18-SSX, that scrambles how genes are switched on. It is treated with surgery, radiotherapy and ifosfamide-based chemotherapy, and in 2024 it became the first solid tumour with an approved engineered T-cell receptor therapy."}],"year":{"facet":"year","value":"2025"},"tags":[]},"sortKeys":{"year":2025}},{"id":"spevatamig","name":"Spevatamig","tldr":"Spevatamig is an experimental bispecific antibody from Phanes Therapeutics in phase 2 trials for gastric & gastro-oesophageal junction cancer, pancreatic ductal adenocarcinoma and biliary tract cancer, aimed at Claudin 18.2 and CD47.","route":"/drugs/spevatamig/","status":"phase-2","kind":"drug","molecule":"spevatamig","modality":"bispecific antibody","sub":"PT886","facets":{"kind":["Treatment"],"cancers":["Gastric & gastro-oesophageal junction cancer","Pancreatic ductal adenocarcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"sph4336","name":"SPH4336","tldr":"SPH4336 is an experimental small-molecule drug from Shanghai Pharmaceuticals in phase 3 trials for HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.","route":"/drugs/sph4336/","status":"phase-3","kind":"drug","molecule":"sph4336","modality":"small molecule","facets":{"kind":["Treatment"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ssgj-612","name":"SSGJ-612","tldr":"SSGJ-612 is an experimental monoclonal antibody from Shenyang Sunshine Pharmaceutical in phase 2 trials, aimed at HER2.","route":"/drugs/ssgj-612/","status":"phase-2","kind":"drug","molecule":"ssgj-612","modality":"monoclonal antibody","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"ssgj-705","name":"SSGJ-705","tldr":"SSGJ-705 is an experimental monoclonal antibody from Shenyang Sunshine Pharmaceutical in phase 2 trials, aimed at PD-1 and HER2.","route":"/drugs/ssgj-705/","status":"phase-2","kind":"drug","molecule":"ssgj-705","modality":"monoclonal antibody","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07022002","name":"SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors","tldr":"A phase 2 trial of SSGJ-705 in advanced solid tumours, run by Shenyang Sunshine Pharmaceutical Co., LTD., now recruiting.","route":"/trials/nct07022002/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07022002","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07646626","name":"SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors","tldr":"A phase 2 trial of SSGJ-705 and SSGJ-612 in advanced solid tumours, run by Shenyang Sunshine Pharmaceutical Co., LTD., now recruiting.","route":"/trials/nct07646626/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07646626","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ssgj-706","name":"SSGJ-706","tldr":"SSGJ-706 is an experimental bispecific antibody from Shenyang Sunshine Pharmaceutical in phase 2 trials for non-small-cell lung cancer, aimed at PD-1 and PD-L1.","route":"/drugs/ssgj-706/","status":"phase-2","kind":"drug","molecule":"ssgj-706","modality":"bispecific antibody","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03678025","name":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer","tldr":"A phase 3 trial of Abiraterone acetate, Bicalutamide, Degarelix, Docetaxel, Flutamide, Goserelin / leuprolide, Histrelin, Leuprolide, Nilutamide, Prednisone and Triptorelin in Prostate cancer, run by SWOG Cancer Research Network, now recruiting.","route":"/trials/nct03678025/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT03678025","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06975293","name":"STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas","tldr":"A phase 1/2 trial of Toripalimab in sarcomas and uterine sarcoma, run by STORM Therapeutics LTD, now recruiting.","route":"/trials/nct06975293/","status":"recruiting","kind":"trial","cancerIcon":"sarcoma","sub":"NCT06975293","facets":{"kind":["Trial"],"cancers":["Sarcomas","Uterine sarcoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Sarcomas","href":"/cancers/sarcoma/","tip":"Sarcomas are dozens of rare cancers of bone and connective tissue. GIST was the first solid tumour cured-in-practice by a targeted pill; synovial sarcoma got the first TCR-T therapy."},{"label":"Uterine sarcoma","href":"/cancers/uterine-sarcoma/","tip":"Uterine sarcomas are rare cancers of the muscle and supporting tissue of the womb, distinct from the far commoner endometrial cancer. Removing the uterus intact is the main treatment and is followed by observation for stage I disease; low-grade stromal sarcomas respond to hormone-blocking pills, while advanced leiomyosarcoma is treated with doxorubicin and trabectedin."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02730299","name":"Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS","tldr":"A phase 3 trial of Omidubicel in Acute lymphoblastic leukaemia and Leukaemia, run by Gamida Cell ltd, completed.","route":"/trials/nct02730299/","status":"completed","kind":"trial","cancerIcon":"all-leukemia","sub":"NCT02730299","facets":{"kind":["Trial"],"cancers":["Acute lymphoblastic leukaemia","Leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."},{"label":"Leukaemia","href":"/cancers/leukaemia/","tip":"Leukaemia means cancer of the blood-forming cells, but the four main types share little beyond the name: acute lymphoblastic and acute myeloid leukaemia are emergencies treated with intensive therapy, while chronic lymphocytic and chronic myeloid leukaemia are slow diseases controlled for years with pills. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06260033","name":"Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer","tldr":"A phase 2 trial of Fluoroestradiol F-18 in Breast cancer, run by City of Hope Medical Center, now recruiting.","route":"/trials/nct06260033/","status":"recruiting","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT06260033","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"sti-6129","name":"STI-6129","tldr":"STI-6129 is an experimental antibody-drug conjugate from Zhejiang ACEA Pharmaceutical in phase 2 trials for multiple myeloma, aimed at CD38.","route":"/drugs/sti-6129/","status":"phase-2","kind":"drug","molecule":"sti-6129","modality":"ADC","facets":{"kind":["Treatment"],"cancers":["Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[]},"sortKeys":{"year":0}},{"id":"stp938","name":"STP938","tldr":"STP938 is a small-molecule inhibitor from Step Pharma, SAS, in registered phase 2 trials for non-Hodgkin lymphoma.","route":"/drugs/stp938/","status":"phase-2","kind":"drug","molecule":"stp938","modality":"Small-molecule inhibitor","sub":"STP938","facets":{"kind":["Treatment"],"cancers":["Non-Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct02952885","name":"Strict IGF-1 Control in Acromegaly","tldr":"A phase 3 trial of Pegvisomant in Pituitary tumours, run by Unity Health Toronto, completed.","route":"/trials/nct02952885/","status":"completed","kind":"trial","cancerIcon":"pituitary-tumours","sub":"NCT02952885","facets":{"kind":["Trial"],"cancers":["Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma","href":"/cancers/pituitary-tumours/","tip":"Pituitary tumours are usually benign growths of the hormone gland at the base of the brain that cause trouble by overproducing hormones or pressing on the optic nerves. Prolactin-producing tumours melt away with a tablet, most others are cured by surgery through the nose, and the rare aggressive ones respond to the chemotherapy drug temozolomide."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07007312","name":"Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML","tldr":"A phase 3 trial of Ziftomenib, Venetoclax, Azacitidine, Daunorubicin and Cytarabine in acute myeloid leukaemia, run by Kura Oncology, Inc., now recruiting.","route":"/trials/nct07007312/","status":"recruiting","kind":"trial","cancerIcon":"aml","sub":"NCT07007312","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia","NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia","href":"/cancers/aml-npm1-kmt2a/","tip":"NPM1-mutated and KMT2A-rearranged leukaemias depend on a protein called menin to keep leukaemia genes switched on. Menin inhibitors, revumenib and ziftomenib, are the first drugs to exploit this, and they produce remissions in patients whose leukaemia had come back after everything else."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04130516","name":"Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab","tldr":"A phase 1/2 trial of LNS8801 and Pembrolizumab in advanced solid tumours, run by Linnaeus Therapeutics, Inc., active and no longer recruiting.","route":"/trials/nct04130516/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04130516","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04524000","name":"Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer","tldr":"A phase 2 trial of Alpelisib and Fulvestrant in advanced solid tumours, run by Novartis Pharmaceuticals, active and no longer recruiting.","route":"/trials/nct04524000/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04524000","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04544189","name":"Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer","tldr":"A phase 2 trial of Alpelisib and Fulvestrant in advanced solid tumours, run by Novartis Pharmaceuticals, active and no longer recruiting.","route":"/trials/nct04544189/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04544189","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05163041","name":"Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression","tldr":"A phase 1/2 trial of Nivolumab in advanced solid tumours, run by BicycleTx Limited, active and no longer recruiting.","route":"/trials/nct05163041/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05163041","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04561362","name":"Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies","tldr":"A phase 1/2 trial of Zelenectide pevedotin and Pembrolizumab in bladder & urothelial cancer, triple-negative breast cancer, HR-positive / HER2-negative breast cancer, HER2-positive breast cancer, non-small-cell lung cancer and ovarian cancer, run by BicycleTx Limited, active and no longer recruiting.","route":"/trials/nct04561362/","status":"active","kind":"trial","cancerIcon":"urothelial","sub":"NCT04561362","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Triple-negative breast cancer","HR-positive / HER2-negative breast cancer","HER2-positive breast cancer","Non-small-cell lung cancer","Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06225596","name":"Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)","tldr":"A phase 2 trial of Zelenectide pevedotin, Pembrolizumab, Carboplatin, Cisplatin, Gemcitabine and Gemcitabine + cisplatin in bladder & urothelial cancer, run by BicycleTx Limited, active and no longer recruiting.","route":"/trials/nct06225596/","status":"active","kind":"trial","cancerIcon":"urothelial","sub":"NCT06225596","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03061812","name":"Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)","tldr":"A phase 3 trial of Rovalpituzumab tesirine, Topotecan and Dexamethasone in Small-cell lung cancer, run by AbbVie, completed.","route":"/trials/nct03061812/","status":"completed","kind":"trial","cancerIcon":"sclc","sub":"NCT03061812","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05917405","name":"Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT","tldr":"A phase 2 trial of Fludarabine, Busulfan and Clofarabine in Acute myeloid leukaemia, run by Nantes University Hospital, now recruiting.","route":"/trials/nct05917405/","status":"recruiting","kind":"trial","cancerIcon":"aml","sub":"NCT05917405","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04632758","name":"Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients","tldr":"A phase 3 trial of Iruplinalkib and Crizotinib in Non-small-cell lung cancer, run by Qilu Pharmaceutical Co., Ltd., with a status the registry has not verified recently.","route":"/trials/nct04632758/","kind":"trial","cancerIcon":"nsclc","sub":"NCT04632758","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06549465","name":"Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)","tldr":"A phase 2 trial of In-111 rosopatamab tetraxetan in prostate cancer, run by Convergent Therapeutics, now recruiting.","route":"/trials/nct06549465/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT06549465","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05226871","name":"Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies","tldr":"A phase 2 trial of Palbociclib, Cetuximab and Fulvestrant in head and neck squamous cell carcinoma, run by Pfizer, active and no longer recruiting.","route":"/trials/nct05226871/","status":"active","kind":"trial","cancerIcon":"head-and-neck","sub":"NCT05226871","facets":{"kind":["Trial"],"cancers":["Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03603795","name":"Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy","tldr":"A phase 2 trial of Eltrombopag in Acute myeloid leukaemia, run by French Innovative Leukemia Organisation, active and no longer recruiting.","route":"/trials/nct03603795/","status":"active","kind":"trial","cancerIcon":"aml","sub":"NCT03603795","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07300943","name":"Study in Advanced Solid Tumor Patients","tldr":"A phase 1/2 trial of CLIO-8221 in advanced solid tumours, run by Callio Therapeutics, now recruiting.","route":"/trials/nct07300943/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07300943","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07278479","name":"Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors","tldr":"A phase 1/2 trial of [212Pb]Pb-MP0712 in neuroendocrine tumours, small-cell lung cancer, pancreatic ductal adenocarcinoma and bladder & urothelial cancer, run by Molecular Partners AG, now recruiting.","route":"/trials/nct07278479/","status":"recruiting","kind":"trial","cancerIcon":"neuroendocrine","sub":"NCT07278479","facets":{"kind":["Trial"],"cancers":["Neuroendocrine tumours","Small-cell lung cancer","Pancreatic ductal adenocarcinoma","Bladder & urothelial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Neuroendocrine tumours","href":"/cancers/neuroendocrine/","tip":"A family of usually slow-growing tumours that start in hormone-producing cells of the gut, pancreas and lungs. They pioneered the idea of using the same molecule to see a tumour on a scan and then to treat it with radiation."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02981368","name":"Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer","tldr":"A phase 2/3 trial of Piflufolastat F-18 / Pylarify TruVu in Prostate cancer, run by Progenics Pharmaceuticals, Inc., completed.","route":"/trials/nct02981368/","status":"completed","kind":"trial","cancerIcon":"prostate","sub":"NCT02981368","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03739684","name":"Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer","tldr":"A phase 3 trial of Piflufolastat F-18 / Pylarify TruVu in Prostate cancer, run by Progenics Pharmaceuticals, Inc., completed.","route":"/trials/nct03739684/","status":"completed","kind":"trial","cancerIcon":"prostate","sub":"NCT03739684","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06754085","name":"Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer","tldr":"A phase 3 trial of Florastamin[18F] Injection in prostate cancer, run by HTA Co., Ltd., now recruiting.","route":"/trials/nct06754085/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT06754085","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00045968","name":"Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer","tldr":"A phase 3 trial of DCVax-L in Glioma & glioblastoma and Brain and spinal cord tumours, run by Northwest Biotherapeutics, with a status the registry has not verified recently.","route":"/trials/nct00045968/","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT00045968","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma","Brain and spinal cord tumours"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."},{"label":"Brain and spinal cord tumours","href":"/cancers/brain-tumours/","tip":"Brain and spinal cord tumours range from slow-growing meningiomas and low-grade gliomas to glioblastoma, the commonest malignant brain tumour in adults, and a distinct set of childhood tumours such as medulloblastoma and diffuse midline glioma. Molecular markers now define them, and treatment is surgery, radiotherapy and, for some, drugs chosen by those markers."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00100243","name":"Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy","tldr":"A phase 2 trial of Abarelix in Prostate cancer, run by PRAECIS Pharmaceuticals Inc., completed.","route":"/trials/nct00100243/","status":"completed","kind":"trial","cancerIcon":"prostate","sub":"NCT00100243","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05386108","name":"Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer","tldr":"A phase 1/2 trial of Elacestrant and Abemaciclib in brain and spinal cord tumours, run by Stemline Therapeutics, Inc., now recruiting.","route":"/trials/nct05386108/","status":"recruiting","kind":"trial","cancerIcon":"brain-tumours","sub":"NCT05386108","facets":{"kind":["Trial"],"cancers":["Brain and spinal cord tumours","Brain metastases"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Brain and spinal cord tumours","href":"/cancers/brain-tumours/","tip":"Brain and spinal cord tumours range from slow-growing meningiomas and low-grade gliomas to glioblastoma, the commonest malignant brain tumour in adults, and a distinct set of childhood tumours such as medulloblastoma and diffuse midline glioma. Molecular markers now define them, and treatment is surgery, radiotherapy and, for some, drugs chosen by those markers."},{"label":"Brain metastases","href":"/cancers/secondary-brain-tumours/","tip":"Brain metastases are cancers that have spread to the brain from elsewhere, most often from the lung, breast or skin. Focused radiation aimed at each spot (radiosurgery) has largely replaced radiation to the whole brain, and for some cancers modern targeted drugs and immunotherapy reach the brain well enough to shrink the deposits on their own."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02477696","name":"Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)","tldr":"A phase 3 trial of Acalabrutinib and Ibrutinib in chronic lymphocytic leukaemia, run by Acerta Pharma BV, active and no longer recruiting.","route":"/trials/nct02477696/","status":"active","kind":"trial","cancerIcon":"cll","sub":"NCT02477696","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia","Relapsed or refractory chronic lymphocytic leukaemia"],"year":["2022"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Relapsed or refractory chronic lymphocytic leukaemia","href":"/cancers/cll-relapsed/","tip":"When chronic lymphocytic leukaemia returns, the usual move is to switch drug class: venetoclax-based therapy after a BTK inhibitor, or a BTK inhibitor after venetoclax. Pirtobrutinib (BRUIN) works after the older BTK inhibitors fail, and CAR-T is approved for patients who have run out of both classes."}],"year":{"facet":"year","value":"2022"},"tags":[]},"sortKeys":{"year":2022}},{"id":"nct04075292","name":"Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia","tldr":"A phase 3 trial of Acalabrutinib, Rituximab and Chlorambucil in chronic lymphocytic leukaemia, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct04075292/","status":"active","kind":"trial","cancerIcon":"cll","sub":"NCT04075292","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia","Chronic lymphocytic leukaemia, first treatment"],"year":["2025"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Chronic lymphocytic leukaemia, first treatment","href":"/cancers/cll-treatment-naive/","tip":"Chronic lymphocytic leukaemia is treated only when it causes problems, and chemotherapy has gone. The first treatment is now either a BTK inhibitor taken indefinitely or a one-year course of venetoclax with obinutuzumab (CLL14), and the two can be combined for a fixed course."}],"year":{"facet":"year","value":"2025"},"tags":[]},"sortKeys":{"year":2025}},{"id":"nct06380660","name":"Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of ACE-86225106 tablet in ovarian cancer and prostate cancer, run by Acerand Therapeutics (Shanghai) Limited, active and no longer recruiting.","route":"/trials/nct06380660/","status":"active","kind":"trial","cancerIcon":"ovarian","sub":"NCT06380660","facets":{"kind":["Trial"],"cancers":["Ovarian cancer","Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06599775","name":"Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer","tldr":"A phase 2 trial of Endoscopic resection in Oesophageal squamous cell carcinoma, run by Shanghai Zhongshan Hospital, not yet recruiting.","route":"/trials/nct06599775/","status":"planned","kind":"trial","cancerIcon":"oesophageal-squamous-cell-carcinoma","sub":"NCT06599775","facets":{"kind":["Trial"],"cancers":["Oesophageal squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Oesophageal squamous cell carcinoma","href":"/cancers/oesophageal-squamous-cell-carcinoma/","tip":"Squamous cell carcinoma of the oesophagus, the world's commonest form, is linked to smoking, alcohol and very hot drinks and sits in the upper and middle gullet. It is treated with chemoradiation, with or without surgery, and immunotherapy has recently joined chemotherapy for advanced disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05689853","name":"Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of AK119 in advanced solid tumours, run by Akeso, now recruiting.","route":"/trials/nct05689853/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05689853","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07284433","name":"Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies","tldr":"A phase 1/2 trial of Allo-QuadCAR01-T in diffuse large B-cell lymphoma and non-Hodgkin lymphoma, run by AvenCell Therapeutics, Inc., now recruiting.","route":"/trials/nct07284433/","status":"recruiting","kind":"trial","cancerIcon":"dlbcl","sub":"NCT07284433","facets":{"kind":["Trial"],"cancers":["Diffuse large B-cell lymphoma","Non-Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."},{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04208178","name":"Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation","tldr":"A phase 3 trial of Alpelisib, Trastuzumab and Pertuzumab in HER2-positive breast cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.","route":"/trials/nct04208178/","status":"active","kind":"trial","cancerIcon":"breast-her2-positive","sub":"NCT04208178","facets":{"kind":["Trial"],"cancers":["HER2-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07346144","name":"Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma","tldr":"A phase 1/2 trial of TGX-007 in glioma & glioblastoma, run by Trogenix ltd, now recruiting.","route":"/trials/nct07346144/","status":"recruiting","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT07346144","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02887040","name":"Study of Antineoplaston Therapy + Radiation vs. Radiation Only in Diffuse, Intrinsic, Brainstem Glioma","tldr":"A phase 3 trial of Antineoplastons in Glioma & glioblastoma, run by Burzynski Research Institute, not yet recruiting.","route":"/trials/nct02887040/","status":"planned","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT02887040","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05147467","name":"Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL","tldr":"A phase 2 trial of APG2575 in chronic lymphocytic leukaemia, run by Ascentage Pharma Group Inc., now recruiting.","route":"/trials/nct05147467/","status":"recruiting","kind":"trial","cancerIcon":"cll","sub":"NCT05147467","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia","Relapsed or refractory chronic lymphocytic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Relapsed or refractory chronic lymphocytic leukaemia","href":"/cancers/cll-relapsed/","tip":"When chronic lymphocytic leukaemia returns, the usual move is to switch drug class: venetoclax-based therapy after a BTK inhibitor, or a BTK inhibitor after venetoclax. Pirtobrutinib (BRUIN) works after the older BTK inhibitors fail, and CAR-T is approved for patients who have run out of both classes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04494503","name":"Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL","tldr":"A phase 1/2 trial of Rituximab and Ibrutinib in chronic lymphocytic leukaemia, run by Ascentage Pharma Group Inc., now recruiting.","route":"/trials/nct04494503/","status":"recruiting","kind":"trial","cancerIcon":"cll","sub":"NCT04494503","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia","Relapsed or refractory chronic lymphocytic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Relapsed or refractory chronic lymphocytic leukaemia","href":"/cancers/cll-relapsed/","tip":"When chronic lymphocytic leukaemia returns, the usual move is to switch drug class: venetoclax-based therapy after a BTK inhibitor, or a BTK inhibitor after venetoclax. Pirtobrutinib (BRUIN) works after the older BTK inhibitors fail, and CAR-T is approved for patients who have run out of both classes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05898399","name":"Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)","tldr":"A phase 1/2 trial of Olaparib in advanced solid tumours, run by Artios Pharma Ltd, now recruiting.","route":"/trials/nct05898399/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05898399","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04665856","name":"Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer","tldr":"A phase 3 trial of Tiragolumab, Atezolizumab, Carboplatin and Etoposide in small-cell lung cancer, run by Hoffmann-La Roche, now completed.","route":"/trials/nct04665856/","status":"completed","kind":"trial","cancerIcon":"sclc","sub":"NCT04665856","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer","Extensive-stage small-cell lung cancer"],"year":["2025"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."},{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"year":{"facet":"year","value":"2025"},"tags":[]},"sortKeys":{"year":2025}},{"id":"nct05433532","name":"Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients","tldr":"A phase 2 trial of Azacitidine, Venetoclax and Flumatinib in Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic myeloid leukaemia and Leukaemia, run by The First Affiliated Hospital of Soochow University, completed.","route":"/trials/nct05433532/","status":"completed","kind":"trial","cancerIcon":"aml","sub":"NCT05433532","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia","Acute lymphoblastic leukaemia","Chronic myeloid leukaemia","Leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."},{"label":"Chronic myeloid leukaemia","href":"/cancers/cml/","tip":"Chronic myeloid leukaemia is a blood cancer driven by a single fused gene, BCR-ABL1, and the model for oncogene-targeted treatment: imatinib in 2001 and the tyrosine kinase inhibitors that followed turned it into a condition most people live with long-term. About half of patients with a sustained deep molecular response can now stop treatment altogether."},{"label":"Leukaemia","href":"/cancers/leukaemia/","tip":"Leukaemia means cancer of the blood-forming cells, but the four main types share little beyond the name: acute lymphoblastic and acute myeloid leukaemia are emergencies treated with intensive therapy, while chronic lymphocytic and chronic myeloid leukaemia are slow diseases controlled for years with pills. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06267729","name":"Study of AZD0754 in Participants With Metastatic Prostate Cancer","tldr":"A phase 1/2 trial of AZD0754 in prostate cancer, run by AstraZeneca, now recruiting.","route":"/trials/nct06267729/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT06267729","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07155226","name":"Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression","tldr":"A phase 1/2 trial of AZD3632 in acute lymphoblastic leukaemia, acute myeloid leukaemia and myelodysplastic syndromes / neoplasms, run by AstraZeneca, now recruiting.","route":"/trials/nct07155226/","status":"recruiting","kind":"trial","cancerIcon":"all-leukemia","sub":"NCT07155226","facets":{"kind":["Trial"],"cancers":["Acute lymphoblastic leukaemia","Acute myeloid leukaemia","Myelodysplastic syndromes / neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."},{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Myelodysplastic syndromes / neoplasms","href":"/cancers/mds/","tip":"Bone-marrow disorders where blood cells are made badly and too few reach the blood; a third progress to acute leukaemia. Treatment ranges from transfusions and growth factors to hypomethylating drugs and, for the fit, transplant."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07109219","name":"Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia","tldr":"A phase 1/2 trial of AZD4512 in acute lymphoblastic leukaemia, run by AstraZeneca, now recruiting.","route":"/trials/nct07109219/","status":"recruiting","kind":"trial","cancerIcon":"all-leukemia","sub":"NCT07109219","facets":{"kind":["Trial"],"cancers":["Acute lymphoblastic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07446855","name":"Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours","tldr":"A phase 1/2 trial of Saruparib in advanced solid tumours, run by AstraZeneca, now recruiting.","route":"/trials/nct07446855/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07446855","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05417594","name":"Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies","tldr":"A phase 1/2 trial of Palacaparib, Temozolomide, Trastuzumab, Trastuzumab deruxtecan and Datopotamab deruxtecan in advanced solid tumours, run by AstraZeneca, now recruiting.","route":"/trials/nct05417594/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05417594","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06706713","name":"Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer","tldr":"A phase 2 trial of BEBT-109 Capsule in non-small-cell lung cancer, run by BeBetter Med Inc, now recruiting.","route":"/trials/nct06706713/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06706713","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06428396","name":"Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)","tldr":"A phase 2 trial of Belzutifan, Fulvestrant, Everolimus and Exemestane in advanced solid tumours, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","route":"/trials/nct06428396/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06428396","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05479994","name":"Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","tldr":"A phase 2 trial of Sonrotoclax in non-Hodgkin lymphoma and chronic lymphocytic leukaemia, run by BeiGene, active and no longer recruiting.","route":"/trials/nct05479994/","status":"active","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT05479994","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma","Chronic lymphocytic leukaemia","Relapsed or refractory chronic lymphocytic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."},{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Relapsed or refractory chronic lymphocytic leukaemia","href":"/cancers/cll-relapsed/","tip":"When chronic lymphocytic leukaemia returns, the usual move is to switch drug class: venetoclax-based therapy after a BTK inhibitor, or a BTK inhibitor after venetoclax. Pirtobrutinib (BRUIN) works after the older BTK inhibitors fail, and CAR-T is approved for patients who have run out of both classes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04662255","name":"Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)","tldr":"A phase 3 trial of Pirtobrutinib, Ibrutinib, Acalabrutinib and Zanubrutinib in mantle cell lymphoma, run by Loxo Oncology, Inc., active and no longer recruiting.","route":"/trials/nct04662255/","status":"active","kind":"trial","cancerIcon":"mantle-cell-lymphoma","sub":"NCT04662255","facets":{"kind":["Trial"],"cancers":["Mantle cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Mantle cell lymphoma","href":"/cancers/mantle-cell-lymphoma/","tip":"An uncommon B-cell lymphoma driven by cyclin D1 that used to behave badly in almost everyone. BTK inhibitors, CAR-T and now BCL2 drugs have changed it from chemotherapy-plus-transplant to targeted combinations."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00889525","name":"Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor","tldr":"A phase 3 trial of Cabergoline in Pituitary tumours, run by Seth Gordhandas Sunderdas Medical College, completed.","route":"/trials/nct00889525/","status":"completed","kind":"trial","cancerIcon":"pituitary-tumours","sub":"NCT00889525","facets":{"kind":["Trial"],"cancers":["Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma","href":"/cancers/pituitary-tumours/","tip":"Pituitary tumours are usually benign growths of the hormone gland at the base of the brain that cause trouble by overproducing hormones or pressing on the optic nerves. Prolactin-producing tumours melt away with a tablet, most others are cured by surgery through the nose, and the rare aggressive ones respond to the chemotherapy drug temozolomide."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07019779","name":"Study of CM518D1 in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of CM518D1 in advanced solid tumours, run by Keymed Biosciences Co.Ltd, now recruiting.","route":"/trials/nct07019779/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07019779","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02340117","name":"Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer","tldr":"A phase 2 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by SynerGene Therapeutics, Inc., active and no longer recruiting.","route":"/trials/nct02340117/","status":"active","kind":"trial","cancerIcon":"pancreatic","sub":"NCT02340117","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06569420","name":"Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC","tldr":"A phase 3 trial of an investigational treatment in non-small-cell lung cancer, run by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., active and no longer recruiting.","route":"/trials/nct06569420/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT06569420","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","ALK-positive non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"ALK-positive non-small-cell lung cancer","href":"/cancers/alk-positive-nsclc/","tip":"ALK-positive lung cancer is driven by a fused ALK gene and is treated with a pill from the start. The newest inhibitors keep the disease under control for years, with lorlatinib holding six in ten patients progression-free at five years, and two years of alectinib after surgery cuts recurrence by three quarters."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07030257","name":"Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors","tldr":"A phase 1/2 trial of CP-383 in colorectal cancer, small-cell lung cancer, head and neck squamous cell carcinoma, bladder & urothelial cancer, non-small-cell lung cancer and pancreatic ductal adenocarcinoma, run by Tasca Therapeutics, now recruiting.","route":"/trials/nct07030257/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT07030257","facets":{"kind":["Trial"],"cancers":["Colorectal cancer","Small-cell lung cancer","Head and neck squamous cell carcinoma","Bladder & urothelial cancer","Non-small-cell lung cancer","Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."},{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07283835","name":"Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin","tldr":"A phase 2 trial of Cretostimogene grenadenorepvec in bladder & urothelial cancer, run by Lepu Biopharma Co., Ltd., now recruiting.","route":"/trials/nct07283835/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT07283835","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Non-muscle-invasive bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Non-muscle-invasive bladder cancer","href":"/cancers/non-muscle-invasive-bladder-cancer/","tip":"Most bladder cancers are found while still confined to the lining. They are scraped out through the urethra and, when higher risk, treated with BCG instilled into the bladder; the challenge is the frequent recurrences and the patients whose tumours stop responding to BCG."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03600233","name":"Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors","tldr":"A phase 2 trial of CVM-1118 in neuroendocrine tumours and pancreatic ductal adenocarcinoma, run by TaiRx, Inc., active and no longer recruiting.","route":"/trials/nct03600233/","status":"active","kind":"trial","cancerIcon":"neuroendocrine","sub":"NCT03600233","facets":{"kind":["Trial"],"cancers":["Neuroendocrine tumours","Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Neuroendocrine tumours","href":"/cancers/neuroendocrine/","tip":"A family of usually slow-growing tumours that start in hormone-producing cells of the gut, pancreas and lungs. They pioneered the idea of using the same molecule to see a tumour on a scan and then to treat it with radiation."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07129993","name":"Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma","tldr":"A phase 2/3 trial of Carboplatin, Cisplatin and Gemcitabine in bladder & urothelial cancer, run by Daiichi Sankyo, now recruiting.","route":"/trials/nct07129993/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT07129993","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01127451","name":"Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma","tldr":"A phase 2 trial of Denileukin diftitox in Melanoma and Advanced melanoma, run by Eisai Inc., completed.","route":"/trials/nct01127451/","status":"completed","kind":"trial","cancerIcon":"melanoma","sub":"NCT01127451","facets":{"kind":["Trial"],"cancers":["Melanoma","Advanced melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"label":"Advanced melanoma","href":"/cancers/advanced-melanoma/","tip":"Advanced melanoma has spread beyond what surgery can remove, and it is the cancer in which immunotherapy first proved it could cure some people: about half of those given nivolumab with ipilimumab are alive ten years later. If immunotherapy fails, options include a cell therapy grown from the patient's own immune cells, a virus injected into the tumour, and targeted pills for BRAF-mutant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05320198","name":"Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia","tldr":"A phase 1/2 trial of DISC-0974 in myeloproliferative neoplasms and myelodysplastic syndromes / neoplasms, run by Disc Medicine, Inc, now recruiting.","route":"/trials/nct05320198/","status":"recruiting","kind":"trial","cancerIcon":"myeloproliferative-neoplasms","sub":"NCT05320198","facets":{"kind":["Trial"],"cancers":["Myeloproliferative neoplasms","Myelodysplastic syndromes / neoplasms","Primary myelofibrosis"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Myeloproliferative neoplasms","href":"/cancers/myeloproliferative-neoplasms/","tip":"Myeloproliferative neoplasms are slow-growing blood cancers in which the marrow overproduces red cells (polycythaemia vera), platelets (essential thrombocythaemia) or scar tissue (myelofibrosis). Almost all carry a mutation in JAK2, CALR or MPL; treatment aims to prevent clots and control symptoms, and only transplant cures myelofibrosis."},{"label":"Myelodysplastic syndromes / neoplasms","href":"/cancers/mds/","tip":"Bone-marrow disorders where blood cells are made badly and too few reach the blood; a third progress to acute leukaemia. Treatment ranges from transfusions and growth factors to hypomethylating drugs and, for the fit, transplant."},{"label":"Primary myelofibrosis","href":"/cancers/primary-myelofibrosis/","tip":"Primary myelofibrosis is a blood cancer in which the marrow scars over, the spleen swells and patients become anaemic and exhausted. JAK inhibitors, ruxolitinib first (COMFORT) and then fedratinib, pacritinib and momelotinib (MOMENTUM), shrink the spleen and relieve symptoms; only a donor stem cell transplant can cure it."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05880394","name":"Study of Dotatate Imaging in Breast Cancer","tldr":"A phase 2 trial of Gallium-68 DOTATATE in Breast cancer, run by Hoag Memorial Hospital Presbyterian, with a status the registry has not verified recently.","route":"/trials/nct05880394/","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT05880394","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06819735","name":"Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors","tldr":"A phase 1/2 trial of DT-7012 in advanced solid tumours, run by Domain Therapeutics Australia Pty Ltd, now recruiting.","route":"/trials/nct06819735/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06819735","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03003962","name":"Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)","tldr":"A phase 3 trial of Durvalumab, Carboplatin, Gemcitabine + cisplatin, Gemcitabine, Cisplatin and Pemetrexed in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct03003962/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT03003962","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","PD-L1-high non-small-cell lung cancer without a driver mutation"],"year":["2023"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"PD-L1-high non-small-cell lung cancer without a driver mutation","href":"/cancers/pdl1-high-nsclc/","tip":"Lung cancers that carry a lot of PD-L1 and no targetable mutation can be treated with an immunotherapy antibody alone instead of chemotherapy. Pembrolizumab keeps about a third of patients alive at five years, roughly double what chemotherapy achieved, and adding chemotherapy is reserved for those who need a fast response."}],"year":{"facet":"year","value":"2023"},"tags":[]},"sortKeys":{"year":2023}},{"id":"nct03682068","name":"Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer","tldr":"A phase 3 trial of Durvalumab, Tremelimumab, Cisplatin, Gemcitabine and Carboplatin in bladder & urothelial cancer, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct03682068/","status":"active","kind":"trial","cancerIcon":"urothelial","sub":"NCT03682068","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04550260","name":"Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC","tldr":"A phase 3 trial of Durvalumab, Cisplatin and Capecitabine in oesophageal cancer, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct04550260/","status":"active","kind":"trial","cancerIcon":"esophageal","sub":"NCT04550260","facets":{"kind":["Trial"],"cancers":["Oesophageal cancer","Oesophageal squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."},{"label":"Oesophageal squamous cell carcinoma","href":"/cancers/oesophageal-squamous-cell-carcinoma/","tip":"Squamous cell carcinoma of the oesophagus, the world's commonest form, is linked to smoking, alcohol and very hot drinks and sits in the upper and middle gullet. It is treated with chemoradiation, with or without surgery, and immunotherapy has recently joined chemotherapy for advanced disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02542293","name":"Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)","tldr":"A phase 3 trial of Durvalumab, Tremelimumab, Carboplatin, Gemcitabine + cisplatin, Gemcitabine and Cisplatin in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct02542293/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT02542293","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":["2022"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"year":{"facet":"year","value":"2022"},"tags":[]},"sortKeys":{"year":2022}},{"id":"nct04375683","name":"Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL","tldr":"A phase 3 trial of Flumatinib in Leukaemia, run by Zhongda Hospital, with a status the registry has not verified recently.","route":"/trials/nct04375683/","kind":"trial","cancerIcon":"leukaemia","sub":"NCT04375683","facets":{"kind":["Trial"],"cancers":["Leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Leukaemia","href":"/cancers/leukaemia/","tip":"Leukaemia means cancer of the blood-forming cells, but the four main types share little beyond the name: acute lymphoblastic and acute myeloid leukaemia are emergencies treated with intensive therapy, while chronic lymphocytic and chronic myeloid leukaemia are slow diseases controlled for years with pills. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05445843","name":"Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.","tldr":"A phase 2 trial of JDQ443 in non-small-cell lung cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.","route":"/trials/nct05445843/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT05445843","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","KRAS G12C-mutant non-small-cell lung cancer"],"year":["2025"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"KRAS G12C-mutant non-small-cell lung cancer","href":"/cancers/kras-g12c-nsclc/","tip":"KRAS G12C lung cancer carries a mutation that was thought impossible to drug for forty years. Sotorasib and adagrasib now shrink about four in ten tumours after chemotherapy and immunotherapy, though the benefit is measured in months, and newer inhibitors and first-line combinations with immunotherapy are in trials."}],"year":{"facet":"year","value":"2025"},"tags":[]},"sortKeys":{"year":2025}},{"id":"nct03876769","name":"Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients","tldr":"A phase 2 trial of Tisagenlecleucel in acute lymphoblastic leukaemia, run by Novartis Pharmaceuticals, active and no longer recruiting.","route":"/trials/nct03876769/","status":"active","kind":"trial","cancerIcon":"all-leukemia","sub":"NCT03876769","facets":{"kind":["Trial"],"cancers":["Acute lymphoblastic leukaemia","High-risk acute lymphoblastic leukaemia in children"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."},{"label":"High-risk acute lymphoblastic leukaemia in children","href":"/cancers/all-paediatric-high-risk/","tip":"High-risk childhood leukaemia means a child aged ten or over, a very high white cell count, T-cell disease, spread to the brain or testes, or adverse genetics, and it is treated with longer and more intensive chemotherapy. Most children are still cured; the T-cell form gained the drug nelarabine after the AALL0434 trial, and cranial radiotherapy has been dropped for almost everyone."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02650401","name":"Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options","tldr":"A phase 1/2 trial of Entrectinib in brain and spinal cord tumours, run by Hoffmann-La Roche, active and no longer recruiting.","route":"/trials/nct02650401/","status":"active","kind":"trial","cancerIcon":"brain-tumours","sub":"NCT02650401","facets":{"kind":["Trial"],"cancers":["Brain and spinal cord tumours"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Brain and spinal cord tumours","href":"/cancers/brain-tumours/","tip":"Brain and spinal cord tumours range from slow-growing meningiomas and low-grade gliomas to glioblastoma, the commonest malignant brain tumour in adults, and a distinct set of childhood tumours such as medulloblastoma and diffuse midline glioma. Molecular markers now define them, and treatment is surgery, radiotherapy and, for some, drugs chosen by those markers."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05316155","name":"Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer","tldr":"A phase 1/2 trial of Erdafitinib in bladder & urothelial cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.","route":"/trials/nct05316155/","status":"active","kind":"trial","cancerIcon":"urothelial","sub":"NCT05316155","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06567015","name":"Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs","tldr":"A phase 1/2 trial of STX-241 in non-small-cell lung cancer, run by Pierre Fabre Medicament, now recruiting.","route":"/trials/nct06567015/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06567015","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05727176","name":"Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement","tldr":"A phase 2 trial of TAS-120 in biliary tract cancer, run by Taiho Oncology, Inc., now recruiting.","route":"/trials/nct05727176/","status":"recruiting","kind":"trial","cancerIcon":"cholangiocarcinoma","sub":"NCT05727176","facets":{"kind":["Trial"],"cancers":["Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01011231","name":"Study of Gamma-Knife Radiosurgery Using Magnetic Resonance Imaging (MRI) Spectroscopy for Recurrent Glioma","tldr":"A phase 2 trial of Gamma Knife in Glioma & glioblastoma, run by University of California, San Francisco, recorded as terminated on the registry.","route":"/trials/nct01011231/","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT01011231","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03301168","name":"Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant","tldr":"A phase 1/2 trial of BPX-501 T cells in acute lymphoblastic leukaemia, acute myeloid leukaemia, non-Hodgkin lymphoma and myelodysplastic syndromes / neoplasms, run by Bellicum Pharmaceuticals, active and no longer recruiting.","route":"/trials/nct03301168/","status":"active","kind":"trial","cancerIcon":"all-leukemia","sub":"NCT03301168","facets":{"kind":["Trial"],"cancers":["Acute lymphoblastic leukaemia","Acute myeloid leukaemia","Non-Hodgkin lymphoma","Myelodysplastic syndromes / neoplasms","Acute myeloid leukaemia in children"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."},{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."},{"label":"Myelodysplastic syndromes / neoplasms","href":"/cancers/mds/","tip":"Bone-marrow disorders where blood cells are made badly and too few reach the blood; a third progress to acute leukaemia. Treatment ranges from transfusions and growth factors to hypomethylating drugs and, for the fit, transplant."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07070518","name":"Study of GV20-0251 in Participants With Solid Tumor Malignancies","tldr":"A phase 1/2 trial of GV20-0251 in endometrial cancer, head and neck squamous cell carcinoma, non-small-cell lung cancer, melanoma, hepatocellular carcinoma and small-cell lung cancer, run by GV20 Therapeutics, now recruiting.","route":"/trials/nct07070518/","status":"recruiting","kind":"trial","cancerIcon":"endometrial","sub":"NCT07070518","facets":{"kind":["Trial"],"cancers":["Endometrial cancer","Head and neck squamous cell carcinoma","Non-small-cell lung cancer","Melanoma","Hepatocellular carcinoma","Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."},{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01394263","name":"Study of Histrelin Subdermal Implant in Patients With Prostate Cancer","tldr":"A phase 3 trial of Histrelin and Goserelin / leuprolide in Prostate cancer, run by Endo USA Inc., a Keenova Therapeutics Company, completed.","route":"/trials/nct01394263/","status":"completed","kind":"trial","cancerIcon":"prostate","sub":"NCT01394263","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06800313","name":"Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer","tldr":"A phase 1/2 trial of JNJ-101556143 Formulation 1 in prostate cancer, run by Janssen Research & Development, LLC, now recruiting.","route":"/trials/nct06800313/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT06800313","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06222879","name":"Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer","tldr":"A phase 1/2 trial of HRS-8080, Trastuzumab rezetecan, SHR-A2009 and Adebrelimab in advanced solid tumours, run by Shandong Suncadia Medicine Co., Ltd., now recruiting.","route":"/trials/nct06222879/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06222879","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05745623","name":"Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors","tldr":"A phase 1/2 trial of ICP-723 in brain and spinal cord tumours, run by Beijing InnoCare Pharma Tech Co., Ltd., now recruiting.","route":"/trials/nct05745623/","status":"recruiting","kind":"trial","cancerIcon":"brain-tumours","sub":"NCT05745623","facets":{"kind":["Trial"],"cancers":["Brain and spinal cord tumours"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Brain and spinal cord tumours","href":"/cancers/brain-tumours/","tip":"Brain and spinal cord tumours range from slow-growing meningiomas and low-grade gliomas to glioblastoma, the commonest malignant brain tumour in adults, and a distinct set of childhood tumours such as medulloblastoma and diffuse midline glioma. Molecular markers now define them, and treatment is surgery, radiotherapy and, for some, drugs chosen by those markers."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04145622","name":"Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors","tldr":"A phase 1/2 trial of Ifinatamab deruxtecan in advanced solid tumours, run by Daiichi Sankyo, now recruiting.","route":"/trials/nct04145622/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04145622","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03386513","name":"Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN","tldr":"A phase 1/2 trial of Pivekimab sunirine in blastic plasmacytoid dendritic cell neoplasm and myeloproliferative neoplasms, run by AbbVie, active and no longer recruiting.","route":"/trials/nct03386513/","status":"active","kind":"trial","cancerIcon":"bpdcn","sub":"NCT03386513","facets":{"kind":["Trial"],"cancers":["Blastic plasmacytoid dendritic cell neoplasm","Myeloproliferative neoplasms"],"year":["2026"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Blastic plasmacytoid dendritic cell neoplasm","href":"/cancers/bpdcn/","tip":"Blastic plasmacytoid dendritic cell neoplasm is a rare aggressive leukaemia-like blood cancer of dendritic-cell precursors, a few hundred US cases a year, that often first appears as bruise-like skin lesions. Two CD123-directed drugs, tagraxofusp and pivekimab sunirine, are the first targeted therapies; allogeneic transplant in first remission is still the only route to long-term control."},{"label":"Myeloproliferative neoplasms","href":"/cancers/myeloproliferative-neoplasms/","tip":"Myeloproliferative neoplasms are slow-growing blood cancers in which the marrow overproduces red cells (polycythaemia vera), platelets (essential thrombocythaemia) or scar tissue (myelofibrosis). Almost all carry a mutation in JAK2, CALR or MPL; treatment aims to prevent clots and control symptoms, and only transplant cures myelofibrosis."}],"year":{"facet":"year","value":"2026"},"tags":[]},"sortKeys":{"year":2026}},{"id":"nct02952508","name":"Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom","tldr":"A phase 2 trial of Iopofosine I 131 single dose in waldenström macroglobulinaemia, multiple myeloma, chronic lymphocytic leukaemia, non-Hodgkin lymphoma, mantle cell lymphoma and diffuse large B-cell lymphoma, run by Cellectar Biosciences, Inc., active and no longer recruiting.","route":"/trials/nct02952508/","status":"active","kind":"trial","cancerIcon":"waldenstrom","sub":"NCT02952508","facets":{"kind":["Trial"],"cancers":["Waldenström macroglobulinaemia","Multiple myeloma","Chronic lymphocytic leukaemia","Non-Hodgkin lymphoma","Mantle cell lymphoma","Diffuse large B-cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Waldenström macroglobulinaemia","href":"/cancers/waldenstrom/","tip":"A slow lymphoma that makes an abnormal IgM antibody, causing thick blood, anaemia and nerve damage. Nearly all cases share one mutation (MYD88 L265P), and BTK inhibitors control it for years."},{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."},{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05862012","name":"Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)","tldr":"A phase 1 trial of ISB 2001 in Multiple myeloma, run by Ichnos Sciences SA, now recruiting.","route":"/trials/nct05862012/","status":"recruiting","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT05862012","facets":{"kind":["Trial"],"cancers":["Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06414460","name":"Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors","tldr":"A phase 1/2 trial of ISM3412 in advanced solid tumours, run by InSilico Medicine Hong Kong Limited, now recruiting.","route":"/trials/nct06414460/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06414460","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06566079","name":"Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors","tldr":"A phase 1/2 trial of ISM6331 in mesothelioma, run by InSilico Medicine Hong Kong Limited, now recruiting.","route":"/trials/nct06566079/","status":"recruiting","kind":"trial","cancerIcon":"mesothelioma","sub":"NCT06566079","facets":{"kind":["Trial"],"cancers":["Mesothelioma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Mesothelioma","href":"/cancers/mesothelioma/","tip":"An asbestos-caused cancer of the lung lining. Immunotherapy doublets replaced chemotherapy in 2020, and mesothelin CAR-T is under study."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07640295","name":"Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations","tldr":"A phase 1/2 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by Jacobio Pharmaceuticals Co., Ltd., now recruiting.","route":"/trials/nct07640295/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT07640295","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04699188","name":"Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","tldr":"A phase 1/2 trial of JDQ443, TNO155 and Tislelizumab in non-small-cell lung cancer and colorectal cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.","route":"/trials/nct04699188/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT04699188","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","Colorectal cancer","KRAS G12C-mutant colorectal cancer","KRAS G12C-mutant non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"KRAS G12C-mutant colorectal cancer","href":"/cancers/kras-g12c-colorectal/","tip":"KRAS G12C bowel cancer carries a mutation that was undruggable for forty years. The first KRAS drugs work only weakly on their own in the bowel, because the tumour switches EGFR back on, so they are given with an anti-EGFR antibody: sotorasib with panitumumab and adagrasib with cetuximab are both approved after chemotherapy."},{"label":"KRAS G12C-mutant non-small-cell lung cancer","href":"/cancers/kras-g12c-nsclc/","tip":"KRAS G12C lung cancer carries a mutation that was thought impossible to drug for forty years. Sotorasib and adagrasib now shrink about four in ten tumours after chemotherapy and immunotherapy, though the benefit is measured in months, and newer inhibitors and first-line combinations with immunotherapy are in trials."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06667960","name":"Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer","tldr":"A phase 1/2 trial of JK06 in advanced solid tumours, run by Salubris Biotherapeutics Inc, now recruiting.","route":"/trials/nct06667960/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06667960","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06942234","name":"Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer","tldr":"A phase 1/2 trial of JSKN016, Capecitabine, Eribulin and Pembrolizumab in advanced solid tumours, run by Jiangsu Alphamab Biopharmaceuticals Co., Ltd, now recruiting.","route":"/trials/nct06942234/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06942234","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04299191","name":"Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors","tldr":"A phase 1/2 trial of LAM561 in glioma & glioblastoma, run by Laminar Pharmaceuticals, now recruiting.","route":"/trials/nct04299191/","status":"recruiting","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT04299191","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01872260","name":"Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer","tldr":"A phase 1/2 trial of LEE011 in advanced solid tumours, run by Novartis Pharmaceuticals, active and no longer recruiting.","route":"/trials/nct01872260/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT01872260","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05768919","name":"Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas","tldr":"A phase 1/2 trial of Treatment Period 1 in glioma & glioblastoma, run by SignPath Pharma, Inc., now recruiting.","route":"/trials/nct05768919/","status":"recruiting","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT05768919","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06650566","name":"Study of LM-299 in Subjects Advanced Malignant Tumors","tldr":"A phase 1/2 trial of LM-299 in advanced solid tumours, run by LaNova Medicines Limited, now recruiting.","route":"/trials/nct06650566/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06650566","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05933265","name":"Study of LP-184 in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of Olaparib, Ipilimumab and Nivolumab in triple-negative breast cancer, non-small-cell lung cancer and pancreatic ductal adenocarcinoma, run by Lantern Pharma Inc., active and no longer recruiting.","route":"/trials/nct05933265/","status":"active","kind":"trial","cancerIcon":"tnbc","sub":"NCT05933265","facets":{"kind":["Trial"],"cancers":["Triple-negative breast cancer","Non-small-cell lung cancer","Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06088290","name":"Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)","tldr":"A phase 3 trial of Lurbinectedin and Doxorubicin in uterine sarcoma, run by PharmaMar, active and no longer recruiting.","route":"/trials/nct06088290/","status":"active","kind":"trial","cancerIcon":"uterine-sarcoma","sub":"NCT06088290","facets":{"kind":["Trial"],"cancers":["Uterine sarcoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Uterine sarcoma","href":"/cancers/uterine-sarcoma/","tip":"Uterine sarcomas are rare cancers of the muscle and supporting tissue of the womb, distinct from the far commoner endometrial cancer. Removing the uterus intact is the main treatment and is followed by observation for stage I disease; low-grade stromal sarcomas respond to hormone-blocking pills, while advanced leiomyosarcoma is treated with doxorubicin and trabectedin."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04956640","name":"Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)","tldr":"A phase 1/2 trial of Olomorasib, Pembrolizumab, Cetuximab, Pemetrexed, Cisplatin and Carboplatin in non-small-cell lung cancer, colorectal cancer, endometrial cancer, ovarian cancer, pancreatic ductal adenocarcinoma and biliary tract cancer, run by Eli Lilly and Company, active and no longer recruiting.","route":"/trials/nct04956640/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT04956640","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","Colorectal cancer","Endometrial cancer","Ovarian cancer","Pancreatic ductal adenocarcinoma","Biliary tract cancer","KRAS G12C-mutant colorectal cancer","KRAS G12C-mutant non-small-cell lung cancer","KRAS G12C-mutant pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."},{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04778397","name":"Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated","tldr":"A phase 3 trial of Magrolimab, Venetoclax, Azacitidine, Cytarabine, Daunorubicin and Idarubicin in Acute myeloid leukaemia, run by Gilead Sciences, recorded as terminated on the registry.","route":"/trials/nct04778397/","kind":"trial","cancerIcon":"aml","sub":"NCT04778397","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05079230","name":"Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia","tldr":"A phase 3 trial of Magrolimab, Venetoclax and Azacitidine in Acute myeloid leukaemia, run by Gilead Sciences, recorded as terminated on the registry.","route":"/trials/nct05079230/","kind":"trial","cancerIcon":"aml","sub":"NCT05079230","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07448116","name":"Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.","tldr":"A phase 1/2 trial of MCLA-129 and Ensartinib in advanced solid tumours, run by Betta Pharmaceuticals Co., Ltd., now recruiting.","route":"/trials/nct07448116/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07448116","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02516241","name":"Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer","tldr":"A phase 3 trial of Durvalumab, Tremelimumab, Cisplatin, Carboplatin and Gemcitabine in bladder & urothelial cancer, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct02516241/","status":"active","kind":"trial","cancerIcon":"urothelial","sub":"NCT02516241","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":["2021"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"year":{"facet":"year","value":"2021"},"tags":[]},"sortKeys":{"year":2021}},{"id":"nct04649060","name":"Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma","tldr":"A phase 3 trial of Melphalan flufenamide, Dexamethasone and Daratumumab in Multiple myeloma, run by Oncopeptides AB, recorded as terminated on the registry.","route":"/trials/nct04649060/","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT04649060","facets":{"kind":["Trial"],"cancers":["Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07102004","name":"Study of MHB088C for Patients With Advanced Solid Malignant Tumors","tldr":"A phase 1/2 trial of QLC5508 in advanced solid tumours, run by Qilu Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07102004/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07102004","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05673057","name":"Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome","tldr":"A phase 1/2 trial of Azacitidine, Venetoclax and Obinutuzumab in acute myeloid leukaemia, run by Molecular Partners AG, active and no longer recruiting.","route":"/trials/nct05673057/","status":"active","kind":"trial","cancerIcon":"aml","sub":"NCT05673057","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05533697","name":"Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors","tldr":"A phase 1/2 trial of Pembrolizumab, Ipilimumab and Nivolumab in advanced solid tumours, run by ModernaTX, Inc., now recruiting.","route":"/trials/nct05533697/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05533697","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05737706","name":"Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation","tldr":"A phase 1 trial of MRTX1133 in Non-small-cell lung cancer and Rectal cancer, run by Mirati Therapeutics Inc., recorded as terminated on the registry.","route":"/trials/nct05737706/","kind":"trial","cancerIcon":"nsclc","sub":"NCT05737706","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","Rectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Rectal cancer","href":"/cancers/rectal-cancer/","tip":"Rectal cancer is bowel cancer in the last part of the large intestine, where surgery can mean a permanent stoma. Treatment now usually gives all the chemotherapy and radiotherapy first, and about half of people whose tumour disappears completely can keep their rectum and avoid surgery altogether."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05498155","name":"Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer","tldr":"A phase 2 trial of Olaparib and Durvalumab in advanced solid tumours, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct05498155/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05498155","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03036098","name":"Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer","tldr":"A phase 3 trial of Nivolumab, Ipilimumab, Gemcitabine, Cisplatin and Carboplatin in bladder & urothelial cancer, run by Bristol-Myers Squibb, active and no longer recruiting.","route":"/trials/nct03036098/","status":"active","kind":"trial","cancerIcon":"urothelial","sub":"NCT03036098","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":["2025"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"year":{"facet":"year","value":"2025"},"tags":[]},"sortKeys":{"year":2025}},{"id":"nct07520006","name":"Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies","tldr":"A phase 1/2 trial of Bexobrutideg, Venetoclax, Rituximab and Obinutuzumab in non-Hodgkin lymphoma and chronic lymphocytic leukaemia, run by Nurix Therapeutics, Inc., now recruiting.","route":"/trials/nct07520006/","status":"recruiting","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT07520006","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma","Chronic lymphocytic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."},{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06616389","name":"Study of ODX (OsteoDex) in Multiple Myeloma","tldr":"A phase 1/2 trial of ODX (Osteodex) in multiple myeloma, run by DexTech Medical AB, now recruiting.","route":"/trials/nct06616389/","status":"recruiting","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT06616389","facets":{"kind":["Trial"],"cancers":["Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06890598","name":"Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer","tldr":"A phase 3 trial of Olomorasib, Pembrolizumab and Durvalumab in non-small-cell lung cancer, run by Eli Lilly and Company, now recruiting.","route":"/trials/nct06890598/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06890598","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","KRAS G12C-mutant non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"KRAS G12C-mutant non-small-cell lung cancer","href":"/cancers/kras-g12c-nsclc/","tip":"KRAS G12C lung cancer carries a mutation that was thought impossible to drug for forty years. Sotorasib and adagrasib now shrink about four in ten tumours after chemotherapy and immunotherapy, though the benefit is measured in months, and newer inhibitors and first-line combinations with immunotherapy are in trials."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07282587","name":"Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma","tldr":"A phase 2 trial of ONC206 in pheochromocytoma and paraganglioma, run by Jazz Pharmaceuticals, now recruiting.","route":"/trials/nct07282587/","status":"recruiting","kind":"trial","cancerIcon":"pheochromocytoma-paraganglioma","sub":"NCT07282587","facets":{"kind":["Trial"],"cancers":["Pheochromocytoma and paraganglioma","Metastatic pheochromocytoma and paraganglioma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pheochromocytoma and paraganglioma","href":"/cancers/pheochromocytoma-paraganglioma/","tip":"Pheochromocytomas and paragangliomas are tumours of adrenaline-producing tissue that cause dangerous blood pressure surges. Surgery after careful blood-pressure blockade cures most, genetic testing finds an inherited cause in nearly half, and for the minority that spread there are now radioactive drugs that home to the tumour and, since 2025, the first oral targeted pill, belzutifan."},{"label":"Metastatic pheochromocytoma and paraganglioma","href":"/cancers/metastatic-ppgl/","tip":"Metastatic pheochromocytoma and paraganglioma is disease that has spread to bone, lymph nodes, liver or lungs, the only way these adrenaline-producing tumours are called malignant. It is often slow, so treatment starts with blood pressure control and watching, then moves through radioactive drugs that home to the tumour, the kinase inhibitor sunitinib, chemotherapy and, since 2025, belzutifan."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05546268","name":"Study of Oral MRT-2359 in Selected Cancer Patients","tldr":"A phase 1/2 trial of Oral MRT-2359 in non-small-cell lung cancer, small-cell lung cancer, neuroendocrine tumours, HR-positive / HER2-negative breast cancer and prostate cancer, run by Monte Rosa Therapeutics, Inc, active and no longer recruiting.","route":"/trials/nct05546268/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT05546268","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","Small-cell lung cancer","Neuroendocrine tumours","HR-positive / HER2-negative breast cancer","Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."},{"label":"Neuroendocrine tumours","href":"/cancers/neuroendocrine/","tip":"A family of usually slow-growing tumours that start in hormone-producing cells of the gut, pancreas and lungs. They pioneered the idea of using the same molecule to see a tumour on a scan and then to treat it with radiation."},{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05287945","name":"Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma","tldr":"A phase 1/2 trial of Orellanine in renal cell carcinoma, run by Oncorena AB, now recruiting.","route":"/trials/nct05287945/","status":"recruiting","kind":"trial","cancerIcon":"rcc","sub":"NCT05287945","facets":{"kind":["Trial"],"cancers":["Renal cell carcinoma","Clear cell renal cell carcinoma","Papillary renal cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."},{"label":"Clear cell renal cell carcinoma","href":"/cancers/clear-cell-rcc/","tip":"Clear cell is the common kidney cancer, driven by loss of the VHL gene that leaves the tumour behaving as if starved of oxygen and flooding itself with blood vessels. That biology explains why anti-angiogenic drugs, immunotherapy and the HIF-2 alpha blocker belzutifan all work."},{"label":"Papillary renal cell carcinoma","href":"/cancers/papillary-rcc/","tip":"Papillary kidney cancer is the second commonest type and does not share the VHL biology of clear cell cancer, so the drugs work differently: the MET-targeting drug cabozantinib beat sunitinib in the first trial run just for this disease, and two hereditary syndromes account for some cases."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05315700","name":"Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration","tldr":"A phase 1/2 trial of ORIC-114 in advanced solid tumours, run by ORIC Pharmaceuticals, now recruiting.","route":"/trials/nct05315700/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05315700","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06596694","name":"Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)","tldr":"A phase 1/2 trial of Patritumab deruxtecan in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting.","route":"/trials/nct06596694/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06596694","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06797635","name":"Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)","tldr":"A phase 2 trial of Patritumab deruxtecan, Pembrolizumab, Carboplatin, Doxorubicin, Epirubicin and Cyclophosphamide in HR-positive / HER2-negative breast cancer, run by Merck Sharp & Dohme LLC, now recruiting.","route":"/trials/nct06797635/","status":"recruiting","kind":"trial","cancerIcon":"breast-hr-positive","sub":"NCT06797635","facets":{"kind":["Trial"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06686394","name":"Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)","tldr":"A phase 1/2 trial of Patritumab deruxtecan, Trastuzumab, Pertuzumab and Tucatinib in HER2-positive breast cancer, run by Merck Sharp & Dohme LLC, now recruiting.","route":"/trials/nct06686394/","status":"recruiting","kind":"trial","cancerIcon":"breast-her2-positive","sub":"NCT06686394","facets":{"kind":["Trial"],"cancers":["HER2-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04634877","name":"Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)","tldr":"A phase 3 trial of Pembrolizumab, Carboplatin, Docetaxel and Cisplatin in endometrial cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","route":"/trials/nct04634877/","status":"active","kind":"trial","cancerIcon":"endometrial","sub":"NCT04634877","facets":{"kind":["Trial"],"cancers":["Endometrial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05609968","name":"Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)","tldr":"A phase 3 trial of Sacituzumab govitecan and Pembrolizumab in non-small-cell lung cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","route":"/trials/nct05609968/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT05609968","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","PD-L1-high non-small-cell lung cancer without a driver mutation"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"PD-L1-high non-small-cell lung cancer without a driver mutation","href":"/cancers/pdl1-high-nsclc/","tip":"Lung cancers that carry a lot of PD-L1 and no targetable mutation can be treated with an immunotherapy antibody alone instead of chemotherapy. Pembrolizumab keeps about a third of patients alive at five years, roughly double what chemotherapy achieved, and adding chemotherapy is reserved for those who need a fast response."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04895358","name":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)","tldr":"A phase 3 trial of Pembrolizumab, Doxorubicin and Capecitabine in advanced solid tumours, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","route":"/trials/nct04895358/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04895358","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05239741","name":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)","tldr":"A phase 3 trial of Pembrolizumab, Oxaliplatin, Bevacizumab and Cetuximab in colorectal cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","route":"/trials/nct05239741/","status":"active","kind":"trial","cancerIcon":"colorectal","sub":"NCT05239741","facets":{"kind":["Trial"],"cancers":["Colorectal cancer","Mismatch-repair deficient (MSI-high) colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Mismatch-repair deficient (MSI-high) colorectal cancer","href":"/cancers/msi-high-colorectal/","tip":"Mismatch-repair deficient bowel cancer has lost its DNA spell-checker, so it carries thousands of mutations that the immune system can recognise. Immunotherapy alone controls most metastatic cases for years and makes most localised tumours disappear before surgery, sometimes so completely that no surgery is needed."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05173987","name":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)","tldr":"A phase 3 trial of Pembrolizumab, Carboplatin, Docetaxel and Cisplatin in endometrial cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","route":"/trials/nct05173987/","status":"active","kind":"trial","cancerIcon":"endometrial","sub":"NCT05173987","facets":{"kind":["Trial"],"cancers":["Endometrial cancer","Advanced or recurrent endometrial cancer","Mismatch-repair-deficient endometrial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."},{"label":"Advanced or recurrent endometrial cancer","href":"/cancers/advanced-recurrent-endometrial-cancer/","tip":"Advanced or recurrent endometrial cancer has spread beyond the uterus or come back after treatment. Chemotherapy plus an immune checkpoint antibody is now the first treatment for everyone, with the biggest gains in mismatch-repair-deficient tumours, and lenvatinib with pembrolizumab is the standard when platinum chemotherapy stops working."},{"label":"Mismatch-repair-deficient endometrial cancer","href":"/cancers/endometrial-mmr-deficient/","tip":"Mismatch-repair-deficient endometrial cancer has lost the machinery that corrects copying errors in DNA, so it accumulates thousands of mutations that make it visible to the immune system. Adding dostarlimab or pembrolizumab to chemotherapy in advanced disease cut the risk of progression by about seventy percent, and many patients remain in remission years later."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03725059","name":"Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)","tldr":"A phase 3 trial of Pembrolizumab, Doxorubicin, Epirubicin and Cyclophosphamide in HR-positive / HER2-negative breast cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","route":"/trials/nct03725059/","status":"active","kind":"trial","cancerIcon":"breast-hr-positive","sub":"NCT03725059","facets":{"kind":["Trial"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04380636","name":"Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)","tldr":"A phase 3 trial of Pembrolizumab, Olaparib, Etoposide, Carboplatin, Cisplatin and Pemetrexed in non-small-cell lung cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","route":"/trials/nct04380636/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT04380636","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","Unresectable stage III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Unresectable stage III non-small-cell lung cancer","href":"/cancers/stage-iii-unresectable-nsclc/","tip":"Stage III lung cancer that cannot be removed is treated with chemotherapy and radiotherapy together, aiming at cure. A year of the immunotherapy antibody durvalumab afterwards raised five-year survival from a third to over 40 percent, and for EGFR-mutated tumours osimertinib after chemoradiation holds the disease for years."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04786964","name":"Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC","tldr":"A phase 3 trial of Cosibelimab, Cisplatin, Carboplatin and Pemetrexed in Non-small-cell lung cancer, run by Checkpoint Therapeutics, Inc., recorded as terminated on the registry.","route":"/trials/nct04786964/","kind":"trial","cancerIcon":"nsclc","sub":"NCT04786964","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05855200","name":"Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer","tldr":"A phase 3 trial of Dostarlimab in colorectal cancer, run by GlaxoSmithKline, now recruiting.","route":"/trials/nct05855200/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT05855200","facets":{"kind":["Trial"],"cancers":["Colorectal cancer","Mismatch-repair deficient (MSI-high) colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Mismatch-repair deficient (MSI-high) colorectal cancer","href":"/cancers/msi-high-colorectal/","tip":"Mismatch-repair deficient bowel cancer has lost its DNA spell-checker, so it carries thousands of mutations that the immune system can recognise. Immunotherapy alone controls most metastatic cases for years and makes most localised tumours disappear before surgery, sometimes so completely that no surgery is needed."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06760637","name":"Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease","tldr":"A phase 3 trial of Atirmociclib, Abemaciclib, Palbociclib and Ribociclib in HR-positive / HER2-negative breast cancer, run by Pfizer, active and no longer recruiting.","route":"/trials/nct06760637/","status":"active","kind":"trial","cancerIcon":"breast-hr-positive","sub":"NCT06760637","facets":{"kind":["Trial"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05804045","name":"Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)","tldr":"A phase 3 trial of Pimicotinib(ABSK021) in tenosynovial giant cell tumour, run by Abbisko Therapeutics Co, Ltd, active and no longer recruiting.","route":"/trials/nct05804045/","status":"active","kind":"trial","cancerIcon":"tenosynovial-giant-cell-tumour","sub":"NCT05804045","facets":{"kind":["Trial"],"cancers":["Tenosynovial giant cell tumour"],"year":["2026"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Tenosynovial giant cell tumour","href":"/cancers/tenosynovial-giant-cell-tumour/","tip":"TGCT is a benign but destructive tumour of the joint lining, classed with soft-tissue sarcomas, in which a few cells carrying a CSF1 gene fusion recruit a crowd of normal immune cells that eat away at the joint. Surgery cures most localised cases, and for diffuse or recurrent disease two pills that block the CSF1 receptor, pexidartinib and vimseltinib, shrink tumours and restore joint function."}],"year":{"facet":"year","value":"2026"},"tags":[]},"sortKeys":{"year":2026}},{"id":"nct07499362","name":"Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)","tldr":"A phase 2 trial of Pimicotinib in tenosynovial giant cell tumour, run by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, now recruiting.","route":"/trials/nct07499362/","status":"recruiting","kind":"trial","cancerIcon":"tenosynovial-giant-cell-tumour","sub":"NCT07499362","facets":{"kind":["Trial"],"cancers":["Tenosynovial giant cell tumour"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Tenosynovial giant cell tumour","href":"/cancers/tenosynovial-giant-cell-tumour/","tip":"TGCT is a benign but destructive tumour of the joint lining, classed with soft-tissue sarcomas, in which a few cells carrying a CSF1 gene fusion recruit a crowd of normal immune cells that eat away at the joint. Surgery cures most localised cases, and for diffuse or recurrent disease two pills that block the CSF1 receptor, pexidartinib and vimseltinib, shrink tumours and restore joint function."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03458260","name":"Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma","tldr":"A phase 2 trial of Pixantrone, Ifosfamide, Etoposide and Rituximab in Non-Hodgkin lymphoma, run by The Lymphoma Academic Research Organisation, completed.","route":"/trials/nct03458260/","status":"completed","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT03458260","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07644039","name":"Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies","tldr":"A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by PharmaMar, now recruiting.","route":"/trials/nct07644039/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07644039","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02659514","name":"Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer","tldr":"A phase 2 trial of Poziotinib in Breast cancer, run by Spectrum Pharmaceuticals, Inc, completed.","route":"/trials/nct02659514/","status":"completed","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT02659514","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05563844","name":"Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)","tldr":"A phase 2 trial of PM 8.4 mg/m^2 in diffuse large B-cell lymphoma, run by Chengdu Zenitar Biomedical Technology Co., Ltd, active and no longer recruiting.","route":"/trials/nct05563844/","status":"active","kind":"trial","cancerIcon":"dlbcl","sub":"NCT05563844","facets":{"kind":["Trial"],"cancers":["Diffuse large B-cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05308264","name":"Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)","tldr":"A phase 1/2 trial of R906289 Monosodium (R289 Na) in myelodysplastic syndromes / neoplasms, run by Rigel Pharmaceuticals, now recruiting.","route":"/trials/nct05308264/","status":"recruiting","kind":"trial","cancerIcon":"mds","sub":"NCT05308264","facets":{"kind":["Trial"],"cancers":["Myelodysplastic syndromes / neoplasms","Lower-risk myelodysplastic syndromes"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Myelodysplastic syndromes / neoplasms","href":"/cancers/mds/","tip":"Bone-marrow disorders where blood cells are made badly and too few reach the blood; a third progress to acute leukaemia. Treatment ranges from transfusions and growth factors to hypomethylating drugs and, for the fit, transplant."},{"label":"Lower-risk myelodysplastic syndromes","href":"/cancers/mds-lower-risk/","tip":"Lower-risk myelodysplastic syndromes rarely turn into leukaemia quickly; the problem is anaemia and the transfusions it demands. Erythropoietin, then luspatercept (COMMANDS) and the telomerase blocker imetelstat (IMerge), free many patients from transfusions for months or years, and lenalidomide does the same for the del(5q) subtype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07125872","name":"Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma","tldr":"A phase 2 trial of CD19 t-haNK in non-Hodgkin lymphoma, run by ImmunityBio, Inc., now recruiting.","route":"/trials/nct07125872/","status":"recruiting","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT07125872","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06118086","name":"Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma","tldr":"A phase 1/2 trial of REM-422 in salivary gland cancers, run by Remix Therapeutics, now recruiting.","route":"/trials/nct06118086/","status":"recruiting","kind":"trial","cancerIcon":"salivary-gland","sub":"NCT06118086","facets":{"kind":["Trial"],"cancers":["Salivary gland cancers","Adenoid cystic carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Salivary gland cancers","href":"/cancers/salivary-gland/","tip":"Salivary gland cancers are a family of over 20 rare cancers, each with its own behaviour and often its own gene fusion. Surgery and radiation treat most; drug therapy is now chosen by the specific subtype, from anti-HER2 or anti-androgen drugs to NTRK inhibitors."},{"label":"Adenoid cystic carcinoma","href":"/cancers/adenoid-cystic-carcinoma/","tip":"Adenoid cystic carcinoma is a slow but relentless cancer of the salivary glands that creeps along nerves and comes back years later, often in the lungs. Surgery with radiotherapy is the only cure, chemotherapy barely works, and the tablets lenvatinib and axitinib can hold spreading disease still for months rather than shrink it."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04683250","name":"Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities","tldr":"A phase 1/2 trial of TAS0953/HM06 in non-small-cell lung cancer, run by Taiho Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct04683250/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT04683250","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","RET fusion-positive non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"RET fusion-positive non-small-cell lung cancer","href":"/cancers/ret-fusion-nsclc/","tip":"RET fusion lung cancer is a rare adenocarcinoma driven by a fused RET gene. The selective pill selpercatinib shrinks most tumours and more than doubles the time to progression compared with chemotherapy and immunotherapy, and pralsetinib is a second option."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05287113","name":"Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck","tldr":"A phase 2 trial of Retifanlimab in head and neck squamous cell carcinoma, run by Incyte Biosciences International Sàrl, active and no longer recruiting.","route":"/trials/nct05287113/","status":"active","kind":"trial","cancerIcon":"head-and-neck","sub":"NCT05287113","facets":{"kind":["Trial"],"cancers":["Head and neck squamous cell carcinoma","Recurrent or metastatic head and neck squamous cell carcinoma"],"year":["2026"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Recurrent or metastatic head and neck squamous cell carcinoma","href":"/cancers/recurrent-metastatic-hnscc/","tip":"When head and neck cancer comes back where it cannot be removed, or spreads elsewhere, it is treated to extend life rather than cure: pembrolizumab, alone or with chemotherapy, is the first choice, cetuximab-based regimens and cheap oral chemotherapy are alternatives, and antibodies that hit two targets at once are in late-stage trials."}],"year":{"facet":"year","value":"2026"},"tags":[]},"sortKeys":{"year":2026}},{"id":"nct07211958","name":"Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation","tldr":"A phase 3 trial of Revumenib in acute myeloid leukaemia, run by Syndax Pharmaceuticals, now recruiting.","route":"/trials/nct07211958/","status":"recruiting","kind":"trial","cancerIcon":"aml","sub":"NCT07211958","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05838729","name":"Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer","tldr":"A phase 1/2 trial of RiMO-301 in advanced solid tumours, run by Coordination Pharmaceuticals, Inc., now recruiting.","route":"/trials/nct05838729/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05838729","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06040541","name":"Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors","tldr":"A phase 1 trial of zoldonrasib (RMC-9805) alone or with daraxonrasib (RMC-6236) in KRAS G12D-mutant solid tumours, including pancreatic, bowel and non-small-cell lung cancer, run by Revolution Medicines, now recruiting.","route":"/trials/nct06040541/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT06040541","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Colorectal cancer","Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03937154","name":"Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer","tldr":"A phase 3 trial of Romiplostim in non-small-cell lung cancer, run by Amgen, active and no longer recruiting.","route":"/trials/nct03937154/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT03937154","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02674568","name":"Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer","tldr":"A phase 2 trial of Rovalpituzumab tesirine in Small-cell lung cancer, run by AbbVie, completed.","route":"/trials/nct02674568/","status":"completed","kind":"trial","cancerIcon":"sclc","sub":"NCT02674568","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04114825","name":"Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer","tldr":"A phase 2 trial of RV001V in prostate cancer, run by RhoVac APS, active and no longer recruiting.","route":"/trials/nct04114825/","status":"active","kind":"trial","cancerIcon":"prostate","sub":"NCT04114825","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05101096","name":"Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors","tldr":"A phase 1/2 trial of Sacituzumab govitecan in triple-negative breast cancer and bladder & urothelial cancer, run by Gilead Sciences, active and no longer recruiting.","route":"/trials/nct05101096/","status":"active","kind":"trial","cancerIcon":"tnbc","sub":"NCT05101096","facets":{"kind":["Trial"],"cancers":["Triple-negative breast cancer","Bladder & urothelial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04454437","name":"Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments","tldr":"A phase 2 trial of Sacituzumab govitecan in triple-negative breast cancer, run by Gilead Sciences, active and no longer recruiting.","route":"/trials/nct04454437/","status":"active","kind":"trial","cancerIcon":"tnbc","sub":"NCT04454437","facets":{"kind":["Trial"],"cancers":["Triple-negative breast cancer","Metastatic triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Metastatic triple-negative breast cancer","href":"/cancers/tnbc-metastatic/","tip":"Triple-negative breast cancer that has spread is not curable, but its treatment has been transformed since 2020. By PD-L1 score, first treatment is pembrolizumab with chemotherapy or with sacituzumab govitecan, or datopotamab deruxtecan or sacituzumab govitecan alone; BRCA carriers can take a PARP inhibitor tablet; and trastuzumab deruxtecan reaches the third of tumours with low HER2."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03964727","name":"Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors","tldr":"A phase 2 trial of Sacituzumab govitecan in advanced solid tumours, run by Gilead Sciences, active and no longer recruiting.","route":"/trials/nct03964727/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT03964727","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":["2026"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"year":{"facet":"year","value":"2026"},"tags":[]},"sortKeys":{"year":2026}},{"id":"nct03547973","name":"Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread","tldr":"A phase 2 trial of Sacituzumab govitecan, Pembrolizumab, Cisplatin, Avelumab, Zimberelimab and Carboplatin in bladder & urothelial cancer, run by Gilead Sciences, active and no longer recruiting.","route":"/trials/nct03547973/","status":"active","kind":"trial","cancerIcon":"urothelial","sub":"NCT03547973","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05119907","name":"Study of Sacituzumab Govitecan in Patients With Solid Tumor","tldr":"A phase 2 trial of Sacituzumab govitecan in advanced solid tumours, run by Gilead Sciences, active and no longer recruiting.","route":"/trials/nct05119907/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05119907","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05840211","name":"Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy","tldr":"A phase 3 trial of Sacituzumab govitecan and Capecitabine in HR-positive / HER2-negative breast cancer, run by Gilead Sciences, active and no longer recruiting.","route":"/trials/nct05840211/","status":"active","kind":"trial","cancerIcon":"breast-hr-positive","sub":"NCT05840211","facets":{"kind":["Trial"],"cancers":["HR-positive / HER2-negative breast cancer","HER2-low and HER2-ultralow metastatic breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"HER2-low and HER2-ultralow metastatic breast cancer","href":"/cancers/her2-low-metastatic-breast-cancer/","tip":"HER2-low is not a new kind of breast cancer but a new way of reading an old test: tumours once called HER2-negative that carry a little HER2 protein. That trace is enough for the antibody-drug conjugate trastuzumab deruxtecan to deliver its chemotherapy payload, and since 2022 it has been the standard for these patients after endocrine therapy or a first chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01045304","name":"Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer","tldr":"A phase 2 trial of Iniparib, Gemcitabine and Carboplatin in Breast cancer, run by Sanofi, completed.","route":"/trials/nct01045304/","status":"completed","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT01045304","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04562389","name":"Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis","tldr":"A phase 3 trial of Selinexor and Ruxolitinib in myeloproliferative neoplasms, run by Karyopharm Therapeutics Inc, active and no longer recruiting.","route":"/trials/nct04562389/","status":"active","kind":"trial","cancerIcon":"myeloproliferative-neoplasms","sub":"NCT04562389","facets":{"kind":["Trial"],"cancers":["Myeloproliferative neoplasms","Primary myelofibrosis"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Myeloproliferative neoplasms","href":"/cancers/myeloproliferative-neoplasms/","tip":"Myeloproliferative neoplasms are slow-growing blood cancers in which the marrow overproduces red cells (polycythaemia vera), platelets (essential thrombocythaemia) or scar tissue (myelofibrosis). Almost all carry a mutation in JAK2, CALR or MPL; treatment aims to prevent clots and control symptoms, and only transplant cures myelofibrosis."},{"label":"Primary myelofibrosis","href":"/cancers/primary-myelofibrosis/","tip":"Primary myelofibrosis is a blood cancer in which the marrow scars over, the spleen swells and patients become anaemic and exhausted. JAK inhibitors, ruxolitinib first (COMFORT) and then fedratinib, pacritinib and momelotinib (MOMENTUM), shrink the spleen and relieve symptoms; only a donor stem cell transplant can cure it."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06247956","name":"Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer","tldr":"A phase 2 trial of Adebrelimab, Capecitabine, Cisplatin, Oxaliplatin and SHR-8068 in gastric & gastro-oesophageal junction cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., active and no longer recruiting.","route":"/trials/nct06247956/","status":"active","kind":"trial","cancerIcon":"gastric","sub":"NCT06247956","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05765032","name":"Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of SHR-A1921 in advanced solid tumours, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., active and no longer recruiting.","route":"/trials/nct05765032/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05765032","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07765446","name":"Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel","tldr":"A phase 2 trial of SIR2501 in advanced solid tumours, run by Sironax USA, Inc., now recruiting.","route":"/trials/nct07765446/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07765446","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06081959","name":"Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer","tldr":"A phase 3 trial of Eribulin, Capecitabine, Gemcitabine and Vinorelbine in advanced solid tumours, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct06081959/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06081959","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04588922","name":"Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML","tldr":"A phase 1/2 trial of Venetoclax and Azacitidine in advanced solid tumours, run by Sellas Life Sciences Group, now recruiting.","route":"/trials/nct04588922/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04588922","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06127238","name":"Study of ST-1898 in Advanced Renal Cell Carcinoma","tldr":"A phase 1/2 trial of ST-1898 tablets in renal cell carcinoma, run by Beijing Scitech-Mq Pharmaceuticals Limited, active and no longer recruiting.","route":"/trials/nct06127238/","status":"active","kind":"trial","cancerIcon":"rcc","sub":"NCT06127238","facets":{"kind":["Trial"],"cancers":["Renal cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06359847","name":"Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer","tldr":"A phase 2 trial of ST-1898 tablets in thyroid cancer, run by Beijing Scitech-Mq Pharmaceuticals Limited, now recruiting.","route":"/trials/nct06359847/","status":"recruiting","kind":"trial","cancerIcon":"thyroid","sub":"NCT06359847","facets":{"kind":["Trial"],"cancers":["Thyroid cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Thyroid cancer","href":"/cancers/thyroid/","tip":"Thyroid cancer is usually curable with surgery and radioactive iodine, the original theranostic. Rare aggressive forms respond to RET and BRAF inhibitors."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04821622","name":"Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC","tldr":"A phase 3 trial of Talazoparib and Enzalutamide in prostate cancer, run by Pfizer, active and no longer recruiting.","route":"/trials/nct04821622/","status":"active","kind":"trial","cancerIcon":"prostate","sub":"NCT04821622","facets":{"kind":["Trial"],"cancers":["Prostate cancer","Metastatic hormone-sensitive prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Metastatic hormone-sensitive prostate cancer","href":"/cancers/prostate-mhspc/","tip":"Metastatic hormone-sensitive prostate cancer is disease that has spread but still responds to lowering testosterone. Hormone therapy alone is no longer enough: adding an androgen receptor inhibitor, and docetaxel for high-volume disease, lengthens life by years."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03155191","name":"Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia","tldr":"A phase 1/2 trial of TBI-1501 in acute lymphoblastic leukaemia, run by Takara Bio Inc., active and no longer recruiting.","route":"/trials/nct03155191/","status":"active","kind":"trial","cancerIcon":"all-leukemia","sub":"NCT03155191","facets":{"kind":["Trial"],"cancers":["Acute lymphoblastic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06731478","name":"Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer","tldr":"A phase 3 trial of Trastuzumab deruxtecan, Pembrolizumab and Trastuzumab in gastric & gastro-oesophageal junction cancer, run by Daiichi Sankyo, now recruiting.","route":"/trials/nct06731478/","status":"recruiting","kind":"trial","cancerIcon":"gastric","sub":"NCT06731478","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer","HER2-positive gastric cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"HER2-positive gastric cancer","href":"/cancers/gastric-her2-positive/","tip":"HER2-positive gastric cancer overexpresses the HER2 growth receptor and is treated with trastuzumab added to chemotherapy, now usually with pembrolizumab as well. After progression the antibody-drug conjugate trastuzumab deruxtecan gives responses that plain chemotherapy cannot."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06072612","name":"Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.","tldr":"A phase 3 trial of Cyclophosphamide and Retifanlimab in advanced solid tumours, run by BriaCell Therapeutics Corporation, now recruiting.","route":"/trials/nct06072612/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06072612","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03315754","name":"Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer","tldr":"A phase 2 trial of Padeliporfin in Prostate cancer, run by Steba Biotech S.A., completed.","route":"/trials/nct03315754/","status":"completed","kind":"trial","cancerIcon":"prostate","sub":"NCT03315754","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06726161","name":"Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC","tldr":"A phase 1/2 trial of RYZ801 in hepatocellular carcinoma, run by RayzeBio, Inc., now recruiting.","route":"/trials/nct06726161/","status":"recruiting","kind":"trial","cancerIcon":"hcc","sub":"NCT06726161","facets":{"kind":["Trial"],"cancers":["Hepatocellular carcinoma","Advanced hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."},{"label":"Advanced hepatocellular carcinoma","href":"/cancers/hcc-advanced/","tip":"Advanced hepatocellular carcinoma has invaded the liver's veins or spread beyond it. Sorafenib was the only drug for a decade; now the combination of the immunotherapy atezolizumab with the anti-angiogenic antibody bevacizumab, or the two-antibody regimen durvalumab with tremelimumab, is standard first line, and several further drugs follow it."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03865082","name":"Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)","tldr":"A phase 2 trial of Nivolumab and Ipilimumab in advanced solid tumours, run by Idera Pharmaceuticals, Inc., active and no longer recruiting.","route":"/trials/nct03865082/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT03865082","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05948475","name":"Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma","tldr":"A phase 3 trial of Tinengotinib in biliary tract cancer, run by TransThera Sciences (Nanjing), Inc., active and no longer recruiting.","route":"/trials/nct05948475/","status":"active","kind":"trial","cancerIcon":"cholangiocarcinoma","sub":"NCT05948475","facets":{"kind":["Trial"],"cancers":["Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03967977","name":"Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma","tldr":"A phase 3 trial of Tislelizumab, Cisplatin, Gemcitabine and Carboplatin in bladder & urothelial cancer, run by BeiGene, active and no longer recruiting.","route":"/trials/nct03967977/","status":"active","kind":"trial","cancerIcon":"urothelial","sub":"NCT03967977","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07100730","name":"Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma","tldr":"A phase 3 trial of TLX-101-Tx + Lomustine in glioma & glioblastoma, run by Telix Pharmaceuticals (Innovations) Pty Limited, now recruiting.","route":"/trials/nct07100730/","status":"recruiting","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT07100730","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06260774","name":"Study of TTX-MC138 in Subjects With Advanced Solid Tumors","tldr":"A phase 1/2 trial of TTX-MC138 in advanced solid tumours, run by TransCode Therapeutics, active and no longer recruiting.","route":"/trials/nct06260774/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06260774","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07736937","name":"Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer","tldr":"A phase 1/2 trial of TUB-040 + Carbo + BEV in ovarian cancer, run by Tubulis GmbH, now recruiting.","route":"/trials/nct07736937/","status":"recruiting","kind":"trial","cancerIcon":"ovarian","sub":"NCT07736937","facets":{"kind":["Trial"],"cancers":["Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06950086","name":"Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of TYK-00540 in HR-positive / HER2-negative breast cancer, run by TYK Medicines, Inc, now recruiting.","route":"/trials/nct06950086/","status":"recruiting","kind":"trial","cancerIcon":"breast-hr-positive","sub":"NCT06950086","facets":{"kind":["Trial"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06079671","name":"Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)","tldr":"A phase 3 trial of Volrustomig in cervical cancer, run by AstraZeneca, now recruiting.","route":"/trials/nct06079671/","status":"recruiting","kind":"trial","cancerIcon":"cervical","sub":"NCT06079671","facets":{"kind":["Trial"],"cancers":["Cervical cancer","Locally advanced cervical cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."},{"label":"Locally advanced cervical cancer","href":"/cancers/locally-advanced-cervical-cancer/","tip":"Locally advanced cervical cancer has grown beyond the cervix or into the pelvic lymph nodes but not to distant organs. It is treated with cisplatin chemotherapy given alongside external radiotherapy and brachytherapy, and two recent trials have improved on that: adding pembrolizumab, and giving six weeks of chemotherapy before the radiotherapy starts."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06799637","name":"Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments","tldr":"A phase 1/2 trial of XNW28012 in pancreatic ductal adenocarcinoma, ovarian cancer and cervical cancer, run by Evopoint Biosciences Inc., now recruiting.","route":"/trials/nct06799637/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT06799637","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Ovarian cancer","Cervical cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07823049","name":"Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy","tldr":"A phase 3 trial of XNW28012 for injection in pancreatic ductal adenocarcinoma, run by Evopoint Biosciences Inc., now recruiting.","route":"/trials/nct07823049/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT07823049","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06580301","name":"Study of YK012 in B-cell Acute Lymphoblastic Leukemia","tldr":"A phase 1/2 trial of YK012 in acute lymphoblastic leukaemia, run by Excyte Biopharma Ltd, now recruiting.","route":"/trials/nct06580301/","status":"recruiting","kind":"trial","cancerIcon":"all-leukemia","sub":"NCT06580301","facets":{"kind":["Trial"],"cancers":["Acute lymphoblastic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06840483","name":"Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer","tldr":"A phase 2 trial of Zelenectide pevedotin in advanced solid tumours, run by BicycleTx Limited, active and no longer recruiting.","route":"/trials/nct06840483/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06840483","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06903377","name":"Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer","tldr":"A phase 1/2 trial of Gecacitinib in non-small-cell lung cancer, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, now recruiting.","route":"/trials/nct06903377/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06903377","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06883526","name":"Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma","tldr":"A phase 1/2 trial of Gecacitinib in non-Hodgkin lymphoma, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, now recruiting.","route":"/trials/nct06883526/","status":"recruiting","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT06883526","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06927687","name":"Study of ZG005 in Patients With Advanced Solid Tumors","tldr":"A phase 2 trial of ZG005 for Injection in advanced solid tumours, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, active and no longer recruiting.","route":"/trials/nct06927687/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06927687","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06938880","name":"Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of ZGGS18 for Injection in advanced solid tumours, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, now recruiting.","route":"/trials/nct06938880/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06938880","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05584800","name":"Study of ZGGS18 in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of ZGGS18 for Injection in advanced solid tumours, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, now recruiting.","route":"/trials/nct05584800/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05584800","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07258121","name":"Study of ZGGS34 in Participants With Advanced Solid Tumors","tldr":"A phase 1/2 trial of ZG006 in advanced solid tumours, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, now recruiting.","route":"/trials/nct07258121/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07258121","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07471776","name":"Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer","tldr":"A phase 2 trial of TROP2 PET in Breast cancer, run by Fudan University, now recruiting.","route":"/trials/nct07471776/","status":"recruiting","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT07471776","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03040973","name":"Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone","tldr":"A phase 2 trial of Capmatinib, Gefitinib and Osimertinib in advanced solid tumours, run by Novartis Pharmaceuticals, active and no longer recruiting.","route":"/trials/nct03040973/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT03040973","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04895436","name":"Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)","tldr":"A phase 2 trial of Venetoclax and Obinutuzumab in chronic lymphocytic leukaemia, run by AbbVie, now recruiting.","route":"/trials/nct04895436/","status":"recruiting","kind":"trial","cancerIcon":"cll","sub":"NCT04895436","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05985655","name":"Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors","tldr":"A phase 1/2 trial of GTAEXS617 in head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, non-small-cell lung cancer, ovarian cancer, HR-positive / HER2-negative breast cancer and triple-negative breast cancer, run by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc., now recruiting.","route":"/trials/nct05985655/","status":"recruiting","kind":"trial","cancerIcon":"head-and-neck","sub":"NCT05985655","facets":{"kind":["Trial"],"cancers":["Head and neck squamous cell carcinoma","Pancreatic ductal adenocarcinoma","Non-small-cell lung cancer","Ovarian cancer","HR-positive / HER2-negative breast cancer","Triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05588648","name":"Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma","tldr":"A phase 1/2 trial of Vactosertib in osteosarcoma, run by MedPacto, Inc., now recruiting.","route":"/trials/nct05588648/","status":"recruiting","kind":"trial","cancerIcon":"osteosarcoma","sub":"NCT05588648","facets":{"kind":["Trial"],"cancers":["Osteosarcoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Osteosarcoma","href":"/cancers/osteosarcoma/","tip":"Osteosarcoma is the most common bone cancer, mostly in teenagers. Chemotherapy plus surgery cures about two-thirds when it has not spread; because no new drug has beaten that chemotherapy in a large trial in 30 years, the next gains are being sought in cellular therapy against GD2, HER2 and B7-H3."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04879043","name":"Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma","tldr":"A phase 1/2 trial of HDP-101 in multiple myeloma, run by Heidelberg Pharma AG, now recruiting.","route":"/trials/nct04879043/","status":"recruiting","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT04879043","facets":{"kind":["Trial"],"cancers":["Multiple myeloma","Relapsed or refractory multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."},{"label":"Relapsed or refractory multiple myeloma","href":"/cancers/myeloma-relapsed-refractory/","tip":"Myeloma almost always returns, and each return is harder to treat. Two kinds of immune therapy aimed at the BCMA protein on myeloma cells, CAR-T cells (KarMMa-3, CARTITUDE-4) and off-the-shelf bispecific antibodies (MajesTEC), now give deep remissions after other drugs fail, and a second target, GPRC5D, gives another option."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05499013","name":"Study to Assess SLN124 in Patients With Polycythemia Vera","tldr":"A phase 1/2 trial of SLN124 in myeloproliferative neoplasms, run by Silence Therapeutics plc, active and no longer recruiting.","route":"/trials/nct05499013/","status":"active","kind":"trial","cancerIcon":"myeloproliferative-neoplasms","sub":"NCT05499013","facets":{"kind":["Trial"],"cancers":["Myeloproliferative neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Myeloproliferative neoplasms","href":"/cancers/myeloproliferative-neoplasms/","tip":"Myeloproliferative neoplasms are slow-growing blood cancers in which the marrow overproduces red cells (polycythaemia vera), platelets (essential thrombocythaemia) or scar tissue (myelofibrosis). Almost all carry a mutation in JAK2, CALR or MPL; treatment aims to prevent clots and control symptoms, and only transplant cures myelofibrosis."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05038735","name":"Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.","tldr":"A phase 3 trial of Alpelisib and Fulvestrant in HR-positive / HER2-negative breast cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.","route":"/trials/nct05038735/","status":"active","kind":"trial","cancerIcon":"breast-hr-positive","sub":"NCT05038735","facets":{"kind":["Trial"],"cancers":["HR-positive / HER2-negative breast cancer","HR-positive metastatic breast cancer after CDK4/6 inhibitors"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"HR-positive metastatic breast cancer after CDK4/6 inhibitors","href":"/cancers/hr-positive-metastatic-post-cdk46/","tip":"When hormone-positive breast cancer grows through a CDK4/6 inhibitor, a blood test picks the next drug. Tumours with an acquired ESR1 mutation respond to the oral degraders elacestrant, camizestrant and imlunestrant; tumours with PIK3CA, AKT1 or PTEN changes to capivasertib, inavolisib or alpelisib; and once endocrine options run out, antibody-drug conjugates come before chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02793583","name":"Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma","tldr":"A phase 2/3 trial of Umbralisib and Bendamustine in Diffuse large B-cell lymphoma, Follicular lymphoma, Marginal zone lymphoma and Mantle cell lymphoma, run by TG Therapeutics, Inc., recorded as terminated on the registry.","route":"/trials/nct02793583/","kind":"trial","cancerIcon":"dlbcl","sub":"NCT02793583","facets":{"kind":["Trial"],"cancers":["Diffuse large B-cell lymphoma","Follicular lymphoma","Marginal zone lymphoma","Mantle cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."},{"label":"Follicular lymphoma","href":"/cancers/follicular-lymphoma/","tip":"Follicular lymphoma is the most common slow-growing lymphoma, defined in about 85% of cases by a BCL2 translocation. Most people live with it for decades, treated only when it causes problems; it can be controlled repeatedly with anti-CD20 antibodies, chemotherapy, bispecifics or CAR-T but rarely cured, and a small share transform into an aggressive lymphoma each year."},{"label":"Marginal zone lymphoma","href":"/cancers/marginal-zone-lymphoma/","tip":"Marginal zone lymphoma is a slow B-cell lymphoma that often grows where the body has been fighting a chronic infection: the stomach with Helicobacter pylori, the eye, the skin or the spleen. Curing the infection cures many early cases; the rest are treated with rituximab, chemotherapy or BTK inhibitors."},{"label":"Mantle cell lymphoma","href":"/cancers/mantle-cell-lymphoma/","tip":"An uncommon B-cell lymphoma driven by cyclin D1 that used to behave badly in almost everyone. BTK inhibitors, CAR-T and now BCL2 drugs have changed it from chemotherapy-plus-transplant to targeted combinations."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03801525","name":"Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)","tldr":"A phase 2/3 trial of Umbralisib and Venetoclax in Chronic lymphocytic leukaemia, run by TG Therapeutics, Inc., recorded as terminated on the registry.","route":"/trials/nct03801525/","kind":"trial","cancerIcon":"cll","sub":"NCT03801525","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04725994","name":"Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer","tldr":"A phase 1/2 trial of IDX-1197+XELOX in gastric & gastro-oesophageal junction cancer, run by Idience Co., Ltd., active and no longer recruiting.","route":"/trials/nct04725994/","status":"active","kind":"trial","cancerIcon":"gastric","sub":"NCT04725994","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04410445","name":"Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence","tldr":"A phase 3 trial of Bempegaldesleukin and Nivolumab in Melanoma, run by Nektar Therapeutics, recorded as terminated on the registry.","route":"/trials/nct04410445/","kind":"trial","cancerIcon":"melanoma","sub":"NCT04410445","facets":{"kind":["Trial"],"cancers":["Melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04090736","name":"Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy","tldr":"A phase 3 trial of Pevonedistat and Azacitidine in Leukaemia, run by PETHEMA Foundation, active and no longer recruiting.","route":"/trials/nct04090736/","status":"active","kind":"trial","cancerIcon":"leukaemia","sub":"NCT04090736","facets":{"kind":["Trial"],"cancers":["Leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Leukaemia","href":"/cancers/leukaemia/","tip":"Leukaemia means cancer of the blood-forming cells, but the four main types share little beyond the name: acute lymphoblastic and acute myeloid leukaemia are emergencies treated with intensive therapy, while chronic lymphocytic and chronic myeloid leukaemia are slow diseases controlled for years with pills. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07221734","name":"Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma","tldr":"A phase 3 trial of Nivolumab in melanoma, run by mAbxience Research S.L., now recruiting.","route":"/trials/nct07221734/","status":"recruiting","kind":"trial","cancerIcon":"melanoma","sub":"NCT07221734","facets":{"kind":["Trial"],"cancers":["Melanoma","Advanced melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"label":"Advanced melanoma","href":"/cancers/advanced-melanoma/","tip":"Advanced melanoma has spread beyond what surgery can remove, and it is the cancer in which immunotherapy first proved it could cure some people: about half of those given nivolumab with ipilimumab are alive ten years later. If immunotherapy fails, options include a cell therapy grown from the patient's own immune cells, a virus injected into the tumour, and targeted pills for BRAF-mutant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04174599","name":"Study to Compare the Efficacy and Safety of F-627 and GRAN®","tldr":"A phase 3 trial of Efbemalenograstim alfa and Filgrastim in Breast cancer, run by EVIVE Biotechnology, completed.","route":"/trials/nct04174599/","status":"completed","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT04174599","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04464226","name":"Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer","tldr":"A phase 3 trial of Darolutamide in advanced solid tumours, run by Bayer, active and no longer recruiting.","route":"/trials/nct04464226/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04464226","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04925479","name":"Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia","tldr":"A phase 1/2 trial of Asciminib in chronic myeloid leukaemia, run by Novartis Pharmaceuticals, now recruiting.","route":"/trials/nct04925479/","status":"recruiting","kind":"trial","cancerIcon":"cml","sub":"NCT04925479","facets":{"kind":["Trial"],"cancers":["Chronic myeloid leukaemia","Chronic myeloid leukaemia, chronic phase"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic myeloid leukaemia","href":"/cancers/cml/","tip":"Chronic myeloid leukaemia is a blood cancer driven by a single fused gene, BCR-ABL1, and the model for oncogene-targeted treatment: imatinib in 2001 and the tyrosine kinase inhibitors that followed turned it into a condition most people live with long-term. About half of patients with a sustained deep molecular response can now stop treatment altogether."},{"label":"Chronic myeloid leukaemia, chronic phase","href":"/cancers/cml-chronic-phase/","tip":"Chronic-phase chronic myeloid leukaemia is the disease that imatinib turned from fatal into manageable: a daily pill blocks the BCR::ABL1 protein that drives it. Blood tests track the leukaemia gene to a millionth, newer pills such as asciminib (ASC4FIRST) reach deeper responses faster, and patients with years of undetectable disease can try stopping."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07354074","name":"Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP","tldr":"A phase 2 trial of Asciminib in chronic myeloid leukaemia, run by Novartis Pharmaceuticals, now recruiting.","route":"/trials/nct07354074/","status":"recruiting","kind":"trial","cancerIcon":"cml","sub":"NCT07354074","facets":{"kind":["Trial"],"cancers":["Chronic myeloid leukaemia","Chronic myeloid leukaemia, chronic phase"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic myeloid leukaemia","href":"/cancers/cml/","tip":"Chronic myeloid leukaemia is a blood cancer driven by a single fused gene, BCR-ABL1, and the model for oncogene-targeted treatment: imatinib in 2001 and the tyrosine kinase inhibitors that followed turned it into a condition most people live with long-term. About half of patients with a sustained deep molecular response can now stop treatment altogether."},{"label":"Chronic myeloid leukaemia, chronic phase","href":"/cancers/cml-chronic-phase/","tip":"Chronic-phase chronic myeloid leukaemia is the disease that imatinib turned from fatal into manageable: a daily pill blocks the BCR::ABL1 protein that drives it. Blood tests track the leukaemia gene to a millionth, newer pills such as asciminib (ASC4FIRST) reach deeper responses faster, and patients with years of undetectable disease can try stopping."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04410133","name":"Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases","tldr":"A phase 3 trial of Fluciclovine F-18 in Brain metastases, run by Blue Earth Diagnostics, completed.","route":"/trials/nct04410133/","status":"completed","kind":"trial","cancerIcon":"secondary-brain-tumours","sub":"NCT04410133","facets":{"kind":["Trial"],"cancers":["Brain metastases"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Brain metastases","href":"/cancers/secondary-brain-tumours/","tip":"Brain metastases are cancers that have spread to the brain from elsewhere, most often from the lung, breast or skin. Focused radiation aimed at each spot (radiosurgery) has largely replaced radiation to the whole brain, and for some cancers modern targeted drugs and immunotherapy reach the brain well enough to shrink the deposits on their own."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06632951","name":"Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)","tldr":"A phase 2 trial of Livmoniplimab, Budigalimab, Docetaxel and Gemcitabine in bladder & urothelial cancer, run by AbbVie, active and no longer recruiting.","route":"/trials/nct06632951/","status":"active","kind":"trial","cancerIcon":"urothelial","sub":"NCT06632951","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06772623","name":"Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations","tldr":"A phase 1/2 trial of Telisotuzumab adizutecan, Budigalimab, Pembrolizumab, Carboplatin, Pemetrexed and Cisplatin in non-small-cell lung cancer, run by AbbVie, now recruiting.","route":"/trials/nct06772623/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06772623","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05379946","name":"Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors","tldr":"A phase 1/2 trial of Garsorasib and IN10018 in advanced solid tumours, run by InventisBio Co., Ltd, active and no longer recruiting.","route":"/trials/nct05379946/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05379946","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04585035","name":"Study to Evaluate D-1553 in Subjects With Solid Tumors","tldr":"A phase 1/2 trial of Garsorasib, Cetuximab and Pembrolizumab in non-small-cell lung cancer, run by InventisBio Co., Ltd, active and no longer recruiting.","route":"/trials/nct04585035/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT04585035","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","KRAS G12C-mutant non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"KRAS G12C-mutant non-small-cell lung cancer","href":"/cancers/kras-g12c-nsclc/","tip":"KRAS G12C lung cancer carries a mutation that was thought impossible to drug for forty years. Sotorasib and adagrasib now shrink about four in ten tumours after chemotherapy and immunotherapy, though the benefit is measured in months, and newer inhibitors and first-line combinations with immunotherapy are in trials."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04851613","name":"Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer","tldr":"A phase 3 trial of Afuresertib in advanced solid tumours, run by Laekna Limited, active and no longer recruiting.","route":"/trials/nct04851613/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04851613","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06909877","name":"Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma","tldr":"A phase 1/2 trial of HH2853 Tablets in peripheral T-cell lymphomas, run by Haihe Biopharma Co., Ltd., now recruiting.","route":"/trials/nct06909877/","status":"recruiting","kind":"trial","cancerIcon":"peripheral-t-cell-lymphoma","sub":"NCT06909877","facets":{"kind":["Trial"],"cancers":["Peripheral T-cell lymphomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Peripheral T-cell lymphomas","href":"/cancers/peripheral-t-cell-lymphoma/","tip":"Peripheral T-cell lymphomas are lymphomas of T cells rather than B cells. They are rarer, more varied and, apart from a few subtypes, harder to treat than B-cell lymphomas; several new drugs help only defined subtypes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01697384","name":"Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer","tldr":"A phase 3 trial of Histrelin in Prostate cancer, run by Endo USA Inc., a Keenova Therapeutics Company, completed.","route":"/trials/nct01697384/","status":"completed","kind":"trial","cancerIcon":"prostate","sub":"NCT01697384","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05583552","name":"Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy","tldr":"A phase 2 trial of Imetelstat in myelodysplastic syndromes / neoplasms and acute myeloid leukaemia, run by GCP-Service International West GmbH, active and no longer recruiting.","route":"/trials/nct05583552/","status":"active","kind":"trial","cancerIcon":"mds","sub":"NCT05583552","facets":{"kind":["Trial"],"cancers":["Myelodysplastic syndromes / neoplasms","Acute myeloid leukaemia","Higher-risk myelodysplastic syndromes"],"year":["2026"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Myelodysplastic syndromes / neoplasms","href":"/cancers/mds/","tip":"Bone-marrow disorders where blood cells are made badly and too few reach the blood; a third progress to acute leukaemia. Treatment ranges from transfusions and growth factors to hypomethylating drugs and, for the fit, transplant."},{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Higher-risk myelodysplastic syndromes","href":"/cancers/mds-higher-risk/","tip":"Higher-risk myelodysplastic syndromes behave like a slow leukaemia and often become one. Azacitidine lengthens life and a donor stem cell transplant is the only cure; every attempt to improve on azacitidine in a large trial, including the venetoclax combination tested in VERONA, has so far failed."}],"year":{"facet":"year","value":"2026"},"tags":[]},"sortKeys":{"year":2026}},{"id":"nct05269316","name":"Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of IMP9064 in advanced solid tumours, run by Impact Therapeutics, Inc., now recruiting.","route":"/trials/nct05269316/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05269316","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05168566","name":"Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer","tldr":"A phase 2 trial of Sutetinib Maleate Capsule in non-small-cell lung cancer, run by Teligene US, now recruiting.","route":"/trials/nct05168566/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT05168566","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06784752","name":"Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET","tldr":"A phase 3 trial of [177Lu]Lu-DOTA-TATE in pancreatic ductal adenocarcinoma, run by Novartis Pharmaceuticals, now recruiting.","route":"/trials/nct06784752/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT06784752","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04342910","name":"Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC","tldr":"A phase 3 trial of Camrelizumab and Rivoceranib (apatinib) in gastric & gastro-oesophageal junction cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.","route":"/trials/nct04342910/","status":"recruiting","kind":"trial","cancerIcon":"gastric","sub":"NCT04342910","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03972488","name":"Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET","tldr":"A phase 3 trial of Lutetium-177 dotatate in pancreatic ductal adenocarcinoma, run by Advanced Accelerator Applications, active and no longer recruiting.","route":"/trials/nct03972488/","status":"active","kind":"trial","cancerIcon":"neuroendocrine","sub":"NCT03972488","facets":{"kind":["Trial"],"cancers":["Neuroendocrine tumours","Small intestinal neuroendocrine tumours","Pancreatic neuroendocrine tumours","Grade 3 well-differentiated neuroendocrine tumour"],"year":["2024"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Neuroendocrine tumours","href":"/cancers/neuroendocrine/","tip":"A family of usually slow-growing tumours that start in hormone-producing cells of the gut, pancreas and lungs. They pioneered the idea of using the same molecule to see a tumour on a scan and then to treat it with radiation."},{"label":"Small intestinal neuroendocrine tumours","href":"/cancers/small-intestinal-net/","tip":"Small intestinal neuroendocrine tumours are slow-growing hormone-producing tumours of the ileum and jejunum, often found only after they have spread to lymph nodes and the liver. Monthly somatostatin analogue injections control symptoms and growth, lutetium-177 dotatate is the main second treatment, and everolimus, cabozantinib and surgery fill in."},{"label":"Pancreatic neuroendocrine tumours","href":"/cancers/pancreatic-net/","tip":"Pancreatic neuroendocrine tumours arise from the hormone-producing islet cells of the pancreas and behave very differently from ordinary pancreatic cancer, often growing for years. Surgery cures localised tumours; advanced disease is treated in sequence with somatostatin analogues, lutetium-177 dotatate, targeted tablets and oral chemotherapy, and a minority secrete insulin or gastrin."},{"label":"Grade 3 well-differentiated neuroendocrine tumour","href":"/cancers/grade-3-net/","tip":"Grade 3 well-differentiated neuroendocrine tumours divide fast enough to be called grade 3 yet still look and behave like their slower relatives rather than like neuroendocrine carcinoma. Recognised as separate since 2017, they keep the somatostatin receptor, respond less well to platinum chemotherapy, and in the NETTER-2 trial were among the first treated with lutetium-177 dotatate up front."}],"year":{"facet":"year","value":"2024"},"tags":[]},"sortKeys":{"year":2024}},{"id":"nct04581473","name":"Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection","tldr":"A phase 1/2 trial of Rivoceranib (apatinib) in gastric & gastro-oesophageal junction cancer and pancreatic ductal adenocarcinoma, run by CARsgen Therapeutics Co., Ltd., active and no longer recruiting.","route":"/trials/nct04581473/","status":"active","kind":"trial","cancerIcon":"gastric","sub":"NCT04581473","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer","Pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06033586","name":"Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera","tldr":"A phase 3 trial of Rusfertide in myeloproliferative neoplasms, run by Protagonist Therapeutics, Inc., active and no longer recruiting.","route":"/trials/nct06033586/","status":"active","kind":"trial","cancerIcon":"myeloproliferative-neoplasms","sub":"NCT06033586","facets":{"kind":["Trial"],"cancers":["Myeloproliferative neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Myeloproliferative neoplasms","href":"/cancers/myeloproliferative-neoplasms/","tip":"Myeloproliferative neoplasms are slow-growing blood cancers in which the marrow overproduces red cells (polycythaemia vera), platelets (essential thrombocythaemia) or scar tissue (myelofibrosis). Almost all carry a mutation in JAK2, CALR or MPL; treatment aims to prevent clots and control symptoms, and only transplant cures myelofibrosis."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07341100","name":"Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC","tldr":"A phase 2 trial of SKB264 in ovarian cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., active and no longer recruiting.","route":"/trials/nct07341100/","status":"active","kind":"trial","cancerIcon":"ovarian","sub":"NCT07341100","facets":{"kind":["Trial"],"cancers":["Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07427394","name":"Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer","tldr":"A phase 2 trial of Camizestrant and Atirmociclib in advanced solid tumours, run by AstraZeneca, now recruiting.","route":"/trials/nct07427394/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07427394","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04581512","name":"Study to Evaluate the Safety and Tolerability of EP0042","tldr":"A phase 1/2 trial of Venetoclax and Azacitidine in acute myeloid leukaemia, chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms and myelodysplastic syndromes / neoplasms, run by Ellipses Pharma, now recruiting.","route":"/trials/nct04581512/","status":"recruiting","kind":"trial","cancerIcon":"aml","sub":"NCT04581512","facets":{"kind":["Trial"],"cancers":["Acute myeloid leukaemia","Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms","Myelodysplastic syndromes / neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms","href":"/cancers/cmml/","tip":"Chronic myelomonocytic leukaemia and its relatives are bone-marrow cancers that behave partly like myelodysplasia (poorly made blood cells) and partly like a proliferative disease (an excess of monocytes or platelets). Hypomethylating agents produce responses in a minority and stabilise counts in more, transplant can cure the fit, and RAS-pathway and JAK inhibitors are in trials."},{"label":"Myelodysplastic syndromes / neoplasms","href":"/cancers/mds/","tip":"Bone-marrow disorders where blood cells are made badly and too few reach the blood; a third progress to acute leukaemia. Treatment ranges from transfusions and growth factors to hypomethylating drugs and, for the fit, transplant."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04954001","name":"Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1","tldr":"A phase 1/2 trial of FCN-159 in childhood cancers, run by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., active and no longer recruiting.","route":"/trials/nct04954001/","status":"active","kind":"trial","cancerIcon":"childhood-cancers","sub":"NCT04954001","facets":{"kind":["Trial"],"cancers":["Childhood cancers"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Childhood cancers","href":"/cancers/childhood-cancers/","tip":"Cancer in children is rare and different from adult cancer: the common types are leukaemias, brain tumours, lymphomas and embryonal tumours such as neuroblastoma and Wilms tumour, most are curable in well-resourced health systems, and the great challenge is bringing the same cures to the majority of children who live where they are not available."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05725200","name":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer","tldr":"A phase 2 trial of Patient-derived organoids in Colorectal cancer, run by Oslo University Hospital, now recruiting.","route":"/trials/nct05725200/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT05725200","facets":{"kind":["Trial"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04349436","name":"Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies","tldr":"A phase 1/2 trial of RP1, intra-tumoral injection, oncolytic virus in merkel cell carcinoma, basal cell carcinoma and cutaneous squamous cell carcinoma, run by Replimune, Inc., active and no longer recruiting.","route":"/trials/nct04349436/","status":"active","kind":"trial","cancerIcon":"merkel-cell-carcinoma","sub":"NCT04349436","facets":{"kind":["Trial"],"cancers":["Merkel cell carcinoma","Basal cell carcinoma","Cutaneous squamous cell carcinoma","Locally advanced and metastatic basal cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Merkel cell carcinoma","href":"/cancers/merkel-cell-carcinoma/","tip":"Merkel cell carcinoma is a rare, fast-growing skin cancer, usually caused by a common virus (Merkel cell polyomavirus) or by sun damage. It was almost untreatable once it spread; PD-1/PD-L1 immunotherapy now gives lasting responses in about half of patients."},{"label":"Basal cell carcinoma","href":"/cancers/basal-cell-carcinoma/","tip":"Basal cell carcinoma is a skin cancer and the most common cancer of all, caused by sun exposure and almost never life-threatening. Nearly all are removed surgically; the rare advanced cases are treated with drugs that block the hedgehog signalling pathway, and with immunotherapy if those fail."},{"label":"Cutaneous squamous cell carcinoma","href":"/cancers/cutaneous-scc/","tip":"Cutaneous squamous cell carcinoma is a sun-related skin cancer with over a million US cases a year, almost all cured by removing them. The 2 to 5% that grow deep or spread respond to PD-1 immunotherapy (cemiplimab, pembrolizumab), which is now also given after surgery in high-risk cases; transplant recipients cannot safely receive it."},{"label":"Locally advanced and metastatic basal cell carcinoma","href":"/cancers/locally-advanced-bcc/","tip":"Locally advanced basal cell carcinoma is a skin cancer that has grown so large or deep, usually on the face, that surgery or radiotherapy can no longer remove it without unacceptable damage. Almost all these tumours depend on the hedgehog growth pathway, and the pills vismodegib and sonidegib shrink about four in ten of them; cemiplimab is used when the pills fail or cannot be tolerated."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06234098","name":"Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors","tldr":"A phase 1/2 trial of AT-1965 Liposome Injection in advanced solid tumours, run by Alyssum Therapeutics, now recruiting.","route":"/trials/nct06234098/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06234098","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01499303","name":"Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer","tldr":"A phase 2 trial of Fostamatinib in Diffuse large B-cell lymphoma, run by AstraZeneca, completed.","route":"/trials/nct01499303/","status":"completed","kind":"trial","cancerIcon":"dlbcl","sub":"NCT01499303","facets":{"kind":["Trial"],"cancers":["Diffuse large B-cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06904235","name":"Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)","tldr":"A phase 2 trial of Palonosetron, Ondansetron and Aprepitant (and fosaprepitant) in childhood cancers, run by Helsinn Healthcare SA, now recruiting.","route":"/trials/nct06904235/","status":"recruiting","kind":"trial","cancerIcon":"childhood-cancers","sub":"NCT06904235","facets":{"kind":["Trial"],"cancers":["Childhood cancers"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Childhood cancers","href":"/cancers/childhood-cancers/","tip":"Cancer in children is rare and different from adult cancer: the common types are leukaemias, brain tumours, lymphomas and embryonal tumours such as neuroblastoma and Wilms tumour, most are curable in well-resourced health systems, and the great challenge is bringing the same cures to the majority of children who live where they are not available."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06353386","name":"Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)","tldr":"A phase 1/2 trial of Opevesostat, Olaparib, Docetaxel, Cabazitaxel, Dexamethasone and Prednisone in prostate cancer, run by Merck Sharp & Dohme LLC, now recruiting.","route":"/trials/nct06353386/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT06353386","facets":{"kind":["Trial"],"cancers":["Prostate cancer","Metastatic castration-resistant prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Metastatic castration-resistant prostate cancer","href":"/cancers/prostate-mcrpc/","tip":"Metastatic castration-resistant prostate cancer is disease that grows despite castrate testosterone. Sequenced treatments now include androgen receptor inhibitors, docetaxel and cabazitaxel, PARP inhibitors for men with BRCA-type mutations, the radioligand 177Lu-PSMA-617 and radium-223 for bone-predominant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06780098","name":"Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)","tldr":"A phase 2 trial of Docetaxel in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting.","route":"/trials/nct06780098/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06780098","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04626479","name":"Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)","tldr":"A phase 1/2 trial of Pembrolizumab, Favezelimab, Belzutifan and Lenvatinib in renal cell carcinoma, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","route":"/trials/nct04626479/","status":"active","kind":"trial","cancerIcon":"rcc","sub":"NCT04626479","facets":{"kind":["Trial"],"cancers":["Renal cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04626518","name":"Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)","tldr":"A phase 1/2 trial of Pembrolizumab, Belzutifan, Lenvatinib and Favezelimab in renal cell carcinoma, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","route":"/trials/nct04626518/","status":"active","kind":"trial","cancerIcon":"rcc","sub":"NCT04626518","facets":{"kind":["Trial"],"cancers":["Renal cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06469944","name":"Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)","tldr":"A phase 1/2 trial of Pembrolizumab, Sacituzumab tirumotecan, Capecitabine, Fluorouracil (5-FU), Oxaliplatin and Patritumab deruxtecan in gastric & gastro-oesophageal junction cancer and oesophageal cancer, run by Merck Sharp & Dohme LLC, now recruiting.","route":"/trials/nct06469944/","status":"recruiting","kind":"trial","cancerIcon":"gastric","sub":"NCT06469944","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer","Oesophageal cancer","Oesophageal and junctional adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."},{"label":"Oesophageal and junctional adenocarcinoma","href":"/cancers/oesophageal-adenocarcinoma/","tip":"Adenocarcinoma of the lower oesophagus and junction grows out of Barrett's oesophagus, the change in the lining caused by long-standing acid reflux. Chemotherapy or chemoradiation before surgery is standard, and HER2, PD-L1 and claudin 18.2 now guide drugs for advanced disease as they do in stomach cancer."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06445972","name":"Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)","tldr":"A phase 1/2 trial of Ramucirumab and Sacituzumab tirumotecan in gastric & gastro-oesophageal junction cancer and oesophageal cancer, run by Merck Sharp & Dohme LLC, now recruiting.","route":"/trials/nct06445972/","status":"recruiting","kind":"trial","cancerIcon":"gastric","sub":"NCT06445972","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer","Oesophageal cancer","Oesophageal and junctional adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."},{"label":"Oesophageal and junctional adenocarcinoma","href":"/cancers/oesophageal-adenocarcinoma/","tip":"Adenocarcinoma of the lower oesophagus and junction grows out of Barrett's oesophagus, the change in the lining caused by long-standing acid reflux. Chemotherapy or chemoradiation before surgery is standard, and HER2, PD-L1 and claudin 18.2 now guide drugs for advanced disease as they do in stomach cancer."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06780111","name":"Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)","tldr":"A phase 1/2 trial of Pembrolizumab, Fluorouracil (5-FU), Oxaliplatin and Sacituzumab tirumotecan in oesophageal cancer, run by Merck Sharp & Dohme LLC, now recruiting.","route":"/trials/nct06780111/","status":"recruiting","kind":"trial","cancerIcon":"esophageal","sub":"NCT06780111","facets":{"kind":["Trial"],"cancers":["Oesophageal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06643884","name":"Suprachoroidal Administration in Subjects With Metastases to the Choroid","tldr":"A phase 2 trial of AU-011 in advanced solid tumours, run by Aura Biosciences, now recruiting.","route":"/trials/nct06643884/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06643884","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00003788","name":"Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas","tldr":"A phase 3 trial of Carmustine, Lomustine, Porfimer sodium and Procarbazine in Brain and spinal cord tumours, run by Colorado Health Foundation, with a status the registry has not verified recently.","route":"/trials/nct00003788/","kind":"trial","cancerIcon":"brain-tumours","sub":"NCT00003788","facets":{"kind":["Trial"],"cancers":["Brain and spinal cord tumours"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Brain and spinal cord tumours","href":"/cancers/brain-tumours/","tip":"Brain and spinal cord tumours range from slow-growing meningiomas and low-grade gliomas to glioblastoma, the commonest malignant brain tumour in adults, and a distinct set of childhood tumours such as medulloblastoma and diffuse midline glioma. Molecular markers now define them, and treatment is surgery, radiotherapy and, for some, drugs chosen by those markers."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04205630","name":"SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma","tldr":"A phase 2 trial of Trastuzumab duocarmazine in Endometrial cancer, run by Byondis B.V., completed.","route":"/trials/nct04205630/","status":"completed","kind":"trial","cancerIcon":"endometrial","sub":"NCT04205630","facets":{"kind":["Trial"],"cancers":["Endometrial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03262935","name":"SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer","tldr":"A phase 3 trial of Trastuzumab duocarmazine, Lapatinib, Capecitabine, Trastuzumab, Vinorelbine and Eribulin in Breast cancer, run by Byondis B.V., completed.","route":"/trials/nct03262935/","status":"completed","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT03262935","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07421700","name":"Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer","tldr":"A phase 1/2 trial of PF-08634404 and Enfortumab vedotin in bladder & urothelial cancer, run by Pfizer, now recruiting.","route":"/trials/nct07421700/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT07421700","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"sys6010","name":"SYS6010","tldr":"SYS6010 is an experimental investigational agent whose form is not stated in the registry from CSPC Megalith Biopharmaceutical in phase 3 trials for non-small-cell lung cancer and head and neck squamous cell carcinoma, with its target not yet stated publicly.","route":"/drugs/sys6010/","status":"phase-3","kind":"drug","molecule":"sys6010","modality":"antibody-drug conjugate (ADC), per the sponsor's pipeline page; form not stated in the registry record","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[]},"sortKeys":{"year":0}},{"id":"sys6023","name":"SYS6023","tldr":"SYS6023 is an experimental antibody-drug conjugate from CSPC Megalith Biopharmaceutical in phase 2 trials for HR-positive / HER2-negative breast cancer, aimed at HER3.","route":"/drugs/sys6023/","status":"phase-2","kind":"drug","molecule":"sys6023","modality":"ADC","facets":{"kind":["Treatment"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02579564","name":"Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients","tldr":"A phase 3 trial of Gemcitabine, Vinorelbine, Paclitaxel / nab-paclitaxel, Pemetrexed, H101 oncolytic adenovirus, Recombinant human endostatin and Cisplatin in Non-small-cell lung cancer, run by Xinqiao Hospital of Chongqing, with a status the registry has not verified recently.","route":"/trials/nct02579564/","kind":"trial","cancerIcon":"nsclc","sub":"NCT02579564","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06343311","name":"T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)","tldr":"A phase 1/2 trial of EB103 in non-Hodgkin lymphoma, hodgkin lymphoma and diffuse large B-cell lymphoma, run by Estrella Biopharma, Inc., now recruiting.","route":"/trials/nct06343311/","status":"recruiting","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT06343311","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma","Hodgkin lymphoma","Diffuse large B-cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."},{"label":"Hodgkin lymphoma","href":"/cancers/hodgkin-lymphoma/","tip":"Hodgkin lymphoma is one of the most curable cancers, where the goal is now to cure with less toxicity, using brentuximab and, from 2026, first-line nivolumab."},{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."}],"tags":[]},"sortKeys":{"year":0}},{"id":"t3011","name":"T3011","tldr":"T3011 is an experimental small-molecule drug from ImmVira Pharma in phase 2 trials for melanoma, head and neck squamous cell carcinoma and sarcomas, aimed at PD-1 and PD-L1.","route":"/drugs/t3011/","status":"phase-2","kind":"drug","molecule":"t3011","modality":"oncolytic virus (intratumoral oncolytic HSV-1, per the sponsor's pipeline page; registered as a drug on ClinicalTrials.gov)","facets":{"kind":["Treatment"],"cancers":["Melanoma","Head and neck squamous cell carcinoma","Sarcomas","Non-small-cell lung cancer","Bladder & urothelial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Sarcomas","href":"/cancers/sarcoma/","tip":"Sarcomas are dozens of rare cancers of bone and connective tissue. GIST was the first solid tumour cured-in-practice by a targeted pill; synovial sarcoma got the first TCR-T therapy."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"tabelecleucel","name":"Tabelecleucel","tldr":"Tabelecleucel is a bank of donor T cells trained against Epstein-Barr virus, approved in Europe in 2022 as the first off-the-shelf T-cell therapy, for EBV-driven lymphoma after transplant when rituximab has failed.","route":"/drugs/tabelecleucel/","status":"approved","kind":"drug","molecule":"tabelecleucel","modality":"Cell therapy: allogeneic off-the-shelf Epstein-Barr virus-specific T cells","facets":{"kind":["Treatment"],"cancers":["Post-transplant lymphoproliferative disorder"],"year":["2022"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Post-transplant lymphoproliferative disorder","href":"/cancers/post-transplant-lymphoproliferative-disorder/","tip":"After an organ or stem cell transplant, the drugs that stop rejection also stop the immune system from policing Epstein-Barr virus, and infected B cells can grow into a lymphoma. The first move is to ease the immunosuppression; then the antibody rituximab, chemotherapy if needed, and, newest of all, off-the-shelf virus-specific T cells that restore the missing immune control."}],"year":{"facet":"year","value":"2022"},"tags":[]},"sortKeys":{"year":2022}},{"id":"nct05862324","name":"TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)","tldr":"A phase 1/2 trial of TAC01-CLDN18.2 in advanced solid tumours, run by Triumvira Immunologics, Inc., active and no longer recruiting.","route":"/trials/nct05862324/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05862324","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"tac01-cldn18-2","name":"TAC01-CLDN18.2","tldr":"TAC01-CLDN18.2 is an experimental TCR-T cell therapy from Triumvira Immunologics in phase 2 trials, aimed at Claudin 18.2.","route":"/drugs/tac01-cldn18-2/","status":"phase-2","kind":"drug","molecule":"tac01-cldn18-2","modality":"TCR-T cell therapy","sub":"TAC01","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05548127","name":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)","tldr":"A phase 1/2 trial of Vepdegestrant and Abemaciclib in advanced solid tumours, run by Pfizer, active and no longer recruiting.","route":"/trials/nct05548127/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05548127","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05573555","name":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)","tldr":"A phase 1/2 trial of Vepdegestrant and Ribociclib in advanced solid tumours, run by Pfizer, active and no longer recruiting.","route":"/trials/nct05573555/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05573555","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06125522","name":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)","tldr":"A phase 1/2 trial of Vepdegestrant in advanced solid tumours, run by Pfizer, active and no longer recruiting.","route":"/trials/nct06125522/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06125522","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"tak-928","name":"TAK-928","tldr":"TAK-928 is an experimental bispecific antibody from Takeda in phase 3 trials for non-small-cell lung cancer, aimed at PD-1 and CD25 (IL-2 receptor alpha).","route":"/drugs/tak-928/","status":"phase-3","kind":"drug","molecule":"tak-928","modality":"bispecific antibody","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00002622","name":"Talc in Treating Patients With Malignant Pleural Effusion","tldr":"A phase 3 trial of Talc in Metastatic cancer, run by Alliance for Clinical Trials in Oncology, completed.","route":"/trials/nct00002622/","status":"completed","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT00002622","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"tar-210","name":"TAR-210","tldr":"TAR-210 is an experimental small molecule (intravesical drug-releasing system) from Janssen Research & Development in phase 3 trials for bladder & urothelial cancer, aimed at FGFR2.","route":"/drugs/tar-210/","status":"phase-3","kind":"drug","molecule":"tar-210","modality":"small molecule (intravesical drug-releasing system)","sub":"JNJ-42756493","facets":{"kind":["Treatment"],"cancers":["Bladder & urothelial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."}],"tags":[]},"sortKeys":{"year":0}},{"id":"tara-002","name":"TARA-002","tldr":"TARA-002 is an experimental cell therapy whose type is not stated from Protara Therapeutics in phase 3 trials for bladder & urothelial cancer, with its target not yet stated publicly.","route":"/drugs/tara-002/","status":"phase-3","kind":"drug","molecule":"tara-002","modality":"cell therapy (type not stated)","facets":{"kind":["Treatment"],"cancers":["Bladder & urothelial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07598955","name":"Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma","tldr":"A phase 1/2 trial of Cyclophosphamide, Fludarabine and EB-CAR30-NK in thymoma and thymic carcinoma, run by Beijing Biotech, now recruiting.","route":"/trials/nct07598955/","status":"recruiting","kind":"trial","cancerIcon":"thymic-epithelial","sub":"NCT07598955","facets":{"kind":["Trial"],"cancers":["Thymoma and thymic carcinoma","Thymoma","Thymic carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Thymoma and thymic carcinoma","href":"/cancers/thymic-epithelial/","tip":"Thymoma and thymic carcinoma are rare tumours of the thymus gland in the chest. Thymomas grow slowly, often cause autoimmune diseases such as myasthenia gravis, and are usually cured by surgery; thymic carcinomas behave like other aggressive cancers and have few effective drugs."},{"label":"Thymoma","href":"/cancers/thymoma/","tip":"Thymoma is the slower-growing kind of thymic epithelial tumour, an indolent cancer of the thymus gland behind the breastbone that often announces itself through the autoimmune disease myasthenia gravis. Complete surgical removal cures most patients, radiotherapy is added when the tumour has grown through its capsule, and chemotherapy is used to shrink large tumours or control spread in the chest."},{"label":"Thymic carcinoma","href":"/cancers/thymic-carcinoma/","tip":"Thymic carcinoma is the aggressive kind of thymic epithelial tumour, a cancer of the thymus that behaves like carcinoma elsewhere and has often spread when found. Surgery is attempted when possible, carboplatin with paclitaxel is the usual chemotherapy, and sunitinib, lenvatinib and the PD-1 antibody pembrolizumab have shown responses in trials, with lenvatinib approved in Japan."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05636618","name":"Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors","tldr":"A phase 1/2 trial of [203Pb]VMT-α-NET in neuroendocrine tumours, pancreatic ductal adenocarcinoma and pheochromocytoma and paraganglioma, run by Perspective Therapeutics, now recruiting.","route":"/trials/nct05636618/","status":"recruiting","kind":"trial","cancerIcon":"neuroendocrine","sub":"NCT05636618","facets":{"kind":["Trial"],"cancers":["Neuroendocrine tumours","Pancreatic ductal adenocarcinoma","Pheochromocytoma and paraganglioma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Neuroendocrine tumours","href":"/cancers/neuroendocrine/","tip":"A family of usually slow-growing tumours that start in hormone-producing cells of the gut, pancreas and lungs. They pioneered the idea of using the same molecule to see a tumour on a scan and then to treat it with radiation."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Pheochromocytoma and paraganglioma","href":"/cancers/pheochromocytoma-paraganglioma/","tip":"Pheochromocytomas and paragangliomas are tumours of adrenaline-producing tissue that cause dangerous blood pressure surges. Surgery after careful blood-pressure blockade cures most, genetic testing finds an inherited cause in nearly half, and for the minority that spread there are now radioactive drugs that home to the tumour and, since 2025, the first oral targeted pill, belzutifan."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03213665","name":"Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)","tldr":"A phase 2 trial of Tazemetostat in Sarcomas, run by National Cancer Institute (NCI), completed.","route":"/trials/nct03213665/","status":"completed","kind":"trial","cancerIcon":"sarcoma","sub":"NCT03213665","facets":{"kind":["Trial"],"cancers":["Sarcomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Sarcomas","href":"/cancers/sarcoma/","tip":"Sarcomas are dozens of rare cancers of bone and connective tissue. GIST was the first solid tumour cured-in-practice by a targeted pill; synovial sarcoma got the first TCR-T therapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"tbi-1301","name":"TBI-1301","tldr":"TBI-1301 is an experimental investigational agent whose form is not stated in the registry from Takara Bio in phase 3 trials for sarcomas, with its target not yet stated publicly.","route":"/drugs/tbi-1301/","status":"phase-3","kind":"drug","molecule":"tbi-1301","modality":"TCR-T cell therapy (per the sponsor's pipeline page; form not stated in the registry record)","facets":{"kind":["Treatment"],"cancers":["Sarcomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Sarcomas","href":"/cancers/sarcoma/","tip":"Sarcomas are dozens of rare cancers of bone and connective tissue. GIST was the first solid tumour cured-in-practice by a targeted pill; synovial sarcoma got the first TCR-T therapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"tbi-1501","name":"TBI-1501","tldr":"TBI-1501 is an experimental CAR-T cell therapy from Takara Bio in phase 2 trials for acute lymphoblastic leukaemia, aimed at CD19.","route":"/drugs/tbi-1501/","status":"phase-2","kind":"drug","molecule":"tbi-1501","modality":"CAR-T cell therapy","facets":{"kind":["Treatment"],"cancers":["Acute lymphoblastic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."}],"tags":[]},"sortKeys":{"year":0}},{"id":"tc011","name":"TC011","tldr":"TC011 is an experimental CAR-T cell therapy from TICAROS in phase 2 trials for diffuse large B-cell lymphoma and follicular lymphoma, aimed at CD19.","route":"/drugs/tc011/","status":"phase-2","kind":"drug","molecule":"tc011","modality":"CAR-T cell therapy","facets":{"kind":["Treatment"],"cancers":["Diffuse large B-cell lymphoma","Follicular lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."},{"label":"Follicular lymphoma","href":"/cancers/follicular-lymphoma/","tip":"Follicular lymphoma is the most common slow-growing lymphoma, defined in about 85% of cases by a BCL2 translocation. Most people live with it for decades, treated only when it causes problems; it can be controlled repeatedly with anti-CD20 antibodies, chemotherapy, bispecifics or CAR-T but rarely cured, and a small share transform into an aggressive lymphoma each year."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07764653","name":"Technetium Tc 99m Sulfur Colloid Injection for Tracing Sentinel Nodes in Breast Cancer","tldr":"A phase 3 trial of Technetium Tc-99m sulfur colloid in Breast cancer, run by HTA Co., Ltd., completed.","route":"/trials/nct07764653/","status":"completed","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT07764653","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00660894","name":"Tegafur-Uracil and Leucovorin or S-1 in Treating Patients With Stage III Colon Cancer That Has Been Completely Removed by Surgery","tldr":"A phase 3 trial of Leucovorin and Tegafur, gimeracil and oteracil in Colorectal cancer, run by Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan, completed.","route":"/trials/nct00660894/","status":"completed","kind":"trial","cancerIcon":"colorectal","sub":"NCT00660894","facets":{"kind":["Trial"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"telisotuzumab-adizutecan","name":"Telisotuzumab adizutecan","tldr":"Telisotuzumab adizutecan is an experimental antibody-drug conjugate from AbbVie in phase 3 trials for colorectal cancer and non-small-cell lung cancer, with its target not yet stated publicly.","route":"/drugs/telisotuzumab-adizutecan/","status":"phase-3","kind":"drug","molecule":"telisotuzumab-adizutecan","modality":"ADC","sub":"ABBV-400","facets":{"kind":["Treatment"],"cancers":["Colorectal cancer","Non-small-cell lung cancer","MET exon 14 and MET-amplified non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"MET exon 14 and MET-amplified non-small-cell lung cancer","href":"/cancers/met-altered-nsclc/","tip":"MET-driven lung cancer comes in three forms: an exon 14 skipping mutation treated with the pills capmatinib or tepotinib, MET amplification that often arises as an escape route from EGFR drugs, and high c-Met protein levels that the antibody-drug conjugate telisotuzumab vedotin targets."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04543955","name":"Telotristat With Lutathera in Neuroendocrine Tumors","tldr":"A phase 2 trial of Telotristat ethyl in Neuroendocrine tumours, run by Lowell Anthony, MD, recorded as terminated on the registry.","route":"/trials/nct04543955/","kind":"trial","cancerIcon":"neuroendocrine","sub":"NCT04543955","facets":{"kind":["Trial"],"cancers":["Neuroendocrine tumours"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Neuroendocrine tumours","href":"/cancers/neuroendocrine/","tip":"A family of usually slow-growing tumours that start in hormone-producing cells of the gut, pancreas and lungs. They pioneered the idea of using the same molecule to see a tumour on a scan and then to treat it with radiation."}],"tags":[]},"sortKeys":{"year":0}},{"id":"tenalisib","name":"Tenalisib","tldr":"Tenalisib is an oral pi3k inhibitor from Rhizen Pharmaceuticals SA, in registered phase 2 trials for triple-negative breast cancer.","route":"/drugs/tenalisib/","status":"phase-2","kind":"drug","molecule":"tenalisib","modality":"Oral PI3K inhibitor","facets":{"kind":["Treatment"],"cancers":["Triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct07583511","name":"Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study","tldr":"A phase 2 trial of Teniposide, Etoposide, Serplulimab and Cisplatin in Small-cell lung cancer, run by Sun Yat-sen University, now recruiting.","route":"/trials/nct07583511/","status":"recruiting","kind":"trial","cancerIcon":"sclc","sub":"NCT07583511","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[]},"sortKeys":{"year":0}},{"id":"tersolisib","name":"Tersolisib","tldr":"Tersolisib is an experimental small-molecule drug from Eli Lilly and in phase 3 trials for HR-positive / HER2-negative breast cancer, aimed at PIK3CA / PI3K-alpha.","route":"/drugs/tersolisib/","status":"phase-3","kind":"drug","molecule":"tersolisib","modality":"small molecule","sub":"STX-478, LY4064809","facets":{"kind":["Treatment"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06084806","name":"Test-retest Evaluation of [18F]F-AraG PET","tldr":"A phase 2 trial of [18F]F-ARAG PET in non-small-cell lung cancer, run by CellSight Technologies, Inc., now recruiting.","route":"/trials/nct06084806/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06084806","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05863195","name":"Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial","tldr":"A phase 3 trial of Cetuximab, Floxuridine, Fluorouracil, Irinotecan, Leucovorin, Oxaliplatin and Panitumumab in Colorectal cancer, run by ECOG-ACRIN Cancer Research Group, now recruiting.","route":"/trials/nct05863195/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT05863195","facets":{"kind":["Trial"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07061951","name":"Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia","tldr":"A phase 2 trial of Mirdametinib in Chronic lymphocytic leukaemia, run by National Cancer Institute (NCI), now recruiting.","route":"/trials/nct07061951/","status":"recruiting","kind":"trial","cancerIcon":"cll","sub":"NCT07061951","facets":{"kind":["Trial"],"cancers":["Chronic lymphocytic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."}],"tags":[]},"sortKeys":{"year":0}},{"id":"tgrx-326","name":"TGRX-326","tldr":"TGRX-326 is an experimental small-molecule drug from Shenzhen TargetRx in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.","route":"/drugs/tgrx-326/","status":"phase-3","kind":"drug","molecule":"tgrx-326","modality":"small molecule","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06453902","name":"TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients","tldr":"A phase 2 trial of TGRX-678 in chronic myeloid leukaemia, run by Shenzhen TargetRx Co., Ltd., now recruiting.","route":"/trials/nct06453902/","status":"recruiting","kind":"trial","cancerIcon":"cml","sub":"NCT06453902","facets":{"kind":["Trial"],"cancers":["Chronic myeloid leukaemia","Chronic myeloid leukaemia, accelerated and blast phase"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic myeloid leukaemia","href":"/cancers/cml/","tip":"Chronic myeloid leukaemia is a blood cancer driven by a single fused gene, BCR-ABL1, and the model for oncogene-targeted treatment: imatinib in 2001 and the tyrosine kinase inhibitors that followed turned it into a condition most people live with long-term. About half of patients with a sustained deep molecular response can now stop treatment altogether."},{"label":"Chronic myeloid leukaemia, accelerated and blast phase","href":"/cancers/cml-advanced-phase/","tip":"Chronic myeloid leukaemia can accelerate and then transform into an acute leukaemia called blast crisis. Tyrosine kinase inhibitors are given at full strength, combined with acute leukaemia chemotherapy in blast phase, to bring the disease back to chronic phase quickly enough for a donor stem cell transplant, the only treatment that cures it."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06206174","name":"TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies","tldr":"A phase 1/2 trial of TGRX-814 in non-Hodgkin lymphoma, acute myeloid leukaemia, acute lymphoblastic leukaemia and myelodysplastic syndromes / neoplasms, run by Shenzhen TargetRx Co., Ltd., now recruiting.","route":"/trials/nct06206174/","status":"recruiting","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT06206174","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma","Acute myeloid leukaemia","Acute lymphoblastic leukaemia","Myelodysplastic syndromes / neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."},{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."},{"label":"Myelodysplastic syndromes / neoplasms","href":"/cancers/mds/","tip":"Bone-marrow disorders where blood cells are made badly and too few reach the blood; a third progress to acute leukaemia. Treatment ranges from transfusions and growth factors to hypomethylating drugs and, for the fit, transplant."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06452706","name":"The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer","tldr":"A phase 2 trial of TQB2102 in advanced solid tumours, run by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct06452706/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06452706","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06861088","name":"The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer","tldr":"A phase 3 trial of Kinisoquin™ in pancreatic ductal adenocarcinoma, run by Quercis Pharma AG, now recruiting.","route":"/trials/nct06861088/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT06861088","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07114861","name":"The KN510713 Study in Combination With mFOLFIRINOX","tldr":"A phase 1/2 trial of Study drug: KN510 120mg/day + KN713 90mg/day, Combination Chemotherapy: mFOLFIRINOX in pancreatic ductal adenocarcinoma, run by New Cancer Cure-Bio Co.,Ltd., now recruiting.","route":"/trials/nct07114861/","status":"recruiting","kind":"trial","cancerIcon":"pancreatic","sub":"NCT07114861","facets":{"kind":["Trial"],"cancers":["Pancreatic ductal adenocarcinoma","Metastatic pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Metastatic pancreatic ductal adenocarcinoma","href":"/cancers/metastatic-pdac/","tip":"Metastatic pancreatic cancer has spread beyond the pancreas, usually to the liver, and is treated with chemotherapy rather than surgery. Three combination regimens lengthen life, a minority of patients qualify for targeted drugs chosen by tumour or inherited mutations, and in 2026 the pan-RAS inhibitor daraxonrasib became the first drug against the KRAS mutation that drives almost every case."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04329728","name":"The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies","tldr":"A phase 1/2 trial of AVM0703 in advanced solid tumours, run by AVM Biotechnology Inc, now recruiting.","route":"/trials/nct04329728/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04329728","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02653755","name":"The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer","tldr":"A phase 2 trial of Prosigna in Breast cancer, run by Dana-Farber Cancer Institute, active and no longer recruiting.","route":"/trials/nct02653755/","status":"active","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT02653755","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04233346","name":"The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation","tldr":"A phase 2 trial of Ponatinib in chronic myeloid leukaemia and acute lymphoblastic leukaemia, run by Otsuka Beijing Research Institute, active and no longer recruiting.","route":"/trials/nct04233346/","status":"active","kind":"trial","cancerIcon":"cml","sub":"NCT04233346","facets":{"kind":["Trial"],"cancers":["Chronic myeloid leukaemia","Acute lymphoblastic leukaemia","Chronic myeloid leukaemia, accelerated and blast phase"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Chronic myeloid leukaemia","href":"/cancers/cml/","tip":"Chronic myeloid leukaemia is a blood cancer driven by a single fused gene, BCR-ABL1, and the model for oncogene-targeted treatment: imatinib in 2001 and the tyrosine kinase inhibitors that followed turned it into a condition most people live with long-term. About half of patients with a sustained deep molecular response can now stop treatment altogether."},{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."},{"label":"Chronic myeloid leukaemia, accelerated and blast phase","href":"/cancers/cml-advanced-phase/","tip":"Chronic myeloid leukaemia can accelerate and then transform into an acute leukaemia called blast crisis. Tyrosine kinase inhibitors are given at full strength, combined with acute leukaemia chemotherapy in blast phase, to bring the disease back to chronic phase quickly enough for a donor stem cell transplant, the only treatment that cures it."}],"tags":[]},"sortKeys":{"year":0}},{"id":"theo-260","name":"THEO-260","tldr":"THEO-260 is an oncolytic virus from Theolytics Limited, in registered phase 2 trials for ovarian cancer.","route":"/drugs/theo-260/","status":"phase-2","kind":"drug","molecule":"theo-260","modality":"Oncolytic virus","sub":"THEO-260","facets":{"kind":["Treatment"],"cancers":["Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct05771584","name":"Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer","tldr":"A phase 2 trial of AST-301 in gastric & gastro-oesophageal junction cancer, run by Aston Sci. Inc., active and no longer recruiting.","route":"/trials/nct05771584/","status":"active","kind":"trial","cancerIcon":"gastric","sub":"NCT05771584","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer","HER2-positive gastric cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"HER2-positive gastric cancer","href":"/cancers/gastric-her2-positive/","tip":"HER2-positive gastric cancer overexpresses the HER2 growth receptor and is treated with trastuzumab added to chemotherapy, now usually with pembrolizumab as well. After progression the antibody-drug conjugate trastuzumab deruxtecan gives responses that plain chemotherapy cannot."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01700946","name":"Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma","tldr":"A phase 2 trial of Dexamethasone, Vincristine, Rituximab, Clofarabine, Cyclophosphamide, Etoposide, Aldesleukin, Asparaginase, Methotrexate, Mercaptopurine, Cytarabine, Mitoxantrone, Teniposide and Vinblastine in Acute lymphoblastic leukaemia, run by St. Jude Children's Research Hospital, completed.","route":"/trials/nct01700946/","status":"completed","kind":"trial","cancerIcon":"all-leukemia","sub":"NCT01700946","facets":{"kind":["Trial"],"cancers":["Acute lymphoblastic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04665609","name":"Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC","tldr":"A phase 3 trial of Thermal ablation in Hepatocellular carcinoma, run by Chinese PLA General Hospital, with a status the registry has not verified recently.","route":"/trials/nct04665609/","kind":"trial","cancerIcon":"hcc","sub":"NCT04665609","facets":{"kind":["Trial"],"cancers":["Hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05208944","name":"THIO Sequenced With Cemiplimab in Advanced NSCLC","tldr":"A phase 2 trial of Cemiplimab in non-small-cell lung cancer, run by Maia Biotechnology, active and no longer recruiting.","route":"/trials/nct05208944/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT05208944","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07649122","name":"This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer.","tldr":"A phase 3 trial of an investigational treatment in prostate cancer, run by Norroy Bioscience Co., LTD, now recruiting.","route":"/trials/nct07649122/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT07649122","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"tilt-123","name":"TILT-123","tldr":"TILT-123 is an oncolytic virus from TILT Biotherapeutics Ltd., in registered phase 2 trials for ovarian cancer.","route":"/drugs/tilt-123/","status":"phase-2","kind":"drug","molecule":"tilt-123","modality":"Oncolytic virus","sub":"TILT-123","facets":{"kind":["Treatment"],"cancers":["Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct03736889","name":"Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors","tldr":"A phase 2 trial of Tislelizumab in advanced solid tumours, run by BeiGene, now recruiting.","route":"/trials/nct03736889/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT03736889","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"tng260","name":"TNG260","tldr":"TNG260 is a small-molecule inhibitor from Tango Therapeutics, Inc., in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer.","route":"/drugs/tng260/","status":"phase-2","kind":"drug","molecule":"tng260","modality":"Small-molecule inhibitor","sub":"TNG260","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"tng456","name":"TNG456","tldr":"TNG456 is an experimental small-molecule drug from Tango Therapeutics in phase 2 trials for non-small-cell lung cancer and glioma & glioblastoma, aimed at PRMT5 (MTAP-deleted cancers).","route":"/drugs/tng456/","status":"phase-2","kind":"drug","molecule":"tng456","modality":"small molecule","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"tng462","name":"TNG462","tldr":"TNG462 is an experimental small-molecule drug from Tango Therapeutics in phase 2 trials for pancreatic ductal adenocarcinoma and non-small-cell lung cancer, aimed at PRMT5 (MTAP-deleted cancers).","route":"/drugs/tng462/","status":"phase-2","kind":"drug","molecule":"tng462","modality":"small molecule","facets":{"kind":["Treatment"],"cancers":["Pancreatic ductal adenocarcinoma","Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"tno155","name":"TNO155","tldr":"TNO155 is a small-molecule inhibitor from Novartis Pharmaceuticals, in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer.","route":"/drugs/tno155/","status":"phase-2","kind":"drug","molecule":"tno155","modality":"Small-molecule inhibitor","sub":"TNO155","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct03330847","name":"To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.","tldr":"A phase 2 trial of Olaparib and Ceralasertib in triple-negative breast cancer, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct03330847/","status":"active","kind":"trial","cancerIcon":"tnbc","sub":"NCT03330847","facets":{"kind":["Trial"],"cancers":["Triple-negative breast cancer","Metastatic triple-negative breast cancer"],"year":["2022"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Metastatic triple-negative breast cancer","href":"/cancers/tnbc-metastatic/","tip":"Triple-negative breast cancer that has spread is not curable, but its treatment has been transformed since 2020. By PD-L1 score, first treatment is pembrolizumab with chemotherapy or with sacituzumab govitecan, or datopotamab deruxtecan or sacituzumab govitecan alone; BRCA carriers can take a PARP inhibitor tablet; and trastuzumab deruxtecan reaches the third of tumours with low HER2."}],"year":{"facet":"year","value":"2022"},"tags":[]},"sortKeys":{"year":2022}},{"id":"nct04853342","name":"To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy","tldr":"A phase 3 trial of Furmonertinib in non-small-cell lung cancer, run by Allist Pharmaceuticals, Inc., now recruiting.","route":"/trials/nct04853342/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT04853342","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06693375","name":"To Evaluate Dose and Safety of NanoEcho Particle-1 Using NanoEcho Imaging Device Examinations of Rectal Lymph Nodes in Healthy Volunteers and Rectal Cancer Patients.","tldr":"A phase 2 trial of Iron oxide nanoparticles in colorectal cancer, run by NanoEcho AB, now recruiting.","route":"/trials/nct06693375/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT06693375","facets":{"kind":["Trial"],"cancers":["Colorectal cancer","Rectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Rectal cancer","href":"/cancers/rectal-cancer/","tip":"Rectal cancer is bowel cancer in the last part of the large intestine, where surgery can mean a permanent stoma. Treatment now usually gives all the chemotherapy and radiotherapy first, and about half of people whose tumour disappears completely can keep their rectum and avoid surgery altogether."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06072131","name":"To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL","tldr":"A phase 3 trial of Belinostat and Pralatrexate in peripheral T-cell lymphomas, run by Acrotech Biopharma Inc., now recruiting.","route":"/trials/nct06072131/","status":"recruiting","kind":"trial","cancerIcon":"peripheral-t-cell-lymphoma","sub":"NCT06072131","facets":{"kind":["Trial"],"cancers":["Peripheral T-cell lymphomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Peripheral T-cell lymphomas","href":"/cancers/peripheral-t-cell-lymphoma/","tip":"Peripheral T-cell lymphomas are lymphomas of T cells rather than B cells. They are rarer, more varied and, apart from a few subtypes, harder to treat than B-cell lymphomas; several new drugs help only defined subtypes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06478719","name":"To Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoembolization","tldr":"A phase 1/2 trial of Placebo in hepatocellular carcinoma, run by Febico Biomedical Corp., now recruiting.","route":"/trials/nct06478719/","status":"recruiting","kind":"trial","cancerIcon":"hcc","sub":"NCT06478719","facets":{"kind":["Trial"],"cancers":["Hepatocellular carcinoma","Intermediate hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."},{"label":"Intermediate hepatocellular carcinoma","href":"/cancers/hcc-intermediate/","tip":"Intermediate hepatocellular carcinoma is several tumours inside a working liver, too many to cut out but with no spread beyond it. The standard treatment for two decades has been chemoembolisation through the hepatic artery, and trials now show that adding immunotherapy and anti-angiogenic drugs to it delays progression."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07795034","name":"To Evaluate the Efficacy and Safety of Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) Combined With NBB-001 and NBB-002 for Patients With Recurrent Head and Neck Malignancies","tldr":"A phase 2 trial of Boron Neutron Capture Therapy in head and neck squamous cell carcinoma, run by Neuboron Bio-SciTech Co., Ltd., now recruiting.","route":"/trials/nct07795034/","status":"recruiting","kind":"trial","cancerIcon":"head-and-neck","sub":"NCT07795034","facets":{"kind":["Trial"],"cancers":["Head and neck squamous cell carcinoma","Recurrent or metastatic head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Recurrent or metastatic head and neck squamous cell carcinoma","href":"/cancers/recurrent-metastatic-hnscc/","tip":"When head and neck cancer comes back where it cannot be removed, or spreads elsewhere, it is treated to extend life rather than cure: pembrolizumab, alone or with chemotherapy, is the first choice, cetuximab-based regimens and cheap oral chemotherapy are alternatives, and antibodies that hit two targets at once are in late-stage trials."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06389006","name":"To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer","tldr":"A phase 2 trial of Disitamab vedotin, Toripalimab, Epirubicin and Cyclophosphamide in HER2-positive breast cancer and HR-positive / HER2-negative breast cancer, run by RemeGen Co., Ltd., now recruiting.","route":"/trials/nct06389006/","status":"recruiting","kind":"trial","cancerIcon":"breast-her2-positive","sub":"NCT06389006","facets":{"kind":["Trial"],"cancers":["HER2-positive breast cancer","HR-positive / HER2-negative breast cancer","High-risk early HR-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."},{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"High-risk early HR-positive breast cancer","href":"/cancers/hr-positive-early-high-risk/","tip":"Most hormone-driven breast cancers are cured with surgery, radiotherapy and five to ten years of endocrine tablets. Women whose tumours are larger, higher grade or have reached the lymph nodes face a higher risk of relapse: two to three years of a CDK4/6 inhibitor added to endocrine therapy cuts recurrence, and genomic tests such as Oncotype DX and MammaPrint decide who also needs chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05541822","name":"To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation","tldr":"A phase 2 trial of Lazertinib in advanced solid tumours, run by Abion Inc, now recruiting.","route":"/trials/nct05541822/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05541822","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06194448","name":"To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations","tldr":"A phase 2 trial of Osimertinib, Carboplatin, Cisplatin and Pemetrexed in advanced solid tumours, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct06194448/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06194448","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06756269","name":"To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years","tldr":"A phase 2 trial of Medium dose for 15-HPV vaccine in advanced solid tumours, run by Shanghai Bovax Biotechnology Co., Ltd., now recruiting.","route":"/trials/nct06756269/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT06756269","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07454187","name":"To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma","tldr":"A phase 1/2 trial of SG2918 in multiple myeloma, run by Hangzhou Sumgen Biotech Co., Ltd., now recruiting.","route":"/trials/nct07454187/","status":"recruiting","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT07454187","facets":{"kind":["Trial"],"cancers":["Multiple myeloma","Relapsed or refractory multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."},{"label":"Relapsed or refractory multiple myeloma","href":"/cancers/myeloma-relapsed-refractory/","tip":"Myeloma almost always returns, and each return is harder to treat. Two kinds of immune therapy aimed at the BCMA protein on myeloma cells, CAR-T cells (KarMMa-3, CARTITUDE-4) and off-the-shelf bispecific antibodies (MajesTEC), now give deep remissions after other drugs fail, and a second target, GPRC5D, gives another option."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06378242","name":"To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2","tldr":"A phase 1/2 trial of Disitamab vedotin in bladder & urothelial cancer, run by RemeGen Co., Ltd., now recruiting.","route":"/trials/nct06378242/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT06378242","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Non-muscle-invasive bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Non-muscle-invasive bladder cancer","href":"/cancers/non-muscle-invasive-bladder-cancer/","tip":"Most bladder cancers are found while still confined to the lining. They are scraped out through the urethra and, when higher risk, treated with BCG instilled into the bladder; the challenge is the frequent recurrences and the patients whose tumours stop responding to BCG."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07368998","name":"To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer","tldr":"A phase 2 trial of Inavolisib and Fulvestrant in advanced solid tumours, run by Hoffmann-La Roche, now recruiting.","route":"/trials/nct07368998/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07368998","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00129142","name":"Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy","tldr":"A phase 3 trial of Toremifene in Prostate cancer, run by GTx, completed.","route":"/trials/nct00129142/","status":"completed","kind":"trial","cancerIcon":"prostate","sub":"NCT00129142","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"tovecimig","name":"Tovecimig","tldr":"Tovecimig is an experimental bispecific antibody from Compass Therapeutics in phase 3 trials for biliary tract cancer and bladder & urothelial cancer, aimed at VEGF / VEGFR.","route":"/drugs/tovecimig/","status":"phase-3","kind":"drug","molecule":"tovecimig","modality":"bispecific antibody","sub":"CTX-009","facets":{"kind":["Treatment"],"cancers":["Biliary tract cancer","Bladder & urothelial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."}],"tags":[]},"sortKeys":{"year":0}},{"id":"tq-b3234","name":"TQ-B3234","tldr":"TQ-B3234 is an experimental small-molecule drug from Chia Tai Tianqing Pharmaceutical in phase 3 trials for rare cancers of childhood, with its target not yet stated publicly.","route":"/drugs/tq-b3234/","status":"phase-3","kind":"drug","molecule":"tq-b3234","modality":"small molecule (structure undisclosed or not yet in PubChem)","facets":{"kind":["Treatment"],"cancers":["Rare cancers of childhood"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Rare cancers of childhood","href":"/cancers/rare-childhood-cancers/","tip":"Some childhood cancers are so rare that no single hospital sees enough to learn from. The NCI groups them together: heart tumours, airway papillomas, cancers of the thyroid, adrenal, nose and throat, melanoma and carcinomas more typical of adults. The answer has been international registries and expert networks that pool every case, so treatment guidance exists even without trials."}],"tags":[]},"sortKeys":{"year":0}},{"id":"tqb2102","name":"TQB2102","tldr":"TQB2102 is an experimental antibody-drug conjugate from Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical in phase 3 trials for HR-positive / HER2-negative breast cancer, HER2-positive breast cancer and biliary tract cancer, aimed at HER2.","route":"/drugs/tqb2102/","status":"phase-3","kind":"drug","molecule":"tqb2102","modality":"ADC","facets":{"kind":["Treatment"],"cancers":["HR-positive / HER2-negative breast cancer","HER2-positive breast cancer","Biliary tract cancer","Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"tqb2450","name":"TQB2450","tldr":"TQB2450 is an experimental monoclonal antibody from Chia Tai Tianqing Pharmaceutical in phase 3 trials for renal cell carcinoma and non-small-cell lung cancer, aimed at PD-L1 and PD-1.","route":"/drugs/tqb2450/","status":"phase-3","kind":"drug","molecule":"tqb2450","modality":"monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Renal cell carcinoma","Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"tqb2825","name":"TQB2825","tldr":"TQB2825 is an experimental bispecific antibody from Chia Tai Tianqing Pharmaceutical in phase 2 trials for diffuse large B-cell lymphoma, aimed at CD20 and CD3.","route":"/drugs/tqb2825/","status":"phase-2","kind":"drug","molecule":"tqb2825","modality":"bispecific antibody","facets":{"kind":["Treatment"],"cancers":["Diffuse large B-cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."}],"tags":[]},"sortKeys":{"year":0}},{"id":"tqb2868","name":"TQB2868","tldr":"TQB2868 is a bispecific antibody from Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., in registered phase 2 trials for pancreatic ductal adenocarcinoma.","route":"/drugs/tqb2868/","status":"phase-2","kind":"drug","molecule":"tqb2868","modality":"Bispecific antibody","sub":"TQB2868","facets":{"kind":["Treatment"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"tqb2922","name":"TQB2922","tldr":"TQB2922 is an experimental bispecific antibody from Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical in phase 2 trials for colorectal cancer, aimed at EGFR and MET.","route":"/drugs/tqb2922/","status":"phase-2","kind":"drug","molecule":"tqb2922","modality":"bispecific antibody","facets":{"kind":["Treatment"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"tqb2930","name":"TQB2930","tldr":"TQB2930 is an experimental bispecific antibody from Chia Tai Tianqing Pharmaceutical in phase 2 trials for HR-positive / HER2-negative breast cancer, aimed at HER2 and EGFR.","route":"/drugs/tqb2930/","status":"phase-2","kind":"drug","molecule":"tqb2930","modality":"bispecific antibody","facets":{"kind":["Treatment"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07047365","name":"TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer","tldr":"A phase 3 trial of TQB2930 and Trastuzumab in HER2-positive breast cancer, run by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct07047365/","status":"recruiting","kind":"trial","cancerIcon":"breast-her2-positive","sub":"NCT07047365","facets":{"kind":["Trial"],"cancers":["HER2-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."}],"tags":[]},"sortKeys":{"year":0}},{"id":"tqb3454","name":"TQB3454","tldr":"TQB3454 is an experimental small-molecule drug from Chia Tai Tianqing Pharmaceutical in phase 3 trials for biliary tract cancer, aimed at IDH1 / IDH2.","route":"/drugs/tqb3454/","status":"phase-3","kind":"drug","molecule":"tqb3454","modality":"small molecule (structure undisclosed or not yet in PubChem)","facets":{"kind":["Treatment"],"cancers":["Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"tqb3616","name":"TQB3616","tldr":"TQB3616 is an experimental small-molecule drug from Chia Tai Tianqing Pharmaceutical in phase 3 trials for HR-positive / HER2-negative breast cancer, aimed at CDK4/6.","route":"/drugs/tqb3616/","status":"phase-3","kind":"drug","molecule":"tqb3616","modality":"small molecule","facets":{"kind":["Treatment"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"tqb3702","name":"TQB3702","tldr":"TQB3702 is a small-molecule inhibitor from Chia Tai Tianqing Pharmaceutical Group Co., Ltd., in registered phase 2 trials for non-Hodgkin lymphoma.","route":"/drugs/tqb3702/","status":"phase-2","kind":"drug","molecule":"tqb3702","modality":"Small-molecule inhibitor","sub":"TQB3702","facets":{"kind":["Treatment"],"cancers":["Non-Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"tqb3909","name":"TQB3909","tldr":"TQB3909 is a small-molecule inhibitor from Chia Tai Tianqing Pharmaceutical Group Co., Ltd., in registered phase 2 trials for metastatic cancer.","route":"/drugs/tqb3909/","status":"phase-2","kind":"drug","molecule":"tqb3909","modality":"Small-molecule inhibitor","sub":"TQB3909","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"tqb6411","name":"TQB6411","tldr":"TQB6411 is an experimental antibody-drug conjugate from Chia Tai Tianqing Pharmaceutical in phase 2 trials for non-small-cell lung cancer and oesophageal cancer, aimed at EGFR and MET.","route":"/drugs/tqb6411/","status":"phase-2","kind":"drug","molecule":"tqb6411","modality":"ADC","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Oesophageal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."}],"tags":[]},"sortKeys":{"year":0}},{"id":"trabedersen","name":"Trabedersen","tldr":"Trabedersen is an experimental investigational agent whose form is not stated in the registry from Oncotelic in phase 3 trials for pancreatic ductal adenocarcinoma, with its target not yet stated publicly.","route":"/drugs/trabedersen/","status":"phase-3","kind":"drug","molecule":"trabedersen","modality":"antisense oligonucleotide (per the sponsor's description; form not stated in the registry record)","sub":"OT-101","facets":{"kind":["Treatment"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02762266","name":"Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization","tldr":"A phase 3 trial of Ethiodized oil in Hepatocellular carcinoma, run by Stanford University, recorded as terminated on the registry.","route":"/trials/nct02762266/","kind":"trial","cancerIcon":"hcc","sub":"NCT02762266","facets":{"kind":["Trial"],"cancers":["Hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05950945","name":"Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer","tldr":"A phase 3 trial of Trastuzumab deruxtecan in HER2-positive breast cancer and HR-positive / HER2-negative breast cancer, run by Daiichi Sankyo, now recruiting.","route":"/trials/nct05950945/","status":"recruiting","kind":"trial","cancerIcon":"breast-her2-positive","sub":"NCT05950945","facets":{"kind":["Trial"],"cancers":["HER2-positive breast cancer","HR-positive / HER2-negative breast cancer","HER2-low and HER2-ultralow metastatic breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."},{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"HER2-low and HER2-ultralow metastatic breast cancer","href":"/cancers/her2-low-metastatic-breast-cancer/","tip":"HER2-low is not a new kind of breast cancer but a new way of reading an old test: tumours once called HER2-negative that carry a little HER2 protein. That trace is enough for the antibody-drug conjugate trastuzumab deruxtecan to deliver its chemotherapy payload, and since 2022 it has been the standard for these patients after endocrine therapy or a first chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"trastuzumab-pamirtecan","name":"Trastuzumab pamirtecan","tldr":"Trastuzumab pamirtecan is DualityBio and BioNTech's HER2 antibody-drug conjugate, in phase 3 trials in breast cancers with high and with modest HER2 expression and in HER2-expressing endometrial cancer.","route":"/drugs/trastuzumab-pamirtecan/","status":"phase-3","kind":"drug","molecule":"trastuzumab-pamirtecan","modality":"Antibody-drug conjugate (anti-HER2 antibody, topoisomerase I inhibitor payload)","sub":"DB-1303","facets":{"kind":["Treatment"],"cancers":["HER2-positive breast cancer","Endometrial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."},{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04423211","name":"Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging","tldr":"A phase 3 trial of Apalutamide, Degarelix, Fluciclovine F-18, Goserelin / leuprolide, Leuprolide, Relugolix and Triptorelin in Prostate cancer, run by ECOG-ACRIN Cancer Research Group, now recruiting.","route":"/trials/nct04423211/","status":"recruiting","kind":"trial","cancerIcon":"prostate","sub":"NCT04423211","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04960709","name":"Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin","tldr":"A phase 3 trial of Durvalumab, Tremelimumab and Enfortumab vedotin in bladder & urothelial cancer, run by AstraZeneca, active and no longer recruiting.","route":"/trials/nct04960709/","status":"active","kind":"trial","cancerIcon":"urothelial","sub":"NCT04960709","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Muscle-invasive and advanced bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Muscle-invasive and advanced bladder cancer","href":"/cancers/muscle-invasive-bladder-cancer/","tip":"Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04514419","name":"Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel","tldr":"A phase 3 trial of Pertuzumab in advanced solid tumours, run by BioRay Pharmaceutical Co., Ltd., active and no longer recruiting.","route":"/trials/nct04514419/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04514419","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00199043","name":"Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma","tldr":"A phase 3 trial of Rasburicase in Leukaemia, run by Goethe University, completed.","route":"/trials/nct00199043/","status":"completed","kind":"trial","cancerIcon":"leukaemia","sub":"NCT00199043","facets":{"kind":["Trial"],"cancers":["Leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Leukaemia","href":"/cancers/leukaemia/","tip":"Leukaemia means cancer of the blood-forming cells, but the four main types share little beyond the name: acute lymphoblastic and acute myeloid leukaemia are emergencies treated with intensive therapy, while chronic lymphocytic and chronic myeloid leukaemia are slow diseases controlled for years with pills. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07188441","name":"Treatment of Newly Diagnosed Central Malignant Germ Cell Tumor People With Teniposide Injection Combined With Cisplatin","tldr":"A phase 2 trial of Teniposide and Cisplatin in Germ cell tumours of childhood and adolescence, run by Chengcheng Guo, now recruiting.","route":"/trials/nct07188441/","status":"recruiting","kind":"trial","cancerIcon":"paediatric-germ-cell-tumours","sub":"NCT07188441","facets":{"kind":["Trial"],"cancers":["Germ cell tumours of childhood and adolescence"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Germ cell tumours of childhood and adolescence","href":"/cancers/paediatric-germ-cell-tumours/","tip":"Germ cell tumours arise from the cells meant to become eggs or sperm and can appear in the gonads, lower back, chest or brain. They are among the most curable childhood cancers because they respond to cisplatin chemotherapy and release blood markers that make monitoring easy. The work now is to cure with less: surgery alone for low-risk tumours, gentler platinum drugs, and protecting hearing."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00136084","name":"Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia","tldr":"A phase 3 trial of Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Etoposide, Mitoxantrone, Prednisone and Vincristine in Leukaemia, run by St. Jude Children's Research Hospital, completed.","route":"/trials/nct00136084/","status":"completed","kind":"trial","cancerIcon":"leukaemia","sub":"NCT00136084","facets":{"kind":["Trial"],"cancers":["Leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Leukaemia","href":"/cancers/leukaemia/","tip":"Leukaemia means cancer of the blood-forming cells, but the four main types share little beyond the name: acute lymphoblastic and acute myeloid leukaemia are emergencies treated with intensive therapy, while chronic lymphocytic and chronic myeloid leukaemia are slow diseases controlled for years with pills. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06011109","name":"Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab","tldr":"A phase 1/2 trial of APG-157 in glioma & glioblastoma, run by Aveta Biomics, Inc., now recruiting.","route":"/trials/nct06011109/","status":"recruiting","kind":"trial","cancerIcon":"glioblastoma","sub":"NCT06011109","facets":{"kind":["Trial"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03367572","name":"Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer","tldr":"A phase 3 trial of Dexamethasone, Palonosetron and Netupitant and palonosetron in Breast cancer, run by University of Rochester NCORP Research Base, completed.","route":"/trials/nct03367572/","status":"completed","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT03367572","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03206671","name":"Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents","tldr":"A phase 3 trial of Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Vindesine, Etoposide, Ifosfamide, Methotrexate, Prednisone and Vincristine in Non-Hodgkin lymphoma, run by University Hospital Muenster, active and no longer recruiting.","route":"/trials/nct03206671/","status":"active","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT03206671","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01594879","name":"Treatment With Medroxyprogesterone Acetate Plus LNG-IUS in Young Women With Early Stage Endometrial Cancer","tldr":"A phase 2 trial of Progestins in Endometrial cancer, run by Korean Gynecologic Oncology Group, with a status the registry has not verified recently.","route":"/trials/nct01594879/","kind":"trial","cancerIcon":"endometrial","sub":"NCT01594879","facets":{"kind":["Trial"],"cancers":["Endometrial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."}],"tags":[]},"sortKeys":{"year":0}},{"id":"tri-611","name":"TRI-611","tldr":"TRI-611 is an experimental protein degrader from TRIANA Biomedicines in phase 2 trials for non-small-cell lung cancer, aimed at ALK.","route":"/drugs/tri-611/","status":"phase-2","kind":"drug","molecule":"tri-611","modality":"protein degrader","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00168181","name":"Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients","tldr":"A phase 3 trial of Pilocarpine in Head and neck squamous cell carcinoma, run by Alberta Health services, completed.","route":"/trials/nct00168181/","status":"completed","kind":"trial","cancerIcon":"head-and-neck","sub":"NCT00168181","facets":{"kind":["Trial"],"cancers":["Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06590857","name":"Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.","tldr":"A phase 1/2 trial of Actinium-225 DOTATATE in HR-positive / HER2-negative breast cancer, run by RayzeBio, Inc., active and no longer recruiting.","route":"/trials/nct06590857/","status":"active","kind":"trial","cancerIcon":"breast-hr-positive","sub":"NCT06590857","facets":{"kind":["Trial"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03379428","name":"Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer","tldr":"A phase 1/2 trial of Trastuzumab and Ibrutinib in advanced solid tumours, run by US Oncology Research, active and no longer recruiting.","route":"/trials/nct03379428/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT03379428","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00671918","name":"Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma","tldr":"A phase 3 trial of Technetium-99m tilmanocept in Breast cancer and Melanoma, run by Navidea Biopharmaceuticals, completed.","route":"/trials/nct00671918/","status":"completed","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT00671918","facets":{"kind":["Trial"],"cancers":["Breast cancer","Melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."},{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06510374","name":"Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer","tldr":"A phase 3 trial of Nadofaragene firadenovec in bladder & urothelial cancer, run by Ferring Pharmaceuticals, now recruiting.","route":"/trials/nct06510374/","status":"recruiting","kind":"trial","cancerIcon":"urothelial","sub":"NCT06510374","facets":{"kind":["Trial"],"cancers":["Bladder & urothelial cancer","Non-muscle-invasive bladder cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Non-muscle-invasive bladder cancer","href":"/cancers/non-muscle-invasive-bladder-cancer/","tip":"Most bladder cancers are found while still confined to the lining. They are scraped out through the urethra and, when higher risk, treated with BCG instilled into the bladder; the challenge is the frequent recurrences and the patients whose tumours stop responding to BCG."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07109414","name":"Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)","tldr":"A phase 2/3 trial of NP-G2-044 in ovarian cancer, run by Novita Pharmaceuticals, Inc., active and no longer recruiting.","route":"/trials/nct07109414/","status":"active","kind":"trial","cancerIcon":"ovarian","sub":"NCT07109414","facets":{"kind":["Trial"],"cancers":["Ovarian cancer","Platinum-resistant ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Platinum-resistant ovarian cancer","href":"/cancers/platinum-resistant-ovarian-cancer/","tip":"Platinum-resistant ovarian cancer grows back within six months of platinum chemotherapy, or during it, and used to be treated with single chemotherapy drugs that shrink a tumour one time in ten. The antibody-drug conjugate mirvetuximab soravtansine, the cortisol-blocking drug relacorilant and pembrolizumab in PD-L1-positive tumours have each extended survival in phase 3 trials since 2023."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07216443","name":"Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome","tldr":"A phase 2 trial of Orca-T in myelodysplastic syndromes / neoplasms, run by Orca Biosystems, Inc., now recruiting.","route":"/trials/nct07216443/","status":"recruiting","kind":"trial","cancerIcon":"mds","sub":"NCT07216443","facets":{"kind":["Trial"],"cancers":["Myelodysplastic syndromes / neoplasms","Higher-risk myelodysplastic syndromes"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Myelodysplastic syndromes / neoplasms","href":"/cancers/mds/","tip":"Bone-marrow disorders where blood cells are made badly and too few reach the blood; a third progress to acute leukaemia. Treatment ranges from transfusions and growth factors to hypomethylating drugs and, for the fit, transplant."},{"label":"Higher-risk myelodysplastic syndromes","href":"/cancers/mds-higher-risk/","tip":"Higher-risk myelodysplastic syndromes behave like a slow leukaemia and often become one. Azacitidine lengthens life and a donor stem cell transplant is the only cure; every attempt to improve on azacitidine in a large trial, including the venetoclax combination tested in VERONA, has so far failed."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06618235","name":"Trial of THEO-260 in Ovarian Cancer Patients","tldr":"A phase 1/2 trial of THEO-260 in ovarian cancer, run by Theolytics Limited, now recruiting.","route":"/trials/nct06618235/","status":"recruiting","kind":"trial","cancerIcon":"ovarian","sub":"NCT06618235","facets":{"kind":["Trial"],"cancers":["Ovarian cancer","High-grade serous ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"High-grade serous ovarian cancer","href":"/cancers/high-grade-serous-ovarian-cancer/","tip":"High-grade serous cancer is the common, aggressive form of ovarian cancer, now known to start in the fallopian tube. It is treated with surgery and platinum chemotherapy, and maintenance PARP inhibitors have changed its course for the half of patients whose tumours cannot repair DNA properly."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07805252","name":"Trial to Study the Safety, Pharmacokinetics and Preliminary Antitumour Activity of ODM-216 in Patients With Cancer","tldr":"A phase 1/2 trial of ODM-216 in advanced solid tumours, run by Orion Corporation, Orion Pharma, now recruiting.","route":"/trials/nct07805252/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07805252","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00066703","name":"Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer","tldr":"A phase 3 trial of Tamoxifen and Triptorelin in Breast cancer, run by ETOP IBCSG Partners Foundation, completed.","route":"/trials/nct00066703/","status":"completed","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT00066703","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00104741","name":"Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer","tldr":"A phase 3 trial of Flutamide and Triptorelin in Prostate cancer, run by UNICANCER, completed.","route":"/trials/nct00104741/","status":"completed","kind":"trial","cancerIcon":"prostate","sub":"NCT00104741","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"trk-950","name":"TRK-950","tldr":"TRK-950 is an experimental investigational agent whose form is not stated in the registry from Toray Industries in phase 2 trials for gastric & gastro-oesophageal junction cancer and melanoma, aimed at NTRK.","route":"/drugs/trk-950/","status":"phase-2","kind":"drug","molecule":"trk-950","modality":"monoclonal antibody (per the sponsor's pipeline page; form not stated in the registry record)","facets":{"kind":["Treatment"],"cancers":["Gastric & gastro-oesophageal junction cancer","Melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."}],"tags":[]},"sortKeys":{"year":0}},{"id":"tst001","name":"TST001","tldr":"TST001 is a monoclonal antibody from Transcenta Therapeutics (Hangzhou) Co., Ltd., in registered phase 2 trials for metastatic cancer.","route":"/drugs/tst001/","status":"phase-2","kind":"drug","molecule":"tst001","modality":"Monoclonal antibody","sub":"TST001","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"tst003","name":"TST003","tldr":"TST003 is a monoclonal antibody from Transcenta Therapeutics (Hangzhou) Co., Ltd., in registered phase 2 trials for colorectal cancer.","route":"/drugs/tst003/","status":"phase-2","kind":"drug","molecule":"tst003","modality":"Monoclonal antibody","sub":"TST003","facets":{"kind":["Treatment"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct04969315","name":"TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma","tldr":"A phase 1/2 trial of TT-10 in renal cell carcinoma, prostate cancer, non-small-cell lung cancer and mesothelioma, run by Portage Biotech, now recruiting.","route":"/trials/nct04969315/","status":"recruiting","kind":"trial","cancerIcon":"rcc","sub":"NCT04969315","facets":{"kind":["Trial"],"cancers":["Renal cell carcinoma","Prostate cancer","Non-small-cell lung cancer","Mesothelioma","Pleural mesothelioma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."},{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Mesothelioma","href":"/cancers/mesothelioma/","tip":"An asbestos-caused cancer of the lung lining. Immunotherapy doublets replaced chemotherapy in 2020, and mesothelin CAR-T is under study."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05458674","name":"Tucatinib+Trastuzumab+Eribulin in HER2+ MBC","tldr":"A phase 2 trial of Tucatinib, Eribulin and Trastuzumab in advanced solid tumours, run by Criterium, Inc., active and no longer recruiting.","route":"/trials/nct05458674/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05458674","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06947967","name":"Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype","tldr":"A phase 3 trial of Cyclophosphamide, Doxorubicin, Prednisone and Vincristine in non-Hodgkin lymphoma, run by Chipscreen Biosciences, Ltd., now recruiting.","route":"/trials/nct06947967/","status":"recruiting","kind":"trial","cancerIcon":"non-hodgkin-lymphoma","sub":"NCT06947967","facets":{"kind":["Trial"],"cancers":["Non-Hodgkin lymphoma","Peripheral T-cell lymphomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."},{"label":"Peripheral T-cell lymphomas","href":"/cancers/peripheral-t-cell-lymphoma/","tip":"Peripheral T-cell lymphomas are lymphomas of T cells rather than B cells. They are rarer, more varied and, apart from a few subtypes, harder to treat than B-cell lymphomas; several new drugs help only defined subtypes."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04589845","name":"Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study","tldr":"A phase 2 trial of Entrectinib, Alectinib, Atezolizumab, Ipatasertib, Trastuzumab emtansine and Inavolisib in advanced solid tumours, run by Hoffmann-La Roche, active and no longer recruiting.","route":"/trials/nct04589845/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT04589845","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"tunlametinib","name":"Tunlametinib","tldr":"Tunlametinib is a Chinese MEK inhibitor approved in 2024 for advanced melanoma with an NRAS mutation, a group with no targeted therapy elsewhere in the world, and in phase 3 trials with vemurafenib for BRAF-mutant disease and for colorectal cancer.","route":"/drugs/tunlametinib/","status":"approved","kind":"drug","molecule":"tunlametinib","modality":"Oral MEK1/2 inhibitor","sub":"HL-085","facets":{"kind":["Treatment"],"cancers":["Melanoma","Colorectal cancer"],"year":["2024"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"year":{"facet":"year","value":"2024"},"tags":[]},"sortKeys":{"year":2024}},{"id":"nct04524689","name":"Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC","tldr":"A phase 2 trial of Tusamitamab ravtansine, Pembrolizumab, Cisplatin, Carboplatin and Pemetrexed in Non-small-cell lung cancer, run by Sanofi, recorded as terminated on the registry.","route":"/trials/nct04524689/","kind":"trial","cancerIcon":"nsclc","sub":"NCT04524689","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04659603","name":"Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors","tldr":"A phase 2 trial of Tusamitamab ravtansine and Gemcitabine in Breast cancer, run by Sanofi, recorded as terminated on the registry.","route":"/trials/nct04659603/","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT04659603","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"tuspetinib","name":"Tuspetinib","tldr":"Tuspetinib is an oral kinase inhibitor from Aptose Biosciences Inc., in registered phase 2 trials for myelodysplastic syndromes / neoplasms, chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms.","route":"/drugs/tuspetinib/","status":"phase-2","kind":"drug","molecule":"tuspetinib","modality":"Oral kinase inhibitor","facets":{"kind":["Treatment"],"cancers":["Myelodysplastic syndromes / neoplasms","Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Myelodysplastic syndromes / neoplasms","href":"/cancers/mds/","tip":"Bone-marrow disorders where blood cells are made badly and too few reach the blood; a third progress to acute leukaemia. Treatment ranges from transfusions and growth factors to hypomethylating drugs and, for the fit, transplant."},{"label":"Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms","href":"/cancers/cmml/","tip":"Chronic myelomonocytic leukaemia and its relatives are bone-marrow cancers that behave partly like myelodysplasia (poorly made blood cells) and partly like a proliferative disease (an excess of monocytes or platelets). Hypomethylating agents produce responses in a minority and stabilise counts in more, transplant can cure the fit, and RAS-pathway and JAK inhibitors are in trials."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct07276373","name":"Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies","tldr":"A phase 1/2 trial of Nivolumab in advanced solid tumours, run by Corcept Therapeutics, now recruiting.","route":"/trials/nct07276373/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT07276373","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01204125","name":"Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients","tldr":"A phase 2 trial of Paclitaxel / nab-paclitaxel and Iniparib in Breast cancer, run by Sanofi, completed.","route":"/trials/nct01204125/","status":"completed","kind":"trial","cancerIcon":"breast-cancer","sub":"NCT01204125","facets":{"kind":["Trial"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease. Which of three receptor patterns the tumour carries decides its treatment: hormone receptor-positive (about 70 percent), HER2-positive (about 15 percent) or triple-negative (about 15 percent). The pages for each type hold the detail; this page holds what they share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04513717","name":"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial","tldr":"A phase 3 trial of Apalutamide, Bicalutamide, Buserelin, Degarelix, Flutamide, Goserelin / leuprolide, Histrelin, Leuprolide, Relugolix and Triptorelin in Prostate cancer, run by NRG Oncology, active and no longer recruiting.","route":"/trials/nct04513717/","status":"active","kind":"trial","cancerIcon":"prostate","sub":"NCT04513717","facets":{"kind":["Trial"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ty-9591","name":"TY-9591","tldr":"TY-9591 is an experimental small-molecule drug from TYK Medicines in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.","route":"/drugs/ty-9591/","status":"phase-3","kind":"drug","molecule":"ty-9591","modality":"small molecule (structure undisclosed or not yet in PubChem)","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05948813","name":"TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases","tldr":"A phase 2 trial of TY-9591 and Osimertinib in non-small-cell lung cancer and brain and spinal cord tumours, run by TYK Medicines, Inc, now recruiting.","route":"/trials/nct05948813/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT05948813","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer","Brain and spinal cord tumours","Brain metastases","EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Brain and spinal cord tumours","href":"/cancers/brain-tumours/","tip":"Brain and spinal cord tumours range from slow-growing meningiomas and low-grade gliomas to glioblastoma, the commonest malignant brain tumour in adults, and a distinct set of childhood tumours such as medulloblastoma and diffuse midline glioma. Molecular markers now define them, and treatment is surgery, radiotherapy and, for some, drugs chosen by those markers."},{"label":"Brain metastases","href":"/cancers/secondary-brain-tumours/","tip":"Brain metastases are cancers that have spread to the brain from elsewhere, most often from the lung, breast or skin. Focused radiation aimed at each spot (radiosurgery) has largely replaced radiation to the whole brain, and for some cancers modern targeted drugs and immunotherapy reach the brain well enough to shrink the deposits on their own."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"tyra-300","name":"TYRA-300","tldr":"TYRA-300 is an experimental small-molecule drug from Tyra Biosciences in phase 2 trials for bladder & urothelial cancer, aimed at FGFR2.","route":"/drugs/tyra-300/","status":"phase-2","kind":"drug","molecule":"tyra-300","modality":"small molecule","facets":{"kind":["Treatment"],"cancers":["Bladder & urothelial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ubamatamab","name":"Ubamatamab","tldr":"Ubamatamab (REGN4018) is Regeneron's investigational MUC16×CD3 bispecific antibody, in phase 1/2 and phase 2 trials for ovarian and endometrial cancer.","route":"/drugs/ubamatamab/","status":"phase-2","kind":"drug","molecule":"ubamatamab","modality":"Bispecific T-cell engager (MUC16×CD3)","facets":{"kind":["Treatment"],"cancers":["Ovarian cancer","Endometrial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ucart22","name":"UCART22","tldr":"UCART22 is an experimental allogeneic CAR T-cell therapy from Cellectis S.A. in phase 2 trials for acute lymphoblastic leukaemia, aimed at CD22.","route":"/drugs/ucart22/","status":"phase-2","kind":"drug","molecule":"ucart22","modality":"allogeneic CAR T-cell therapy","facets":{"kind":["Treatment"],"cancers":["Acute lymphoblastic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ugn-103","name":"UGN-103","tldr":"UGN-103 is an experimental chemotherapy (mitomycin) delivered via hydrogel from UroGen Pharma in phase 3 trials for bladder & urothelial cancer, with its target not yet stated publicly.","route":"/drugs/ugn-103/","status":"phase-3","kind":"drug","molecule":"ugn-103","modality":"chemotherapy (mitomycin) delivered via hydrogel","facets":{"kind":["Treatment"],"cancers":["Bladder & urothelial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ugn-104","name":"UGN-104","tldr":"UGN-104 is an experimental chemotherapy (mitomycin) delivered via hydrogel from UroGen Pharma in phase 3 trials for bladder & urothelial cancer, with its target not yet stated publicly.","route":"/drugs/ugn-104/","status":"phase-3","kind":"drug","molecule":"ugn-104","modality":"chemotherapy (mitomycin) delivered via hydrogel","facets":{"kind":["Treatment"],"cancers":["Bladder & urothelial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."}],"tags":[]},"sortKeys":{"year":0}},{"id":"uliledlimab","name":"Uliledlimab","tldr":"Uliledlimab is an experimental investigational agent whose form is not stated in the registry from TJ Biopharma in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.","route":"/drugs/uliledlimab/","status":"phase-3","kind":"drug","molecule":"uliledlimab","modality":"antibody (INN stem -mab; form not stated in the registry record)","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"upifitamab-rilsodotin","name":"Upifitamab rilsodotin","tldr":"Upifitamab rilsodotin is an antibody-drug conjugate from Mersana Therapeutics, in registered phase 2 trials for ovarian cancer, non-small-cell lung cancer.","route":"/drugs/upifitamab-rilsodotin/","status":"phase-2","kind":"drug","molecule":"upifitamab-rilsodotin","modality":"Antibody-drug conjugate","facets":{"kind":["Treatment"],"cancers":["Ovarian cancer","Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct07217704","name":"Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.","tldr":"A phase 3 trial of [18F]FAPI-74 PET/CT in oesophageal cancer and gastric & gastro-oesophageal junction cancer, run by SOFIE, now recruiting.","route":"/trials/nct07217704/","status":"recruiting","kind":"trial","cancerIcon":"esophageal","sub":"NCT07217704","facets":{"kind":["Trial"],"cancers":["Oesophageal cancer","Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."},{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"utomilumab","name":"Utomilumab","tldr":"Utomilumab is a monoclonal antibody from Pfizer, in registered phase 3 trials for ovarian cancer.","route":"/drugs/utomilumab/","status":"phase-3","kind":"drug","molecule":"utomilumab","modality":"Monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"vactosertib","name":"Vactosertib","tldr":"Vactosertib is an oral serine/threonine kinase inhibitor from MedPacto, Inc., in registered phase 2 trials for osteosarcoma.","route":"/drugs/vactosertib/","status":"phase-2","kind":"drug","molecule":"vactosertib","modality":"Oral serine/threonine kinase inhibitor","facets":{"kind":["Treatment"],"cancers":["Osteosarcoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Osteosarcoma","href":"/cancers/osteosarcoma/","tip":"Osteosarcoma is the most common bone cancer, mostly in teenagers. Chemotherapy plus surgery cures about two-thirds when it has not spread; because no new drug has beaten that chemotherapy in a large trial in 30 years, the next gains are being sought in cellular therapy against GD2, HER2 and B7-H3."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct04703192","name":"Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)","tldr":"A phase 2 trial of Valemetostat Tosylate in peripheral T-cell lymphomas and non-Hodgkin lymphoma, run by Daiichi Sankyo, active and no longer recruiting.","route":"/trials/nct04703192/","status":"active","kind":"trial","cancerIcon":"peripheral-t-cell-lymphoma","sub":"NCT04703192","facets":{"kind":["Trial"],"cancers":["Peripheral T-cell lymphomas","Non-Hodgkin lymphoma"],"year":["2024"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Peripheral T-cell lymphomas","href":"/cancers/peripheral-t-cell-lymphoma/","tip":"Peripheral T-cell lymphomas are lymphomas of T cells rather than B cells. They are rarer, more varied and, apart from a few subtypes, harder to treat than B-cell lymphomas; several new drugs help only defined subtypes."},{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of about sixty cancers of B cells, T cells or NK cells, from slow-growing follicular lymphoma to aggressive diffuse large B-cell and Burkitt lymphomas. This page is the map; each subtype has its own page with its own treatment."}],"year":{"facet":"year","value":"2024"},"tags":[]},"sortKeys":{"year":2024}},{"id":"nct03463252","name":"Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC","tldr":"A phase 2/3 trial of Progestins in Endometrial cancer, run by West China Second University Hospital, now recruiting.","route":"/trials/nct03463252/","status":"recruiting","kind":"trial","cancerIcon":"endometrial","sub":"NCT03463252","facets":{"kind":["Trial"],"cancers":["Endometrial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."}],"tags":[]},"sortKeys":{"year":0}},{"id":"varegacestat","name":"Varegacestat","tldr":"Varegacestat is an experimental small-molecule drug from Immunome in phase 3 trials for desmoid tumour, with its target not yet stated publicly.","route":"/drugs/varegacestat/","status":"phase-3","kind":"drug","molecule":"varegacestat","modality":"small molecule","sub":"AL102","facets":{"kind":["Treatment"],"cancers":["Desmoid tumour"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Desmoid tumour","href":"/cancers/desmoid-tumour/","tip":"Desmoid tumours are locally aggressive growths of fibroblast-like cells, classed with soft-tissue sarcomas, driven by WNT mutations, that never spread to distant organs but can invade nerves, bowel and muscle. Many stop growing or shrink on their own, so watching first is standard; if they progress, the gamma-secretase inhibitor nirogacestat, approved in 2023, shrinks tumours and relieves pain."}],"tags":[]},"sortKeys":{"year":0}},{"id":"vb15010","name":"VB15010","tldr":"VB15010 is a small-molecule inhibitor from Zhejiang Yangli Pharmaceutical Technology Co., Ltd., in registered phase 2 trials for ovarian cancer, prostate cancer, pancreatic ductal adenocarcinoma.","route":"/drugs/vb15010/","status":"phase-2","kind":"drug","molecule":"vb15010","modality":"Small-molecule inhibitor","sub":"VB15010","facets":{"kind":["Treatment"],"cancers":["Ovarian cancer","Prostate cancer","Pancreatic ductal adenocarcinoma","Biliary tract cancer","Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"vc004","name":"VC004","tldr":"VC004 is an experimental small-molecule drug from Jiangsu vcare pharmaceutical technology co. in phase 3 trials, with its target not yet stated publicly.","route":"/drugs/vc004/","status":"phase-3","kind":"drug","molecule":"vc004","modality":"small molecule","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"vebreltinib","name":"Vebreltinib","tldr":"Vebreltinib is a Chinese MET inhibitor approved in 2023 for lung cancers with a MET exon 14 skipping mutation, and the first drug tested in a phase 3 trial for glioblastomas carrying a PTPRZ1-MET fusion.","route":"/drugs/vebreltinib/","status":"approved","kind":"drug","molecule":"vebreltinib","modality":"Oral selective MET tyrosine kinase inhibitor","sub":"PLB1001","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Glioma & glioblastoma","Small-cell lung cancer"],"year":["2023"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"year":{"facet":"year","value":"2023"},"tags":[]},"sortKeys":{"year":2023}},{"id":"velzatinib","name":"Velzatinib","tldr":"Velzatinib is an experimental investigational agent whose form is not stated in the registry from GlaxoSmithKline in phase 3 trials for gastrointestinal stromal tumour, with its target not yet stated publicly.","route":"/drugs/velzatinib/","status":"phase-3","kind":"drug","molecule":"velzatinib","modality":"not stated (registered as a drug or biological on ClinicalTrials.gov)","sub":"GSK6042981","facets":{"kind":["Treatment"],"cancers":["Gastrointestinal stromal tumour"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Gastrointestinal stromal tumour","href":"/cancers/gist/","tip":"GIST is a sarcoma of the gut wall driven almost always by a KIT or PDGFRA mutation. It was the proof that a pill can control a solid tumour: imatinib turned a median survival of about a year into one of eight years or more, and the mutation now dictates which drug to use."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05909397","name":"Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer","tldr":"A phase 3 trial of Vepdegestrant and Palbociclib in advanced solid tumours, run by Pfizer, active and no longer recruiting.","route":"/trials/nct05909397/","status":"active","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05909397","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"vepugratinib","name":"Vepugratinib","tldr":"Vepugratinib is an experimental small-molecule drug from Eli Lilly and in phase 3 trials for bladder & urothelial cancer, with its target not yet stated publicly.","route":"/drugs/vepugratinib/","status":"phase-3","kind":"drug","molecule":"vepugratinib","modality":"small molecule","facets":{"kind":["Treatment"],"cancers":["Bladder & urothelial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."}],"tags":[]},"sortKeys":{"year":0}},{"id":"vibostolimab","name":"Vibostolimab","tldr":"Vibostolimab is a monoclonal antibody from Merck Sharp & Dohme LLC, in registered phase 2 trials for non-small-cell lung cancer.","route":"/drugs/vibostolimab/","status":"phase-2","kind":"drug","molecule":"vibostolimab","modality":"Monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct00821860","name":"Video-Assisted Surgery or Talc Pleurodesis in Treating Patients With Malignant Mesothelioma","tldr":"A phase 3 trial of Talc in Mesothelioma and Metastatic cancer, run by Papworth Hospital NHS Foundation Trust, completed.","route":"/trials/nct00821860/","status":"completed","kind":"trial","cancerIcon":"mesothelioma","sub":"NCT00821860","facets":{"kind":["Trial"],"cancers":["Mesothelioma","Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Mesothelioma","href":"/cancers/mesothelioma/","tip":"An asbestos-caused cancer of the lung lining. Immunotherapy doublets replaced chemotherapy in 2020, and mesothelin CAR-T is under study."},{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"vistusertib","name":"Vistusertib","tldr":"Vistusertib is an oral serine/threonine kinase inhibitor from AstraZeneca, in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer.","route":"/drugs/vistusertib/","status":"phase-2","kind":"drug","molecule":"vistusertib","modality":"Oral serine/threonine kinase inhibitor","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"visugromab","name":"Visugromab","tldr":"Visugromab is CatalYm's antibody against GDF-15, a tumour-made signal that both blocks immune cells and causes cancer wasting; it is in a phase 3 trial with PD-1 blockade after durable responses in patients whose cancers had stopped responding to checkpoint inhibitors.","route":"/drugs/visugromab/","status":"phase-3","kind":"drug","molecule":"visugromab","modality":"Anti-GDF-15 monoclonal antibody, intravenous","sub":"CTL-002","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06264180","name":"VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]","tldr":"A phase 3 trial of Vusolimogene oderparepvec, Nivolumab, Relatlimab + nivolumab and Pembrolizumab in Advanced melanoma, run by Replimune, Inc., now recruiting.","route":"/trials/nct06264180/","status":"recruiting","kind":"trial","cancerIcon":"advanced-melanoma","sub":"NCT06264180","facets":{"kind":["Trial"],"cancers":["Advanced melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Advanced melanoma","href":"/cancers/advanced-melanoma/","tip":"Advanced melanoma has spread beyond what surgery can remove, and it is the cancer in which immunotherapy first proved it could cure some people: about half of those given nivolumab with ipilimumab are alive ten years later. If immunotherapy fails, options include a cell therapy grown from the patient's own immune cells, a virus injected into the tumour, and targeted pills for BRAF-mutant disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05205330","name":"Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers","tldr":"A phase 1/2 trial of Balstilimab in colorectal cancer and gastric & gastro-oesophageal junction cancer, run by Rottapharm Biotech, active and no longer recruiting.","route":"/trials/nct05205330/","status":"active","kind":"trial","cancerIcon":"colorectal","sub":"NCT05205330","facets":{"kind":["Trial"],"cancers":["Colorectal cancer","Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04373369","name":"Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer","tldr":"A phase 2 trial of Vorolanib and Atezolizumab in Extensive-stage small-cell lung cancer, run by Washington University School of Medicine, recorded as terminated on the registry.","route":"/trials/nct04373369/","kind":"trial","cancerIcon":"extensive-stage-sclc","sub":"NCT04373369","facets":{"kind":["Trial"],"cancers":["Extensive-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07047001","name":"Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma","tldr":"A phase 2 trial of Vorolanib in Renal cell carcinoma, run by Dong Wen, active and no longer recruiting.","route":"/trials/nct07047001/","status":"active","kind":"trial","cancerIcon":"rcc","sub":"NCT07047001","facets":{"kind":["Trial"],"cancers":["Renal cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06523049","name":"Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy","tldr":"A phase 2 trial of Vorolanib and Sintilimab in Renal cell carcinoma, run by Hao Zeng, not yet recruiting.","route":"/trials/nct06523049/","status":"planned","kind":"trial","cancerIcon":"rcc","sub":"NCT06523049","facets":{"kind":["Trial"],"cancers":["Renal cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."}],"tags":[]},"sortKeys":{"year":0}},{"id":"vrn110755","name":"VRN110755","tldr":"VRN110755 is an experimental small-molecule drug from Voronoi in phase 2 trials for non-small-cell lung cancer, aimed at EGFR.","route":"/drugs/vrn110755/","status":"phase-2","kind":"drug","molecule":"vrn110755","modality":"small molecule (structure undisclosed or not yet in PubChem)","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"vs-7375","name":"VS-7375","tldr":"VS-7375 is an experimental small-molecule drug from Verastem in phase 2 trials for pancreatic ductal adenocarcinoma, non-small-cell lung cancer and colorectal cancer, aimed at KRAS.","route":"/drugs/vs-7375/","status":"phase-2","kind":"drug","molecule":"vs-7375","modality":"small molecule (structure undisclosed or not yet in PubChem)","facets":{"kind":["Treatment"],"cancers":["Pancreatic ductal adenocarcinoma","Non-small-cell lung cancer","Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"vudalimab","name":"Vudalimab","tldr":"Vudalimab is a bispecific antibody from Xencor, Inc., in registered phase 2 trials for ovarian cancer, endometrial cancer, cervical cancer.","route":"/drugs/vudalimab/","status":"phase-2","kind":"drug","molecule":"vudalimab","modality":"Bispecific antibody","facets":{"kind":["Treatment"],"cancers":["Ovarian cancer","Endometrial cancer","Cervical cancer","Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."},{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."},{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct02022358","name":"Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays?","tldr":"A phase 2 trial of Glucarpidase, Methotrexate and Leucovorin in Osteosarcoma, run by University College, London, recorded as terminated on the registry.","route":"/trials/nct02022358/","kind":"trial","cancerIcon":"osteosarcoma","sub":"NCT02022358","facets":{"kind":["Trial"],"cancers":["Osteosarcoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Osteosarcoma","href":"/cancers/osteosarcoma/","tip":"Osteosarcoma is the most common bone cancer, mostly in teenagers. Chemotherapy plus surgery cures about two-thirds when it has not spread; because no new drug has beaten that chemotherapy in a large trial in 30 years, the next gains are being sought in cellular therapy against GD2, HER2 and B7-H3."}],"tags":[]},"sortKeys":{"year":0}},{"id":"wjb001","name":"WJB001","tldr":"WJB001 is a small-molecule inhibitor from Wigen Biomedicine Technology (Shanghai) Co., Ltd., in registered phase 2 trials for metastatic cancer.","route":"/drugs/wjb001/","status":"phase-2","kind":"drug","molecule":"wjb001","modality":"Small-molecule inhibitor","sub":"WJB001","facets":{"kind":["Treatment"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"nct02823405","name":"X4P-001 and Pembrolizumab in Patients With Advanced Melanoma","tldr":"A phase 1 trial of Mavorixafor and Pembrolizumab in Melanoma, run by X4 Pharmaceuticals, completed.","route":"/trials/nct02823405/","status":"completed","kind":"trial","cancerIcon":"melanoma","sub":"NCT02823405","facets":{"kind":["Trial"],"cancers":["Melanoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05709249","name":"Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer","tldr":"A phase 3 trial of XLJDOD compound granule in colorectal cancer, run by Jiangsu Famous Medical Technology Co., Ltd., now recruiting.","route":"/trials/nct05709249/","status":"recruiting","kind":"trial","cancerIcon":"colorectal","sub":"NCT05709249","facets":{"kind":["Trial"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"xnw27011","name":"XNW27011","tldr":"XNW27011 is an experimental antibody-drug conjugate from Astellas Pharma Global Development in phase 2 trials for pancreatic ductal adenocarcinoma, non-small-cell lung cancer and ovarian cancer, aimed at Claudin 18.2.","route":"/drugs/xnw27011/","status":"phase-2","kind":"drug","molecule":"xnw27011","modality":"ADC","facets":{"kind":["Treatment"],"cancers":["Pancreatic ductal adenocarcinoma","Non-small-cell lung cancer","Ovarian cancer","Colorectal cancer","Biliary tract cancer","Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"xnw5004","name":"XNW5004","tldr":"XNW5004 is an experimental small-molecule drug from Evopoint Biosciences in phase 2 trials for follicular lymphoma and prostate cancer, aimed at EZH2.","route":"/drugs/xnw5004/","status":"phase-2","kind":"drug","molecule":"xnw5004","modality":"small molecule (structure undisclosed or not yet in PubChem)","facets":{"kind":["Treatment"],"cancers":["Follicular lymphoma","Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Follicular lymphoma","href":"/cancers/follicular-lymphoma/","tip":"Follicular lymphoma is the most common slow-growing lymphoma, defined in about 85% of cases by a BCL2 translocation. Most people live with it for decades, treated only when it causes problems; it can be controlled repeatedly with anti-CD20 antibodies, chemotherapy, bispecifics or CAR-T but rarely cured, and a small share transform into an aggressive lymphoma each year."},{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05684965","name":"XTX301 in Patients With Advanced Solid Tumors","tldr":"A phase 1/2 trial of XTX301 in advanced solid tumours, run by Xilio Development, Inc., now recruiting.","route":"/trials/nct05684965/","status":"recruiting","kind":"trial","cancerIcon":"metastatic-cancer","sub":"NCT05684965","facets":{"kind":["Trial"],"cancers":["Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"xzp-3287","name":"XZP-3287","tldr":"XZP-3287 is an experimental small-molecule drug from Sihuan Pharmaceutical in phase 3 trials for HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.","route":"/drugs/xzp-3287/","status":"phase-3","kind":"drug","molecule":"xzp-3287","modality":"small molecule","facets":{"kind":["Treatment"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"yl201","name":"YL201","tldr":"YL201 is an experimental antibody-drug conjugate from MediLink Therapeutics (Suzhou) in phase 3 trials for nasopharyngeal carcinoma, non-small-cell lung cancer and small-cell lung cancer, aimed at B7-H3.","route":"/drugs/yl201/","status":"phase-3","kind":"drug","molecule":"yl201","modality":"ADC","facets":{"kind":["Treatment"],"cancers":["Nasopharyngeal carcinoma","Non-small-cell lung cancer","Small-cell lung cancer","Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Nasopharyngeal carcinoma","href":"/cancers/nasopharyngeal/","tip":"A cancer at the back of the nose caused largely by the Epstein-Barr virus and common in southern China and Southeast Asia. Radiation cures most early cases; adding chemotherapy and, recently, PD-1 immunotherapy has improved outcomes in advanced disease, and a blood test for viral DNA can detect it early."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."},{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"yl202","name":"YL202","tldr":"YL202 is an experimental antibody-drug conjugate (ADC) from MediLink Therapeutics (Suzhou) in phase 3 trials for non-small-cell lung cancer, HR-positive / HER2-negative breast cancer and colorectal cancer, aimed at HER3.","route":"/drugs/yl202/","status":"phase-3","kind":"drug","molecule":"yl202","modality":"antibody-drug conjugate (ADC)","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","HR-positive / HER2-negative breast cancer","Colorectal cancer","Cervical cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00858429","name":"Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver Metastases","tldr":"A phase 1 trial of Capecitabine and Doxifluridine in Hepatocellular carcinoma and Metastatic cancer, run by Northwestern University, completed.","route":"/trials/nct00858429/","status":"completed","kind":"trial","cancerIcon":"hcc","sub":"NCT00858429","facets":{"kind":["Trial"],"cancers":["Hepatocellular carcinoma","Metastatic cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."},{"label":"Metastatic cancer","href":"/cancers/metastatic-cancer/","tip":"Metastatic cancer means the original cancer has spread to other parts of the body, most often the bones, liver, lungs or brain. It keeps the name of where it started, is treated with therapies that reach the whole body, and can increasingly be controlled for years; with limited spread it is sometimes treated with the aim of cure."}],"tags":[]},"sortKeys":{"year":0}},{"id":"zalifrelimab","name":"Zalifrelimab","tldr":"Zalifrelimab is a monoclonal antibody from Nelum Corp, in registered phase 2 trials for pancreatic ductal adenocarcinoma.","route":"/drugs/zalifrelimab/","status":"phase-2","kind":"drug","molecule":"zalifrelimab","modality":"Monoclonal antibody","facets":{"kind":["Treatment"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"zamtocabtagene-autoleucel","name":"Zamtocabtagene autoleucel","tldr":"Zamtocabtagene autoleucel is an experimental CAR-T cell therapy from Miltenyi Biomedicine in phase 2 trials for diffuse large B-cell lymphoma, primary CNS lymphoma and mantle cell lymphoma, aimed at CD19 and CD20.","route":"/drugs/zamtocabtagene-autoleucel/","status":"phase-2","kind":"drug","molecule":"zamtocabtagene-autoleucel","modality":"CAR-T cell therapy","sub":"CART2019","facets":{"kind":["Treatment"],"cancers":["Diffuse large B-cell lymphoma","Primary CNS lymphoma","Mantle cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."},{"label":"Primary CNS lymphoma","href":"/cancers/primary-cns-lymphoma/","tip":"Primary CNS lymphoma is a lymphoma confined to the brain, eyes and spinal fluid. Unlike most brain tumours it is chemo-sensitive: high-dose methotrexate-based treatment cures a substantial minority, and consolidation with a stem-cell transplant has replaced whole-brain radiation for the fit."},{"label":"Mantle cell lymphoma","href":"/cancers/mantle-cell-lymphoma/","tip":"An uncommon B-cell lymphoma driven by cyclin D1 that used to behave badly in almost everyone. BTK inhibitors, CAR-T and now BCL2 drugs have changed it from chemotherapy-plus-transplant to targeted combinations."}],"tags":[]},"sortKeys":{"year":0}},{"id":"zanzalintinib","name":"Zanzalintinib","tldr":"Zanzalintinib is an experimental small-molecule drug from Exelixis in phase 3 trials for neuroendocrine tumours, head and neck squamous cell carcinoma and renal cell carcinoma, aimed at VEGF / VEGFR and MET.","route":"/drugs/zanzalintinib/","status":"phase-3","kind":"drug","molecule":"zanzalintinib","modality":"small molecule","sub":"XL092","facets":{"kind":["Treatment"],"cancers":["Neuroendocrine tumours","Head and neck squamous cell carcinoma","Renal cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Neuroendocrine tumours","href":"/cancers/neuroendocrine/","tip":"A family of usually slow-growing tumours that start in hormone-producing cells of the gut, pancreas and lungs. They pioneered the idea of using the same molecule to see a tumour on a scan and then to treat it with radiation."},{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01497275","name":"Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma","tldr":"A phase 2 trial of Rituximab, Bortezomib and Ibritumomab tiuxetan in Mantle cell lymphoma, run by Duke University, recorded as terminated on the registry.","route":"/trials/nct01497275/","kind":"trial","cancerIcon":"mantle-cell-lymphoma","sub":"NCT01497275","facets":{"kind":["Trial"],"cancers":["Mantle cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Mantle cell lymphoma","href":"/cancers/mantle-cell-lymphoma/","tip":"An uncommon B-cell lymphoma driven by cyclin D1 that used to behave badly in almost everyone. BTK inhibitors, CAR-T and now BCL2 drugs have changed it from chemotherapy-plus-transplant to targeted combinations."}],"tags":[]},"sortKeys":{"year":0}},{"id":"zg006","name":"ZG006","tldr":"ZG006 is an experimental investigational agent whose form is not stated in the registry from Suzhou Zelgen Biopharmaceuticals in phase 3 trials for non-small-cell lung cancer and neuroendocrine tumours, with its target not yet stated publicly.","route":"/drugs/zg006/","status":"phase-3","kind":"drug","molecule":"zg006","modality":"trispecific T-cell engager antibody (DLL3 x DLL3 x CD3, per the sponsor's pipeline page; form not stated in the registry record)","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Neuroendocrine tumours"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Neuroendocrine tumours","href":"/cancers/neuroendocrine/","tip":"A family of usually slow-growing tumours that start in hormone-producing cells of the gut, pancreas and lungs. They pioneered the idea of using the same molecule to see a tumour on a scan and then to treat it with radiation."}],"tags":[]},"sortKeys":{"year":0}},{"id":"zimberelimab","name":"Zimberelimab","tldr":"Zimberelimab is a PD-1 antibody approved in China in 2021 for relapsed classical Hodgkin lymphoma, and the checkpoint partner in Arcus and Gilead's Western trials of the TIGIT antibody domvanalimab.","route":"/drugs/zimberelimab/","status":"approved","kind":"drug","molecule":"zimberelimab","modality":"Anti-PD-1 monoclonal antibody, intravenous","sub":"GLS-010","facets":{"kind":["Treatment"],"cancers":["Hodgkin lymphoma","Cervical cancer"],"year":["2021"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Hodgkin lymphoma","href":"/cancers/hodgkin-lymphoma/","tip":"Hodgkin lymphoma is one of the most curable cancers, where the goal is now to cure with less toxicity, using brentuximab and, from 2026, first-line nivolumab."},{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."}],"year":{"facet":"year","value":"2021"},"tags":[]},"sortKeys":{"year":2021}},{"id":"zipalertinib","name":"Zipalertinib","tldr":"Zipalertinib is an experimental small-molecule drug from Taiho Oncology in phase 3 trials for non-small-cell lung cancer, aimed at EGFR.","route":"/drugs/zipalertinib/","status":"phase-3","kind":"drug","molecule":"zipalertinib","modality":"small molecule","sub":"CLN-081, TAS6417","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"girentuximab-zr89","name":"Zirconium-89 girentuximab","tldr":"Zirconium-89 girentuximab is Telix's PET scan that tells whether a kidney mass is clear cell renal cell carcinoma without a biopsy; the phase 3 ZIRCON trial met its endpoints in 2023 and the product is under regulatory review.","route":"/drugs/girentuximab-zr89/","status":"phase-3","kind":"drug","molecule":"girentuximab-zr89","modality":"PET imaging antibody labelled with zirconium-89","sub":"TLX250-CDx","facets":{"kind":["Treatment"],"cancers":["Renal cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct00390234","name":"Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma","tldr":"A phase 2 trial of Ziv-aflibercept in Ovarian cancer, Uterine sarcoma, Uterine carcinosarcoma and Leiomyosarcoma, run by National Cancer Institute (NCI), completed.","route":"/trials/nct00390234/","status":"completed","kind":"trial","cancerIcon":"ovarian","sub":"NCT00390234","facets":{"kind":["Trial"],"cancers":["Ovarian cancer","Uterine sarcoma","Uterine carcinosarcoma","Leiomyosarcoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Uterine sarcoma","href":"/cancers/uterine-sarcoma/","tip":"Uterine sarcomas are rare cancers of the muscle and supporting tissue of the womb, distinct from the far commoner endometrial cancer. Removing the uterus intact is the main treatment and is followed by observation for stage I disease; low-grade stromal sarcomas respond to hormone-blocking pills, while advanced leiomyosarcoma is treated with doxorubicin and trabectedin."},{"label":"Uterine carcinosarcoma","href":"/cancers/uterine-carcinosarcoma/","tip":"Uterine carcinosarcoma is a two-faced cancer with a carcinoma part and a sarcoma-like part that both come from the same faulty epithelial cell. It is treated as a high-grade endometrial cancer, with surgery, carboplatin-paclitaxel and often radiotherapy, and its frequent HER2 expression is opening a route to antibody-drug conjugates."},{"label":"Leiomyosarcoma","href":"/cancers/leiomyosarcoma/","tip":"Leiomyosarcoma is a cancer of smooth muscle, most often in the womb, the abdomen behind the bowel or the wall of a large vein. Surgery is the only cure; for spread disease, doxorubicin-based chemotherapy, trabectedin and gemcitabine-docetaxel are the standards, with no targeted drug yet."}],"tags":[]},"sortKeys":{"year":0}},{"id":"zl-1310","name":"ZL-1310","tldr":"ZL-1310 is an experimental antibody-drug conjugate from Zai Lab (Shanghai) in phase 3 trials for non-small-cell lung cancer, aimed at DLL3.","route":"/drugs/zl-1310/","status":"phase-3","kind":"drug","molecule":"zl-1310","modality":"ADC","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"zovegalisib","name":"Zovegalisib","tldr":"Zovegalisib is an experimental small-molecule drug from Relay Therapeutics in phase 3 trials for HR-positive / HER2-negative breast cancer, aimed at PIK3CA / PI3K-alpha.","route":"/drugs/zovegalisib/","status":"phase-3","kind":"drug","molecule":"zovegalisib","modality":"small molecule","facets":{"kind":["Treatment"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}}]